Cover
Cover - USD ($) $ in Millions | 12 Months Ended | ||
Sep. 30, 2023 | Nov. 10, 2023 | Mar. 31, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Sep. 30, 2023 | ||
Current Fiscal Year End Date | --09-30 | ||
Document Transition Report | false | ||
Securities Act File Number | 1-33901 | ||
Entity Registrant Name | Oaktree Specialty Lending Corporation | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 26-1219283 | ||
Entity Address, Address Line One | 333 South Grand Avenue | ||
Entity Address, Address Line Two | 28th Floor | ||
Entity Address, City or Town | Los Angeles | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 90071 | ||
City Area Code | 213 | ||
Local Phone Number | 830-6300 | ||
Title of 12(b) Security | Common Stock, par value $0.01 per share | ||
Trading Symbol | OCSL | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 1,411.2 | ||
Entity Common Stock, Shares Outstanding | 77,225,329 | ||
Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement relating to the registrant’s 2024 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission, or the SEC, within 120 days following the end of the Company’s fiscal year, are incorporated by reference in Part III of this Annual Report on Form 10-K as indicated herein. | ||
Entity Central Index Key | 0001414932 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Audit Information
Audit Information | 12 Months Ended |
Sep. 30, 2023 | |
Audit Information [Abstract] | |
Auditor Name | Ernst & Young LLP |
Auditor Location | Los Angeles, CA |
Auditor Firm ID | 42 |
Consolidated Statements of Asse
Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 | |||
ASSETS | |||||
Investments at fair value | $ 2,892,420 | $ 2,494,111 | |||
Cash and cash equivalents | 136,450 | 23,528 | |||
Restricted cash | 9,089 | 2,836 | |||
Interest, dividends and fees receivable | 44,570 | 35,598 | |||
Due from portfolio companies | 6,317 | 22,495 | |||
Receivables from unsettled transactions | 55,441 | 4,692 | |||
Due from broker | 54,260 | 45,530 | |||
Deferred financing costs | 12,541 | 7,350 | |||
Deferred offering costs | 160 | 32 | |||
Deferred tax asset, net | 0 | 1,687 | |||
Derivative assets at fair value | 4,910 | 6,789 | |||
Other assets | 1,681 | 1,665 | |||
Total assets | 3,217,839 | 2,646,313 | |||
Liabilities: | |||||
Accounts payable, accrued expenses and other liabilities | 2,950 | 3,701 | |||
Base management fee and incentive fee payable | 19,547 | 15,940 | |||
Due to affiliate | 4,310 | 3,180 | |||
Interest payable | 16,007 | 7,936 | |||
Payables from unsettled transactions | 11,006 | 26,981 | |||
Derivative liability at fair value | 47,519 | 41,969 | |||
Deferred tax liability | 5 | 0 | |||
Credit facilities payable | 710,000 | 700,000 | |||
Unsecured notes payable (net of $7,076 and $5,020 of unamortized financing costs as of September 30, 2023 and September 30, 2022, respectively) | 890,731 | 601,043 | |||
Total liabilities | 1,702,075 | 1,400,750 | |||
Commitments and contingencies (Note 13) | |||||
Net assets: | |||||
Common stock, $0.01 par value per share, 250,000 shares authorized; 77,225 and 61,125 shares issued and outstanding as of September 30, 2023 and September 30, 2022, respectively | [1] | 772 | 611 | ||
Additional paid-in-capital | 2,166,330 | 1,827,721 | |||
Accumulated overdistributed earnings | (651,338) | (582,769) | |||
Total net assets (equivalent to $19.63 and $20.38 per common share as of September 30, 2023 and September 30, 2022, respectively) (Note 11) | [1] | 1,515,764 | 1,245,563 | ||
Total liabilities and net assets | 3,217,839 | 2,646,313 | |||
Control investments | |||||
ASSETS | |||||
Investments at fair value | 297,091 | [2],[3] | 214,165 | [4],[5] | |
Affiliate investments | |||||
ASSETS | |||||
Investments at fair value | 23,349 | 26,196 | |||
Non-control/Non-affiliate investments | |||||
ASSETS | |||||
Investments at fair value | $ 2,571,980 | [6] | $ 2,253,750 | [7] | |
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The issued and outstanding shares and net asset value per share reflect the reverse stock split on a retroactive basis.[2]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[3]Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[4]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[5]Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[6]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.[7]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. |
Consolidated Statements of As_2
Consolidated Statements of Assets and Liabilities (Parenthetical) shares in Thousands, $ in Thousands | 12 Months Ended | ||||
Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | ||||
Investment, cost | $ 3,044,119 | $ 2,617,754 | |||
Unamortized financing costs | $ 7,076 | $ 5,020 | |||
Common stock, par value, (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | |||
Common stock, shares authorized (in shares) | shares | 250,000 | 250,000 | |||
Common stock, shares issued (in shares) | shares | 77,225 | 61,125 | |||
Common stock, shares outstanding (in shares) | shares | [1] | 77,225 | 61,125 | ||
Net asset value per common share (in dollars per share) | $ / shares | [1] | $ 19.63 | $ 20.38 | ||
Stock split, conversion ratio | 0.3333 | ||||
Control investments | |||||
Investment, cost | $ 345,245 | [2],[3] | $ 260,305 | [4],[5] | |
Affiliate investments | |||||
Investment, cost | 24,898 | 27,353 | |||
Non-control/Non-affiliate investments | |||||
Investment, cost | $ 2,673,976 | [6] | $ 2,330,096 | [7] | |
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis.[2]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[3]Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[4]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[5]Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[6]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.[7]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. |
Consolidated Statements of Oper
Consolidated Statements of Operations shares in Thousands, $ in Thousands | 12 Months Ended | |||
Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) $ / shares shares | ||
Investment Income | ||||
Interest on cash and cash equivalents | $ 4,080 | $ 452 | $ 9 | |
Total interest income | 348,765 | 228,916 | 174,381 | |
Interest income, PIK | 19,764 | 20,526 | 16,447 | |
Fee income | 6,546 | 6,631 | 14,098 | |
Dividend income | 4,211 | 6,447 | 4,459 | |
Total investment income | 379,286 | 262,520 | 209,385 | |
Expenses: | ||||
Base management fee | 44,899 | 39,556 | 32,288 | |
Part I incentive fee | 35,831 | 26,644 | 21,598 | |
Part II incentive fee | 0 | (8,791) | 17,615 | |
Professional fees | 6,244 | 4,418 | 4,231 | |
Directors fees | 640 | 603 | 607 | |
Interest expense | 111,642 | 46,929 | 30,518 | |
Administrator expense | 1,252 | 1,246 | 1,510 | |
General and administrative expenses | 3,528 | 2,986 | 2,725 | |
Total expenses | 204,036 | 113,591 | 111,092 | |
Fees waived | (5,525) | (3,000) | (1,608) | |
Net expenses | 198,511 | 110,591 | 109,484 | |
Net investment income before taxes | 180,775 | 151,929 | 99,901 | |
(Provision) benefit for taxes on net investment income | 0 | (3,308) | (2,795) | |
Excise tax | (78) | 0 | 0 | |
Net investment income | 180,697 | 148,621 | 97,106 | |
Unrealized appreciation (depreciation): | ||||
Foreign currency forward contracts | 59 | 4,877 | 1,689 | |
Net unrealized appreciation (depreciation) | (28,555) | (136,248) | 114,519 | |
Realized gains (losses): | ||||
Foreign currency forward contracts | (5,765) | 13,726 | (674) | |
Net realized gains (losses) | (33,155) | 17,179 | 26,420 | |
(Provision) benefit for taxes on realized and unrealized gains (losses) | (1,656) | (329) | (785) | |
Net realized and unrealized gains (losses), net of taxes | (63,366) | (119,398) | 140,154 | |
Net increase (decrease) in net assets resulting from operations | $ 117,331 | $ 29,223 | $ 237,260 | |
Net investment income per common share - basic and diluted (in dollars per share) | $ / shares | [1] | $ 2.51 | $ 2.45 | $ 1.80 |
Earnings (loss) per common share - basic (dollars per share) | $ / shares | [1] | 1.63 | 0.48 | 4.39 |
Earnings (loss) per common share - diluted (dollars per share) | $ / shares | [1] | $ 1.63 | $ 0.48 | $ 4.39 |
Weighted average common shares outstanding - basic (shares) | shares | [1] | 72,119 | 60,727 | 54,039 |
Weighted average common shares outstanding - diluted (shares) | shares | [1] | 72,119 | 60,727 | 54,039 |
Stock split, conversion ratio | 0.3333 | |||
Control investments | ||||
Investment Income | ||||
Interest income | $ 21,203 | $ 14,043 | $ 11,792 | |
Interest income, PIK | 309 | 0 | 0 | |
Fee income | 51 | 50 | 59 | |
Dividend income | 4,200 | 6,366 | 4,459 | |
Unrealized appreciation (depreciation): | ||||
Net unrealized appreciation (depreciation) | (2,014) | (33,306) | 31,731 | |
Realized gains (losses): | ||||
Realized gain (loss) | 0 | 1,868 | 0 | |
Affiliate investments | ||||
Investment Income | ||||
Interest income | 2,620 | 1,744 | 716 | |
Fee income | 20 | 20 | 20 | |
Unrealized appreciation (depreciation): | ||||
Net unrealized appreciation (depreciation) | (392) | (683) | 568 | |
Non-control/Non-affiliate investments | ||||
Investment Income | ||||
Interest income | 320,862 | 212,677 | 161,864 | |
Interest income, PIK | 19,455 | 20,526 | 16,447 | |
Fee income | 6,475 | 6,561 | 14,019 | |
Dividend income | 11 | 81 | 0 | |
Unrealized appreciation (depreciation): | ||||
Net unrealized appreciation (depreciation) | (26,208) | (107,136) | 80,531 | |
Realized gains (losses): | ||||
Realized gain (loss) | $ (27,390) | $ 1,585 | $ 27,094 | |
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis. |
Consolidated Statements of Chan
Consolidated Statements of Changes in Net Assets shares in Thousands, $ in Thousands | 12 Months Ended | |||||
Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) $ / shares shares | ||||
Operations: | ||||||
Net investment income | $ 180,697 | $ 148,621 | $ 97,106 | |||
Net unrealized appreciation (depreciation) | (28,555) | (136,248) | 114,519 | |||
Net realized gains (losses) | (33,155) | 17,179 | 26,420 | |||
(Provision) benefit for taxes on realized and unrealized gains (losses) | (1,656) | (329) | (785) | |||
Net increase (decrease) in net assets resulting from operations | 117,331 | 29,223 | 237,260 | |||
Stockholder transactions: | ||||||
Net increase (decrease) in net assets from stockholder transactions | (185,900) | (118,657) | (82,020) | |||
Capital share transactions: | ||||||
Issuance of common stock in connection with mergers | 334,034 | 0 | 242,704 | |||
Issuance of common stock under dividend reinvestment plan | 5,854 | 3,409 | 2,170 | |||
Repurchase of common stock under dividend reinvestment plan | (2,418) | (1,857) | (2,170) | |||
Issuance of common stock in connection with the "at the market" offering | 1,300 | 20,622 | 0 | |||
Net increase (decrease) in net assets from capital share transactions | 338,770 | 22,174 | 242,704 | |||
Total increase (decrease) in net assets | 270,201 | (67,260) | 397,944 | |||
Net assets | $ 1,515,764 | [1] | $ 1,245,563 | [1] | $ 1,312,823 | |
Net asset value per common share (in dollars per share) | $ / shares | [2] | $ 19.63 | $ 20.38 | $ 21.84 | ||
Common shares outstanding at end of period (in shares) | shares | [2] | 77,225 | 61,125 | 60,120 | ||
Stock split, conversion ratio | 0.3333 | |||||
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The issued and outstanding shares and net asset value per share reflect the reverse stock split on a retroactive basis.[2]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis. |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Operating activities: | |||
Net increase (decrease) in net assets resulting from operations | $ 117,331 | $ 29,223 | $ 237,260 |
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities: | |||
Net unrealized (appreciation) depreciation | 28,555 | 136,248 | (114,519) |
Net realized (gains) losses | 33,155 | (17,179) | (26,420) |
PIK interest income | (19,764) | (20,526) | (16,447) |
Accretion of original issue discount on investments | (22,314) | (29,091) | (29,391) |
Accretion of original issue discount on unsecured notes payable | 783 | 679 | 572 |
Amortization of deferred financing costs | 4,599 | 3,740 | 4,151 |
Deferred taxes | 1,670 | (973) | 133 |
Purchases of investments | (742,144) | (702,063) | (1,120,168) |
Proceeds from the sales and repayments of investments | 911,975 | 693,745 | 792,161 |
Cash received from mergers | 22,317 | 0 | 20,945 |
Changes in operating assets and liabilities: | |||
(Increase) decrease in interest, dividends and fees receivable | 578 | (16,115) | (8,495) |
(Increase) decrease in due from portfolio companies | 16,283 | (20,505) | 1,360 |
(Increase) decrease in receivables from unsettled transactions | (50,742) | 3,458 | 2,514 |
(Increase) decrease in due from broker | (8,730) | (43,890) | (1,640) |
(Increase) decrease in other assets | 14 | 619 | (1,427) |
Increase (decrease) in accounts payable, accrued expenses and other liabilities | (53,118) | 677 | (426) |
Increase (decrease) in base management fee and incentive fee payable | (489) | (16,709) | 19,516 |
Increase (decrease) in due to affiliate | 408 | (1,177) | 1,119 |
Increase (decrease) in interest payable | 4,379 | 3,339 | 1,163 |
Increase (decrease) in payables from unsettled transactions | (15,975) | 18,895 | 7,608 |
Increase (decrease) in director fees payable | (9) | 0 | (90) |
Net cash provided by (used in) operating activities | 228,762 | 22,395 | (230,521) |
Financing activities: | |||
Distributions paid in cash | (180,046) | (115,248) | (79,850) |
Borrowings under credit facilities | 572,000 | 300,000 | 505,000 |
Repayments of borrowings under credit facilities | (787,000) | (230,000) | (529,582) |
Issuance of unsecured notes | 296,511 | 0 | 349,020 |
Repayments of secured borrowings | 0 | 0 | (9,341) |
Shares issued under the "at the market" offering | 1,370 | 20,839 | 0 |
Repurchases of common stock under dividend reinvestment plan | (2,418) | (1,857) | (2,170) |
Deferred financing costs paid | (10,596) | (334) | (8,890) |
Offering costs paid | (235) | (215) | 0 |
Net cash provided by (used in) financing activities | (110,414) | (26,815) | 224,187 |
Effect of exchange rate changes on foreign currency | 827 | (851) | (1,127) |
Net increase (decrease) in cash and cash equivalents and restricted cash | 119,175 | (5,271) | (7,461) |
Cash and cash equivalents and restricted cash, beginning of period | 26,364 | 31,635 | 39,096 |
Cash and cash equivalents and restricted cash, end of period | 145,539 | 26,364 | 31,635 |
Supplemental information: | |||
Cash paid for interest | 98,189 | 39,171 | 24,006 |
Non-cash financing activities: | |||
Issuance of shares of common stock under dividend reinvestment plan | 3,436 | 3,409 | 2,170 |
Deferred financing costs | 442 | 0 | (162) |
Deferred offering costs | 12 | 0 | 0 |
Issuance of shares in connection with mergers | 334,034 | 0 | 242,704 |
Reconciliation to the Consolidated Statements of Assets and Liabilities | |||
Cash and cash equivalents | 136,450 | 23,528 | 29,334 |
Restricted cash | 9,089 | 2,836 | 2,301 |
Total cash and cash equivalents and restricted cash | $ 145,539 | $ 26,364 | $ 31,635 |
Consolidated Schedule of Invest
Consolidated Schedule of Investments € in Thousands, £ in Thousands, $ in Thousands | Sep. 30, 2023 USD ($) shares | Sep. 30, 2023 EUR (€) shares | Sep. 30, 2023 GBP (£) shares | Sep. 30, 2022 USD ($) shares | Sep. 30, 2022 EUR (€) shares | Sep. 30, 2022 GBP (£) shares | Sep. 30, 2021 USD ($) | |||||||
Investment, cost | $ 3,044,119 | $ 2,617,754 | ||||||||||||
Investments at fair value | $ 2,892,420 | $ 2,494,111 | ||||||||||||
Investment owned, percent of net assets | 190.82% | 190.82% | 190.82% | 200.24% | 200.24% | 200.24% | ||||||||
Money market funds, at carrying value | $ 145,539 | $ 26,364 | ||||||||||||
Money market funds, percent of net assets | 9.60% | 9.60% | 9.60% | 2.10% | 2.10% | 2.10% | ||||||||
Investment owned and money market funds, percent of net assets | 200.40% | 200.40% | 200.40% | 202.40% | 202.40% | 202.40% | ||||||||
Total investment owned, at cost and money market funds, at carrying value | $ 3,189,658 | [1],[2],[3],[4] | $ 2,644,118 | |||||||||||
Total investment owned, at fair value and money market funds, at carrying value | 3,037,959 | [1],[2],[3],[4] | $ 2,520,475 | |||||||||||
Control investments | ||||||||||||||
Investment owned, ownership percentage | [5],[6] | 17.20% | 17.20% | 17.20% | ||||||||||
Investment, principal | 209,970 | $ 170,245 | ||||||||||||
Investment, cost | 345,245 | [7],[8] | 260,305 | [5],[6] | ||||||||||
Investments at fair value | $ 297,091 | [7],[8] | $ 214,165 | [5],[6] | $ 270,765 | |||||||||
Investment owned, percent of net assets | 19.60% | [7],[8] | 19.60% | [7],[8] | 19.60% | [7],[8] | 17.20% | 17.20% | 17.20% | |||||
Affiliate Investments | ||||||||||||||
Investment, interest rate | [9] | 2.10% | 2.10% | 2.10% | ||||||||||
Investment, principal | $ 21,852 | $ 24,490 | ||||||||||||
Investment, cost | 24,898 | [10] | 27,353 | [9] | ||||||||||
Investments at fair value | $ 23,349 | [10] | $ 26,196 | [9] | 18,289 | |||||||||
Investment owned, percent of net assets | 1.50% | [10] | 1.50% | [10] | 1.50% | [10] | 2.10% | 2.10% | 2.10% | |||||
Non-control/Non-affiliate investments | ||||||||||||||
Investment, cost | $ 2,673,976 | [11] | $ 2,330,096 | [12] | ||||||||||
Investments at fair value | $ 2,571,980 | [11] | $ 2,253,750 | [12] | ||||||||||
Investment owned, percent of net assets | 169.70% | [11] | 169.70% | [11] | 169.70% | [11] | 180.90% | [12] | 180.90% | [12] | 180.90% | [12] | ||
Investment, Identifier [Axis]: 107 Fair Street LLC, Real Estate Development, First Lien Term Loan | ||||||||||||||
Investment, interest rate | [11],[13],[14],[15],[16],[17] | 12.50% | 12.50% | 12.50% | ||||||||||
Investment, principal | [11],[13],[15],[17],[18] | $ 1,269 | ||||||||||||
Investment, cost | [11],[13],[15],[17] | 1,240 | ||||||||||||
Investments at fair value | [11],[13],[15],[17] | $ 1,214 | ||||||||||||
Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC, Real Estate Development, First Lien Revolver | ||||||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 11% | 11% | 11% | ||||||||||
Investment, principal | [11],[13],[15],[18] | $ 18,869 | ||||||||||||
Investment, cost | [11],[13],[15] | 18,687 | ||||||||||||
Investments at fair value | [11],[13],[15] | $ 18,443 | ||||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.80% | 9.80% | 9.80% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 389 | ||||||||||||
Investment, cost | [12],[19],[20] | 387 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 727 | ||||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 7% | 7% | 7% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | (31) | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan | ||||||||||||||
Investment, interest rate | [11],[13],[14],[15],[16],[17] | 12% | 12% | 12% | ||||||||||
Investment, principal | [11],[13],[15],[17],[18] | $ 4,070 | ||||||||||||
Investment, cost | [11],[13],[15],[17] | 4,038 | ||||||||||||
Investments at fair value | [11],[13],[15],[17] | $ 4,022 | ||||||||||||
Investment, Identifier [Axis]: A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24],[25] | 14.25% | 14.25% | 14.25% | ||||||||||
Investment, principal | [11],[13],[18],[24],[25] | $ 21,434 | ||||||||||||
Investment, cost | [11],[13],[24],[25] | 21,612 | ||||||||||||
Investments at fair value | [11],[13],[24],[25] | $ 21,220 | ||||||||||||
Investment, Identifier [Axis]: A.T. Holdings II SÀRL, Biotechnology, First Lien Term Loan | ||||||||||||||
Investment, interest rate, paid in kind | 20% | [11],[13],[24] | 20% | [11],[13],[24] | 20% | [11],[13],[24] | 10.50% | [12],[19],[26] | 10.50% | [12],[19],[26] | 10.50% | [12],[19],[26] | ||
Investment, principal | $ 6,021 | [11],[13],[18],[24] | $ 33,997 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 6,013 | [11],[13],[24] | 33,960 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 5,900 | [11],[13],[24] | $ 34,891 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6.25% | 6.25% | 6.25% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.80% | 9.80% | 9.80% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 14,685 | ||||||||||||
Investment, cost | [12],[19],[20] | 14,217 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 14,431 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.90% | 11.90% | 11.90% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 3,446 | ||||||||||||
Investment, cost | [11],[13],[16] | 3,411 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 3,383 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.15% | 12.15% | 12.15% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 17,901 | ||||||||||||
Investment, cost | [11],[13],[16] | 17,743 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 17,575 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.13% | 12.13% | 12.13% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 963 | ||||||||||||
Investment, cost | [11],[13],[16] | 948 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 945 | ||||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[16],[24] | 7.50% | [11],[13],[16],[24] | 7.50% | [11],[13],[16],[24] | 7.50% | [12],[19],[20],[26] | 7.50% | [12],[19],[20],[26] | 7.50% | [12],[19],[20],[26] | ||
Investment, interest rate | 13.04% | [11],[13],[14],[16],[24] | 13.04% | [11],[13],[14],[16],[24] | 13.04% | [11],[13],[14],[16],[24] | 11.20% | [12],[19],[20],[21],[26] | 11.20% | [12],[19],[20],[21],[26] | 11.20% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 6,589 | [11],[13],[16],[18],[24] | $ 6,589 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 6,305 | [11],[13],[16],[24] | 6,256 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 6,276 | [11],[13],[16],[24] | $ 6,262 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[15],[24] | 7.50% | [11],[13],[15],[24] | 7.50% | [11],[13],[15],[24] | 7.50% | [12],[19],[20],[23],[26] | 7.50% | [12],[19],[20],[23],[26] | 7.50% | [12],[19],[20],[23],[26] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18],[24] | $ 0 | [12],[19],[20],[22],[23],[26] | ||||||||||
Investment, cost | (38) | [11],[13],[15],[16],[24] | (38) | [12],[19],[20],[23],[26] | ||||||||||
Investments at fair value | $ (38) | [11],[13],[15],[16],[24] | $ (37) | [12],[19],[20],[23],[26] | ||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 28,948 | [11],[13],[24] | 28,948 | [11],[13],[24] | 28,948 | [11],[13],[24] | 28,948 | [12],[19],[26] | 28,948 | [12],[19],[26] | 28,948 | [12],[19],[26] | ||
Investment, cost | $ 174 | [11],[13],[24] | $ 174 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 6 | [11],[13],[24] | $ 73 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[16],[24] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [11],[14],[16],[24] | 8.86% | 8.86% | 8.86% | ||||||||||
Investment, principal | € | [11],[16],[18],[24] | € 5,500 | ||||||||||||
Investment, cost | [11],[16],[24] | $ 6,024 | ||||||||||||
Investments at fair value | [11],[16],[24] | $ 5,825 | ||||||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[26] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 7.94% | 7.94% | 7.94% | ||||||||||
Investment, principal | € | [12],[19],[20],[22],[26] | € 24,838 | ||||||||||||
Investment, cost | [12],[19],[20],[26] | $ 27,752 | ||||||||||||
Investments at fair value | [12],[19],[20],[26] | $ 22,143 | ||||||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 17,870 | [11],[13] | 17,870 | [11],[13] | 17,870 | [11],[13] | 14,410 | [12],[19] | 14,410 | [12],[19] | 14,410 | [12],[19] | ||
Investment, cost | $ 1,733 | [11],[13] | $ 1,352 | [12],[19] | ||||||||||
Investments at fair value | $ 2,826 | [11],[13] | $ 1,291 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.75% | [11],[13],[16] | 7.75% | [11],[13],[16] | 7.75% | [11],[13],[16] | 7.75% | [12],[19],[20] | 7.75% | [12],[19],[20] | 7.75% | [12],[19],[20] | ||
Investment, interest rate | 13.17% | [11],[13],[14],[16] | 13.17% | [11],[13],[14],[16] | 13.17% | [11],[13],[14],[16] | 10.88% | [12],[19],[20],[21] | 10.88% | [12],[19],[20],[21] | 10.88% | [12],[19],[20],[21] | ||
Investment, principal | $ 17,873 | [11],[13],[16],[18] | $ 14,414 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 17,655 | [11],[13],[16] | 14,154 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 17,687 | [11],[13],[16] | $ 13,910 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: APX Group Inc., Electrical Components & Equipment, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, principal | [12],[22],[26] | $ 2,075 | ||||||||||||
Investment, cost | [12],[26] | 1,733 | ||||||||||||
Investments at fair value | [12],[26] | $ 1,645 | ||||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [12],[22] | $ 5,500 | ||||||||||||
Investment, cost | [12] | 5,408 | ||||||||||||
Investments at fair value | [12] | $ 3,641 | ||||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, principal | [12],[22] | $ 2,500 | ||||||||||||
Investment, cost | [12] | 2,220 | ||||||||||||
Investments at fair value | [12] | $ 1,926 | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[24] | 6% | 6% | 6% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[24] | (13) | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[24] | $ (23) | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 11.63% | 11.63% | 11.63% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 3,276 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 3,267 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | 3,084 | ||||||||||||
Investment, Identifier [Axis]: ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment, principal | [11],[13],[18],[24],[25] | 12,222 | ||||||||||||
Investment, cost | [11],[13],[24],[25] | 12,260 | ||||||||||||
Investments at fair value | [11],[13],[24],[25] | $ 11,795 | ||||||||||||
Investment, Identifier [Axis]: Access CIG, LLC, Diversified Support Services, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [12],[20],[21] | 10.82% | 10.82% | 10.82% | ||||||||||
Investment, principal | [12],[20],[22] | $ 20,000 | ||||||||||||
Investment, cost | [12],[20] | 19,927 | ||||||||||||
Investments at fair value | [12],[20] | $ 19,075 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 11.55% | 11.55% | 11.55% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 2,033 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 2,013 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 2,027 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.55% | 11.55% | 11.55% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 20,234 | ||||||||||||
Investment, cost | [11],[13],[16] | 20,150 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 20,194 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | |||||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (2) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (8) | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 9.14% | 9.14% | 9.14% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 500 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 462 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 495 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 15,976 | ||||||||||||
Investment, cost | [12],[19],[20] | 15,686 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 15,944 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 0 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ (6) | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 7% | [12],[19],[20],[23] | 7% | [12],[19],[20],[23] | 7% | [12],[19],[20],[23] | ||
Investment, interest rate | 12.72% | [11],[13],[14],[15],[16] | 12.72% | [11],[13],[14],[15],[16] | 12.72% | [11],[13],[14],[15],[16] | 10.64% | [12],[19],[20],[21],[23] | 10.64% | [12],[19],[20],[21],[23] | 10.64% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 1,333 | [11],[13],[15],[16],[18] | $ 914 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 1,322 | [11],[13],[15],[16] | 890 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 1,324 | [11],[13],[15],[16] | $ 898 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.63% | 9.63% | 9.63% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 27,349 | ||||||||||||
Investment, cost | [12],[19],[20] | 27,038 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 27,158 | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.34% | 12.34% | 12.34% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 6,400 | ||||||||||||
Investment, cost | [11],[13],[16] | 6,335 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 6,380 | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.34% | 12.34% | 12.34% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 25,332 | ||||||||||||
Investment, cost | [11],[13],[16] | 25,288 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 25,253 | ||||||||||||
Investment, Identifier [Axis]: Aden & Anais Merger Sub, Inc., Apparel, Accessories & Luxury Goods, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 51,645 | 51,645 | 51,645 | ||||||||||
Investment, cost | [12],[19] | $ 5,165 | ||||||||||||
Investments at fair value | [12],[19] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: AirStrip Technologies, Inc., Application Software, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 5,715 | [11],[13] | 5,715 | [11],[13] | 5,715 | [11],[13] | 5,715 | [12],[19] | 5,715 | [12],[19] | 5,715 | [12],[19] | ||
Investment, cost | $ 90 | [11],[13] | $ 90 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 11.64% | 11.64% | 11.64% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 23,338 | ||||||||||||
Investment, cost | [12],[19],[20] | 22,057 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 22,141 | ||||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[27] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [11],[13],[16],[18],[27] | $ 23,562 | ||||||||||||
Investment, cost | [11],[13],[16],[27] | 22,795 | ||||||||||||
Investments at fair value | [11],[13],[16],[27] | $ 9,797 | ||||||||||||
Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | 5.50% | [11],[14],[16],[24] | 5.50% | [11],[14],[16],[24] | 5.50% | [11],[14],[16],[24] | 5.50% | [12],[20],[21],[26] | 5.50% | [12],[20],[21],[26] | 5.50% | [12],[20],[21],[26] | ||
Investment, principal | $ 4,050 | [11],[18],[24] | $ 4,050 | [12],[22],[26] | ||||||||||
Investment, cost | 3,577 | [11],[24] | 3,518 | [12],[26] | ||||||||||
Investments at fair value | $ 2,918 | [11],[24] | $ 3,057 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 11.50% | 11.50% | 11.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[16] | 11.99% | 11.99% | 11.99% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 9,057 | ||||||||||||
Investment, cost | [11],[13],[16] | 8,434 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 8,332 | ||||||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 598,283 | 598,283 | 598,283 | ||||||||||
Investment, cost | [11],[13] | $ 642 | ||||||||||||
Investments at fair value | [11],[13] | $ 1,915 | ||||||||||||
Investment, Identifier [Axis]: Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | ||
Investment, interest rate | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 11.20% | [12],[19],[20],[21] | 11.20% | [12],[19],[20],[21] | 11.20% | [12],[19],[20],[21] | ||
Investment, principal | $ 17,053 | [11],[13],[16],[18] | $ 13,134 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 16,982 | [11],[13],[16] | 12,847 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 15,929 | [11],[13],[16] | $ 13,068 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 10% | 10% | 10% | ||||||||||
Investment, principal | [12],[19],[22],[26] | $ 24,043 | ||||||||||||
Investment, cost | [12],[19],[26] | 23,747 | ||||||||||||
Investments at fair value | [12],[19],[26] | $ 23,923 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | 471,253 | [11],[24] | 471,253 | [11],[24] | 471,253 | [11],[24] | 587,930 | [12],[26] | 587,930 | [12],[26] | 587,930 | [12],[26] | ||
Investment, cost | $ 849 | [11],[24] | $ 5,308 | [12],[26] | ||||||||||
Investments at fair value | $ 4,298 | [11],[24] | $ 3,974 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | 141,640 | [11],[13],[24],[28] | 141,640 | [11],[13],[24],[28] | 141,640 | [11],[13],[24],[28] | 124,780 | [12],[19],[26],[29] | 124,780 | [12],[19],[26],[29] | 124,780 | [12],[19],[26],[29] | ||
Investment, cost | $ 566 | [11],[13],[24],[28] | $ 485 | [12],[19],[26],[29] | ||||||||||
Investments at fair value | $ 368 | [11],[13],[24],[28] | $ 212 | [12],[19],[26],[29] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 3.50% | 3.50% | 3.50% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 28,464 | ||||||||||||
Investment, cost | [11],[13],[24] | 28,329 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 27,687 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 3.50% | 3.50% | 3.50% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 2,121 | ||||||||||||
Investment, cost | [11],[13],[24] | 1,945 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 2,063 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 3 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 3.50% | 3.50% | 3.50% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 27,692 | ||||||||||||
Investment, cost | [11],[13],[24] | 27,582 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 26,936 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 4 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 3.50% | 3.50% | 3.50% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 2,064 | ||||||||||||
Investment, cost | [11],[13],[24] | 1,891 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 2,007 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 10% | 10% | 10% | ||||||||||
Investment, principal | [12],[19],[22],[26] | $ 23,522 | ||||||||||||
Investment, cost | [12],[19],[26] | 23,264 | ||||||||||||
Investments at fair value | [12],[19],[26] | $ 23,404 | ||||||||||||
Investment, Identifier [Axis]: American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8.75% | [11],[13],[16] | 8.75% | [11],[13],[16] | 8.75% | [11],[13],[16] | 8.75% | [12],[19],[20] | 8.75% | [12],[19],[20] | 8.75% | [12],[19],[20] | ||
Investment, interest rate | 14.14% | [11],[13],[14],[16] | 14.14% | [11],[13],[14],[16] | 14.14% | [11],[13],[14],[16] | 12.30% | [12],[19],[20],[21] | 12.30% | [12],[19],[20],[21] | 12.30% | [12],[19],[20],[21] | ||
Investment, principal | $ 17,048 | [11],[13],[16],[18] | $ 14,760 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 16,440 | [11],[13],[16] | 14,492 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 15,087 | [11],[13],[16] | $ 13,284 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: American Tire Distributors, Inc., Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | [11],[16] | 6.25% | [11],[16] | 6.25% | [11],[16] | 6.25% | [12],[20] | 6.25% | [12],[20] | 6.25% | [12],[20] | ||
Investment, interest rate | 11.81% | [11],[14],[16] | 11.81% | [11],[14],[16] | 11.81% | [11],[14],[16] | 9.03% | [12],[20],[21] | 9.03% | [12],[20],[21] | 9.03% | [12],[20],[21] | ||
Investment, principal | $ 19,115 | [11],[16],[18] | $ 9,895 | [12],[20],[22] | ||||||||||
Investment, cost | 18,278 | [11],[16] | 9,772 | [12],[20] | ||||||||||
Investments at fair value | $ 16,798 | [11],[16] | $ 9,293 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[26] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 7.92% | 7.92% | 7.92% | ||||||||||
Investment, principal | [12],[19],[20],[22],[26] | $ 15,220 | ||||||||||||
Investment, cost | [12],[19],[20],[26] | 13,973 | ||||||||||||
Investments at fair value | [12],[19],[20],[26] | $ 14,687 | ||||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[16],[24] | 8% | [11],[13],[16],[24] | 8% | [11],[13],[16],[24] | 8% | [12],[19],[20],[26] | 8% | [12],[19],[20],[26] | 8% | [12],[19],[20],[26] | ||
Investment, interest rate | 13.54% | [11],[13],[14],[16],[24] | 13.54% | [11],[13],[14],[16],[24] | 13.54% | [11],[13],[14],[16],[24] | 11.67% | [12],[19],[20],[21],[26] | 11.67% | [12],[19],[20],[21],[26] | 11.67% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 12,500 | [11],[13],[16],[18],[24] | $ 12,500 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 12,188 | [11],[13],[16],[24] | 12,188 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 11,865 | [11],[13],[16],[24] | $ 11,958 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[16] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [11],[14],[16] | 9.40% | 9.40% | 9.40% | ||||||||||
Investment, principal | [11],[16],[18] | $ 3,700 | ||||||||||||
Investment, cost | [11],[16] | 3,067 | ||||||||||||
Investments at fair value | [11],[16] | $ 2,669 | ||||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Products, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.42% | 7.42% | 7.42% | ||||||||||
Investment, principal | [12],[20],[22] | $ 2,736 | ||||||||||||
Investment, cost | [12],[20] | 2,260 | ||||||||||||
Investments at fair value | [12],[20] | $ 2,189 | ||||||||||||
Investment, Identifier [Axis]: Ankura Consulting Group LLC, Research & Consulting Services, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.78% | 10.78% | 10.78% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 4,346 | ||||||||||||
Investment, cost | [12],[19],[20] | 4,281 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 3,813 | ||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 8.46% | 8.46% | 8.46% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 892 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 863 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 846 | ||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 8.46% | 8.46% | 8.46% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 34,458 | ||||||||||||
Investment, cost | [12],[19],[20] | 33,737 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 33,738 | ||||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 7% | [12],[19],[20],[26] | 7% | [12],[19],[20],[26] | 7% | [12],[19],[20],[26] | ||
Investment, interest rate | 10.95% | [11],[13],[14],[16],[24] | 10.95% | [11],[13],[14],[16],[24] | 10.95% | [11],[13],[14],[16],[24] | 8% | [12],[19],[20],[21],[26] | 8% | [12],[19],[20],[21],[26] | 8% | [12],[19],[20],[21],[26] | ||
Investment, principal | € | € 3,017 | [11],[13],[16],[18],[24] | € 1,964 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | $ 3,331 | [11],[13],[16],[24] | $ 2,176 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 3,226 | [11],[13],[16],[24] | $ 1,927 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | [11],[13],[16],[24] | 5.75% | [11],[13],[16],[24] | 5.75% | [11],[13],[16],[24] | 7% | [12],[19],[20],[26] | 7% | [12],[19],[20],[26] | 7% | [12],[19],[20],[26] | ||
Investment, interest rate | 11.57% | [11],[13],[14],[16],[24] | 11.57% | [11],[13],[14],[16],[24] | 11.57% | [11],[13],[14],[16],[24] | 9.19% | [12],[19],[20],[21],[26] | 9.19% | [12],[19],[20],[21],[26] | 9.19% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 10,519 | [11],[13],[16],[18],[24] | £ 18,636 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 10,400 | [11],[13],[16],[24] | $ 23,139 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 10,624 | [11],[13],[16],[24] | $ 20,826 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 5.75% | [12],[19],[20],[26] | 5.75% | [12],[19],[20],[26] | 5.75% | [12],[19],[20],[26] | ||
Investment, interest rate | 12.46% | [11],[13],[14],[16],[24] | 12.46% | [11],[13],[14],[16],[24] | 12.46% | [11],[13],[14],[16],[24] | 8.81% | [12],[19],[20],[21],[26] | 8.81% | [12],[19],[20],[21],[26] | 8.81% | [12],[19],[20],[21],[26] | ||
Investment, principal | £ 4,949 | [11],[13],[16],[18],[24] | $ 10,519 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | $ 6,318 | [11],[13],[16],[24] | 10,357 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 6,101 | [11],[13],[16],[24] | $ 10,328 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 7% | [11],[13],[16],[24] | 5.75% | [12],[19],[20],[23],[26] | 5.75% | [12],[19],[20],[23],[26] | 5.75% | [12],[19],[20],[23],[26] | ||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.46% | 12.46% | 12.46% | ||||||||||
Investment, principal | £ | £ 23,675 | [11],[13],[16],[18],[24] | £ 0 | [12],[19],[20],[22],[23],[26] | ||||||||||
Investment, cost | $ 28,713 | [11],[13],[16],[24] | $ (44) | [12],[19],[20],[23],[26] | ||||||||||
Investments at fair value | $ 29,185 | [11],[13],[16],[24] | 0 | [12],[19],[20],[23],[26] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 9.70% | 9.70% | 9.70% | ||||||||||
Investment, principal | £ | [11],[13],[16],[18],[24] | £ 3,649 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | $ 4,094 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 3,914 | ||||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | 1,783,332 | 1,783,332 | |||||||||||
Investments at fair value | $ 89 | 370 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | 6.75% | 6.75% | |||||||||||
Investment, interest rate | 12.14% | 12.14% | 12.14% | |||||||||||
Investment, principal | $ 21,852 | |||||||||||||
Investments at fair value | $ 21,823 | 24,225 | ||||||||||||
Investment owned, percent of net assets | 1.40% | 1.40% | 1.40% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | 1,129,453 | 1,129,453 | |||||||||||
Investments at fair value | $ 1,005 | $ 1,223 | ||||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | [10],[13] | 1,783,332 | [10],[13] | 1,783,332 | [10],[13] | 1,609,201 | [9],[19] | 1,609,201 | [9],[19] | 1,609,201 | [9],[19] | ||
Investment, cost | $ 804 | [10],[13] | $ 764 | [9],[19] | ||||||||||
Investments at fair value | $ 89 | [10],[13] | $ 370 | [9],[19] | 587 | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [10],[13],[15],[16] | 6.75% | [10],[13],[15],[16] | 6.75% | [10],[13],[15],[16] | 6.75% | [9],[19],[20],[23] | 6.75% | [9],[19],[20],[23] | 6.75% | [9],[19],[20],[23] | ||
Investment, interest rate | 12.14% | [10],[13],[14],[15],[16] | 12.14% | [10],[13],[14],[15],[16] | 12.14% | [10],[13],[14],[15],[16] | 10.42% | [9],[19],[20],[21],[23] | 10.42% | [9],[19],[20],[21],[23] | 10.42% | [9],[19],[20],[21],[23] | ||
Investment, principal | $ 21,852 | [10],[13],[15],[16],[18] | $ 24,490 | [9],[19],[20],[22],[23] | ||||||||||
Investment, cost | 21,855 | [10],[13],[15],[16] | 24,490 | [9],[19],[20],[23] | ||||||||||
Investments at fair value | $ 21,823 | [10],[13],[15],[16] | $ 24,225 | [9],[19],[20],[23] | 15,712 | |||||||||
Investment owned, percent of net assets | 1.90% | 1.90% | 1.90% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | [10],[13] | 1,129,453 | [10],[13] | 1,129,453 | [10],[13] | 1,019,169 | [9],[19] | 1,019,169 | [9],[19] | 1,019,169 | [9],[19] | ||
Investment, cost | $ 1,159 | [10],[13] | $ 1,019 | [9],[19] | ||||||||||
Investments at fair value | $ 1,005 | [10],[13] | $ 1,223 | [9],[19] | 1,152 | |||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | [10],[13] | 78,045 | [10],[13] | 78,045 | [10],[13] | 70,425 | [9],[19] | 70,425 | [9],[19] | 70,425 | [9],[19] | ||
Investment, cost | $ 0 | [10],[13] | $ 0 | [9],[19] | ||||||||||
Investments at fair value | $ 0 | [10],[13] | $ 0 | [9],[19] | 0 | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | 78,045 | 78,045 | |||||||||||
Investments at fair value | $ 0 | $ 0 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Associated Asphalt Partners, LLC, Construction Materials, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, interest rate | [12],[20],[21] | 8.06% | 8.06% | 8.06% | ||||||||||
Investment, principal | [12],[20],[22] | $ 2,501 | ||||||||||||
Investment, cost | [12],[20] | 2,331 | ||||||||||||
Investments at fair value | [12],[20] | $ 1,934 | ||||||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [11],[16] | 5.25% | [11],[16] | 5.25% | [11],[16] | 5.25% | [12],[20] | 5.25% | [12],[20] | 5.25% | [12],[20] | ||
Investment, interest rate | 10.90% | [11],[14],[16] | 10.90% | [11],[14],[16] | 10.90% | [11],[14],[16] | 8.37% | [12],[20],[21] | 8.37% | [12],[20],[21] | 8.37% | [12],[20],[21] | ||
Investment, principal | $ 8,490 | [11],[16],[18] | $ 5,640 | [12],[20],[22] | ||||||||||
Investment, cost | 8,168 | [11],[16] | 5,482 | [12],[20] | ||||||||||
Investments at fair value | $ 6,414 | [11],[16] | $ 4,822 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 11% | 11% | 11% | ||||||||||
Investment, principal | [12],[19],[22],[26] | $ 13,346 | ||||||||||||
Investment, cost | [12],[19],[26] | 12,929 | ||||||||||||
Investments at fair value | [12],[19],[26] | 12,812 | ||||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment, principal | [12],[19],[22],[26],[30] | 8,309 | ||||||||||||
Investment, cost | [12],[19],[26],[30] | 8,264 | ||||||||||||
Investments at fair value | [12],[19],[26],[30] | $ 8,309 | ||||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19],[26] | 328,149 | 328,149 | 328,149 | ||||||||||
Investment, cost | [12],[19],[26] | $ 973 | ||||||||||||
Investments at fair value | [12],[19],[26] | $ 16 | ||||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[16],[24] | 6% | [11],[13],[16],[24] | 6% | [11],[13],[16],[24] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | ||
Investment, interest rate | 11.49% | [11],[13],[14],[16],[24] | 11.49% | [11],[13],[14],[16],[24] | 11.49% | [11],[13],[14],[16],[24] | 8.78% | [12],[19],[20],[21],[26] | 8.78% | [12],[19],[20],[21],[26] | 8.78% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 29,509 | [11],[13],[16],[18],[24] | $ 22,425 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 29,164 | [11],[13],[16],[24] | 22,086 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 28,284 | [11],[13],[16],[24] | $ 21,326 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (108) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (78) | ||||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 50,470 | ||||||||||||
Investment, cost | [11],[13],[16] | 49,679 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 49,688 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 8.12% | 8.12% | 8.12% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 2,546 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 2,503 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 2,395 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 10.65% | 10.65% | 10.65% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 3,247 | ||||||||||||
Investment, cost | [11],[13],[16] | 3,216 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 3,169 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 10.65% | 10.65% | 10.65% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,261 | ||||||||||||
Investment, cost | [11],[13],[16] | 1,269 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,231 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | ||
Investment, interest rate | 14.15% | [11],[13],[14],[16] | 14.15% | [11],[13],[14],[16] | 14.15% | [11],[13],[14],[16] | 11.62% | [12],[19],[20],[21] | 11.62% | [12],[19],[20],[21] | 11.62% | [12],[19],[20],[21] | ||
Investment, principal | $ 8,920 | [11],[13],[16],[18] | $ 7,166 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 8,819 | [11],[13],[16] | 7,059 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 8,492 | [11],[13],[16] | $ 6,915 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [12],[19],[20],[23] | 8.50% | [12],[19],[20],[23] | 8.50% | [12],[19],[20],[23] | ||
Investment, interest rate | 14.15% | [11],[13],[14],[16] | 14.15% | [11],[13],[14],[16] | 14.15% | [11],[13],[14],[16] | 11.62% | [12],[19],[20],[21],[23] | 11.62% | [12],[19],[20],[21],[23] | 11.62% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 2,091 | [11],[13],[16],[18] | $ 4,227 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 2,068 | [11],[13],[16] | 4,070 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 1,991 | [11],[13],[16] | $ 3,839 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 14.15% | 14.15% | 14.15% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 4,361 | ||||||||||||
Investment, cost | [11],[13],[16] | 4,297 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 4,152 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 13% | 13% | 13% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 2,221 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 2,188 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 2,178 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.02% | 11.02% | 11.02% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 40,660 | ||||||||||||
Investment, cost | [11],[13],[16] | 40,440 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 40,213 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 1,702 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 1,660 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 1,617 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 8.31% | 8.31% | 8.31% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 33,078 | ||||||||||||
Investment, cost | [12],[19],[20] | 32,612 | ||||||||||||
Investments at fair value | [12],[19],[20] | 32,053 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment, principal | [12],[19],[22],[23],[26],[30] | 0 | ||||||||||||
Investment, cost | [12],[19],[23],[26],[30] | 0 | ||||||||||||
Investments at fair value | [12],[19],[23],[26],[30] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate | 8% | [11],[13],[14],[16],[24] | 8% | [11],[13],[14],[16],[24] | 8% | [11],[13],[14],[16],[24] | 10.25% | [12],[19],[20],[21],[26] | 10.25% | [12],[19],[20],[21],[26] | 10.25% | [12],[19],[20],[21],[26] | ||
Investment, interest rate, paid in kind | [11],[13],[24] | 2.25% | 2.25% | 2.25% | ||||||||||
Investment, principal | $ 6,757 | [11],[13],[18],[24] | $ 5,322 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 6,560 | [11],[13],[24] | 5,111 | [12],[19],[26] | ||||||||||
Investments at fair value | 6,225 | [11],[13],[24] | $ 5,114 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[23],[26] | 10.25% | 10.25% | 10.25% | ||||||||||
Investment, principal | 3,316 | [11],[13],[18],[24],[25] | $ 0 | [12],[19],[22],[23],[26] | ||||||||||
Investment, cost | 3,335 | [11],[13],[24],[25] | 0 | [12],[19],[23],[26] | ||||||||||
Investments at fair value | $ 3,169 | [11],[13],[24],[25] | 0 | [12],[19],[23],[26] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8% | 8% | 8% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 2.25% | 2.25% | 2.25% | ||||||||||
Investment, principal | $ 0 | [11],[13],[15],[18],[24] | 2,353 | [12],[19],[22],[26],[30] | ||||||||||
Investment, cost | 0 | [11],[13],[15],[24] | 2,353 | [12],[19],[26],[30] | ||||||||||
Investments at fair value | $ 0 | [11],[13],[15],[24] | $ 2,353 | [12],[19],[26],[30] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 4 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 8% | 8% | 8% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[24] | 2.25% | 2.25% | 2.25% | ||||||||||
Investment, principal | [11],[13],[15],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[24] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[24] | 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 5 | ||||||||||||||
Investment, principal | [11],[13],[15],[18],[24],[25] | 0 | ||||||||||||
Investment, cost | [11],[13],[15],[24],[25] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[24],[25] | 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 | ||||||||||||||
Investment, principal | [11],[13],[15],[18],[24],[25] | 0 | ||||||||||||
Investment, cost | [11],[13],[15],[24],[25] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[24],[25] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 26,131 | [11],[13],[24] | 26,131 | [11],[13],[24] | 26,131 | [11],[13],[24] | 21,177 | [12],[19],[26] | 21,177 | [12],[19],[26] | 21,177 | [12],[19],[26] | ||
Investment, cost | $ 225 | [11],[13],[24] | $ 125 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 3 | [11],[13],[24] | $ 98 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[16] | 7% | [11],[16] | 7% | [11],[16] | 7% | [12],[20] | 7% | [12],[20] | 7% | [12],[20] | ||
Investment, interest rate | 12.43% | [11],[14],[16] | 12.43% | [11],[14],[16] | 12.43% | [11],[14],[16] | 9.50% | [12],[20],[21] | 9.50% | [12],[20],[21] | 9.50% | [12],[20],[21] | ||
Investment, principal | $ 30,625 | [11],[16],[18] | $ 30,625 | [12],[20],[22] | ||||||||||
Investment, cost | 30,370 | [11],[16] | 30,276 | [12],[20] | ||||||||||
Investments at fair value | $ 29,989 | [11],[16] | $ 29,017 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [11],[13] | 394,297 | [11],[13] | 394,297 | [11],[13] | 298,460 | [12],[19] | 298,460 | [12],[19] | 298,460 | [12],[19] | ||
Investment, cost | $ 424 | [11],[13] | $ 298 | [12],[19] | ||||||||||
Investments at fair value | $ 158 | [11],[13] | $ 349 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan | ||||||||||||||
Investment, interest rate | 9% | [11],[13],[14],[16] | 9% | [11],[13],[14],[16] | 9% | [11],[13],[14],[16] | 9% | [12],[19],[20],[21] | 9% | [12],[19],[20],[21] | 9% | [12],[19],[20],[21] | ||
Investment, principal | $ 5,257 | [11],[13],[18] | $ 3,979 | [12],[19],[22] | ||||||||||
Investment, cost | 5,258 | [11],[13] | 3,980 | [12],[19] | ||||||||||
Investments at fair value | $ 5,251 | [11],[13] | $ 3,960 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,708,618 | [11],[13] | 1,708,618 | [11],[13] | 1,708,618 | [11],[13] | 1,293,324 | [12],[19] | 1,293,324 | [12],[19] | 1,293,324 | [12],[19] | ||
Investment, cost | $ 1,711 | [11],[13] | $ 1,293 | [12],[19] | ||||||||||
Investments at fair value | $ 1,999 | [11],[13] | $ 1,280 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [11],[13] | 394,297 | [11],[13] | 394,297 | [11],[13] | 298,460 | [12],[19] | 298,460 | [12],[19] | 298,460 | [12],[19] | ||
Investment, cost | $ 395 | [11],[13] | $ 298 | [12],[19] | ||||||||||
Investments at fair value | $ 442 | [11],[13] | $ 295 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 829 | [13] | 829 | [13] | 829 | [13] | 829 | [5],[6],[19] | 829 | [5],[6],[19] | 829 | [5],[6],[19] | ||
Investment, principal | $ 0 | |||||||||||||
Investment, cost | $ 0 | [13] | 0 | [5],[6],[19] | ||||||||||
Investments at fair value | $ 0 | [13] | $ 0 | [5],[6],[19] | 0 | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 34,984,460 | [13] | 34,984,460 | [13] | 34,984,460 | [13] | 34,984,460 | [5],[6],[19] | 34,984,460 | [5],[6],[19] | 34,984,460 | [5],[6],[19] | ||
Investment, principal | $ 0 | |||||||||||||
Investment, cost | $ 34,984 | [13] | 34,984 | [5],[6],[19] | ||||||||||
Investments at fair value | $ 27,638 | [13] | $ 27,638 | [5],[6],[19] | 27,638 | |||||||||
Investment owned, percent of net assets | 1.80% | 1.80% | 1.80% | 2.20% | 2.20% | 2.20% | ||||||||
Investment, Identifier [Axis]: CCO Holdings LLC, Cable & Satellite, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, principal | [12],[22],[26] | $ 2,097 | ||||||||||||
Investment, cost | [12],[26] | 1,746 | ||||||||||||
Investments at fair value | [12],[26] | $ 1,603 | ||||||||||||
Investment, Identifier [Axis]: CITGO Holding, Inc., Oil & Gas Refining & Marketing, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [12],[22] | $ 7,857 | ||||||||||||
Investment, cost | [12] | 7,857 | ||||||||||||
Investments at fair value | [12] | $ 7,807 | ||||||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., Oil & Gas Refining & Marketing, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 6.25% | 6.25% | 6.25% | ||||||||||
Investment, interest rate | [12],[20],[21] | 9.37% | 9.37% | 9.37% | ||||||||||
Investment, principal | [12],[20],[22] | $ 795 | ||||||||||||
Investment, cost | [12],[20] | 770 | ||||||||||||
Investments at fair value | [12],[20] | $ 797 | ||||||||||||
Investment, Identifier [Axis]: CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[27] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [11],[13],[16],[18],[27] | $ 727 | ||||||||||||
Investment, cost | [11],[13],[16],[27] | 462 | ||||||||||||
Investments at fair value | [11],[13],[16],[27] | $ 396 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.31% | 9.31% | 9.31% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 2% | 2% | 2% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 14,294 | ||||||||||||
Investment, cost | [12],[19],[20] | 13,471 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 13,143 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 37 | ||||||||||||
Investment, cost | [11],[13],[16] | 37 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 37 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 3,031 | ||||||||||||
Investment, cost | [11],[13],[16] | 2,899 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 3,031 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,557 | ||||||||||||
Investment, cost | [11],[13],[16] | 1,489 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,557 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,024 | ||||||||||||
Investment, cost | [11],[13],[16] | 994 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,024 | ||||||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Health Care Services, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | [10],[13] | 1,080,399 | [10],[13] | 1,080,399 | [10],[13] | 1,080,399 | [9],[19] | 1,080,399 | [9],[19] | 1,080,399 | [9],[19] | ||
Investment, cost | $ 1,080 | [10],[13] | $ 1,080 | [9],[19] | ||||||||||
Investments at fair value | $ 432 | [10],[13] | $ 378 | [9],[19] | 838 | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | 1,080,399 | 1,080,399 | |||||||||||
Investments at fair value | $ 432 | $ 378 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Carvana Co., Automotive Retail, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 5.63% | 5.63% | 5.63% | ||||||||||
Investment, principal | [12],[22],[26] | $ 6,700 | ||||||||||||
Investment, cost | [12],[26] | 5,825 | ||||||||||||
Investments at fair value | [12],[26] | $ 4,724 | ||||||||||||
Investment, Identifier [Axis]: CircusTrix Holdings, LLC, Leisure Facilities, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 8.62% | 8.62% | 8.62% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 10,692 | ||||||||||||
Investment, cost | [12],[19],[20] | 10,004 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 10,209 | ||||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | 7.50% | [11],[14],[16],[24] | 7.50% | [11],[14],[16],[24] | 7.50% | [11],[14],[16],[24] | 7.50% | [12],[20],[21],[26] | 7.50% | [12],[20],[21],[26] | 7.50% | [12],[20],[21],[26] | ||
Investment, principal | $ 2,632 | [11],[18],[24] | $ 4,311 | [12],[22],[26] | ||||||||||
Investment, cost | 2,632 | [11],[24] | 4,311 | [12],[26] | ||||||||||
Investments at fair value | $ 2,017 | [11],[24] | $ 3,132 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | 7.75% | [11],[14],[16],[24] | 7.75% | [11],[14],[16],[24] | 7.75% | [11],[14],[16],[24] | 5.13% | [12],[20],[21],[26] | 5.13% | [12],[20],[21],[26] | 5.13% | [12],[20],[21],[26] | ||
Investment, principal | $ 176 | [11],[18],[24] | $ 1,374 | [12],[22],[26] | ||||||||||
Investment, cost | 170 | [11],[24] | 1,229 | [12],[26] | ||||||||||
Investments at fair value | $ 141 | [11],[24] | $ 1,163 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 3 | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [12],[22],[26] | $ 676 | ||||||||||||
Investment, cost | [12],[26] | 648 | ||||||||||||
Investments at fair value | [12],[26] | $ 512 | ||||||||||||
Investment, Identifier [Axis]: Condor Merger Sub Inc., Systems Software, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | 7.38% | [11],[14],[16] | 7.38% | [11],[14],[16] | 7.38% | [11],[14],[16] | 7.38% | [12],[20],[21] | 7.38% | [12],[20],[21] | 7.38% | [12],[20],[21] | ||
Investment, principal | $ 8,420 | [11],[18] | $ 8,420 | [12],[22] | ||||||||||
Investment, cost | 8,261 | [11] | 8,243 | [12] | ||||||||||
Investments at fair value | $ 7,059 | [11] | $ 6,900 | [12] | ||||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[16],[27] | 8.50% | [11],[13],[16],[27] | 8.50% | [11],[13],[16],[27] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | ||
Investment, interest rate | [12],[19],[20],[21] | 11.62% | 11.62% | 11.62% | ||||||||||
Investment, principal | $ 22,084 | [11],[13],[16],[18],[27] | $ 22,537 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 21,336 | [11],[13],[16],[27] | 21,642 | [12],[19],[20] | ||||||||||
Investments at fair value | 16,040 | [11],[13],[16],[27] | 20,396 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Warrants | ||||||||||||||
Investment, cost | 706 | [11],[13] | 648 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 457 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Convergeone Holdings, Inc., IT Consulting & Other Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [12],[20],[21] | 8.12% | 8.12% | 8.12% | ||||||||||
Investment, principal | [12],[20],[22] | $ 11,913 | ||||||||||||
Investment, cost | [12],[20] | 11,697 | ||||||||||||
Investments at fair value | [12],[20] | $ 8,596 | ||||||||||||
Investment, Identifier [Axis]: Conviva Inc., Application Software, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 417,851 | [11],[13] | 417,851 | [11],[13] | 417,851 | [11],[13] | 417,851 | [12],[19] | 417,851 | [12],[19] | 417,851 | [12],[19] | ||
Investment, cost | $ 605 | [11],[13] | $ 605 | [12],[19] | ||||||||||
Investments at fair value | $ 894 | [11],[13] | $ 894 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 1,099 | 1,099 | 1,099 | ||||||||||
Investment, cost | [12],[19] | $ 690 | ||||||||||||
Investments at fair value | [12],[19] | $ 2,340 | ||||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 11% | 11% | 11% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 916 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 898 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 898 | ||||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 8.88% | 8.88% | 8.88% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 13,712 | ||||||||||||
Investment, cost | [12],[19],[20] | 13,554 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 13,583 | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (20) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (20) | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.82% | 12.82% | 12.82% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 13,157 | ||||||||||||
Investment, cost | [11],[13],[16] | 12,855 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 12,858 | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (15) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (13) | ||||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5% | [11],[16] | 5% | [11],[16] | 5% | [11],[16] | 5% | [12],[20] | 5% | [12],[20] | 5% | [12],[20] | ||
Investment, interest rate | 10.39% | [11],[14],[16] | 10.39% | [11],[14],[16] | 10.39% | [11],[14],[16] | 7.65% | [12],[20],[21] | 7.65% | [12],[20],[21] | 7.65% | [12],[20],[21] | ||
Investment, principal | $ 14,750 | [11],[16],[18] | $ 10,336 | [12],[20],[22] | ||||||||||
Investment, cost | 14,173 | [11],[16] | 9,716 | [12],[20] | ||||||||||
Investments at fair value | $ 14,616 | [11],[16] | $ 9,681 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | ||
Investment, interest rate | [14],[16] | 11.47% | 11.47% | 11.47% | ||||||||||
Investment, principal | $ 933 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 920 | [11],[13],[15],[16] | (13) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 918 | [11],[13],[15],[16] | $ (26) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | ||
Investment, interest rate | 11.52% | [11],[13],[14],[16] | 11.52% | [11],[13],[14],[16] | 11.52% | [11],[13],[14],[16] | 8.81% | [12],[19],[20],[21] | 8.81% | [12],[19],[20],[21] | 8.81% | [12],[19],[20],[21] | ||
Investment, principal | $ 18,013 | [11],[13],[16],[18] | $ 18,200 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 17,690 | [11],[13],[16] | 17,790 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 17,812 | [11],[13],[16] | $ 17,843 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | [11],[16] | 4.75% | [11],[16] | 4.75% | [11],[16] | 4.75% | [12],[20] | 4.75% | [12],[20] | 4.75% | [12],[20] | ||
Investment, interest rate | 10.12% | [11],[14],[16] | 10.12% | [11],[14],[16] | 10.12% | [11],[14],[16] | 7.33% | [12],[20],[21] | 7.33% | [12],[20],[21] | 7.33% | [12],[20],[21] | ||
Investment, principal | $ 4,950 | [11],[16],[18] | $ 5,000 | [12],[20],[22] | ||||||||||
Investment, cost | 4,871 | [11],[16] | 4,906 | [12],[20] | ||||||||||
Investments at fair value | $ 4,831 | [11],[16] | $ 4,760 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Delivery Hero FinCo LLC, Internet & Direct Marketing Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20],[26] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [12],[20],[21],[26] | 8.49% | 8.49% | 8.49% | ||||||||||
Investment, principal | [12],[20],[22],[26] | $ 4,988 | ||||||||||||
Investment, cost | [12],[20],[26] | 4,882 | ||||||||||||
Investments at fair value | [12],[20],[26] | $ 4,757 | ||||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 2 | [11],[13],[24] | 2 | [11],[13],[24] | 2 | [11],[13],[24] | 2 | [12],[19],[26] | 2 | [12],[19],[26] | 2 | [12],[19],[26] | ||
Investment, cost | $ 2 | [11],[13],[24] | $ 2 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 2 | [11],[13],[24] | $ 2 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 419 | [11],[13],[24] | 419 | [11],[13],[24] | 419 | [11],[13],[24] | 419 | [12],[19],[26] | 419 | [12],[19],[26] | 419 | [12],[19],[26] | ||
Investment, cost | $ 419 | [11],[13],[24] | $ 419 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 419 | [11],[13],[24] | $ 419 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan | ||||||||||||||
Investment, interest rate | 3% | [11],[13],[14],[15],[16],[24] | 3% | [11],[13],[14],[15],[16],[24] | 3% | [11],[13],[14],[15],[16],[24] | 10% | [12],[19],[20],[21],[23],[26] | 10% | [12],[19],[20],[21],[23],[26] | 10% | [12],[19],[20],[21],[23],[26] | ||
Investment, interest rate, paid in kind | [11],[13],[15],[24] | 7% | 7% | 7% | ||||||||||
Investment, principal | $ 17,465 | [11],[13],[15],[18],[24] | $ 4,183 | [12],[19],[22],[23],[26] | ||||||||||
Investment, cost | 17,465 | [11],[13],[15],[24] | 4,183 | [12],[19],[23],[26] | ||||||||||
Investments at fair value | $ 17,465 | [11],[13],[15],[24] | $ 4,183 | [12],[19],[23],[26] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 31 | [11],[13],[24] | 31 | [11],[13],[24] | 31 | [11],[13],[24] | 31 | [12],[19],[26] | 31 | [12],[19],[26] | 31 | [12],[19],[26] | ||
Investment, cost | $ 0 | [11],[13],[24] | $ 0 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 0 | [11],[13],[24] | $ 0 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Delta Topco, Inc., Systems Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [12],[20],[21] | 9.34% | 9.34% | 9.34% | ||||||||||
Investment, principal | [12],[20],[22] | $ 6,680 | ||||||||||||
Investment, cost | [12],[20] | 6,647 | ||||||||||||
Investments at fair value | [12],[20] | $ 5,934 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 9% | 9% | 9% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 14.54% | 14.54% | 14.54% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 20,757 | ||||||||||||
Investment, cost | [11],[13],[16] | 20,146 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 20,653 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 9% | 9% | 9% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 12.67% | 12.67% | 12.67% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 2% | 2% | 2% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 24,396 | ||||||||||||
Investment, cost | [12],[19],[20] | 23,083 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 22,993 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 9% | 9% | 9% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | (135) | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ (129) | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan | ||||||||||||||
Investment, interest rate, paid in kind | [11],[13] | 8% | 8% | 8% | ||||||||||
Investment, principal | [11],[13],[18] | $ 654 | ||||||||||||
Investment, cost | [11],[13] | 653 | ||||||||||||
Investments at fair value | [11],[13] | $ 631 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 6,397,254 | [11],[13] | 6,397,254 | [11],[13] | 6,397,254 | [11],[13] | 5,403,823 | [12],[19] | 5,403,823 | [12],[19] | 5,403,823 | [12],[19] | ||
Investment, cost | $ 1,642 | [11],[13] | $ 1,405 | [12],[19] | ||||||||||
Investments at fair value | $ 1,152 | [11],[13] | $ 1,297 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 6.50% | [12],[19],[20],[23] | 6.50% | [12],[19],[20],[23] | 6.50% | [12],[19],[20],[23] | ||
Investment, interest rate | 12.49% | [11],[13],[14],[15],[16] | 12.49% | [11],[13],[14],[15],[16] | 12.49% | [11],[13],[14],[15],[16] | 9.41% | [12],[19],[20],[21],[23] | 9.41% | [12],[19],[20],[21],[23] | 9.41% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 284 | [11],[13],[15],[16],[18] | $ 251 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 265 | [11],[13],[15],[16] | 228 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 252 | [11],[13],[15],[16] | $ 239 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | ||
Investment, interest rate | 12.49% | [11],[13],[14],[16] | 12.49% | [11],[13],[14],[16] | 12.49% | [11],[13],[14],[16] | 9.91% | [12],[19],[20],[21] | 9.91% | [12],[19],[20],[21] | 9.91% | [12],[19],[20],[21] | ||
Investment, principal | $ 12,386 | [11],[13],[16],[18] | $ 9,902 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 12,208 | [11],[13],[16] | 9,599 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 12,101 | [11],[13],[16] | $ 9,793 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5% | [11],[16] | 5% | [11],[16] | 5% | [11],[16] | 5% | [12],[20] | 5% | [12],[20] | 5% | [12],[20] | ||
Investment, interest rate | 10.43% | [11],[14],[16] | 10.43% | [11],[14],[16] | 10.43% | [11],[14],[16] | 8.12% | [12],[20],[21] | 8.12% | [12],[20],[21] | 8.12% | [12],[20],[21] | ||
Investment, principal | $ 4,641 | [11],[16],[18] | $ 19,242 | [12],[20],[22] | ||||||||||
Investment, cost | 4,619 | [11],[16] | 18,970 | [12],[20] | ||||||||||
Investments at fair value | $ 4,546 | [11],[16] | $ 17,973 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 30,031 | [13] | 30,031 | [13] | 30,031 | [13] | 30,031 | [5],[6],[19] | 30,031 | [5],[6],[19] | 30,031 | [5],[6],[19] | ||
Investment, cost | $ 15,222 | [13] | $ 15,222 | [5],[6],[19] | ||||||||||
Investments at fair value | $ 2,711 | [13] | $ 4,946 | [5],[6],[19] | 18,065 | |||||||||
Investment owned, percent of net assets | 0.20% | 0.20% | 0.20% | 0.40% | 0.40% | 0.40% | ||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 5% | [13],[16] | 5% | [13],[16] | 5% | [13],[16] | 5% | [5],[6],[19],[20],[23] | 5% | [5],[6],[19],[20],[23] | 5% | [5],[6],[19],[20],[23] | ||
Investment, interest rate | 10.54% | [13],[14],[16] | 10.54% | [13],[14],[16] | 10.54% | [13],[14],[16] | 5% | 5% | 5% | |||||
Investment, principal | $ 5,574 | [13],[16],[18] | $ 0 | [5],[6],[19],[20],[22],[23] | ||||||||||
Investment, cost | 5,574 | [13],[16] | 0 | [5],[6],[19],[20],[23] | ||||||||||
Investments at fair value | $ 5,574 | [13],[16] | $ 0 | [5],[6],[19],[20],[23] | 0 | |||||||||
Investment owned, percent of net assets | 0.40% | 0.40% | 0.40% | 0% | 0% | 0% | ||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [5],[6],[19],[20] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [5],[6],[19],[20],[21] | 8.68% | 8.68% | 8.68% | ||||||||||
Investment, principal | [5],[6],[19],[20],[22] | $ 14,333 | ||||||||||||
Investment, cost | [5],[6],[19],[20] | 14,333 | ||||||||||||
Investments at fair value | $ 14,333 | [5],[6],[19],[20] | 27,381 | |||||||||||
Investment owned, percent of net assets | 1.20% | 1.20% | 1.20% | |||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [13],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [13],[14],[16] | 10.54% | 10.54% | 10.54% | ||||||||||
Investment, principal | [13],[16],[18] | $ 14,068 | ||||||||||||
Investment, cost | [13],[16] | 14,068 | ||||||||||||
Investments at fair value | $ 14,068 | [13],[16] | $ 14,333 | |||||||||||
Investment owned, percent of net assets | 0.90% | 0.90% | 0.90% | |||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [13],[15],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [13],[14],[15],[16] | 10.42% | 10.42% | 10.42% | ||||||||||
Investment, principal | [13],[15],[16],[18] | $ 2,090 | ||||||||||||
Investment, cost | [13],[15],[16] | 2,090 | ||||||||||||
Investments at fair value | $ 2,090 | [13],[15],[16] | $ 0 | |||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | |||||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 12,500 | [11],[13] | 12,500 | [11],[13] | 12,500 | [11],[13] | 12,500 | [12],[19] | 12,500 | [12],[19] | 12,500 | [12],[19] | ||
Investment, cost | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 488 | [11],[13] | 488 | [11],[13] | 488 | [11],[13] | 488 | [12],[19] | 488 | [12],[19] | 488 | [12],[19] | ||
Investment, cost | $ 488 | [11],[13] | $ 488 | [12],[19] | ||||||||||
Investments at fair value | $ 1,345 | [11],[13] | $ 966 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Eagleview Technology Corporation, Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | ||
Investment, interest rate | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 11.17% | [12],[19],[20],[21] | 11.17% | [12],[19],[20],[21] | 11.17% | [12],[19],[20],[21] | ||
Investment, principal | $ 8,974 | [11],[13],[16],[18] | $ 8,974 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 8,884 | [11],[13],[16] | 8,884 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 7,987 | [11],[13],[16] | $ 8,503 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate | 3% | [11],[13],[14],[16],[24] | 3% | [11],[13],[14],[16],[24] | 3% | [11],[13],[14],[16],[24] | 3% | [12],[19],[20],[21],[26] | 3% | [12],[19],[20],[21],[26] | 3% | [12],[19],[20],[21],[26] | ||
Investment, interest rate, paid in kind | 6% | [11],[13],[24] | 6% | [11],[13],[24] | 6% | [11],[13],[24] | 6% | [12],[19],[26] | 6% | [12],[19],[26] | 6% | [12],[19],[26] | ||
Investment, principal | $ 11,065 | [11],[13],[18],[24] | $ 10,418 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 10,953 | [11],[13],[24] | 10,275 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 10,677 | [11],[13],[24] | $ 10,231 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate | 3% | [11],[13],[14],[16],[24] | 3% | [11],[13],[14],[16],[24] | 3% | [11],[13],[14],[16],[24] | 3% | [12],[19],[20],[21],[23],[26] | 3% | [12],[19],[20],[21],[23],[26] | 3% | [12],[19],[20],[21],[23],[26] | ||
Investment, interest rate, paid in kind | [11],[13],[24] | 6% | 6% | 6% | ||||||||||
Investment, principal | $ 1,772 | [11],[13],[18],[24] | $ 0 | [12],[19],[22],[23],[26] | ||||||||||
Investment, cost | 1,748 | [11],[13],[24] | 3 | [12],[19],[23],[26] | ||||||||||
Investments at fair value | $ 1,710 | [11],[13],[24] | $ 0 | [12],[19],[23],[26] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[15],[16],[24] | 3% | 3% | 3% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[15],[24] | 6% | 6% | 6% | ||||||||||
Investment, principal | [11],[13],[15],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[24] | 1 | ||||||||||||
Investments at fair value | [11],[13],[15],[24] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[15],[16],[24] | 3% | 3% | 3% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[15],[24] | 6% | 6% | 6% | ||||||||||
Investment, principal | [11],[13],[15],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[24] | 1 | ||||||||||||
Investments at fair value | [11],[13],[15],[24] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[16] | 11.32% | 11.32% | 11.32% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 14,736 | ||||||||||||
Investment, cost | [11],[13],[16] | 14,368 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 14,368 | ||||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software,First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 6% | 6% | 6% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (41) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (41) | ||||||||||||
Investment, Identifier [Axis]: FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [11],[16] | 6.75% | [11],[16] | 6.75% | [11],[16] | 6.75% | [12],[20] | 6.75% | [12],[20] | 6.75% | [12],[20] | ||
Investment, interest rate | 12.18% | [11],[14],[16] | 12.18% | [11],[14],[16] | 12.18% | [11],[14],[16] | 9.87% | [12],[20],[21] | 9.87% | [12],[20],[21] | 9.87% | [12],[20],[21] | ||
Investment, principal | $ 31,074 | [11],[16],[18] | $ 25,061 | [12],[20],[22] | ||||||||||
Investment, cost | 29,127 | [11],[16] | 24,685 | [12],[20] | ||||||||||
Investments at fair value | $ 19,917 | [11],[16] | $ 21,646 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan | ||||||||||||||
Investment, interest rate | 9% | [11],[13],[14],[15],[16] | 9% | [11],[13],[14],[15],[16] | 9% | [11],[13],[14],[15],[16] | 9% | [12],[19],[20],[21],[31] | 9% | [12],[19],[20],[21],[31] | 9% | [12],[19],[20],[21],[31] | ||
Investment, principal | $ 59,950 | [11],[13],[15],[18] | $ 27,850 | [12],[19],[22],[31] | ||||||||||
Investment, cost | 59,950 | [11],[13],[15] | 27,850 | [12],[19],[31] | ||||||||||
Investments at fair value | $ 59,950 | [11],[13],[15] | $ 27,850 | [12],[19],[31] | ||||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 3,750 | [11],[13],[24] | 3,750 | [11],[13],[24] | 3,750 | [11],[13],[24] | 2,500 | [12],[19],[26],[31] | 2,500 | [12],[19],[26],[31] | 2,500 | [12],[19],[26],[31] | ||
Investment, cost | $ 0 | [11],[13],[24] | $ 0 | [12],[19],[26],[31] | ||||||||||
Investments at fair value | $ 3 | [11],[13],[24] | $ 3 | [12],[19],[26],[31] | ||||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[24] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[15],[16],[24] | 12.55% | 12.55% | 12.55% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[24] | $ 258 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[24] | 234 | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[24] | $ 234 | ||||||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[16],[24] | 12.55% | 12.55% | 12.55% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 11,742 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 11,509 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 11,511 | ||||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, First Lien Term Loan | ||||||||||||||
Investment, interest rate | 9% | 9% | 9% | |||||||||||
Investments at fair value | $ 0 | 7,500 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, Membership Interest | ||||||||||||||
Investment owned, balance (in shares) | shares | 1 | 1 | 1 | |||||||||||
Investments at fair value | $ 0 | 698 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, First Lien Term Loan | ||||||||||||||
Investment, interest rate | 11% | [11],[13],[14],[16],[24] | 11% | [11],[13],[14],[16],[24] | 11% | [11],[13],[14],[16],[24] | 11% | [12],[19],[20],[21],[26] | 11% | [12],[19],[20],[21],[26] | 11% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 11,918 | [11],[13],[18],[24] | $ 9,466 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 11,612 | [11],[13],[24] | 9,071 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 11,144 | [11],[13],[24] | $ 9,008 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 417,011 | [11],[13],[24] | 417,011 | [11],[13],[24] | 417,011 | [11],[13],[24] | 331,200 | [12],[19],[26] | 331,200 | [12],[19],[26] | 331,200 | [12],[19],[26] | ||
Investment, cost | $ 427 | [11],[13],[24] | $ 405 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 42 | [11],[13],[24] | $ 66 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | 6% | [11],[14],[16],[24] | 6% | [11],[14],[16],[24] | 6% | [11],[14],[16],[24] | 6% | [12],[20],[21],[26] | 6% | [12],[20],[21],[26] | 6% | [12],[20],[21],[26] | ||
Investment, principal | $ 4,881 | [11],[18],[24] | $ 4,881 | [12],[22],[26] | ||||||||||
Investment, cost | 4,469 | [11],[24] | 4,420 | [12],[26] | ||||||||||
Investments at fair value | $ 3,577 | [11],[24] | $ 3,845 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 10.60% | 10.60% | 10.60% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 1,280 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 1,268 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 1,262 | ||||||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.67% | 10.67% | 10.67% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 25,128 | ||||||||||||
Investment, cost | [12],[19],[20] | 24,915 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 24,851 | ||||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 1,638 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 1,535 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 1,535 | ||||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 23,774 | ||||||||||||
Investment, cost | [11],[13],[16] | 23,110 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 23,110 | ||||||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 10.57% | 10.57% | 10.57% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 2,456 | ||||||||||||
Investment, cost | [11],[13],[16] | 2,055 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 2,063 | ||||||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.37% | 7.37% | 7.37% | ||||||||||
Investment, principal | [12],[20],[22] | $ 5,572 | ||||||||||||
Investment, cost | [12],[20] | 5,435 | ||||||||||||
Investments at fair value | [12],[20] | $ 4,848 | ||||||||||||
Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes | ||||||||||||||
Investment, basis spread, variable rate | [11],[16],[24] | 2.85% | 2.85% | 2.85% | ||||||||||
Investment, interest rate | [11],[14],[16],[24] | 6.56% | 6.56% | 6.56% | ||||||||||
Investment, principal | € | [11],[16],[18],[24] | € 1,000 | ||||||||||||
Investment, cost | [11],[16],[24] | $ 876 | ||||||||||||
Investments at fair value | [11],[16],[24] | $ 963 | ||||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (27) | [11],[13],[15],[16] | (27) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (35) | [11],[13],[15],[16] | $ (25) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | ||
Investment, interest rate | 13.42% | [11],[13],[14],[16] | 13.42% | [11],[13],[14],[16] | 13.42% | [11],[13],[14],[16] | 11.04% | [12],[19],[20],[21] | 11.04% | [12],[19],[20],[21] | 11.04% | [12],[19],[20],[21] | ||
Investment, principal | $ 17,444 | [11],[13],[16],[18] | $ 14,311 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 17,276 | [11],[13],[16] | 14,041 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 17,096 | [11],[13],[16] | $ 14,060 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (54) | [11],[13],[15],[16] | (54) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (70) | [11],[13],[15],[16] | $ (50) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., Education Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [11],[16] | 5.25% | [11],[16] | 5.25% | [11],[16] | 5.25% | [12],[20] | 5.25% | [12],[20] | 5.25% | [12],[20] | ||
Investment, interest rate | 10.67% | [11],[14],[16] | 10.67% | [11],[14],[16] | 10.67% | [11],[14],[16] | 8.38% | [12],[20],[21] | 8.38% | [12],[20],[21] | 8.38% | [12],[20],[21] | ||
Investment, principal | $ 14,347 | [11],[16],[18] | $ 9,392 | [12],[20],[22] | ||||||||||
Investment, cost | 13,871 | [11],[16] | 9,080 | [12],[20] | ||||||||||
Investments at fair value | $ 13,618 | [11],[16] | $ 8,582 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Harrow , Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 11.89% | 11.89% | 11.89% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 7,448 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 7,296 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 7,301 | ||||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[24] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[24] | (82) | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[24] | $ (79) | ||||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.04% | 12.04% | 12.04% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 1,432 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 1,399 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 1,404 | ||||||||||||
Investment, Identifier [Axis]: Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes | ||||||||||||||
Investment, interest rate | [11],[14],[16],[24] | 4.46% | 4.46% | 4.46% | ||||||||||
Investment, principal | [11],[18],[24] | $ 6,808 | ||||||||||||
Investment, cost | [11],[24] | 5,490 | ||||||||||||
Investments at fair value | [11],[24] | $ 5,873 | ||||||||||||
Investment, Identifier [Axis]: IAMGOLD Corporation, Gold, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 8.25% | 8.25% | 8.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 13.62% | 13.62% | 13.62% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 23,975 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 23,310 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 23,328 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.40% | 11.40% | 11.40% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 44,550 | ||||||||||||
Investment, cost | [11],[13],[16] | 42,918 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 35,046 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Products, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.42% | 9.42% | 9.42% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 35,625 | ||||||||||||
Investment, cost | [12],[19],[20] | 34,806 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 31,528 | ||||||||||||
Investment, Identifier [Axis]: IPC Corp., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 6.50% | [12],[19],[20] | 6.50% | [12],[19],[20] | 6.50% | [12],[19],[20] | ||
Investment, interest rate | 11.92% | [11],[13],[14],[16] | 11.92% | [11],[13],[14],[16] | 11.92% | [11],[13],[14],[16] | 9.44% | [12],[19],[20],[21] | 9.44% | [12],[19],[20],[21] | 9.44% | [12],[19],[20],[21] | ||
Investment, principal | $ 40,587 | [11],[13],[16],[18] | $ 34,357 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 39,935 | [11],[13],[16] | 33,612 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 38,963 | [11],[13],[16] | $ 32,639 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.42% | 9.42% | 9.42% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 8,569 | ||||||||||||
Investment, cost | [12],[19],[20] | 8,401 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 8,407 | ||||||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 11.67% | 11.67% | 11.67% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 3.50% | 3.50% | 3.50% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 22,619 | ||||||||||||
Investment, cost | [12],[19],[20] | 22,162 | ||||||||||||
Investments at fair value | [12],[19],[20] | 22,275 | ||||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment, principal | [12],[19],[22],[30] | 13,083 | ||||||||||||
Investment, cost | [12],[19],[30] | 13,083 | ||||||||||||
Investments at fair value | [12],[19],[30] | $ 13,083 | ||||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 12.45% | 12.45% | 12.45% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 12,161 | ||||||||||||
Investment, cost | [12],[19],[20] | 11,944 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 11,942 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 350,241 | 350,241 | 350,241 | |||||||||||
Investment, cost | $ 0 | |||||||||||||
Investments at fair value | $ 147 | |||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[15],[16] | 16.06% | 16.06% | 16.06% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 688 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 688 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 688 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 10.75% | 10.75% | 10.75% | |||||||||||
Investment, interest rate, paid in kind | [11],[13],[16] | 16.06% | 16.06% | 16.06% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 26,613 | ||||||||||||
Investment, cost | [11],[13],[16] | 26,492 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 24,484 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[16] | 16.05% | 16.05% | 16.05% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 787 | ||||||||||||
Investment, cost | [11],[13],[16] | 771 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 787 | ||||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [13],[16],[24] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | 11.14% | [13],[14],[16],[24] | 11.14% | [13],[14],[16],[24] | 11.14% | [13],[14],[16],[24] | 11% | [12],[19],[20],[21],[26] | 11% | [12],[19],[20],[21],[26] | 11% | [12],[19],[20],[21],[26] | ||
Investment, interest rate, paid in kind | [13],[16],[24] | 2.75% | 2.75% | 2.75% | ||||||||||
Investment, principal | $ 7,179 | [13],[16],[18],[24] | $ 6,817 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 6,969 | [13],[16],[24] | 6,553 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 6,568 | [13],[16],[24] | $ 6,408 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[23],[26] | 11% | 11% | 11% | ||||||||||
Investment, principal | [12],[19],[22],[23],[26] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[23],[26] | 0 | ||||||||||||
Investments at fair value | [12],[19],[23],[26] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 112,990 | [11],[13],[24] | 112,990 | [11],[13],[24] | 112,990 | [11],[13],[24] | 56,999 | [12],[19],[26] | 56,999 | [12],[19],[26] | 56,999 | [12],[19],[26] | ||
Investment, cost | $ 300 | [11],[13],[24] | $ 135 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 105 | [11],[13],[24] | $ 609 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Diversified Financial Services, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 1,078,284 | 1,078,284 | 1,078,284 | ||||||||||
Investment, cost | [11],[13] | $ 113 | ||||||||||||
Investments at fair value | [11],[13] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Other Diversified Financial Services, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 1,078,284 | 1,078,284 | 1,078,284 | ||||||||||
Investment, cost | [12],[19] | $ 113 | ||||||||||||
Investments at fair value | [12],[19] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (99) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (86) | ||||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 5% | [12],[19],[20] | 5% | [12],[19],[20] | 5% | [12],[19],[20] | ||
Investment, interest rate | 12.93% | [11],[13],[14],[16] | 12.93% | [11],[13],[14],[16] | 12.93% | [11],[13],[14],[16] | 8.55% | [12],[19],[20],[21] | 8.55% | [12],[19],[20],[21] | 8.55% | [12],[19],[20],[21] | ||
Investment, principal | $ 33,414 | [11],[13],[16],[18] | $ 18,660 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 32,539 | [11],[13],[16] | 18,567 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 32,659 | [11],[13],[16] | $ 18,134 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 12.17% | 12.17% | 12.17% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 13,674 | ||||||||||||
Investment, cost | [12],[19],[20] | 13,514 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 13,154 | ||||||||||||
Investment, Identifier [Axis]: Ivanti Software, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [11],[16] | 7.25% | [11],[16] | 7.25% | [11],[16] | 7.25% | [12],[20] | 7.25% | [12],[20] | 7.25% | [12],[20] | ||
Investment, interest rate | 12.78% | [11],[14],[16] | 12.78% | [11],[14],[16] | 12.78% | [11],[14],[16] | 10.33% | [12],[20],[21] | 10.33% | [12],[20],[21] | 10.33% | [12],[20],[21] | ||
Investment, principal | $ 13,939 | [11],[16],[18] | $ 10,247 | [12],[20],[22] | ||||||||||
Investment, cost | 12,661 | [11],[16] | 10,196 | [12],[20] | ||||||||||
Investments at fair value | 10,094 | [11],[16] | 7,702 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: JP Morgan Prime Money Market Fund, Institutional Shares | ||||||||||||||
Investment, cost | 83,262 | |||||||||||||
Investments at fair value | $ 83,262 | |||||||||||||
Money market funds, at carrying value | $ 5,261 | |||||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.62% | 10.62% | 10.62% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 36,234 | ||||||||||||
Investment, cost | [12],[19],[20] | 35,170 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 36,392 | ||||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [12],[20],[21] | 11.12% | 11.12% | 11.12% | ||||||||||
Investment, principal | [12],[20],[22] | $ 528 | ||||||||||||
Investment, cost | [12],[20] | 478 | ||||||||||||
Investments at fair value | [12],[20] | $ 481 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 10.17% | 10.17% | 10.17% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 329 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 311 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 292 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 11.84% | 11.84% | 11.84% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 272 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 246 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 238 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (47) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (47) | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.17% | 10.17% | 10.17% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 13,623 | ||||||||||||
Investment, cost | [12],[19],[20] | 13,487 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 13,351 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.84% | 11.84% | 11.84% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 16,752 | ||||||||||||
Investment, cost | [11],[13],[16] | 16,623 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 16,500 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.80% | 11.80% | 11.80% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 38,015 | ||||||||||||
Investment, cost | [11],[13],[16] | 37,447 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 37,445 | ||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | ||
Investment, interest rate | [12],[19],[20],[21],[23] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 1,710 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (41) | [11],[13],[15],[16] | 1,672 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (172) | [11],[13],[15],[16] | $ 1,651 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 19,236 | ||||||||||||
Investment, cost | [12],[19],[20] | 18,894 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 18,707 | ||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 2,736 | ||||||||||||
Investment, cost | [11],[13],[16] | 2,595 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 2,558 | ||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 23,494 | ||||||||||||
Investment, cost | [11],[13],[16] | 23,128 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 21,967 | ||||||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., Electronic Components, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 6.75% | 6.75% | 6.75% | ||||||||||
Investment, interest rate | [12],[20],[21] | 9.87% | 9.87% | 9.87% | ||||||||||
Investment, principal | [12],[20],[22] | $ 2,140 | ||||||||||||
Investment, cost | [12],[20] | 2,092 | ||||||||||||
Investments at fair value | [12],[20] | $ 1,890 | ||||||||||||
Investment, Identifier [Axis]: LaserShip, Inc., Air Freight & Logistics, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.38% | 10.38% | 10.38% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 2,394 | ||||||||||||
Investment, cost | [12],[19],[20] | 2,370 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 1,867 | ||||||||||||
Investment, Identifier [Axis]: Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[16],[24] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, interest rate | [11],[14],[16],[24] | 14.95% | 14.95% | 14.95% | ||||||||||
Investment, principal | [11],[16],[18],[24] | $ 26,422 | ||||||||||||
Investment, cost | [11],[16],[24] | 24,920 | ||||||||||||
Investments at fair value | [11],[16],[24] | $ 27,512 | ||||||||||||
Investment, Identifier [Axis]: Lift Brands Holdings, Inc., Leisure Facilities, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 2,000,000 | [11],[13] | 2,000,000 | [11],[13] | 2,000,000 | [11],[13] | 2,000,000 | [12],[19] | 2,000,000 | [12],[19] | 2,000,000 | [12],[19] | ||
Investment, cost | $ 1,399 | [11],[13] | $ 1,399 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5% | [11],[13],[16] | 5% | [11],[13],[16] | 5% | [11],[13],[16] | 5% | [12],[19],[20] | 5% | [12],[19],[20] | 5% | [12],[19],[20] | ||
Investment, interest rate | 10.65% | [11],[13],[14],[16] | 10.65% | [11],[13],[14],[16] | 10.65% | [11],[13],[14],[16] | 8.67% | [12],[19],[20],[21] | 8.67% | [12],[19],[20],[21] | 8.67% | [12],[19],[20],[21] | ||
Investment, principal | $ 45,243 | [11],[13],[16],[18] | $ 41,008 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 44,717 | [11],[13],[16] | 40,243 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 43,886 | [11],[13],[16] | $ 39,573 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 559 | [11],[13] | 559 | [11],[13] | 559 | [11],[13] | 451 | [12],[19] | 451 | [12],[19] | 451 | [12],[19] | ||
Investment, principal | [11],[13],[18] | |||||||||||||
Investment, cost | 563 | [11],[13] | $ 451 | [12],[19] | ||||||||||
Investments at fair value | $ 372 | [11],[13] | $ 451 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | ||
Investment, interest rate | 13.99% | [11],[13],[14],[16] | 13.99% | [11],[13],[14],[16] | 13.99% | [11],[13],[14],[16] | 11.38% | [12],[19],[20],[21] | 11.38% | [12],[19],[20],[21] | 11.38% | [12],[19],[20],[21] | ||
Investment, principal | $ 5,403 | [11],[13],[16],[18] | $ 4,357 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 5,348 | [11],[13],[16] | 4,285 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 5,160 | [11],[13],[16] | $ 4,226 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[15],[16] | 8.50% | [11],[13],[15],[16] | 8.50% | [11],[13],[15],[16] | 8.50% | [12],[19],[20],[23] | 8.50% | [12],[19],[20],[23] | 8.50% | [12],[19],[20],[23] | ||
Investment, interest rate | 13.99% | [11],[13],[14],[15],[16] | 13.99% | [11],[13],[14],[15],[16] | 13.99% | [11],[13],[14],[15],[16] | 11.38% | [12],[19],[20],[21],[23] | 11.38% | [12],[19],[20],[21],[23] | 11.38% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 2,939 | [11],[13],[15],[16],[18] | $ 2,370 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 2,884 | [11],[13],[15],[16] | 2,323 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 2,745 | [11],[13],[15],[16] | $ 2,265 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [11],[13],[15],[16] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | 6% | [12],[19],[20],[23] | ||
Investment, interest rate | [11],[13],[14],[15],[16] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | $ 964 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 936 | [11],[13],[15],[16] | (23) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 938 | [11],[13],[15],[16] | $ (54) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 18,390 | ||||||||||||
Investment, cost | [12],[19],[20] | 18,088 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 17,691 | ||||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.52% | 11.52% | 11.52% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 20,125 | ||||||||||||
Investment, cost | [11],[13],[16] | 19,912 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 19,823 | ||||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.52% | 11.52% | 11.52% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 2,631 | ||||||||||||
Investment, cost | [11],[13],[16] | 2,587 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 2,591 | ||||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16] | 12.83% | 12.83% | 12.83% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 1,466 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 1,215 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 1,282 | ||||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.89% | 12.89% | 12.89% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 40,538 | ||||||||||||
Investment, cost | [11],[13],[16] | 39,873 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 39,833 | ||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [11],[13],[15],[16] | 5.50% | [11],[13],[15],[16] | 5.50% | [11],[13],[15],[16] | 5.50% | [12],[19],[20],[23] | 5.50% | [12],[19],[20],[23] | 5.50% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (28) | [11],[13],[15],[16] | (13) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (47) | [11],[13],[15],[16] | $ (51) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [11],[13],[16] | 5.50% | [11],[13],[16] | 5.50% | [11],[13],[16] | 5.50% | [12],[19],[20] | 5.50% | [12],[19],[20] | 5.50% | [12],[19],[20] | ||
Investment, interest rate | 10.99% | [11],[13],[14],[16] | 10.99% | [11],[13],[14],[16] | 10.99% | [11],[13],[14],[16] | 9.17% | [12],[19],[20],[21] | 9.17% | [12],[19],[20],[21] | 9.17% | [12],[19],[20],[21] | ||
Investment, principal | $ 13,973 | [11],[13],[16],[18] | $ 29,565 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 13,936 | [11],[13],[16] | 29,128 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 13,685 | [11],[13],[16] | $ 28,734 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [11],[13],[16] | 5.50% | [11],[13],[16] | 5.50% | [11],[13],[16] | 5.50% | [12],[19],[20],[23] | 5.50% | [12],[19],[20],[23] | 5.50% | [12],[19],[20],[23] | ||
Investment, interest rate | [11],[13],[14],[16] | 10.99% | 10.99% | 10.99% | ||||||||||
Investment, principal | $ 21,328 | [11],[13],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 21,021 | [11],[13],[16] | (12) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 20,888 | [11],[13],[16] | $ (96) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [12],[19],[20],[21],[26] | 11.50% | [12],[19],[20],[21],[26] | 11.50% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 8,568 | [11],[13],[18],[24] | $ 17,203 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 8,495 | [11],[13],[24] | 16,954 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 8,132 | [11],[13],[24] | $ 16,644 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [11],[13],[14],[16],[24] | 11.50% | [12],[19],[20],[21],[23],[26] | 11.50% | [12],[19],[20],[21],[23],[26] | 11.50% | [12],[19],[20],[21],[23],[26] | ||
Investment, principal | $ 4,284 | [11],[13],[18],[24] | $ 0 | [12],[19],[22],[23],[26] | ||||||||||
Investment, cost | 4,247 | [11],[13],[24] | 0 | [12],[19],[23],[26] | ||||||||||
Investments at fair value | $ 4,066 | [11],[13],[24] | $ 0 | [12],[19],[23],[26] | ||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 11.50% | 11.50% | 11.50% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 8,568 | ||||||||||||
Investment, cost | [11],[13],[24] | 8,495 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 8,132 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate | 8% | [11],[13],[14],[16],[24] | 8% | [11],[13],[14],[16],[24] | 8% | [11],[13],[14],[16],[24] | 8% | [12],[19],[20],[21],[26] | 8% | [12],[19],[20],[21],[26] | 8% | [12],[19],[20],[21],[26] | ||
Investment, interest rate, paid in kind | 1.75% | [11],[13],[24] | 1.75% | [11],[13],[24] | 1.75% | [11],[13],[24] | 1.75% | [12],[19],[26] | 1.75% | [12],[19],[26] | 1.75% | [12],[19],[26] | ||
Investment, principal | $ 9,106 | [11],[13],[18],[24] | $ 7,215 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 8,580 | [11],[13],[24] | 6,650 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 8,013 | [11],[13],[24] | $ 6,440 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21],[23],[26] | 8% | 8% | 8% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[23],[26] | 1.75% | 1.75% | 1.75% | ||||||||||
Investment, principal | [12],[19],[22],[23],[26] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[23],[26] | 1 | ||||||||||||
Investments at fair value | [12],[19],[23],[26] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19],[26] | 209,588 | 209,588 | 209,588 | ||||||||||
Investment, cost | [12],[19],[26] | $ 480 | ||||||||||||
Investments at fair value | [12],[19],[26] | $ 170 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13],[24] | 259,877 | 259,877 | 259,877 | ||||||||||
Investment, principal | [11],[13],[18],[24] | |||||||||||||
Investment, cost | [11],[13],[24] | 545 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 78 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13],[24] | 66,817 | 66,817 | 66,817 | ||||||||||
Investment, principal | [11],[13],[18],[24] | |||||||||||||
Investment, cost | [11],[13],[24] | 23 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 33 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 7% | [11],[13],[15],[16] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (43) | [11],[13],[15],[16] | (54) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (76) | [11],[13],[15],[16] | $ (100) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.64% | 10.64% | 10.64% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 1.50% | 1.50% | 1.50% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 45,665 | ||||||||||||
Investment, cost | [12],[19],[20] | 44,689 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 44,523 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.52% | 12.52% | 12.52% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 5,248 | ||||||||||||
Investment, cost | [11],[13],[16] | 5,220 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 5,164 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.52% | 12.52% | 12.52% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 46,687 | ||||||||||||
Investment, cost | [11],[13],[16] | 46,239 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 45,940 | ||||||||||||
Investment, Identifier [Axis]: Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [11],[13],[16] | 6.75% | [11],[13],[16] | 6.75% | [11],[13],[16] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | ||
Investment, interest rate | 12.51% | [11],[13],[14],[16] | 12.51% | [11],[13],[14],[16] | 12.51% | [11],[13],[14],[16] | 9.89% | [12],[19],[20],[21] | 9.89% | [12],[19],[20],[21] | 9.89% | [12],[19],[20],[21] | ||
Investment, principal | $ 54,559 | [11],[13],[16],[18] | $ 46,499 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 54,236 | [11],[13],[16] | 45,802 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 53,168 | [11],[13],[16] | $ 45,421 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: NFP Corp., Diversified Financial Services, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [11],[14],[16] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, principal | [11],[18] | $ 10,191 | ||||||||||||
Investment, cost | [11] | 9,831 | ||||||||||||
Investments at fair value | [11] | $ 8,743 | ||||||||||||
Investment, Identifier [Axis]: NFP Corp., Other Diversified Financial Services, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, principal | [12],[22] | $ 10,191 | ||||||||||||
Investment, cost | [12] | 9,773 | ||||||||||||
Investments at fair value | [12] | $ 7,966 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.29% | 12.29% | 12.29% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[16],[24] | 2% | 2% | 2% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 73,362 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 72,459 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 69,694 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | |||||||||||
Investment, cost | [11],[13],[16],[24] | $ 0 | ||||||||||||
Investments at fair value | [11],[24] | $ 903 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | |||||||||||
Investment, cost | [11],[16],[24] | $ 0 | ||||||||||||
Investments at fair value | [11],[24] | $ 903 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[26] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 9.99% | 9.99% | 9.99% | ||||||||||
Investment, principal | [12],[19],[20],[22],[26] | $ 58,713 | ||||||||||||
Investment, cost | [12],[19],[20],[26] | 57,655 | ||||||||||||
Investments at fair value | [12],[19],[20],[26] | $ 56,805 | ||||||||||||
Investment, Identifier [Axis]: Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [11],[13],[16] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | 8.50% | [12],[19],[20] | ||
Investment, interest rate | 13.99% | [11],[13],[14],[16] | 13.99% | [11],[13],[14],[16] | 13.99% | [11],[13],[14],[16] | 12.17% | [12],[19],[20],[21] | 12.17% | [12],[19],[20],[21] | 12.17% | [12],[19],[20],[21] | ||
Investment, principal | $ 30,339 | [11],[13],[16],[18] | $ 22,560 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 30,021 | [11],[13],[16] | 22,241 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 29,007 | [11],[13],[16] | $ 21,524 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 9.50% | [11],[13],[16] | 9.50% | [11],[13],[16] | 9.50% | [11],[13],[16] | 10.50% | [12],[19],[20] | 10.50% | [12],[19],[20] | 10.50% | [12],[19],[20] | ||
Investment, interest rate | 14.89% | [11],[13],[14],[16] | 14.89% | [11],[13],[14],[16] | 14.89% | [11],[13],[14],[16] | 14.17% | [12],[19],[20],[21] | 14.17% | [12],[19],[20],[21] | 14.17% | [12],[19],[20],[21] | ||
Investment, principal | $ 64,606 | [11],[13],[16],[18] | $ 50,459 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 64,720 | [11],[13],[16] | 49,301 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 63,185 | [11],[13],[16] | $ 51,972 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Membership Interest | ||||||||||||||
Investment owned, ownership percentage | 87.50% | [15],[24],[32],[33] | 87.50% | [15],[24],[32],[33] | 87.50% | [15],[24],[32],[33] | 87.50% | [5],[6],[23],[26],[34],[35] | 87.50% | [5],[6],[23],[26],[34],[35] | 87.50% | [5],[6],[23],[26],[34],[35] | ||
Investment, cost | $ 0 | [15],[24],[32],[33] | $ 0 | [5],[6],[23],[26],[34],[35] | ||||||||||
Investments at fair value | $ 0 | [15],[24],[32],[33] | $ 0 | [5],[6],[23],[26],[34],[35] | 0 | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | [13],[15],[16],[24],[32] | 4.50% | [13],[15],[16],[24],[32] | 4.50% | [13],[15],[16],[24],[32] | 4.50% | [5],[6],[19],[20],[23],[26],[34] | 4.50% | [5],[6],[19],[20],[23],[26],[34] | 4.50% | [5],[6],[19],[20],[23],[26],[34] | ||
Investment, interest rate | 9.76% | [13],[14],[15],[16],[24],[32] | 9.76% | [13],[14],[15],[16],[24],[32] | 9.76% | [13],[14],[15],[16],[24],[32] | 6.30% | [5],[6],[19],[20],[21],[23],[26],[34] | 6.30% | [5],[6],[19],[20],[21],[23],[26],[34] | 6.30% | [5],[6],[19],[20],[21],[23],[26],[34] | ||
Investment, principal | $ 58,349 | [13],[15],[16],[18],[24],[32] | $ 59,662 | [5],[6],[19],[20],[22],[23],[26],[34] | ||||||||||
Investment, cost | 50,330 | [13],[15],[16],[24],[32] | 50,194 | [5],[6],[19],[20],[23],[26],[34] | ||||||||||
Investments at fair value | $ 50,017 | [13],[15],[16],[24],[32] | $ 50,283 | [5],[6],[19],[20],[23],[26],[34] | 55,582 | |||||||||
Investment owned, percent of net assets | 3.30% | 3.30% | 3.30% | 4% | 4% | 4% | ||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4% | 4% | 4% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.12% | 7.12% | 7.12% | ||||||||||
Investment, principal | [12],[20],[22] | $ 3,323 | ||||||||||||
Investment, cost | [12],[20] | 3,162 | ||||||||||||
Investments at fair value | [12],[20] | $ 3,207 | ||||||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | ||
Investment, interest rate | 12.49% | [11],[13],[14],[16] | 12.49% | [11],[13],[14],[16] | 12.49% | [11],[13],[14],[16] | 10.05% | [12],[19],[20],[21] | 10.05% | [12],[19],[20],[21] | 10.05% | [12],[19],[20],[21] | ||
Investment, principal | $ 9,323 | [11],[13],[16],[18] | $ 7,519 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 9,210 | [11],[13],[16] | 7,389 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 9,183 | [11],[13],[16] | $ 7,237 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 10% | [11],[13],[16] | 10% | [11],[13],[16] | 10% | [11],[13],[16] | 2% | [12],[19],[20] | 2% | [12],[19],[20] | 2% | [12],[19],[20] | ||
Investment, interest rate | [12],[19],[20],[21] | 5.08% | 5.08% | 5.08% | ||||||||||
Investment, interest rate, paid in kind | 15.67% | [11],[13],[16] | 15.67% | [11],[13],[16] | 15.67% | [11],[13],[16] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | ||
Investment, principal | $ 25,712 | [11],[13],[16],[18] | $ 21,557 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 25,615 | [11],[13],[16] | 21,267 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 25,069 | [11],[13],[16] | $ 21,557 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 10% | [11],[13],[15],[16] | 10% | [11],[13],[15],[16] | 10% | [11],[13],[15],[16] | 2% | [12],[19],[20],[23] | 2% | [12],[19],[20],[23] | 2% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (11) | [11],[13],[15],[16] | (31) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (69) | [11],[13],[15],[16] | 0 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 10% | 10% | 10% | ||||||||||
Investment, interest rate, paid in kind | [11],[13],[15],[16] | 15.64% | 15.64% | 15.64% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 1,210 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 1,193 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 1,169 | ||||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (42) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (36) | ||||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 13.12% | 13.12% | 13.12% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 15,231 | ||||||||||||
Investment, cost | [11],[13],[16] | 14,892 | ||||||||||||
Investments at fair value | [11],[13],[16] | 14,945 | ||||||||||||
Investment, Identifier [Axis]: Other cash accounts | ||||||||||||||
Investment, cost | 62,277 | |||||||||||||
Investments at fair value | $ 62,277 | |||||||||||||
Money market funds, at carrying value | $ 21,103 | |||||||||||||
Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | 7.75% | [11],[14],[16] | 7.75% | [11],[14],[16] | 7.75% | [11],[14],[16] | 7.75% | [12],[20],[21] | 7.75% | [12],[20],[21] | 7.75% | [12],[20],[21] | ||
Investment, principal | $ 4,519 | [11],[18] | $ 7,776 | [12],[22] | ||||||||||
Investment, cost | 4,550 | [11] | 7,820 | [12] | ||||||||||
Investments at fair value | $ 3,305 | [11] | $ 5,846 | [12] | ||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 7% | 7% | 7% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 0 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | (21) | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ (13) | ||||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.28% | 9.28% | 9.28% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 26,154 | ||||||||||||
Investment, cost | [12],[19],[20] | 25,712 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 25,893 | ||||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[23] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[23] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [12],[19],[20],[22],[23] | $ 2,228 | ||||||||||||
Investment, cost | [12],[19],[20],[23] | 2,186 | ||||||||||||
Investments at fair value | [12],[19],[20],[23] | $ 2,203 | ||||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7% | 7% | 7% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (53) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (54) | ||||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.32% | 12.32% | 12.32% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 10,895 | ||||||||||||
Investment, cost | [11],[13],[16] | 10,505 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 10,495 | ||||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 100,000 | [11],[13] | 100,000 | [11],[13] | 100,000 | [11],[13] | 80,515 | [12],[19] | 80,515 | [12],[19] | 80,515 | [12],[19] | ||
Investment, cost | $ 109 | [11],[13] | $ 79 | [12],[19] | ||||||||||
Investments at fair value | $ 248 | [11],[13] | $ 89 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [11],[13],[15],[16] | 6.50% | [11],[13],[15],[16] | 6.50% | [11],[13],[15],[16] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (34) | [11],[13],[15],[16] | (34) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (3) | [11],[13],[15],[16] | $ (49) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | ||
Investment, interest rate | 12.01% | [11],[13],[14],[16] | 12.01% | [11],[13],[14],[16] | 12.01% | [11],[13],[14],[16] | 10.42% | [12],[19],[20],[21] | 10.42% | [12],[19],[20],[21] | 10.42% | [12],[19],[20],[21] | ||
Investment, principal | $ 38,414 | [11],[13],[16],[18] | $ 33,775 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 37,960 | [11],[13],[16] | 32,931 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 38,380 | [11],[13],[16] | $ 33,116 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5% | [11],[16] | 5% | [11],[16] | 5% | [11],[16] | 5% | [12],[20] | 5% | [12],[20] | 5% | [12],[20] | ||
Investment, interest rate | 10.42% | [11],[14],[16] | 10.42% | [11],[14],[16] | 10.42% | [11],[14],[16] | 8.13% | [12],[20],[21] | 8.13% | [12],[20],[21] | 8.13% | [12],[20],[21] | ||
Investment, principal | $ 9,676 | [11],[16],[18] | $ 9,850 | [12],[20],[22] | ||||||||||
Investment, cost | 9,518 | [11],[16] | 9,460 | [12],[20] | ||||||||||
Investments at fair value | $ 9,551 | [11],[16] | $ 9,374 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | ||
Investment, interest rate | 11.57% | [11],[13],[14],[16] | 11.57% | [11],[13],[14],[16] | 11.57% | [11],[13],[14],[16] | 8.88% | [12],[19],[20],[21] | 8.88% | [12],[19],[20],[21] | 8.88% | [12],[19],[20],[21] | ||
Investment, principal | $ 22,375 | [11],[13],[16],[18] | $ 17,976 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 22,189 | [11],[13],[16] | 17,690 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 21,896 | [11],[13],[16] | $ 17,537 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 7.25% | [12],[19],[20] | 7.25% | [12],[19],[20] | 7.25% | [12],[19],[20] | ||
Investment, interest rate | 12.74% | [11],[13],[14],[16] | 12.74% | [11],[13],[14],[16] | 12.74% | [11],[13],[14],[16] | 10.92% | [12],[19],[20],[21] | 10.92% | [12],[19],[20],[21] | 10.92% | [12],[19],[20],[21] | ||
Investment, principal | $ 36,499 | [11],[13],[16],[18] | $ 28,627 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 35,458 | [11],[13],[16] | 28,198 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 33,214 | [11],[13],[16] | $ 27,482 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [11],[13],[15],[16] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | 8% | [12],[19],[20],[23] | ||
Investment, interest rate | [11],[13],[14],[15],[16] | 13.45% | 13.45% | 13.45% | ||||||||||
Investment, principal | $ 3,003 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 2,926 | [11],[13],[15],[16] | (53) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 2,801 | [11],[13],[15],[16] | $ (111) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | ||
Investment, interest rate | 13.45% | [11],[13],[14],[16] | 13.45% | [11],[13],[14],[16] | 13.45% | [11],[13],[14],[16] | 10.68% | [12],[19],[20],[21] | 10.68% | [12],[19],[20],[21] | 10.68% | [12],[19],[20],[21] | ||
Investment, principal | $ 67,244 | [11],[13],[16],[18] | $ 48,689 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 66,353 | [11],[13],[16] | 47,951 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 64,406 | [11],[13],[16] | $ 47,155 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.78% | 12.78% | 12.78% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 24,503 | ||||||||||||
Investment, cost | [11],[13],[16] | 24,255 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 24,081 | ||||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.78% | 12.78% | 12.78% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 2,819 | ||||||||||||
Investment, cost | [11],[13],[16] | 2,797 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 2,771 | ||||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.01% | 10.01% | 10.01% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 23,275 | ||||||||||||
Investment, cost | [12],[19],[20] | 22,722 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 22,810 | ||||||||||||
Investment, Identifier [Axis]: Project Boost Purchaser, LLC, Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 11.12% | 11.12% | 11.12% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 5,250 | ||||||||||||
Investment, cost | [12],[19],[20] | 5,168 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 5,047 | ||||||||||||
Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | [11],[13],[16],[24] | 5.75% | [11],[13],[16],[24] | 5.75% | [11],[13],[16],[24] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | ||
Investment, interest rate | 11.21% | [11],[13],[14],[16],[24] | 11.21% | [11],[13],[14],[16],[24] | 11.21% | [11],[13],[14],[16],[24] | 8.39% | [12],[19],[20],[21],[26] | 8.39% | [12],[19],[20],[21],[26] | 8.39% | [12],[19],[20],[21],[26] | ||
Investment, principal | £ | £ 4,626 | [11],[13],[16],[18],[24] | £ 3,501 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | $ 5,897 | [11],[13],[16],[24] | $ 4,646 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 5,166 | [11],[13],[16],[24] | $ 3,367 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: QuorumLabs, Inc., Application Software, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 64,887,669 | [11],[13] | 64,887,669 | [11],[13] | 64,887,669 | [11],[13] | 64,887,669 | [12],[19] | 64,887,669 | [12],[19] | 64,887,669 | [12],[19] | ||
Investment, cost | $ 375 | [11],[13] | $ 375 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: RP Escrow Issuer LLC, Health Care Distributors, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, principal | [12],[22] | $ 1,325 | ||||||||||||
Investment, cost | [12] | 1,218 | ||||||||||||
Investments at fair value | [12] | $ 1,097 | ||||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.33% | 7.33% | 7.33% | ||||||||||
Investment, principal | [12],[20],[22] | $ 3,400 | ||||||||||||
Investment, cost | [12],[20] | 3,202 | ||||||||||||
Investments at fair value | [12],[20] | $ 2,880 | ||||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [12],[22] | $ 4,755 | ||||||||||||
Investment, cost | [12] | 4,720 | ||||||||||||
Investments at fair value | [12] | $ 3,109 | ||||||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [11],[13],[15],[16] | 6.50% | [11],[13],[15],[16] | 6.50% | [11],[13],[15],[16] | 6.50% | [12],[19],[20],[23] | 6.50% | [12],[19],[20],[23] | 6.50% | [12],[19],[20],[23] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | (43) | [11],[13],[15],[16] | (43) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ (47) | [11],[13],[15],[16] | $ (64) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 6.50% | [11],[13],[16] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | ||
Investment, interest rate | [11],[13],[14],[16] | 11.92% | 11.92% | 11.92% | ||||||||||
Investment, interest rate, paid in kind | [12],[19],[20] | 10.59% | 10.59% | 10.59% | ||||||||||
Investment, principal | $ 32,329 | [11],[13],[16],[18] | $ 24,692 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 32,070 | [11],[13],[16] | 24,265 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 31,779 | [11],[13],[16] | $ 24,101 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Renaissance Holding Corp., Diversified Banks, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[20],[21] | 10.12% | 10.12% | 10.12% | ||||||||||
Investment, principal | [12],[20],[22] | $ 3,542 | ||||||||||||
Investment, cost | [12],[20] | 3,515 | ||||||||||||
Investments at fair value | [12],[20] | $ 3,402 | ||||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 8.25% | [11],[13],[16],[24] | 8.25% | [11],[13],[16],[24] | 8.25% | [11],[13],[16],[24] | 8.25% | [12],[19],[20],[26] | 8.25% | [12],[19],[20],[26] | 8.25% | [12],[19],[20],[26] | ||
Investment, interest rate | 13.90% | [11],[13],[14],[16],[24] | 13.90% | [11],[13],[14],[16],[24] | 13.90% | [11],[13],[14],[16],[24] | 11.92% | [12],[19],[20],[21],[26] | 11.92% | [12],[19],[20],[21],[26] | 11.92% | [12],[19],[20],[21],[26] | ||
Investment, interest rate, paid in kind | [11],[13],[16],[24] | 0.50% | 0.50% | 0.50% | ||||||||||
Investment, principal | $ 36,707 | [11],[13],[16],[18],[24] | $ 37,656 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 35,548 | [11],[13],[16],[24] | 35,775 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 34,505 | [11],[13],[16],[24] | $ 36,187 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 8.25% | [11],[13],[16],[24] | 8.25% | [11],[13],[16],[24] | 8.25% | [11],[13],[16],[24] | 8.25% | [12],[19],[20],[23],[26] | 8.25% | [12],[19],[20],[23],[26] | 8.25% | [12],[19],[20],[23],[26] | ||
Investment, interest rate | 13.90% | [11],[13],[14],[16],[24] | 13.90% | [11],[13],[14],[16],[24] | 13.90% | [11],[13],[14],[16],[24] | 11.92% | [12],[19],[20],[21],[23],[26] | 11.92% | [12],[19],[20],[21],[23],[26] | 11.92% | [12],[19],[20],[21],[23],[26] | ||
Investment, interest rate, paid in kind | [11],[13],[16],[24] | 0.50% | 0.50% | 0.50% | ||||||||||
Investment, principal | $ 13,504 | [11],[13],[16],[18],[24] | $ 11,393 | [12],[19],[20],[22],[23],[26] | ||||||||||
Investment, cost | 13,058 | [11],[13],[16],[24] | 10,583 | [12],[19],[20],[23],[26] | ||||||||||
Investments at fair value | $ 12,694 | [11],[13],[16],[24] | $ 10,760 | [12],[19],[20],[23],[26] | ||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 204,454 | [11],[13],[24] | 204,454 | [11],[13],[24] | 204,454 | [11],[13],[24] | 164,660 | [12],[19],[26] | 164,660 | [12],[19],[26] | 164,660 | [12],[19],[26] | ||
Investment, cost | $ 1,202 | [11],[13],[24] | $ 1,202 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 756 | [11],[13],[24] | 74 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 1,037 | 1,037 | 1,037 | ||||||||||
Investment, cost | [11],[13] | $ 1,037 | ||||||||||||
Investments at fair value | [11],[13] | $ 951 | ||||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 14.18% | 14.18% | 14.18% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 8,010 | ||||||||||||
Investment, cost | [11],[13],[16] | 7,799 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 7,778 | ||||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (35) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (68) | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc, Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | ||||||||||||||
Investment, interest rate, paid in kind | 12% | 12% | 12% | |||||||||||
Investment, principal | $ 15,874 | |||||||||||||
Investments at fair value | $ 15,874 | $ 0 | ||||||||||||
Investment owned, percent of net assets | 1% | 1% | 1% | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [13] | 1,184,630 | 1,184,630 | 1,184,630 | ||||||||||
Investment, cost | [13] | $ 40,093 | ||||||||||||
Investments at fair value | [13] | $ 36,226 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [13] | 66,686 | 66,686 | 66,686 | ||||||||||
Investment, cost | [13] | $ 0 | ||||||||||||
Investments at fair value | [13] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 1 | ||||||||||||||
Investment, interest rate, paid in kind | [13] | 12% | 12% | 12% | ||||||||||
Investment, principal | [13],[18] | $ 15,874 | ||||||||||||
Investment, cost | [13] | 14,100 | ||||||||||||
Investments at fair value | [13] | $ 15,874 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 2 | ||||||||||||||
Investment, interest rate, paid in kind | [13],[15] | 12% | 12% | 12% | ||||||||||
Investment, principal | [13],[15],[18] | $ 1,359 | ||||||||||||
Investment, cost | [13],[15] | 1,337 | ||||||||||||
Investments at fair value | [13],[15] | $ 1,359 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal & Glass Containers, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 415 | 415 | 415 | ||||||||||
Investment, cost | [12],[19] | $ 681 | ||||||||||||
Investments at fair value | [12],[19] | 681 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,184,630 | 1,184,630 | 1,184,630 | |||||||||||
Investments at fair value | $ 36,226 | 0 | ||||||||||||
Investment owned, percent of net assets | 2.40% | 2.40% | 2.40% | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | ||||||||||||||
Investment, interest rate, paid in kind | 12% | 12% | 12% | |||||||||||
Investment, principal | $ 1,359 | |||||||||||||
Investments at fair value | $ 1,359 | 0 | ||||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 66,686 | 66,686 | 66,686 | |||||||||||
Investments at fair value | $ 0 | $ 0 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | |||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 10.38% | 10.38% | 10.38% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 4,452 | ||||||||||||
Investment, cost | [11],[13],[16] | 3,806 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 4,184 | ||||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [11],[13],[16] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | 8% | [12],[19],[20] | ||
Investment, interest rate | 13.63% | [11],[13],[14],[16] | 13.63% | [11],[13],[14],[16] | 13.63% | [11],[13],[14],[16] | 10.74% | [12],[19],[20],[21] | 10.74% | [12],[19],[20],[21] | 10.74% | [12],[19],[20],[21] | ||
Investment, principal | $ 12,034 | [11],[13],[16],[18] | $ 9,109 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 11,250 | [11],[13],[16] | 8,972 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 9,928 | [11],[13],[16] | $ 8,289 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.63% | 7.63% | 7.63% | ||||||||||
Investment, principal | [12],[20],[22] | $ 1,500 | ||||||||||||
Investment, cost | [12],[20] | 1,410 | ||||||||||||
Investments at fair value | [12],[20] | $ 1,393 | ||||||||||||
Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [11],[13],[16] | 6.75% | [11],[13],[16] | 6.75% | [11],[13],[16] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | ||
Investment, interest rate | 12.40% | [11],[13],[14],[16] | 12.40% | [11],[13],[14],[16] | 12.40% | [11],[13],[14],[16] | 10.42% | [12],[19],[20],[21] | 10.42% | [12],[19],[20],[21] | 10.42% | [12],[19],[20],[21] | ||
Investment, principal | $ 25,527 | [11],[13],[16],[18] | $ 20,766 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 23,859 | [11],[13],[16] | 19,550 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 19,954 | [11],[13],[16] | $ 18,188 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Sabert Corporation, Metal & Glass Containers, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.63% | 7.63% | 7.63% | ||||||||||
Investment, principal | [12],[20],[22] | $ 1,691 | ||||||||||||
Investment, cost | [12],[20] | 1,610 | ||||||||||||
Investments at fair value | [12],[20] | $ 1,623 | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 10% | 10% | 10% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | (95) | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ (93) | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 10% | 10% | 10% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 15.24% | 15.24% | 15.24% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 25,558 | ||||||||||||
Investment, cost | [11],[13],[16] | 24,777 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 24,791 | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 991,019 | 991,019 | 991,019 | ||||||||||
Investment, cost | [11],[13] | $ 327 | ||||||||||||
Investments at fair value | [11],[13] | $ 1,625 | ||||||||||||
Investment, Identifier [Axis]: Scilex Holding Co, Biotechnology, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[24] | 9,307 | 9,307 | 9,307 | ||||||||||
Investment, cost | [11],[24] | $ 78 | ||||||||||||
Investments at fair value | [11],[24] | $ 13 | ||||||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest | ||||||||||||||
Investment owned, ownership percentage | 87.50% | [15],[24],[32],[33],[36] | 87.50% | [15],[24],[32],[33],[36] | 87.50% | [15],[24],[32],[33],[36] | 87.50% | [5],[6],[23],[26],[34],[35],[37] | 87.50% | [5],[6],[23],[26],[34],[35],[37] | 87.50% | [5],[6],[23],[26],[34],[35],[37] | ||
Investment, cost | $ 54,791 | [15],[24],[32],[33],[36] | $ 49,322 | [5],[6],[23],[26],[34],[35],[37] | ||||||||||
Investments at fair value | $ 28,878 | [15],[24],[32],[33],[36] | $ 20,715 | [5],[6],[23],[26],[34],[35],[37] | 37,651 | |||||||||
Investment owned, percent of net assets | 1.90% | 1.90% | 1.90% | 1.70% | 1.70% | 1.70% | ||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt | ||||||||||||||
Investment, basis spread, variable rate | 7% | [13],[15],[16],[24],[32] | 7% | [13],[15],[16],[24],[32] | 7% | [13],[15],[16],[24],[32] | 7% | [5],[6],[19],[20],[23],[26],[34] | 7% | [5],[6],[19],[20],[23],[26],[34] | 7% | [5],[6],[19],[20],[23],[26],[34] | ||
Investment, interest rate | 12.26% | [13],[14],[15],[16],[24],[32] | 12.26% | [13],[14],[15],[16],[24],[32] | 12.26% | [13],[14],[15],[16],[24],[32] | 8.80% | [5],[6],[19],[20],[21],[23],[26],[34] | 8.80% | [5],[6],[19],[20],[21],[23],[26],[34] | 8.80% | [5],[6],[19],[20],[21],[23],[26],[34] | ||
Investment, principal | $ 112,656 | [13],[15],[16],[18],[24],[32] | $ 96,250 | [5],[6],[19],[20],[22],[23],[26],[34] | ||||||||||
Investment, cost | 112,656 | [13],[15],[16],[24],[32] | 96,250 | [5],[6],[19],[20],[23],[26],[34] | ||||||||||
Investments at fair value | $ 112,656 | [13],[15],[16],[24],[32] | $ 96,250 | [5],[6],[19],[20],[23],[26],[34] | $ 96,250 | |||||||||
Investment owned, percent of net assets | 7.40% | 7.40% | 7.40% | 7.70% | 7.70% | 7.70% | ||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.88% | 12.88% | 12.88% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 7,191 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 6,934 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 6,937 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.88% | 12.88% | 12.88% | ||||||||||
Investment, principal | [11],[13],[16],[18],[24] | $ 2,697 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | 2,601 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 2,602 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[24] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[24] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[24] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[24] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[24] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[24] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[24] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13],[24] | 58,210 | 58,210 | 58,210 | ||||||||||
Investment, cost | [11],[13],[24] | $ 182 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 87 | ||||||||||||
Investment, Identifier [Axis]: ShareThis, Inc., Application Software, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 345,452 | [11],[13] | 345,452 | [11],[13] | 345,452 | [11],[13] | 345,452 | [12],[19] | 345,452 | [12],[19] | 345,452 | [12],[19] | ||
Investment, cost | $ 367 | [11],[13] | $ 367 | [12],[19] | ||||||||||
Investments at fair value | $ 0 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: SiO2 Medical Products, Inc., Metal & Glass Containers, First Lien Term Loan | ||||||||||||||
Investment, interest rate | [12],[19],[20],[21] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate, paid in kind | [12],[19] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [12],[19],[22] | $ 46,121 | ||||||||||||
Investment, cost | [12],[19] | 45,413 | ||||||||||||
Investments at fair value | [12],[19] | $ 45,295 | ||||||||||||
Investment, Identifier [Axis]: SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [11],[13],[16] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | 7.50% | [12],[19],[20] | ||
Investment, interest rate | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 13.04% | [11],[13],[14],[16] | 10.48% | [12],[19],[20],[21] | 10.48% | [12],[19],[20],[21] | 10.48% | [12],[19],[20],[21] | ||
Investment, principal | $ 821 | [11],[13],[16],[18] | $ 3,195 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 813 | [11],[13],[16] | 3,163 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 776 | [11],[13],[16] | $ 2,997 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Sorrento Therapeutics, Inc., Biotechnology, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 66,000 | [11],[24] | 66,000 | [11],[24] | 66,000 | [11],[24] | 50,000 | [12],[26] | 50,000 | [12],[26] | 50,000 | [12],[26] | ||
Investment, cost | $ 139 | [11],[24] | $ 197 | [12],[26] | ||||||||||
Investments at fair value | $ 6 | [11],[24] | $ 79 | [12],[26] | ||||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 5% | [11],[13],[15],[16] | 5% | [11],[13],[15],[16] | 5% | [11],[13],[15],[16] | 5.25% | [12],[19],[20],[23] | 5.25% | [12],[19],[20],[23] | 5.25% | [12],[19],[20],[23] | ||
Investment, interest rate | 10.42% | [11],[13],[14],[15],[16] | 10.42% | [11],[13],[14],[15],[16] | 10.42% | [11],[13],[14],[15],[16] | 8.03% | [12],[19],[20],[21],[23] | 8.03% | [12],[19],[20],[21],[23] | 8.03% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 618 | [11],[13],[15],[16],[18] | $ 866 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 576 | [11],[13],[15],[16] | 813 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 577 | [11],[13],[15],[16] | $ 796 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [11],[13],[16] | 5.25% | [11],[13],[16] | 5.25% | [11],[13],[16] | 5.25% | [12],[19],[20] | 5.25% | [12],[19],[20] | 5.25% | [12],[19],[20] | ||
Investment, interest rate | 10.67% | [11],[13],[14],[16] | 10.67% | [11],[13],[14],[16] | 10.67% | [11],[13],[14],[16] | 8.30% | [12],[19],[20],[21] | 8.30% | [12],[19],[20],[21] | 8.30% | [12],[19],[20],[21] | ||
Investment, principal | $ 4,488 | [11],[13],[16],[18] | $ 4,534 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 4,423 | [11],[13],[16] | 4,455 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 4,425 | [11],[13],[16] | $ 4,427 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.32% | 12.32% | 12.32% | ||||||||||
Investment, principal | € | [11],[13],[16],[18],[24] | € 23,731 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | $ 26,772 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 24,937 | ||||||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Other Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[26] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 10% | 10% | 10% | ||||||||||
Investment, principal | £ | [12],[19],[20],[22],[26] | £ 16,911 | ||||||||||||
Investment, cost | [12],[19],[20],[26] | $ 19,414 | ||||||||||||
Investments at fair value | [12],[19],[20],[26] | $ 16,360 | ||||||||||||
Investment, Identifier [Axis]: Sunland Asphalt & Construction, LLC, Construction & Engineering, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 8.88% | 8.88% | 8.88% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 42,618 | ||||||||||||
Investment, cost | [12],[19],[20] | 41,654 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 41,723 | ||||||||||||
Investment, Identifier [Axis]: Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 13.32% | 13.32% | 13.32% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 49,520 | ||||||||||||
Investment, cost | [11],[13],[16] | 48,536 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 49,148 | ||||||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [12],[20],[21] | 7.42% | 7.42% | 7.42% | ||||||||||
Investment, principal | [12],[20],[22] | $ 3,466 | ||||||||||||
Investment, cost | [12],[20] | 3,141 | ||||||||||||
Investments at fair value | [12],[20] | $ 3,056 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[38] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[38] | 12.44% | 12.44% | 12.44% | ||||||||||
Investment, principal | [11],[13],[16],[18],[38] | $ 1,552 | ||||||||||||
Investment, cost | [11],[13],[16],[38] | 1,540 | ||||||||||||
Investments at fair value | [11],[13],[16],[38] | $ 1,478 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[38] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[38] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [11],[13],[16],[18],[38] | $ 32,104 | ||||||||||||
Investment, cost | [11],[13],[16],[38] | 31,861 | ||||||||||||
Investments at fair value | [11],[13],[16],[38] | $ 30,579 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[38] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[38] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [11],[13],[16],[18],[38] | $ 2,749 | ||||||||||||
Investment, cost | [11],[13],[16],[38] | 2,726 | ||||||||||||
Investments at fair value | [11],[13],[16],[38] | $ 2,618 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16],[38] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [11],[13],[14],[15],[16],[38] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18],[38] | $ 1,099 | ||||||||||||
Investment, cost | [11],[13],[15],[16],[38] | 1,062 | ||||||||||||
Investments at fair value | [11],[13],[15],[16],[38] | $ 943 | ||||||||||||
Investment, Identifier [Axis]: Swordfish Merger Sub LLC, Auto Parts & Equipment, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6.75% | 6.75% | 6.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 9.81% | 9.81% | 9.81% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 12,500 | ||||||||||||
Investment, cost | [12],[19],[20] | 12,474 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 11,469 | ||||||||||||
Investment, Identifier [Axis]: TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt | ||||||||||||||
Investment, interest rate | 11.50% | [11],[14],[16],[17],[24] | 11.50% | [11],[14],[16],[17],[24] | 11.50% | [11],[14],[16],[17],[24] | 11.50% | [12],[19],[20],[21],[26] | 11.50% | [12],[19],[20],[21],[26] | 11.50% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 4,984 | [11],[17],[18],[24] | $ 4,984 | [12],[19],[22],[26] | ||||||||||
Investment, cost | 4,894 | [11],[17],[24] | 4,866 | [12],[19],[26] | ||||||||||
Investments at fair value | $ 4,785 | [11],[17],[24] | $ 4,872 | [12],[19],[26] | ||||||||||
Investment, Identifier [Axis]: THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan | ||||||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 13% | 13% | 13% | ||||||||||
Investment, principal | [11],[13],[18],[24] | $ 50,419 | ||||||||||||
Investment, cost | [11],[13],[24] | 49,842 | ||||||||||||
Investments at fair value | [11],[13],[24] | $ 49,869 | ||||||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[20] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [12],[20],[21] | 8.15% | 8.15% | 8.15% | ||||||||||
Investment, principal | [12],[20],[22] | $ 12,032 | ||||||||||||
Investment, cost | [12],[20] | 10,949 | ||||||||||||
Investments at fair value | [12],[20] | $ 10,827 | ||||||||||||
Investment, Identifier [Axis]: Tacala, LLC, Restaurants, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 8% | [11],[16] | 8% | [11],[16] | 8% | [11],[16] | 7.50% | [12],[20] | 7.50% | [12],[20] | 7.50% | [12],[20] | ||
Investment, interest rate | 13.43% | [11],[14],[16] | 13.43% | [11],[14],[16] | 13.43% | [11],[14],[16] | 10.62% | [12],[20],[21] | 10.62% | [12],[20],[21] | 10.62% | [12],[20],[21] | ||
Investment, principal | $ 12,843 | [11],[16],[18] | $ 9,448 | [12],[20],[22] | ||||||||||
Investment, cost | 12,603 | [11],[16] | 9,338 | [12],[20] | ||||||||||
Investments at fair value | $ 12,464 | [11],[16] | $ 8,692 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[15],[16],[24] | 6% | [11],[13],[15],[16],[24] | 6% | [11],[13],[15],[16],[24] | 6% | [12],[19],[20],[23],[26] | 6% | [12],[19],[20],[23],[26] | 6% | [12],[19],[20],[23],[26] | ||
Investment, principal | $ 0 | [11],[13],[15],[16],[18],[24] | $ 0 | [12],[19],[20],[22],[23],[26] | ||||||||||
Investment, cost | (29) | [11],[13],[15],[16],[24] | (29) | [12],[19],[20],[23],[26] | ||||||||||
Investments at fair value | $ (22) | [11],[13],[15],[16],[24] | $ (28) | [12],[19],[20],[23],[26] | ||||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[16],[24] | 6% | [11],[13],[16],[24] | 6% | [11],[13],[16],[24] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | 6% | [12],[19],[20],[26] | ||
Investment, interest rate | 11.42% | [11],[13],[14],[16],[24] | 11.42% | [11],[13],[14],[16],[24] | 11.42% | [11],[13],[14],[16],[24] | 8.68% | [12],[19],[20],[21],[26] | 8.68% | [12],[19],[20],[21],[26] | 8.68% | [12],[19],[20],[21],[26] | ||
Investment, principal | $ 28,826 | [11],[13],[16],[18],[24] | $ 23,215 | [12],[19],[20],[22],[26] | ||||||||||
Investment, cost | 28,595 | [11],[13],[16],[24] | 22,815 | [12],[19],[20],[26] | ||||||||||
Investments at fair value | $ 28,537 | [11],[13],[16],[24] | $ 22,843 | [12],[19],[20],[26] | ||||||||||
Investment, Identifier [Axis]: Tecta America Corp., Construction & Engineering, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 11.62% | 11.62% | 11.62% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 5,203 | ||||||||||||
Investment, cost | [12],[19],[20] | 5,125 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 5,034 | ||||||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 9.75% | [11],[13],[15],[16] | 9.75% | [11],[13],[15],[16] | 9.75% | [11],[13],[15],[16] | 9.25% | [12],[19],[20],[23] | 9.25% | [12],[19],[20],[23] | 9.25% | [12],[19],[20],[23] | ||
Investment, interest rate | 15.17% | [11],[13],[14],[15],[16] | 15.17% | [11],[13],[14],[15],[16] | 15.17% | [11],[13],[14],[15],[16] | 12.20% | [12],[19],[20],[21],[23] | 12.20% | [12],[19],[20],[21],[23] | 12.20% | [12],[19],[20],[21],[23] | ||
Investment, principal | $ 1,861 | [11],[13],[15],[16],[18] | $ 1,231 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 1,845 | [11],[13],[15],[16] | 1,210 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 1,802 | [11],[13],[15],[16] | $ 1,187 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 9.75% | [11],[13],[16] | 9.75% | [11],[13],[16] | 9.75% | [11],[13],[16] | 9.25% | [12],[19],[20] | 9.25% | [12],[19],[20] | 9.25% | [12],[19],[20] | ||
Investment, interest rate | 15.26% | [11],[13],[14],[16] | 15.26% | [11],[13],[14],[16] | 15.26% | [11],[13],[14],[16] | 12.11% | [12],[19],[20],[21] | 12.11% | [12],[19],[20],[21] | 12.11% | [12],[19],[20],[21] | ||
Investment, principal | $ 23,423 | [11],[13],[16],[18] | $ 18,323 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 23,207 | [11],[13],[16] | 17,956 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 22,814 | [11],[13],[16] | $ 17,865 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Ten-X LLC, Interactive Media & Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.32% | 11.32% | 11.32% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 19,947 | ||||||||||||
Investment, cost | [11],[13],[16] | 19,013 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 19,199 | ||||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 668,879 | 668,879 | 668,879 | ||||||||||
Investment, principal | [12],[19],[22] | |||||||||||||
Investment, cost | [12],[19] | 2,028 | ||||||||||||
Investments at fair value | [12],[19] | $ 4,077 | ||||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 13.17% | 13.17% | 13.17% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 29,663 | ||||||||||||
Investment, cost | [12],[19],[20] | 29,352 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 29,031 | ||||||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7.30% | [11],[13],[16],[27] | 7.30% | [11],[13],[16],[27] | 7.30% | [11],[13],[16],[27] | 7.30% | [12],[19],[20] | 7.30% | [12],[19],[20] | 7.30% | [12],[19],[20] | ||
Investment, interest rate | [12],[19],[20],[21] | 10.44% | 10.44% | 10.44% | ||||||||||
Investment, principal | $ 19,163 | [11],[13],[16],[18],[27] | $ 15,674 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 19,163 | [11],[13],[16],[27] | 15,605 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 18,340 | [11],[13],[16],[27] | $ 15,682 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 12.50% | [11],[13],[16],[27] | 12.50% | [11],[13],[16],[27] | 12.50% | [11],[13],[16],[27] | 12.50% | [12],[19],[20] | 12.50% | [12],[19],[20] | 12.50% | [12],[19],[20] | ||
Investment, interest rate | [12],[19],[20],[21] | 16.17% | 16.17% | 16.17% | ||||||||||
Investment, principal | $ 4,641 | [11],[13],[16],[18],[27] | $ 3,789 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 4,641 | [11],[13],[16],[27] | 3,774 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 4,170 | [11],[13],[16],[27] | $ 3,800 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7% | 7% | 7% | ||||||||||
Investment, interest rate, paid in kind | 12.65% | 12.65% | 12.65% | |||||||||||
Investment, principal | [11],[13],[16],[18] | $ 46,832 | ||||||||||||
Investment, cost | [11],[13],[16] | 45,698 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 37,231 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 10,616 | 10,616 | 10,616 | ||||||||||
Investment, cost | [11],[13] | $ 120 | ||||||||||||
Investments at fair value | [11],[13] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 358,299 | 358,299 | 358,299 | ||||||||||
Investment, cost | [11],[13] | $ 2,912 | ||||||||||||
Investments at fair value | [11],[13] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 3 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 60,862 | 60,862 | 60,862 | ||||||||||
Investment, cost | [11],[13] | $ 1,207 | ||||||||||||
Investments at fair value | [11],[13] | $ 108 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 4 | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 32,447 | 32,447 | 32,447 | ||||||||||
Investment, cost | [11],[13] | $ 33,353 | ||||||||||||
Investments at fair value | [11],[13] | $ 31,701 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 11.17% | 11.17% | 11.17% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 37,494 | ||||||||||||
Investment, cost | [12],[19],[20] | 36,569 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 35,807 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 1 | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 8,434 | 8,434 | 8,434 | ||||||||||
Investment, cost | [12],[19] | $ 101 | ||||||||||||
Investments at fair value | [12],[19] | $ 69 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 2 | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 284,650 | 284,650 | 284,650 | ||||||||||
Investment, cost | [12],[19] | $ 2,409 | ||||||||||||
Investments at fair value | [12],[19] | $ 2,320 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 3 | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 48,352 | 48,352 | 48,352 | ||||||||||
Investment, cost | [12],[19] | $ 979 | ||||||||||||
Investments at fair value | [12],[19] | $ 979 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 4 | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19],[23] | 23,201 | 23,201 | 23,201 | ||||||||||
Investment, cost | [12],[19],[23] | $ 22,986 | ||||||||||||
Investments at fair value | [12],[19],[23] | $ 26,487 | ||||||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [11],[13],[16] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | 6% | [12],[19],[20] | ||
Investment, interest rate | 11.42% | [11],[13],[14],[16] | 11.42% | [11],[13],[14],[16] | 11.42% | [11],[13],[14],[16] | 9.12% | [12],[19],[20],[21] | 9.12% | [12],[19],[20],[21] | 9.12% | [12],[19],[20],[21] | ||
Investment, principal | $ 11,671 | [11],[13],[16],[18] | $ 6,016 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 11,646 | [11],[13],[16] | 5,908 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 11,363 | [11],[13],[16] | $ 5,895 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes | ||||||||||||||
Investment, basis spread, variable rate | [11],[16],[24] | 7.71% | 7.71% | 7.71% | ||||||||||
Investment, interest rate | [11],[14],[16],[24] | 13.06% | 13.06% | 13.06% | ||||||||||
Investment, principal | [11],[16],[18],[24] | $ 1,000 | ||||||||||||
Investment, cost | [11],[16],[24] | 816 | ||||||||||||
Investments at fair value | [11],[16],[24] | $ 917 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | [11],[14],[16],[24] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [11],[18],[24] | $ 4,500 | ||||||||||||
Investment, cost | [11],[24] | 4,115 | ||||||||||||
Investments at fair value | [11],[24] | $ 2,953 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | [11],[14],[16],[24] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, principal | [11],[18],[24] | $ 300 | ||||||||||||
Investment, cost | [11],[24] | 264 | ||||||||||||
Investments at fair value | [11],[24] | $ 245 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 1 | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [12],[22],[26] | $ 4,500 | ||||||||||||
Investment, cost | [12],[26] | 4,060 | ||||||||||||
Investments at fair value | [12],[26] | $ 3,026 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 2 | ||||||||||||||
Investment, interest rate | [12],[20],[21],[26] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, principal | [12],[22],[26] | $ 300 | ||||||||||||
Investment, cost | [12],[26] | 258 | ||||||||||||
Investments at fair value | [12],[26] | $ 238 | ||||||||||||
Investment, Identifier [Axis]: Virgin Pulse, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 12.68% | 12.68% | 12.68% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,140 | ||||||||||||
Investment, cost | [11],[13],[16] | 927 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,139 | ||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | [11],[16] | 3.75% | [11],[16] | 3.75% | [11],[16] | 3.75% | [12],[20] | 3.75% | [12],[20] | 3.75% | [12],[20] | ||
Investment, interest rate | 9.27% | [11],[14],[16] | 9.27% | [11],[14],[16] | 9.27% | [11],[14],[16] | 6.56% | [12],[20],[21] | 6.56% | [12],[20],[21] | 6.56% | [12],[20],[21] | ||
Investment, principal | $ 11,792 | [11],[16],[18] | $ 7,564 | [12],[20],[22] | ||||||||||
Investment, cost | 11,281 | [11],[16] | 6,989 | [12],[20] | ||||||||||
Investments at fair value | $ 11,127 | [11],[16] | $ 6,795 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.56% | 10.56% | 10.56% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 6,000 | ||||||||||||
Investment, cost | [12],[19],[20] | 5,855 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 5,070 | ||||||||||||
Investment, Identifier [Axis]: WPEngine, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 10.19% | 10.19% | 10.19% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 40,536 | ||||||||||||
Investment, cost | [12],[19],[20] | 39,947 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 40,131 | ||||||||||||
Investment, Identifier [Axis]: WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [11],[13],[16] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | 7% | [12],[19],[20] | ||
Investment, interest rate | 12.65% | [11],[13],[14],[16] | 12.65% | [11],[13],[14],[16] | 12.65% | [11],[13],[14],[16] | 10.67% | [12],[19],[20],[21] | 10.67% | [12],[19],[20],[21] | 10.67% | [12],[19],[20],[21] | ||
Investment, principal | $ 5,000 | [11],[13],[16],[18] | $ 5,000 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 4,925 | [11],[13],[16] | 4,925 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 4,263 | [11],[13],[16] | $ 4,538 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 19.64% | 19.64% | 19.64% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 2,316 | ||||||||||||
Investment, cost | [12],[19],[20] | 2,293 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 2,264 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 21.68% | 21.68% | 21.68% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,565 | ||||||||||||
Investment, cost | [11],[13],[16] | 1,551 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,464 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 21.68% | 21.68% | 21.68% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 1,323 | ||||||||||||
Investment, cost | [11],[13],[16] | 1,311 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 1,237 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | 4,871 | [11],[13] | 4,871 | [11],[13] | 4,871 | [11],[13] | 3,621 | [12],[19] | 3,621 | [12],[19] | 3,621 | [12],[19] | ||
Investment, cost | $ 46 | [11],[13] | $ 0 | [12],[19] | ||||||||||
Investments at fair value | $ 107 | [11],[13] | $ 192 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock | ||||||||||||||
Investment owned, balance (in shares) | shares | 127,452 | [11],[13] | 127,452 | [11],[13] | 127,452 | [11],[13] | 18,032 | [12],[19] | 18,032 | [12],[19] | 18,032 | [12],[19] | ||
Investment, cost | $ 2,057 | [11],[13] | $ 216 | [12],[19] | ||||||||||
Investments at fair value | $ 1,319 | [11],[13] | $ 296 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | [11],[16] | 6.25% | [11],[16] | 6.25% | [11],[16] | 6.25% | [12],[20] | 6.25% | [12],[20] | 6.25% | [12],[20] | ||
Investment, interest rate | 11.67% | [11],[14],[16] | 11.67% | [11],[14],[16] | 11.67% | [11],[14],[16] | 9.37% | [12],[20],[21] | 9.37% | [12],[20],[21] | 9.37% | [12],[20],[21] | ||
Investment, principal | $ 8,983 | [11],[16],[18] | $ 25,499 | [12],[20],[22] | ||||||||||
Investment, cost | 8,698 | [11],[16] | 24,632 | [12],[20] | ||||||||||
Investments at fair value | $ 8,678 | [11],[16] | $ 23,204 | [12],[20] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [12],[19] | 109,420 | 109,420 | 109,420 | ||||||||||
Investment, cost | [12],[19] | $ 1,842 | ||||||||||||
Investments at fair value | [12],[19] | $ 1,799 | ||||||||||||
Investment, Identifier [Axis]: Zayo Group Holdings, Inc., Alternative Carriers, Fixed Rate Bond | ||||||||||||||
Investment, interest rate | [12],[20],[21] | 4% | 4% | 4% | ||||||||||
Investment, principal | [12],[22] | $ 250 | ||||||||||||
Investment, cost | [12] | 212 | ||||||||||||
Investments at fair value | [12] | $ 201 | ||||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20] | 8.25% | 8.25% | 8.25% | ||||||||||
Investment, interest rate | [12],[19],[20],[21] | 11.92% | 11.92% | 11.92% | ||||||||||
Investment, principal | [12],[19],[20],[22] | $ 19,578 | ||||||||||||
Investment, cost | [12],[19],[20] | 19,542 | ||||||||||||
Investments at fair value | [12],[19],[20] | $ 16,152 | ||||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals,First Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 4% | 4% | 4% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 9.32% | 9.32% | 9.32% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 19,578 | ||||||||||||
Investment, cost | [11],[13],[16] | 19,568 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 19,489 | ||||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [12],[19],[20],[26] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [12],[19],[20],[21],[26] | 9.72% | 9.72% | 9.72% | ||||||||||
Investment, principal | £ | [12],[19],[20],[22],[26] | £ 18,000 | ||||||||||||
Investment, cost | [12],[19],[20],[26] | $ 23,804 | ||||||||||||
Investments at fair value | [12],[19],[20],[26] | $ 16,552 | ||||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited,Specialized Finance, Second Lien Term Loan | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16],[24] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [11],[13],[14],[16],[24] | 12.72% | 12.72% | 12.72% | ||||||||||
Investment, principal | £ | [11],[13],[16],[18],[24] | £ 20,000 | ||||||||||||
Investment, cost | [11],[13],[16],[24] | $ 25,841 | ||||||||||||
Investments at fair value | [11],[13],[16],[24] | $ 22,914 | ||||||||||||
Investment, Identifier [Axis]: athenahealth Group Inc., Health Care Technology, Preferred Equity | ||||||||||||||
Investment owned, balance (in shares) | shares | 21,523 | [11],[13] | 21,523 | [11],[13] | 21,523 | [11],[13] | 18,635 | [12],[19] | 18,635 | [12],[19] | 18,635 | [12],[19] | ||
Investment, cost | $ 20,789 | [11],[13] | $ 18,264 | [12],[19] | ||||||||||
Investments at fair value | $ 20,074 | [11],[13] | $ 16,575 | [12],[19] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [11],[13],[15],[16] | 6.75% | [11],[13],[15],[16] | 6.75% | [11],[13],[15],[16] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | ||
Investment, interest rate | [11],[13],[14],[15],[16] | 12.14% | 12.14% | 12.14% | ||||||||||
Investment, principal | $ 377 | [11],[13],[15],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 334 | [11],[13],[15],[16] | (31) | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 296 | [11],[13],[15],[16] | $ (32) | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | 6.75% | [12],[19],[20] | ||
Investment, interest rate | 12.63% | [11],[13],[14],[16] | 12.63% | [11],[13],[14],[16] | 12.63% | [11],[13],[14],[16] | 9.49% | [12],[19],[20],[21] | 9.49% | [12],[19],[20],[21] | 9.49% | [12],[19],[20],[21] | ||
Investment, interest rate, paid in kind | [11],[13] | |||||||||||||
Investment, principal | $ 24,427 | [11],[13],[16],[18] | $ 19,203 | [12],[19],[20],[22] | ||||||||||
Investment, cost | 24,135 | [11],[13],[16] | 18,874 | [12],[19],[20] | ||||||||||
Investments at fair value | $ 23,548 | [11],[13],[16] | $ 18,867 | [12],[19],[20] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 7.25% | [11],[13],[16] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | 6.75% | [12],[19],[20],[23] | ||
Investment, interest rate | [11],[13],[14],[16] | 12.63% | 12.63% | 12.63% | ||||||||||
Investment, principal | $ 3,636 | [11],[13],[16],[18] | $ 0 | [12],[19],[20],[22],[23] | ||||||||||
Investment, cost | 3,602 | [11],[13],[16] | 0 | [12],[19],[20],[23] | ||||||||||
Investments at fair value | $ 3,574 | [11],[13],[16] | $ 0 | [12],[19],[20],[23] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[16] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [11],[13],[14],[16] | 11.75% | 11.75% | 11.75% | ||||||||||
Investment, principal | [11],[13],[16],[18] | $ 5,212 | ||||||||||||
Investment, cost | [11],[13],[16] | 4,987 | ||||||||||||
Investments at fair value | [11],[13],[16] | $ 4,990 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment, basis spread, variable rate | [11],[13],[15],[16] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [11],[13],[15],[16],[18] | $ 0 | ||||||||||||
Investment, cost | [11],[13],[15],[16] | 0 | ||||||||||||
Investments at fair value | [11],[13],[15],[16] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment owned, balance (in shares) | shares | [11],[13] | 53,700 | 53,700 | 53,700 | ||||||||||
Investment, cost | [11],[13] | $ 175 | ||||||||||||
Investments at fair value | [11],[13] | $ 258 | ||||||||||||
[1]All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.[2]Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.[3]Equity ownership may be held in shares or units of companies related to the portfolio companies.[4]See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.[5]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[6]Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[7]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[8]Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[9]Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.[10]Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.[11]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.[12]Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.[13] As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). ten twenty ten twenty ten twenty ten twenty |
Consolidated Schedule of Inve_2
Consolidated Schedule of Investments - Derivatives € in Thousands, £ in Thousands, $ in Thousands | Sep. 30, 2023 USD ($) | Sep. 30, 2023 EUR (€) | Sep. 30, 2023 GBP (£) | Sep. 30, 2022 USD ($) | Sep. 30, 2022 EUR (€) | Sep. 30, 2022 GBP (£) |
Schedule of Investments [Line Items] | ||||||
Derivative assets | $ 4,910 | $ 6,789 | ||||
Derivative liability at fair value | (47,519) | (41,969) | ||||
Foreign currency forward contract | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative assets | 4,910 | 6,789 | ||||
Derivative liability at fair value | 0 | 0 | ||||
Interest rate swap | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative assets | 0 | |||||
Derivative liability at fair value | (47,519) | $ (41,969) | ||||
Interest rate | 2.70% | 2.70% | 2.70% | |||
Floating interest rate | 1.658% | 1.658% | 1.658% | |||
Notional amount | $ 350,000 | |||||
Interest Rate Swap Maturing 2027 | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative liability at fair value | $ (40,519) | |||||
Interest rate | 2.70% | 2.70% | 2.70% | |||
Floating interest rate | 1.658% | 1.658% | 1.658% | |||
Notional amount | $ 350,000 | |||||
Interest Rate Swap Maturing 2029 | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative liability at fair value | $ (7,000) | |||||
Interest rate | 7.10% | 7.10% | 7.10% | |||
Floating interest rate | 3.1255% | 3.1255% | 3.1255% | |||
Notional amount | $ 300,000 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 10, 2022, 1 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 43,179 | |||||
Notional Amount to be Sold | € | € 41,444 | |||||
Derivative assets | 2,466 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 10, 2022 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 43,179 | |||||
Notional Amount to be Sold | € | € 41,444 | |||||
Derivative assets | 2,466 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 9, 2023 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 42,182 | |||||
Notional Amount to be Sold | € | € 38,026 | |||||
Derivative assets | 1,857 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 10, 2022 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 45,692 | |||||
Notional Amount to be Sold | £ | £ 37,033 | |||||
Derivative assets | 4,323 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 19, 2022, 2 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 45,692 | |||||
Notional Amount to be Sold | £ | £ 37,033 | |||||
Derivative assets | 4,323 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 9, 2023 | ||||||
Schedule of Investments [Line Items] | ||||||
Notional Amount to be Purchased | 72,098 | |||||
Notional Amount to be Sold | £ | £ 56,556 | |||||
Derivative assets | 3,053 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing February 15, 2029 | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative assets | 0 | |||||
Derivative liability at fair value | (7,000) | |||||
Notional amount | 300,000 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing January 15, 2027 | ||||||
Schedule of Investments [Line Items] | ||||||
Derivative assets | 0 | |||||
Derivative liability at fair value | (40,519) | (41,969) | ||||
Notional amount | $ 350,000 | $ 350,000 |
Consolidated Schedule of Inve_3
Consolidated Schedule of Investments - Parenthetical - $ / shares | 12 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Schedule of Investments [Line Items] | ||
Percentage of total assets representing qualifying assets | 73.60% | 75.70% |
Percentage of total assets representing non-qualifying assets | 26.40% | 24.30% |
Share-Based Payment Arrangement, Tranche One | ||
Schedule of Investments [Line Items] | ||
Investment owned, balance, shares, VWAP threshold (in dollars per share) | $ 15 | $ 15 |
Investment owned, balance, shares, VWAP number of trading days | 10 days | 10 days |
Investment owned, balance, shares, VWAP, number of consecutive trading days | 20 days | 20 days |
Share-Based Payment Arrangement, Tranche Two | ||
Schedule of Investments [Line Items] | ||
Investment owned, balance, shares, VWAP threshold (in dollars per share) | $ 20 | $ 20 |
Investment owned, balance, shares, VWAP number of trading days | 10 days | 10 days |
Investment owned, balance, shares, VWAP, number of consecutive trading days | 20 days | 20 days |
Organization
Organization | 12 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | Organization Oaktree Specialty Lending Corporation (together with its consolidated subsidiaries, the "Company") is a specialty finance company that looks to provide customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company was formed in late 2007 and operates as a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act. The Company has qualified and elected to be treated as a regulated investment company ("RIC") under the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes. The Company's investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. The Company may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions. The Company is externally managed by Oaktree Fund Advisors, LLC ("Oaktree"), pursuant to an investment advisory agreement between the Company and Oaktree (as amended and restated, the "Investment Advisory Agreement"). Oaktree is an affiliate of Oaktree Capital Management, L.P. ("OCM"), the Company's external investment adviser from October 17, 2017 through May 3, 2020. Oaktree Fund Administration, LLC ("Oaktree Administrator"), a subsidiary of OCM, provides certain administrative and other services necessary for the Company to operate pursuant to an administration agreement between the Company and Oaktree Administrator (the "Administration Agreement"). See Note 10. In 2019, Brookfield Corporation (f/k/a Brookfield Asset Management Inc.) ("Brookfield") acquired a majority economic interest in Oaktree Capital Group, LLC. Oaktree and its affiliates operate as an independent business within Brookfield, with their own product offerings and investment, marketing and support teams. On March 19, 2021, the Company acquired Oaktree Strategic Income Corporation (“OCSI”), pursuant to that certain Agreement and Plan of Merger (the “OCSI Merger Agreement”), dated as of October 28, 2020, by and among OCSI, the Company, Lion Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OCSI Merger Agreement, OCSI was merged with and into the Company in a two-step transaction, with the Company as the surviving company (the "OCSI Merger”). On January 23, 2023, the Company acquired Oaktree Strategic Income II, Inc. (“OSI2”) pursuant to that certain Agreement and Plan of Merger (the “OSI2 Merger Agreement”), dated as of September 14, 2022, by and among OSI2, the Company, Project Superior Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into the Company in a two-step transaction with the Company as the surviving company (the “OSI2 Merger”). For further information, see Note 14 "Merger with OSI2." |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Significant Accounting Policies Basis of Presentation: The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-K and Regulation S-X. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, Financial Services - Investment Companies ("ASC 946"). Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding as of and for the years ended September 30, 2022 and September 30, 2021 have been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. Use of Estimates: The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition. Consolidation: The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries. As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value. Fair Value Measurements: Oaktree, as the valuation designee of our Board pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of our assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: • Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date. • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions. Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations. Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources. If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company’s historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company’s industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company’s ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable. Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates. Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board’s oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022. Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments: • The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team; • Preliminary valuations are then reviewed and discussed with management of Oaktree; • Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree; • Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee; • The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee; and • Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio. The fair value of the Company's investments as of September 30, 2023 and September 30, 2022 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material. With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax asset, net," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities. Foreign Currency Translation: The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. Derivative Instruments: Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations. Interest Rate Swaps The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities. Investment Income: Interest Income Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management’s judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management’s judgment, is likely to continue timely payment of its remaining obligations. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively. As of September 30, 2022, there were no investments on non-accrual status. In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. PIK Interest Income The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company’s debt investments increases the recorded cost bases of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company’s stockholders, even though the Company has not yet collected the cash and may never do so. Fee Income Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered. Dividend Income The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment. Cash and Cash Equivalents and Restricted Cash: Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets. As of September 30, 2023, included in restricted cash was $9.1 million that was held at Deutsche Bank Trust Company Americas in connection with the OSI2 Citibank Facility (defined in Note 6. Borrowings). Pursuant to the terms of the OSI2 Citibank Facility, the Company was restricted in terms of access to the $9.1 million until the occurrence of the periodic distribution dates and, in connection therewith, the Company’s submission of its required periodic reporting schedules and verifications of the Company’s compliance with the terms of the OSI2 Citibank Facility. As of September 30, 2022, included in restricted cash was $2.8 million that was held at Wells Fargo Bank, N.A. in connection with the Citibank Facility (as defined in Note 6. Borrowings). Pursuant to the terms of the Citibank Facility, the Company was restricted in terms of access to $2.8 million as of September 30, 2022, until t he occurrence of the periodic distribution dates and, in connection therewith, the Company’s submission of its required periodic reporting schedules and verifications of the Company’s compliance with the terms of the Citibank Facility. Due from Portfolio Companies: Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company ( e.g. , principal payments on the scheduled amortization payment date). Receivables/Payables from Unsettled Transactions: Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date. Deferred Financing Costs: Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company’s unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment. Deferred Offering Costs: Legal fees and other costs incurred in connection with the Company’s shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed. Income Taxes: The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. The Company did not incur a U.S. federal excise tax for calendar year 2021. For the calendar year 2022, the Company incurred $0.1 million of excise tax. The Company does not expect to incur a U.S. federal excise tax for calendar year 2023. The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company’s Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences. FASB ASC Topic 740, Accounting for Uncertainty in Income Taxes ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2020, 2021 and 2022. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months. |
Portfolio Investments
Portfolio Investments | 12 Months Ended |
Sep. 30, 2023 | |
Schedule of Investments [Abstract] | |
Portfolio Investments | Portfolio Investments As of September 30, 2023, 190.8% of net assets at fair value, or $2.9 billion, was invested in 143 portfolio companies, including (i) $141.5 million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) $50.0 million in subordinated notes and LLC equity interests of OCSI Glick JV LLC ("Glick JV" and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of September 30, 2023, 9.6% of net assets at fair value, or $145.5 million, was invested in cash and cash equivalents (including $9.1 million of restricted cash). In comparison, as of September 30, 2022, 200.2% of net assets at fair value, or $2.5 billion, was invested in 149 portfolio investments, including (i) $117.0 million in subordinated notes and LLC equity interests of SLF JV I and (ii) $50.3 million in subordinated notes and LLC equity interests of Glick JV. As of September 30, 2022, 2.1% of net assets at fair value, or $26.4 million, was invested in cash and cash equivalents (including $2.8 million of restricted cash). As of September 30, 2023, 86.5% of the Company's portfolio at fair value consisted of senior secured debt investments and 7.5% consisted of subordinated debt investments, including the debt investments in the JVs. As of September 30, 2022, 86.9% of the Company's portfolio at fair value consisted of senior secured debt investments and 8.1% consisted of subordinated debt investments, including the debt investments in the JVs. The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants, limited partnership interests or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain. During the years ended September 30, 2023, 2022 and 2021, the Company recorded net realized gains (losses) of $(33.2) million, $17.2 million and $26.4 million, respectively. During the years ended September 30, 2023, 2022 and 2021, the Company recorded net unrealized appreciation (depreciation) of $(28.6) million, $(136.2) million and $114.5 million, respectively. The composition of the Company's investments as of September 30, 2023 and September 30, 2022 at cost and fair value was as follows: September 30, 2023 September 30, 2022 Cost Fair Value Cost Fair Value Investments in debt securities $ 2,654,484 $ 2,557,102 $ 2,294,392 $ 2,223,329 Investments in equity securities 171,858 143,767 127,596 103,534 Debt investments in the JVs 162,986 162,673 146,444 146,533 Equity investments in the JVs 54,791 28,878 49,322 20,715 Total $ 3,044,119 $ 2,892,420 $ 2,617,754 $ 2,494,111 The following table presents the composition of the Company's debt investments as of September 30, 2023 and September 30, 2022 at fixed rates and floating rates: September 30, 2023 September 30, 2022 Fair Value % of Debt Fair Value % of Debt Floating rate debt securities, including the debt investments in the JVs $ 2,345,205 86.23 % $ 2,049,644 86.49 % Fixed rate debt securities 374,570 13.77 320,218 13.51 Total $ 2,719,775 100.00 % $ 2,369,862 100.00 % The following table presents the financial instruments carried at fair value as of September 30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level 1 Level 2 Level 3 Measured at Net Asset Value (a) Total Investments in debt securities (senior secured) $ — $ 208,694 $ 2,292,691 $ — $ 2,501,385 Investments in debt securities (subordinated, including the debt investments in the JVs) — 28,666 189,724 — 218,390 Investments in equity securities (preferred) — — 86,057 — 86,057 Investments in equity securities (common and warrants, including LLC equity interests of the JVs) 4,317 1,953 51,440 28,878 86,588 Total investments at fair value 4,317 239,313 2,619,912 28,878 2,892,420 Cash equivalents 83,262 — — — 83,262 Derivative assets — 4,910 — — 4,910 Total assets at fair value $ 87,579 $ 244,223 $ 2,619,912 $ 28,878 $ 2,980,592 Derivative liability $ — $ 47,519 $ — $ — $ 47,519 Total liabilities at fair value $ — $ 47,519 $ — $ — $ 47,519 __________ (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. The following table presents the financial instruments carried at fair value as of September 30, 2022 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level 1 Level 2 Level 3 Measured at Net Asset Value (a) Total Investments in debt securities (senior secured) $ — $ 255,803 $ 1,910,606 $ — $ 2,166,409 Investments in debt securities (subordinated, including the debt investments in the JVs) — 44,065 159,388 — 203,453 Investments in equity securities (preferred) — — 79,523 — 79,523 Investments in equity securities (common and warrants, including LLC equity interests of the JVs) 4,053 — 19,958 20,715 44,726 Total investments at fair value 4,053 299,868 2,169,475 20,715 2,494,111 Cash equivalents 5,261 — — — 5,261 Derivative assets — 6,789 — — 6,789 Total assets at fair value $ 9,314 $ 306,657 $ 2,169,475 $ 20,715 $ 2,506,161 Derivative liability $ — $ 41,969 $ — $ — $ 41,969 Total liabilities at fair value $ — $ 41,969 $ — $ — $ 41,969 __________ (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation) in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology. Transfers between levels are recognized at the beginning of the reporting period. The following table provides a roll-forward in the changes in fair value from September 30, 2022 to September 30, 2023 for all investments for which the Company determined fair value using unobservable (Level 3) factors: Investments Senior Secured Debt Subordinated Preferred Common Total Fair value as of September 30, 2022 $ 1,910,606 $ 159,388 $ 79,523 $ 19,958 $ 2,169,475 Purchases (a) 1,080,654 30,690 14,296 5,611 1,131,251 Sales and repayments (650,437) (1,396) — (13,894) (665,727) Transfers in (b)(c) 19,075 — — 40,093 59,168 Transfers out (c) (40,093) — — — (40,093) Capitalized PIK interest income 15,016 628 — — 15,644 Accretion of OID 16,322 1,449 — — 17,771 Net unrealized appreciation (depreciation) (37,253) (1,035) (7,762) (2,921) (48,971) Net realized gains (losses) (21,199) — — 2,593 (18,606) Fair value as of September 30, 2023 $ 2,292,691 $ 189,724 $ 86,057 $ 51,440 $ 2,619,912 Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of September 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the year ended September 30, 2023 $ (48,680) $ (1,035) $ (7,762) $ (6,513) $ (63,990) __________ (a) Includes Level 3 investments acquired in connection with the OSI2 Merger during the year ended September 30, 2023. (b) There was one transfer into Level 3 from Level 2 for an investment during the year ended September 30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity. (c) There was one investment restructuring in which Level 3 senior secured debt was exchanged for Level 3 common equity during the year ended September 30, 2023. The following table provides a roll-forward in the changes in fair value from September 30, 2021 to September 30, 2022 for all investments for which the Company determined fair value using unobservable (Level 3) factors: Investments Senior Secured Debt Subordinated Preferred Common Total Fair value as of September 30, 2021 $ 1,878,536 $ 176,317 $ 63,565 $ 43,163 $ 2,161,581 Purchases 490,081 7,960 19,662 2,807 520,510 Sales and repayments (476,813) (22,525) (163) (13,034) (512,535) Transfers in (a)(c) 49,843 — — — 49,843 Transfers out (a)(b) (17,070) — — (5,838) (22,908) Capitalized PIK interest income 22,855 313 — — 23,168 Accretion of OID 24,422 2,060 — — 26,482 Net unrealized appreciation (depreciation) (67,455) (4,737) (3,029) (6,642) (81,863) Net realized gains (losses) 6,207 — (512) (498) 5,197 Fair value as of September 30, 2022 $ 1,910,606 $ 159,388 $ 79,523 $ 19,958 $ 2,169,475 Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of September 30, 2022 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the year ended September 30, 2022 $ (53,013) $ (4,885) $ (3,264) $ (11,751) $ (72,913) __________ (a) There were transfers into/out of Level 3 from/to Level 2 for certain investments during the year ended September 30, 2022 as a result of a change in the number of market quotes available and/or a change in market liquidity. (b) There was one transfer out of Level 3 in connection with a transaction in which Level 3 common equity was exchanged for Level 1 common equity. (c) There was one transfer into Level 3 from Level 2 as a result of an investment restructuring in which Level 2 senior secured debt was exchanged for Level 3 senior secured debt. Significant Unobservable Inputs for Level 3 Investments The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2023: Asset Fair Value Valuation Technique Unobservable Input Range Weighted Senior Secured Debt $ 1,904,140 Market Yield Market Yield (b) 9.0% - 32.0% 14.7% 64,802 Enterprise Value EBITDA Multiple (c) 3.0x - 6.0x 4.6x 33,816 Transaction Precedent Transaction Price (d) N/A - N/A N/A 289,933 Broker quotations Broker Quoted Price (e) N/A - N/A N/A Subordinated Debt 22,881 Market Yield Market Yield (b) 10.0% - 22.0% 11.2% 4,170 Broker Quotations Broker Quoted Price (e) N/A - N/A N/A Debt Investments in the JVs 162,673 Enterprise Value N/A (f) N/A - N/A N/A Preferred & Common Equity 32,318 Enterprise Value Revenue Multiple (c) 0.4x - 3.2x 0.5x 103,661 Enterprise Value EBITDA Multiple (c) 1.7x - 15.1x 8.8x 1,097 Enterprise Value Asset Multiple (c) 1.0x - 1.4x 1.4x 421 Transaction Precedent Transaction Price (d) N/A - N/A N/A Total $ 2,619,912 __________ (a) Weighted averages are calculated based on fair value of investments. (b) Used when market participants would take into account market yield when pricing the investment. (c) Used when market participants would use such multiples when pricing the investment. (d) Used when there is an observable transaction or pending event for the investment. (e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2022: Asset Fair Value Valuation Technique Unobservable Input Range Weighted Senior Secured Debt $ 1,599,148 Market Yield Market Yield (b) 9.0% - 30.0% 13.7% 14,333 Enterprise Value EBITDA Multiple (c) 5.0x - 7.0x 6.0x 297,125 Broker Quotations Broker Quoted Price (e) N/A - N/A N/A Subordinated Debt 12,855 Market Yield Market Yield (b) 10.0% - 19.0% 13.8% Debt Investments in the JVs 146,533 Enterprise Value N/A (f) N/A - N/A N/A Preferred & Common Equity 61,693 Enterprise Value Revenue Multiple (c) 0.4x - 10.1x 4.3x 36,913 Enterprise Value EBITDA Multiple (c) 3.0x - 20.0x 11.4x 3 Enterprise Value Asset Multiple (c) 0.9x - 1.1x 1.0x 872 Transaction Precedent Transaction Price (d) N/A - N/A N/A Total $ 2,169,475 __________ (a) Weighted averages are calculated based on fair value of investments. (b) Used when market participants would take into account market yield when pricing the investment. (c) Used when market participants would use such multiples when pricing the investment. (d) Used when there is an observable transaction or pending event for the investment. (e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively. Under the EV technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt or equity securities is the earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively. Financial Instruments Disclosed, But Not Carried, At Fair Value The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2023 and the level of each financial liability within the fair value hierarchy: Carrying Fair Value Level 1 Level 2 Level 3 Syndicated Facility payable $ 430,000 $ 430,000 $ — $ — $ 430,000 OSI2 Citibank Facility payable 280,000 280,000 — — 280,000 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount) 298,241 286,437 — 286,437 — 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 306,412 301,784 — 301,784 — 2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 286,078 289,980 — 289,980 — Total $ 1,600,731 $ 1,588,201 $ — $ 878,201 $ 710,000 The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2022 and the level of each financial liability within the fair value hierarchy: Carrying Fair Value Level 1 Level 2 Level 3 Syndicated Facility payable $ 540,000 $ 540,000 $ — $ — $ 540,000 Citibank Facility payable 160,000 160,000 — — 160,000 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount) 296,991 283,077 — 283,077 — 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 304,052 294,028 — 294,028 — Total $ 1,301,043 $ 1,277,105 $ — $ 577,105 $ 700,000 The principal values of the credit facilities payable approximate fair value due to their variable interest rates and are included in Level 3 of the hierarchy. Oaktree used market quotes as of the valuation date to estimate the fair value of the Company's 3.500% notes due 2025 (the "2025 Notes"), 2.700% notes due 2027 (the "2027 Notes") and 7.100% notes due 2029 (the "2029 Notes"), which are included in Level 2 of the hierarchy. Portfolio Composition Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Senior secured debt $ 2,594,640 85.24 % $ 2,227,245 85.08 % Debt investments in the JVs 162,986 5.35 % 146,444 5.59 % Preferred equity 99,597 3.27 % 85,300 3.26 % Common equity and warrants 72,261 2.37 % 42,296 1.62 % Subordinated debt 59,844 1.97 % 67,147 2.57 % LLC equity interests of the JVs 54,791 1.80 % 49,322 1.88 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Senior secured debt $ 2,501,385 86.47 % 165.01 % $ 2,166,409 86.86 % 173.93 % Debt investments in the JVs 162,673 5.62 % 10.73 % 146,533 5.88 % 11.77 % Preferred equity 86,057 2.98 % 5.68 % 79,523 3.19 % 6.38 % Common equity and warrants 57,710 2.00 % 3.81 % 24,011 0.96 % 1.93 % Subordinated debt 55,717 1.93 % 3.68 % 56,920 2.28 % 4.57 % LLC equity interests of the JVs 28,878 1.00 % 1.91 % 20,715 0.83 % 1.66 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Northeast $ 1,012,955 33.27 % $ 747,420 28.55 % International 418,595 13.75 % 301,242 11.51 % West 393,390 12.92 % 358,306 13.69 % Southeast 375,247 12.33 % 356,041 13.60 % Midwest 360,506 11.84 % 373,236 14.26 % South 202,374 6.65 % 168,819 6.45 % Southwest 153,318 5.04 % 221,308 8.45 % Northwest 127,734 4.20 % 91,382 3.49 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Northeast $ 945,422 32.69 % 62.37 % $ 696,368 27.93 % 55.90 % International 414,079 14.32 % 27.32 % 279,646 11.21 % 22.45 % West 384,055 13.28 % 25.34 % 345,251 13.84 % 27.72 % Southeast 354,444 12.25 % 23.38 % 344,567 13.82 % 27.66 % Midwest 350,620 12.12 % 23.13 % 356,934 14.31 % 28.66 % South 188,541 6.52 % 12.44 % 166,230 6.66 % 13.35 % Southwest 130,455 4.51 % 8.61 % 214,984 8.62 % 17.26 % Northwest 124,804 4.31 % 8.23 % 90,131 3.61 % 7.24 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Application Software $ 468,483 15.39 % $ 391,938 14.98 % Multi-Sector Holdings (1) 219,469 7.21 195,766 7.48 Data Processing & Outsourced Services 133,410 4.38 120,477 4.60 Biotechnology 126,349 4.15 109,960 4.20 Health Care Technology 106,915 3.51 100,084 3.82 Industrial Machinery & Supplies & Components 99,511 3.27 81,787 3.12 Pharmaceuticals 84,948 2.79 126,508 4.83 Real Estate Operating Companies 83,754 2.75 47,585 1.82 Broadline Retail 83,290 2.74 67,926 2.59 Health Care Services 81,560 2.68 58,674 2.24 Specialized Finance 73,035 2.40 80,864 3.09 Personal Care Products 68,146 2.24 53,214 2.03 Fertilizers & Agricultural Chemicals 64,720 2.13 49,301 1.88 Environmental & Facilities Services 63,064 2.07 20,857 0.80 Health Care Distributors 62,044 2.04 57,112 2.18 Diversified Financial Services 61,725 2.03 29,300 1.12 Internet Services & Infrastructure 60,934 2.00 54,095 2.07 Automotive Retail 57,596 1.89 59,254 2.26 Airport Services 55,961 1.84 43,322 1.65 Metal, Glass & Plastic Containers 55,530 1.82 47,704 1.82 Home Improvement Retail 54,236 1.78 45,802 1.75 Insurance Brokers 52,856 1.74 35,628 1.36 Aerospace & Defense 51,797 1.70 61,963 2.37 Diversified Metals & Mining 49,842 1.64 — — Auto Parts & Equipment 48,536 1.59 12,474 0.48 Real Estate Services 44,717 1.47 40,243 1.54 Soft Drinks & Non-alcoholic Beverages 42,628 1.40 — — Other Specialty Retail 41,088 1.35 — — Leisure Facilities 39,076 1.28 39,768 1.52 Specialty Chemicals 38,640 1.27 37,319 1.43 Distributors 37,666 1.24 25,278 0.97 Electrical Components & Equipment 32,440 1.07 33,814 1.29 Advertising 25,597 0.84 28,245 1.08 Passenger Airlines 24,920 0.82 — — Real Estate Development 23,965 0.79 — — Home Furnishings 23,859 0.78 19,550 0.75 Diversified Support Services 23,435 0.77 37,992 1.45 Gold 23,310 0.77 — — Systems Software 23,111 0.76 14,890 0.57 Health Care Equipment 22,441 0.74 24,353 0.93 Construction & Engineering 22,102 0.73 60,996 2.33 Oil & Gas Storage & Transportation 22,042 0.72 22,290 0.85 Interactive Media & Services 19,013 0.62 — — Integrated Telecommunication Services 18,801 0.62 34,628 1.32 Hotels, Resorts & Cruise Lines 17,195 0.56 13,960 0.53 Consumer Finance 16,440 0.54 14,492 0.55 Education Services 13,871 0.46 9,080 0.35 Restaurants 12,603 0.41 9,338 0.36 Movies & Entertainment 12,188 0.40 26,161 1.00 Health Care Supplies 11,646 0.38 36,471 1.39 Food Distributors 5,897 0.19 4,646 0.18 Apparel Retail 4,999 0.16 5,268 0.20 Air Freight & Logistics 4,925 0.16 7,295 0.28 Integrated Oil & Gas 4,894 0.16 4,866 0.19 Research & Consulting Services 4,871 0.16 9,187 0.35 Cable & Satellite 4,619 0.15 20,716 0.79 Other Specialized REITs 4,379 0.14 — — Paper & Plastic Packaging Products & Materials 3,254 0.11 — — Housewares & Specialties 2,908 0.10 2,293 0.09 Leisure Products 2,055 0.07 — — Technology Distributors 813 0.03 3,163 0.12 Soft Drinks — — 34,272 1.31 IT Consulting & Other Services — — 11,697 0.45 Oil & Gas Refining & Marketing — — 8,627 0.33 Trading Companies & Distributors — — 7,628 0.29 Apparel, Accessories & Luxury Goods — — 5,165 0.20 Specialized REITs — — 4,318 0.16 Diversified Banks — — 3,515 0.13 Construction Materials — — 2,331 0.09 Electronic Components — — 2,092 0.08 Alternative Carriers — — 212 0.01 $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Application Software $ 455,719 15.73 % 30.03 % $ 384,589 15.43 % 30.87 % Multi-Sector Holdings (1) 193,431 6.69 12.76 167,248 6.71 13.43 Biotechnology 125,678 4.35 8.29 108,465 4.35 8.71 Data Processing & Outsourced Services 125,259 4.33 8.26 111,335 4.46 8.94 Industrial Machinery & Supplies & Components 98,352 3.40 6.49 81,008 3.25 6.50 Health Care Technology 95,404 3.30 6.29 97,315 3.90 7.81 Real Estate Operating Companies 82,463 2.85 5.44 48,062 1.93 3.86 Pharmaceuticals 80,455 2.78 5.31 119,511 4.79 9.59 Specialized Finance 69,590 2.41 4.59 73,087 2.93 5.87 Broadline Retail 69,040 2.39 4.55 70,419 2.82 5.65 Health Care Services 66,683 2.31 4.40 45,943 1.84 3.69 Fertilizers & Agricultural Chemicals 63,185 2.18 4.17 51,972 2.08 4.17 Environmental & Facilities Services 62,413 2.16 4.12 20,585 0.83 1.65 Health Care Distributors 60,865 2.10 4.02 54,662 2.19 4.39 Internet Services & Infrastructure 60,579 2.09 4.00 53,797 2.16 4.32 Diversified Financial Services 60,003 2.07 3.96 24,326 0.98 1.95 Personal Care Products 59,928 2.07 3.95 50,150 2.01 4.03 Automotive Retail 55,805 1.93 3.68 57,629 2.31 4.63 Airport Services 54,453 1.88 3.59 42,883 1.72 3.44 Metal, Glass & Plastic Containers 53,459 1.85 3.53 47,599 1.91 3.82 Home Improvement Retail 53,168 1.84 3.51 45,421 1.82 3.65 Insurance Brokers 53,050 1.83 3.50 33,081 1.33 2.66 Aerospace & Defense 51,862 1.79 3.42 61,881 2.48 4.97 Diversified Metals & Mining 49,869 1.72 3.29 — — — Auto Parts & Equipment 49,148 1.70 3.24 11,469 0.46 0.92 Real Estate Services 43,886 1.52 2.90 39,573 1.59 3.18 Soft Drinks & Non-alcoholic Beverages 42,391 1.47 2.80 — — — Other Specialty Retail 41,115 1.42 2.71 — — — Specialty Chemicals 38,615 1.34 2.55 33,969 1.36 2.73 Distributors 37,311 1.29 2.46 24,494 0.98 1.97 Leisure Facilities 36,963 1.28 2.44 39,258 1.57 3.15 Electrical Components & Equipment 32,573 1.13 2.15 32,933 1.32 2.64 Passenger Airlines 27,512 0.95 1.82 — — — Real Estate Development 23,679 0.82 1.56 — — — Diversified Support Services 23,352 0.81 1.54 36,712 1.47 2.95 Gold 23,328 0.81 1.54 — — — Health Care Equipment 22,436 0.78 1.48 24,161 0.97 1.94 Systems Software 21,968 0.76 1.45 12,834 0.51 1.03 Construction & Engineering 21,903 0.76 1.45 61,188 2.45 4.91 Home Furnishings 19,954 0.69 1.32 18,188 0.73 1.46 Interactive Media & Services 19,199 0.66 1.27 — — — Hotels, Resorts & Cruise Lines 16,991 0.59 1.12 13,985 0.56 1.12 Integrated Telecommunication Services 16,492 0.57 1.09 32,201 1.29 2.59 Oil & Gas Storage & Transportation 16,040 0.55 1.06 20,853 0.84 1.67 Consumer Finance 15,087 0.52 1.00 13,284 0.53 1.07 Education Services 13,618 0.47 0.90 8,582 0.34 0.69 Restaurants 12,464 0.43 0.82 8,692 0.35 0.70 Advertising 11,955 0.41 0.79 26,948 1.08 2.16 Movies & Entertainment 11,865 0.41 0.78 26,645 1.07 2.14 Health Care Supplies 11,363 0.39 0.75 36,577 1.47 2.94 Food Distributors 5,166 0.18 0.34 3,367 0.13 0.27 Apparel Retail 5,002 0.17 0.33 5,223 0.21 0.42 Research & Consulting Services 4,831 0.17 0.32 8,573 0.34 0.69 Integrated Oil & Gas 4,785 0.17 0.32 4,872 0.20 0.39 Cable & Satellite 4,546 0.16 0.30 19,576 0.78 1.57 Air Freight & Logistics 4,263 0.15 0.28 6,405 0.26 0.51 Other Specialized REITs 3,198 0.11 0.21 — — — Paper & Plastic Packaging Products & Materials 3,061 0.11 0.20 — — — Housewares & Specialties 2,808 0.10 0.19 2,456 0.10 0.20 Leisure Products 2,063 0.07 0.14 — — — Technology Distributors 776 0.03 0.05 2,997 0.12 0.24 Soft Drinks — — — 33,670 1.35 2.70 Oil & Gas Refining & Marketing — — — 8,604 0.34 0.69 IT Consulting & Other Services — — — 8,596 0.34 0.69 Trading Companies & Distributors — — — 5,567 0.22 0.45 Diversified Banks — — — 3,402 0.14 0.27 Specialized REITs — — — 3,264 0.13 0.26 Construction Materials — — — 1,934 0.08 0.16 Electronic Components — — — 1,890 0.08 0.15 Alternative Carriers — — — 201 0.01 0.02 Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % ___________________ (1) This industry includes the Company's investments in the JVs. As of September 30, 2023 and September 30, 2022, the Company had no single investment that represented greater than 10% of the total investment portfolio at fair value. Income, consisting of interest, dividends, fees, other investment income and realization of gains or losses, may fluctuate and in any given period can be highly concentrated among several investments. Senior Loan Fund JV I, LLC In May 2014, the Company entered into an LLC agreement with Kemper to form SLF JV I. The Company co-invests in senior secured loans of middle-market companies and other corporate debt securities with Kemper through its investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by the Company and one representative selected by Kemper (with approval from a representative of each required). Since the Company does not have a controlling financial interest in SLF JV I, the Company does not consolidate SLF JV I. SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to the Company and Kemper by SLF JV I. The subordinated notes issued by SLF JV I (the "SLF JV I Notes") are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV I’s secured debt. As of September 30, 2023 and September 30, 2022, the Company and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. SLF JV I has a revolving credit facility with Bank of America, N.A. (the "SLF JV I Facility"), which permitted up to $270.0 million of borrowings (subject to borrowing base and other limitations) as of September 30, 2023. Borrowings under the SLF JV I Facility are secured by all of the assets of SLF JV I Funding II LLC, a special purpose financing subsidiary of SLF JV I. As of September 30, 2023, the revolving period of the SLF JV I Facility was scheduled to expire August 12, 2026 and the maturity date was August 17, 2026. As of September 30, 2023, borrowings under the SLF JV I Facility accrued interest at a rate equal to daily SOFR plus 2.00% per annum. $149.0 million of borrowings were outstanding under the SLF JV I Facility as of September 30, 2023. As of September 30, 2023 and September 30, 2022, SLF JV I had total assets of $376.1 million and $385.2 million, respectively. SLF JV I's portfolio primarily consisted of senior secured loans to 48 and 60 portfolio companies as of September 30, 2023 and September 30, 2022, respectively. The portfolio companies in SLF JV I are in industries similar to those in which the Company may invest directly. As of September 30, 2023, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of $141.5 million in aggregate, at fair value. As of September 30, 2022, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of $117.0 million in aggregate, at fair value. As of September 30, 2023, the Company and Kemper had funded approximately $190.5 million to SLF JV I, of which $166.7 million was from the Company. As of September 30, 2022, the Company and Kemper had funded approximately $165.5 million to SLF JV I, of which $144.8 million was from the Company. As of September 30, 2023, the Company had aggregate commitments to fund SLF JV I of $13.1 million, of which approximately $9.8 million was to fund additional SLF JV I Notes and approximately $3.3 million was to fund LLC equity interests in SLF JV I. During the year ended September 30, 2023, the Company contributed $16.4 million to fund additional SLF JV I Notes and approximately $5.5 million to fund additional LLC equity interests in SLF JV I. As of September 30, 2022, the Company had aggregate commitments to fund SLF JV I of |
Fee Income
Fee Income | 12 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Fee Income | Fee IncomeFor the years ended September 30, 2023, 2022 and 2021, the Company recorded total fee income of $6.5 million, $6.6 million and $14.1 million, respectively, of which $0.9 million, $0.9 million and $0.6 million respectively, was recurring in nature. Recurring fee income primarily consisted of servicing fees and certain exit fees. |
Share Data and Net Assets
Share Data and Net Assets | 12 Months Ended |
Sep. 30, 2023 | |
Stockholders' Equity Note [Abstract] | |
Share Data and Net Assets | Share Data and Net Assets The share and per share information for the years ended September 30, 2022 and September 30, 2021 disclosed in Note 5 have been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. Earnings per Share The following table sets forth the computation of basic and diluted earnings per share, pursuant to ASC Topic 260-10, Earnings per Share , for the years ended September 30, 2023, 2022 and 2021: (Share amounts in thousands) Year ended Year ended Year ended Earnings (loss) per common share — basic and diluted: Net increase (decrease) in net assets resulting from operations $ 117,331 $ 29,223 $ 237,260 Weighted average common shares outstanding — basic and diluted 72,119 60,727 54,039 Earnings (loss) per common share — basic and diluted $ 1.63 $ 0.48 $ 4.39 Changes in Net Assets The following table presents the changes in net assets for the years ended September 30, 2023, 2022 and 2021: Common Stock (Share amounts in thousands) Shares Par Value Additional paid-in-capital Accumulated Overdistributed Earnings Total Net Assets Balance as of September 30, 2020 46,987 $ 470 $ 1,488,713 $ (574,304) $ 914,879 Net investment income — — — 97,106 97,106 Net unrealized appreciation (depreciation) — — — 114,519 114,519 Net realized gains (losses) — — — 26,420 26,420 (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (785) (785) Distributions to stockholders — — — (82,020) (82,020) Reclassification of additional paid-in capital — — 74,271 (74,271) — Issuance of common stock in connection with the OCSI Merger 13,133 131 242,573 — 242,704 Issuance of common stock under dividend reinvestment plan 113 1 2,169 — 2,170 Repurchases of common stock under dividend reinvestment plan (113) (1) (2,169) — (2,170) Balance as of September 30, 2021 60,120 601 1,805,557 (493,335) 1,312,823 Net investment income — — — 148,621 148,621 Net unrealized appreciation (depreciation) — — — (136,248) (136,248) Net realized gains (losses) — — — 17,179 17,179 (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (329) (329) Distributions to stockholders — — — (118,657) (118,657) Issuance of common stock in connection with the "at the market" offering 934 9 20,613 — 20,622 Issuance of common stock under dividend reinvestment plan 166 2 3,407 — 3,409 Repurchase of common stock under dividend reinvestment plan (95) (1) (1,856) — (1,857) Balance as of September 30, 2022 61,125 611 1,827,721 (582,769) 1,245,563 Net investment income — — — 180,697 180,697 Net unrealized appreciation (depreciation) — — — (28,555) (28,555) Net realized gains (losses) — — — (33,155) (33,155) (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (1,656) (1,656) Distributions to stockholders — — — (185,900) (185,900) Issuance of common stock in connection with the OSI2 Merger 15,860 159 333,875 — 334,034 Issuance of common stock in connection with the "at the market" offering 69 1 1,299 — 1,300 Issuance of common stock under dividend reinvestment plan 297 3 5,851 — 5,854 Repurchase of common stock under dividend reinvestment plan (126) (2) (2,416) — (2,418) Balance as of September 30, 2023 77,225 $ 772 $ 2,166,330 $ (651,338) $ 1,515,764 Distributions Distributions to common stockholders are recorded on the ex-dividend date. The amount to be paid out as a dividend is determined by the Board of Directors and is based on management’s estimate of the Company’s annual taxable income. Net realized capital gains, if any, may be distributed to stockholders or retained for reinvestment. The Company has adopted a dividend reinvestment plan (“DRIP”) that provides for reinvestment of any distributions the Company declares in cash on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Company’s Board of Directors declares a cash distribution, then the Company’s stockholders who have not “opted out” of the Company’s DRIP will have their cash distribution automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. If the Company’s shares are trading at a premium to net asset value, the Company typically issues new shares to implement the DRIP with such shares issued at the greater of the most recently computed net asset value per share of common stock or 95% of the current market price per share of common stock on the payment date for such distribution. If the Company’s shares are trading at a discount to net asset value, the Company typically purchases shares in the open market in connection with the Company’s obligations under the DRIP. For income tax purposes, the Company has reported its distributions for the 2022 calendar year as ordinary income. The character of such distributions was appropriately reported to the Internal Revenue Service and stockholders for the 2022 calendar year. To the extent the Company’s taxable earnings for a fiscal and taxable year fall below the amount of distributions paid for the fiscal and taxable year, a portion of the total amount of the Company’s distributions for the fiscal and taxable year is deemed a return of capital for U.S. federal income tax purposes to the Company’s stockholders. For the year ended September 30, 2023, no portion of the distributions was deemed a return of capital for tax purposes. The following table reflects the distributions per share that the Company has paid, including shares issued under the DRIP, on its common stock during the years ended September 30, 2023, 2022 and 2021: Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly November 10, 2022 December 15, 2022 December 30, 2022 $ 0.54 $ 32.0 million 53,369 (1) $ 1.1 million Special November 10, 2022 December 15, 2022 December 30, 2022 0.42 24.8 million 41,510 (1) 0.8 million Quarterly January 27, 2023 March 15, 2023 March 31, 2023 0.55 41.1 million 68,412 (2) 1.3 million Quarterly April 28, 2023 June 15, 2023 June 30, 2023 0.55 41.3 million 57,279 (2) 1.1 million Quarterly July 28, 2023 September 15, 2023 September 29, 2023 0.55 40.9 million 76,766 (1) 1.5 million Total for the year ended September 30, 2023 $ 2.61 $ 180.0 million 297,336 $ 5.9 million Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly October 13, 2021 December 15, 2021 December 31, 2021 $ 0.465 $ 27.2 million 35,990 (1) $ 0.8 million Quarterly January 28, 2022 March 15, 2022 March 31, 2022 0.48 28.5 million 34,804 (1) 0.8 million Quarterly April 29, 2022 June 15, 2022 June 30, 2022 0.495 29.4 million 43,676 (2) 0.9 million Quarterly July 29, 2022 September 15, 2022 September 30, 2022 0.51 30.2 million 51,181 (2) 1.0 million Total for the year ended September 30, 2022 $ 1.95 $ 115.3 million 165,651 $ 3.4 million Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly November 13, 2020 December 15, 2020 December 31, 2020 $ 0.33 $ 15.0 million 31,321 (2) $ 0.5 million Quarterly January 29, 2021 March 15, 2021 March 31, 2021 0.36 16.4 million 27,234 (2) 0.5 million Quarterly April 30, 2021 June 15, 2021 June 30, 2021 0.39 22.9 million 25,660 (2) 0.5 million Quarterly July 30, 2021 September 15, 2021 September 30, 2021 0.435 25.5 million 28,358 (2) 0.6 million Total for the year ended September 30, 2021 $ 1.515 $ 79.8 million 112,573 $ 2.2 million __________ (1) New shares were issued and distributed. (2) Shares were purchased on the open market and distributed. (3) Totals may not sum due to rounding. Common Stock Issuances On January 23, 2023, in connection with the OSI2 Merger, the Company issued an aggregate of 15,860,200 shares of common stock to former OSI2 stockholders. On March 19, 2021, in connection with the OCSI Merger, the Company issued an aggregate of 13,133,337 shares of common stock to former OCSI stockholders. There were no other common stock issuances during the year ended September 30, 2021. During the year ended September 30, 2023, the Company issued 171,645 shares of common stock as part of the DRIP. During the year ended September 30, 2022, the Company issued an aggregate of 70,794 shares of common stock as part of the DRIP. On February 7, 2022, the Company entered into an equity distribution agreement by and among the Company, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by the Company of shares of common stock, having an aggregate offering price of up to $125.0 million. The equity distribution agreement was amended on February 8, 2023 to allow for the sale of shares of the Company’s common stock having an aggregate offering price of up to $125 million under the Company’s current registration statement and on August 8, 2023 to add Jefferies LLC as an additional placement agent and to remove SMBC Nikko Securities America, Inc. as replacement agent. Sales of the common stock may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. In connection with the "at the market" offering, the Company issued and sold 68,752 shares of common stock during the year ended September 30, 2023 for net proceeds of $1.3 million (net of offering costs). Number of Shares Issued Gross Proceeds Placement Agent Fees Net Proceeds (1) Average Sales Price per Share (2) "At the market" offering 68,752 $ 1,384 $ 14 $ 1,370 $ 20.13 (1) Net proceeds excludes offering costs of $0.1 million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. In connection with the "at the market" offering, the Company issued and sold 933,733 shares of common stock during the year ended September 30, 2022 for net proceeds of $20.6 million (net of offering costs). Number of Shares Issued Gross Proceeds Placement Agent Fees Net Proceeds (1) Average Sales Price per Share (2) "At the market" offering 933,733 $ 21,049 $ 210 $ 20,839 $ 22.54 __________ (1) Net proceeds excludes offering costs of $0.2 million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. |
Borrowings
Borrowings | 12 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Borrowings | Borrowings Syndicated Facility On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the “Syndicated Facility”) pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank. As of September 30, 2023, the size of the Syndicated Facility was $1.218 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of $1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances. As of September 30, 2023, (i) the period during which the Company may make drawings with respect to $1.035 billion of commitments will expire on June 23, 2027 and the maturity date is June 23, 2028, (ii) the period during which the Company may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iii) the interest rate margin for (a) SOFR loans (which may be 1- or 3-month, at the Company’s option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%. The Syndicated Facility is secured by substantially all of the Company’s assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OSI 2 Senior Lending SPV, LLC) or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. As of September 30, 2023, except for assets that were held by OSI 2 Senior Lending SPV, LLC and certain immaterial subsidiaries, substantially all of the Company's assets are pledged as collateral under the Syndicated Facility. The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company’s portfolio companies’ businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders’ equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of September 30, 2023, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company’s portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. As of September 30, 2023 and September 30, 2022, the Company had $430.0 million and $540.0 million of borrowings outstanding under the Syndicated Facility, respectively, which had a fair value of $430.0 million and $540.0 million, respectively. The Company's borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 6.792%, 2.876% and 2.197% for the years ended September 30, 2023, 2022 and 2021, respectively. For the years ended September 30, 2023, 2022 and 2021, the Company recorded interest expense (inclusive of fees) of $50.0 million, $19.5 million and $13.8 million, respectively, related to the Syndicated Facility. Citibank Facility On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the “Citibank Facility”) with OCSL Senior Funding II LLC (formerly OCSI Senior Funding II LLC), the Company’s wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OSI2 Citibank Facility, the Citibank Facility was terminated. In connection with the termination of the Citibank Facility, the Company accelerated $0.6 million of deferred financing costs into interest expense during the year ended September 30, 2023. As of September 30, 2022, the Company had $160.0 million outstanding under the Citibank Facility, which had a fair value of $160.0 million. The Company's borrowings under the Citibank Facility bore interest at a weighted average interest rate of 6.781%, 3.179% and 2.086% for the years ended September 30, 2023 and 2022 and the period from March 19, 2021 to September 30, 2021, respectively. For the years ended September 30, 2023 and 2022 and the period from March 19, 2021 to September 30, 2021, the Company recorded interest expense (inclusive of fees) of $8.0 million, $5.8 million and $1.9 million, respectively, related to the Citibank Facility. OSI2 Citibank Facility On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the “OSI2 Citibank Facility”) with OSI 2 Senior Lending SPV, LLC (“OSI 2 SPV”), the Company’s wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent. As of September 30, 2023, the Company was able to borrow up to $400 million under the OSI2 Citibank Facility (subject to borrowing base and other limitations). As of September 30, 2023, the OSI2 Citibank Facility has a reinvestment period through May 25, 2025, during which advances may be made, and matures on January 26, 2027. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to (a) in the case of a lender that is identified as a conduit lender, the lesser of (i) the applicable commercial paper rate for such conduit lender and (ii) SOFR plus 2.00% per annum on broadly syndicated loans and 2.75% on all other eligible loans and (b) for all other lenders, SOFR plus 2.00% per annum on broadly syndicated loans and 2.75% per annum on all other eligible loans, in all cases subject to a minimum overall rate of SOFR plus 2.50% per annum. After the reinvestment period, the applicable spread is 4.00% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility. The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV’s assets. As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility. As of September 30, 2023, the Company had $280.0 million outstanding under the OSI2 Citibank Facility, which had a fair value of $280.0 million. The Company’s borrowings under the OSI2 Citibank Facility bore interest at a weighted average interest rate of 7.666% for the period from January 23, 2023 to September 30, 2023. For the period from January 23, 2023 to September 30, 2023, the Company recorded interest expense (inclusive of fees) of $14.6 million related to the OSI2 Citibank Facility. 2025 Notes On February 25, 2020, the Company issued $300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of $293.8 million after deducting OID of $2.5 million, underwriting commissions and discounts of $3.0 million and offering costs of $0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes. The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a “make-whole” premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. During the year ended September 30, 2023, the Company did not repurchase any of the 2025 Notes in the open market. The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. 2027 Notes On May 18, 2021, the Company issued $350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of $344.8 million after deducting OID of $1.0 million, underwriting commissions and discounts of $3.5 million and offering costs of $0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes. The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2027 Notes is paid semi-annually on January 15 and July 15, beginning on January 15, 2022, at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a “make-whole” premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. During the year ended September 30, 2023, the Company did not repurchase any of the 2027 Notes in the open market. The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of $350 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. 2029 Notes On August 15, 2023, the Company issued $300.0 million in aggregate principal amount of the 2029 Notes for net proceeds of $292.9 million after deducting OID of $3.5 million, underwriting commissions and discounts of $3.0 million and offering costs of $0.6 million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes. The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a “make-whole” premium, if applicable. In addition, holders of the 2029 Notes can require the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. During the year ended September 30, 2023, the Company did not repurchase any of the 2029 Notes in the open market. The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of $300 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of September 30, 2023 and September 30, 2022: As of September 30, 2023 As of September 30, 2022 ($ in millions) 2025 Notes 2027 Notes 2029 Notes 2025 Notes 2027 Notes Principal $ 300.0 $ 350.0 $ 300.0 $ 300.0 $ 350.0 Unamortized financing costs (1.1) (2.5) (3.5) (1.8) (3.2) Unaccreted discount (0.7) (0.6) (3.4) (1.2) (0.7) Interest rate swap fair value adjustment — (40.5) (7.0) — (42.0) Net carrying value $ 298.2 $ 306.4 $ 286.1 $ 297.0 $ 304.1 Fair Value $ 286.4 $ 301.8 $ 290.0 $ 283.1 $ 294.0 The below table presents the components of interest and other debt expenses related to the 2025 Notes, the 2027 Notes and the 2029 Notes for the year ended September 30, 2023: ($ in millions) 2025 Notes 2027 Notes 2029 Notes Coupon interest $ 10.5 $ 9.5 $ 2.7 Amortization of financing costs and discount 1.3 0.9 0.2 Effect of interest rate swap — 13.4 0.6 Total interest expense $ 11.8 $ 23.8 $ 3.5 Coupon interest rate (net of effect of interest rate swaps) 3.500 % 6.539 % 8.490 % The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the year ended September 30, 2022: ($ in millions) 2025 Notes 2027 Notes Coupon interest $ 10.5 $ 9.5 Amortization of financing costs and discount 1.3 0.9 Effect of interest rate swap — (0.4) Total interest expense $ 11.8 $ 10.0 Coupon interest rate (net of effect of interest rate swap for 2027 Notes) 3.500 % 2.585 % The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the year ended September 30, 2021: ($ in millions) 2025 Notes 2027 Notes Coupon interest $ 10.5 $ 3.5 Amortization of financing costs and discount 1.3 0.3 Effect of interest rate swap — (1.1) Total interest expense $ 11.8 $ 2.7 Coupon interest rate (net of effect of interest rate swap for 2027 Notes) 3.500 % 1.813 % |
Taxable_Distributable Income an
Taxable/Distributable Income and Dividend Distributions | 12 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Taxable/Distributable Income and Dividend Distributions | Taxable/Distributable Income and Dividend Distributions Taxable income differs from net increase (decrease) in net assets resulting from operations primarily due to: (1) unrealized appreciation (depreciation) on investments and foreign currency, as gains and losses are not included in taxable income until they are realized; (2) origination and exit fees received in connection with investments in portfolio companies; (3) organizational costs; (4) income or loss recognition on exited investments; and (5) recognition of interest income on certain loans. As of September 30, 2023, the Company had net capital loss carryforwards of $558.3 million to offset net capital gains that will not expire, to the extent available and permitted by U.S. federal income tax law, of which $70.3 million are available to offset future short-term capital gains and $488.0 million are available to offset future long-term capital gains. A portion of such net capital loss carryfowards represented a realized loss under sections 382 and 383 of the Code, which is carried forward to future years to offset future gains subject to certain limitations. Listed below is a reconciliation of "net increase (decrease) in net assets resulting from operations" to taxable income for the years ended September 30, 2023, 2022 and 2021. Year ended Year ended Year ended Net increase (decrease) in net assets resulting from operations $ 117,331 $ 29,223 $ 237,260 Net unrealized (appreciation) depreciation 28,555 136,248 (114,519) Book/tax difference due to organizational costs — (87) (87) Book/tax difference due to capital losses suspended (utilized) 34,607 (16,490) (41,625) Other book/tax differences (14,691) (6,506) 11,863 Taxable/Distributable Income (1) $ 165,802 $ 142,388 $ 92,892 __________ (1) The Company's taxable income for the year ended September 30, 2023 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2023. Therefore, the final taxable income may be different than the estimate. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences. When assessing the realizability of deferred tax assets, the Company considers whether it is probable that some or all of the deferred tax assets will not be realized. In determining whether the deferred tax assets are realizable, the Company considers the period of expiration of the tax asset, historical and projected taxable income and tax liabilities for the tax jurisdiction in which the tax asset is located. The deferred tax asset recognized by the Company, as it relates to the higher tax basis in the carrying value of certain assets compared to the book basis of those assets, will be recognized in future years by these taxable entities. Deferred tax assets are based on the amount of the tax benefit that the Company’s management has determined is more likely than not to be realized in future periods. In determining the realizability of this tax benefit, management considered numerous factors that will give rise to pre-tax income in future periods. Among these are the historical and expected future book and tax basis pre-tax income of the Company and unrealized gains in the Company’s assets at the determination date. Based on these and other factors, the Company determined that, as of September 30, 2023, $8.1 million of the $8.1 million deferred tax assets would not more likely than not be realized in future periods. As of September 30, 2023, the Company recorded a net deferred tax liability of less than $0.1 million on the Consolidated Statements of Assets and Liabilities. For the year ended September 30, 2023, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of $1.7 million, which was composed primarily of a deferred income tax expense. For the year ended September 30, 2022, the Company recognized a provision for income tax related to net investment income of $3.3 million, which was all current income tax expense. For the year ended September 30, 2022, the Company also recognized a total provision for income tax related to realized and unrealized gains (losses) of $0.3 million, which was composed of (i) a current income tax expense of approximately $1.3 million and (ii) a deferred income tax benefit of approximately $1.0 million, which resulted from unrealized depreciation on investments held by the Company’s wholly-owned taxable subsidiaries. For the year ended September 30, 2021, the Company recognized a total provision for income tax related to realized and unrealized gains of $0.8 million, which was composed of (i) a current income tax expense of approximately $0.7 million, and (ii) a deferred income tax expense of approximately $0.1 million, which resulted from unrealized appreciation on investments held by the Company’s wholly-owned taxable subsidiaries. For the year ended September 30, 2021, the Company recognized a provision for income tax related to net investment income of $2.8 million, which was all current income tax expense. As of September 30, 2023, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows: Undistributed ordinary income, net $ 33,525 Net realized capital losses (509,832) Unrealized losses, net (175,031) Accumulated overdistributed earnings $ (651,338) The aggregate cost of investments for U.S. federal income tax purposes was $3,070.0 million as of September 30, 2023. As of September 30, 2023, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was $529.5 million. As of September 30, 2023, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was $704.5 million. Net unrealized depreciation based on the aggregate cost of investments for U.S. federal income tax purposes was $175.0 million. |
Realized Gains or Losses and Ne
Realized Gains or Losses and Net Unrealized Appreciation or Depreciation | 12 Months Ended |
Sep. 30, 2023 | |
Investment Company [Abstract] | |
Realized Gains or Losses and Net Unrealized Appreciation or Depreciation | Realized Gains or Losses and Net Unrealized Appreciation or Depreciation Realized Gains or Losses Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption and the cost basis of the investment without regard to unrealized appreciation or depreciation previously recognized, and include investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with the Company's determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules. During the year ended September 30, 2023, the Company recorded an aggregate net realized loss of $33.2 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) SIO2 Medical Products Inc. $ (13.9) Convergeone Holdings Inc. (6.0) Foreign currency forward contracts (5.8) Aden & Anais Merger Sub Inc. (5.2) Radiology Partners Inc. (4.2) Carvana Co. (2.8) Impel Neuropharma Inc. (2.3) ASP Unifrax Holdings Inc. (2.1) WP CPP Holdings LLC (1.3) Global Medical Response Inc. (1.0) Athenex Inc. 6.5 Tersera Therapeutics LLC 5.2 CorEvitas Group Holdings LP 4.0 Other, net (4.3) Total, net $ (33.2) During the year ended September 30, 2022, the Company recorded an aggregate net realized gain of $17.2 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) Foreign currency forward contracts $ 13.7 OmniSYS Acquisition Corporation 2.2 First Star Speir Aviation Limited 1.9 TigerConnect Inc. 1.8 WP CPP Holdings, LLC (1.7) Other, net (0.7) Total, net $ 17.2 During the year ended September 30, 2021, the Company recorded an aggregate net realized gain of $26.4 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) PLATO Learning Inc. $ 7.8 Keypath Education Holdings, LLC 6.8 L Squared Capital Partners LLC 3.4 LTI Holdings, Inc. 2.6 BX Commercial Mortgage Trust 2020-VIVA 2.6 California Pizza Kitchen Inc. (1.8) Refac Optical Group (1.3) Other, net 6.3 Total, net $ 26.4 Net Unrealized Appreciation or Depreciation Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation. During the years ended September 30, 2023, 2022 and 2021, the Company recorded net unrealized appreciation (depreciation) of $(28.6) million, $(136.2) million and $114.5 million, respectively. For the year ended September 30, 2023, this consisted of $49.1 million of net unrealized depreciation on debt investments and $4.9 million of net unrealized depreciation on equity investments, partially offset by $25.4 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and $0.1 million of net unrealized appreciation of foreign currency forward contracts. For the year ended September 30, 2022, this consisted of $94.1 million of net unrealized depreciation on debt investments, $35.4 million of net unrealized depreciation on equity investments and $11.7 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains), partially offset by $4.9 million of net unrealized appreciation of foreign currency forward contracts. For the year ended September 30, 2021, this consisted of $70.0 million of net unrealized appreciation on debt investments, $36.3 million of net unrealized appreciation on equity investments, $6.6 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and $1.7 million of net unrealized appreciation of foreign currency forward contracts. During the year ended September 30, 2023, unrealized depreciation included a one-time unrealized loss of $20.7 million that resulted solely from accounting adjustments related to the OSI2 Merger. During the year ended September 30, 2021, unrealized depreciation included a one-time unrealized gain of $34.1 million that resulted solely from accounting adjustments related to the OCSI Merger. |
Concentration of Credit Risk
Concentration of Credit Risk | 12 Months Ended |
Sep. 30, 2023 | |
Risks and Uncertainties [Abstract] | |
Concentration of Credit Risk | Concentration of Credit Risks The Company deposits its cash with financial institutions and at times such balances are in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Sep. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions As of September 30, 2023 and September 30, 2022, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of $19.5 million and $15.9 million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree. Investment Advisory Agreement The Company is party to the Investment Advisory Agreement. Under the Investment Advisory Agreement, the Company pays Oaktree a fee for its services under the Investment Advisory Agreement consisting of two components: a base management fee and an incentive fee. The cost of both the base management fee payable to Oaktree and any incentive fees earned by Oaktree is ultimately borne by common stockholders of the Company. The investment advisory agreement with Oaktree was amended and restated on March 19, 2021 in connection with the closing of the OCSI Merger and on January 23, 2023 in connection with the closing of OSI2 Merger. The term “Investment Advisory Agreement” refers collectively to the agreements with Oaktree. Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-to-year if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the Company’s outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 days’ written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company. Base Management Fee Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019, the base management fee on the Company’s gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the Company’s net asset value will be 1.00%. For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the OCSI Merger, Oaktree waived an aggregate of $6 million of base management fees otherwise payable to Oaktree in the two years following the closing of the OCSI Merger on March 19, 2021 at a rate of $750,000 per quarter (with such amount appropriately prorated for any partial quarter). In connection with the OSI2 Merger, Oaktree waived an aggregate of $9.0 million of base management fees payable to Oaktree as follows: $6.0 million at a rate of $1.5 million per quarter (with such amount appropriately prorated for any partial quarter) in the first year following closing of the OSI2 Merger on January 23, 2023 and $3.0 million at a rate of $750,000 per quarter (with such amount appropriately prorated for any partial quarter) in the second year following closing of the OSI2 Merger. For the years ended September 30, 2023, 2022 and 2021, the base management fee incurred under the Investment Advisory Agreement was $39.4 million (net of waiver), $36.6 million (net of waiver) and $30.7 million (net of waiver), respectively. Incentive Fee The incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the “incentive fee on income” or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the “pre-incentive fee net investment income” of the Company for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a “hurdle rate”), expressed as a rate of return on the value of the Company’s net assets at the end of the most recently completed quarter, of 1.50%, subject to a “catch up” feature. For this purpose, “pre-incentive fee net investment income” means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the Company’s operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income. Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows: • No incentive fee is payable to Oaktree in any quarter in which the Company’s pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the “preferred return”) on net assets; • 100% of the Company’s pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the “catch-up” provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company’s pre-incentive fee net investment income when the Company’s pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; and • For any quarter in which the Company’s pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company’s pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved. There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle. For the years ended September 30, 2023, 2022 and 2021, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was $35.8 million, $26.6 million and $21.6 million, respectively. Under the Investment Advisory Agreement, the second part of the incentive fee (the "capital gains incentive fee") is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company’s realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company’s portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of September 30, 2023, the Company paid $9.6 million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). For the years ended September 30, 2023 and September 30, 2022, the Company did not incur any capital gains incentive fees under the Investment Advisory Agreement. For the year ended September 30, 2021, the Company incurred $8.8 million of capital gains incentive fees under the Investment Advisory Agreement. GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company’s portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the year ended September 30, 2023, there were no accrued capital gains incentive fees. For the year ended September 30, 2022, $8.8 million of previously accrued capital gains incentive fees were reversed. For the year ended September 30, 2021, $17.6 million of accrued capital gains incentive fees were expensed. As of September 30, 2023, the total accrued capital gains incentive fee liability was zero. Indemnification The Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser. Administrative Services The Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company’s Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company’s Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company’s business and affairs, in each case, as it shall determine to be desirable or as reasonably required by the Company’s Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation. Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company’s stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company’s net asset value, overseeing the preparation and filing of the Company’s tax returns, and generally overseeing the payment of the Company’s expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company’s behalf, managerial assistance to the Company’s portfolio companies. For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company’s allocable portion of the rent of the Company’s principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company’s allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non- investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days’ written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company’s outstanding voting securities. For the years ended September 30, 2023, 2022 and 2021, the Company accrued administrative expenses of $1.5 million, $1.5 million and $1.7 million, respectively, including $0.3 million, $0.3 million and $0.2 million of general and administrative expenses, respectively. As of September 30, 2023 and September 30, 2022, $4.3 million and $3.2 million, respectively, was included in “Due to affiliate” in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator. |
Financial Highlights
Financial Highlights | 12 Months Ended |
Sep. 30, 2023 | |
Investment Company [Abstract] | |
Financial Highlights | Financial Highlights (Share amounts in thousands) Year ended Year ended Year ended Year ended Year ended Net asset value per share at beginning of period $20.38 $21.84 $19.47 $19.81 $18.26 Net investment income (1) 2.51 2.45 1.80 1.53 1.45 Net unrealized appreciation (depreciation) (1)(7) (0.17) (2.23) 2.19 (0.44) 0.82 Net realized gains (losses) (1) (0.46) 0.28 0.49 (0.30) 0.44 (Provision) benefit for taxes on realized and unrealized gains (losses) (1) (0.02) (0.01) (0.02) 0.04 (0.02) Distributions of net investment income to stockholders (2.61) (1.95) (1.52) (1.17) (1.14) Issuance of common stock — — (0.57) — — Net asset value per share at end of period $19.63 $20.38 $21.84 $19.47 $19.81 Per share market value at beginning of period $18.00 $21.18 $14.52 $15.54 $14.88 Per share market value at end of period $20.12 $18.00 $21.18 $14.52 $15.54 Total return (2) 27.30% (6.71)% 57.61% 2.10% 12.56% Common shares outstanding at beginning of period 61,125 60,120 46,987 46,987 46,987 Common shares outstanding at end of period 77,225 61,125 60,120 46,987 46,987 Net assets at beginning of period $1,245,563 $1,312,823 $914,879 $930,630 $858,035 Net assets at end of period $1,515,764 $1,245,563 $1,312,823 $914,879 $930,630 Average net assets (3) $1,437,728 $1,308,518 $1,150,662 $871,305 $909,264 Ratio of net investment income to average net assets (3) 12.57% 11.36% 8.44% 8.26% 7.47% Ratio of total expenses to average net assets (3) 14.19% 8.68% 9.65% 7.57% 9.65% Ratio of net expenses to average net assets (3) 13.81% 8.45% 9.51% 8.16% 8.78% Ratio of portfolio turnover to average investments at fair value 26.12% 26.99% 39.66% 38.99% 32.50% Weighted average outstanding debt (4) $1,659,701 $1,361,151 $964,390 $647,080 $573,891 Average debt per share (1) $23.01 $22.41 $17.85 $13.77 $12.21 Asset coverage ratio at end of period (5) 187.74% 188.64% 201.68% 227.22% 294.91% __________ (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of $1,660.0 million, $1,350.0 million, $1,280.0 million, $714.8 million and $476.1 million as of September 30, 2023, 2022, 2021, 2020 and 2019, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) For the year ended September 30, 2023, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OSI2 Merger. For the year ended September 30, 2021, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OCSI Merger. Senior Securities Information about our senior securities (including debt securities and other indebtedness) is shown in the following table as of the fiscal years ended September 30 for the years indicated below. Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) Syndicated Facility and Prior ING Facility Fiscal 2014 $ 267,395 2,595 — N/A Fiscal 2015 383,495 2,389 — N/A Fiscal 2016 472,495 2,208 — N/A Fiscal 2017 226,495 2,274 — N/A Fiscal 2018 241,000 2,330 — N/A Fiscal 2019 314,825 2,949 — N/A Fiscal 2020 414,825 2,272 — N/A Fiscal 2021 495,000 2,017 — N/A Fiscal 2022 540,000 1,886 — N/A Fiscal 2023 430,000 1,877 — N/A Citibank Facility Fiscal 2021 $ 135,000 2,017 — N/A Fiscal 2022 160,000 1,886 — N/A OSI2 Citibank Facility Fiscal 2023 $ 280,000 1,877 — N/A Sumitomo Facility Fiscal 2014 $ 50,000 2,595 — N/A Fiscal 2015 43,800 2,389 — N/A Fiscal 2016 43,800 2,208 — N/A Fiscal 2017 29,500 2,274 — N/A Convertible Notes Fiscal 2014 $ 115,000 2,595 — N/A Fiscal 2015 115,000 2,389 — N/A Secured Borrowings Fiscal 2014 $ 84,750 2,595 — N/A Fiscal 2015 21,787 2,389 — N/A Fiscal 2016 18,929 2,208 — N/A Fiscal 2017 13,489 2,274 — N/A Fiscal 2018 12,314 2,330 — N/A 2019 Notes Fiscal 2014 $ 250,000 2,595 — N/A Fiscal 2015 250,000 2,389 — N/A Fiscal 2016 250,000 2,208 — N/A Fiscal 2017 250,000 2,274 — N/A Fiscal 2018 228,825 2,330 — N/A Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) 2024 Notes Fiscal 2014 $ 75,000 2,595 — 966.96 Fiscal 2015 75,000 2,389 — 991.94 Fiscal 2016 75,000 2,208 — 993.70 Fiscal 2017 75,000 2,274 — 1,006.74 Fiscal 2018 75,000 2,330 — 1,010.72 Fiscal 2019 75,000 2,949 — 1,012.76 2025 Notes Fiscal 2020 $ 300,000 2,272 — N/A Fiscal 2021 300,000 2,017 — N/A Fiscal 2022 300,000 1,886 — N/A Fiscal 2023 300,000 1,877 — N/A 2027 Notes Fiscal 2021 $ 350,000 2,017 — N/A Fiscal 2022 350,000 1,886 — N/A Fiscal 2023 350,000 1,877 — N/A 2028 Notes Fiscal 2014 $ 86,250 2,595 — 943.73 Fiscal 2015 86,250 2,389 — 988.06 Fiscal 2016 86,250 2,208 — 999.29 Fiscal 2017 86,250 2,274 — 1,007.51 Fiscal 2018 86,250 2,330 — 994.82 Fiscal 2019 86,250 2,949 — 993.33 2029 Notes Fiscal 2023 $ 300,000 1,877 — N/A Total Senior Securities Fiscal 2014 $ 928,395 2,595 — Fiscal 2015 975,332 2,389 — Fiscal 2016 946,474 2,208 — Fiscal 2017 680,734 2,274 — Fiscal 2018 643,389 2,330 — Fiscal 2019 476,075 2,949 — Fiscal 2020 714,825 2,272 — Fiscal 2021 1,280,000 2,017 — Fiscal 2022 1,350,000 1,886 — Fiscal 2023 1,660,000 1,877 — ______________ (1) This table excludes any SBA-guaranteed debentures outstanding during the relevant periods because the SEC has granted the Company exemptive relief that permits it to exclude such debentures from the definition of senior securities in the asset coverage ratio the Company is required to maintain under the Investment Company Act. (2) Total amount of each class of senior securities outstanding at the end of the period, presented in thousands. (3) The asset coverage ratio for a class of senior securities representing indebtedness is calculated as the Company's consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by total senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the “Asset Coverage Per Unit.” (4) The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it. The “-” indicates information that the Securities and Exchange Commission expressly does not require to be disclosed for certain types of senior securities. |
Derivative Instruments
Derivative Instruments | 12 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Derivative Instruments The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, JPMorgan Chase Bank, N.A. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of September 30, 2023, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts. In connection with the issuance of the 2027 Notes and 2029 Notes, the Company entered into interest rate swap agreements with the Royal Bank of Canada pursuant to ISDA Master Agreements. As of September 30, 2023, the Company paid $54.3 million to the Royal Bank of Canada to cover collateral obligations under the terms of the interest swap agreements, which is included in due from broker on the Consolidated Statement of Assets and Liabilities. Certain information related to the Company’s foreign currency forward contracts is presented below as of September 30, 2023. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract $ 42,182 € 38,026 11/9/2023 $ 1,857 $ — Derivative asset Foreign currency forward contract $ 72,098 £ 56,556 11/9/2023 3,053 — Derivative asset $ 4,910 $ — Certain information related to the Company’s foreign currency forward contracts is presented below as of September 30, 2022. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract $ 43,179 € 41,444 11/10/2022 $ 2,466 $ — Derivative asset Foreign currency forward contract $ 45,692 £ 37,033 11/10/2022 4,323 — Derivative asset $ 6,789 $ — Certain information related to the Company’s interest rate swaps is presented below as of September 30, 2023. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap $ 350,000 1/15/2027 $ — $ 40,519 Derivative liability Interest rate swap 300,000 2/15/2029 — 7,000 Derivative liability $ — $ 47,519 Certain information related to the Company’s interest rate swap is presented below as of September 30, 2022. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap $ 350,000 1/15/2027 $ — $ 41,969 Derivative liability $ — $ 41,969 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Off-Balance Sheet Arrangements The Company may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of its portfolio companies. As of September 30, 2023, the Company's only off-balance sheet arrangements consisted of $232.7 million of unfunded commitments, which was comprised of $205.6 million to provide debt and equity financing to certain of its portfolio companies and $27.1 million to provide financing to the JVs. Of the $205.6 million, approximately $154.2 million can be drawn immediately with the remaining amount subject to certain milestones that must be met by portfolio companies or other restrictions. As of September 30, 2022, the Company's only off-balance sheet arrangements consisted of $224.2 million of unfunded commitments, which was comprised of $175.2 million to provide debt and equity financing to certain of its portfolio companies and $49.0 million to provide financing to the JVs. Such commitments are subject to the portfolio companies' satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in the Consolidated Statements of Assets and Liabilities. A list of unfunded commitments by investment (consisting of revolvers, term loans with delayed draw components, subordinated notes and LLC equity interests in the JVs, preferred stock and limited partnership interests) as of September 30, 2023 and September 30, 2022 is shown in the table below: September 30, 2023 September 30, 2022 107-109 Beech OAK22 LLC $ 26,969 $ — Delta Leasing SPV II LLC 14,639 27,187 BioXcel Therapeutics, Inc. 14,547 11,785 OCSI Glick JV LLC 13,998 13,998 Senior Loan Fund JV I, LLC 13,125 35,000 Fairbridge Strategic Capital Funding LLC 13,090 22,150 MND Holdings III Corp 9,122 — Seres Therapeutics, Inc. 8,090 — Assembled Brands Capital LLC 7,514 2,008 iCIMs, Inc. 7,466 6,930 Grove Hotel Parcel Owner, LLC 5,286 4,293 scPharmaceuticals Inc. 5,212 — Kings Buyer, LLC 5,189 1,537 Avalara, Inc. 5,047 — Mindbody, Inc. 4,762 4,000 Accupac, Inc. 4,500 4,605 107 Fair Street LLC 4,227 — Harrow, Inc. 4,011 — Inventus Power, Inc. 3,792 — Dominion Diagnostics, LLC 3,484 11,148 Establishment Labs Holdings Inc. 3,384 5,075 OTG Management, LLC 3,190 3,789 PRGX Global, Inc. 3,127 2,518 Salus Workers' Compensation, LLC 3,102 — ADC Therapeutics SA 3,020 3,020 Relativity ODA LLC 2,762 2,218 LSL Holdco, LLC 2,650 427 Spanx, LLC 2,473 2,226 Impel Pharmaceuticals Inc. 2,458 — SCP Eye Care Services, LLC 2,356 — 112-126 Van Houten Real22 LLC 2,343 — MRI Software LLC 2,261 5,196 Supreme Fitness Group NY Holdings, LLC 2,199 1,527 Tahoe Bidco B.V. 2,162 1,741 Coupa Holdings, LLC 2,075 — Galileo Parent, Inc. 2,061 — Oranje Holdco, Inc. 1,904 — SIO2 Medical Products, Inc. 1,821 — Pluralsight, LLC 1,787 3,532 Evergreen IX Borrower 2023, LLC 1,626 — Berner Food & Beverage, LLC 1,622 1,392 PPW Aero Buyer, Inc. 1,466 — Liquid Environmental Solutions Corporation 1,383 1,115 Acquia Inc. 1,376 1,326 Digital.AI Software Holdings, Inc. 1,078 826 Finastra USA, Inc. 960 — MHE Intermediate Holdings, LLC 821 1,429 Telestream Holdings Corporation 407 528 Coyote Buyer, LLC 400 1,333 ASP-R-PAC Acquisition Co LLC 396 — BAART Programs, Inc. — 8,645 Marinus Pharmaceuticals, Inc. — 5,734 RumbleOn, Inc. — 4,822 Ardonagh Midco 3 PLC — 4,372 Innocoll Pharmaceuticals Limited — 4,195 Mesoblast, Inc. — 3,553 Dialyze Holdings, LLC — 3,431 Thrasio, LLC — 2,578 Apptio, Inc. — 1,338 CorEvitas, LLC — 915 109 Montgomery Owner LLC — 477 GKD Index Partners, LLC — 320 Total $ 232,740 $ 224,239 |
Merger with OSI2
Merger with OSI2 | 12 Months Ended |
Sep. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Merger with OSI2 | Merger with OSI2 On January 23, 2023, the Company completed its previously announced acquisition of OSI2. The Company was the accounting survivor of the OSI2 Merger. In accordance with the terms of the OSI2 Merger Agreement, at the effective time of the OSI2 Merger, each outstanding share of OSI2 common stock was converted into the right to receive 0.9115 shares of the Company’s common stock (with OSI2’s stockholders receiving cash in lieu of fractional shares of the Company’s common stock). As a result of the Merger, the Company issued an aggregate of 15,860,200 shares of its common stock to former OSI2 stockholders. The OSI2 Merger was accounted for as an asset acquisition in accordance with the asset acquisition method of accounting as detailed in ASC 805-50, Business Combinations—Related Issues (“ASC 805”). The Company determined the fair value of the shares of the Company’s common stock that were issued to former OSI2 stockholders pursuant to the OSI2 Merger Agreement plus transaction costs to be the consideration paid in connection with the OSI2 Merger under ASC 805. The consideration paid to OSI2 stockholders, as determined in accordance with ASC 805, was more than the aggregate fair values of the assets acquired and liabilities assumed, which resulted in a purchase premium (the “purchase premium”). The consideration paid was allocated to the individual assets acquired and liabilities assumed based on the relative fair values of net identifiable assets acquired other than “non-qualifying” assets (for example, cash). As a result, the purchase premium was allocated to the cost basis of the OSI2 investments acquired by the Company on a pro-rata basis based on their relative fair values as of the effective time of the OSI2 Merger. Immediately following the OSI2 Merger, the investments were marked to their respective fair values in accordance with ASC 820 which resulted in $20.7 million of unrealized depreciation in the Consolidated Statement of Operations as a result of the OSI2 Merger. The purchase premium allocated to the debt investments acquired will amortize over the life of each respective debt investment through interest income, with a corresponding adjustment recorded to unrealized depreciation on such investment acquired through its ultimate disposition. The purchase premium allocated to equity investments acquired will not amortize over the life of such investments through interest income and, assuming no subsequent change to the fair value of the equity investments acquired and disposition of such equity investments at fair value, the Company will recognize a realized loss with a corresponding reversal of the unrealized depreciation on disposition of such equity investments acquired. The OSI2 Merger was considered a tax-free reorganization, and the Company has elected to carry forward the historical cost basis of the acquired OSI2 investments for tax purposes. The following table summarizes the allocation of the consideration paid to the assets acquired and liabilities assumed as a result of the OSI2 Merger: Common stock issued by the Company (1) $ 334,034 Transaction costs 1,932 Consideration paid $ 335,966 Investments $ 592,809 Cash and cash equivalents 22,317 Other assets 6,679 Total assets acquired $ 621,805 Debt $ 225,000 Other liabilities 60,839 Total liabilities acquired 285,839 Total net assets acquired $ 335,966 __________ (1) Common stock issued by the Company includes $19 of cash paid in lieu of issuing fractional shares. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events The Company’s management evaluated subsequent events through the date of issuance of the Consolidated Financial Statements. There have been no subsequent events that occurred during such period that would require disclosure in, or would be required to be recognized in the Consolidated Financial Statements as of and for the year ended September 30, 2023, except as discussed below. Distribution Declaration On November 8, 2023, the Company’s Board of Directors declared quarterly and special distributions of $0.55 per share and $0.07 per share, respectively, payable in cash on December 29, 2023 to stockholders of record on December 15, 2023. |
Schedule_12-14
Schedule 12-14 | 12 Months Ended |
Sep. 30, 2023 | |
Investments in and Advances to Affiliates [Abstract] | |
Schedule 12-14 | Schedule 12-14 Oaktree Specialty Lending Corporation Schedule of Investments in and Advances to Affiliates (in thousands, except share and per share amounts, percentages and as otherwise indicated) Year ended September 30, 2023 Portfolio Company Industry Investment Type Index Spread Cash PIK Rate Maturity Date Shares Principal Net Realized Gain (Loss) Amount of Interest, Fees or Dividends Credited in Income (2) Fair Value at October 1, 2022 Gross Additions (3) Gross Reductions (4) Fair Value at September 30, 2023 % of Total Net Assets Control Investments C5 Technology Holdings, LLC Data Processing & Outsourced Services Common Stock 829 $ — $ — $ — $ — $ — $ — — % C5 Technology Holdings, LLC Data Processing & Outsourced Services Preferred Equity 34,984,460 — — 27,638 — — 27,638 1.8 % Dominion Diagnostics, LLC Health Care Services First Lien Term Loan SOFR+ 5.00 % 10.54 % 8/28/2025 14,068 — 1,459 14,333 — (265) 14,068 0.9 % Dominion Diagnostics, LLC Health Care Services First Lien Term Loan SOFR+ 5.00 % 10.42 % 8/28/2025 2,090 — 10 — 2,090 — 2,090 0.1 % Dominion Diagnostics, LLC Health Care Services First Lien Revolver SOFR+ 5.00 % 10.54 % 8/28/2025 5,574 — 266 — 5,574 — 5,574 0.4 % Dominion Diagnostics, LLC Health Care Services Common Stock 30,031 — — 4,946 — (2,235) 2,711 0.2 % OCSI Glick JV LLC (5) Multi-Sector Holdings Subordinated Debt SOFR+ 4.50 % 9.76 % 10/20/2028 58,349 — 6,748 50,283 1,448 (1,714) 50,017 3.3 % OCSI Glick JV LLC (5) Multi-Sector Holdings Membership Interest 87.50 % — — — — — — — % Senior Loan Fund JV I, LLC (6) Multi-Sector Holdings Subordinated Debt SOFR+ 7.00 % 12.26 % 12/29/2028 112,656 — 12,726 96,250 16,406 — 112,656 7.4 % Senior Loan Fund JV I, LLC (6) Multi-Sector Holdings Membership Interest 87.50 % — 4,200 20,715 8,163 — 28,878 1.9 % SIO2 Medical Products, Inc. Metal, Glass & Plastic Containers First Lien Term Loan 12.00 % 8/3/2028 15,874 — 340 — 16,653 (779) 15,874 1.0 % SIO2 Medical Products, Inc. Metal, Glass & Plastic Containers First Lien Term Loan 12.00 % 8/3/2028 1,359 — 14 — 1,359 — 1,359 0.1 % SIO2 Medical Products, Inc. Metal, Glass & Plastic Containers Common Stock 1,184,630 — — — 40,093 (3,867) 36,226 2.4 % SIO2 Medical Products, Inc. Metal, Glass & Plastic Containers Warrants 66,686 — — — — — — — % Total Control Investments $ 209,970 $ — $ 25,763 $ 214,165 $ 91,786 $ (8,860) $ 297,091 19.6 % Affiliate Investments Assembled Brands Capital LLC Specialized Finance First Lien Revolver SOFR+ 6.75 % 12.14 % 1/25/2026 21,852 — 2,640 24,225 2,467 (4,869) 21,823 1.4 % Assembled Brands Capital LLC Specialized Finance Common Stock 1,783,332 — — 370 40 (321) 89 — % Assembled Brands Capital LLC Specialized Finance Preferred Equity 1,129,453 — — 1,223 139 (357) 1,005 0.1 % Assembled Brands Capital LLC Specialized Finance Warrants 78,045 — — — — — — — % Caregiver Services, Inc. Health Care Services Preferred Equity 1,080,399 — — 378 54 — 432 — % Total Affiliate Investments $ 21,852 $ — $ 2,640 $ 26,196 $ 2,700 $ (5,547) $ 23,349 1.5 % Total Control & Affiliate Investments $ 231,822 $ — $ 28,403 $ 240,361 $ 94,486 $ (14,407) $ 320,440 21.1 % This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements. ______________________ (1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments. (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category. (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category. (5) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required). (6) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required). Schedule 12-14 Oaktree Specialty Lending Corporation Schedule of Investments in and Advances to Affiliates (in thousands, except share and per share amounts, percentages and as otherwise indicated) Year ended September 30, 2022 Portfolio Company Industry Investment Type Index Spread Cash PIK Rate Maturity Date Shares Principal Net Realized Gain (Loss) Amount of Interest, Fees or Dividends Credited in Income (2) Fair Value at October 1, 2021 Gross Additions (3) Gross Reductions (4) Fair Value at September 30, 2022 % of Total Net Assets Control Investments C5 Technology Holdings, LLC Data Processing & Outsourced Services Common Stock 829 $ — $ — $ — $ — $ — $ — $ — — % C5 Technology Holdings, LLC Data Processing & Outsourced Services Preferred Equity 34,984,460 — — — 27,638 — — 27,638 2.2 % Dominion Diagnostics, LLC Health Care Services First Lien Term Loan L+ 5.00 % 8.68 % 2/28/2024 14,333 — 1,367 27,381 — (13,048) 14,333 1.2 % Dominion Diagnostics, LLC Health Care Services First Lien Revolver L+ 5.00 % 2/28/2024 — — 57 — — — — — % Dominion Diagnostics, LLC Health Care Services Common Stock 30,031 — — 3,308 18,065 — (13,119) 4,946 0.4 % First Star Speir Aviation Limited (5) Airlines First Lien Term Loan 9.00 % 12/15/2025 — 7,500 — 7,500 — (7,500) — — % First Star Speir Aviation Limited (5) Airlines Membership Interest 100 % — (5,632) 158 698 — (698) — — % OCSI Glick JV LLC (6) Multi-Sector Holdings Subordinated Debt L+ 4.50 % 6.30 % 10/20/2028 59,662 — 4,667 55,582 1,538 (6,837) 50,283 4.0 % OCSI Glick JV LLC (6) Multi-Sector Holdings Membership Interest 87.50 % — — — — — — — — % Senior Loan Fund JV I, LLC (7) Multi-Sector Holdings Subordinated Debt L+ 7.00 % 8.80 % 12/29/2028 96,250 — 8,001 96,250 — — 96,250 7.7 % Senior Loan Fund JV I, LLC (7) Multi-Sector Holdings Membership Interest 87.50 % — — 2,901 37,651 — (16,936) 20,715 1.7 % Total Control Investments $ 170,245 $ 1,868 $ 20,459 $ 270,765 $ 1,538 $ (58,138) $ 214,165 17.2 % Affiliate Investments Assembled Brands Capital LLC Specialized Finance First Lien Revolver L+ 6.75 % 10.42 % 10/17/2023 24,490 — 1,764 15,712 14,996 (6,483) 24,225 1.9 % Assembled Brands Capital LLC Specialized Finance Common Stock 1,609,201 — — 587 — (217) 370 — % Assembled Brands Capital LLC Specialized Finance Preferred Equity 1,019,169 — — 1,152 71 — 1,223 0.1 % Assembled Brands Capital LLC Specialized Finance Warrants 70,425 — — — — — — — % Caregiver Services, Inc. Health Care Services Preferred Equity 1,080,399 — — 838 — (460) 378 — % Total Affiliate Investments $ 24,490 $ — $ 1,764 $ 18,289 $ 15,067 $ (7,160) $ 26,196 2.1 % Total Control & Affiliate Investments $ 194,735 $ 1,868 $ 22,223 $ 289,054 $ 16,605 $ (65,298) $ 240,361 19.3 % This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements. ______________________ (1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments. (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category. (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category. (5) First Star Speir Aviation Limited is a wholly-owned holding company formed by the Company in order to facilitate its investment strategy. In accordance with ASU 2013-08, the Company has deemed the holding company to be an investment company under GAAP and therefore deemed it appropriate to consolidate the financial results and financial position of the holding company and to recognize dividend income versus a combination of interest income and dividend income. Accordingly, the debt and equity investments in the wholly-owned holding company are disregarded for accounting purposes since the economic substance of these instruments are equity investments in the operating entities. (6) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required). (7) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required). |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Pay vs Performance Disclosure | |||
Net increase (decrease) in net assets resulting from operations | $ 117,331 | $ 29,223 | $ 237,260 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Sep. 30, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
N-2
N-2 - USD ($) | 3 Months Ended | 12 Months Ended | |||||||||||||||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2023 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2021 | Sep. 30, 2020 | |||||
Cover [Abstract] | |||||||||||||||||||||
Entity Central Index Key | 0001414932 | ||||||||||||||||||||
Amendment Flag | false | ||||||||||||||||||||
Securities Act File Number | 1-33901 | ||||||||||||||||||||
Document Type | 10-K | ||||||||||||||||||||
Entity Registrant Name | Oaktree Specialty Lending Corporation | ||||||||||||||||||||
Entity Address, Address Line One | 333 South Grand Avenue | ||||||||||||||||||||
Entity Address, Address Line Two | 28th Floor | ||||||||||||||||||||
Entity Address, City or Town | Los Angeles | ||||||||||||||||||||
Entity Address, State or Province | CA | ||||||||||||||||||||
Entity Address, Postal Zip Code | 90071 | ||||||||||||||||||||
City Area Code | 213 | ||||||||||||||||||||
Local Phone Number | 830-6300 | ||||||||||||||||||||
Entity Well-known Seasoned Issuer | Yes | ||||||||||||||||||||
Entity Emerging Growth Company | false | ||||||||||||||||||||
Fee Table [Abstract] | |||||||||||||||||||||
Shareholder Transaction Expenses [Table Text Block] | Stockholder transaction expenses: Sales load (as a percentage of offering price) —% (1) Offering expenses (as a percentage of offering price) —% (2) Dividend reinvestment plan fees Up to $15 (3) Total stockholder transaction expenses (as a percentage of offering price) —% (4) Annual expenses (as a percentage of net assets attributable to common stock): Base management fees 3.03% (5) Incentive fees (17.5%) 2.52% (6) Interest payments on borrowed funds (including other costs of servicing and offering debt securities) 8.26% (7) Other expenses 0.77% (8) Acquired fund fees and expenses 1.62% (9) Total annual expenses 16.20% (10) __________ (1) If applicable, the prospectus or prospectus supplement relating to an offering of our common stock will disclose the applicable sales load. (2) In the event that we conduct an offering of our securities, the related prospectus or prospectus supplement will disclose the estimated offering expenses. (3) The expenses of administering our dividend reinvestment plan are included in “Other expenses.” The plan administrator’s fees under the plan are paid by us. If a participant elects by notice to the plan administrator in advance of termination to have the plan administrator sell part or all of the shares held by the plan administrator in the participant’s account and remit the proceeds to the participant, the plan administrator is authorized to deduct a transaction fee of up to $15 plus a $0.10 per share fee from the proceeds. (4) Total stockholder transaction expenses may include sales load and will be disclosed in a future prospectus supplement, if any. (5) Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of our total gross assets at the end of each quarter, including any investments made with borrowings, but excluding cash and cash equivalents; provided, however, the base management fee will be calculated at an annual rate of 1.00% of the value of our total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents, that exceeds the product of (i) 200% (calculated in accordance with the Investment Company Act and giving effect to exemptive relief we have received with respect to debentures issued by a small business investment company subsidiary) and (ii) our net assets. For purposes of this table, we have assumed $3.1 billion of total gross assets (excluding cash and cash equivalents), which was the actual amount of our total gross assets as of September 30, 2023 and does not reflect the waiver by Oaktree of certain base management fees following completion of the Mergers. The base management fee net of such waiver would be 2.77% of net assets attributable to common stock. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee.” (6) The incentive fee consists of two parts. Under the Investment Advisory Agreement, the incentive fee on income is calculated and payable quarterly in arrears based upon our pre-incentive fee net investment income for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a “hurdle rate”), expressed as a rate of return on the value of our net assets at the end of the most recently completed quarter, of 1.50%, subject to a “catch up” feature. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee” for additional information. Under the Investment Advisory Agreement, the second part of the incentive fee (the “capital gains incentive fee”) is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of our realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gains incentive fees under the Investment Advisory Agreement. Any realized capital gains or losses and unrealized capital depreciation with respect to our portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee” for additional information. The incentive fee referenced in the table above is based on actual amounts of the incentive fee on income incurred during the three months ended September 30, 2023 annualized for a full year and the capital gains incentive fee payable under the Investment Advisory Agreement as of September 30, 2023. (7) “Interest payments on borrowed funds (including other costs of servicing and offering debt securities)” is calculated as (1) the weighted average interest rate in effect as of September 30, 2023 multiplied by the actual debt outstanding as of September 30, 2023 of $1,660.0 million plus (2) unused fees and the expected amortization of deferred financing costs and discounts based on the unamortized financing costs and discounts as of September 30, 2023. The weighted average interest rate for our borrowings as of September 30, 2023 was 7.0% (exclusive of deferred financing costs and inclusive of the impact of an interest rate swap designated as a hedging instrument). The amount of leverage that we employ at any particular time will depend on, among other things, our Board of Directors’ assessment of market and other factors at the time of any proposed borrowing. (8) “Other expenses” are based on estimated amounts for the current fiscal year. These expenses include certain expenses allocated to us under the Investment Advisory Agreement, including travel expenses incurred by the Adviser’s personnel in connection with investigating and monitoring our investments, such as investment due diligence and payments made under the Administration Agreement for the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement. (9) Our stockholders indirectly bear the expenses of underlying funds or other investment vehicles that would be an investment company under section 3(a) of the Investment Company Act but for the exceptions to that definition provided for in sections 3(c)(1) and 3(c)(7) of the Investment Company Act ("Acquired Funds") in which we invest. This amount includes the annual expenses of SLF JV I and the Glick JV, which we refer to collectively as the "JVs". There are no fees paid by the JVs to the Adviser. See Note 3 to our Consolidated Financial Statements in this Form 10-K for more information on the JVs. The annual expenses of the JVs include interest payments on the subordinated notes held by Kemper and GF Debt Funding 2014 LLC, or GF Debt Funding, an entity advised by affiliates of GF Equity Funding, as applicable, which represented 11.4% of such expenses, and exclude interest payments on the subordinated notes held by us. (10) “Total annual expenses” is presented as a percentage of net assets attributable to common stockholders because our common stockholders bear all of our fees and expenses and includes all fees and expenses of our consolidated subsidiaries. “Total annual expenses” does not reflect any potential provision (benefit) for income taxes because of the uncertainties associated with determining such amounts in future periods. | ||||||||||||||||||||
Sales Load [Percent] | 0% | ||||||||||||||||||||
Dividend Reinvestment and Cash Purchase Fees | $ 15 | ||||||||||||||||||||
Other Transaction Expenses [Abstract] | |||||||||||||||||||||
Other Transaction Expense 1 [Percent] | 0% | ||||||||||||||||||||
Annual Expenses [Table Text Block] | Stockholder transaction expenses: Sales load (as a percentage of offering price) —% (1) Offering expenses (as a percentage of offering price) —% (2) Dividend reinvestment plan fees Up to $15 (3) Total stockholder transaction expenses (as a percentage of offering price) —% (4) Annual expenses (as a percentage of net assets attributable to common stock): Base management fees 3.03% (5) Incentive fees (17.5%) 2.52% (6) Interest payments on borrowed funds (including other costs of servicing and offering debt securities) 8.26% (7) Other expenses 0.77% (8) Acquired fund fees and expenses 1.62% (9) Total annual expenses 16.20% (10) __________ (1) If applicable, the prospectus or prospectus supplement relating to an offering of our common stock will disclose the applicable sales load. (2) In the event that we conduct an offering of our securities, the related prospectus or prospectus supplement will disclose the estimated offering expenses. (3) The expenses of administering our dividend reinvestment plan are included in “Other expenses.” The plan administrator’s fees under the plan are paid by us. If a participant elects by notice to the plan administrator in advance of termination to have the plan administrator sell part or all of the shares held by the plan administrator in the participant’s account and remit the proceeds to the participant, the plan administrator is authorized to deduct a transaction fee of up to $15 plus a $0.10 per share fee from the proceeds. (4) Total stockholder transaction expenses may include sales load and will be disclosed in a future prospectus supplement, if any. (5) Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of our total gross assets at the end of each quarter, including any investments made with borrowings, but excluding cash and cash equivalents; provided, however, the base management fee will be calculated at an annual rate of 1.00% of the value of our total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents, that exceeds the product of (i) 200% (calculated in accordance with the Investment Company Act and giving effect to exemptive relief we have received with respect to debentures issued by a small business investment company subsidiary) and (ii) our net assets. For purposes of this table, we have assumed $3.1 billion of total gross assets (excluding cash and cash equivalents), which was the actual amount of our total gross assets as of September 30, 2023 and does not reflect the waiver by Oaktree of certain base management fees following completion of the Mergers. The base management fee net of such waiver would be 2.77% of net assets attributable to common stock. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee.” (6) The incentive fee consists of two parts. Under the Investment Advisory Agreement, the incentive fee on income is calculated and payable quarterly in arrears based upon our pre-incentive fee net investment income for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a “hurdle rate”), expressed as a rate of return on the value of our net assets at the end of the most recently completed quarter, of 1.50%, subject to a “catch up” feature. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee” for additional information. Under the Investment Advisory Agreement, the second part of the incentive fee (the “capital gains incentive fee”) is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of our realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gains incentive fees under the Investment Advisory Agreement. Any realized capital gains or losses and unrealized capital depreciation with respect to our portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee” for additional information. The incentive fee referenced in the table above is based on actual amounts of the incentive fee on income incurred during the three months ended September 30, 2023 annualized for a full year and the capital gains incentive fee payable under the Investment Advisory Agreement as of September 30, 2023. (7) “Interest payments on borrowed funds (including other costs of servicing and offering debt securities)” is calculated as (1) the weighted average interest rate in effect as of September 30, 2023 multiplied by the actual debt outstanding as of September 30, 2023 of $1,660.0 million plus (2) unused fees and the expected amortization of deferred financing costs and discounts based on the unamortized financing costs and discounts as of September 30, 2023. The weighted average interest rate for our borrowings as of September 30, 2023 was 7.0% (exclusive of deferred financing costs and inclusive of the impact of an interest rate swap designated as a hedging instrument). The amount of leverage that we employ at any particular time will depend on, among other things, our Board of Directors’ assessment of market and other factors at the time of any proposed borrowing. (8) “Other expenses” are based on estimated amounts for the current fiscal year. These expenses include certain expenses allocated to us under the Investment Advisory Agreement, including travel expenses incurred by the Adviser’s personnel in connection with investigating and monitoring our investments, such as investment due diligence and payments made under the Administration Agreement for the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement. (9) Our stockholders indirectly bear the expenses of underlying funds or other investment vehicles that would be an investment company under section 3(a) of the Investment Company Act but for the exceptions to that definition provided for in sections 3(c)(1) and 3(c)(7) of the Investment Company Act ("Acquired Funds") in which we invest. This amount includes the annual expenses of SLF JV I and the Glick JV, which we refer to collectively as the "JVs". There are no fees paid by the JVs to the Adviser. See Note 3 to our Consolidated Financial Statements in this Form 10-K for more information on the JVs. The annual expenses of the JVs include interest payments on the subordinated notes held by Kemper and GF Debt Funding 2014 LLC, or GF Debt Funding, an entity advised by affiliates of GF Equity Funding, as applicable, which represented 11.4% of such expenses, and exclude interest payments on the subordinated notes held by us. (10) “Total annual expenses” is presented as a percentage of net assets attributable to common stockholders because our common stockholders bear all of our fees and expenses and includes all fees and expenses of our consolidated subsidiaries. “Total annual expenses” does not reflect any potential provision (benefit) for income taxes because of the uncertainties associated with determining such amounts in future periods. | ||||||||||||||||||||
Management Fees [Percent] | 3.03% | ||||||||||||||||||||
Interest Expenses on Borrowings [Percent] | 8.26% | ||||||||||||||||||||
Incentive Fees [Percent] | 2.52% | ||||||||||||||||||||
Acquired Fund Fees and Expenses [Percent] | 1.62% | ||||||||||||||||||||
Other Annual Expenses [Abstract] | |||||||||||||||||||||
Other Annual Expenses [Percent] | 0.77% | ||||||||||||||||||||
Total Annual Expenses [Percent] | 16.20% | ||||||||||||||||||||
Expense Example [Table Text Block] | The following example demonstrates the projected dollar amount of total cumulative expenses that would be incurred over various periods with respect to a hypothetical investment in our common stock assuming that we hold no cash or liabilities other than debt. In calculating the following expense amounts, we have assumed that our annual operating expenses remain at the levels set forth in the table above. The example does not include any sales load or offering expenses. An investor would pay the following expenses on a $1,000 investment 1 Year 3 Years 5 Years 10 Years Assuming a 5% annual return (assumes no return from net realized capital gains) $ 130 $ 376 $ 600 $ 1,075 Assuming a 5% annual return (assumes return entirely from net realized capital gains) $ 139 $ 396 $ 628 $ 1,107 | ||||||||||||||||||||
Expense Example, Year 01 | $ 130 | ||||||||||||||||||||
Expense Example, Years 1 to 3 | 376 | ||||||||||||||||||||
Expense Example, Years 1 to 5 | 600 | ||||||||||||||||||||
Expense Example, Years 1 to 10 | $ 1,075 | ||||||||||||||||||||
Purpose of Fee Table , Note [Text Block] | The following table is intended to assist stockholders in understanding the costs and expenses that an investor in shares of our common stock will bear directly or indirectly. We caution you that some of the percentages indicated in the table below are estimates and may vary. | ||||||||||||||||||||
Basis of Transaction Fees, Note [Text Block] | The expenses of administering our dividend reinvestment plan are included in “Other expenses.” The plan administrator’s fees under the plan are paid by us. If a participant elects by notice to the plan administrator in advance of termination to have the plan administrator sell part or all of the shares held by the plan administrator in the participant’s account and remit the proceeds to the participant, the plan administrator is authorized to deduct a transaction fee of up to $15 plus a $0.10 per share fee from the proceeds. | ||||||||||||||||||||
Other Transaction Fees, Note [Text Block] | In the event that we conduct an offering of our securities, the related prospectus or prospectus supplement will disclose the estimated offering expenses. | ||||||||||||||||||||
Other Expenses, Note [Text Block] | “Other expenses” are based on estimated amounts for the current fiscal year. These expenses include certain expenses allocated to us under the Investment Advisory Agreement, including travel expenses incurred by the Adviser’s personnel in connection with investigating and monitoring our investments, such as investment due diligence and payments made under the Administration Agreement for the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement. | ||||||||||||||||||||
Management Fee not based on Net Assets, Note [Text Block] | Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of our total gross assets at the end of each quarter, including any investments made with borrowings, but excluding cash and cash equivalents; provided, however, the base management fee will be calculated at an annual rate of 1.00% of the value of our total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents, that exceeds the product of (i) 200% (calculated in accordance with the Investment Company Act and giving effect to exemptive relief we have received with respect to debentures issued by a small business investment company subsidiary) and (ii) our net assets. For purposes of this table, we have assumed $3.1 billion of total gross assets (excluding cash and cash equivalents), which was the actual amount of our total gross assets as of September 30, 2023 and does not reflect the waiver by Oaktree of certain base management fees following completion of the Mergers. The base management fee net of such waiver would be 2.77% of net assets attributable to common stock. See “Item 1. Business - Investment Advisory Agreement - Management and Incentive Fee.” | ||||||||||||||||||||
Acquired Fund Fees and Expenses, Note [Text Block] | Our stockholders indirectly bear the expenses of underlying funds or other investment vehicles that would be an investment company under section 3(a) of the Investment Company Act but for the exceptions to that definition provided for in sections 3(c)(1) and 3(c)(7) of the Investment Company Act ("Acquired Funds") in which we invest. This amount includes the annual expenses of SLF JV I and the Glick JV, which we refer to collectively as the "JVs". There are no fees paid by the JVs to the Adviser. See Note 3 to our Consolidated Financial Statements in this Form 10-K for more information on the JVs. The annual expenses of the JVs include interest payments on the subordinated notes held by Kemper and GF Debt Funding 2014 LLC, or GF Debt Funding, an entity advised by affiliates of GF Equity Funding, as applicable, which represented 11.4% of such expenses, and exclude interest payments on the subordinated notes held by us. | ||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities [Table Text Block] | Information about our senior securities (including debt securities and other indebtedness) is shown in the following table as of the fiscal years ended September 30 for the years indicated below. Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) Syndicated Facility and Prior ING Facility Fiscal 2014 $ 267,395 2,595 — N/A Fiscal 2015 383,495 2,389 — N/A Fiscal 2016 472,495 2,208 — N/A Fiscal 2017 226,495 2,274 — N/A Fiscal 2018 241,000 2,330 — N/A Fiscal 2019 314,825 2,949 — N/A Fiscal 2020 414,825 2,272 — N/A Fiscal 2021 495,000 2,017 — N/A Fiscal 2022 540,000 1,886 — N/A Fiscal 2023 430,000 1,877 — N/A Citibank Facility Fiscal 2021 $ 135,000 2,017 — N/A Fiscal 2022 160,000 1,886 — N/A OSI2 Citibank Facility Fiscal 2023 $ 280,000 1,877 — N/A Sumitomo Facility Fiscal 2014 $ 50,000 2,595 — N/A Fiscal 2015 43,800 2,389 — N/A Fiscal 2016 43,800 2,208 — N/A Fiscal 2017 29,500 2,274 — N/A Convertible Notes Fiscal 2014 $ 115,000 2,595 — N/A Fiscal 2015 115,000 2,389 — N/A Secured Borrowings Fiscal 2014 $ 84,750 2,595 — N/A Fiscal 2015 21,787 2,389 — N/A Fiscal 2016 18,929 2,208 — N/A Fiscal 2017 13,489 2,274 — N/A Fiscal 2018 12,314 2,330 — N/A 2019 Notes Fiscal 2014 $ 250,000 2,595 — N/A Fiscal 2015 250,000 2,389 — N/A Fiscal 2016 250,000 2,208 — N/A Fiscal 2017 250,000 2,274 — N/A Fiscal 2018 228,825 2,330 — N/A Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) 2024 Notes Fiscal 2014 $ 75,000 2,595 — 966.96 Fiscal 2015 75,000 2,389 — 991.94 Fiscal 2016 75,000 2,208 — 993.70 Fiscal 2017 75,000 2,274 — 1,006.74 Fiscal 2018 75,000 2,330 — 1,010.72 Fiscal 2019 75,000 2,949 — 1,012.76 2025 Notes Fiscal 2020 $ 300,000 2,272 — N/A Fiscal 2021 300,000 2,017 — N/A Fiscal 2022 300,000 1,886 — N/A Fiscal 2023 300,000 1,877 — N/A 2027 Notes Fiscal 2021 $ 350,000 2,017 — N/A Fiscal 2022 350,000 1,886 — N/A Fiscal 2023 350,000 1,877 — N/A 2028 Notes Fiscal 2014 $ 86,250 2,595 — 943.73 Fiscal 2015 86,250 2,389 — 988.06 Fiscal 2016 86,250 2,208 — 999.29 Fiscal 2017 86,250 2,274 — 1,007.51 Fiscal 2018 86,250 2,330 — 994.82 Fiscal 2019 86,250 2,949 — 993.33 2029 Notes Fiscal 2023 $ 300,000 1,877 — N/A Total Senior Securities Fiscal 2014 $ 928,395 2,595 — Fiscal 2015 975,332 2,389 — Fiscal 2016 946,474 2,208 — Fiscal 2017 680,734 2,274 — Fiscal 2018 643,389 2,330 — Fiscal 2019 476,075 2,949 — Fiscal 2020 714,825 2,272 — Fiscal 2021 1,280,000 2,017 — Fiscal 2022 1,350,000 1,886 — Fiscal 2023 1,660,000 1,877 — ______________ (1) This table excludes any SBA-guaranteed debentures outstanding during the relevant periods because the SEC has granted the Company exemptive relief that permits it to exclude such debentures from the definition of senior securities in the asset coverage ratio the Company is required to maintain under the Investment Company Act. (2) Total amount of each class of senior securities outstanding at the end of the period, presented in thousands. (3) The asset coverage ratio for a class of senior securities representing indebtedness is calculated as the Company's consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by total senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the “Asset Coverage Per Unit.” (4) The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it. The “-” indicates information that the Securities and Exchange Commission expressly does not require to be disclosed for certain types of senior securities. | ||||||||||||||||||||
Senior Securities Amount | $ 1,660,000,000 | $ 1,350,000,000 | $ 1,660,000,000 | $ 476,075,000 | $ 643,389,000 | $ 680,734,000 | $ 946,474,000 | $ 975,332,000 | $ 928,395,000 | $ 1,280,000,000 | $ 714,825,000 | ||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,886 | $ 1,877 | $ 2,949 | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | $ 2,017 | $ 2,272 | ||||||||||
Senior Securities Averaging Method, Note [Text Block] | Calculated on a daily average basis. | ||||||||||||||||||||
Senior Securities Headings, Note [Text Block] | This table excludes any SBA-guaranteed debentures outstanding during the relevant periods because the SEC has granted the Company exemptive relief that permits it to exclude such debentures from the definition of senior securities in the asset coverage ratio the Company is required to maintain under the Investment Company Act. (2) Total amount of each class of senior securities outstanding at the end of the period, presented in thousands. (3) The asset coverage ratio for a class of senior securities representing indebtedness is calculated as the Company's consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by total senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the “Asset Coverage Per Unit.” (4) The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it. The “-” indicates information that the Securities and Exchange Commission expressly does not require to be disclosed for certain types of senior securities. | ||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Investment Objectives and Practices [Text Block] | Our investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. We may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions. Our portfolio may also include certain structured finance and other non-traditional structures. We invest in companies that typically possess resilient business models with strong underlying fundamentals. We intend to deploy capital across credit and economic cycles with a focus on long-term results, which we believe will enable us to build lasting partnerships with financial sponsors and management teams, and we may seek to opportunistically take advantage of dislocations in the financial markets and other situations that may benefit from Oaktree’s credit and structuring expertise. Sponsors may include financial sponsors, such as an institutional investor or a private equity firm, or a strategic entity seeking to invest in a portfolio company. Oaktree is generally focused on middle-market companies, which we define as companies with enterprise values of between $100 million and $750 million. We generally invest in securities that are rated below investment grade by rating agencies or that would be rated below investment grade if they were rated. Below investment grade securities, which are often referred to as “high yield” and “junk,” have predominantly speculative characteristics with respect to the issuer’s capacity to pay interest and repay principal.In the current market environment, Oaktree intends to focus on the following area, in which Oaktree believes there is less competition and thus potential for greater returns, for our new investment opportunities: (1) situational lending, which we define to include directly originated loans to non-sponsor companies that are hard to understand and value using traditional underwriting techniques, (2) select sponsor lending, which we define to include financing to support leveraged buyouts of companies with specialized sponsors that have expertise in certain industries, (3) stressed sector and rescue lending, which we define to include opportunistic private loans in industries experiencing stress or limited access to capital and (4) public credit, where we seek discounted, high quality public debt investments particularly in times of market dislocation. | ||||||||||||||||||||
Risk Factors [Table Text Block] | Risk Factors Investing in our securities involves a number of significant risks. In addition to the other information contained in this annual report on Form 10-K, you should consider carefully the following information before making an investment in our securities. The risks set out below are not the only risks we face. Additional risks and uncertainties not presently known to us or not presently deemed material by us might also impair our operations and performance. If any of the following events occur, our business, financial condition and results of operations could be materially and adversely affected. In such case, our net asset value and the trading price of our securities could decline, and you may lose part or all of your investment. The risk factors described below are the principal risk factors associated with an investment in us as well as those factors generally associated with an investment company with investment objectives, investment policies, capital structure or trading markets similar to ours. An investment in our securities involves risks. The following is a summary of the principal risks that you should carefully consider before investing in our securities. • Global economic, political and market conditions, including those caused by inflation and a rising interest rate environment, have (and in the future, could further) adversely affect our business, results of operations and financial condition and those of our portfolio companies. • Changes in interest rates may affect our cost of capital and net investment income. • A significant portion of our investment portfolio is and will continue to be recorded at fair value and, as a result, there is and will continue to be uncertainty as to the value of our portfolio investments. • Our ability to achieve our investment objective depends on our Adviser’s ability to support our investment process; if our Adviser were to lose key personnel or they were to resign, our ability to achieve our investment objective could be significantly harmed. • Because we borrow money, the potential for loss on amounts invested in us will be magnified and may increase the risk of investing in us. • There are significant potential conflicts of interest that could adversely impact our investment returns. • Regulations governing our operation as a Business Development Company and RIC affect our ability to raise, and the way in which we raise, additional capital or borrow for investment purposes, which may have a negative effect on our growth. • Our investments in portfolio companies may be risky, and we could lose all or parts of our investments. • Shares of closed-end investment companies, including Business Development Companies, may trade at a discount to their net asset value. • The market price of our common stock may fluctuate significantly. • Economic recessions or downturns may have a material adverse effect on our business, financial condition and results of operations, and could impair the ability of our portfolio companies to repay debt or pay interest. Risks Relating to Our Business and Structure Global economic, political and market conditions, including those caused by inflation and a rising interest rate environment have (and in the future, could further) adversely affect our business, results of operations and financial condition and those of our portfolio companies. Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector and re-pricing of credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. During the spring of 2020, the occurrence of these events during the initial onset of the COVID-19 pandemic negatively impacted the fair value of the investments that we held and, if they were to occur again in the future, could limit our investment originations (including as a result of the investment professionals of our Adviser diverting their time to the restructuring of certain investments), negatively impact our operating results and limit our ability to grow. More recently, the fair value of our investments has been adversely affected by increasing market yields. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) have adversely impacted, and could in the future further impact, the operations of certain of our portfolio companies. If the financial results of middle-market companies, like those in which we invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions decreased and may in the future decrease the value of collateral securing some of our loans and the value of our equity investments. Such conditions have required and may in the future require us to modify the payment terms of our investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of our portfolio companies has been, and in the future may be, negatively impacted by these economic or other conditions, which can result in our receipt of reduced interest income from our portfolio companies and/or realized and unrealized losses related to our investments, and, in turn, may adversely affect distributable income and have a material adverse effect on our results of operations. We have acquired, and may in the future opportunistically acquire the securities and obligations of distressed companies. These investments in distressed companies are subject to significant risks, including lack of income, extraordinary expenses, uncertainty with respect to satisfaction of debt, lower-than-expected investment values or income potentials and resale restrictions. We have acquired, and may in the future acquire, the securities and other obligations of distressed or bankrupt companies. At times, distressed debt obligations may not produce income and may require us to bear certain extraordinary expenses (including legal, accounting, valuation and transaction expenses) in order to protect and recover our investment. Therefore, when we invest in distressed debt, our ability to achieve current income for our stockholders may be diminished, particularly where the portfolio company has negative EBITDA. We also are subject to significant uncertainty as to when and in what manner and for what value the distressed debt we acquire will eventually be satisfied whether through a refinancing, restructuring, liquidation, an exchange offer or plan of reorganization involving the distressed debt securities or a payment of some amount in satisfaction of the obligation. In addition, even if an exchange offer is made or plan of reorganization is adopted with respect to distressed debt held by us, there can be no assurance that the securities or other assets received by us in connection with such exchange offer or plan of reorganization will not have a lower value or income potential than may have been anticipated when the investment was made. Moreover, any securities received by us upon completion of an exchange offer or plan of reorganization may be restricted as to resale. As a result of our participation in negotiations with respect to any exchange offer or plan of reorganization with respect to an issuer of distressed debt, we may be restricted from disposing of such securities. Changes in interest rates may affect our cost of capital and net investment income. General interest rate fluctuations and changes in credit spreads on floating rate loans may have a substantial negative impact on our investments and investment opportunities and, accordingly, may have a material adverse effect on our rate of return on invested capital, our net investment income, our net asset value and the market price of our common stock. The majority of our debt investments have, and are expected to have, variable interest rates that reset periodically based on benchmarks such as the Secured Overnight Financing Rate, or SOFR, the federal funds rate or prime rate. Increases in interest rates have made and will continue to make it more difficult for our portfolio companies to service their obligations under the debt investments that we will hold and increase defaults even where our investment income increases. Rising interest rates could also cause borrowers to shift cash from other productive uses to the payment of interest, which may have a material adverse effect on their business and operations and could, over time, lead to increased defaults. Additionally, as interest rates increase and the corresponding risk of a default by borrowers increases, the liquidity of higher interest rate loans may decrease as fewer investors may be willing to purchase such loans in the secondary market in light of the increased risk of a default by the borrower and the heightened risk of a loss of an investment in such loans. All of these risks may be exacerbated when interest rates rise rapidly and/or significantly. Decreases in credit spreads on debt that pays a floating rate of return would have an impact on the income generation of our floating rate assets. Trading prices for debt that pays a fixed rate of return tend to fall as interest rates rise. Trading prices tend to fluctuate more for fixed rate securities that have longer maturities. Conversely, if interest rates were to decline, borrowers may refinance their loans at lower interest rates, which could shorten the average life of the loans and reduce the associated returns on the investment, as well as require our Adviser and the Investment Professionals to incur management time and expense to re-deploy such proceeds, including on terms that may not be as favorable as our existing loans. In addition, because we borrow to fund our investments, a portion of our net investment income is dependent upon the difference between the interest rate at which we borrow funds and the interest rate at which we invest these funds. Portions of our investment portfolio and our borrowings have floating rate components. As a result, the recent significant changes in market interest rates have increased our interest expense as has the incurrence of additional fixed rate borrowings. In periods of rising interest rates, such as in the current market, our cost of funds increases, which tends to reduce our net investment income. We may hedge against interest rate fluctuations by using standard hedging instruments such as interest rate swap agreements, futures, options and forward contracts, subject to applicable legal requirements, including all necessary registrations (or exemptions from registration) with the Commodity Futures Trading Commission. In addition, our interest expense may not decrease at the same rate as overall interest rates because of our fixed rate borrowings, which could lead to greater declines in our net investment income. These activities may limit our ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on our business, financial condition and results of operations. Most U.S. dollar London Interbank Offered Rate, or LIBOR, loans are no longer published after June 30, 2023 although certain synthetic rates will be published through September 30, 2024. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, supports replacing U.S.-dollar LIBOR with SOR. As of September 30, 2023, primarily all of our loan agreements with portfolio companies as well as our credit facilities and interest rate swap agreements either include fallback language to address a LIBOR replacement or such agreements have been amended to no longer utilize LIBOR as a factor in determining the interest rate. The transition away from LIBOR to alternative reference rates has been complex and the transition of our remaining loan agreements with portfolio companies to a LIBOR replacement could have a material adverse effect on our business, financial condition and results of operations, including as a result of any changes in the pricing of our investments, changes to the documentation for certain of our investments and the pace of such changes, disputes and other actions regarding the interpretation of current and prospective loan documentation or modifications to processes and systems. The general increase in interest rates has had the effect of increasing our net investment income, which makes it easier for our Adviser to receive incentive fees. The general increase in interest rates has had the effect of increasing the interest rate that we receive on many of our debt investments. Accordingly, it has become easier for our Adviser to meet the quarterly hurdle rate for payment of income incentive fees under the Investment Advisory Agreement and has resulted in an increase in the amount of the income-based incentive fee payable to our Adviser. A significant portion of our investment portfolio is and will continue to be recorded at fair value and, as a result, there is and will continue to be uncertainty as to the value of our portfolio investments. Under the Investment Company Act, we are required to carry our portfolio investments at market value or, if there is no readily available market value, at fair value as determined by our Adviser in its capacity as our valuation designee. Typically, there is not a public market for the securities of the privately held companies in which we have invested and will generally continue to invest. As a result, our Adviser values these securities quarterly at fair value under the oversight of our Board of Directors. The fair value of such securities may change, potentially materially, between the date of the fair value determination and the release of the financial results for the corresponding period or the next date at which fair value is determined. Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio company’s earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, our Adviser's determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. In addition, any investments that include OID or PIK interest may have unreliable valuations because their continuing accruals require ongoing judgments about the collectability of their deferred payments and the value of their underlying collateral. Due to these uncertainties, our Adviser's fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments. As a result, investors purchasing our common stock based on an overstated net asset value would pay a higher price than the realizable value of our investments might warrant. In addition, the participation of the Investment Professionals in the valuation process could result in a conflict of interest as the management fee payable to our Adviser is based on our gross assets and the incentive fees earned by the Adviser are based, in part, on unrealized gains and losses. Our ability to achieve our investment objective depends on our Adviser’s ability to support our investment process; if our Adviser were to lose key personnel or they were to resign, our ability to achieve our investment objective could be significantly harmed. We depend on the investment expertise, skill and network of business contacts of the senior personnel of our Adviser. Our Adviser evaluates, negotiates, structures, executes, monitors and services our investments. Key personnel of our Adviser have departed in the past and current key personnel could depart at any time. Our Adviser’s capabilities in structuring the investment process, providing competent, attentive and efficient services to us, and facilitating access to financing on acceptable terms depend on the employment of investment professionals in adequate number and of adequate sophistication to match the corresponding flow of transactions. The departure of key personnel or of a significant number of the investment professionals or partners of our Adviser could have a material adverse effect on our ability to achieve our investment objective. Our Adviser may need to hire, train, supervise and manage new investment professionals to participate in our investment selection and monitoring process and may not be able to find investment professionals in a timely manner or at all. In addition, our Adviser may resign on 60 days’ notice. If we are unable to quickly find a new investment adviser or hire internal management with similar expertise and ability to provide the same or equivalent services on acceptable terms, our operations are likely to experience a disruption and our ability to achieve our investment objective and pay distributions would likely be materially and adversely affected. Our business model depends to a significant extent upon strong referral relationships, and the inability of the personnel associated with our Adviser to maintain or develop these relationships, or the failure of these relationships to generate investment opportunities, could adversely affect our business. We expect that personnel associated with our Adviser will maintain and develop their relationships with intermediaries, banks and other sources, and we will rely to a significant extent upon these relationships to provide us with potential investment opportunities. If these individuals fail to maintain their existing relationships or develop new relationships with other sources of investment opportunities, we may not be able to grow or maintain our investment portfolio. In addition, individuals with whom the personnel associated with our Adviser have relationships are not obligated to provide us with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for us. The failure of the personnel associated with our Adviser to maintain existing relationships, grow new relationships, or for those relationships to generate investment opportunities could have an adverse effect on our business, financial condition and results of operations. We may face increasing competition for investment opportunities, which could reduce returns and result in losses. We compete for investments with other Business Development Companies, public and private funds (including hedge funds, mezzanine funds and CLOs) and private equity funds (to the extent they provide an alternative form of financing), as well as traditional financial services companies such as commercial and investment banks, commercial financing companies and other sources of financing. Many of our competitors are substantially larger and have considerably greater financial, technical and marketing resources than we do. For example, some competitors may have a lower cost of capital and access to funding sources that are not available to us. In addition, some of our competitors may have higher risk tolerances or different risk assessments than we have. These characteristics could allow our competitors to consider a wider variety of investments, establish more relationships and offer better pricing and more flexible structuring than we are able to do. We may lose investment opportunities if we do not match our competitors’ pricing, terms and structure. If we are forced to match our competitors’ pricing, terms and structure, we may not be able to achieve acceptable returns on our investments or may bear substantial risk of capital loss. A significant increase in the number and/or the size of our competitors in this target market could force us to accept less attractive investment terms. Furthermore, many of our competitors are not subject to, the regulatory restrictions that the Investment Company Act imposes on us as a Business Development Company. The incentive fee we pay to our Adviser relating to capital gains may be effectively greater than 17.5%. The Adviser may be entitled to receive an incentive fee based on our capital gains, calculated on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each fiscal year. As a result of the operation of the cumulative method of calculating such capital gains portion of the incentive fee, the cumulative aggregate capital gains fee received by our Adviser could be effectively greater than 17.5%, depending on the timing and extent of subsequent net realized capital losses or net unrealized depreciation. This result would occur to the extent that, following receipt by the Adviser of a capital gain incentive fee, we subsequently realized capital depreciation and capital losses in excess of cumulative realized capital gains. We cannot predict whether, or to what extent, this payment calculation would affect your investment in our securities. Our ability to enter into transactions with our affiliates is restricted. We are prohibited under the Investment Company Act from participating in certain transactions with certain of our affiliates without the prior approval of our independent directors and, in some cases, the SEC. Any person that owns, directly or indirectly, 5% or more of our outstanding voting securities is our affiliate for purposes of the Investment Company Act, and we are generally prohibited from buying or selling any securities (other than our securities) from or to such affiliate, absent the prior approval of our independent directors. The Investment Company Act also prohibits certain “joint” transactions with certain of our affiliates, which could include investments in the same portfolio company (whether at the same or different times), without prior approval of our independent directors and, in some cases, the SEC. If a person acquires more than 25% of our voting securities, we will be prohibited from buying or selling any security (other than any security of which we are the issuer) from or to such person or certain of that person’s affiliates, or entering into prohibited joint transactions with such person, absent the prior approval of the SEC. Similar restrictions limit our ability to transact business with our officers or directors or their affiliates. As a result of these restrictions, except in situations described below, we may be prohibited from buying or selling any security (other than any security of which we are the issuer) from or to any portfolio company of a private equity fund managed by our Adviser without the prior approval of the SEC, which may limit the scope of investment opportunities that would otherwise be available to us. We may also invest alongside funds managed by our Adviser and its affiliates in certain circumstances where doing so is consistent with applicable law and SEC staff interpretations. For example, we may invest alongside such accounts consistent with guidance promulgated by the staff of the SEC permitting us and such other accounts to purchase interests in a single class of privately placed securities so long as certain conditions are met, including that our Adviser, acting on our behalf and on behalf of other clients, negotiates no term other than price. A failure on our part to maintain our qualification as a Business Development Company would significantly reduce our operating flexibility. If we fail to continuously qualify as a Business Development Company, we might be subject to regulation as a registered closed-end investment company under the Investment Company Act, which would significantly decrease our operating flexibility. In addition, failure to comply with the requirements imposed on Business Development Companies by the Investment Company Act could cause the SEC to bring an enforcement action against us. Regulations governing our operation as a Business Development Company and RIC affect our ability to raise, and the way in which we raise, additional capital or borrow for investment purposes, which may have a negative effect on our growth. In order to qualify for the tax benefits available to RICs and to minimize corporate-level U.S. federal income taxes, we intend to distribute (or be deemed to distribute) to our stockholders at least 90% of our taxable income each taxable year, except that we may retain certain net capital gains for investment, and treat such amounts as deemed distributions to our stockholders. If we elect to treat any amounts as deemed distributions, we would be subject to U.S. federal income tax at the U.S. corporate income tax rate on such deemed distributions on behalf of our stockholders. As a Business Development Company, we are required to invest at least 70% of our total assets primarily in securities of U.S. private or thinly-traded public companies, cash, cash equivalents, U.S. government securities and other high-quality debt instruments that mature in one year or less from the date of investment. As a Business Development Company, we may issue “senior securities,” including borrowing money from banks or other financial institutions only in amounts such that our asset coverage, as defined in the Investment Company Act, equals at least 150% after such incurrence or issuance. These requirements limit the amount that we may borrow, may unfavorably limit our investment opportunities and may reduce our ability in comparison to other companies to profit from favorable spreads between the rates at which we can borrow and the rates at which we can lend. If the value of our assets declines, we may be unable to satisfy the asset coverage test, which could prohibit us from paying distributions and could prevent us from being subject to tax as a RIC. If we cannot satisfy the asset coverage test, we may be required to sell a portion of our investments and, depending on the nature of our debt financing, repay a portion of our indebtedness at a time when such sales may be disadvantageous. Because we will continue to need capital to grow our investment portfolio, these limitations may prevent us from incurring debt and require us to raise additional equity at a time when it may be disadvantageous to do so. As a result of these requirements we need to periodically access the capital markets to raise cash to fund new investments at a more frequent pace than our privately owned competitors. We generally are not able to issue or sell our common stock at a price below net asset value per share, which may be a disadvantage as compared with other public companies or private investment funds. When our common stock trades at a discount to net asset value, this restriction could adversely affect our ability to raise capital. We may, however, sell our common stock, or warrants, options or rights to acquire our common stock, at a price below the current net asset value of the common stock if our Board of Directors and independent directors determine that such sale is in our best interests and the best interests of our stockholders, and our stockholders as well as those stockholders that are not affiliated with us approve such sale in accordance with the requirements of the Investment Company Act. In any such case, the price at which our securities are to be issued and sold may not be less than a price that, in the determination of our Board of Directors, closely approximates the market value of such securities (less any underwriting commission or discount). We also may make rights offerings to our stockholders at prices less than net asset value, subject to applicable requirements of the Investment Company Act. If we raise additional funds by issuing more shares of our common stock or issuing senior securities convertible into, or exchangeable for, our common stock, the percentage ownership of our stockholders may decline at that time and such stockholders may experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on terms favorable to us or at all. If additional funds are not available to us, we could be forced to curtail or cease new investment activities. In addition, we may in the future seek to securitize our portfolio securities to generate cash for funding new investments. To securitize loans, we would likely create a wholly-owned subsidiary and contribute a pool of loans to the subsidiary. We would then sell interests in the subsidiary on a non-recourse basis to purchasers and we would retain all or a portion of the equity in the subsidiary. An inability to successfully securitize our loan portfolio could limit our ability to grow our business or fully execute our business strategy and may decrease our earnings, if any. The securitization market is subject to changing market conditions and we may not be able to access this market when we would otherwise deem appropriate. Moreover, the successful securitization of our portfolio might expose us to losses as the residual investments in which we do not sell interests will tend to be those that are riskier and more apt to generate losses. The Investment Company Act also may impose restrictions on the structure of any securitization. Our Board of Directors may change our investment objective, operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse. Our Board of Directors has the authority to modify or waive our current investment objective, operating policies and strategies without prior notice and without stockholder approval. We cannot predict the effect any changes to our current investment objective, operating policies and strategies would have on our business, net asset value, operating results and value of our stock. However, the effects might be adverse, which could negatively impact our ability to pay you distributions and cause you to lose part or all of your investment. Changes in laws or regulations governing our operations may adversely affect our business or cause us to alter our business strategy. We and our portfolio companies are subject to regulation at the local, state and federal level. New legislation may be enacted or new interpretations, rulings or regulations could be adopted, including those governing the types of investments we are permitted to make or that impose limits on our ability to pledge a significant amount of our assets to secure loans or that restrict the operations of a portfolio company, any of which could harm us and our stockholders and the value of our investments, potentially with retroactive effect. Any amendment or repeal of legislation, or changes in regulations or regulatory interpretations thereof, could create uncertainty in the near term, which could have a material adverse impact on our business, financial condition and results of operations. Additionally, any changes to the laws and regulations governing our operations relating to permitted investments may cause us to alter our investment strategy in order to avail ourselves of new or different opportunities. Such changes could result in material differences to the strategies and plans set forth herein and may result in our investment focus shifting from the areas of expertise of our Adviser to other types of investments in which our Adviser may have less expertise or little or no experience. Thus, any such changes, if they occur, could have a material adverse effect on our results of operations and the value of your investment. Our sustainability initiatives, specifically relating to ESG matters, may impose additional costs and expose us to emerging areas of risk. Sustainability ris | ||||||||||||||||||||
Effects of Leverage [Text Block] | Borrowings, also known as leverage, magnify the potential for loss on invested equity capital. We expect to continue to use leverage to partially finance our investments, through borrowings from banks and other lenders and/or issuing unsecured notes, which will increase the risks of investing in our common stock, including the likelihood of default. We borrow under our credit facilities and unsecured notes. On November 30, 2017, we entered into a Senior Secured Revolving Credit Agreement, or as amended and/or restated from time to time, the Syndicated Facility, with the lenders, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A. as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. On January 23, 2023, we became party to a revolving credit facility, or as amended and/or restated from time to time, the OSI2 Citibank Facility, with OSI 2 Senior Lending SPV, LLC, or OSI 2 SPV, our wholly-owned and consolidated subsidiary, as the borrower, us, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent. In addition, we have three series of unsecured notes outstanding: our 3.500% notes due 2025, or the 2025 Notes, our 2.700% notes due 2027, or the 2027 Notes, and our 7.100% Notes due 2029, or the 2029 Notes. We may issue other debt securities or enter into other types of borrowing arrangements in the future. If the value of our assets decreases, leveraging would cause net asset value to decline more sharply than it otherwise would have had we not leveraged. Similarly, any decrease in our income would cause net income to decline more sharply than it would have had we not borrowed. To the extent we incur additional leverage, these effects would be further magnified, increasing the risk of investing in us. Such a decline could negatively affect our ability to make common stock distributions or scheduled debt payments. Leverage is generally considered a speculative investment technique and we only intend to use leverage if expected returns will exceed the cost of borrowing. As of September 30, 2023, we had $710.0 million of outstanding indebtedness under our credit facilities, $300.0 million of outstanding 2025 Notes, $350.0 million of outstanding 2027 Notes and $300.0 million of outstanding 2029 Notes. These debt instruments require periodic payments of interest. The weighted average interest rate charged on our borrowings as of September 30, 2023 was 7.0% (exclusive of deferred financing costs and inclusive of the impact of an interest rate swap designated as a hedging instrument). We will need to generate sufficient cash flow to make these required interest payments. In order for us to cover our annual interest payments on indebtedness, we must achieve annual returns on our September 30, 2023 total assets of at least 3.70%. If we are unable to meet the financial obligations under our credit facilities, the lenders under such credit facilities will have a superior claim to our assets over our stockholders. If we are unable to meet the financial obligations under the 2025 Notes, 2027 Notes or 2029 Notes, the holders thereof will have the right to declare the principal amount and accrued and unpaid interest on such notes to be due and payable immediately. | ||||||||||||||||||||
Annual Interest Rate, Current [Percent] | 7% | ||||||||||||||||||||
Annual Coverage Return Rate [Percent] | 3.70% | ||||||||||||||||||||
Effects of Leverage [Table Text Block] | Assumed Return on Portfolio (Net of Expenses) - 10% - 5% 0% 5% 10% Corresponding net return to common stockholder -28.18% -17.90% -7.61% 2.67% 12.95% | ||||||||||||||||||||
Return at Minus Ten [Percent] | (28.18%) | ||||||||||||||||||||
Return at Minus Five [Percent] | (17.90%) | ||||||||||||||||||||
Return at Zero [Percent] | (7.61%) | ||||||||||||||||||||
Return at Plus Five [Percent] | 2.67% | ||||||||||||||||||||
Return at Plus Ten [Percent] | 12.95% | ||||||||||||||||||||
Effects of Leverage, Purpose [Text Block] | The following table illustrates the effect of leverage on returns from an investment in our common stock assuming various annual returns, net of expenses. The calculations in the table below are hypothetical and actual returns may be higher or lower than those appearing below. | ||||||||||||||||||||
Share Price [Table Text Block] | Sale Price NAV (1) High Low Premium (Discount) of High Sales Price to NAV (2) Premium (Discount) of Low Sales Price to NAV (2) Cash Distribution per Share (3) Year ended September 30, 2022 First quarter $ 22.03 $ 22.86 $ 21.09 3.8 % (4.3) % $ 0.465 Second quarter $ 21.79 $ 23.43 $ 21.39 7.5 % (1.8) % $ 0.480 Third quarter $ 20.67 $ 22.83 $ 18.60 10.4 % (10.0) % $ 0.495 Fourth quarter $ 20.38 $ 21.75 $ 17.61 6.7 % (13.6) % $ 0.510 Year ended September 30, 2023 First quarter $ 19.63 $ 21.69 $ 17.58 10.5 % (10.4) % $ 0.960 Second quarter $ 19.66 $ 21.48 $ 17.70 9.3 % (10.0) % $ 0.550 Third quarter $ 19.58 $ 20.05 $ 17.99 2.4 % (8.1) % $ 0.550 Fourth quarter $ 19.63 $ 20.71 $ 19.24 5.5 % (2.0) % $ 0.550 Year ending September 30, 2024 First quarter (through November 10, 2023) * $ 20.17 $ 18.41 * * $0.620 (4) __________ * Not determinable at the time of filing. (1) NAV per share is determined as of the last day in the relevant quarter and therefore may not reflect the NAV per share on the date of the high and low sales prices. The NAVs shown are based on outstanding shares at the end of each period. (2) Calculated as the respective high or low sales price less NAV, divided by NAV. (3) Represents the distribution declared in the specified quarter. We have adopted an “opt out” dividend reinvestment plan for our common stockholders. Distributions by us are generally taxable to U.S. stockholders as ordinary income or capital gains. (4) On November 8, 2023, our Board of Directors declared a quarterly distribution of $0.55 per share payable on December 29, 2023 to stockholders of record on December 15, 2023. On November 8, 2023, our Board of Directors also declared a special distribution of $0.07 per share payable on December 29, 2023 to stockholders of record on December 15, 2023. | ||||||||||||||||||||
Lowest Price or Bid | 19.24 | $ 17.99 | $ 17.70 | $ 17.58 | 17.61 | $ 18.60 | $ 21.39 | $ 21.09 | |||||||||||||
Highest Price or Bid | $ 20.71 | $ 20.05 | $ 21.48 | $ 21.69 | $ 21.75 | $ 22.83 | $ 23.43 | $ 22.86 | |||||||||||||
Highest Price or Bid, Premium (Discount) to NAV [Percent] | 5.50% | 2.40% | 9.30% | 10.50% | 6.70% | 10.40% | 7.50% | 3.80% | |||||||||||||
Lowest Price or Bid, Premium (Discount) to NAV [Percent] | (2.00%) | (8.10%) | (10.00%) | (10.40%) | (13.60%) | (10.00%) | (1.80%) | (4.30%) | |||||||||||||
NAV Per Share | $ 19.63 | [1] | $ 19.58 | $ 19.66 | $ 19.63 | $ 20.38 | [1] | $ 20.67 | $ 21.79 | $ 22.03 | $ 19.63 | [1] | $ 19.81 | $ 18.26 | $ 21.84 | [1] | $ 19.47 | ||||
Global Economic, Political and Market Conditions Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Global economic, political and market conditions, including those caused by inflation and a rising interest rate environment have (and in the future, could further) adversely affect our business, results of operations and financial condition and those of our portfolio companies. Any disruptions in the capital markets, as a result of inflation and a rising interest environment or otherwise, may increase the spread between the yields realized on risk-free and higher risk securities and can result in illiquidity in parts of the capital markets, significant write-offs in the financial sector and re-pricing of credit risk in the broadly syndicated market. These and any other unfavorable economic conditions could increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. During the spring of 2020, the occurrence of these events during the initial onset of the COVID-19 pandemic negatively impacted the fair value of the investments that we held and, if they were to occur again in the future, could limit our investment originations (including as a result of the investment professionals of our Adviser diverting their time to the restructuring of certain investments), negatively impact our operating results and limit our ability to grow. More recently, the fair value of our investments has been adversely affected by increasing market yields. In addition, market conditions (including inflation, supply chain issues and decreased consumer demand) have adversely impacted, and could in the future further impact, the operations of certain of our portfolio companies. If the financial results of middle-market companies, like those in which we invest, experience deterioration, it could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults, and further deterioration in market conditions will further depress the outlook for those companies. Further, adverse economic conditions decreased and may in the future decrease the value of collateral securing some of our loans and the value of our equity investments. Such conditions have required and may in the future require us to modify the payment terms of our investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of our portfolio companies has been, and in the future may be, negatively impacted by these economic or other conditions, which can result in our receipt of reduced interest income from our portfolio companies and/or realized and unrealized losses related to our investments, and, in turn, may adversely affect distributable income and have a material adverse effect on our results of operations. | ||||||||||||||||||||
Acquired Securities of Distressed Companies Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We have acquired, and may in the future opportunistically acquire the securities and obligations of distressed companies. These investments in distressed companies are subject to significant risks, including lack of income, extraordinary expenses, uncertainty with respect to satisfaction of debt, lower-than-expected investment values or income potentials and resale restrictions. We have acquired, and may in the future acquire, the securities and other obligations of distressed or bankrupt companies. At times, distressed debt obligations may not produce income and may require us to bear certain extraordinary expenses (including legal, accounting, valuation and transaction expenses) in order to protect and recover our investment. Therefore, when we invest in distressed debt, our ability to achieve current income for our stockholders may be diminished, particularly where the portfolio company has negative EBITDA. We also are subject to significant uncertainty as to when and in what manner and for what value the distressed debt we acquire will eventually be satisfied whether through a refinancing, restructuring, liquidation, an exchange offer or plan of reorganization involving the distressed debt securities or a payment of some amount in satisfaction of the obligation. In addition, even if an exchange offer is made or plan of reorganization is adopted with respect to distressed debt held by us, there can be no assurance that the securities or other assets received by us in connection with such exchange offer or plan of reorganization will not have a lower value or income potential than may have been anticipated when the investment was made. Moreover, any securities received by us upon completion of an exchange offer or plan of reorganization may be restricted as to resale. As a result of our participation in negotiations with respect to any exchange offer or plan of reorganization with respect to an issuer of distressed debt, we may be restricted from disposing of such securities. | ||||||||||||||||||||
Interest Rate Fluctuation Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Changes in interest rates may affect our cost of capital and net investment income. General interest rate fluctuations and changes in credit spreads on floating rate loans may have a substantial negative impact on our investments and investment opportunities and, accordingly, may have a material adverse effect on our rate of return on invested capital, our net investment income, our net asset value and the market price of our common stock. The majority of our debt investments have, and are expected to have, variable interest rates that reset periodically based on benchmarks such as the Secured Overnight Financing Rate, or SOFR, the federal funds rate or prime rate. Increases in interest rates have made and will continue to make it more difficult for our portfolio companies to service their obligations under the debt investments that we will hold and increase defaults even where our investment income increases. Rising interest rates could also cause borrowers to shift cash from other productive uses to the payment of interest, which may have a material adverse effect on their business and operations and could, over time, lead to increased defaults. Additionally, as interest rates increase and the corresponding risk of a default by borrowers increases, the liquidity of higher interest rate loans may decrease as fewer investors may be willing to purchase such loans in the secondary market in light of the increased risk of a default by the borrower and the heightened risk of a loss of an investment in such loans. All of these risks may be exacerbated when interest rates rise rapidly and/or significantly. Decreases in credit spreads on debt that pays a floating rate of return would have an impact on the income generation of our floating rate assets. Trading prices for debt that pays a fixed rate of return tend to fall as interest rates rise. Trading prices tend to fluctuate more for fixed rate securities that have longer maturities. Conversely, if interest rates were to decline, borrowers may refinance their loans at lower interest rates, which could shorten the average life of the loans and reduce the associated returns on the investment, as well as require our Adviser and the Investment Professionals to incur management time and expense to re-deploy such proceeds, including on terms that may not be as favorable as our existing loans. In addition, because we borrow to fund our investments, a portion of our net investment income is dependent upon the difference between the interest rate at which we borrow funds and the interest rate at which we invest these funds. Portions of our investment portfolio and our borrowings have floating rate components. As a result, the recent significant changes in market interest rates have increased our interest expense as has the incurrence of additional fixed rate borrowings. In periods of rising interest rates, such as in the current market, our cost of funds increases, which tends to reduce our net investment income. We may hedge against interest rate fluctuations by using standard hedging instruments such as interest rate swap agreements, futures, options and forward contracts, subject to applicable legal requirements, including all necessary registrations (or exemptions from registration) with the Commodity Futures Trading Commission. In addition, our interest expense may not decrease at the same rate as overall interest rates because of our fixed rate borrowings, which could lead to greater declines in our net investment income. These activities may limit our ability to participate in the benefits of lower interest rates with respect to the hedged borrowings. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on our business, financial condition and results of operations. Most U.S. dollar London Interbank Offered Rate, or LIBOR, loans are no longer published after June 30, 2023 although certain synthetic rates will be published through September 30, 2024. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, supports replacing U.S.-dollar LIBOR with SOR. As of September 30, 2023, primarily all of our loan agreements with portfolio companies as well as our credit facilities and interest rate swap agreements either include fallback language to address a LIBOR replacement or such agreements have been amended to no longer utilize LIBOR as a factor in determining the interest rate. The transition away from LIBOR to alternative reference rates has been complex and the transition of our remaining loan agreements with portfolio companies to a LIBOR replacement could have a material adverse effect on our business, financial condition and results of operations, including as a result of any changes in the pricing of our investments, changes to the documentation for | ||||||||||||||||||||
Increase in Interest Rates Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | The general increase in interest rates has had the effect of increasing our net investment income, which makes it easier for our Adviser to receive incentive fees. The general increase in interest rates has had the effect of increasing the interest rate that we receive on many of our debt investments. Accordingly, it has become easier for our Adviser to meet the quarterly hurdle rate for payment of income incentive fees under the Investment Advisory Agreement and has resulted in an increase in the amount of the income-based incentive fee payable to our Adviser. | ||||||||||||||||||||
Uncertainty of Value of Investment Portfolio Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | A significant portion of our investment portfolio is and will continue to be recorded at fair value and, as a result, there is and will continue to be uncertainty as to the value of our portfolio investments. Under the Investment Company Act, we are required to carry our portfolio investments at market value or, if there is no readily available market value, at fair value as determined by our Adviser in its capacity as our valuation designee. Typically, there is not a public market for the securities of the privately held companies in which we have invested and will generally continue to invest. As a result, our Adviser values these securities quarterly at fair value under the oversight of our Board of Directors. The fair value of such securities may change, potentially materially, between the date of the fair value determination and the release of the financial results for the corresponding period or the next date at which fair value is determined. Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio company’s earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, our Adviser's determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. In addition, any investments that include OID or PIK interest may have unreliable valuations because their continuing accruals require ongoing judgments about the collectability of their deferred payments and the value of their underlying collateral. Due to these uncertainties, our Adviser's fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments. As a result, investors purchasing our common stock based on an overstated net asset value would pay a higher price than the realizable value of our investments might warrant. In addition, the participation of the Investment Professionals in the valuation process could result in a conflict of interest as the management fee payable to our Adviser is based on our gross assets and the incentive fees earned by the Adviser are based, in part, on unrealized gains and losses. | ||||||||||||||||||||
Adviser Support Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Our ability to achieve our investment objective depends on our Adviser’s ability to support our investment process; if our Adviser were to lose key personnel or they were to resign, our ability to achieve our investment objective could be significantly harmed. We depend on the investment expertise, skill and network of business contacts of the senior personnel of our Adviser. Our Adviser evaluates, negotiates, structures, executes, monitors and services our investments. Key personnel of our Adviser have departed in the past and current key personnel could depart at any time. Our Adviser’s capabilities in structuring the investment process, providing competent, attentive and efficient services to us, and facilitating access to financing on acceptable terms depend on the employment of investment professionals in adequate number and of adequate sophistication to match the corresponding flow of transactions. The departure of key personnel or of a significant number of the investment professionals or partners of our Adviser could have a material adverse effect on our ability to achieve our investment objective. Our Adviser may need to hire, train, supervise and manage new investment professionals to participate in our investment selection and monitoring process and may not be able to find investment professionals in a timely manner or at all. In addition, our Adviser may resign on 60 days’ notice. If we are unable to quickly find a new investment adviser or hire internal management with similar expertise and ability to provide the same or equivalent services on acceptable terms, our operations are likely to experience a disruption and our ability to achieve our investment objective and pay distributions would likely be materially and adversely affected. | ||||||||||||||||||||
Referral Relationships Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Our business model depends to a significant extent upon strong referral relationships, and the inability of the personnel associated with our Adviser to maintain or develop these relationships, or the failure of these relationships to generate investment opportunities, could adversely affect our business. We expect that personnel associated with our Adviser will maintain and develop their relationships with intermediaries, banks and other sources, and we will rely to a significant extent upon these relationships to provide us with potential investment opportunities. If these individuals fail to maintain their existing relationships or develop new relationships with other sources of investment opportunities, we may not be able to grow or maintain our investment portfolio. In addition, individuals with whom the personnel associated with our Adviser have relationships are not obligated to provide us with investment opportunities, and, therefore, there is no assurance that such relationships will generate investment opportunities for us. The failure of the personnel associated with our Adviser to maintain existing relationships, grow new relationships, or for those relationships to generate investment opportunities could have an adverse effect on our business, financial condition and results of operations. | ||||||||||||||||||||
Competition for Investment Opportunities Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We may face increasing competition for investment opportunities, which could reduce returns and result in losses. We compete for investments with other Business Development Companies, public and private funds (including hedge funds, mezzanine funds and CLOs) and private equity funds (to the extent they provide an alternative form of financing), as well as traditional financial services companies such as commercial and investment banks, commercial financing companies and other sources of financing. Many of our competitors are substantially larger and have considerably greater financial, technical and marketing resources than we do. For example, some competitors may have a lower cost of capital and access to funding sources that are not available to us. In addition, some of our competitors may have higher risk tolerances or different risk assessments than we have. These characteristics could allow our competitors to consider a wider variety of investments, establish more relationships and offer better pricing and more flexible structuring than we are able to do. We may lose investment opportunities if we do not match our competitors’ pricing, terms and structure. If we are forced to match our competitors’ pricing, terms and structure, we may not be able to achieve acceptable returns on our investments or may bear substantial risk of capital loss. A significant increase in the number and/or the size of our competitors in this target market could force us to accept less attractive investment terms. Furthermore, many of our competitors are not subject to, the regulatory restrictions that the Investment Company Act imposes on us as a Business Development Company. | ||||||||||||||||||||
Incentive Fee Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | The incentive fee we pay to our Adviser relating to capital gains may be effectively greater than 17.5%. The Adviser may be entitled to receive an incentive fee based on our capital gains, calculated on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each fiscal year. As a result of the operation of the cumulative method of calculating such capital gains portion of the incentive fee, the cumulative aggregate capital gains fee received by our Adviser could be effectively greater than 17.5%, depending on the timing and extent of subsequent net realized capital losses or net unrealized depreciation. This result would occur to the extent that, following receipt by the Adviser of a capital gain incentive fee, we subsequently realized capital depreciation and capital losses in excess of cumulative realized capital gains. We cannot predict whether, or to what extent, this payment calculation would affect your investment in our securities. | ||||||||||||||||||||
Restriction on Transactions with Affiliates Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Our ability to enter into transactions with our affiliates is restricted. We are prohibited under the Investment Company Act from participating in certain transactions with certain of our affiliates without the prior approval of our independent directors and, in some cases, the SEC. Any person that owns, directly or indirectly, 5% or more of our outstanding voting securities is our affiliate for purposes of the Investment Company Act, and we are generally prohibited from buying or selling any securities (other than our securities) from or to such affiliate, absent the prior approval of our independent directors. The Investment Company Act also prohibits certain “joint” transactions with certain of our affiliates, which could include investments in the same portfolio company (whether at the same or different times), without prior approval of our independent directors and, in some cases, the SEC. If a person acquires more than 25% of our voting securities, we will be prohibited from buying or selling any security (other than any security of which we are the issuer) from or to such person or certain of that person’s affiliates, or entering into prohibited joint transactions with such person, absent the prior approval of the SEC. Similar restrictions limit our ability to transact business with our officers or directors or their affiliates. As a result of these restrictions, except in situations described below, we may be prohibited from buying or selling any security (other than any security of which we are the issuer) from or to any portfolio company of a private equity fund managed by our Adviser without the prior approval of the SEC, which may limit the scope of investment opportunities that would otherwise be available to us. We may also invest alongside funds managed by our Adviser and its affiliates in certain circumstances where doing so is consistent with applicable law and SEC staff interpretations. For example, we may invest alongside such accounts consistent with guidance promulgated by the staff of the SEC permitting us and such other accounts to purchase interests in a single class of privately placed securities so long as certain conditions are met, including that our Adviser, acting on our behalf and on behalf of other clients, negotiates no term other than price. | ||||||||||||||||||||
Qualification as Business Development Company Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | A failure on our part to maintain our qualification as a Business Development Company would significantly reduce our operating flexibility.If we fail to continuously qualify as a Business Development Company, we might be subject to regulation as a registered closed-end investment company under the Investment Company Act, which would significantly decrease our operating flexibility. In addition, failure to comply with the requirements imposed on Business Development Companies by the Investment Company Act could cause the SEC to bring an enforcement action against us. | ||||||||||||||||||||
Ability to Raise Capital Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Regulations governing our operation as a Business Development Company and RIC affect our ability to raise, and the way in which we raise, additional capital or borrow for investment purposes, which may have a negative effect on our growth. In order to qualify for the tax benefits available to RICs and to minimize corporate-level U.S. federal income taxes, we intend to distribute (or be deemed to distribute) to our stockholders at least 90% of our taxable income each taxable year, except that we may retain certain net capital gains for investment, and treat such amounts as deemed distributions to our stockholders. If we elect to treat any amounts as deemed distributions, we would be subject to U.S. federal income tax at the U.S. corporate income tax rate on such deemed distributions on behalf of our stockholders. As a Business Development Company, we are required to invest at least 70% of our total assets primarily in securities of U.S. private or thinly-traded public companies, cash, cash equivalents, U.S. government securities and other high-quality debt instruments that mature in one year or less from the date of investment. As a Business Development Company, we may issue “senior securities,” including borrowing money from banks or other financial institutions only in amounts such that our asset coverage, as defined in the Investment Company Act, equals at least 150% after such incurrence or issuance. These requirements limit the amount that we may borrow, may unfavorably limit our investment opportunities and may reduce our ability in comparison to other companies to profit from favorable spreads between the rates at which we can borrow and the rates at which we can lend. If the value of our assets declines, we may be unable to satisfy the asset coverage test, which could prohibit us from paying distributions and could prevent us from being subject to tax as a RIC. If we cannot satisfy the asset coverage test, we may be required to sell a portion of our investments and, depending on the nature of our debt financing, repay a portion of our indebtedness at a time when such sales may be disadvantageous. Because we will continue to need capital to grow our investment portfolio, these limitations may prevent us from incurring debt and require us to raise additional equity at a time when it may be disadvantageous to do so. As a result of these requirements we need to periodically access the capital markets to raise cash to fund new investments at a more frequent pace than our privately owned competitors. We generally are not able to issue or sell our common stock at a price below net asset value per share, which may be a disadvantage as compared with other public companies or private investment funds. When our common stock trades at a discount to net asset value, this restriction could adversely affect our ability to raise capital. We may, however, sell our common stock, or warrants, options or rights to acquire our common stock, at a price below the current net asset value of the common stock if our Board of Directors and independent directors determine that such sale is in our best interests and the best interests of our stockholders, and our stockholders as well as those stockholders that are not affiliated with us approve such sale in accordance with the requirements of the Investment Company Act. In any such case, the price at which our securities are to be issued and sold may not be less than a price that, in the determination of our Board of Directors, closely approximates the market value of such securities (less any underwriting commission or discount). We also may make rights offerings to our stockholders at prices less than net asset value, subject to applicable requirements of the Investment Company Act. If we raise additional funds by issuing more shares of our common stock or issuing senior securities convertible into, or exchangeable for, our common stock, the percentage ownership of our stockholders may decline at that time and such stockholders may experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on terms favorable to us or at all. If additional funds are not available to us, we could be forced to curtail or cease new investment activities. In addition, we may in the future seek to securitize our portfolio securities to generate cash for funding new investments. To securitize loans, we would likely create a wholly-owned subsidiary and contribute a pool of loans to the subsidiary. We would then sell interests in the subsidiary on a non-recourse basis to purchasers and we would retain all or a portion of the equity in the subsidiary. An inability to successfully securitize our loan portfolio could limit our ability to grow our business or fully execute our business strategy and may decrease our earnings, if any. The securitization market is subject to changing market conditions and we may not be able to access this market when we would otherwise deem appropriate. Moreover, the successful securitization of our portfolio might expose us to losses as the residual investments in which we do not sell interests will tend to be those that are riskier and more apt to generate losses. The Investment Company Act also may impose restrictions on the structure of any securitization. | ||||||||||||||||||||
Board of Directors Decisions Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Our Board of Directors may change our investment objective, operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse. Our Board of Directors has the authority to modify or waive our current investment objective, operating policies and strategies without prior notice and without stockholder approval. We cannot predict the effect any changes to our current investment objective, operating policies and strategies would have on our business, net asset value, operating results and value of our stock. However, the effects might be adverse, which could negatively impact our ability to pay you distributions and cause you to lose part or all of your investment. | ||||||||||||||||||||
Changes in Laws Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Changes in laws or regulations governing our operations may adversely affect our business or cause us to alter our business strategy. We and our portfolio companies are subject to regulation at the local, state and federal level. New legislation may be enacted or new interpretations, rulings or regulations could be adopted, including those governing the types of investments we are permitted to make or that impose limits on our ability to pledge a significant amount of our assets to secure loans or that restrict the operations of a portfolio company, any of which could harm us and our stockholders and the value of our investments, potentially with retroactive effect. Any amendment or repeal of legislation, or changes in regulations or regulatory interpretations thereof, could create uncertainty in the near term, which could have a material adverse impact on our business, financial condition and results of operations. | ||||||||||||||||||||
Sustainability Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Our sustainability initiatives, specifically relating to ESG matters, may impose additional costs and expose us to emerging areas of risk. Sustainability risk means an ESG event or condition that, if it occurs, could cause an actual or a potential material negative impact on the value of the investment, or Sustainability Risk. While Sustainability Risks are only some of the many factors the Adviser will consider in making an investment, there is no guarantee that Oaktree will successfully identify and mitigate all Sustainability Risks. The act of selecting and evaluating Sustainability Risks is subjective by nature, and there is no guarantee that the criteria utilized or judgment exercised by Oaktree, its affiliates or a third-party ESG advisor will reflect the beliefs or values, internal policies or preferred practices of any particular stockholder or other asset managers or market trends. To the extent that Oaktree or a third-party advisor engages with underlying investments on sustainability-related and ESG-related practices, potential enhancements and risk mitigants, such steps may not achieve the desired financial results, or the market or society may not view any such changes as desirable. Successful engagement on the part of Oaktree will depend on Oaktree’s skill in properly identifying and analyzing Sustainability Risks and other factors (which may involve qualitative and subjective judgements) and their related value, together with the quality of the data provided in respect of the impact of Sustainability Risks in respect of the relevant investment and there can be no assurance that the strategy or techniques employed will be successful. The materiality of sustainability and ESG risks on an individual asset and on a portfolio as a whole depends on many factors, including the relevant industry, location, investment strategy, asset class and investment style. Sustainability Risks and ESG factors, issues and considerations do not apply in every instance or with respect to each investment held, or proposed to be made by us, and will vary greatly based on numerous criteria, including location, asset class, industry, investment strategy, and issuer-specific and investment-specific characteristics. Considering Sustainability Risks when evaluating an investment may result in the selection or exclusion of certain investments based on Oaktree’s view of certain sustainability-related and other factors and carries the risk that we may underperform compared to other funds that do not take sustainability-related factors into account. Although Oaktree considers the application of its sustainability framework to be an opportunity to enhance or protect the performance of its investments over the long-term, Oaktree cannot guarantee that its sustainability program, which depends in part on qualitative judgments, will positively impact the financial performance of any individual investment or us as a whole. In assessing a particular investment, Oaktree may be dependent upon information and data obtained through third parties that may be incomplete, inaccurate or unavailable, which could cause Oaktree to incorrectly identify, prioritize, assess or analyze the investment’s sustainability and ESG practices and/or Sustainability Risks and opportunities. Oaktree does not intend to independently verify certain of the sustainability and ESG-related information reported by our investments, and may decide in its discretion not to utilize, report on, or consider certain information provided by such investments. To the extent that Oaktree provides reports of material sustainability and ESG issues to investors, such reports will be based on Oaktree’s or the applicable investment management team’s sole and subjective determination of whether and how to report on whether any material sustainability or ESG issue has occurred in respect of an investment and Oaktree makes no representations that all Sustainability Risks or ESG issues will or should be discussed in such reports. Sustainability-related practices differ by region, industry and issue and are evolving accordingly, and an investment’s sustainability-related practices or Oaktree’s assessment of such practices may change over time. Oaktree in certain circumstances could determine in its discretion that it is not feasible or practical to implement or complete certain of its sustainability and ESG initiatives based on cost, timing or other considerations. It is also possible that market dynamics or other factors will make it impractical, inadvisable or impossible for the Adviser to adhere to all elements of our investment strategy, including with respect to sustainability and ESG risk management, whether with respect to one or more individual Investments or to our portfolio generally. | ||||||||||||||||||||
Global Climate Change Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We and/or our portfolio companies may be materially and adversely impacted by global climate change. Global climate change is widely considered to be a significant threat to the global economy. Real estate and similar assets in particular may face risks associated with climate change, including risks related to the impact of climate-related legislation and regulation (both domestically and internationally), risks related to climate-related business trends, and risks stemming from the physical impacts of climate change, such as the increasing frequency or severity of extreme weather events and rising sea levels and temperatures. The market’s focus on climate change may not have a positive impact on our investments. Financial resources and public and private investment into business activities seeking to address climate change, reduce emissions and promote adaptation to climate change-related impacts are increasing. While financial and non-financial benefits may flow from these types of investments, Oaktree cannot guarantee that such activities will improve the financial or environmental, social and governance-related performance of the investment, reduce emissions or promote adaptation to climate change-related impacts and Oaktree may also not find itself in a position to maximize opportunities presented by such business activities whether in respect of financial or non-financial returns. | ||||||||||||||||||||
Cyber Security Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We may face a breach of our cyber security, which could result in adverse consequences to our operations and exposure of confidential information. Cybersecurity incidents and cyber-attacks have been occurring globally at a more frequent and severe level and are expected to continue to increase in frequency and severity in the future. The information and technology systems of Oaktree, its affiliates, portfolio companies, issuers and service providers may be vulnerable to damage or interruption from cybersecurity breaches, computer viruses or other malicious code, network failures, computer and telecommunication failures, infiltration by unauthorized persons and other security breaches, usage errors or malfeasance by their respective professionals or service providers, power, communications or other service outages, and catastrophic events such as fires, tornadoes, floods, hurricanes, earthquakes or terrorist incidents. If unauthorized parties gain access to such information and technology systems, or if personnel abuse or misuse their access privileges, they may be able to steal, publish, delete or modify private and sensitive information, including non-public personal information related to our stockholders (and their beneficial owners) and material non-public information. Although Oaktree has implemented, and portfolio companies, issuers and service providers may implement, various measures to manage risks relating to these types of events, such systems could prove to be inadequate and, if compromised, could become inoperable for extended periods of time, cease to function properly or fail to adequately secure private information. Oaktree does not control the cybersecurity plans and systems put in place by third-party service providers, and such third-party service providers may have limited indemnification obligations to Oaktree, its affiliates, us, our stockholders and/or a portfolio company or issuer, each of whom could be negatively impacted as a result. Breaches such as those involving covertly introduced malware, impersonation of authorized users and industrial or other espionage may not be identified in a timely manner or at all, even with sophisticated prevention and detection systems. This could potentially result in further harm and prevent such breaches from being addressed appropriately. The failure of these systems and/or of disaster recovery plans for any reason could cause significant interruptions in Oaktree’s, its affiliates’, our and/or a portfolio company’s or issuer’s operations and result in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal information relating to stockholders (and their beneficial owners), material non-public information and the intellectual property and trade secrets and other sensitive information of Oaktree and/or portfolio companies or issuers. We, Oaktree and/or a portfolio company could be required to make a significant investment to remedy the effects of any such failures, harm to our reputations, legal claims that we or our respective affiliates may be subjected to regulatory action or enforcement arising out of applicable privacy and other laws, adverse publicity, and other events that may affect our business and financial performance. | ||||||||||||||||||||
Data Privacy Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We and our portfolio companies will be subject to regulations related to privacy, data protection and information securities, and any failure to comply with these requirements could result in fines, sanctions or other penalties, which could have a material adverse effect on our business and our reputation. The adoption, interpretation and application of consumer protection, data protection and/or privacy laws and regulations in the United States, Europe or other jurisdictions, or Privacy Laws, could significantly impact current and planned privacy and information security related practices, the collection, use, sharing, retention and safeguarding of personal data and current and planned business activities of Oaktree and us and/or our portfolio companies, and increase compliance costs and require the dedication of additional time and resources to compliance for such entities. A failure to comply with such Privacy Laws by any such entity or their service providers could result in fines, sanctions or other penalties, which could materially and adversely affect the results of operations and overall business, as well as have a negative impact on reputation and our performance. As Privacy Laws are implemented, interpreted and applied, compliance costs are likely to increase, particularly in the context of ensuring that adequate data protection and data transfer mechanisms are in place. For example, California has passed the California Consumer Privacy Act of 2018 and the California Privacy Rights Act of 2020, each of which broadly impacts businesses that handle various types of personal data. Such laws impose stringent legal and operational obligations on regulated businesses, as well as the potential for significant penalties. Other jurisdictions, including other U.S. states, already have, have proposed or are considering similar Privacy Laws, which impose, or could impose if enacted, similarly significant costs, potential liabilities and operational and legal obligations. Such Privacy Laws and regulations are expected to vary from jurisdiction to jurisdiction, thus increasing costs, operational and legal burdens, and the potential for significant liability for regulated entities, which could include Oaktree, the Adviser and us and/or our portfolio companies. | ||||||||||||||||||||
Artificial Intelligence Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We are subject to risks associated with artificial intelligence and machine learning technology. Recent technological advances in artificial intelligence and machine learning technology, or Machine Learning Technology, including OpenAI’s release of its ChatGPT application, pose risks to us, Oaktree and our portfolio investments. While Oaktree may utilize Machine Learning Technology in connection with its business activities, including investment activities, Oaktree intends to periodically evaluate and/or adjust internal policies governing use of Machine Learning Technology by its personnel. Notwithstanding any such policies, Oaktree personnel, portfolio managers, senior executives, Industry Specialists and other associated persons of Oaktree or any affiliates of Oaktree could, unbeknownst to Oaktree, utilize Machine Learning Technology in contravention of such policies. We, Oaktree and our portfolio investments could be further exposed to the risks of Machine Learning Technology if third-party service providers or any counterparties, whether or not known to Oaktree, also use Machine Learning Technology in their business activities. Oaktree will not be in a position to control the use of Machine Learning Technology in third-party products or services, including those provided by Oaktree’s and its affiliates service providers. Use of Machine Learning Technology by any of the parties described in the previous paragraph could include the input of confidential information (including material non-public information)—either by third parties in contravention of non-disclosure agreements, or by Oaktree personnel or the aforementioned Oaktree advisors and affiliates in contravention of Oaktree’s policies, contractual or other obligations or restrictions to which any of the foregoing or any of their affiliates or representatives are subject, or otherwise in violation of applicable laws or regulations relating to treatment of confidential and/or personally identifiable information (including material non-public information) —into Machine Learning Technology applications, resulting in such confidential information becoming part of a dataset that is accessible by other third-party Machine Learning Technology applications and users. Independent of its context of use, Machine Learning Technology is generally highly reliant on the collection and analysis of large amounts of data, and it is not possible or practicable to incorporate all relevant data into the model that Machine Learning Technology utilizes to operate. Certain data in such models will inevitably contain a degree of inaccuracy and error – potentially materially so – and could otherwise be inadequate or flawed, which would be likely to degrade the effectiveness of Machine Learning Technology. To the extent that we, Oaktree or our portfolio investments are exposed to the risks of Machine Learning Technology use, any such inaccuracies or errors could have adverse impacts on us, Oaktree or our portfolio investments. Conversely, to the extent competitors of Oaktree and its portfolio companies utilize Machine Learning Technology more extensively than Oaktree and its portfolio companies, there is a possibility that such competitors will gain a competitive advantage. Machine Learning Technology and its applications, including in the private investment and financial sectors, continue to develop rapidly, and it is impossible to predict the future risks that may arise from such developments. | ||||||||||||||||||||
Inability to Invest Offering Proceeds Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We may be unable to invest a significant portion of the net proceeds from an offering of our securities on acceptable terms within an attractive timeframe. Delays in investing the net proceeds raised in an offering of our securities may cause our performance to be worse than that of fully invested Business Development Companies or other lenders or investors pursuing comparable investment strategies. We cannot assure you that we will be able to identify any investments that meet our investment objective or that any investment that we make will produce a positive return. We may be unable to invest the net proceeds of any offering on acceptable terms within the time period that we anticipate or at all, which could harm our financial condition and operating results. | ||||||||||||||||||||
Allocation of Net Offering Proceeds Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | We may allocate the net proceeds from an offering in ways with which you may not agree. We have significant flexibility in investing the net proceeds of an offering, and may do so in a way with which you may not agree. Additionally, our Adviser will select our investments subsequent to the closing of an offering, and our stockholders will have no input with respect to such investment decisions. Further, other than general limitations that may be included in a future credit facility, the holders of our debt securities will generally not have veto power or a vote in approving any changes to our investment or operational policies. These factors increase the uncertainty, and thus the risk, of investing in our securities. In addition, pending such investments, we will invest the net proceeds from an offering primarily in high quality, short-term debt securities, consistent with our Business Development Company election and our election to be taxed as a RIC, at yields significantly below the returns which we expect to achieve when our portfolio is fully invested in securities meeting our investment objective. If we are not able to identify or gain access to suitable investments, our income may be limited. | ||||||||||||||||||||
Conflicts of Interest Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Relating to Conflicts of Interest Our base management fee may induce our Adviser to incur leverage. Our base management fee is payable based upon our gross assets, which includes borrowings for investment purposes, which may encourage our Adviser to use leverage to make additional investments. Given the subjective nature of the investment decisions made by our Adviser on our behalf and the discretion related to incurring leverage in connection with any such investments, it will be difficult to monitor this potential conflict of interest between us and our Adviser. Our incentive fee may induce our Adviser to make speculative investments. The incentive fee payable by us to our Adviser may create an incentive for it to make investments on our behalf that are risky or more speculative than would be the case in the absence of such compensation arrangement, which could result in higher investment losses, particularly during cyclical economic downturns. The incentive fee payable to our Adviser includes a component based on a percentage of our net investment income (subject to a hurdle rate), which may encourage our Adviser to use leverage to increase the return on our investments or otherwise manipulate our income so as to recognize income in quarters where the hurdle rate is exceeded and may result in an obligation for us to pay an incentive fee to the Adviser even if we have incurred a loss for an applicable period. The incentive fee payable by us to our Adviser also may create an incentive for our Adviser to invest on our behalf in instruments that have a deferred interest feature. Under these investments, we would accrue the interest over the life of the investment but would not receive the cash income from the investment until the end of the investment’s term, if at all. Our net investment income used to calculate the income portion of our incentive fee, however, includes accrued interest. Thus, a portion of the incentive fee would be based on income that we have not yet received in cash and may never receive in cash if the portfolio company is unable to satisfy such interest payment obligation to us. While we may make incentive fee payments on income accruals that we may not collect in the future and with respect to which we do not have a formal “clawback” right against our Adviser, the amount of accrued income written off in any period will reduce the income in the period in which such write-off was taken and thereby reduce such period’s incentive fee payment. In addition, our Adviser may be entitled to receive an incentive fee based upon net capital gains realized on our investments. Unlike the portion of the incentive fee based on income, there is no performance threshold applicable to the portion of the incentive fee based on net capital gains. As a result, our Adviser may have a tendency to invest more in investments that are likely to result in capital gains as compared to income producing securities. Such a practice could result in our investing in more speculative securities than would otherwise be the case, which could result in higher investment losses, particularly during economic downturns. Given the subjective nature of the investment decisions made by our Adviser on our behalf, we will be unable to monitor these potential conflicts of interest between us and our Adviser. There may be conflicts of interest related to obligations that Oaktree’s senior management and investment team have to Other Oaktree Funds. Actual and potential conflicts between Oaktree and its affiliates, on one hand, and us and our portfolio companies, on the other hand, are expected to occur. Oaktree manages or sub-advises other funds and accounts, or collectively, the Other Oaktree Funds, which present the possibility of overlapping investments, and thus the potential for conflicts of interest. Many of the investments targeted by us will be appropriate for certain Other Oaktree Funds, and in retrospect or at different points in the market cycle, investments that were made by us may seem more appropriate for an Other Oaktree Fund, and vice versa. Many of the investments targeted by us may be appropriate for Other Oaktree Funds within those strategies. Our stockholders have no ability to challenge such allocation. Such procedures give Oaktree broad authority to allocate investment opportunities, notwithstanding the potential conflicts of interest that may exist. For example, management fees or incentive allocations and fees and liquidity provisions may differ significantly between us and the Other Oaktree Funds, creating an economic incentive for Oaktree to allocate investments that may be appropriate for a lower fee or more liquid strategy to a higher fee or less liquid strategy. In addition, there are potential conflicts of interests between the interests of us and our stockholders, on the one hand, and the business interests of Oaktree, on the other hand. Potential conflicts of interests include, but are not limited to, the fact that Oaktree serves as our investment adviser. If any matter arises that Oaktree determines in its good faith judgment constitutes an actual conflict of interest, Oaktree may take such actions as may be necessary or appropriate to prevent or reduce the conflict. Our executive officers and directors, and certain members of our Adviser, serve or may serve as officers, directors or principals of entities that operate in the same or a related line of business as we do or of investment funds managed by our affiliates. For example, Oaktree presently serves as the investment adviser to OLPG, a private Business Development Company, and OSCF, a continuously offered Business Development Company. All of our executive officers serve in substantially similar capacities for OLPG, and one of our independent directors serves as an independent director of OSCF. OLPG and OSCF invest in senior secured loans, including first lien, unitranche and second lien debt instruments that pay interest at rates which are determined periodically on the basis of a floating base lending rate, made to private middle-market companies whose debt is rated below investment grade, similar to those we target for investment. Oaktree and its affiliates also manage or sub-advise other Business Development Companies, registered investment companies and private investment funds and accounts, and may manage other such funds and accounts in the future, which have investment mandates that are similar, in whole and in part, with ours. Therefore, there may be certain investment opportunities that satisfy the investment criteria for OLPG, OSCF and us as well as other Business Development Companies and Other Oaktree Funds. In addition, Oaktree and its affiliates may have obligations to investors in other entities that they advise or sub-advise, the fulfillment of which might not be in the best interests of us or our stockholders. An investment in us is not an investment in any of these other entities. For example, the personnel of our Adviser may face conflicts of interest in the allocation of investment opportunities to us and such other funds and accounts. Moreover, the Adviser and the Investment Professionals are engaged in other business activities which divert their time and attention. The Investment Professionals will devote as much time to us as such professionals deem appropriate to perform their duties in accordance with the Investment Advisory Agreement. However, such persons may be committed to providing investment advisory and other services for other clients, and engage in other business ventures in which we have no interest. As a result of these separate business activities, the Adviser may have conflicts of interest in allocating management time, services and functions among us, other advisory clients and other business ventures. Oaktree has investment allocation guidelines that govern the allocation of investment opportunities among the investment funds and accounts managed or sub-advised by Oaktree and its affiliates. To the extent an investment opportunity is appropriate for OLPG, OSCF or us or any other investment fund or account managed or sub-advised by Oaktree or its affiliates, Oaktree will adhere to its investment allocation guidelines in order to determine a fair and equitable allocation. In addition, affiliates of our Adviser have received exemptive relief from the SEC to allow certain managed funds and accounts, each of whose investment adviser is OCM or an investment adviser controlling, controlled by or under common control with OCM, such as our Adviser, as well as proprietary accounts (subject to certain conditions) to participate in negotiated co-investment transactions where doing so is consistent with the applicable registered fund’s or Business Development Company’s investment objective and strategies as well as regulatory requirements and other pertinent factors, and pursuant to the conditions of the exemptive relief. Each potential co-investment opportunity that falls under the terms of the exemptive relief and is appropriate for us and any affiliated fund or account, and satisfies the then-current board-established criteria, will be offered to us and such other eligible funds and accounts. If there is a sufficient amount of securities to satisfy all participants, the securities will be allocated among the participants in accordance with their proposed order size and if there is an insufficient amount of securities to satisfy all participants, the securities will be allocated pro rata based on the investment proposed by the applicable investment adviser to such participant, up to the amount proposed to be invested by each, which is reviewed and approved by an independent committee of legal, compliance and accounting professionals at our Adviser. We may also invest alongside funds managed by our Adviser and its affiliates in certain circumstances where doing so is consistent with applicable law and SEC staff interpretations. For example, we may invest alongside such accounts consistent with guidance promulgated by the staff of the SEC permitting us and such other accounts to purchase interests in a single class of privately placed securities so long as certain conditions are met, including that our Adviser, acting on our behalf and on behalf of other clients, negotiates no term other than price or terms related to price. Although Oaktree will endeavor to allocate investment opportunities in a fair and equitable manner, we and our common stockholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of our Adviser. We might not participate in each individual opportunity, but will, on an overall basis, be entitled to participate equitably with other entities managed by Oaktree and its affiliates. Oaktree seeks to treat all clients fairly and equitably such that none receive preferential treatment vis-à-vis the others over time, in a manner consistent with its fiduciary duty to each of them; however, in some instances, especially in instances of limited liquidity, the factors may not result in pro rata allocations or may result in situations where certain funds or accounts receive allocations where others do not. Pursuant to the Investment Advisory Agreement, our Adviser’s liability is limited and we are required to indemnify our Adviser against certain liabilities. This may lead our Adviser to act in a riskier manner in performing its duties and obligations under the Investment Advisory Agreement than it would if it were acting for its own account, and creates a potential conflict of interest. In addition, we may make investments in different parts of the capital structure of companies in which Other Oaktree Funds already hold an investment. Generally speaking, Oaktree expects that we will make such investments only when, at the time of investment, Oaktree believes such investment is in our best interests and either the possibility of actual adversity is remote, our investment is small and non-controlling or the Adviser believes that such investment is appropriate for us in light of the particular circumstances, notwithstanding the potential for conflict. If any conflict were to arise, however, Oaktree will be permitted to take certain actions that, in the absence of such conflict, it would not take, such as causing us to remain passive, investing in the same class of securities to align interests, divesting investments or taking other actions to reduce adversity, which may have the effect of benefiting certain Other Oaktree Funds, and not us. Given that we generally intend to invest higher in the capital structure, it is likely we will remain passive in the event of a conflict, meaning that we must rely on other investors holding the same types of securities or obligations to advocate on behalf of our class. Oaktree has no obligation to advise these other holders of any potential claims they may have of which Oaktree may be aware or to consider their interests when advocating on behalf of the Other Oaktree Funds that hold investments in lower parts of the capital structure. Under certain circumstances, we potentially will be offered an opportunity to make an investment in a transaction in which one or more Other Oaktree Funds is expected to make an investment, or in a company in which one or more Other Oaktree Funds already has made, or concurrently will make, an investment. The Investment Company Act and the exemptive relief also impose restrictions on our ability to participate in certain transactions with other Oaktree Funds. As a result, we and the Other Oaktree Fund potentially will have conflicting interests in negotiating the terms of such investments. In negotiating the purchase of such investments, the nature of the covenants, and other terms and conditions of such securities, the Other Oaktree Funds potentially will have interests that conflict with ours. In that regard, subject to the requirements of the Investment Company Act and the exemptive relief, actions may be taken for the Other Oaktree Funds that are adverse to us. Such conflicts also have the potential to arise in the negotiations of amendments or waivers or in a workout or bankruptcy. It is possible that in a bankruptcy proceeding, our interests would be subordinated or otherwise adversely affected by virtue of such Other Oaktree Funds’ involvement and actions relating to its investment. Oaktree will seek to manage such conflicts in good faith and in a manner it believes is consistent with its duties to us and the Other Oaktree Funds and under the Investment Company Act and the exemptive relief, if applicable. Pursuant to the Administration Agreement, Oaktree Administrator furnishes us with the facilities, including our principal executive office, and administrative services necessary to conduct our day-to-day operations. We pay Oaktree Administrator its allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including, without limitation a portion of the rent at market rates and the compensation of our Chief Financial Officer, Chief Compliance Officer, their respective staffs and other non-investment professionals at Oaktree that perform duties for us. This arrangement creates conflicts of interest that our Board of Directors must monitor. | ||||||||||||||||||||
Use of Leverage Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Relating to Our Use of Leverage Because we borrow money, the potential for loss on amounts invested in us will be magnified and may increase the risk of investing in us. Borrowings, also known as leverage, magnify the potential for loss on invested equity capital. We expect to continue to use leverage to partially finance our investments, through borrowings from banks and other lenders and/or issuing unsecured notes, which will increase the risks of investing in our common stock, including the likelihood of default. We borrow under our credit facilities and unsecured notes. On November 30, 2017, we entered into a Senior Secured Revolving Credit Agreement, or as amended and/or restated from time to time, the Syndicated Facility, with the lenders, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A. as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. On January 23, 2023, we became party to a revolving credit facility, or as amended and/or restated from time to time, the OSI2 Citibank Facility, with OSI 2 Senior Lending SPV, LLC, or OSI 2 SPV, our wholly-owned and consolidated subsidiary, as the borrower, us, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent. In addition, we have three series of unsecured notes outstanding: our 3.500% notes due 2025, or the 2025 Notes, our 2.700% notes due 2027, or the 2027 Notes, and our 7.100% Notes due 2029, or the 2029 Notes. We may issue other debt securities or enter into other types of borrowing arrangements in the future. If the value of our assets decreases, leveraging would cause net asset value to decline more sharply than it otherwise would have had we not leveraged. Similarly, any decrease in our income would cause net income to decline more sharply than it would have had we not borrowed. To the extent we incur additional leverage, these effects would be further magnified, increasing the risk of investing in us. Such a decline could negatively affect our ability to make common stock distributions or scheduled debt payments. Leverage is generally considered a speculative investment technique and we only intend to use leverage if expected returns will exceed the cost of borrowing. As of September 30, 2023, we had $710.0 million of outstanding indebtedness under our credit facilities, $300.0 million of outstanding 2025 Notes, $350.0 million of outstanding 2027 Notes and $300.0 million of outstanding 2029 Notes. These debt instruments require periodic payments of interest. The weighted average interest rate charged on our borrowings as of September 30, 2023 was 7.0% (exclusive of deferred financing costs and inclusive of the impact of an interest rate swap designated as a hedging instrument). We will need to generate sufficient cash flow to make these required interest payments. In order for us to cover our annual interest payments on indebtedness, we must achieve annual returns on our September 30, 2023 total assets of at least 3.70%. If we are unable to meet the financial obligations under our credit facilities, the lenders under such credit facilities will have a superior claim to our assets over our stockholders. If we are unable to meet the financial obligations under the 2025 Notes, 2027 Notes or 2029 Notes, the holders thereof will have the right to declare the principal amount and accrued and unpaid interest on such notes to be due and payable immediately. The Small Business Credit Availability Act, or the SBCAA, among other things, amended Section 61(a) of the Investment Company Act to add a new Section 61(a)(2) that reduces the asset coverage requirement applicable to Business Development Companies from 200% to 150% (i.e., the amount of debt may not exceed 66.67% of the value of the Business Development Company’s assets) so long as the Business Development Company meets certain disclosure requirements and obtains certain approvals. At a special meeting of stockholders held on June 28, 2019, our stockholders approved the application of the reduced asset coverage requirements in Section 61(a)(2) of the Investment Company Act to us, effective as of June 29, 2019. When we incur additional leverage, our net asset value will decline more sharply if the value of our assets declines and the effects of leverage described above will be magnified. Illustration. The following table illustrates the effect of leverage on returns from an investment in our common stock assuming various annual returns, net of expenses. The calculations in the table below are hypothetical and actual returns may be higher or lower than those appearing below. Assumed Return on Portfolio (Net of Expenses) - 10% - 5% 0% 5% 10% Corresponding net return to common stockholder -28.18% -17.90% -7.61% 2.67% 12.95% For purposes of this table, we have assumed $3,116.5 million in total assets (less all liabilities and indebtedness not represented by senior securities), $1,660.0 million in debt outstanding, $1,515.8 million in net assets as of September 30, 2023, and a weighted average interest rate of 7.0% as of September 30, 2023 (exclusive of deferred financing costs and inclusive of the impact of an interest rate swap designated as a hedging instrument). Actual interest payments may be different. Substantially all of our assets are subject to security interests under our credit facilities and if we default on our obligations under any such facility, we may suffer adverse consequences, including foreclosure on our assets. As of September 30, 2023, substantially all of our assets were pledged as collateral under our credit facilities and may be pledged as collateral under future credit facilities. If we default on our obligations under these facilities, the lenders may have the right to foreclose upon and sell, or otherwise transfer, the collateral subject to their security interests or their superior claim. In such event, we may be forced to sell our investments to raise funds to repay our outstanding borrowings in order to avoid foreclosure and these forced sales may be at times and at prices we would not consider advantageous. Moreover, such deleveraging of our company could significantly impair our ability to effectively operate our business in the manner in which we have historically operated. As a result, we could be forced to curtail or cease new investment activities and lower or eliminate the distributions that we have historically paid to our stockholders. In addition, if the lenders exercise their right to sell the assets pledged under our credit facilities or future credit facilities, such sales may be completed at distressed sale prices, thereby diminishing or potentially eliminating the amount of cash available to us after repayment of the amounts outstanding under the credit facilities. We may enter into reverse repurchase agreements, which are another form of leverage. We may enter into reverse repurchase agreements as part of our management of our temporary investment portfolio. Our entry into any such reverse repurchase agreements would be subject to the Investment Company Act limitations on leverage. In connection with entry into a reverse repurchase agreement, we would effectively pledge our assets as collateral to secure a short-term loan. Generally, the other party to the agreement would make a loan to us in an amount equal to a percentage of the fair value of the collateral we have pledged. At the maturity of the reverse repurchase agreement, we will be required to repay the loan and then receive back our collateral. While used as collateral, the assets continue to pay principal and interest which are for the benefit of us. Our use of reverse repurchase agreements, if any, involves many of the same risks involved in our use of leverage. For example, the market value of the securities acquired in the reverse repurchase agreement may decline below the price of the securities that we have sold but we would remain obligated to purchase those securities, meaning that we bear the risk of loss that the proceeds at settlement are less than the fair value of the securities pledged. In addition, the market value of the securities retained by us may decline. If a buyer of securities under a reverse repurchase agreement were to file for bankruptcy or experience insolvency, we would be adversely affected. In addition, due to the interest costs associated with reverse repurchase agreements, our net asset value would decline, and, in some cases, we may be worse off than if we had not used such agreements. | ||||||||||||||||||||
Distributions Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Related to Distributions Because we intend to distribute at least 90% of our taxable income each taxable year to our stockholders in connection with our election to be treated as a RIC, we will continue to need additional capital to finance our growth. In order to qualify for the tax benefits available to RICs and to minimize corporate-level U.S. federal income taxes, we intend to distribute (or be demed to distribute) to our stockholders at least 90% of our taxable income each taxable year, except that we may retain certain net capital gains for investment, and treat such amounts as deemed distributions to our stockholders. If we elect to treat any amounts as deemed distributions, we would be subject to U.S. federal income tax at the U.S. corporate income tax rate applicable to net capital gains on such deemed distributions on behalf of our stockholders. As a result of these requirements, we will likely need to raise capital from other sources to grow our business. Because we will continue to need capital to grow our investment portfolio, these limitations together with the asset coverage requirements applicable to us may prevent us from incurring debt and require us to raise additional equity at a time when it may be disadvantageous to do so. We may not be able to pay you distributions, our distributions may not grow over time and a portion of our distributions may be a return of capital. We intend to pay distributions to our stockholders out of assets legally available for distribution. We cannot assure you that we will achieve investment results that will allow us to sustain a specified level of cash distributions or periodic increases in cash distributions. In addition, the inability to satisfy the asset coverage test applicable to us as a Business Development Company can limit our ability to pay distributions. All distributions will be paid at the discretion of our Board of Directors and will depend on our earnings, our financial condition, maintenance of our ability to be subject to tax as a RIC, compliance with applicable Business Development Company regulations and such other factors as our Board of Directors may deem relevant from time to time. We cannot assure you that we will continue to pay distributions to our stockholders at current levels, or at all. When we make distributions, our distributions generally will be treated as dividends for U.S. federal income tax purposes to the extent such distributions are paid out of our current or accumulated earnings and profits. Distributions in excess of current and accumulated earnings and profits will be treated as a non-taxable return of capital to the extent of a stockholder's basis in our stock and, assuming that a stockholder holds our stock as a capital asset, thereafter as a capital gain. A return of capital generally is a return of a stockholder’s investment rather than a return of earnings or gains derived from our investment activities. Moreover, we may pay all or a substantial portion of our distributions from the proceeds of the sale of shares of our common stock or from borrowings in anticipation of future cash flow, which could constitute a return of stockholders’ capital and will lower such stockholders’ tax basis in our shares, which may result in increased tax liability to stockholders when they sell or otherwise dispose of such shares. The tax liability incurred by such stockholders upon the sale or other disposition of shares of our common stock may increase even if such shares are sold at a loss. We will be subject to corporate-level U.S. federal income tax if we are unable to maintain our qualification as a RIC under Subchapter M of the Code or do not satisfy the Annual Distribution Requirement. To maintain our tax status as a RIC and be relieved of U.S. federal taxes on income and gains distributed (or be deemed distributed) to our stockholders, we must meet the following annual distribution, income source and asset diversification requirements: • The Annual Distribution Requirement will be satisfied if we distribute dividends to our stockholders each taxable year of an amount generally at least equal to 90% of the sum of our net taxable income plus realized net short-term capital gains in excess of realized net long-term capital losses, if any. Because we use debt financing, we are and may, in the future, be subject to certain financial covenants under our debt arrangements that could, under certain circumstances, restrict us from making distributions necessary to satisfy the Annual Distribution Requirement. If we are unable to obtain cash from other sources, we could fail to qualify for RIC tax treatment and thus could become subject to corporate-level U.S. federal income tax. • The 90% Gross Income Test will be satisfied if we earn at least 90% of our gross income for each taxable year from dividends, interest, gains from the sale of stock or securities or similar sources. • The Diversification Tests will be satisfied if, at the end of each quarter of our taxable year, at least 50% of the value of our assets consist of cash, cash equivalents, U.S. government securities, securities of other RICs, and other acceptable securities; and no more than 25% of the value of our assets can be invested in the securities, other than U.S. government securities or securities of other RICs, of one issuer, of two or more issuers that are controlled, as determined under applicable Code rules, by us and that are engaged in the same or similar or related trades or businesses or of certain “qualified publicly traded partnerships.” Failure to meet these requirements may result in our having to dispose of certain investments quickly in order to prevent the loss of RIC status. Because most of our investments will be in private companies, and therefore will be relatively illiquid, any such dispositions could be made at disadvantageous prices and could cause us to incur substantial losses. If we fail to be subject to tax as a RIC and are subject to corporate-level U.S. federal corporate income tax, the resulting corporate taxes could substantially reduce our net assets, the amount of income available for distribution and the amount of our distributions. We may have difficulty paying our required distributions if we are required to recognize income for U.S. federal income tax purposes before or without receiving cash representing such income. For U.S. federal income tax purposes, we generally are required to include in income certain amounts that we have not yet received in cash, such as OID or certain income accruals on contingent payment debt instruments, which may occur if we receive warrants in connection with the origination of a loan or possibly in other circumstances. Such OID is generally required to be included in income before we receive any corresponding cash payments. In addition, our loans typically contain PIK interest provisions. Any PIK interest, computed at the contractual rate specified in each loan agreement, is generally required to be added to the principal balance of the loan and recorded as interest income. We also may be required to include in income certain other amounts that we do not receive, and may never receive, in cash. To avoid the imposition of corporate-level tax on us, this non-cash source of income may need to be distributed (or deemed distributed) to our stockholders in cash or, in the event that we determine to do so, in shares of our common stock, even though we may have not yet collected and may never collect the cash relating to such income. Since, in certain cases, we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the Annual Distribution Requirement necessary to be relieved of corporate-level U.S. federal taxes on income and gains distributed (or deemed distributed) to our stockholders. Accordingly, we may have to sell or otherwise dispose of some of our investments at times and/or at prices we would not consider advantageous, raise additional debt or equity capital or forgo new investment opportunities for this purpose. If we are not able to obtain cash from other sources, we may fail to satisfy the Annual Distribution Requirement and thus become subject to corporate-level U.S. federal income tax. We may in the future choose to pay distributions partly in our own stock, in which case you may be subject to tax in excess of the cash you receive. We may distribute taxable distributions that are payable in part in our stock. In accordance with certain applicable Treasury Regulations and other related administrative pronouncements or interpretations therefore issued by the Internal Revenue Service, or the IRS, a RIC may be eligible to treat a distribution of its own stock as fulfilling its RIC distribution requirements if each stockholder is permitted to elect to receive his or her entire distribution in either cash or stock of the RIC, subject to the satisfaction of certain guidelines. If too many stockholders elect to receive cash, each stockholder electing to receive cash must receive a pro rata amount of cash (with the balance of the distribution paid in stock). If these and certain other requirements are met, the amount of the distribution paid in stock for U.S. federal income tax purposes generally will be equal to the amount of cash that could have been received instead of stock. Taxable stockholders receiving such distributions will be required to include the full amount of the distribution as ordinary income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of their share of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be subject to tax with respect to such distributions in excess of any cash received. If a U.S. stockholder sells the stock it receives as a distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the distribution, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such distribution, including in respect of all or a portion of such distribution that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on a distribution, such sales may put downward pressure on the trading price of our stock. | ||||||||||||||||||||
Investment Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Relating to Our Investments Our investments in portfolio companies may be risky, and we could lose all or parts of our investments. The companies in which we invest are typically highly leveraged, and, in most cases, our investments in such companies are not rated by any rating agency. If such investments were rated, we believe that they would likely receive a rating from a nationally recognized statistical rating organization of below investment grade (i.e., below BBB- or Baa), which is often referred to as "high yield" and “junk.” Exposure to below investment grade securities involves certain risks, and those securities are viewed as having predominately speculative characteristics with respect to the issuer's capacity to pay interest and repay principal. Investing in small and mid-sized companies involves a number of significant risks. Certain of our debt investments consist of debt securities for which issuers are not required to make principal payments until the maturity of such debt securities, which could result in a substantial loss to us if such issuers are unable to refinance or repay their debt at maturity. Increases in interest rates may affect the ability of our portfolio companies to repay debt or pay interest, which may in turn affect the value of our portfolio investments, and our business, financial condition and results of operations. Among other things, our portfolio companies: • may have limited financial resources, may be more susceptible to rising interest rates and inflation, may have limited or negative EBITDA and may be unable to meet their obligations under their debt instruments that we hold, which may be accompanied by a deterioration in the value of any collateral and a reduction in the likelihood of us realizing any guarantees from subsidiaries or affiliates of our portfolio companies that we may have obtained in connection with our investments, as well as a corresponding decrease in the value of the equity components of our investments; • may have shorter operating histories, narrower product lines, smaller market shares and/or significant customer concentrations than larger businesses, which tend to render them more vulnerable to competitors’ actions and market conditions, as well as general economic downturns; • may operate in regulated industries and/or provide services to federal, state or local governments, or operate in industries that provide services to regulated industries or federal, state or local governments, any of which could lead to delayed payments for services or subject the company to changing payment and reimbursement rates or other terms; • may not have collateral sufficient to pay any outstanding interest or principal due to us in the event of a default by these companies; • are more likely to depend on the management talents and efforts of a small group of people; therefore, the death, disability, resignation or termination of one or more of these persons could have a material adverse impact on our portfolio company and, in turn, on us; • may have difficulty accessing the capital markets to fund capital needs, which may limit their ability to grow or repay outstanding indebtedness at maturity; • may not have audited financial statements or be subject to the Sarbanes-Oxley Act and other rules that govern public companies; • generally have less predictable operating results, may from time to time be parties to litigation, may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence, and may require substantial additional capital to support their operations, finance expansion or maintain their competitive position; and • generally have less publicly available information about their businesses, operations and financial condition. These factors may make certain of our portfolio companies more susceptible to the adverse events in the economy. As a result of the limitations associated with certain of our portfolio companies, we must therefore rely on the ability of our Adviser to obtain adequate information through due diligence to evaluate the creditworthiness and potential returns from investing in these companies. In addition, certain of our officers and directors may serve as directors on the boards of such companies. To the extent that litigation arises out of our investments in these companies, our officers and directors may be named as defendants in such litigation, which could result in an expenditure of funds (through our indemnification of such officers and directors) and the diversion of management time and resources. Finally, little public information generally exists about privately owned companies, and these companies may not have third-party debt ratings or audited financial statements. We must therefore rely on the ability of our Adviser to obtain adequate information through due diligence to evaluate the creditworthiness and potential returns from investing in these companies. Additionally, these companies and their financial information will not generally be subject to the Sarbanes-Oxley Act and other rules that govern public companies. We may be exposed to higher risks with respect to our investments that include OID or PIK interest. Our investments may include OID and contractual PIK interest, which typically represents contractual interest added to a loan balance and due at the end of such loan’s term. To the extent OID or PIK interest constitute a portion of our income, we are exposed to typical risks associated with such income being required to be included in taxable and accounting income prior to receipt of cash, including the following: • OID and PIK instruments may have higher yields, which reflect the payment deferral and credit risk associated with these instruments; • OID and PIK accruals may create uncertainty about the source of our distributions to stockholders; • OID and PIK instruments may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred payments and the value of the collateral; and • OID and PIK instruments may represent a higher credit risk than coupon loans. If we acquire the securities and obligations of distressed or bankrupt companies, such investments may be subject to significant risks, including lack of income, extraordinary expenses, uncertainty with respect to satisfaction of debt, lower-than-expected investment values or income potentials and resale restrictions. We may acquire the securities and other obligations of distressed or bankrupt companies. At times, distressed debt obligations may not produce income and may require us to bear certain extraordinary expenses (including legal, accounting, valuation and transaction expenses) in order to protect and recover our investment. Therefore, to the extent we invest in distressed debt, our ability to achieve current income for our stockholders may be diminished, particularly where the portfolio company has negative EBITDA. We also will be subject to significant uncertainty as to when and in what manner and for what value the distressed debt we invest in will eventually be satisfied whether through a liquidation, an exchange offer or plan of reorganization involving the distressed debt securities or a payment of some amount in satisfaction of the obligation. In addition, even if an exchange offer is made or plan of reorganization is adopted with respect to distressed debt held by us, there can be no assurance that the securities or other assets received by us in connection with such exchange offer or plan of reorganization will not have a lower value or income potential than may have been anticipated when the investment was made. Moreover, any securities received by us upon completion of an exchange offer or plan of reorganization may be restricted as to resale. As a result of our participation in negotiations with respect to any exchange offer or plan of reorganization with respect to an issuer of distressed debt, we may be restricted from disposing of such securities. Inflation may adversely affect the business, results of operations and financial condition of our portfolio companies. Certain of our portfolio companies may be impacted by inflation. If such portfolio companies are unable pass any increases in their costs along to their customers, it could adversely affect their results and their ability to pay interest and principal on our loans. In addition, any projected future decreases in our portfolio companies’ operating results due to inflation could adversely impact the fair value of those investments. Any decreases in the fair value of our investments could result in future unrealized losses and therefore reduce our net assets resulting from operations. The lack of liquidity in our investments may adversely affect our business. We invest, and will continue to invest, in companies whose securities are not publicly traded, and whose securities are subject to legal and other restrictions on resale or are otherwise less liquid than publicly traded securities. In fact, all of our assets may be invested in illiquid securities. The illiquidity of these investments may make it difficult for us to sell these investments when desired. In addition, if we are required to liquidate all or a portion of our portfolio quickly, we may realize significantly less than the value at which we had previously recorded these investments and suffer losses. Our investments may be subject to contractual or legal restrictions on resale or are otherwise illiquid because there is usually no established trading market for such investments. In addition, we may also face restrictions on our ability to liquidate our investments if our Adviser or any of its affiliates have material nonpublic information regarding the portfolio company. We may not have the funds or ability to make additional investments in our portfolio companies. After our initial investment in a portfolio company, we may be called upon from time to time to provide additional funds to such company or have the opportunity to increase our investment through a follow-on investment. There is no assurance that we will make, or will have sufficient funds to make, follow-on investments. Any decisions not to make a follow-on investment or any inability on our part to make such an investment may have a negative impact on a portfolio company in need of such an investment, may result in a missed opportunity for us to increase our participation in a successful operation, may reduce the expected yield on the investment or impair the value of our investment in any such portfolio company. Some of our portfolio companies are highly leveraged. Our investments include companies with significant leverage. Such investments are inherently more sensitive to declines in revenues and to increases in expenses and interest rates. The leveraged capital structure of such investments increases the exposure of the portfolio companies to adverse economic factors, such as downturns in the economy or deterioration in the condition of the portfolio company or its industry. Additionally, the securities acquired by us may be the most junior in what will typically be a complex capital structure, and thus subject to the greatest risk of loss. Our portfolio companies may incur debt that ranks equally with, or senior to, our investments in such companies. We invest primarily in first lien, second lien and subordinated debt issued by middle-market companies. Our portfolio companies may have, or may be permitted to incur, other debt that ranks equally with, or senior to, the debt in which we invest. By their terms, such debt instruments may entitle the holders to receive payments of interest or principal on or before the dates on which we are entitled to receive payments with respect to the debt instruments in which we invest. Also, in the event of insolvency, liquidation, dissolution, reorganization or bankruptcy of a portfolio company, holders of debt instruments ranking senior to our investment in that portfolio company would typically be entitled to receive payment in full before we receive any distribution. After repaying such senior creditors, such portfolio company may not have any remaining assets to use for repaying its obligation to us. In the case of debt ranking equally with debt instruments in which we invest, we would have to share on an equal basis any distributions with other creditors holding such debt in the event of an insolvency, liquidation, dissolution, reorganization or bankruptcy of the relevant portfolio company. The disposition of our investments may result in contingent liabilities. In connection with the disposition of an investment in private securities, we may be required to make representations about the business and financial affairs of the portfolio company typical of those made in connection with the sale of a business. We may also be required to indemnify the purchasers of such investment to the extent that any such representations turn out to be inaccurate or with respect to certain potential liabilities. These arrangements may result in contingent liabilities that ultimately yield funding obligations that must be satisfied through our return of certain distributions previously made to us. There may be circumstances where our debt investments could be subordinated to claims of other creditors or we could be subject to lender liability claims. Even though we have structured some of our investments as senior loans, if one of our portfolio companies were to enter bankruptcy proceedings, a bankruptcy court might re-characterize our debt investment and subordinate all or a portion of our claim to that of other creditors, depending on the facts and circumstances, including the extent to which we actually provided managerial assistance to that portfolio company. We may also be subject to lender liability claims for actions taken by us with respect to a borrower’s business or instances where we exercise control over the borrower. It is possible that we could become subject to a lender’s liability claim, including as a result of actions taken in rendering significant managerial assistance. Second priority liens on collateral securing loans that we make to our portfolio companies may be subject to control by senior creditors with first priority liens. If there is a default, the value of the collateral may not be sufficient to repay in full both the first priority creditors and us. Certain loans that we make to portfolio companies are secured on a second priority basis by the same collateral securing senior secured debt of such companies. The first priority liens on the collateral secures the portfolio company’s obligations under any outstanding senior debt and may secure certain other future debt that may be permitted to be incurred by the company under the agreements governing the loans. The holders of obligations secured by the first priority liens on the collateral will generally control the liquidation of and be entitled to receive proceeds from any realization of the collateral to repay their obligations in full before us. In addition, the value of the collateral in the event of liquidation will depend on market and economic conditions, the availability of buyers and other factors. There can be no assurance that the proceeds, if any, from the sale or sales of all of the collateral would be sufficient to satisfy the loan obligations secured by the second priority liens after payment in full of all obligations secured by the first priority liens on the collateral. If such proceeds are not sufficient to repay amounts outstanding under the loan obligations secured by the second priority liens, then we, to the extent not repaid from the proceeds of the sale of the collateral, will only have an unsecured claim against the company’s remaining assets, if any. The rights we may have with respect to the collateral securing the loans we make to our portfolio companies with senior debt outstanding may also be limited pursuant to the terms of one or more inter-creditor agreements that we enter into with the holders of senior debt. Under such an inter-creditor agreement, at any time that obligations that have the benefit of the first priority liens are outstanding, any of the following actions may be taken with respect to the collateral and will be at the direction of the holders of the obligations secured by the first priority liens: the ability to cause the commencement of enforcement proceedings against the collateral; the ability to control the conduct of such proceedings; the approval of amendments to collateral documents; releases of liens on the collateral; and waivers of past defaults under collateral documents. We may not have the ability to control or direct such actions, even if our rights are adversely affected. If we make unsecured debt investments, we may lack adequate protection in the event our portfolio companies become distressed or insolvent and will likely experience a lower recovery than more senior debtholders in the event such portfolio companies default on their indebtedness. We have made, and may in the future make, unsecured debt investments in portfolio companies. Unsecured debt investments are unsecured and junior to other indebtedness of the portfolio company. As a consequence, the holder of an unsecured debt investment may lack adequate protection in the event the portfolio company becomes distressed or insolvent and will likely experience a lower recovery than more senior debtholders in the event the portfolio company defaults on its indebtedness. In addition, unsecured debt investments of small and mid-sized companies are often highly illiquid and in adverse market conditions may experience steep declines in valuation even if they are fully performing. Our investments may include “covenant-lite” loans, which may give us fewer rights and subject us to greater risk of loss than loans with financial maintenance covenants. Although the loans in which we expect to invest will generally have financial maintenance covenants, which are used to proactively address materially adverse changes in a portfolio company’s financial performance, we do invest to a lesser extent in “covenant-lite” loans. We use the term “covenant-lite” to refer generally to loans that do not have financial maintenance covenants. Generally, “covenant-lite” loans provide borrower companies more freedom to negatively impact lenders because their covenants are incurrence-based, which means they are only tested and can only be breached following an affirmative action of the borrower, rather than by a deterioration in the borrower’s financial condition or operating results. Accordingly, to the extent we invest in “covenant-lite” loans, we may have fewer rights against a borrower and may have a greater risk of loss on such investments as compared to investments in or exposure to loans with financial maintenance covenants. Our portfolio companies may prepay loans, which may reduce our yields if capital returned cannot be invested in transactions with equal or greater expected yields. The loans in our investment portfolio may be prepaid at any time, generally with little advance notice. Whether a loan is prepaid will depend both on the continued positive performance of the portfolio company and the existence of favorable financing market conditions that allow such company the ability to replace existing financing with less expensive capital. As market conditions change, we do not know when, and if, prepayment may be possible for each portfolio company. In some cases, the prepayment of a loan may reduce our achievable yield if the capital returned cannot be invested in transactions with equal or greater expected yields, which could have a material adverse effect on our business, financial condition and results of operations. We may incur greater risk with respect to investments we acquire through assignments or participations of interests. We may acquire loans through assignments or participations of interests in such loans. The purchaser of an assignment typically succeeds to all the rights and obligations of the assigning institution and becomes a lender under the credit agreement with respect to such debt obligation. However, the purchaser’s rights can be more restricted than those of the assigning institution, and we may not be able to unilaterally enforce all rights and remedies under an assigned debt obligation and with regard to any associated collateral. A participation typically results in a contractual relationship only with the institution participating out the interest and not directly with the borrower. Sellers of participations typically include banks, broker-dealers, other financial institutions and lending institutions. In purchasing participations, we generally will have no right to enforce compliance by the borrower with the terms of the loan agreement against the borrower, and we may not directly benefit from the collateral supporting the debt obligation in which we have purchased the participation. As a result, we will be exposed to the credit risk of both the borrower and the institution selling the participation. Further, in purchasing participations in lending syndicates, we will not be able to conduct the same level of due diligence on a borrower or the quality of the loan with respect to which we are buying a participation as we would conduct if we were investing directly in the loan. This difference may result in us being exposed to greater credit or fraud risk with respect to such loans than we expected when initially purchasing the participation. We generally do not, and do not expect to, control our portfolio companies. We do not, and do not expect to, control most of our portfolio companies. As a result, we are subject to the risk that a portfolio company may make business decisions with which we disagree and the management of such company, as representatives of the holders of their common equity, may take risks or otherwise act in ways that do not serve our interests as a debt investor, including actions that could decrease the value of our investment. Due to the lack of liquidity for the majority of our investments, we may not be able to dispose of our interests in our portfolio companies as readily as we would like or at an appropriate valuation. Defaults by our portfolio companies would harm our operating results. A portfolio company’s failure to satisfy financial or operating covenants imposed by us or other lenders could lead to defaults and, potentially, termination of its loans and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize a portfolio company’s ability to meet its obligations under the debt or equity securities that we hold. We may incur expenses to the extent necessary to seek recovery upon default or to negotiate new terms, which may include the waiver of certain financial covenants, with a defaulting portfolio company. In addition, we may write-down the value of a portfolio company investment upon the worsening of the financial condition of the portfolio company or in anticipation of a default, which could also have a material adverse effect on our business, financial condition and results of operations. Our portfolio companies may experience financial distress and our investments in such companies may be restructured. Our portfolio companies may experience financial distress from time to time. Debt investments in such companies may cease to be income-producing, may require us to bear certain expenses to protect our investment and may subject us to uncertainty as to when, in what manner and for what value such distressed debt will eventually be satisfied, including through liquidation, reorganization or bankruptcy. Any restructuring can fundamentally alter the nature of the related investment, and restructurings may not be subject to the same underwriting standards that our Adviser employs in connection with the origination of an investment. In addition, we may write-down the value of our investment in any such company to reflect the status of financial distress and future prospects of the business. Any restructuring could alter, reduce or delay the payment of interest or principal on any investment, which could delay the timing and reduce the amount of payments made to us. For example, if an exchange offer is made or plan of reorganization is adopted with respect to the debt securities we currently hold, there can be no assurance that the securities or other assets received by us in connection with such exchange offer or plan of reorganization will have a value or income potential similar to what we anticipated when our original investment was made or even at the time of restructuring. Restructurings of investments might also result in extensions of the term thereof, which could delay the timing of payments made to us, or we may receive equity securities, which may require significantly more of our management’s time and attention or carry restrictions on their disposition. We cannot assure you that any particular restructuring strategy pursued by our Adviser will maximize the value of or recovery on any investment. We may not realize gains from our equity investments. Certain investments that we have made in the past and may make in the future include warrants or other equity securities. In addition, we have made in the past and may make in the future direct equity investments in companies. Our goal is ultimately to realize gains upon our disposition of such equity interests. However, the equity interests we receive may not appreciate in value and, in fact, may decline in value. Accordingly, we may not be able to realize gains from our equity interests, and any gains that we do realize on the disposition of any equity interests may not be sufficient to offset any other losses we experience. We also may be unable to realize any value if a portfolio company does not have a liquidity event, such as a sale of the business, recapitalization or public offering, which would allow us to sell the underlying equity interests. We may seek puts or similar rights to give us the right to sell our equity securities back to the portfolio company issuer. We may be unable to exercise these put rights for the consideration provided in our investment documents if the issuer is in financial distress. We are subject to certain risks associated with foreign investments. We have made in the past and may make in the future investments in foreign companies. Investing in foreign companies may expose us to additional risks not typically associated with investing in U.S. companies. These risks include changes in foreign exchange rates, exchange control regulations, political and social instability, expropriation, imposition of foreign taxes, less liquid markets and less available information than is generally the case in the U.S., higher transaction costs, less government supervision of exchanges, brokers and issuers, less developed bankruptcy laws, difficulty in enforcing contractual obligations, lack of uniform accounting and auditing standards and greater price volatility. In addition, our foreign investments generally do not constitute "qualifying assets" under the Investment Company Act. Our success will depend, in part, on our ability to anticipate and effectively manage these and other risks. We cannot assure you that these and other factors will not have a material adverse effect on our business as a whole. We may have foreign currency risks related to our investments denominated in currencies other than the U.S. dollar. As of September 30, 2023, a portion of our investments are, and may continue to be, denominated in currencies other than the U.S. dollar. Changes in the rates of exchange between the U.S. dollar and other currencies will have an effect, which could be adverse, on our performance, amounts available for withdrawal and the value of securities distributed by us. Among the factors that may affect currency values are trade balances, the level of short-term interest rates, differences in relative values of similar assets in different currencies, long-term opportunities for investment and capital appreciation and political developments. Additionally, a particular foreign country may impose exchange controls, devalue its currency or take other measures relating to its currency which could adversely affect us. Finally, we could incur costs in connection with conversions between various currencies. We may expose ourselves to risks if we engage in hedging transactions. Subject to applicable provisions of the Investment Company Act and applicable regulations promulgated by the Commodity Futures Trading Commission, we have in the past and may in the future enter into hedging transactions, which may expose us to risks associated with such transactions. Such hedging may utilize instruments such as forward contracts, currency options and interest rate swaps, caps, collars and floors to seek to hedge against fluctuations in the relative values of our portfolio positions and amounts due under any credit facility from changes in currency exchange rates and market interest rates. Use of these hedging instruments may include counterparty credit risk. Hedging against a decline in the values of our portfolio positions does not eliminate the possibility of fluctuations in the values of such positions and amounts due under our credit facilities or prevent losses if the values of such positions decline. However, such hedging can establish other positions designed to gain from those same developments, thereby offsetting the decline in the value of such portfolio positions. Such hedging transactions may also limit the opportunity for gain if the values of the underlying portfolio positions should increase. Moreover, it may not be possible to hedge against an exchange rate or interest rate fluctuation that is so generally anticipated that we are not able to enter into a hedging transaction at an acceptable price. The success of any hedging transactions will depend on our ability to correctly predict movements in currencies and interest rates. Therefore, while we may enter into such transactions to seek to reduce currency exchange rate and interest rate risks, unanticipated changes in currency exchange rate or interest rates may result in poorer overall investment performance than if we had not engaged in any such hedging transactions. In addition, the degree of correlation between price movements of the instruments used in a hedging strategy and price movements in the portfolio positions being hedged may vary. Moreover, for a variety of reasons, we may not seek to (or be able to) establish a perfect correlation between such hedging instruments and the portfolio holdings or credit facilities being hedged. Any such imperfect correlation may prevent us from achieving the intended hedge and expose us to risk of loss. In addition, it may not be possible to hedge fully or perfectly against currency fluctuations affecting the value of securities denominated in non-U.S. currencies because the value of those securities is likely to fluctuate as a result of factors not related to currency fluctuations. We are a non-diversified investment company within the meaning of the Investment Company Act, and therefore have few restrictions with respect to the proportion of our assets that may be invested in securities of a single industry or issuer. We are classified as a non-diversified investment company within the meaning of the Investment Company Act, which means that we are not limited by the Investment Company Act with respect to the proportion of our assets that we may invest in securities of a single industry or issuer, excluding limitations on investments in other investment companies. We cannot predict the industries or sectors in which our investment strategy may cause us to concentrate and cannot predict the level of our diversification among industries or issuers. To the extent that we assume large positions in a certain type of security or the securities of a small number of industries or issuers, our net asset value may fluctuate to a greater extent than that of a diversified investment company as a result of changes in the financial condition or the market’s assessment of the security, industry or issuer. We may also be more susceptible to any single economic or regulatory occurrence than a diversified investment company. Beyond RIC diversification requirements, we do not have fixed guidel | ||||||||||||||||||||
Common Stock Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Relating to Our Common Stock Shares of closed-end investment companies, including Business Development Companies, may trade at a discount to their net asset value. Shares of closed-end investment companies, including Business Development Companies, may trade at a discount from net asset value. This characteristic of closed-end investment companies and Business Development Companies is separate and distinct from the risk that our net asset value per share may decline. During the last two years, shares of our common stock have traded both above and below our net asset value. We cannot predict whether our common stock will trade at, above or below net asset value. Investing in our common stock may involve an above average degree of risk. The investments we make in accordance with our investment objective may result in a higher amount of risk than alternative investment options and a higher risk of volatility or loss of principal. Our investments in portfolio companies involve higher levels of risk, and therefore, an investment in our shares may not be suitable for someone with lower risk tolerance. The market price of our common stock may fluctuate significantly. The market price and liquidity of the market for shares of our common stock may be significantly affected by numerous factors, some of which are beyond our control and may not be directly related to our operating performance. These factors include: • significant volatility in the market price and trading volume of securities of Business Development Companies or other companies in our sector, which are not necessarily related to the operating performance of these companies; • inability to obtain any exemptive relief that may be required by us from the SEC; • changes in regulatory policies, accounting pronouncements or tax guidelines, particularly with respect to RICs and Business Development Companies; • loss of our Business Development Company or RIC status; • changes in earnings or variations in operating results or distributions that exceed our net investment income; • increases in expenses associated with defense of litigation and responding to SEC inquiries; • changes in accounting guidelines governing valuation of our investments; • changes in the value of our portfolio of investments and any derivative instruments, including as a result of general economic conditions, interest rate shifts and changes in the performance of our portfolio companies; • any shortfall in investment income or net investment income or any increase in losses from levels expected by investors or securities analysts; • departure of our Adviser’s key personnel; and • general economic trends and other external factors. Sales of substantial amounts of our common stock in the public market may have an adverse effect on the market price of our common stock. Sales of substantial amounts of our common stock, including by large stockholders, or the availability of such common stock for sale, could adversely affect the prevailing market prices for our common stock. If this occurs and continues for a sustained period of time, it could impair our ability to raise additional capital through the sale of securities should we desire to do so. Certain provisions of our restated certificate of incorporation and fourth amended and restated bylaws as well as the Delaware General Corporation Law could deter takeover attempts and have an adverse impact on the price of our common stock. Our restated certificate of incorporation and our fourth amended and restated bylaws as well as the Delaware General Corporation Law contain provisions that may have the effect of discouraging a third party from making an acquisition proposal for us. These anti-takeover provisions may inhibit a change in control in circumstances that could give the holders of our common stock the opportunity to realize a premium over the market price for our common stock. Stockholders may incur dilution if we issue securities to subscribe to, convert to or purchase shares of our common stock. The Investment Company Act prohibits us from selling shares of our common stock at a price below the current net asset value per share of such stock with certain exceptions. One such exception is stockholder approval, within one year prior, of any such sales of common stock. On March 17, 2023, our stockholders approved a proposal to authorize us, with the approval of our Board of Directors, to sell or otherwise issue shares of our common stock at a price below its then current net asset value per share, provided that the number of shares issued does not exceed 25% of our then outstanding common stock. Such authorization will expire on March 16, 2024, but we expect to seek similar authorizations from our stockholders in the future. Any decision to sell common stock at a price below its then current net asset value will be subject to the determination by the Board of Directors that such issuance is in our and our stockholders’ best interests. If we were to sell shares of our common stock below net asset value per share, such sales would result in an immediate dilution to the net asset value per share. This dilution would occur as a result of the sale of shares at a price below the then current net asset value per share of our common stock and a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance. The greater the difference between the sales price and the net asset value per share at the time of the offering, the more significant the dilutive impact would be. Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect, if any, cannot be currently predicted. However, if, for example, we sold an additional 10% of our common stock at a 5% discount from net asset value, an existing stockholder who did not participate in that offering for its proportionate interest would suffer net asset value dilution of up to 0.5% or $5 per $1,000 of net asset value. Another exception is prior stockholder approval of issuances of securities to subscribe to, convert to or purchase shares of our common stock even if the subscription, conversion or purchase price per share of our common stock is below the net asset value per share of our common stock at the time of any such subscription, conversion or purchase. At our 2011 annual meeting of stockholders, our stockholders approved a proposal to authorize us to issue securities to subscribe to, convert to, or purchase shares of our common stock in one or more offerings, including under such circumstance. Such authorization has no expiration. Any decision to sell securities to subscribe to, convert to, or purchase shares of our common stock will be subject to the determination by our Board of Directors that such issuance is in our and our stockholders’ best interests. If we issue securities to subscribe to, convert to or purchase shares of common stock, the exercise or conversion of such securities would increase the number of outstanding shares of our common stock. Any such exercise or conversion would be dilutive on the voting power of existing stockholders, and could be dilutive with regard to distributions and our net asset value, and other economic aspects of the common stock. Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect cannot be predicted; however, the table below illustrates the impact on the net asset value per common share of a Business Development Company that would be experienced upon the exercise of a subscription right to acquire shares of common stock of the Business Development Company. Example of Impact of Exercise of Subscription Right to Acquire Common Stock on Net Asset Value Per Share The example assumes that the Business Development Company has 1,000,000 shares of common stock outstanding, $15,000,000 in total assets and $5,000,000 in total liabilities at the time of the exercise of the subscription right. As a result, the net asset value and net asset value per common share of the Business Development Company are $10,000,000 and $10.00, respectively. Further, the example assumes that the subscription right permits the holder thereof to acquire 250,000 common shares under the following three different scenarios: (i) with an exercise price equal to a 10% premium to the Business Development Company’s net asset value per share at the time of exercise, or $11.00 per share, (ii) with an exercise price equal to the Business Development Company’s net asset value per share at the time of exercise, or $10.00 per share, and (iii) with an exercise price equal to a 10% discount to the Business Development Company’s net asset value per share at the time of exercise, or $9.00 per share. Subscription Rights Exercise Price Net Asset Value Per Share Net Asset Value Per Share 10% premium to net asset value per common share $ 10.00 $ 10.20 Net asset value per common share $ 10.00 $ 10.00 10% discount to net asset value per common share $ 10.00 $ 9.80 Although have we chosen to demonstrate the impact on the net asset value per common share of a Business Development Company that would be experienced by existing stockholders of the Business Development Company upon the exercise of a subscription right to acquire shares of common stock of the Business Development Company, the results noted above would be similar in connection with the exercise or conversion of other securities exercisable or convertible into shares of the Business Development Company’s common stock. In addition, the example does not take into account the impact of other securities that may be issued in connection with the issuance of exercisable or convertible securities (e.g., the issuance of shares of common stock in conjunction with the issuance of subscription rights to acquire shares of common stock). | ||||||||||||||||||||
Notes Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | Risks Related to Our Notes The Notes are unsecured and therefore are effectively subordinated to any secured indebtedness we have currently incurred or may incur in the future. The 2025 Notes, the 2027 Notes and the 2029 Notes, which we refer to collectively as the "Notes", are not secured by any of our assets or any of the assets of our subsidiaries. As a result, the Notes are effectively subordinated to any secured indebtedness we or our subsidiaries have currently incurred and may incur in the future (or any indebtedness that is initially unsecured to which we subsequently grant security) to the extent of the value of the assets securing such indebtedness. In any liquidation, dissolution, bankruptcy or other similar proceeding, the holders of any of our existing or future secured indebtedness and the secured indebtedness of our subsidiaries may assert rights against the assets pledged to secure that indebtedness in order to receive full payment of their indebtedness before the assets may be used to pay other creditors, including the holders of the Notes. As of September 30, 2023, we had $710 million of outstanding borrowings under our credit facilities, all of which is secured. The Notes are structurally subordinated to the indebtedness and other liabilities of our subsidiaries The Notes are obligations exclusively of Oaktree Specialty Lending Corporation and not of any of our subsidiaries. None of our subsidiaries is a guarantor of the Notes and the Notes are not required to be guaranteed by any subsidiaries we may acquire or create in the future. The assets of such subsidiaries are not directly available to satisfy the claims of our creditors, including holders of the Notes. Except to the extent we are a creditor with recognized claims against our subsidiaries, all claims of creditors (including trade creditors) and holders of preferred stock, if any, of our subsidiaries have priority over our equity interests in such subsidiaries (and therefore the claims of our creditors, including holders of the Notes) with respect to the assets of such subsidiaries. Even if we are recognized as a creditor of one or more of our subsidiaries, our claims are effectively subordinated to any security interests in the assets of any such subsidiary and to any indebtedness or other liabilities of any such subsidiary senior to our claims. Consequently, the Notes are structurally subordinated to all indebtedness and other liabilities (including trade payables) of any of our subsidiaries and any subsidiaries that we may in the future acquire or establish as financing vehicles or otherwise. As of September 30, 2023, our subsidiaries had $280.0 million of outstanding borrowings under the OSI2 Citibank Facility, all of which is structurally senior to the Notes. In addition, our subsidiaries may incur substantial additional indebtedness in the future, all of which would be structurally senior to the Notes. The indentures under which the Notes are issued contains limited protection for holders of the Notes. The indentures under which the Notes are issued offers limited protection to holders of the Notes. The terms of the indentures and the Notes do not restrict our or any of our subsidiaries’ ability to engage in, or otherwise be a party to, a variety of corporate transactions, circumstances or events that could have a material adverse impact on investments in the Notes. In particular, the terms of the indenture and the Notes do not place any restrictions on our or our subsidiaries’ ability to: • issue securities or otherwise incur additional indebtedness or other obligations, including (1) any indebtedness or other obligations that would be equal in right of payment to the Notes, (2) any indebtedness or other obligations that would be secured and therefore rank effectively senior in right of payment to the Notes to the extent of the values of the assets securing such debt, (3) indebtedness of ours that is guaranteed by one or more of our subsidiaries and which therefore is structurally senior to the Notes and (4) securities, indebtedness or obligations issued or incurred by our subsidiaries that would be senior to our equity interests in our subsidiaries and therefore rank structurally senior to the Notes with respect to the assets of our subsidiaries, in each case other than an incurrence of indebtedness or other obligation that would cause a violation of Section 18(a)(1)(A) of the Investment Company Act as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions, whether or not we continue to be subject to such provisions of the Investment Company Act, but giving effect, in either case, to any exemptive relief granted to us by the SEC; • pay dividends on, or purchase or redeem or make any payments in respect of, capital stock or other securities ranking junior in right of payment to the Notes; • sell assets (other than certain limited restrictions on our ability to consolidate, merge or sell all or substantially all of our assets); • enter into transactions with affiliates; • create liens (including liens on the shares of our subsidiaries) or enter into sale and leaseback transactions; • make investments; or • create restrictions on the payment of dividends or other amounts to us from our subsidiaries. Furthermore, the terms of the indenture and the Notes do not protect holders of the Notes in the event that we experience changes (including significant adverse changes) in our financial condition, results of operations or credit ratings, as they do not require that we or our subsidiaries adhere to any financial tests or ratios or specified levels of net worth, revenues, income, cash flow or liquidity. Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the Notes may have important consequences for holders of the Notes, including making it more difficult for us to satisfy our obligations with respect to the Notes or negatively affecting the trading value of the Notes. Certain of our current debt instruments include more protections for their holders than the indenture and the Notes. In addition, other debt we issue or incur in the future could contain more protections for its holders than the indenture and the Notes, including additional covenants and events of default. The issuance or incurrence of any such debt with incremental protections could affect the market for and trading levels and prices of the Notes. An active trading market for the Notes may not exist, which could limit your ability to sell the Notes or affect the market price of the Notes. We cannot provide any assurances that an active trading market for the Notes will exist in the future or that holders will be able to sell their Notes. Even if an active trading market does exist, the Notes may trade at a discount from their initial offering price depending on prevailing interest rates, the market for similar securities, our credit ratings, if any, general economic conditions, our financial condition, performance and prospects and other factors. To the extent an active trading market does not exist, the liquidity and trading price for the Notes may be harmed. Accordingly, holder of the Notes may be required to bear the financial risk of an investment in the Notes for an indefinite period of time. If we default on our obligations to pay our other indebtedness, we may not be able to make payments on the Notes. Any default under the agreements governing our indebtedness, including our credit facilities and our Notes or other indebtedness to which we may be a party that is not waived by the required lenders or holders, and the remedies sought by the holders of such indebtedness could make us unable to pay principal, premium, if any, and interest on the Notes and substantially decrease the market value of the Notes. If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our indebtedness, we could be in default under the terms of the agreements governing such indebtedness. In the event of such default, the holders of such indebtedness could elect to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest, the lenders under our credit facilities or other debt we may incur in the future could elect to terminate their commitments, cease making further loans and institute foreclosure proceedings against our assets, and we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to seek to obtain waivers from the required lenders under our credit facilities or the required holders of our Notes or other debt that we may incur in the future to avoid being in default. If we breach our covenants under our credit facilities, our Notes or other debt and seek a waiver, we may not be able to obtain a waiver from the required lenders or holders. If this occurs, we would be in default and our lenders or debt holders could exercise their rights as described above, and we could be forced into bankruptcy or liquidation. If we are unable to repay debt, lenders having secured obligations, including the lenders under our credit facilities, could proceed against the collateral securing the debt. Because our credit facilities and our Notes have, and any future credit facilities will likely have, customary cross-default provisions, if the indebtedness thereunder or under any future credit facility is accelerated, we may be unable to repay or finance the amounts due. In the event holders of any debt securities we have outstanding exercise their rights to accelerate following a cross-default, those holders would be entitled to receive the principal amount of their investment, subject to any subordination arrangements that may be in place. We cannot assure you that we will have sufficient liquidity to be able to repay such amounts, in which case we would be in default under the accelerated debt and holders would have the ability to sue us to recover amounts then owing. | ||||||||||||||||||||
General Risk [Member] | |||||||||||||||||||||
General Description of Registrant [Abstract] | |||||||||||||||||||||
Risk [Text Block] | General Risk Factors Economic recessions or downturns may have a material adverse effect on our business, financial condition and results of operations, and could impair the ability of our portfolio companies to repay debt or pay interest. Economic recessions or downturns may result in a prolonged period of market illiquidity which could have a material adverse effect on our business, financial condition and results of operations. Unfavorable economic conditions also could increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. These events could limit our investment originations, limit our ability to grow and negatively impact our operating results. In addition, uncertainty with regard to economic recovery from recessions or downturns could also have a negative impact on our business, financial condition and results of operations. When recessionary conditions exist, the financial results of middle-market companies, like those in which we invest, typically experience deterioration, which could ultimately lead to difficulty in meeting debt service requirements and an increase in defaults. Additionally, there can be reduced demand for certain of our portfolio companies’ products and services and/or other economic consequences, such as decreased margins or extended payment terms. Further, adverse economic conditions may decrease the value of collateral securing some of our loans and the value of our equity investments. Such conditions may require us to modify the payment terms of our investments, including changes in PIK interest provisions and/or cash interest rates. The performance of certain of our portfolio companies has been, and in the future may be, negatively impacted by these economic or other conditions, which may result in our receipt of reduced interest income from our portfolio companies and/or realized and unrealized losses related to our investments, and, in turn, may adversely affect distributable income and have a material adverse effect on our results of operations. Global economic, political and market conditions, including downgrades of the U.S. credit rating, may adversely affect our business, results of operations and financial condition. The current global financial market situation, as well as various social and political tensions in the United States and around the world, may contribute to increased market volatility, may have long-term effects on the United States and worldwide financial markets and may cause economic uncertainties or deterioration in the U.S. and worldwide. The impact of downgrades by rating agencies to the U.S. government’s sovereign credit rating or its perceived creditworthiness as well as potential government shutdowns and uncertainty surrounding transfers of power could adversely affect the U.S. and global financial markets and economic conditions. Several European Union, or EU, countries have faced budget issues, some of which may have negative long-term effects for the economies of those countries and other EU countries. In addition, the fiscal policy of large foreign nations, may have a severe impact on the worldwide and U.S. financial markets. Additionally, trade wars and volatility in the U.S. repo market, the U.S. high yield bond markets, the global stock markets and global markets for commodities may affect other financial markets worldwide. In addition, while governments worldwide have used stimulus measures recently to reduce volatility in the financial markets, volatility has returned as such measures are phased out, and the long-term impacts of such stimulus on fiscal policy and inflation remain unknown. We cannot predict the effects of these or similar events in the future on the U.S. and global economies and securities markets or on our investments. We monitor developments in economic, political and market conditions and seek to manage our investments in a manner consistent with achieving our investment objective, but there can be no assurance that we will be successful in doing so. We may experience fluctuations in our quarterly originations and results. We could experience fluctuations in our quarterly originations and results due to a number of factors, including our ability or inability to make investments in companies that meet our investment criteria, the interest rate payable on the debt securities we acquire, changes in accrual status of our portfolio company investments, distributions, the level of our expenses, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we encounter competition in our market and general economic conditions. In addition, expected originations for a given quarter may be delayed past quarter-end and into the next quarter as a result of factors outside of our control. As a result of these factors, originations or results for any period should not be relied upon as being indicative of performance in future periods. Control deficiencies could prevent us from accurately and timely reporting our financial results. We may identify deficiencies in our internal control over financial reporting in the future, including significant deficiencies and material weaknesses. A “significant deficiency” is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of a company’s financial reporting. A "material weakness" is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. Our failure to identify deficiencies in our internal control over financial reporting in a timely manner or remediate any deficiencies, or the identification of material weaknesses or significant deficiencies in the future could prevent us from accurately and timely reporting our financial results. We incur significant costs as a result of being a publicly traded company. As a publicly-traded company, we incur legal, accounting and other expenses, including costs associated with the periodic reporting requirements applicable to a company whose securities are registered under the Exchange Act, as well as additional corporate governance requirements, including requirements under the Sarbanes-Oxley Act, and other rules implemented by the SEC and the listing standards of the Nasdaq Global Select Market. We may be the target of litigation or similar proceedings in the future. We could generally be subject to litigation or similar proceedings in the future, including securities litigation and derivative actions by our stockholders whether as a result of the Mergers or otherwise . Any litigation or similar proceedings could result in substantial costs, divert management’s attention and resources from our business or otherwise have a material adverse effect on our business, financial condition and results of operations. | ||||||||||||||||||||
2025 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 300,000,000 | $ 300,000,000 | $ 300,000,000 | $ 300,000,000 | $ 300,000,000 | ||||||||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,886 | $ 1,877 | $ 2,017 | $ 2,272 | ||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Title [Text Block] | 2025 Notes | ||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On February 25, 2020, the Company issued $300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of $293.8 million after deducting OID of $2.5 million, underwriting commissions and discounts of $3.0 million and offering costs of $0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes. The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. | ||||||||||||||||||||
Long Term Debt, Dividends and Covenants [Text Block] | The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. | ||||||||||||||||||||
2027 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 350,000,000 | $ 350,000,000 | $ 350,000,000 | $ 350,000,000 | |||||||||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,886 | $ 1,877 | $ 2,017 | |||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Title [Text Block] | 2027 Notes | ||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On May 18, 2021, the Company issued $350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of $344.8 million after deducting OID of $1.0 million, underwriting commissions and discounts of $3.5 million and offering costs of $0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes. The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. | ||||||||||||||||||||
Long Term Debt, Dividends and Covenants [Text Block] | The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. | ||||||||||||||||||||
2029 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 300,000,000 | $ 300,000,000 | |||||||||||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,877 | |||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On August 15, 2023, the Company issued $300.0 million in aggregate principal amount of the 2029 Notes for net proceeds of $292.9 million after deducting OID of $3.5 million, underwriting commissions and discounts of $3.0 million and offering costs of $0.6 million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes. The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a “make-whole” premium, if applicable. In addition, holders of the 2029 Notes can require the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. During the year ended September 30, 2023, the Company did not repurchase any of the 2029 Notes in the open market. | ||||||||||||||||||||
Long Term Debt, Dividends and Covenants [Text Block] | The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of $300 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. | ||||||||||||||||||||
Syndicated Facility [Member] | |||||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Title [Text Block] | Syndicated Facility | ||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the “Syndicated Facility”) pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank. As of September 30, 2023, the size of the Syndicated Facility was $1.218 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of $1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances. As of September 30, 2023, (i) the period during which the Company may make drawings with respect to $1.035 billion of commitments will expire on June 23, 2027 and the maturity date is June 23, 2028, (ii) the period during which the Company may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iii) the interest rate margin for (a) SOFR loans (which may be 1- or 3-month, at the Company’s option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%. | ||||||||||||||||||||
Long Term Debt, Dividends and Covenants [Text Block] | The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company’s portfolio companies’ businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders’ equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of September 30, 2023, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company’s portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. | ||||||||||||||||||||
Citibank Facility [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 160,000,000 | $ 135,000,000 | |||||||||||||||||||
Senior Securities Coverage per Unit | $ 1,886 | $ 2,017 | |||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Title [Text Block] | Citibank Facility | ||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the “Citibank Facility”) with OCSL Senior Funding II LLC (formerly OCSI Senior Funding II LLC), the Company’s wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OSI2 Citibank Facility, the Citibank Facility was terminated. In connection with the termination of the Citibank Facility, the Company accelerated $0.6 million of deferred financing costs into interest expense during the year ended September 30, 2023. | ||||||||||||||||||||
OSI2 Citibank Facility [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 280,000,000 | $ 280,000,000 | |||||||||||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,877 | |||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | |||||||||||||||||||||
Long Term Debt, Title [Text Block] | OSI2 Citibank Facility | ||||||||||||||||||||
Long Term Debt, Structuring [Text Block] | On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the “OSI2 Citibank Facility”) with OSI 2 Senior Lending SPV, LLC (“OSI 2 SPV”), the Company’s wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent.As of September 30, 2023, the Company was able to borrow up to $400 million under the OSI2 Citibank Facility (subject to borrowing base and other limitations). | ||||||||||||||||||||
Long Term Debt, Dividends and Covenants [Text Block] | As of September 30, 2023, the OSI2 Citibank Facility has a reinvestment period through May 25, 2025, during which advances may be made, and matures on January 26, 2027. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to (a) in the case of a lender that is identified as a conduit lender, the lesser of (i) the applicable commercial paper rate for such conduit lender and (ii) SOFR plus 2.00% per annum on broadly syndicated loans and 2.75% on all other eligible loans and (b) for all other lenders, SOFR plus 2.00% per annum on broadly syndicated loans and 2.75% per annum on all other eligible loans, in all cases subject to a minimum overall rate of SOFR plus 2.50% per annum. After the reinvestment period, the applicable spread is 4.00% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility. The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV’s assets. As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility. | ||||||||||||||||||||
Syndicated Facility And Prior I N G Facility [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 430,000,000 | $ 540,000,000 | $ 430,000,000 | $ 314,825,000 | $ 241,000,000 | $ 226,495,000 | $ 472,495,000 | $ 383,495,000 | $ 267,395,000 | $ 495,000,000 | $ 414,825,000 | ||||||||||
Senior Securities Coverage per Unit | $ 1,877 | $ 1,886 | $ 1,877 | $ 2,949 | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | $ 2,017 | $ 2,272 | ||||||||||
Sumitomo Facility [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 29,500,000 | $ 43,800,000 | $ 43,800,000 | $ 50,000,000 | |||||||||||||||||
Senior Securities Coverage per Unit | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | |||||||||||||||||
Convertible Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 115,000,000 | $ 115,000,000 | |||||||||||||||||||
Senior Securities Coverage per Unit | $ 2,389 | $ 2,595 | |||||||||||||||||||
Secured Borrowings [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 12,314,000 | $ 13,489,000 | $ 18,929,000 | $ 21,787,000 | $ 84,750,000 | ||||||||||||||||
Senior Securities Coverage per Unit | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | ||||||||||||||||
2019 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 228,825,000 | $ 250,000,000 | $ 250,000,000 | $ 250,000,000 | $ 250,000,000 | ||||||||||||||||
Senior Securities Coverage per Unit | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | ||||||||||||||||
2024 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 75,000,000 | $ 75,000,000 | $ 75,000,000 | $ 75,000,000 | $ 75,000,000 | $ 75,000,000 | |||||||||||||||
Senior Securities Coverage per Unit | $ 2,949 | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | |||||||||||||||
Senior Securities Average Market Value per Unit | $ 1,012.76 | $ 1,010.72 | $ 1,006.74 | $ 993.70 | $ 991.94 | $ 966.96 | |||||||||||||||
2028 Notes [Member] | |||||||||||||||||||||
Financial Highlights [Abstract] | |||||||||||||||||||||
Senior Securities Amount | $ 86,250,000 | $ 86,250,000 | $ 86,250,000 | $ 86,250,000 | $ 86,250,000 | $ 86,250,000 | |||||||||||||||
Senior Securities Coverage per Unit | $ 2,949 | $ 2,330 | $ 2,274 | $ 2,208 | $ 2,389 | $ 2,595 | |||||||||||||||
Senior Securities Average Market Value per Unit | $ 993.33 | $ 994.82 | $ 1,007.51 | $ 999.29 | $ 988.06 | $ 943.73 | |||||||||||||||
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation: The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-K and Regulation S-X. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, Financial Services - Investment Companies ("ASC 946"). Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding as of and for the years ended September 30, 2022 and September 30, 2021 have been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. |
Use of Estimates | Use of Estimates: The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition. |
Consolidation | Consolidation: The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries. |
Fair Value Measurements | Fair Value Measurements: Oaktree, as the valuation designee of our Board pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of our assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: • Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date. • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions. Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations. Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources. If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company’s historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company’s industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company’s ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable. Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates. Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board’s oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022. Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments: • The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team; • Preliminary valuations are then reviewed and discussed with management of Oaktree; • Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree; • Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee; • The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee; and • Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio. The fair value of the Company's investments as of September 30, 2023 and September 30, 2022 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material. With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax asset, net," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities. |
Foreign Currency Translation | Foreign Currency Translation: The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. |
Derivative Instruments | Derivative Instruments: Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations. Interest Rate Swaps The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities. |
Investment Income | Investment Income: Interest Income Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management’s judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management’s judgment, is likely to continue timely payment of its remaining obligations. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively. As of September 30, 2022, there were no investments on non-accrual status. In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. PIK Interest Income The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company’s debt investments increases the recorded cost bases of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company’s stockholders, even though the Company has not yet collected the cash and may never do so. Fee Income Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered. Dividend Income The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment. |
Cash and Cash Equivalents and Restricted Cash | Cash and Cash Equivalents and Restricted Cash: Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets. |
Due From Portfolio Companies | Due from Portfolio Companies: Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company ( e.g. , principal payments on the scheduled amortization payment date). |
Receivables/Payables from Unsettled Transactions | Receivables/Payables from Unsettled Transactions: Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date. |
Deferred Financing Costs | Deferred Financing Costs: Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company’s unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment. |
Deferred Offering Costs | Deferred Offering Costs: Legal fees and other costs incurred in connection with the Company’s shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity |
Income Taxes | Income Taxes: The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. The Company did not incur a U.S. federal excise tax for calendar year 2021. For the calendar year 2022, the Company incurred $0.1 million of excise tax. The Company does not expect to incur a U.S. federal excise tax for calendar year 2023. The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company’s Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences. FASB ASC Topic 740, Accounting for Uncertainty in Income Taxes ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2020, 2021 and 2022. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months. |
Portfolio Investments (Tables)
Portfolio Investments (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Schedule of Investments [Abstract] | |
Composition of Investments | The composition of the Company's investments as of September 30, 2023 and September 30, 2022 at cost and fair value was as follows: September 30, 2023 September 30, 2022 Cost Fair Value Cost Fair Value Investments in debt securities $ 2,654,484 $ 2,557,102 $ 2,294,392 $ 2,223,329 Investments in equity securities 171,858 143,767 127,596 103,534 Debt investments in the JVs 162,986 162,673 146,444 146,533 Equity investments in the JVs 54,791 28,878 49,322 20,715 Total $ 3,044,119 $ 2,892,420 $ 2,617,754 $ 2,494,111 The following table presents the composition of the Company's debt investments as of September 30, 2023 and September 30, 2022 at fixed rates and floating rates: September 30, 2023 September 30, 2022 Fair Value % of Debt Fair Value % of Debt Floating rate debt securities, including the debt investments in the JVs $ 2,345,205 86.23 % $ 2,049,644 86.49 % Fixed rate debt securities 374,570 13.77 320,218 13.51 Total $ 2,719,775 100.00 % $ 2,369,862 100.00 % The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Application Software $ 468,483 15.39 % $ 391,938 14.98 % Multi-Sector Holdings (1) 219,469 7.21 195,766 7.48 Data Processing & Outsourced Services 133,410 4.38 120,477 4.60 Biotechnology 126,349 4.15 109,960 4.20 Health Care Technology 106,915 3.51 100,084 3.82 Industrial Machinery & Supplies & Components 99,511 3.27 81,787 3.12 Pharmaceuticals 84,948 2.79 126,508 4.83 Real Estate Operating Companies 83,754 2.75 47,585 1.82 Broadline Retail 83,290 2.74 67,926 2.59 Health Care Services 81,560 2.68 58,674 2.24 Specialized Finance 73,035 2.40 80,864 3.09 Personal Care Products 68,146 2.24 53,214 2.03 Fertilizers & Agricultural Chemicals 64,720 2.13 49,301 1.88 Environmental & Facilities Services 63,064 2.07 20,857 0.80 Health Care Distributors 62,044 2.04 57,112 2.18 Diversified Financial Services 61,725 2.03 29,300 1.12 Internet Services & Infrastructure 60,934 2.00 54,095 2.07 Automotive Retail 57,596 1.89 59,254 2.26 Airport Services 55,961 1.84 43,322 1.65 Metal, Glass & Plastic Containers 55,530 1.82 47,704 1.82 Home Improvement Retail 54,236 1.78 45,802 1.75 Insurance Brokers 52,856 1.74 35,628 1.36 Aerospace & Defense 51,797 1.70 61,963 2.37 Diversified Metals & Mining 49,842 1.64 — — Auto Parts & Equipment 48,536 1.59 12,474 0.48 Real Estate Services 44,717 1.47 40,243 1.54 Soft Drinks & Non-alcoholic Beverages 42,628 1.40 — — Other Specialty Retail 41,088 1.35 — — Leisure Facilities 39,076 1.28 39,768 1.52 Specialty Chemicals 38,640 1.27 37,319 1.43 Distributors 37,666 1.24 25,278 0.97 Electrical Components & Equipment 32,440 1.07 33,814 1.29 Advertising 25,597 0.84 28,245 1.08 Passenger Airlines 24,920 0.82 — — Real Estate Development 23,965 0.79 — — Home Furnishings 23,859 0.78 19,550 0.75 Diversified Support Services 23,435 0.77 37,992 1.45 Gold 23,310 0.77 — — Systems Software 23,111 0.76 14,890 0.57 Health Care Equipment 22,441 0.74 24,353 0.93 Construction & Engineering 22,102 0.73 60,996 2.33 Oil & Gas Storage & Transportation 22,042 0.72 22,290 0.85 Interactive Media & Services 19,013 0.62 — — Integrated Telecommunication Services 18,801 0.62 34,628 1.32 Hotels, Resorts & Cruise Lines 17,195 0.56 13,960 0.53 Consumer Finance 16,440 0.54 14,492 0.55 Education Services 13,871 0.46 9,080 0.35 Restaurants 12,603 0.41 9,338 0.36 Movies & Entertainment 12,188 0.40 26,161 1.00 Health Care Supplies 11,646 0.38 36,471 1.39 Food Distributors 5,897 0.19 4,646 0.18 Apparel Retail 4,999 0.16 5,268 0.20 Air Freight & Logistics 4,925 0.16 7,295 0.28 Integrated Oil & Gas 4,894 0.16 4,866 0.19 Research & Consulting Services 4,871 0.16 9,187 0.35 Cable & Satellite 4,619 0.15 20,716 0.79 Other Specialized REITs 4,379 0.14 — — Paper & Plastic Packaging Products & Materials 3,254 0.11 — — Housewares & Specialties 2,908 0.10 2,293 0.09 Leisure Products 2,055 0.07 — — Technology Distributors 813 0.03 3,163 0.12 Soft Drinks — — 34,272 1.31 IT Consulting & Other Services — — 11,697 0.45 Oil & Gas Refining & Marketing — — 8,627 0.33 Trading Companies & Distributors — — 7,628 0.29 Apparel, Accessories & Luxury Goods — — 5,165 0.20 Specialized REITs — — 4,318 0.16 Diversified Banks — — 3,515 0.13 Construction Materials — — 2,331 0.09 Electronic Components — — 2,092 0.08 Alternative Carriers — — 212 0.01 $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Application Software $ 455,719 15.73 % 30.03 % $ 384,589 15.43 % 30.87 % Multi-Sector Holdings (1) 193,431 6.69 12.76 167,248 6.71 13.43 Biotechnology 125,678 4.35 8.29 108,465 4.35 8.71 Data Processing & Outsourced Services 125,259 4.33 8.26 111,335 4.46 8.94 Industrial Machinery & Supplies & Components 98,352 3.40 6.49 81,008 3.25 6.50 Health Care Technology 95,404 3.30 6.29 97,315 3.90 7.81 Real Estate Operating Companies 82,463 2.85 5.44 48,062 1.93 3.86 Pharmaceuticals 80,455 2.78 5.31 119,511 4.79 9.59 Specialized Finance 69,590 2.41 4.59 73,087 2.93 5.87 Broadline Retail 69,040 2.39 4.55 70,419 2.82 5.65 Health Care Services 66,683 2.31 4.40 45,943 1.84 3.69 Fertilizers & Agricultural Chemicals 63,185 2.18 4.17 51,972 2.08 4.17 Environmental & Facilities Services 62,413 2.16 4.12 20,585 0.83 1.65 Health Care Distributors 60,865 2.10 4.02 54,662 2.19 4.39 Internet Services & Infrastructure 60,579 2.09 4.00 53,797 2.16 4.32 Diversified Financial Services 60,003 2.07 3.96 24,326 0.98 1.95 Personal Care Products 59,928 2.07 3.95 50,150 2.01 4.03 Automotive Retail 55,805 1.93 3.68 57,629 2.31 4.63 Airport Services 54,453 1.88 3.59 42,883 1.72 3.44 Metal, Glass & Plastic Containers 53,459 1.85 3.53 47,599 1.91 3.82 Home Improvement Retail 53,168 1.84 3.51 45,421 1.82 3.65 Insurance Brokers 53,050 1.83 3.50 33,081 1.33 2.66 Aerospace & Defense 51,862 1.79 3.42 61,881 2.48 4.97 Diversified Metals & Mining 49,869 1.72 3.29 — — — Auto Parts & Equipment 49,148 1.70 3.24 11,469 0.46 0.92 Real Estate Services 43,886 1.52 2.90 39,573 1.59 3.18 Soft Drinks & Non-alcoholic Beverages 42,391 1.47 2.80 — — — Other Specialty Retail 41,115 1.42 2.71 — — — Specialty Chemicals 38,615 1.34 2.55 33,969 1.36 2.73 Distributors 37,311 1.29 2.46 24,494 0.98 1.97 Leisure Facilities 36,963 1.28 2.44 39,258 1.57 3.15 Electrical Components & Equipment 32,573 1.13 2.15 32,933 1.32 2.64 Passenger Airlines 27,512 0.95 1.82 — — — Real Estate Development 23,679 0.82 1.56 — — — Diversified Support Services 23,352 0.81 1.54 36,712 1.47 2.95 Gold 23,328 0.81 1.54 — — — Health Care Equipment 22,436 0.78 1.48 24,161 0.97 1.94 Systems Software 21,968 0.76 1.45 12,834 0.51 1.03 Construction & Engineering 21,903 0.76 1.45 61,188 2.45 4.91 Home Furnishings 19,954 0.69 1.32 18,188 0.73 1.46 Interactive Media & Services 19,199 0.66 1.27 — — — Hotels, Resorts & Cruise Lines 16,991 0.59 1.12 13,985 0.56 1.12 Integrated Telecommunication Services 16,492 0.57 1.09 32,201 1.29 2.59 Oil & Gas Storage & Transportation 16,040 0.55 1.06 20,853 0.84 1.67 Consumer Finance 15,087 0.52 1.00 13,284 0.53 1.07 Education Services 13,618 0.47 0.90 8,582 0.34 0.69 Restaurants 12,464 0.43 0.82 8,692 0.35 0.70 Advertising 11,955 0.41 0.79 26,948 1.08 2.16 Movies & Entertainment 11,865 0.41 0.78 26,645 1.07 2.14 Health Care Supplies 11,363 0.39 0.75 36,577 1.47 2.94 Food Distributors 5,166 0.18 0.34 3,367 0.13 0.27 Apparel Retail 5,002 0.17 0.33 5,223 0.21 0.42 Research & Consulting Services 4,831 0.17 0.32 8,573 0.34 0.69 Integrated Oil & Gas 4,785 0.17 0.32 4,872 0.20 0.39 Cable & Satellite 4,546 0.16 0.30 19,576 0.78 1.57 Air Freight & Logistics 4,263 0.15 0.28 6,405 0.26 0.51 Other Specialized REITs 3,198 0.11 0.21 — — — Paper & Plastic Packaging Products & Materials 3,061 0.11 0.20 — — — Housewares & Specialties 2,808 0.10 0.19 2,456 0.10 0.20 Leisure Products 2,063 0.07 0.14 — — — Technology Distributors 776 0.03 0.05 2,997 0.12 0.24 Soft Drinks — — — 33,670 1.35 2.70 Oil & Gas Refining & Marketing — — — 8,604 0.34 0.69 IT Consulting & Other Services — — — 8,596 0.34 0.69 Trading Companies & Distributors — — — 5,567 0.22 0.45 Diversified Banks — — — 3,402 0.14 0.27 Specialized REITs — — — 3,264 0.13 0.26 Construction Materials — — — 1,934 0.08 0.16 Electronic Components — — — 1,890 0.08 0.15 Alternative Carriers — — — 201 0.01 0.02 Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % ___________________ (1) This industry includes the Company's investments in the JVs. SLF JV I Portfolio as of September 30, 2023 Portfolio Company Industry Type of Investment Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Shares Principal Cost Fair Value (3) Notes Access CIG, LLC Diversified Support Services First Lien Term Loan SOFR+ 5.00% 10.32% 8/18/2028 $ 8,596 $ 8,503 $ 8,499 ADB Companies, LLC Construction & Engineering First Lien Term Loan SOFR+ 6.50% 11.90% 12/18/2025 1,149 1,135 1,128 (4) ADB Companies, LLC Construction & Engineering First Lien Term Loan SOFR+ 6.50% 12.15% 12/18/2025 6,771 6,701 6,648 (4) Altice France S.A. Integrated Telecommunication Services First Lien Term Loan L+ 4.00% 9.63% 8/14/2026 2,969 2,853 2,810 Alvogen Pharma US, Inc. Pharmaceuticals First Lien Term Loan SOFR+ 7.50% 13.04% 6/30/2025 8,798 8,737 8,218 (4) American Rock Salt Company LLC Diversified Metals & Mining First Lien Term Loan SOFR+ 4.00% 9.43% 6/9/2028 4,957 4,734 4,614 American Tire Distributors, Inc. Distributors First Lien Term Loan SOFR+ 6.25% 11.81% 10/20/2028 4,824 4,763 4,239 (4) Amplify Finco Pty Ltd. Movies & Entertainment First Lien Term Loan SOFR+ 4.15% 9.54% 11/26/2026 7,720 7,643 7,720 Anastasia Parent, LLC Personal Care Products First Lien Term Loan SOFR+ 3.75% 9.40% 8/11/2025 1,523 1,191 1,099 (4) ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & Materials First Lien Revolver SOFR+ 6.00% 12/29/2027 — (7) (29) (4)(5) ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & Materials First Lien Term Loan SOFR+ 6.00% 11.63% 12/29/2027 4,134 4,076 3,892 (4) Astra Acquisition Corp. Application Software First Lien Term Loan SOFR+ 5.25% 10.90% 10/25/2028 5,052 4,888 3,817 (4) Asurion, LLC Property & Casualty Insurance First Lien Term Loan SOFR+ 4.00% 9.42% 8/19/2028 4,950 4,747 4,809 Asurion, LLC Property & Casualty Insurance First Lien Term Loan SOFR+ 4.25% 9.67% 8/19/2028 1,990 1,884 1,937 Asurion, LLC Property & Casualty Insurance Second Lien Term Loan SOFR+ 5.25% 10.68% 1/20/2029 4,346 4,036 3,871 athenahealth Group Inc. Health Care Technology First Lien Term Loan SOFR+ 3.25% 8.57% 2/15/2029 4,320 4,080 4,251 Aurora Lux Finco S.À.R.L. Airport Services First Lien Term Loan SOFR+ 6.00% 11.49% 12/24/2026 6,289 6,216 6,028 (4) BAART Programs, Inc. Health Care Services First Lien Term Loan SOFR+ 5.00% 10.65% 6/11/2027 1,753 1,742 1,711 (4) BAART Programs, Inc. Health Care Services First Lien Term Loan SOFR+ 5.00% 10.65% 6/11/2027 6,306 6,247 6,155 (4) C5 Technology Holdings, LLC Data Processing & Outsourced Services Common Stock 171 — — (4) C5 Technology Holdings, LLC Data Processing & Outsourced Services Preferred Equity 7,193,540 7,194 5,683 (4) Centerline Communications, LLC Wireless Telecommunication Services First Lien Term Loan SOFR+ 6.00% 11.55% 8/10/2027 2,354 2,322 2,281 Centerline Communications, LLC Wireless Telecommunication Services First Lien Term Loan SOFR+ 6.00% 11.55% 8/10/2027 1,983 1,954 1,921 Centerline Communications, LLC Wireless Telecommunication Services First Lien Revolver SOFR+ 6.00% 11.57% 8/10/2027 600 592 581 Centerline Communications, LLC Wireless Telecommunication Services First Lien Term Loan SOFR+ 6.00% 11.55% 8/10/2027 1,960 1,935 1,899 Covetrus, Inc. Health Care Distributors First Lien Term Loan SOFR+ 5.00% 10.39% 10/13/2029 6,343 5,983 6,285 (4) Curium Bidco S.à.r.l. Biotechnology First Lien Term Loan SOFR+ 4.50% 9.89% 7/31/2029 8,730 8,642 8,730 DirecTV Financing, LLC Cable & Satellite First Lien Term Loan SOFR+ 5.00% 10.43% 8/2/2027 5,799 5,715 5,681 (4) DTI Holdco, Inc. Research & Consulting Services First Lien Term Loan SOFR+ 4.75% 10.12% 4/26/2029 7,920 7,792 7,729 (4) Gibson Brands, Inc. Leisure Products First Lien Term Loan SOFR+ 5.00% 10.57% 8/11/2028 7,369 7,295 6,190 (4) Harbor Purchaser Inc. Education Services First Lien Term Loan SOFR+ 5.25% 10.67% 4/9/2029 7,920 7,731 7,517 (4) Indivior Finance S.À.R.L. Pharmaceuticals First Lien Term Loan SOFR+ 5.25% 10.90% 6/30/2026 7,331 7,249 7,340 INW Manufacturing, LLC Personal Care Products First Lien Term Loan SOFR+ 5.75% 11.40% 3/25/2027 9,000 8,839 7,080 (4) KDC/ONE Development Corp Inc Personal Care Products First Lien Term Loan SOFR+ 5.00% 10.32% 8/15/2028 10,000 9,666 9,665 Portfolio Company Industry Type of Investment Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Shares Principal Cost Fair Value (3) Notes LABL, Inc. Office Services & Supplies First Lien Term Loan SOFR+ 5.00% 10.42% 10/29/2028 $ 3,962 $ 3,815 $ 3,955 LaserAway Intermediate Holdings II, LLC Health Care Services First Lien Term Loan SOFR+ 5.75% 11.32% 10/14/2027 7,369 7,269 7,267 Lightbox Intermediate, L.P. Real Estate Services First Lien Term Loan SOFR+ 5.00% 10.65% 5/9/2026 11,249 11,106 10,912 (4) McAfee Corp. Systems Software First Lien Term Loan SOFR+ 3.75% 9.18% 3/1/2029 5,940 5,654 5,812 Mindbody, Inc. Internet Services & Infrastructure First Lien Revolver SOFR+ 7.00% 2/14/2025 — (2) (8) (4)(5) Mindbody, Inc. Internet Services & Infrastructure First Lien Term Loan SOFR+ 7.00% 12.52% 2/14/2025 4,669 4,648 4,594 (4) Mitchell International, Inc. Application Software First Lien Term Loan SOFR+ 3.75% 9.18% 10/15/2028 2,985 2,845 2,941 MRI Software LLC Application Software First Lien Revolver SOFR+ 5.50% 2/10/2026 — (3) (7) (4)(5) MRI Software LLC Application Software First Lien Term Loan SOFR+ 5.50% 10.99% 2/10/2026 8,319 8,164 8,147 (4) MRI Software LLC Application Software First Lien Term Loan SOFR+ 5.50% 10.99% 2/10/2026 2,211 2,210 2,165 (4) Northern Star Industries Inc. Electrical Components & Equipment First Lien Term Loan SOFR+ 4.76% 10.15% 3/31/2025 6,615 6,608 6,565 OEConnection LLC Application Software First Lien Term Loan SOFR+ 4.00% 9.43% 9/25/2026 10,987 10,827 10,971 Park Place Technologies, LLC Internet Services & Infrastructure First Lien Term Loan SOFR+ 5.00% 10.42% 11/10/2027 9,825 9,492 9,698 (4) Planview Parent, Inc. Application Software First Lien Term Loan SOFR+ 4.00% 9.65% 12/17/2027 2,416 2,298 2,390 Planview Parent, Inc. Application Software Second Lien Term Loan SOFR+ 7.25% 12.74% 12/18/2028 4,503 4,435 4,098 (4) Pluralsight, LLC Application Software First Lien Revolver SOFR+ 8.00% 13.45% 4/6/2027 318 301 297 (4)(5) Pluralsight, LLC Application Software First Lien Term Loan SOFR+ 8.00% 13.45% 4/6/2027 8,116 7,850 7,773 (4) Renaissance Holding Corp. Education Services First Lien Term Loan SOFR+ 4.75% 9.99% 4/5/2030 5,000 4,860 4,969 SHO Holding I Corporation Footwear First Lien Term Loan SOFR+ 5.23% 10.86% 4/27/2024 138 138 94 SHO Holding I Corporation Footwear First Lien Term Loan SOFR+ 5.25% 10.88% 4/27/2024 8,113 8,111 5,531 SM Wellness Holdings, Inc. Health Care Services First Lien Term Loan SOFR+ 4.75% 10.38% 4/17/2028 2,977 2,580 2,799 (4) Southern Veterinary Partners, LLC Health Care Facilities First Lien Term Loan SOFR+ 4.00% 9.43% 10/5/2027 7,680 7,642 7,643 Spanx, LLC Apparel Retail First Lien Term Loan SOFR+ 5.25% 10.67% 11/20/2028 8,843 8,713 8,717 (4) SPX Flow, Inc. Industrial Machinery & Supplies & Components First Lien Term Loan SOFR+ 4.50% 9.92% 4/5/2029 8,801 8,442 8,794 Star Parent, Inc. Life Sciences Tools & Services First Lien Term Loan SOFR+ 4.00% 9.33% 9/19/2030 8,000 7,880 7,834 TIBCO Software Inc. Application Software First Lien Term Loan SOFR+ 4.50% 9.99% 3/30/2029 8,215 7,559 7,913 Touchstone Acquisition, Inc. Health Care Supplies First Lien Term Loan SOFR+ 6.00% 11.42% 12/29/2028 7,212 7,103 7,022 (4) Veritas US Inc. Application Software First Lien Term Loan SOFR+ 5.00% 10.43% 9/1/2025 6,305 6,257 5,500 Windstream Services II, LLC Integrated Telecommunication Services First Lien Term Loan SOFR+ 6.25% 11.67% 9/21/2027 6,148 6,008 5,939 (4) WP CPP Holdings, LLC Aerospace & Defense First Lien Term Loan SOFR+ 3.75% 9.27% 4/30/2025 1,965 1,920 1,855 (4) Total Portfolio Investments $ 332,637 $ 331,808 $ 322,179 _________ (1) Represents the interest rate as of September 30, 2023. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR and/or LIBOR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All the SOFR shown above is in U.S. dollars. As of September 30, 2023, the reference rates for SLF JV I's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39% and the 30-day LIBOR at 5.43%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. (3) Represents the current determination of fair value as of September 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein. (4) This investment was held by both the Company and SLF JV I as of September 30, 2023. SLF JV I Portfolio as of September 30, 2022 Portfolio Company Industry Type of Investment Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Shares Principal Cost Fair Value (3) Notes Access CIG, LLC Diversified Support Services First Lien Term Loan L+ 3.75% 6.82% 2/27/2025 $ 10,093 $ 10,028 $ 9,692 ADB Companies, LLC Construction & Engineering First Lien Term Loan SOFR+ 6.25% 9.80% 12/18/2025 8,518 8,389 8,371 (4) Altice France S.A. Integrated Telecommunication Services First Lien Term Loan L+ 4.00% 6.91% 8/14/2026 3,000 2,841 2,730 Alvogen Pharma US, Inc. Pharmaceuticals First Lien Term Loan SOFR+ 7.50% 11.20% 6/30/2025 9,267 9,166 9,221 (4) American Tire Distributors, Inc. Distributors First Lien Term Loan L+ 6.25% 9.03% 10/20/2028 4,873 4,812 4,576 (4) Amplify Finco Pty Ltd. Movies & Entertainment First Lien Term Loan L+ 4.25% 7.92% 11/26/2026 7,800 7,722 7,527 (4) Anastasia Parent, LLC Personal Products First Lien Term Loan L+ 3.75% 7.42% 8/11/2025 1,539 1,203 1,232 (4) Apptio, Inc. Application Software First Lien Term Loan L+ 6.00% 8.46% 1/10/2025 4,615 4,580 4,519 (4) Apptio, Inc. Application Software First Lien Revolver L+ 6.00% 8.46% 1/10/2025 154 151 146 (4)(5) ASP-R-PAC Acquisition Co LLC Paper Packaging First Lien Term Loan L+ 6.00% 9.67% 12/29/2027 4,176 4,103 4,080 ASP-R-PAC Acquisition Co LLC Paper Packaging First Lien Revolver L+ 6.00% 12/29/2027 (9) (11) (5) Astra Acquisition Corp. Application Software First Lien Term Loan L+ 5.25% 8.37% 10/25/2028 5,052 4,858 4,319 (4) Asurion, LLC Property & Casualty Insurance First Lien Term Loan SOFR+ 4.00% 7.70% 8/19/2028 5,000 4,753 4,276 Asurion, LLC Property & Casualty Insurance Second Lien Term Loan L+ 5.25% 8.37% 1/20/2029 4,346 3,981 3,347 Aurora Lux Finco S.À.R.L. Airport Services First Lien Term Loan L+ 6.00% 8.78% 12/24/2026 6,338 6,242 6,027 (4) BAART Programs, Inc. Health Care Services First Lien Term Loan L+ 5.00% 8.12% 6/11/2027 6,371 6,311 6,148 BAART Programs, Inc. Health Care Services First Lien Term Loan L+ 5.00% 8.12% 6/11/2027 1,771 1,751 1,664 (4)(5) Blackhawk Network Holdings, Inc. Data Processing & Outsourced Services First Lien Term Loan L+ 3.00% 6.03% 6/15/2025 9,575 9,566 8,977 BYJU's Alpha, Inc. Application Software First Lien Term Loan L+ 6.00% 8.98% 11/24/2026 7,444 7,347 5,455 C5 Technology Holdings, LLC Data Processing & Outsourced Services Common Stock 171 — — (4) C5 Technology Holdings, LLC Data Processing & Outsourced Services Preferred Equity 7,193,540 7,194 5,683 (4) Centerline Communications, LLC Wireless Telecommunication Services First Lien Term Loan SOFR+ 5.50% 9.12% 8/10/2027 4,358 4,286 4,280 Centerline Communications, LLC Wireless Telecommunication Services First Lien Term Loan SOFR+ 5.50% 9.12% 8/10/2027 449 432 413 Centerline Communications, LLC Wireless Telecommunication Services First Lien Revolver SOFR+ 5.50% 8/10/2027 — (10) (11) (5) CITGO Petroleum Corp. Oil & Gas Refining & Marketing First Lien Term Loan L+ 6.25% 9.37% 3/28/2024 7,038 6,967 7,057 (4) City Football Group Limited Movies & Entertainment First Lien Term Loan L+ 3.50% 6.48% 7/21/2028 6,451 6,419 6,166 Convergeone Holdings, Inc. IT Consulting & Other Services First Lien Term Loan L+ 5.00% 8.12% 1/4/2026 7,373 7,206 5,320 (4) Covetrus, Inc. Health Care Distributors First Lien Term Loan SOFR+ 5.00% 7.65% 9/20/2029 5,375 5,053 5,035 (4) Curium Bidco S.à.r.l. Biotechnology First Lien Term Loan L+ 4.00% 7.67% 7/9/2026 5,820 5,776 5,587 Dealer Tire, LLC Distributors First Lien Term Loan L+ 4.25% 7.37% 12/12/2025 2,992 2,935 2,924 Delivery Hero FinCo LLC Internet & Direct Marketing Retail First Lien Term Loan SOFR+ 5.75% 8.49% 8/12/2027 6,035 5,876 5,756 (4) DirecTV Financing, LLC Cable & Satellite First Lien Term Loan L+ 5.00% 8.12% 8/2/2027 6,436 6,332 6,012 (4) Domtar Corporation Paper Products First Lien Term Loan L+ 5.50% 8.26% 11/30/2028 4,100 4,065 3,921 DTI Holdco, Inc. Research & Consulting Services First Lien Term Loan SOFR+ 4.75% 7.33% 4/26/2029 8,000 7,849 7,616 (4) Eagle Parent Corp. Industrial Machinery First Lien Term Loan SOFR+ 4.25% 7.80% 4/2/2029 4,478 4,373 4,367 eResearch Technology, Inc. Application Software First Lien Term Loan L+ 4.50% 7.62% 2/4/2027 7,331 7,258 6,859 Portfolio Company Industry Type of Investment Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Shares Principal Cost Fair Value (3) Notes Gibson Brands, Inc. Leisure Products First Lien Term Loan L+ 5.00% 7.94% 8/11/2028 $ 7,444 $ 7,369 $ 6,029 Global Medical Response, Inc. Health Care Services First Lien Term Loan L+ 4.25% 7.37% 3/14/2025 1,979 1,979 1,722 (4) Global Medical Response, Inc. Health Care Services First Lien Term Loan L+ 4.25% 6.81% 10/2/2025 2,192 2,165 1,912 Harbor Purchaser Inc. Education Services First Lien Term Loan SOFR+ 5.25% 8.38% 4/9/2029 8,000 7,774 7,310 (4) Indivior Finance S.À.R.L. Pharmaceuticals First Lien Term Loan L+ 5.25% 8.80% 6/30/2026 7,406 7,293 7,286 INW Manufacturing, LLC Personal Products First Lien Term Loan L+ 5.75% 9.42% 3/25/2027 9,500 9,282 8,408 (4) Iris Holding, Inc. Metal & Glass Containers First Lien Term Loan SOFR+ 4.75% 7.89% 6/28/2028 5,000 4,624 4,610 LaserAway Intermediate Holdings II, LLC Health Care Services First Lien Term Loan L+ 5.75% 8.23% 10/14/2027 7,444 7,318 7,323 Lightbox Intermediate, L.P. Real Estate Services First Lien Term Loan L+ 5.00% 8.67% 5/9/2026 7,367 7,315 7,109 (4) LogMeIn, Inc. Application Software First Lien Term Loan L+ 4.75% 7.80% 8/31/2027 7,860 7,751 5,494 LTI Holdings, Inc. Electronic Components First Lien Term Loan L+ 3.25% 6.37% 9/6/2025 7,366 7,282 6,835 Mindbody, Inc. Internet Services & Infrastructure First Lien Term Loan L+ 7.00% 10.64% 2/14/2025 4,687 4,651 4,570 (4) Mindbody, Inc. Internet Services & Infrastructure First Lien Revolver L+ 8.00% 2/14/2025 — (4) (12) (4)(5) MRI Software LLC Application Software First Lien Term Loan L+ 5.50% 9.17% 2/10/2026 6,139 6,104 5,966 (4) MRI Software LLC Application Software First Lien Revolver L+ 5.50% 2/10/2026 (3) (10) (4)(5) Northern Star Industries Inc. Electrical Components & Equipment First Lien Term Loan L+ 4.75% 7.87% 3/31/2025 6,685 6,673 6,484 OEConnection LLC Application Software First Lien Term Loan L+ 4.00% 7.12% 9/25/2026 7,777 7,741 7,505 (4) Park Place Technologies, LLC Internet Services & Infrastructure First Lien Term Loan SOFR+ 5.00% 8.13% 11/10/2027 4,925 4,781 4,687 (4) Peloton Interactive, Inc. Leisure Products First Lien Term Loan SOFR+ 6.50% 8.35% 5/25/2027 5,486 5,251 5,371 Planview Parent, Inc. Application Software Second Lien Term Loan L+ 7.25% 10.92% 12/18/2028 4,503 4,435 4,323 (4) Pluralsight, LLC Application Software First Lien Term Loan L+ 8.00% 10.68% 4/6/2027 6,796 6,694 6,582 (4) Pluralsight, LLC Application Software First Lien Revolver L+ 8.00% 4/6/2027 — (6) (13) (4)(5) RevSpring, Inc. Commercial Printing First Lien Term Loan L+ 4.00% 7.67% 10/11/2025 9,625 9,607 9,304 Sabert Corporation Metal & Glass Containers First Lien Term Loan L+ 4.50% 7.63% 12/10/2026 2,536 2,511 2,435 (4) SHO Holding I Corporation Footwear First Lien Term Loan L+ 5.25% 8.06% 4/27/2024 8,201 8,194 7,176 SHO Holding I Corporation Footwear First Lien Term Loan L+ 5.23% 8.04% 4/27/2024 138 138 121 Sorenson Communications, LLC Communications Equipment First Lien Term Loan L+ 5.50% 9.17% 3/17/2026 2,553 2,528 2,454 Spanx, LLC Apparel Retail First Lien Term Loan L+ 5.25% 8.30% 11/20/2028 8,933 8,776 8,721 (4) SPX Flow, Inc. Industrial Machinery First Lien Term Loan SOFR+ 4.50% 7.63% 4/5/2029 7,500 7,184 6,966 (4) Supermoose Borrower, LLC Application Software First Lien Term Loan L+ 3.75% 7.42% 8/29/2025 7,743 7,479 6,827 (4) Surgery Center Holdings, Inc. Health Care Facilities First Lien Term Loan L+ 3.75% 6.51% 8/31/2026 3,377 3,365 3,213 TIBCO Software Inc. Application Software First Lien Term Loan SOFR+ 4.50% 8.15% 3/30/2029 6,256 5,693 5,629 (4) Touchstone Acquisition, Inc. Health Care Supplies First Lien Term Loan L+ 6.00% 9.12% 12/29/2028 7,285 7,155 7,140 (4) Veritas US Inc. Application Software First Lien Term Loan L+ 5.00% 8.67% 9/1/2025 6,365 6,290 5,087 Windstream Services II, LLC Integrated Telecommunication Services First Lien Term Loan L+ 6.25% 9.37% 9/21/2027 7,818 7,596 7,115 (4) WP CPP Holdings, LLC Aerospace & Defense Second Lien Term Loan L+ 7.75% 10.56% 4/30/2026 6,000 5,972 5,070 (4) WP CPP Holdings, LLC Aerospace & Defense First Lien Term Loan L+ 3.75% 6.56% 4/30/2025 1,985 1,910 1,783 (4) Zayo Group Holdings, Inc. Alternative Carriers First Lien Term Loan L+ 3.00% 6.12% 3/9/2027 2,155 2,000 1,812 Total Portfolio Investments $ 383,194 $ 382,673 $ 359,625 _________ (1) Represents the interest rate as of September 30, 2022. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All the LIBOR shown above is in U.S. dollars. As of September 30, 2022, the reference rates for SLF JV I's variable rate loans were the 30-day LIBOR at 3.12%, the 90-day LIBOR at 3.67%, the 30-day SOFR at 3.03%, the 90-day SOFR at 3.55% and the 180-day SOFR at 3.98%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. (3) Represents the current determination of fair value as of September 30, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein. (4) This investment was held by both the Company and SLF JV I as of September 30, 2022. (5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. Glick JV Portfolio as of September 30, 2023 Portfolio Company Industry Investment Type Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Principal Cost Fair Value (3) Notes Access CIG, LLC Diversified Support Services First Lien Term Loan SOFR+ 5.00% 10.32% 8/18/2028 $ 2,000 $ 1,960 $ 1,978 ADB Companies, LLC Construction & Engineering First Lien Term Loan SOFR+ 6.50% 11.90% 12/18/2025 574 568 564 (4) ADB Companies, LLC Construction & Engineering First Lien Term Loan SOFR+ 6.50% 12.15% 12/18/2025 3,746 3,709 3,678 (4) Alvogen Pharma US, Inc. Pharmaceuticals First Lien Term Loan SOFR+ 7.50% 13.04% 6/30/2025 6,230 6,185 5,819 (4) American Rock Salt Company LLC Diversified Metals & Mining First Lien Term Loan SOFR+ 4.00% 9.43% 6/9/2028 2,478 2,367 2,307 American Tire Distributors, Inc. Distributors First Lien Term Loan SOFR+ 6.25% 11.81% 10/20/2028 2,860 2,825 2,514 (4) Amplify Finco Pty Ltd. Movies & Entertainment First Lien Term Loan SOFR+ 4.15% 9.54% 11/26/2026 2,895 2,866 2,895 Amynta Agency Borrower Inc. Property & Casualty Insurance First Lien Term Loan SOFR+ 5.00% 10.42% 2/28/2028 2,993 2,913 2,997 Anastasia Parent, LLC Personal Care Products First Lien Term Loan SOFR+ 3.75% 9.40% 8/11/2025 907 705 654 (4) ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & Materials First Lien Term Loan SOFR+ 6.00% 11.63% 12/29/2027 1,716 1,692 1,616 (4) ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & Materials First Lien Revolver SOFR+ 6.00% 12/29/2027 — (3) (12) (4)(5) Astra Acquisition Corp. Application Software First Lien Term Loan SOFR+ 5.25% 10.90% 10/25/2028 2,078 2,039 1,570 (4) Asurion, LLC Property & Casualty Insurance First Lien Term Loan SOFR+ 4.00% 9.42% 8/19/2028 1,980 1,899 1,924 Asurion, LLC Property & Casualty Insurance First Lien Term Loan SOFR+ 4.25% 9.67% 8/19/2028 995 942 968 Asurion, LLC Property & Casualty Insurance Second Lien Term Loan SOFR+ 5.25% 10.68% 1/20/2029 2,423 2,244 2,158 athenahealth Group Inc. Health Care Technology First Lien Term Loan SOFR+ 3.25% 8.57% 2/15/2029 1,772 1,674 1,744 Aurora Lux Finco S.À.R.L. Airport Services First Lien Term Loan SOFR+ 6.00% 11.49% 12/24/2026 3,628 3,586 3,478 (4) BAART Programs, Inc. Health Care Services First Lien Term Loan SOFR+ 5.00% 10.65% 6/11/2027 3,363 3,332 3,282 (4) BAART Programs, Inc. Health Care Services First Lien Term Loan SOFR+ 5.00% 10.65% 6/11/2027 800 795 780 (4) Covetrus, Inc. Health Care Distributors First Lien Term Loan SOFR+ 5.00% 10.39% 10/13/2029 2,766 2,607 2,741 (4) Curium Bidco S.à.r.l. Biotechnology First Lien Term Loan SOFR+ 4.50% 9.89% 7/31/2029 2,841 2,820 2,841 DirecTV Financing, LLC Cable & Satellite First Lien Term Loan SOFR+ 5.00% 10.43% 8/2/2027 2,460 2,435 2,410 (4) Portfolio Company Industry Investment Type Index Spread Cash Interest Rate (1)(2) PIK Maturity Date Principal Cost Fair Value (3) Notes DTI Holdco, Inc. Research & Consulting Services First Lien Term Loan SOFR+ 4.75% 10.12% 4/26/2029 $ 2,970 $ 2,922 $ 2,899 (4) Gibson Brands, Inc. Leisure Products First Lien Term Loan SOFR+ 5.00% 10.57% 8/11/2028 3,930 3,891 3,301 (4) Harbor Purchaser Inc. Education Services First Lien Term Loan SOFR+ 5.25% 10.67% 4/9/2029 3,960 3,865 3,759 (4) Indivior Finance S.À.R.L. Pharmaceuticals First Lien Term Loan SOFR+ 5.25% 10.90% 6/30/2026 3,910 3,866 3,915 INW Manufacturing, LLC Personal Care Products First Lien Term Loan SOFR+ 5.75% 11.40% 3/25/2027 2,250 2,210 1,770 (4) KDC/ONE Development Corp Inc Personal Care Products First Lien Term Loan SOFR+ 5.00% 10.32% 8/15/2028 4,500 4,350 4,349 LaserAway Intermediate Holdings II, LLC Health Care Services First Lien Term Loan SOFR+ 5.75% 11.32% 10/14/2027 3,930 3,877 3,876 MRI Software LLC Application Software First Lien Term Loan SOFR+ 5.50% 10.99% 2/10/2026 1,630 1,616 1,596 (4) MRI Software LLC Application Software First Lien Revolver SOFR+ 5.50% 2/10/2026 — (1) (3) (4)(5) Northern Star Industries Inc. Electrical Components & Equipment First Lien Term Loan SOFR+ 4.76% 10.15% 3/31/2025 5,198 5,192 5,159 OEConnection LLC Application Software First Lien Term Loan SOFR+ 4.00% 9.43% 9/25/2026 3,849 3,830 3,843 Planview Parent, Inc. Application Software First Lien Term Loan SOFR+ 4.00% 9.65% 12/17/2027 683 650 676 Planview Parent, Inc. Application Software Second Lien Term Loan SOFR+ 7.25% 12.74% 12/18/2028 2,842 2,799 2,586 (4) Pluralsight, LLC Application Software First Lien Te |
Schedule of Financial Instruments Carried at Fair Value | The following table presents the financial instruments carried at fair value as of September 30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level 1 Level 2 Level 3 Measured at Net Asset Value (a) Total Investments in debt securities (senior secured) $ — $ 208,694 $ 2,292,691 $ — $ 2,501,385 Investments in debt securities (subordinated, including the debt investments in the JVs) — 28,666 189,724 — 218,390 Investments in equity securities (preferred) — — 86,057 — 86,057 Investments in equity securities (common and warrants, including LLC equity interests of the JVs) 4,317 1,953 51,440 28,878 86,588 Total investments at fair value 4,317 239,313 2,619,912 28,878 2,892,420 Cash equivalents 83,262 — — — 83,262 Derivative assets — 4,910 — — 4,910 Total assets at fair value $ 87,579 $ 244,223 $ 2,619,912 $ 28,878 $ 2,980,592 Derivative liability $ — $ 47,519 $ — $ — $ 47,519 Total liabilities at fair value $ — $ 47,519 $ — $ — $ 47,519 __________ (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. The following table presents the financial instruments carried at fair value as of September 30, 2022 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level 1 Level 2 Level 3 Measured at Net Asset Value (a) Total Investments in debt securities (senior secured) $ — $ 255,803 $ 1,910,606 $ — $ 2,166,409 Investments in debt securities (subordinated, including the debt investments in the JVs) — 44,065 159,388 — 203,453 Investments in equity securities (preferred) — — 79,523 — 79,523 Investments in equity securities (common and warrants, including LLC equity interests of the JVs) 4,053 — 19,958 20,715 44,726 Total investments at fair value 4,053 299,868 2,169,475 20,715 2,494,111 Cash equivalents 5,261 — — — 5,261 Derivative assets — 6,789 — — 6,789 Total assets at fair value $ 9,314 $ 306,657 $ 2,169,475 $ 20,715 $ 2,506,161 Derivative liability $ — $ 41,969 $ — $ — $ 41,969 Total liabilities at fair value $ — $ 41,969 $ — $ — $ 41,969 __________ |
Schedule of Roll-Forward in the Changes in Fair Value | The following table provides a roll-forward in the changes in fair value from September 30, 2022 to September 30, 2023 for all investments for which the Company determined fair value using unobservable (Level 3) factors: Investments Senior Secured Debt Subordinated Preferred Common Total Fair value as of September 30, 2022 $ 1,910,606 $ 159,388 $ 79,523 $ 19,958 $ 2,169,475 Purchases (a) 1,080,654 30,690 14,296 5,611 1,131,251 Sales and repayments (650,437) (1,396) — (13,894) (665,727) Transfers in (b)(c) 19,075 — — 40,093 59,168 Transfers out (c) (40,093) — — — (40,093) Capitalized PIK interest income 15,016 628 — — 15,644 Accretion of OID 16,322 1,449 — — 17,771 Net unrealized appreciation (depreciation) (37,253) (1,035) (7,762) (2,921) (48,971) Net realized gains (losses) (21,199) — — 2,593 (18,606) Fair value as of September 30, 2023 $ 2,292,691 $ 189,724 $ 86,057 $ 51,440 $ 2,619,912 Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of September 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the year ended September 30, 2023 $ (48,680) $ (1,035) $ (7,762) $ (6,513) $ (63,990) __________ (a) Includes Level 3 investments acquired in connection with the OSI2 Merger during the year ended September 30, 2023. (b) There was one transfer into Level 3 from Level 2 for an investment during the year ended September 30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity. (c) There was one investment restructuring in which Level 3 senior secured debt was exchanged for Level 3 common equity during the year ended September 30, 2023. The following table provides a roll-forward in the changes in fair value from September 30, 2021 to September 30, 2022 for all investments for which the Company determined fair value using unobservable (Level 3) factors: Investments Senior Secured Debt Subordinated Preferred Common Total Fair value as of September 30, 2021 $ 1,878,536 $ 176,317 $ 63,565 $ 43,163 $ 2,161,581 Purchases 490,081 7,960 19,662 2,807 520,510 Sales and repayments (476,813) (22,525) (163) (13,034) (512,535) Transfers in (a)(c) 49,843 — — — 49,843 Transfers out (a)(b) (17,070) — — (5,838) (22,908) Capitalized PIK interest income 22,855 313 — — 23,168 Accretion of OID 24,422 2,060 — — 26,482 Net unrealized appreciation (depreciation) (67,455) (4,737) (3,029) (6,642) (81,863) Net realized gains (losses) 6,207 — (512) (498) 5,197 Fair value as of September 30, 2022 $ 1,910,606 $ 159,388 $ 79,523 $ 19,958 $ 2,169,475 Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of September 30, 2022 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the year ended September 30, 2022 $ (53,013) $ (4,885) $ (3,264) $ (11,751) $ (72,913) __________ (a) There were transfers into/out of Level 3 from/to Level 2 for certain investments during the year ended September 30, 2022 as a result of a change in the number of market quotes available and/or a change in market liquidity. (b) There was one transfer out of Level 3 in connection with a transaction in which Level 3 common equity was exchanged for Level 1 common equity. (c) There was one transfer into Level 3 from Level 2 as a result of an investment restructuring in which Level 2 senior secured debt was exchanged for Level 3 senior secured debt. |
Schedule of Significant Unobservable Inputs for Level 3 Investments | The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2023: Asset Fair Value Valuation Technique Unobservable Input Range Weighted Senior Secured Debt $ 1,904,140 Market Yield Market Yield (b) 9.0% - 32.0% 14.7% 64,802 Enterprise Value EBITDA Multiple (c) 3.0x - 6.0x 4.6x 33,816 Transaction Precedent Transaction Price (d) N/A - N/A N/A 289,933 Broker quotations Broker Quoted Price (e) N/A - N/A N/A Subordinated Debt 22,881 Market Yield Market Yield (b) 10.0% - 22.0% 11.2% 4,170 Broker Quotations Broker Quoted Price (e) N/A - N/A N/A Debt Investments in the JVs 162,673 Enterprise Value N/A (f) N/A - N/A N/A Preferred & Common Equity 32,318 Enterprise Value Revenue Multiple (c) 0.4x - 3.2x 0.5x 103,661 Enterprise Value EBITDA Multiple (c) 1.7x - 15.1x 8.8x 1,097 Enterprise Value Asset Multiple (c) 1.0x - 1.4x 1.4x 421 Transaction Precedent Transaction Price (d) N/A - N/A N/A Total $ 2,619,912 __________ (a) Weighted averages are calculated based on fair value of investments. (b) Used when market participants would take into account market yield when pricing the investment. (c) Used when market participants would use such multiples when pricing the investment. (d) Used when there is an observable transaction or pending event for the investment. (e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2022: Asset Fair Value Valuation Technique Unobservable Input Range Weighted Senior Secured Debt $ 1,599,148 Market Yield Market Yield (b) 9.0% - 30.0% 13.7% 14,333 Enterprise Value EBITDA Multiple (c) 5.0x - 7.0x 6.0x 297,125 Broker Quotations Broker Quoted Price (e) N/A - N/A N/A Subordinated Debt 12,855 Market Yield Market Yield (b) 10.0% - 19.0% 13.8% Debt Investments in the JVs 146,533 Enterprise Value N/A (f) N/A - N/A N/A Preferred & Common Equity 61,693 Enterprise Value Revenue Multiple (c) 0.4x - 10.1x 4.3x 36,913 Enterprise Value EBITDA Multiple (c) 3.0x - 20.0x 11.4x 3 Enterprise Value Asset Multiple (c) 0.9x - 1.1x 1.0x 872 Transaction Precedent Transaction Price (d) N/A - N/A N/A Total $ 2,169,475 __________ (a) Weighted averages are calculated based on fair value of investments. (b) Used when market participants would take into account market yield when pricing the investment. (c) Used when market participants would use such multiples when pricing the investment. (d) Used when there is an observable transaction or pending event for the investment. (e) Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f) Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. |
Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value | The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2023 and the level of each financial liability within the fair value hierarchy: Carrying Fair Value Level 1 Level 2 Level 3 Syndicated Facility payable $ 430,000 $ 430,000 $ — $ — $ 430,000 OSI2 Citibank Facility payable 280,000 280,000 — — 280,000 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount) 298,241 286,437 — 286,437 — 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 306,412 301,784 — 301,784 — 2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 286,078 289,980 — 289,980 — Total $ 1,600,731 $ 1,588,201 $ — $ 878,201 $ 710,000 The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2022 and the level of each financial liability within the fair value hierarchy: Carrying Fair Value Level 1 Level 2 Level 3 Syndicated Facility payable $ 540,000 $ 540,000 $ — $ — $ 540,000 Citibank Facility payable 160,000 160,000 — — 160,000 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount) 296,991 283,077 — 283,077 — 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment) 304,052 294,028 — 294,028 — Total $ 1,301,043 $ 1,277,105 $ — $ 577,105 $ 700,000 |
Schedule of Portfolio Composition | Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Senior secured debt $ 2,594,640 85.24 % $ 2,227,245 85.08 % Debt investments in the JVs 162,986 5.35 % 146,444 5.59 % Preferred equity 99,597 3.27 % 85,300 3.26 % Common equity and warrants 72,261 2.37 % 42,296 1.62 % Subordinated debt 59,844 1.97 % 67,147 2.57 % LLC equity interests of the JVs 54,791 1.80 % 49,322 1.88 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Senior secured debt $ 2,501,385 86.47 % 165.01 % $ 2,166,409 86.86 % 173.93 % Debt investments in the JVs 162,673 5.62 % 10.73 % 146,533 5.88 % 11.77 % Preferred equity 86,057 2.98 % 5.68 % 79,523 3.19 % 6.38 % Common equity and warrants 57,710 2.00 % 3.81 % 24,011 0.96 % 1.93 % Subordinated debt 55,717 1.93 % 3.68 % 56,920 2.28 % 4.57 % LLC equity interests of the JVs 28,878 1.00 % 1.91 % 20,715 0.83 % 1.66 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Northeast $ 1,012,955 33.27 % $ 747,420 28.55 % International 418,595 13.75 % 301,242 11.51 % West 393,390 12.92 % 358,306 13.69 % Southeast 375,247 12.33 % 356,041 13.60 % Midwest 360,506 11.84 % 373,236 14.26 % South 202,374 6.65 % 168,819 6.45 % Southwest 153,318 5.04 % 221,308 8.45 % Northwest 127,734 4.20 % 91,382 3.49 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Northeast $ 945,422 32.69 % 62.37 % $ 696,368 27.93 % 55.90 % International 414,079 14.32 % 27.32 % 279,646 11.21 % 22.45 % West 384,055 13.28 % 25.34 % 345,251 13.84 % 27.72 % Southeast 354,444 12.25 % 23.38 % 344,567 13.82 % 27.66 % Midwest 350,620 12.12 % 23.13 % 356,934 14.31 % 28.66 % South 188,541 6.52 % 12.44 % 166,230 6.66 % 13.35 % Southwest 130,455 4.51 % 8.61 % 214,984 8.62 % 17.26 % Northwest 124,804 4.31 % 8.23 % 90,131 3.61 % 7.24 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Senior secured loans (1) $332,637 $383,194 Weighted average interest rate on senior secured loans (2) 10.62% 8.33% Number of borrowers in SLF JV I 48 60 Largest exposure to a single borrower (1) $11,286 $10,093 Total of five largest loan exposures to borrowers (1) $54,051 $48,139 __________ (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. Below is a summary of the Glick JV's portfolio, followed by a listing of the individual loans in the Glick JV's portfolio as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Senior secured loans (1) $130,589 $143,225 Weighted average current interest rate on senior secured loans (2) 10.77% 8.52% Number of borrowers in the Glick JV 38 43 Largest loan exposure to a single borrower (1) $6,230 $6,562 Total of five largest loan exposures to borrowers (1) $28,396 $28,973 __________ (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. (Share amounts in thousands) Year ended Year ended Year ended Year ended Year ended Net asset value per share at beginning of period $20.38 $21.84 $19.47 $19.81 $18.26 Net investment income (1) 2.51 2.45 1.80 1.53 1.45 Net unrealized appreciation (depreciation) (1)(7) (0.17) (2.23) 2.19 (0.44) 0.82 Net realized gains (losses) (1) (0.46) 0.28 0.49 (0.30) 0.44 (Provision) benefit for taxes on realized and unrealized gains (losses) (1) (0.02) (0.01) (0.02) 0.04 (0.02) Distributions of net investment income to stockholders (2.61) (1.95) (1.52) (1.17) (1.14) Issuance of common stock — — (0.57) — — Net asset value per share at end of period $19.63 $20.38 $21.84 $19.47 $19.81 Per share market value at beginning of period $18.00 $21.18 $14.52 $15.54 $14.88 Per share market value at end of period $20.12 $18.00 $21.18 $14.52 $15.54 Total return (2) 27.30% (6.71)% 57.61% 2.10% 12.56% Common shares outstanding at beginning of period 61,125 60,120 46,987 46,987 46,987 Common shares outstanding at end of period 77,225 61,125 60,120 46,987 46,987 Net assets at beginning of period $1,245,563 $1,312,823 $914,879 $930,630 $858,035 Net assets at end of period $1,515,764 $1,245,563 $1,312,823 $914,879 $930,630 Average net assets (3) $1,437,728 $1,308,518 $1,150,662 $871,305 $909,264 Ratio of net investment income to average net assets (3) 12.57% 11.36% 8.44% 8.26% 7.47% Ratio of total expenses to average net assets (3) 14.19% 8.68% 9.65% 7.57% 9.65% Ratio of net expenses to average net assets (3) 13.81% 8.45% 9.51% 8.16% 8.78% Ratio of portfolio turnover to average investments at fair value 26.12% 26.99% 39.66% 38.99% 32.50% Weighted average outstanding debt (4) $1,659,701 $1,361,151 $964,390 $647,080 $573,891 Average debt per share (1) $23.01 $22.41 $17.85 $13.77 $12.21 Asset coverage ratio at end of period (5) 187.74% 188.64% 201.68% 227.22% 294.91% __________ (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of $1,660.0 million, $1,350.0 million, $1,280.0 million, $714.8 million and $476.1 million as of September 30, 2023, 2022, 2021, 2020 and 2019, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) For the year ended September 30, 2023, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OSI2 Merger. For the year ended September 30, 2021, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OCSI Merger. Senior Securities Information about our senior securities (including debt securities and other indebtedness) is shown in the following table as of the fiscal years ended September 30 for the years indicated below. Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) Syndicated Facility and Prior ING Facility Fiscal 2014 $ 267,395 2,595 — N/A Fiscal 2015 383,495 2,389 — N/A Fiscal 2016 472,495 2,208 — N/A Fiscal 2017 226,495 2,274 — N/A Fiscal 2018 241,000 2,330 — N/A Fiscal 2019 314,825 2,949 — N/A Fiscal 2020 414,825 2,272 — N/A Fiscal 2021 495,000 2,017 — N/A Fiscal 2022 540,000 1,886 — N/A Fiscal 2023 430,000 1,877 — N/A Citibank Facility Fiscal 2021 $ 135,000 2,017 — N/A Fiscal 2022 160,000 1,886 — N/A OSI2 Citibank Facility Fiscal 2023 $ 280,000 1,877 — N/A Sumitomo Facility Fiscal 2014 $ 50,000 2,595 — N/A Fiscal 2015 43,800 2,389 — N/A Fiscal 2016 43,800 2,208 — N/A Fiscal 2017 29,500 2,274 — N/A Convertible Notes Fiscal 2014 $ 115,000 2,595 — N/A Fiscal 2015 115,000 2,389 — N/A Secured Borrowings Fiscal 2014 $ 84,750 2,595 — N/A Fiscal 2015 21,787 2,389 — N/A Fiscal 2016 18,929 2,208 — N/A Fiscal 2017 13,489 2,274 — N/A Fiscal 2018 12,314 2,330 — N/A 2019 Notes Fiscal 2014 $ 250,000 2,595 — N/A Fiscal 2015 250,000 2,389 — N/A Fiscal 2016 250,000 2,208 — N/A Fiscal 2017 250,000 2,274 — N/A Fiscal 2018 228,825 2,330 — N/A Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) 2024 Notes Fiscal 2014 $ 75,000 2,595 — 966.96 Fiscal 2015 75,000 2,389 — 991.94 Fiscal 2016 75,000 2,208 — 993.70 Fiscal 2017 75,000 2,274 — 1,006.74 Fiscal 2018 75,000 2,330 — 1,010.72 Fiscal 2019 75,000 2,949 — 1,012.76 2025 Notes Fiscal 2020 $ 300,000 2,272 — N/A Fiscal 2021 300,000 2,017 — N/A Fiscal 2022 300,000 1,886 — N/A Fiscal 2023 300,000 1,877 — N/A 2027 Notes Fiscal 2021 $ 350,000 2,017 — N/A Fiscal 2022 350,000 1,886 — N/A Fiscal 2023 350,000 1,877 — N/A 2028 Notes Fiscal 2014 $ 86,250 2,595 — 943.73 Fiscal 2015 86,250 2,389 — 988.06 Fiscal 2016 86,250 2,208 — 999.29 Fiscal 2017 86,250 2,274 — 1,007.51 Fiscal 2018 86,250 2,330 — 994.82 Fiscal 2019 86,250 2,949 — 993.33 2029 Notes Fiscal 2023 $ 300,000 1,877 — N/A Total Senior Securities Fiscal 2014 $ 928,395 2,595 — Fiscal 2015 975,332 2,389 — Fiscal 2016 946,474 2,208 — Fiscal 2017 680,734 2,274 — Fiscal 2018 643,389 2,330 — Fiscal 2019 476,075 2,949 — Fiscal 2020 714,825 2,272 — Fiscal 2021 1,280,000 2,017 — Fiscal 2022 1,350,000 1,886 — Fiscal 2023 1,660,000 1,877 — ______________ (1) This table excludes any SBA-guaranteed debentures outstanding during the relevant periods because the SEC has granted the Company exemptive relief that permits it to exclude such debentures from the definition of senior securities in the asset coverage ratio the Company is required to maintain under the Investment Company Act. (2) Total amount of each class of senior securities outstanding at the end of the period, presented in thousands. (3) The asset coverage ratio for a class of senior securities representing indebtedness is calculated as the Company's consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by total senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the “Asset Coverage Per Unit.” (4) The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it. The “-” indicates information that the Securities and Exchange Commission expressly does not require to be disclosed for certain types of senior securities. |
Summarized Financial Information | Below is certain summarized financial information for SLF JV I as of September 30, 2023 and September 30, 2022 and for the years ended September 30, 2023, 2022 and 2021: September 30, 2023 September 30, 2022 Selected Balance Sheet Information: Investments at fair value (cost September 30, 2023:$331,808; cost September 30, 2022: $382,673) $ 322,179 $ 359,625 Cash and cash equivalents 31,950 14,274 Restricted cash 2,987 5,642 Other assets 18,988 5,686 Total assets $ 376,104 $ 385,227 Senior credit facility payable $ 149,000 $ 230,000 Secured borrowings 38,845 — SLF JV I Notes payable at fair value (proceeds September 30, 2023: $128,750; proceeds September 30, 2022: $110,000) 128,750 110,000 Other liabilities 26,630 21,539 Total liabilities $ 343,225 $ 361,539 Members' equity 32,879 23,688 Total liabilities and members' equity $ 376,104 $ 385,227 Year ended September 30, 2023 Year ended September 30, 2022 Year ended September 30, 2021 Selected Statements of Operations Information: Interest income $ 38,984 $ 24,014 $ 20,018 Other income 290 198 565 Total investment income 39,274 24,212 20,583 Senior credit facility and secured borrowing interest expense 19,002 7,713 5,706 SLF JV I Notes interest expense 14,544 9,146 8,444 Other expenses 442 253 260 Total expenses (1) 33,988 17,112 14,410 Net investment income 5,286 7,100 6,173 Net unrealized appreciation (depreciation) 13,416 (23,661) 13,270 Net realized gains (losses) (10,962) 534 399 Net income (loss) $ 7,740 $ (16,027) $ 19,842 __________ (1) There are no management fees or incentive fees charged at SLF JV I. Below is certain summarized financial information for the Glick JV as of September 30, 2023 and September 30, 2022 and for the years ended September 30, 2023 and 2022 and for the period from March 19, 2021 to September 30, 2021: September 30, 2023 September 30, 2022 Selected Balance Sheet Information: Investments at fair value (cost September 30, 2023: $127,788; September 30, 2022: 140,083) $ 123,343 $ 133,144 Cash and cash equivalents 12,119 7,021 Restricted cash 184 1,788 Other assets 5,521 4,855 Total assets $ 141,167 $ 146,808 Senior credit facility payable $ 53,000 $ 82,082 Glick JV Notes payable at fair value (proceeds September 30, 2023: $66,685; September 30, 2022: 68,185) 57,201 57,463 Secured borrowings 18,106 — Other liabilities 12,860 7,263 Total liabilities $ 141,167 $ 146,808 Members' equity — — Total liabilities and members' equity $ 141,167 $ 146,808 For the year ended September 30, 2023 For the year ended September 30, 2022 For the period from March 19, 2021 to September 30, 2021 Selected Statements of Operations Information: Interest income $ 14,043 $ 9,703 $ 4,643 Fee income 63 149 67 Total investment income 14,106 9,852 4,710 Senior credit facility and secured borrowing interest expense 6,560 2,747 1,157 Glick JV Notes interest expense 6,056 3,576 1,780 Other expenses 182 168 95 Total expenses (1) 12,798 6,491 3,032 Net investment income 1,308 3,361 1,678 Net unrealized appreciation (depreciation) 1,254 (3,216) (1,710) Realized gain (loss) (2,562) (145) 32 Net income (loss) $ — $ — $ — __________ (1) There are no management fees or incentive fees charged at the Glick JV. |
Share Data and Net Assets (Tabl
Share Data and Net Assets (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Stockholders' Equity Note [Abstract] | |
Schedule of Basic and Diluted Earnings Per Share | The following table sets forth the computation of basic and diluted earnings per share, pursuant to ASC Topic 260-10, Earnings per Share , for the years ended September 30, 2023, 2022 and 2021: (Share amounts in thousands) Year ended Year ended Year ended Earnings (loss) per common share — basic and diluted: Net increase (decrease) in net assets resulting from operations $ 117,331 $ 29,223 $ 237,260 Weighted average common shares outstanding — basic and diluted 72,119 60,727 54,039 Earnings (loss) per common share — basic and diluted $ 1.63 $ 0.48 $ 4.39 |
Schedule of Changes in Net Assets | The following table presents the changes in net assets for the years ended September 30, 2023, 2022 and 2021: Common Stock (Share amounts in thousands) Shares Par Value Additional paid-in-capital Accumulated Overdistributed Earnings Total Net Assets Balance as of September 30, 2020 46,987 $ 470 $ 1,488,713 $ (574,304) $ 914,879 Net investment income — — — 97,106 97,106 Net unrealized appreciation (depreciation) — — — 114,519 114,519 Net realized gains (losses) — — — 26,420 26,420 (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (785) (785) Distributions to stockholders — — — (82,020) (82,020) Reclassification of additional paid-in capital — — 74,271 (74,271) — Issuance of common stock in connection with the OCSI Merger 13,133 131 242,573 — 242,704 Issuance of common stock under dividend reinvestment plan 113 1 2,169 — 2,170 Repurchases of common stock under dividend reinvestment plan (113) (1) (2,169) — (2,170) Balance as of September 30, 2021 60,120 601 1,805,557 (493,335) 1,312,823 Net investment income — — — 148,621 148,621 Net unrealized appreciation (depreciation) — — — (136,248) (136,248) Net realized gains (losses) — — — 17,179 17,179 (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (329) (329) Distributions to stockholders — — — (118,657) (118,657) Issuance of common stock in connection with the "at the market" offering 934 9 20,613 — 20,622 Issuance of common stock under dividend reinvestment plan 166 2 3,407 — 3,409 Repurchase of common stock under dividend reinvestment plan (95) (1) (1,856) — (1,857) Balance as of September 30, 2022 61,125 611 1,827,721 (582,769) 1,245,563 Net investment income — — — 180,697 180,697 Net unrealized appreciation (depreciation) — — — (28,555) (28,555) Net realized gains (losses) — — — (33,155) (33,155) (Provision) benefit for taxes on realized and unrealized gains (losses) — — — (1,656) (1,656) Distributions to stockholders — — — (185,900) (185,900) Issuance of common stock in connection with the OSI2 Merger 15,860 159 333,875 — 334,034 Issuance of common stock in connection with the "at the market" offering 69 1 1,299 — 1,300 Issuance of common stock under dividend reinvestment plan 297 3 5,851 — 5,854 Repurchase of common stock under dividend reinvestment plan (126) (2) (2,416) — (2,418) Balance as of September 30, 2023 77,225 $ 772 $ 2,166,330 $ (651,338) $ 1,515,764 |
Schedule of Distributions | The following table reflects the distributions per share that the Company has paid, including shares issued under the DRIP, on its common stock during the years ended September 30, 2023, 2022 and 2021: Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly November 10, 2022 December 15, 2022 December 30, 2022 $ 0.54 $ 32.0 million 53,369 (1) $ 1.1 million Special November 10, 2022 December 15, 2022 December 30, 2022 0.42 24.8 million 41,510 (1) 0.8 million Quarterly January 27, 2023 March 15, 2023 March 31, 2023 0.55 41.1 million 68,412 (2) 1.3 million Quarterly April 28, 2023 June 15, 2023 June 30, 2023 0.55 41.3 million 57,279 (2) 1.1 million Quarterly July 28, 2023 September 15, 2023 September 29, 2023 0.55 40.9 million 76,766 (1) 1.5 million Total for the year ended September 30, 2023 $ 2.61 $ 180.0 million 297,336 $ 5.9 million Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly October 13, 2021 December 15, 2021 December 31, 2021 $ 0.465 $ 27.2 million 35,990 (1) $ 0.8 million Quarterly January 28, 2022 March 15, 2022 March 31, 2022 0.48 28.5 million 34,804 (1) 0.8 million Quarterly April 29, 2022 June 15, 2022 June 30, 2022 0.495 29.4 million 43,676 (2) 0.9 million Quarterly July 29, 2022 September 15, 2022 September 30, 2022 0.51 30.2 million 51,181 (2) 1.0 million Total for the year ended September 30, 2022 $ 1.95 $ 115.3 million 165,651 $ 3.4 million Distribution Date Declared Record Date Payment Date Amount Cash DRIP Shares DRIP Shares Quarterly November 13, 2020 December 15, 2020 December 31, 2020 $ 0.33 $ 15.0 million 31,321 (2) $ 0.5 million Quarterly January 29, 2021 March 15, 2021 March 31, 2021 0.36 16.4 million 27,234 (2) 0.5 million Quarterly April 30, 2021 June 15, 2021 June 30, 2021 0.39 22.9 million 25,660 (2) 0.5 million Quarterly July 30, 2021 September 15, 2021 September 30, 2021 0.435 25.5 million 28,358 (2) 0.6 million Total for the year ended September 30, 2021 $ 1.515 $ 79.8 million 112,573 $ 2.2 million __________ (1) New shares were issued and distributed. (2) Shares were purchased on the open market and distributed. (3) Totals may not sum due to rounding. |
Schedule of Common Stock Issued and Sold | In connection with the "at the market" offering, the Company issued and sold 68,752 shares of common stock during the year ended September 30, 2023 for net proceeds of $1.3 million (net of offering costs). Number of Shares Issued Gross Proceeds Placement Agent Fees Net Proceeds (1) Average Sales Price per Share (2) "At the market" offering 68,752 $ 1,384 $ 14 $ 1,370 $ 20.13 (1) Net proceeds excludes offering costs of $0.1 million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. In connection with the "at the market" offering, the Company issued and sold 933,733 shares of common stock during the year ended September 30, 2022 for net proceeds of $20.6 million (net of offering costs). Number of Shares Issued Gross Proceeds Placement Agent Fees Net Proceeds (1) Average Sales Price per Share (2) "At the market" offering 933,733 $ 21,049 $ 210 $ 20,839 $ 22.54 __________ (1) Net proceeds excludes offering costs of $0.2 million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. |
Borrowings (Tables)
Borrowings (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Components of Debt | The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of September 30, 2023 and September 30, 2022: As of September 30, 2023 As of September 30, 2022 ($ in millions) 2025 Notes 2027 Notes 2029 Notes 2025 Notes 2027 Notes Principal $ 300.0 $ 350.0 $ 300.0 $ 300.0 $ 350.0 Unamortized financing costs (1.1) (2.5) (3.5) (1.8) (3.2) Unaccreted discount (0.7) (0.6) (3.4) (1.2) (0.7) Interest rate swap fair value adjustment — (40.5) (7.0) — (42.0) Net carrying value $ 298.2 $ 306.4 $ 286.1 $ 297.0 $ 304.1 Fair Value $ 286.4 $ 301.8 $ 290.0 $ 283.1 $ 294.0 The below table presents the components of interest and other debt expenses related to the 2025 Notes, the 2027 Notes and the 2029 Notes for the year ended September 30, 2023: ($ in millions) 2025 Notes 2027 Notes 2029 Notes Coupon interest $ 10.5 $ 9.5 $ 2.7 Amortization of financing costs and discount 1.3 0.9 0.2 Effect of interest rate swap — 13.4 0.6 Total interest expense $ 11.8 $ 23.8 $ 3.5 Coupon interest rate (net of effect of interest rate swaps) 3.500 % 6.539 % 8.490 % The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the year ended September 30, 2022: ($ in millions) 2025 Notes 2027 Notes Coupon interest $ 10.5 $ 9.5 Amortization of financing costs and discount 1.3 0.9 Effect of interest rate swap — (0.4) Total interest expense $ 11.8 $ 10.0 Coupon interest rate (net of effect of interest rate swap for 2027 Notes) 3.500 % 2.585 % The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the year ended September 30, 2021: ($ in millions) 2025 Notes 2027 Notes Coupon interest $ 10.5 $ 3.5 Amortization of financing costs and discount 1.3 0.3 Effect of interest rate swap — (1.1) Total interest expense $ 11.8 $ 2.7 Coupon interest rate (net of effect of interest rate swap for 2027 Notes) 3.500 % 1.813 % |
Taxable_Distributable Income _2
Taxable/Distributable Income and Dividend Distributions (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations | Listed below is a reconciliation of "net increase (decrease) in net assets resulting from operations" to taxable income for the years ended September 30, 2023, 2022 and 2021. Year ended Year ended Year ended Net increase (decrease) in net assets resulting from operations $ 117,331 $ 29,223 $ 237,260 Net unrealized (appreciation) depreciation 28,555 136,248 (114,519) Book/tax difference due to organizational costs — (87) (87) Book/tax difference due to capital losses suspended (utilized) 34,607 (16,490) (41,625) Other book/tax differences (14,691) (6,506) 11,863 Taxable/Distributable Income (1) $ 165,802 $ 142,388 $ 92,892 __________ (1) The Company's taxable income for the year ended September 30, 2023 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2023. Therefore, the final taxable income may be different than the estimate. |
Components of Accumulated Overdistributed Earnings | As of September 30, 2023, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows: Undistributed ordinary income, net $ 33,525 Net realized capital losses (509,832) Unrealized losses, net (175,031) Accumulated overdistributed earnings $ (651,338) |
Realized Gains or Losses and _2
Realized Gains or Losses and Net Unrealized Appreciation or Depreciation (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Investment Company [Abstract] | |
Schedule of Aggregate Net Realized Gains | During the year ended September 30, 2023, the Company recorded an aggregate net realized loss of $33.2 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) SIO2 Medical Products Inc. $ (13.9) Convergeone Holdings Inc. (6.0) Foreign currency forward contracts (5.8) Aden & Anais Merger Sub Inc. (5.2) Radiology Partners Inc. (4.2) Carvana Co. (2.8) Impel Neuropharma Inc. (2.3) ASP Unifrax Holdings Inc. (2.1) WP CPP Holdings LLC (1.3) Global Medical Response Inc. (1.0) Athenex Inc. 6.5 Tersera Therapeutics LLC 5.2 CorEvitas Group Holdings LP 4.0 Other, net (4.3) Total, net $ (33.2) During the year ended September 30, 2022, the Company recorded an aggregate net realized gain of $17.2 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) Foreign currency forward contracts $ 13.7 OmniSYS Acquisition Corporation 2.2 First Star Speir Aviation Limited 1.9 TigerConnect Inc. 1.8 WP CPP Holdings, LLC (1.7) Other, net (0.7) Total, net $ 17.2 During the year ended September 30, 2021, the Company recorded an aggregate net realized gain of $26.4 million, which consisted of the following: ($ in millions) Portfolio Company Net Realized Gain (Loss) PLATO Learning Inc. $ 7.8 Keypath Education Holdings, LLC 6.8 L Squared Capital Partners LLC 3.4 LTI Holdings, Inc. 2.6 BX Commercial Mortgage Trust 2020-VIVA 2.6 California Pizza Kitchen Inc. (1.8) Refac Optical Group (1.3) Other, net 6.3 Total, net $ 26.4 |
Financial Highlights (Tables)
Financial Highlights (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Investment Company [Abstract] | |
Schedule of Financial Highlights | Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Senior secured debt $ 2,594,640 85.24 % $ 2,227,245 85.08 % Debt investments in the JVs 162,986 5.35 % 146,444 5.59 % Preferred equity 99,597 3.27 % 85,300 3.26 % Common equity and warrants 72,261 2.37 % 42,296 1.62 % Subordinated debt 59,844 1.97 % 67,147 2.57 % LLC equity interests of the JVs 54,791 1.80 % 49,322 1.88 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Senior secured debt $ 2,501,385 86.47 % 165.01 % $ 2,166,409 86.86 % 173.93 % Debt investments in the JVs 162,673 5.62 % 10.73 % 146,533 5.88 % 11.77 % Preferred equity 86,057 2.98 % 5.68 % 79,523 3.19 % 6.38 % Common equity and warrants 57,710 2.00 % 3.81 % 24,011 0.96 % 1.93 % Subordinated debt 55,717 1.93 % 3.68 % 56,920 2.28 % 4.57 % LLC equity interests of the JVs 28,878 1.00 % 1.91 % 20,715 0.83 % 1.66 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets: September 30, 2023 September 30, 2022 Cost: % of Total Investments % of Total Investments Northeast $ 1,012,955 33.27 % $ 747,420 28.55 % International 418,595 13.75 % 301,242 11.51 % West 393,390 12.92 % 358,306 13.69 % Southeast 375,247 12.33 % 356,041 13.60 % Midwest 360,506 11.84 % 373,236 14.26 % South 202,374 6.65 % 168,819 6.45 % Southwest 153,318 5.04 % 221,308 8.45 % Northwest 127,734 4.20 % 91,382 3.49 % Total $ 3,044,119 100.00 % $ 2,617,754 100.00 % September 30, 2023 September 30, 2022 Fair Value: % of Total Investments % of Net Assets % of Total Investments % of Net Assets Northeast $ 945,422 32.69 % 62.37 % $ 696,368 27.93 % 55.90 % International 414,079 14.32 % 27.32 % 279,646 11.21 % 22.45 % West 384,055 13.28 % 25.34 % 345,251 13.84 % 27.72 % Southeast 354,444 12.25 % 23.38 % 344,567 13.82 % 27.66 % Midwest 350,620 12.12 % 23.13 % 356,934 14.31 % 28.66 % South 188,541 6.52 % 12.44 % 166,230 6.66 % 13.35 % Southwest 130,455 4.51 % 8.61 % 214,984 8.62 % 17.26 % Northwest 124,804 4.31 % 8.23 % 90,131 3.61 % 7.24 % Total $ 2,892,420 100.00 % 190.82 % $ 2,494,111 100.00 % 200.24 % Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Senior secured loans (1) $332,637 $383,194 Weighted average interest rate on senior secured loans (2) 10.62% 8.33% Number of borrowers in SLF JV I 48 60 Largest exposure to a single borrower (1) $11,286 $10,093 Total of five largest loan exposures to borrowers (1) $54,051 $48,139 __________ (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. Below is a summary of the Glick JV's portfolio, followed by a listing of the individual loans in the Glick JV's portfolio as of September 30, 2023 and September 30, 2022: September 30, 2023 September 30, 2022 Senior secured loans (1) $130,589 $143,225 Weighted average current interest rate on senior secured loans (2) 10.77% 8.52% Number of borrowers in the Glick JV 38 43 Largest loan exposure to a single borrower (1) $6,230 $6,562 Total of five largest loan exposures to borrowers (1) $28,396 $28,973 __________ (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. (Share amounts in thousands) Year ended Year ended Year ended Year ended Year ended Net asset value per share at beginning of period $20.38 $21.84 $19.47 $19.81 $18.26 Net investment income (1) 2.51 2.45 1.80 1.53 1.45 Net unrealized appreciation (depreciation) (1)(7) (0.17) (2.23) 2.19 (0.44) 0.82 Net realized gains (losses) (1) (0.46) 0.28 0.49 (0.30) 0.44 (Provision) benefit for taxes on realized and unrealized gains (losses) (1) (0.02) (0.01) (0.02) 0.04 (0.02) Distributions of net investment income to stockholders (2.61) (1.95) (1.52) (1.17) (1.14) Issuance of common stock — — (0.57) — — Net asset value per share at end of period $19.63 $20.38 $21.84 $19.47 $19.81 Per share market value at beginning of period $18.00 $21.18 $14.52 $15.54 $14.88 Per share market value at end of period $20.12 $18.00 $21.18 $14.52 $15.54 Total return (2) 27.30% (6.71)% 57.61% 2.10% 12.56% Common shares outstanding at beginning of period 61,125 60,120 46,987 46,987 46,987 Common shares outstanding at end of period 77,225 61,125 60,120 46,987 46,987 Net assets at beginning of period $1,245,563 $1,312,823 $914,879 $930,630 $858,035 Net assets at end of period $1,515,764 $1,245,563 $1,312,823 $914,879 $930,630 Average net assets (3) $1,437,728 $1,308,518 $1,150,662 $871,305 $909,264 Ratio of net investment income to average net assets (3) 12.57% 11.36% 8.44% 8.26% 7.47% Ratio of total expenses to average net assets (3) 14.19% 8.68% 9.65% 7.57% 9.65% Ratio of net expenses to average net assets (3) 13.81% 8.45% 9.51% 8.16% 8.78% Ratio of portfolio turnover to average investments at fair value 26.12% 26.99% 39.66% 38.99% 32.50% Weighted average outstanding debt (4) $1,659,701 $1,361,151 $964,390 $647,080 $573,891 Average debt per share (1) $23.01 $22.41 $17.85 $13.77 $12.21 Asset coverage ratio at end of period (5) 187.74% 188.64% 201.68% 227.22% 294.91% __________ (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of $1,660.0 million, $1,350.0 million, $1,280.0 million, $714.8 million and $476.1 million as of September 30, 2023, 2022, 2021, 2020 and 2019, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) For the year ended September 30, 2023, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OSI2 Merger. For the year ended September 30, 2021, the amount shown for net unrealized appreciation (depreciation) includes the effect of the timing of common stock issuances in connection with the OCSI Merger. Senior Securities Information about our senior securities (including debt securities and other indebtedness) is shown in the following table as of the fiscal years ended September 30 for the years indicated below. Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) Syndicated Facility and Prior ING Facility Fiscal 2014 $ 267,395 2,595 — N/A Fiscal 2015 383,495 2,389 — N/A Fiscal 2016 472,495 2,208 — N/A Fiscal 2017 226,495 2,274 — N/A Fiscal 2018 241,000 2,330 — N/A Fiscal 2019 314,825 2,949 — N/A Fiscal 2020 414,825 2,272 — N/A Fiscal 2021 495,000 2,017 — N/A Fiscal 2022 540,000 1,886 — N/A Fiscal 2023 430,000 1,877 — N/A Citibank Facility Fiscal 2021 $ 135,000 2,017 — N/A Fiscal 2022 160,000 1,886 — N/A OSI2 Citibank Facility Fiscal 2023 $ 280,000 1,877 — N/A Sumitomo Facility Fiscal 2014 $ 50,000 2,595 — N/A Fiscal 2015 43,800 2,389 — N/A Fiscal 2016 43,800 2,208 — N/A Fiscal 2017 29,500 2,274 — N/A Convertible Notes Fiscal 2014 $ 115,000 2,595 — N/A Fiscal 2015 115,000 2,389 — N/A Secured Borrowings Fiscal 2014 $ 84,750 2,595 — N/A Fiscal 2015 21,787 2,389 — N/A Fiscal 2016 18,929 2,208 — N/A Fiscal 2017 13,489 2,274 — N/A Fiscal 2018 12,314 2,330 — N/A 2019 Notes Fiscal 2014 $ 250,000 2,595 — N/A Fiscal 2015 250,000 2,389 — N/A Fiscal 2016 250,000 2,208 — N/A Fiscal 2017 250,000 2,274 — N/A Fiscal 2018 228,825 2,330 — N/A Class and Year(1) Total Amount Outstanding Exclusive of Treasury Securities (2) Asset Coverage Per Unit(3) Involuntary Liquidating Preference Per Unit(4) Average Market Value Per Unit(5) 2024 Notes Fiscal 2014 $ 75,000 2,595 — 966.96 Fiscal 2015 75,000 2,389 — 991.94 Fiscal 2016 75,000 2,208 — 993.70 Fiscal 2017 75,000 2,274 — 1,006.74 Fiscal 2018 75,000 2,330 — 1,010.72 Fiscal 2019 75,000 2,949 — 1,012.76 2025 Notes Fiscal 2020 $ 300,000 2,272 — N/A Fiscal 2021 300,000 2,017 — N/A Fiscal 2022 300,000 1,886 — N/A Fiscal 2023 300,000 1,877 — N/A 2027 Notes Fiscal 2021 $ 350,000 2,017 — N/A Fiscal 2022 350,000 1,886 — N/A Fiscal 2023 350,000 1,877 — N/A 2028 Notes Fiscal 2014 $ 86,250 2,595 — 943.73 Fiscal 2015 86,250 2,389 — 988.06 Fiscal 2016 86,250 2,208 — 999.29 Fiscal 2017 86,250 2,274 — 1,007.51 Fiscal 2018 86,250 2,330 — 994.82 Fiscal 2019 86,250 2,949 — 993.33 2029 Notes Fiscal 2023 $ 300,000 1,877 — N/A Total Senior Securities Fiscal 2014 $ 928,395 2,595 — Fiscal 2015 975,332 2,389 — Fiscal 2016 946,474 2,208 — Fiscal 2017 680,734 2,274 — Fiscal 2018 643,389 2,330 — Fiscal 2019 476,075 2,949 — Fiscal 2020 714,825 2,272 — Fiscal 2021 1,280,000 2,017 — Fiscal 2022 1,350,000 1,886 — Fiscal 2023 1,660,000 1,877 — ______________ (1) This table excludes any SBA-guaranteed debentures outstanding during the relevant periods because the SEC has granted the Company exemptive relief that permits it to exclude such debentures from the definition of senior securities in the asset coverage ratio the Company is required to maintain under the Investment Company Act. (2) Total amount of each class of senior securities outstanding at the end of the period, presented in thousands. (3) The asset coverage ratio for a class of senior securities representing indebtedness is calculated as the Company's consolidated total assets, less all liabilities and indebtedness not represented by senior securities, divided by total senior securities representing indebtedness. This asset coverage ratio is multiplied by $1,000 to determine the “Asset Coverage Per Unit.” (4) The amount to which such class of senior security would be entitled upon the involuntary liquidation of the issuer in preference to any security junior to it. The “-” indicates information that the Securities and Exchange Commission expressly does not require to be disclosed for certain types of senior securities. |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Foreign Currency Forward Contracts and Interest Rate Swap | Certain information related to the Company’s foreign currency forward contracts is presented below as of September 30, 2023. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract $ 42,182 € 38,026 11/9/2023 $ 1,857 $ — Derivative asset Foreign currency forward contract $ 72,098 £ 56,556 11/9/2023 3,053 — Derivative asset $ 4,910 $ — Certain information related to the Company’s foreign currency forward contracts is presented below as of September 30, 2022. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract $ 43,179 € 41,444 11/10/2022 $ 2,466 $ — Derivative asset Foreign currency forward contract $ 45,692 £ 37,033 11/10/2022 4,323 — Derivative asset $ 6,789 $ — Certain information related to the Company’s interest rate swaps is presented below as of September 30, 2023. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap $ 350,000 1/15/2027 $ — $ 40,519 Derivative liability Interest rate swap 300,000 2/15/2029 — 7,000 Derivative liability $ — $ 47,519 Certain information related to the Company’s interest rate swap is presented below as of September 30, 2022. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap $ 350,000 1/15/2027 $ — $ 41,969 Derivative liability $ — $ 41,969 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Unfunded Commitments | A list of unfunded commitments by investment (consisting of revolvers, term loans with delayed draw components, subordinated notes and LLC equity interests in the JVs, preferred stock and limited partnership interests) as of September 30, 2023 and September 30, 2022 is shown in the table below: September 30, 2023 September 30, 2022 107-109 Beech OAK22 LLC $ 26,969 $ — Delta Leasing SPV II LLC 14,639 27,187 BioXcel Therapeutics, Inc. 14,547 11,785 OCSI Glick JV LLC 13,998 13,998 Senior Loan Fund JV I, LLC 13,125 35,000 Fairbridge Strategic Capital Funding LLC 13,090 22,150 MND Holdings III Corp 9,122 — Seres Therapeutics, Inc. 8,090 — Assembled Brands Capital LLC 7,514 2,008 iCIMs, Inc. 7,466 6,930 Grove Hotel Parcel Owner, LLC 5,286 4,293 scPharmaceuticals Inc. 5,212 — Kings Buyer, LLC 5,189 1,537 Avalara, Inc. 5,047 — Mindbody, Inc. 4,762 4,000 Accupac, Inc. 4,500 4,605 107 Fair Street LLC 4,227 — Harrow, Inc. 4,011 — Inventus Power, Inc. 3,792 — Dominion Diagnostics, LLC 3,484 11,148 Establishment Labs Holdings Inc. 3,384 5,075 OTG Management, LLC 3,190 3,789 PRGX Global, Inc. 3,127 2,518 Salus Workers' Compensation, LLC 3,102 — ADC Therapeutics SA 3,020 3,020 Relativity ODA LLC 2,762 2,218 LSL Holdco, LLC 2,650 427 Spanx, LLC 2,473 2,226 Impel Pharmaceuticals Inc. 2,458 — SCP Eye Care Services, LLC 2,356 — 112-126 Van Houten Real22 LLC 2,343 — MRI Software LLC 2,261 5,196 Supreme Fitness Group NY Holdings, LLC 2,199 1,527 Tahoe Bidco B.V. 2,162 1,741 Coupa Holdings, LLC 2,075 — Galileo Parent, Inc. 2,061 — Oranje Holdco, Inc. 1,904 — SIO2 Medical Products, Inc. 1,821 — Pluralsight, LLC 1,787 3,532 Evergreen IX Borrower 2023, LLC 1,626 — Berner Food & Beverage, LLC 1,622 1,392 PPW Aero Buyer, Inc. 1,466 — Liquid Environmental Solutions Corporation 1,383 1,115 Acquia Inc. 1,376 1,326 Digital.AI Software Holdings, Inc. 1,078 826 Finastra USA, Inc. 960 — MHE Intermediate Holdings, LLC 821 1,429 Telestream Holdings Corporation 407 528 Coyote Buyer, LLC 400 1,333 ASP-R-PAC Acquisition Co LLC 396 — BAART Programs, Inc. — 8,645 Marinus Pharmaceuticals, Inc. — 5,734 RumbleOn, Inc. — 4,822 Ardonagh Midco 3 PLC — 4,372 Innocoll Pharmaceuticals Limited — 4,195 Mesoblast, Inc. — 3,553 Dialyze Holdings, LLC — 3,431 Thrasio, LLC — 2,578 Apptio, Inc. — 1,338 CorEvitas, LLC — 915 109 Montgomery Owner LLC — 477 GKD Index Partners, LLC — 320 Total $ 232,740 $ 224,239 |
Merger with OSI2 (Tables)
Merger with OSI2 (Tables) | 12 Months Ended |
Sep. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Allocation of Consideration Paid to the Assets Acquired and Liabilities Assumed | The following table summarizes the allocation of the consideration paid to the assets acquired and liabilities assumed as a result of the OSI2 Merger: Common stock issued by the Company (1) $ 334,034 Transaction costs 1,932 Consideration paid $ 335,966 Investments $ 592,809 Cash and cash equivalents 22,317 Other assets 6,679 Total assets acquired $ 621,805 Debt $ 225,000 Other liabilities 60,839 Total liabilities acquired 285,839 Total net assets acquired $ 335,966 __________ (1) Common stock issued by the Company includes $19 of cash paid in lieu of issuing fractional shares. |
Significant Accounting Polici_3
Significant Accounting Policies (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Sep. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | |
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Restricted cash | $ 9,089 | $ 2,836 | $ 2,301 | |
Excise tax | 78 | $ 100 | 0 | $ 0 |
Wells Fargo Bank, N.A. | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Restricted cash | $ 2,800 | |||
Deutsche Bank Trust Company Americas | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Restricted cash | $ 9,100 | |||
Investment Owned, Cost | Five Debt Securities, Non-Accrual Status | Investment Type Concentration Risk | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Concentration risk | 2.40% | |||
Investment Owned, Cost | Non-Accrual Status, Debt Securities | Investment Type Concentration Risk | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Concentration risk | 0% | |||
Investment Owned, Fair Value | Five Debt Securities, Non-Accrual Status | Investment Type Concentration Risk | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Concentration risk | 1.80% | |||
Investment Owned, Fair Value | Non-Accrual Status, Debt Securities | Investment Type Concentration Risk | ||||
Restricted Cash and Cash Equivalents Items [Line Items] | ||||
Concentration risk | 0% |
Portfolio Investments - Narrati
Portfolio Investments - Narrative (Details) | 6 Months Ended | 12 Months Ended | ||||||
Sep. 30, 2021 USD ($) | Sep. 30, 2023 USD ($) member borrower | Sep. 30, 2022 USD ($) borrower | Sep. 30, 2021 USD ($) | Aug. 15, 2023 | May 18, 2021 | Sep. 30, 2020 USD ($) | Feb. 25, 2020 | |
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investment owned, percent of net assets | 190.82% | 200.24% | ||||||
Investments at fair value | $ 2,892,420,000 | $ 2,494,111,000 | ||||||
Number of borrowers | borrower | 143 | 149 | ||||||
Money market funds, percent of net assets | 9.60% | 2.10% | ||||||
Cash, cash equivalents and restricted cash | $ 31,635,000 | $ 145,539,000 | $ 26,364,000 | $ 31,635,000 | $ 39,096,000 | |||
Restricted cash | 2,301,000 | 9,089,000 | 2,836,000 | 2,301,000 | ||||
Net realized gains (losses) | (33,155,000) | 17,179,000 | 26,420,000 | |||||
Net unrealized appreciation (depreciation) | (28,555,000) | (136,248,000) | 114,519,000 | |||||
Credit facilities payable | 710,000,000 | 700,000,000 | ||||||
Assets | 3,217,839,000 | 2,646,313,000 | ||||||
Unfunded commitments | 232,740,000 | 224,239,000 | ||||||
Investment owned, at cost | 3,044,119,000 | 2,617,754,000 | ||||||
SLF JV I, LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | 141,500,000 | 117,000,000 | ||||||
OCSI Glick JV LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 50,000,000 | $ 50,300,000 | ||||||
Investment Owned, At Fair Value | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investment owned, percent of net assets | 190.82% | 200.24% | ||||||
Investments at fair value | $ 2,892,420,000 | $ 2,494,111,000 | ||||||
Investment Owned, At Fair Value | Investment Type Concentration Risk | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Concentration risk | 100% | 100% | ||||||
Senior secured debt | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investment owned, percent of net assets | 165.01% | 173.93% | ||||||
Investments at fair value | $ 2,501,385,000 | $ 2,166,409,000 | ||||||
Investment owned, at cost | $ 2,594,640,000 | $ 2,227,245,000 | ||||||
Senior secured debt | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Concentration risk | 86.47% | 86.86% | ||||||
Subordinated debt securities, including JV debt instruments | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 218,390,000 | $ 203,453,000 | ||||||
Subordinated debt securities, including JV debt instruments | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Concentration risk | 7.50% | 8.10% | ||||||
SLF JV I | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 141,500,000 | $ 117,000,000 | ||||||
SLF JV I Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | 112,700,000 | 96,300,000 | ||||||
Investment owned, at cost | 112,700,000 | 96,300,000 | ||||||
Interest income | $ 12,700,000 | 8,000,000 | 7,400,000 | |||||
Investment, basis spread, variable rate | 7% | |||||||
Investment, interest rate, floor | 1% | |||||||
SLF JV I, LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 28,900,000 | 20,700,000 | ||||||
Investment owned, at cost | 54,800,000 | 49,300,000 | ||||||
Dividend income | 4,200,000 | 2,900,000 | 900,000 | |||||
OCSI Glick JV LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | 50,000,000 | 50,300,000 | ||||||
Investment owned, at cost | 50,300,000 | 50,200,000 | ||||||
Glick JV Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Interest income | 2,400,000 | $ 6,700,000 | 4,700,000 | |||||
Investment, basis spread, variable rate | 4.50% | |||||||
2025 Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Interest rate, percentage | 3.50% | 3.50% | ||||||
2027 Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Interest rate, percentage | 2.70% | 2.70% | ||||||
2029 Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Interest rate, percentage | 7.10% | 7.10% | ||||||
The JVs | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Money market funds, percent of net assets | 9.60% | |||||||
Cash, cash equivalents and restricted cash | $ 145,500,000 | |||||||
Restricted cash | 9,100,000 | |||||||
SLF JV I | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 322,179,000 | $ 359,625,000 | ||||||
Number of borrowers | borrower | 48 | 60 | ||||||
Restricted cash | $ 2,987,000 | $ 5,642,000 | ||||||
Number of board of directors | member | 4 | |||||||
Number of board of directors selected by company | member | 2 | |||||||
Number of board of directors selected by counterparty | member | 2 | |||||||
Number of investment committee members selected by company | member | 1 | |||||||
Number of investment committee members selected by counterparty | member | 1 | |||||||
Investment owned, ownership percentage | 87.50% | 87.50% | ||||||
Credit facilities payable | $ 149,000,000 | $ 230,000,000 | ||||||
Assets | 376,104,000 | 385,227,000 | ||||||
Financial support funded by company and counterparty | 190,500,000 | 165,500,000 | ||||||
Financial support funded by company for investee | 166,700,000 | 144,800,000 | ||||||
Unfunded commitments | 13,100,000 | 35,000,000 | ||||||
Investment owned, at cost | 331,808,000 | 382,673,000 | ||||||
Interest income | 38,984,000 | 24,014,000 | 20,018,000 | |||||
Investments sold | 31,800,000 | 9,700,000 | 48,000,000 | |||||
Proceeds from sale of investments | 30,600,000 | 9,700,000 | 47,200,000 | |||||
Gain (loss) on sale of investments | (200,000) | 500,000 | $ 2,500,000 | |||||
SLF JV I | SLF JV I Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Unfunded commitments | 9,800,000 | 26,200,000 | ||||||
Financial support funded during the period | 16,400,000 | |||||||
SLF JV I | SLF JV I, LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Unfunded commitments | 3,300,000 | 8,800,000 | ||||||
Financial support funded during the period | 5,500,000 | |||||||
SLF JV I | SLF JV I Facility | Revolving Credit Facility | Line of Credit | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Borrowing capacity | 270,000,000 | $ 270,000,000 | ||||||
Credit facilities payable | $ 149,000,000 | |||||||
SLF JV I | SLF JV I Facility | Revolving Credit Facility | Line of Credit | Until November 3, 2023 | Secured Overnight Financing Rate | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Debt instrument, basis spread, variable rate | 2% | |||||||
SLF JV I | Kemper | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investment owned, ownership percentage | 12.50% | 12.50% | ||||||
OCSI Glick JV LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 123,343,000 | $ 133,144,000 | ||||||
Number of borrowers | borrower | 38 | 43 | ||||||
Restricted cash | $ 184,000 | $ 1,788,000 | ||||||
Number of board of directors | member | 4 | |||||||
Number of board of directors selected by company | member | 2 | |||||||
Number of board of directors selected by counterparty | member | 2 | |||||||
Number of investment committee members selected by company | member | 1 | |||||||
Number of investment committee members selected by counterparty | member | 1 | |||||||
Credit facilities payable | $ 53,000,000 | 82,082,000 | ||||||
Assets | 141,167,000 | 146,808,000 | ||||||
Financial support funded by company and counterparty | 84,000,000 | 84,000,000 | ||||||
Financial support funded by company for investee | 73,500,000 | 73,500,000 | ||||||
Investment owned, at cost | 127,788,000 | 140,083,000 | ||||||
Interest income | $ 4,643,000 | 14,043,000 | 9,703,000 | |||||
Investments sold | 6,500,000 | |||||||
Proceeds from sale of investments | 6,300,000 | |||||||
Financial commitment to investee by company and counterparty, aggregate amount | 100,000,000 | 100,000,000 | ||||||
Financial commitment to investee, aggregate amount | 87,500,000 | 87,500,000 | ||||||
Financial commitment to investee by counterparty, aggregate amount | 12,500,000 | $ 12,500,000 | ||||||
OCSI Glick JV LLC | Glick JV LLC | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 50,000,000 | |||||||
Investment owned, ownership percentage | 87.50% | 12.50% | ||||||
Unfunded commitments | $ 1,600,000 | $ 1,600,000 | ||||||
Investment owned, at cost | 50,000,000 | |||||||
Financial commitment to investee, aggregate amount | $ 8,700,000 | 8,700,000 | ||||||
OCSI Glick JV LLC | Glick JV Notes | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Investments at fair value | $ 50,300,000 | |||||||
Investment owned, ownership percentage | 87.50% | 12.50% | ||||||
Unfunded commitments | $ 12,400,000 | $ 12,400,000 | ||||||
Investment owned, at cost | 50,300,000 | |||||||
Financial commitment to investee, aggregate amount | 78,800,000 | $ 78,800,000 | ||||||
OCSI Glick JV LLC | Glick JV Facility | Revolving Credit Facility | Line of Credit | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Borrowing capacity | 80,000,000 | |||||||
Credit facilities payable | $ 53,000,000 | |||||||
OCSI Glick JV LLC | Glick JV Facility | Revolving Credit Facility | Line of Credit | Until November 3, 2023 | Secured Overnight Financing Rate | ||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||
Debt instrument, basis spread, variable rate | 2% |
Portfolio Investments - Composi
Portfolio Investments - Composition of Investments (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 3,044,119 | $ 2,617,754 |
Investments at fair value | 2,892,420 | 2,494,111 |
Debt investments, fair value | $ 2,719,775 | $ 2,369,862 |
% of Debt Portfolio | 100% | 100% |
Investments in debt securities | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 2,654,484 | $ 2,294,392 |
Investments at fair value | 2,557,102 | 2,223,329 |
Investments in equity securities | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | 171,858 | 127,596 |
Investments at fair value | 143,767 | 103,534 |
Debt investments in the JVs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | 162,986 | 146,444 |
Investments at fair value | 162,673 | 146,533 |
Equity investments in the JVs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | 54,791 | 49,322 |
Investments at fair value | 28,878 | 20,715 |
Floating rate debt securities, including the debt investments in the JVs | ||
Schedule of Investments [Line Items] | ||
Debt investments, fair value | $ 2,345,205 | $ 2,049,644 |
% of Debt Portfolio | 86.23% | 86.49% |
Fixed rate debt securities | ||
Schedule of Investments [Line Items] | ||
Debt investments, fair value | $ 374,570 | $ 320,218 |
% of Debt Portfolio | 13.77% | 13.51% |
Portfolio Investments - Schedul
Portfolio Investments - Schedule of Financial Instruments Carried at Fair Value (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Cash equivalents | 83,262 | 5,261 |
Derivative assets | 4,910 | 6,789 |
Total assets at fair value | 2,980,592 | 2,506,161 |
Derivative liability | 47,519 | 41,969 |
Total liabilities at fair value | 47,519 | 41,969 |
Carrying Value | 1,600,731 | 1,301,043 |
Fair Value | 1,588,201 | 1,277,105 |
Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 2,501,385 | 2,166,409 |
Subordinated debt securities, including JV debt instruments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 218,390 | 203,453 |
Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 86,057 | 79,523 |
Equity Securities, Common And Warrants, Including JV Investments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 86,588 | 44,726 |
2027 Notes | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 306,412 | 304,052 |
Fair Value | 301,784 | 294,028 |
Level 1 | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 4,317 | 4,053 |
Cash equivalents | 83,262 | 5,261 |
Derivative assets | 0 | 0 |
Total assets at fair value | 87,579 | 9,314 |
Derivative liability | 0 | 0 |
Total liabilities at fair value | 0 | 0 |
Fair Value | 0 | 0 |
Level 1 | Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Level 1 | Subordinated debt securities, including JV debt instruments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Level 1 | Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Level 1 | Equity Securities, Common And Warrants, Including JV Investments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 4,317 | 4,053 |
Level 1 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 239,313 | 299,868 |
Cash equivalents | 0 | 0 |
Derivative assets | 4,910 | 6,789 |
Total assets at fair value | 244,223 | 306,657 |
Derivative liability | 47,519 | 41,969 |
Total liabilities at fair value | 47,519 | 41,969 |
Fair Value | 878,201 | 577,105 |
Level 2 | Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 208,694 | 255,803 |
Level 2 | Subordinated debt securities, including JV debt instruments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 28,666 | 44,065 |
Level 2 | Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Level 2 | Equity Securities, Common And Warrants, Including JV Investments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 1,953 | 0 |
Level 2 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 301,784 | 294,028 |
Level 3 | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 2,619,912 | 2,169,475 |
Cash equivalents | 0 | 0 |
Derivative assets | 0 | 0 |
Total assets at fair value | 2,619,912 | 2,169,475 |
Derivative liability | 0 | 0 |
Total liabilities at fair value | 0 | 0 |
Fair Value | 710,000 | 700,000 |
Level 3 | Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 2,292,691 | 1,910,606 |
Level 3 | Subordinated debt securities, including JV debt instruments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 189,724 | 159,388 |
Level 3 | Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 86,057 | 79,523 |
Level 3 | Equity Securities, Common And Warrants, Including JV Investments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 51,440 | 19,958 |
Level 3 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Fair Value Measured at Net Asset Value Per Share | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 28,878 | 20,715 |
Cash equivalents | 0 | 0 |
Derivative assets | 0 | 0 |
Total assets at fair value | 28,878 | 20,715 |
Derivative liability | 0 | 0 |
Total liabilities at fair value | 0 | 0 |
Fair Value Measured at Net Asset Value Per Share | Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Fair Value Measured at Net Asset Value Per Share | Subordinated debt securities, including JV debt instruments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Fair Value Measured at Net Asset Value Per Share | Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | 0 | 0 |
Fair Value Measured at Net Asset Value Per Share | Equity Securities, Common And Warrants, Including JV Investments | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 28,878 | $ 20,715 |
Portfolio Investments - Roll-Fo
Portfolio Investments - Roll-Forward in the Changes in Fair Value (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | $ 2,169,475 | $ 2,161,581 |
Purchases (a) | 1,131,251 | 520,510 |
Sales and repayments | (665,727) | (512,535) |
Transfers in | 59,168 | 49,843 |
Transfers out | (40,093) | (22,908) |
Capitalized PIK interest income | 15,644 | 23,168 |
Accretion of OID | 17,771 | 26,482 |
Fair value, ending balance | $ 2,619,912 | $ 2,169,475 |
Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Gain (Loss), Investment and Derivative, Operating, and Foreign Currency Transaction, after Tax | Gain (Loss), Investment and Derivative, Operating, and Foreign Currency Transaction, after Tax |
Net unrealized appreciation (depreciation) relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations | $ (63,990) | $ (72,913) |
Net unrealized appreciation (depreciation) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Net unrealized appreciation (depreciation) | Gain (Loss), Investment and Derivative, Operating, and Foreign Currency Transaction, after Tax |
Total gains or losses included in earnings | $ (48,971) | $ (81,863) |
Net realized gains (losses) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Realized gain (loss) | Gain (Loss), Investment and Derivative, Operating, and Foreign Currency Transaction, after Tax |
Total gains or losses included in earnings | $ (18,606) | $ 5,197 |
Senior secured debt | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | 1,910,606 | 1,878,536 |
Purchases (a) | 1,080,654 | 490,081 |
Sales and repayments | (650,437) | (476,813) |
Transfers in | 19,075 | 49,843 |
Transfers out | (40,093) | (17,070) |
Capitalized PIK interest income | 15,016 | 22,855 |
Accretion of OID | 16,322 | 24,422 |
Fair value, ending balance | 2,292,691 | 1,910,606 |
Net unrealized appreciation (depreciation) relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations | (48,680) | (53,013) |
Senior secured debt | Net unrealized appreciation (depreciation) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | (37,253) | (67,455) |
Senior secured debt | Net realized gains (losses) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | (21,199) | 6,207 |
Subordinated debt | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | 159,388 | 176,317 |
Purchases (a) | 30,690 | 7,960 |
Sales and repayments | (1,396) | (22,525) |
Transfers in | 0 | 0 |
Transfers out | 0 | 0 |
Capitalized PIK interest income | 628 | 313 |
Accretion of OID | 1,449 | 2,060 |
Fair value, ending balance | 189,724 | 159,388 |
Net unrealized appreciation (depreciation) relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations | (1,035) | (4,885) |
Subordinated debt | Net unrealized appreciation (depreciation) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | (1,035) | (4,737) |
Subordinated debt | Net realized gains (losses) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | 0 | 0 |
Preferred equity | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | 79,523 | 63,565 |
Purchases (a) | 14,296 | 19,662 |
Sales and repayments | 0 | (163) |
Transfers in | 0 | 0 |
Transfers out | 0 | 0 |
Capitalized PIK interest income | 0 | 0 |
Accretion of OID | 0 | 0 |
Fair value, ending balance | 86,057 | 79,523 |
Net unrealized appreciation (depreciation) relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations | (7,762) | (3,264) |
Preferred equity | Net unrealized appreciation (depreciation) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | (7,762) | (3,029) |
Preferred equity | Net realized gains (losses) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | 0 | (512) |
Common equity and warrants | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Fair value, beginning balance | 19,958 | 43,163 |
Purchases (a) | 5,611 | 2,807 |
Sales and repayments | (13,894) | (13,034) |
Transfers in | 40,093 | 0 |
Transfers out | 0 | (5,838) |
Capitalized PIK interest income | 0 | 0 |
Accretion of OID | 0 | 0 |
Fair value, ending balance | 51,440 | 19,958 |
Net unrealized appreciation (depreciation) relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations | (6,513) | (11,751) |
Common equity and warrants | Net unrealized appreciation (depreciation) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | (2,921) | (6,642) |
Common equity and warrants | Net realized gains (losses) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Total gains or losses included in earnings | $ 2,593 | $ (498) |
Portfolio Investments - Signifi
Portfolio Investments - Significant Unobservable Inputs for Level 3 Investments (Details) $ in Thousands | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Senior secured debt | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 2,501,385 | 2,166,409 |
Debt investments in the JVs | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 162,673 | 146,533 |
Level 3 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 2,619,912 | 2,169,475 |
Level 3 | Senior secured debt | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 2,292,691 | 1,910,606 |
Level 3 | Senior secured debt | Valuation, Market Approach | Measurement Input, Market Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 1,904,140 | $ 1,599,148 |
Level 3 | Senior secured debt | Valuation, Market Approach | Measurement Input, Market Yield | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.090 | 0.090 |
Level 3 | Senior secured debt | Valuation, Market Approach | Measurement Input, Market Yield | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.320 | 0.300 |
Level 3 | Senior secured debt | Valuation, Market Approach | Measurement Input, Market Yield | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.147 | 0.137 |
Level 3 | Senior secured debt | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 64,802 | $ 14,333 |
Level 3 | Senior secured debt | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 3 | 5 |
Level 3 | Senior secured debt | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 6 | 7 |
Level 3 | Senior secured debt | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 4.6 | 6 |
Level 3 | Senior secured debt | Valuation, Transaction Precedent | Measurement Input, Transaction Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 33,816 | |
Level 3 | Senior secured debt | Valuation, Broker Quotations | Measurement Input, Transaction Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 297,125 | |
Level 3 | Senior secured debt | Valuation, Broker Quotations | Measurement Input, Broker Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 289,933 | |
Level 3 | Subordinated Debt | Valuation, Market Approach | Measurement Input, Market Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 22,881 | $ 12,855 |
Level 3 | Subordinated Debt | Valuation, Market Approach | Measurement Input, Market Yield | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.100 | 0.100 |
Level 3 | Subordinated Debt | Valuation, Market Approach | Measurement Input, Market Yield | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.220 | 0.190 |
Level 3 | Subordinated Debt | Valuation, Market Approach | Measurement Input, Market Yield | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.112 | 0.138 |
Level 3 | Subordinated Debt | Valuation, Broker Quotations | Measurement Input, Broker Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 4,170 | |
Level 3 | Debt investments in the JVs | Valuation, Enterprise Value | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | 162,673 | $ 146,533 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Revenue Multiple | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 32,318 | $ 61,693 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Revenue Multiple | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.4 | 0.4 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Revenue Multiple | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 3.2 | 10.1 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Revenue Multiple | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 0.5 | 4.3 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 103,661 | $ 36,913 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 1.7 | 3 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 15.1 | 20 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, EBITDA Multiple | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 8.8 | 11.4 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Asset Multiple | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 1,097 | $ 3 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Asset Multiple | Minimum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 1 | 0.9 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Asset Multiple | Maximum | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 1.4 | 1.1 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Enterprise Value | Measurement Input, Asset Multiple | Weighted Average | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investment Company, Investment Owned, Measurement Input | 1.4 | 1 |
Level 3 | Equity Securities, Preferred & Common | Valuation, Transaction Precedent | Measurement Input, Transaction Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Investments at fair value | $ 421 | $ 872 |
Portfolio Investments - Sched_2
Portfolio Investments - Schedule of Financial Instruments Disclosed, but Carried at Fair Value (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Schedule of Investments [Line Items] | ||
Carrying Value | $ 1,600,731 | $ 1,301,043 |
Fair Value | 1,588,201 | 1,277,105 |
Syndicated Facility | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 430,000 | 540,000 |
Fair Value | 430,000 | 540,000 |
OSI2 Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 280,000 | |
Fair Value | 280,000 | |
Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 160,000 | |
Fair Value | 160,000 | |
2025 Notes | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 298,241 | 296,991 |
Fair Value | 286,437 | 283,077 |
2027 Notes | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 306,412 | 304,052 |
Fair Value | 301,784 | 294,028 |
2029 Notes | ||
Schedule of Investments [Line Items] | ||
Carrying Value | 286,078 | |
Fair Value | 289,980 | |
Level 1 | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 1 | Syndicated Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 1 | OSI2 Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 1 | Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 1 | 2025 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 1 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 1 | 2029 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 2 | ||
Schedule of Investments [Line Items] | ||
Fair Value | 878,201 | 577,105 |
Level 2 | Syndicated Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 2 | OSI2 Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 2 | Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | |
Level 2 | 2025 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 286,437 | 283,077 |
Level 2 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 301,784 | 294,028 |
Level 2 | 2029 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 289,980 | |
Level 3 | ||
Schedule of Investments [Line Items] | ||
Fair Value | 710,000 | 700,000 |
Level 3 | Syndicated Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 430,000 | 540,000 |
Level 3 | OSI2 Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 280,000 | |
Level 3 | Citibank Facility | ||
Schedule of Investments [Line Items] | ||
Fair Value | 160,000 | |
Level 3 | 2025 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | 0 |
Level 3 | 2027 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | 0 | $ 0 |
Level 3 | 2029 Notes | ||
Schedule of Investments [Line Items] | ||
Fair Value | $ 0 |
Portfolio Investments - Portfol
Portfolio Investments - Portfolio Composition (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 3,044,119 | $ 2,617,754 |
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Investment owned, percent of net assets | 190.82% | 200.24% |
Northeast | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 1,012,955 | $ 747,420 |
Investments at fair value | $ 945,422 | $ 696,368 |
Investment owned, percent of net assets | 62.37% | 55.90% |
International | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 418,595 | $ 301,242 |
Investments at fair value | $ 414,079 | $ 279,646 |
Investment owned, percent of net assets | 27.32% | 22.45% |
West | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 393,390 | $ 358,306 |
Investments at fair value | $ 384,055 | $ 345,251 |
Investment owned, percent of net assets | 25.34% | 27.72% |
Southeast | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 375,247 | $ 356,041 |
Investments at fair value | $ 354,444 | $ 344,567 |
Investment owned, percent of net assets | 23.38% | 27.66% |
Midwest | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 360,506 | $ 373,236 |
Investments at fair value | $ 350,620 | $ 356,934 |
Investment owned, percent of net assets | 23.13% | 28.66% |
South | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 202,374 | $ 168,819 |
Investments at fair value | $ 188,541 | $ 166,230 |
Investment owned, percent of net assets | 12.44% | 13.35% |
Southwest | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 153,318 | $ 221,308 |
Investments at fair value | $ 130,455 | $ 214,984 |
Investment owned, percent of net assets | 8.61% | 17.26% |
Northwest | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 127,734 | $ 91,382 |
Investments at fair value | $ 124,804 | $ 90,131 |
Investment owned, percent of net assets | 8.23% | 7.24% |
Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Investment Owned, At Cost | Geographic Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Investment Owned, At Cost | Geographic Concentration Risk | Northeast | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 33.27% | 28.55% |
Investment Owned, At Cost | Geographic Concentration Risk | International | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 13.75% | 11.51% |
Investment Owned, At Cost | Geographic Concentration Risk | West | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 12.92% | 13.69% |
Investment Owned, At Cost | Geographic Concentration Risk | Southeast | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 12.33% | 13.60% |
Investment Owned, At Cost | Geographic Concentration Risk | Midwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 11.84% | 14.26% |
Investment Owned, At Cost | Geographic Concentration Risk | South | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 6.65% | 6.45% |
Investment Owned, At Cost | Geographic Concentration Risk | Southwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 5.04% | 8.45% |
Investment Owned, At Cost | Geographic Concentration Risk | Northwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.20% | 3.49% |
Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Investment owned, percent of net assets | 190.82% | 200.24% |
Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Investment Owned, At Fair Value | Geographic Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Investment Owned, At Fair Value | Geographic Concentration Risk | Northeast | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 32.69% | 27.93% |
Investment Owned, At Fair Value | Geographic Concentration Risk | International | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 14.32% | 11.21% |
Investment Owned, At Fair Value | Geographic Concentration Risk | West | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 13.28% | 13.84% |
Investment Owned, At Fair Value | Geographic Concentration Risk | Southeast | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 12.25% | 13.82% |
Investment Owned, At Fair Value | Geographic Concentration Risk | Midwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 12.12% | 14.31% |
Investment Owned, At Fair Value | Geographic Concentration Risk | South | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 6.52% | 6.66% |
Investment Owned, At Fair Value | Geographic Concentration Risk | Southwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.51% | 8.62% |
Investment Owned, At Fair Value | Geographic Concentration Risk | Northwest | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.31% | 3.61% |
Senior secured debt | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 2,594,640 | $ 2,227,245 |
Investments at fair value | $ 2,501,385 | $ 2,166,409 |
Investment owned, percent of net assets | 165.01% | 173.93% |
Senior secured debt | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 85.24% | 85.08% |
Senior secured debt | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 86.47% | 86.86% |
Debt investments in the JVs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 162,986 | $ 146,444 |
Investments at fair value | $ 162,673 | $ 146,533 |
Investment owned, percent of net assets | 10.73% | 11.77% |
Debt investments in the JVs | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 5.35% | 5.59% |
Debt investments in the JVs | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 5.62% | 5.88% |
Preferred equity | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 99,597 | $ 85,300 |
Investments at fair value | $ 86,057 | $ 79,523 |
Investment owned, percent of net assets | 5.68% | 6.38% |
Preferred equity | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 3.27% | 3.26% |
Preferred equity | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.98% | 3.19% |
Common equity and warrants | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 72,261 | $ 42,296 |
Investments at fair value | $ 57,710 | $ 24,011 |
Investment owned, percent of net assets | 3.81% | 1.93% |
Common equity and warrants | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.37% | 1.62% |
Common equity and warrants | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2% | 0.96% |
Subordinated debt | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 59,844 | $ 67,147 |
Investments at fair value | $ 55,717 | $ 56,920 |
Investment owned, percent of net assets | 3.68% | 4.57% |
Subordinated debt | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.97% | 2.57% |
Subordinated debt | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.93% | 2.28% |
LLC equity interests of the JVs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 54,791 | $ 49,322 |
Investments at fair value | $ 28,878 | $ 20,715 |
Investment owned, percent of net assets | 1.91% | 1.66% |
LLC equity interests of the JVs | Investment Owned, At Cost | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.80% | 1.88% |
LLC equity interests of the JVs | Investment Owned, At Fair Value | Investment Type Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1% | 0.83% |
Portfolio Investments - Portf_2
Portfolio Investments - Portfolio of Investments by Industry (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 3,044,119 | $ 2,617,754 |
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Investment owned, percent of net assets | 190.82% | 200.24% |
Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 2,892,420 | $ 2,494,111 |
Investment owned, percent of net assets | 190.82% | 200.24% |
Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 100% | 100% |
Application Software | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 468,483 | $ 391,938 |
Application Software | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 15.39% | 14.98% |
Application Software | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 455,719 | $ 384,589 |
Investment owned, percent of net assets | 30.03% | 30.87% |
Application Software | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 15.73% | 15.43% |
Multi-Sector Holdings | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 219,469 | $ 195,766 |
Multi-Sector Holdings | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 7.21% | 7.48% |
Multi-Sector Holdings | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 193,431 | $ 167,248 |
Investment owned, percent of net assets | 12.76% | 13.43% |
Multi-Sector Holdings | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 6.69% | 6.71% |
Data Processing & Outsourced Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 133,410 | $ 120,477 |
Data Processing & Outsourced Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.38% | 4.60% |
Data Processing & Outsourced Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 125,259 | $ 111,335 |
Investment owned, percent of net assets | 8.26% | 8.94% |
Data Processing & Outsourced Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.33% | 4.46% |
Biotechnology | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 126,349 | $ 109,960 |
Biotechnology | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.15% | 4.20% |
Biotechnology | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 125,678 | $ 108,465 |
Investment owned, percent of net assets | 8.29% | 8.71% |
Biotechnology | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 4.35% | 4.35% |
Health Care Technology | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 106,915 | $ 100,084 |
Health Care Technology | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 3.51% | 3.82% |
Health Care Technology | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 95,404 | $ 97,315 |
Investment owned, percent of net assets | 6.29% | 7.81% |
Health Care Technology | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 3.30% | 3.90% |
Industrial Machinery & Supplies & Components | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 99,511 | $ 81,787 |
Industrial Machinery & Supplies & Components | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 3.27% | 3.12% |
Industrial Machinery & Supplies & Components | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 98,352 | $ 81,008 |
Investment owned, percent of net assets | 6.49% | 6.50% |
Industrial Machinery & Supplies & Components | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 3.40% | 3.25% |
Pharmaceuticals | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 84,948 | $ 126,508 |
Pharmaceuticals | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.79% | 4.83% |
Pharmaceuticals | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 80,455 | $ 119,511 |
Investment owned, percent of net assets | 5.31% | 9.59% |
Pharmaceuticals | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.78% | 4.79% |
Real Estate Operating Companies | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 83,754 | $ 47,585 |
Real Estate Operating Companies | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.75% | 1.82% |
Real Estate Operating Companies | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 82,463 | $ 48,062 |
Investment owned, percent of net assets | 5.44% | 3.86% |
Real Estate Operating Companies | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.85% | 1.93% |
Broadline Retail | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 83,290 | $ 67,926 |
Broadline Retail | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.74% | 2.59% |
Broadline Retail | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 69,040 | $ 70,419 |
Investment owned, percent of net assets | 4.55% | 5.65% |
Broadline Retail | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.39% | 2.82% |
Health Care Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 81,560 | $ 58,674 |
Health Care Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.68% | 2.24% |
Health Care Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 66,683 | $ 45,943 |
Investment owned, percent of net assets | 4.40% | 3.69% |
Health Care Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.31% | 1.84% |
Specialized Finance | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 73,035 | $ 80,864 |
Specialized Finance | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.40% | 3.09% |
Specialized Finance | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 69,590 | $ 73,087 |
Investment owned, percent of net assets | 4.59% | 5.87% |
Specialized Finance | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.41% | 2.93% |
Personal Care Products | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 68,146 | $ 53,214 |
Personal Care Products | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.24% | 2.03% |
Personal Care Products | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 59,928 | $ 50,150 |
Investment owned, percent of net assets | 3.95% | 4.03% |
Personal Care Products | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.07% | 2.01% |
Fertilizers & Agricultural Chemicals | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 64,720 | $ 49,301 |
Fertilizers & Agricultural Chemicals | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.13% | 1.88% |
Fertilizers & Agricultural Chemicals | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 63,185 | $ 51,972 |
Investment owned, percent of net assets | 4.17% | 4.17% |
Fertilizers & Agricultural Chemicals | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.18% | 2.08% |
Environmental & Facilities Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 63,064 | $ 20,857 |
Environmental & Facilities Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.07% | 0.80% |
Environmental & Facilities Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 62,413 | $ 20,585 |
Investment owned, percent of net assets | 4.12% | 1.65% |
Environmental & Facilities Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.16% | 0.83% |
Health Care Distributors | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 62,044 | $ 57,112 |
Health Care Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.04% | 2.18% |
Health Care Distributors | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 60,865 | $ 54,662 |
Investment owned, percent of net assets | 4.02% | 4.39% |
Health Care Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.10% | 2.19% |
Diversified Financial Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 61,725 | $ 29,300 |
Diversified Financial Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.03% | 1.12% |
Diversified Financial Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 60,003 | $ 24,326 |
Investment owned, percent of net assets | 3.96% | 1.95% |
Diversified Financial Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.07% | 0.98% |
Internet Services & Infrastructure | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 60,934 | $ 54,095 |
Internet Services & Infrastructure | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2% | 2.07% |
Internet Services & Infrastructure | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 60,579 | $ 53,797 |
Investment owned, percent of net assets | 4% | 4.32% |
Internet Services & Infrastructure | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 2.09% | 2.16% |
Automotive Retail | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 57,596 | $ 59,254 |
Automotive Retail | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.89% | 2.26% |
Automotive Retail | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 55,805 | $ 57,629 |
Investment owned, percent of net assets | 3.68% | 4.63% |
Automotive Retail | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.93% | 2.31% |
Airport Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 55,961 | $ 43,322 |
Airport Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.84% | 1.65% |
Airport Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 54,453 | $ 42,883 |
Investment owned, percent of net assets | 3.59% | 3.44% |
Airport Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.88% | 1.72% |
Metal, Glass & Plastic Containers | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 55,530 | $ 47,704 |
Metal, Glass & Plastic Containers | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.82% | 1.82% |
Metal, Glass & Plastic Containers | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 53,459 | $ 47,599 |
Investment owned, percent of net assets | 3.53% | 3.82% |
Metal, Glass & Plastic Containers | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.85% | 1.91% |
Home Improvement Retail | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 54,236 | $ 45,802 |
Home Improvement Retail | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.78% | 1.75% |
Home Improvement Retail | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 53,168 | $ 45,421 |
Investment owned, percent of net assets | 3.51% | 3.65% |
Home Improvement Retail | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.84% | 1.82% |
Insurance Brokers | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 52,856 | $ 35,628 |
Insurance Brokers | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.74% | 1.36% |
Insurance Brokers | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 53,050 | $ 33,081 |
Investment owned, percent of net assets | 3.50% | 2.66% |
Insurance Brokers | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.83% | 1.33% |
Aerospace & Defense | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 51,797 | $ 61,963 |
Aerospace & Defense | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.70% | 2.37% |
Aerospace & Defense | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 51,862 | $ 61,881 |
Investment owned, percent of net assets | 3.42% | 4.97% |
Aerospace & Defense | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.79% | 2.48% |
Diversified Metals & Mining | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 49,842 | $ 0 |
Diversified Metals & Mining | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.64% | 0% |
Diversified Metals & Mining | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 49,869 | $ 0 |
Investment owned, percent of net assets | 3.29% | 0% |
Diversified Metals & Mining | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.72% | 0% |
Auto Parts & Equipment | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 48,536 | $ 12,474 |
Auto Parts & Equipment | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.59% | 0.48% |
Auto Parts & Equipment | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 49,148 | $ 11,469 |
Investment owned, percent of net assets | 3.24% | 0.92% |
Auto Parts & Equipment | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.70% | 0.46% |
Real Estate Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 44,717 | $ 40,243 |
Real Estate Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.47% | 1.54% |
Real Estate Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 43,886 | $ 39,573 |
Investment owned, percent of net assets | 2.90% | 3.18% |
Real Estate Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.52% | 1.59% |
Soft Drinks & Non-alcoholic Beverages | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 42,628 | $ 0 |
Soft Drinks & Non-alcoholic Beverages | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.40% | 0% |
Soft Drinks & Non-alcoholic Beverages | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 42,391 | $ 0 |
Investment owned, percent of net assets | 2.80% | 0% |
Soft Drinks & Non-alcoholic Beverages | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.47% | 0% |
Other Specialty Retail | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 41,088 | $ 0 |
Other Specialty Retail | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.35% | 0% |
Other Specialty Retail | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 41,115 | $ 0 |
Investment owned, percent of net assets | 2.71% | 0% |
Other Specialty Retail | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.42% | 0% |
Leisure Facilities | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 39,076 | $ 39,768 |
Leisure Facilities | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.28% | 1.52% |
Leisure Facilities | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 36,963 | $ 39,258 |
Investment owned, percent of net assets | 2.44% | 3.15% |
Leisure Facilities | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.28% | 1.57% |
Specialty Chemicals | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 38,640 | $ 37,319 |
Specialty Chemicals | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.27% | 1.43% |
Specialty Chemicals | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 38,615 | $ 33,969 |
Investment owned, percent of net assets | 2.55% | 2.73% |
Specialty Chemicals | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.34% | 1.36% |
Distributors | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 37,666 | $ 25,278 |
Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.24% | 0.97% |
Distributors | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 37,311 | $ 24,494 |
Investment owned, percent of net assets | 2.46% | 1.97% |
Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.29% | 0.98% |
Electrical Components & Equipment | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 32,440 | $ 33,814 |
Electrical Components & Equipment | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.07% | 1.29% |
Electrical Components & Equipment | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 32,573 | $ 32,933 |
Investment owned, percent of net assets | 2.15% | 2.64% |
Electrical Components & Equipment | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 1.13% | 1.32% |
Advertising | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 25,597 | $ 28,245 |
Advertising | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.84% | 1.08% |
Advertising | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 11,955 | $ 26,948 |
Investment owned, percent of net assets | 0.79% | 2.16% |
Advertising | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.41% | 1.08% |
Passenger Airlines | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 24,920 | $ 0 |
Passenger Airlines | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.82% | 0% |
Passenger Airlines | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 27,512 | $ 0 |
Investment owned, percent of net assets | 1.82% | 0% |
Passenger Airlines | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.95% | 0% |
Real Estate Development | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 23,965 | $ 0 |
Real Estate Development | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.79% | 0% |
Real Estate Development | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 23,679 | $ 0 |
Investment owned, percent of net assets | 1.56% | 0% |
Real Estate Development | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.82% | 0% |
Home Furnishings | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 23,859 | $ 19,550 |
Home Furnishings | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.78% | 0.75% |
Home Furnishings | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 19,954 | $ 18,188 |
Investment owned, percent of net assets | 1.32% | 1.46% |
Home Furnishings | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.69% | 0.73% |
Diversified Support Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 23,435 | $ 37,992 |
Diversified Support Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.77% | 1.45% |
Diversified Support Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 23,352 | $ 36,712 |
Investment owned, percent of net assets | 1.54% | 2.95% |
Diversified Support Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.81% | 1.47% |
Gold | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 23,310 | $ 0 |
Gold | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.77% | 0% |
Gold | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 23,328 | $ 0 |
Investment owned, percent of net assets | 1.54% | 0% |
Gold | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.81% | 0% |
Systems Software | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 23,111 | $ 14,890 |
Systems Software | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.76% | 0.57% |
Systems Software | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 21,968 | $ 12,834 |
Investment owned, percent of net assets | 1.45% | 1.03% |
Systems Software | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.76% | 0.51% |
Health Care Equipment | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 22,441 | $ 24,353 |
Health Care Equipment | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.74% | 0.93% |
Health Care Equipment | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 22,436 | $ 24,161 |
Investment owned, percent of net assets | 1.48% | 1.94% |
Health Care Equipment | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.78% | 0.97% |
Construction & Engineering | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 22,102 | $ 60,996 |
Construction & Engineering | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.73% | 2.33% |
Construction & Engineering | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 21,903 | $ 61,188 |
Investment owned, percent of net assets | 1.45% | 4.91% |
Construction & Engineering | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.76% | 2.45% |
Oil & Gas Storage & Transportation | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 22,042 | $ 22,290 |
Oil & Gas Storage & Transportation | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.72% | 0.85% |
Oil & Gas Storage & Transportation | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 16,040 | $ 20,853 |
Investment owned, percent of net assets | 1.06% | 1.67% |
Oil & Gas Storage & Transportation | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.55% | 0.84% |
Interactive Media & Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 19,013 | $ 0 |
Interactive Media & Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.62% | 0% |
Interactive Media & Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 19,199 | $ 0 |
Investment owned, percent of net assets | 1.27% | 0% |
Interactive Media & Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.66% | 0% |
Integrated Telecommunication Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 18,801 | $ 34,628 |
Integrated Telecommunication Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.62% | 1.32% |
Integrated Telecommunication Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 16,492 | $ 32,201 |
Investment owned, percent of net assets | 1.09% | 2.59% |
Integrated Telecommunication Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.57% | 1.29% |
Hotels, Resorts & Cruise Lines | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 17,195 | $ 13,960 |
Hotels, Resorts & Cruise Lines | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.56% | 0.53% |
Hotels, Resorts & Cruise Lines | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 16,991 | $ 13,985 |
Investment owned, percent of net assets | 1.12% | 1.12% |
Hotels, Resorts & Cruise Lines | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.59% | 0.56% |
Consumer Finance | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 16,440 | $ 14,492 |
Consumer Finance | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.54% | 0.55% |
Consumer Finance | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 15,087 | $ 13,284 |
Investment owned, percent of net assets | 1% | 1.07% |
Consumer Finance | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.52% | 0.53% |
Education Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 13,871 | $ 9,080 |
Education Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.46% | 0.35% |
Education Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 13,618 | $ 8,582 |
Investment owned, percent of net assets | 0.90% | 0.69% |
Education Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.47% | 0.34% |
Restaurants | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 12,603 | $ 9,338 |
Restaurants | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.41% | 0.36% |
Restaurants | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 12,464 | $ 8,692 |
Investment owned, percent of net assets | 0.82% | 0.70% |
Restaurants | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.43% | 0.35% |
Movies & Entertainment | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 12,188 | $ 26,161 |
Movies & Entertainment | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.40% | 1% |
Movies & Entertainment | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 11,865 | $ 26,645 |
Investment owned, percent of net assets | 0.78% | 2.14% |
Movies & Entertainment | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.41% | 1.07% |
Health Care Supplies | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 11,646 | $ 36,471 |
Health Care Supplies | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.38% | 1.39% |
Health Care Supplies | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 11,363 | $ 36,577 |
Investment owned, percent of net assets | 0.75% | 2.94% |
Health Care Supplies | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.39% | 1.47% |
Food Distributors | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 5,897 | $ 4,646 |
Food Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.19% | 0.18% |
Food Distributors | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 5,166 | $ 3,367 |
Investment owned, percent of net assets | 0.34% | 0.27% |
Food Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.18% | 0.13% |
Apparel Retail | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,999 | $ 5,268 |
Apparel Retail | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.16% | 0.20% |
Apparel Retail | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 5,002 | $ 5,223 |
Investment owned, percent of net assets | 0.33% | 0.42% |
Apparel Retail | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.17% | 0.21% |
Air Freight & Logistics | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,925 | $ 7,295 |
Air Freight & Logistics | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.16% | 0.28% |
Air Freight & Logistics | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 4,263 | $ 6,405 |
Investment owned, percent of net assets | 0.28% | 0.51% |
Air Freight & Logistics | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.15% | 0.26% |
Integrated Oil & Gas | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,894 | $ 4,866 |
Integrated Oil & Gas | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.16% | 0.19% |
Integrated Oil & Gas | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 4,785 | $ 4,872 |
Investment owned, percent of net assets | 0.32% | 0.39% |
Integrated Oil & Gas | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.17% | 0.20% |
Research & Consulting Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,871 | $ 9,187 |
Research & Consulting Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.16% | 0.35% |
Research & Consulting Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 4,831 | $ 8,573 |
Investment owned, percent of net assets | 0.32% | 0.69% |
Research & Consulting Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.17% | 0.34% |
Cable & Satellite | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,619 | $ 20,716 |
Cable & Satellite | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.15% | 0.79% |
Cable & Satellite | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 4,546 | $ 19,576 |
Investment owned, percent of net assets | 0.30% | 1.57% |
Cable & Satellite | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.16% | 0.78% |
Other Specialized REITs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 4,379 | $ 0 |
Other Specialized REITs | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.14% | 0% |
Other Specialized REITs | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 3,198 | $ 0 |
Investment owned, percent of net assets | 0.21% | 0% |
Other Specialized REITs | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.11% | 0% |
Paper & Plastic Packaging Products & Materials | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 3,254 | $ 0 |
Paper & Plastic Packaging Products & Materials | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.11% | 0% |
Paper & Plastic Packaging Products & Materials | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 3,061 | $ 0 |
Investment owned, percent of net assets | 0.20% | 0% |
Paper & Plastic Packaging Products & Materials | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.11% | 0% |
Housewares & Specialties | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 2,908 | $ 2,293 |
Housewares & Specialties | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.10% | 0.09% |
Housewares & Specialties | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 2,808 | $ 2,456 |
Investment owned, percent of net assets | 0.19% | 0.20% |
Housewares & Specialties | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.10% | 0.10% |
Leisure Products | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 2,055 | $ 0 |
Leisure Products | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.07% | 0% |
Leisure Products | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 2,063 | $ 0 |
Investment owned, percent of net assets | 0.14% | 0% |
Leisure Products | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.07% | 0% |
Technology Distributors | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 813 | $ 3,163 |
Technology Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.03% | 0.12% |
Technology Distributors | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 776 | $ 2,997 |
Investment owned, percent of net assets | 0.05% | 0.24% |
Technology Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0.03% | 0.12% |
Soft Drinks | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 34,272 |
Soft Drinks | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 1.31% |
Soft Drinks | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 33,670 |
Investment owned, percent of net assets | 0% | 2.70% |
Soft Drinks | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 1.35% |
IT Consulting & Other Services | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 11,697 |
IT Consulting & Other Services | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.45% |
IT Consulting & Other Services | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 8,596 |
Investment owned, percent of net assets | 0% | 0.69% |
IT Consulting & Other Services | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.34% |
Oil & Gas Refining & Marketing | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 8,627 |
Oil & Gas Refining & Marketing | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.33% |
Oil & Gas Refining & Marketing | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 8,604 |
Investment owned, percent of net assets | 0% | 0.69% |
Oil & Gas Refining & Marketing | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.34% |
Trading Companies & Distributors | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 7,628 |
Trading Companies & Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.29% |
Trading Companies & Distributors | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 5,567 |
Investment owned, percent of net assets | 0% | 0.45% |
Trading Companies & Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.22% |
Apparel, Accessories & Luxury Goods | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 5,165 |
Apparel, Accessories & Luxury Goods | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.20% |
Specialized REITs | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 4,318 |
Specialized REITs | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.16% |
Specialized REITs | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 3,264 |
Investment owned, percent of net assets | 0% | 0.26% |
Specialized REITs | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.13% |
Diversified Banks | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 3,515 |
Diversified Banks | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.13% |
Diversified Banks | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 3,402 |
Investment owned, percent of net assets | 0% | 0.27% |
Diversified Banks | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.14% |
Construction Materials | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 2,331 |
Construction Materials | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.09% |
Construction Materials | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 1,934 |
Investment owned, percent of net assets | 0% | 0.16% |
Construction Materials | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.08% |
Electronic Components | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 2,092 |
Electronic Components | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.08% |
Electronic Components | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 1,890 |
Investment owned, percent of net assets | 0% | 0.15% |
Electronic Components | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.08% |
Alternative Carriers | ||
Schedule of Investments [Line Items] | ||
Investment owned, at cost | $ 0 | $ 212 |
Alternative Carriers | Investment Owned, At Cost | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.01% |
Alternative Carriers | Investment Owned, At Fair Value | ||
Schedule of Investments [Line Items] | ||
Investments at fair value | $ 0 | $ 201 |
Investment owned, percent of net assets | 0% | 0.02% |
Alternative Carriers | Investment Owned, At Fair Value | Investment Sector Concentration Risk | ||
Schedule of Investments [Line Items] | ||
Concentration risk | 0% | 0.01% |
Portfolio Investments - Summary
Portfolio Investments - Summary of Portfolio (Details) € in Thousands, £ in Thousands, $ in Thousands | Sep. 30, 2023 USD ($) borrower | Sep. 30, 2023 EUR (€) borrower | Sep. 30, 2023 GBP (£) borrower | Sep. 30, 2022 USD ($) borrower | Sep. 30, 2022 EUR (€) borrower | Sep. 30, 2022 GBP (£) borrower | |||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Number of borrowers | borrower | 143 | 143 | 143 | 149 | 149 | 149 | |||||||
Investment, Identifier [Axis]: 107 Fair Street LLC, Real Estate Development, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[5] | $ 1,269 | |||||||||||
Investment, interest rate | [1],[2],[3],[5],[6],[7] | 12.50% | 12.50% | 12.50% | |||||||||
Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC, Real Estate Development, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4] | $ 18,869 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 11% | 11% | 11% | |||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 389 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.80% | 9.80% | 9.80% | |||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 0 | |||||||||||
Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[5] | $ 4,070 | |||||||||||
Investment, interest rate | [1],[2],[3],[5],[6],[7] | 12% | 12% | 12% | |||||||||
Investment, Identifier [Axis]: A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14],[15] | $ 21,434 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14],[15] | 14.25% | 14.25% | 14.25% | |||||||||
Investment, Identifier [Axis]: A.T. Holdings II SÀRL, Biotechnology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,021 | [1],[3],[4],[14] | 33,997 | [8],[9],[10],[16] | |||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 14,685 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.80% | 9.80% | 9.80% | |||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 3,446 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.90% | 11.90% | 11.90% | |||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 17,901 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.15% | 12.15% | 12.15% | |||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 963 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.13% | 12.13% | 12.13% | |||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,589 | [1],[3],[4],[7],[14] | $ 6,589 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 13.04% | [1],[3],[6],[7],[14] | 13.04% | [1],[3],[6],[7],[14] | 13.04% | [1],[3],[6],[7],[14] | 11.20% | [8],[9],[11],[12],[16] | 11.20% | [8],[9],[11],[12],[16] | 11.20% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7],[14] | $ 0 | [8],[9],[10],[11],[13],[16] | |||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | € | [3],[4],[7],[14] | € 5,500 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 8.86% | 8.86% | 8.86% | |||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | € | [8],[9],[10],[11],[16] | € 24,838 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 7.94% | 7.94% | 7.94% | |||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 17,873 | [1],[3],[4],[7] | $ 14,414 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.17% | [1],[3],[6],[7] | 13.17% | [1],[3],[6],[7] | 13.17% | [1],[3],[6],[7] | 10.88% | [8],[9],[11],[12] | 10.88% | [8],[9],[11],[12] | 10.88% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: APX Group Inc., Electrical Components & Equipment, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 2,075 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 5,500 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 2,500 | |||||||||||
Investment, interest rate | [9],[11],[12] | 5.25% | 5.25% | 5.25% | |||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[14] | $ 0 | |||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 3,276 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 11.63% | 11.63% | 11.63% | |||||||||
Investment, Identifier [Axis]: ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14],[15] | $ 12,222 | |||||||||||
Investment, Identifier [Axis]: Access CIG, LLC, Diversified Support Services, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 20,000 | |||||||||||
Investment, interest rate | [9],[11],[12] | 10.82% | 10.82% | 10.82% | |||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 2,033 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 11.55% | 11.55% | 11.55% | |||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 20,234 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.55% | 11.55% | 11.55% | |||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 500 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 9.14% | 9.14% | 9.14% | |||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 15,976 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.12% | 9.12% | 9.12% | |||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,333 | [1],[2],[3],[4],[7] | $ 914 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 12.72% | [1],[2],[3],[6],[7] | 12.72% | [1],[2],[3],[6],[7] | 12.72% | [1],[2],[3],[6],[7] | 10.64% | [8],[9],[11],[12],[13] | 10.64% | [8],[9],[11],[12],[13] | 10.64% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 27,349 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.63% | 9.63% | 9.63% | |||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 6,400 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.34% | 12.34% | 12.34% | |||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 25,332 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.34% | 12.34% | 12.34% | |||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 23,338 | |||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[17] | $ 23,562 | |||||||||||
Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,050 | [3],[4],[14] | $ 4,050 | [9],[10],[16] | |||||||||
Investment, interest rate | 5.50% | [3],[6],[7],[14] | 5.50% | [3],[6],[7],[14] | 5.50% | [3],[6],[7],[14] | 5.50% | [9],[11],[12],[16] | 5.50% | [9],[11],[12],[16] | 5.50% | [9],[11],[12],[16] | |
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 9,057 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 5% | 5% | 5% | |||||||||
Investment, Identifier [Axis]: Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 17,053 | [1],[3],[4],[7] | $ 13,134 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 11.20% | [8],[9],[11],[12] | 11.20% | [8],[9],[11],[12] | 11.20% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[16] | $ 24,043 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 10% | 10% | 10% | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 28,464 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 2,121 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 27,692 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 2,064 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[16] | $ 23,522 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 10% | 10% | 10% | |||||||||
Investment, Identifier [Axis]: American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 17,048 | [1],[3],[4],[7] | $ 14,760 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 14.14% | [1],[3],[6],[7] | 14.14% | [1],[3],[6],[7] | 14.14% | [1],[3],[6],[7] | 12.30% | [8],[9],[11],[12] | 12.30% | [8],[9],[11],[12] | 12.30% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: American Tire Distributors, Inc., Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 19,115 | [3],[4],[7] | $ 9,895 | [9],[10],[11] | |||||||||
Investment, interest rate | 11.81% | [3],[6],[7] | 11.81% | [3],[6],[7] | 11.81% | [3],[6],[7] | 9.03% | [9],[11],[12] | 9.03% | [9],[11],[12] | 9.03% | [9],[11],[12] | |
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[16] | $ 15,220 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 7.92% | 7.92% | 7.92% | |||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 12,500 | [1],[3],[4],[7],[14] | $ 12,500 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 13.54% | [1],[3],[6],[7],[14] | 13.54% | [1],[3],[6],[7],[14] | 13.54% | [1],[3],[6],[7],[14] | 11.67% | [8],[9],[11],[12],[16] | 11.67% | [8],[9],[11],[12],[16] | 11.67% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[7] | $ 3,700 | |||||||||||
Investment, interest rate | [3],[6],[7] | 9.40% | 9.40% | 9.40% | |||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Products, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 2,736 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.42% | 7.42% | 7.42% | |||||||||
Investment, Identifier [Axis]: Ankura Consulting Group LLC, Research & Consulting Services, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 4,346 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.78% | 10.78% | 10.78% | |||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 892 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 8.46% | 8.46% | 8.46% | |||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 34,458 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 8.46% | 8.46% | 8.46% | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | € | € 3,017 | [1],[3],[4],[7],[14] | € 1,964 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 10.95% | [1],[3],[6],[7],[14] | 10.95% | [1],[3],[6],[7],[14] | 10.95% | [1],[3],[6],[7],[14] | 8% | [8],[9],[11],[12],[16] | 8% | [8],[9],[11],[12],[16] | 8% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 10,519 | [1],[3],[4],[7],[14] | £ 18,636 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 11.57% | [1],[3],[6],[7],[14] | 11.57% | [1],[3],[6],[7],[14] | 11.57% | [1],[3],[6],[7],[14] | 9.19% | [8],[9],[11],[12],[16] | 9.19% | [8],[9],[11],[12],[16] | 9.19% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ 4,949 | [1],[3],[4],[7],[14] | $ 10,519 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 12.46% | [1],[3],[6],[7],[14] | 12.46% | [1],[3],[6],[7],[14] | 12.46% | [1],[3],[6],[7],[14] | 8.81% | [8],[9],[11],[12],[16] | 8.81% | [8],[9],[11],[12],[16] | 8.81% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | £ 23,675 | [1],[3],[4],[7],[14] | £ 0 | [8],[9],[10],[11],[13],[16] | |||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.46% | 12.46% | 12.46% | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | [1],[3],[4],[7],[14] | £ 3,649 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 9.70% | 9.70% | 9.70% | |||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 21,852 | ||||||||||||
Investment, interest rate | 12.14% | 12.14% | 12.14% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 21,852 | [1],[2],[4],[7],[18] | $ 24,490 | [8],[10],[11],[13],[19] | |||||||||
Investment, interest rate | 12.14% | [1],[2],[6],[7],[18] | 12.14% | [1],[2],[6],[7],[18] | 12.14% | [1],[2],[6],[7],[18] | 10.42% | [8],[11],[12],[13],[19] | 10.42% | [8],[11],[12],[13],[19] | 10.42% | [8],[11],[12],[13],[19] | |
Investment, Identifier [Axis]: Associated Asphalt Partners, LLC, Construction Materials, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 2,501 | |||||||||||
Investment, interest rate | [9],[11],[12] | 8.06% | 8.06% | 8.06% | |||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,490 | [3],[4],[7] | $ 5,640 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.90% | [3],[6],[7] | 10.90% | [3],[6],[7] | 10.90% | [3],[6],[7] | 8.37% | [9],[11],[12] | 8.37% | [9],[11],[12] | 8.37% | [9],[11],[12] | |
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[16] | $ 13,346 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 11% | 11% | 11% | |||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[16],[20] | $ 8,309 | |||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 29,509 | [1],[3],[4],[7],[14] | $ 22,425 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 11.49% | [1],[3],[6],[7],[14] | 11.49% | [1],[3],[6],[7],[14] | 11.49% | [1],[3],[6],[7],[14] | 8.78% | [8],[9],[11],[12],[16] | 8.78% | [8],[9],[11],[12],[16] | 8.78% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 50,470 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.64% | 12.64% | 12.64% | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 2,546 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 8.12% | 8.12% | 8.12% | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 3,247 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 10.65% | 10.65% | 10.65% | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,261 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 10.65% | 10.65% | 10.65% | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,920 | [1],[3],[4],[7] | $ 7,166 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 14.15% | [1],[3],[6],[7] | 14.15% | [1],[3],[6],[7] | 14.15% | [1],[3],[6],[7] | 11.62% | [8],[9],[11],[12] | 11.62% | [8],[9],[11],[12] | 11.62% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,091 | [1],[3],[4],[7] | $ 4,227 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 14.15% | [1],[3],[6],[7] | 14.15% | [1],[3],[6],[7] | 14.15% | [1],[3],[6],[7] | 11.62% | [8],[9],[11],[12],[13] | 11.62% | [8],[9],[11],[12],[13] | 11.62% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 4,361 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 14.15% | 14.15% | 14.15% | |||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 2,221 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 13% | 13% | 13% | |||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 40,660 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.02% | 11.02% | 11.02% | |||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 1,702 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 10.75% | 10.75% | 10.75% | |||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 33,078 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 8.31% | 8.31% | 8.31% | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[13],[16],[20] | $ 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,757 | [1],[3],[4],[14] | $ 5,322 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 8% | [1],[3],[6],[7],[14] | 8% | [1],[3],[6],[7],[14] | 8% | [1],[3],[6],[7],[14] | 10.25% | [8],[9],[11],[12],[16] | 10.25% | [8],[9],[11],[12],[16] | 10.25% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,316 | [1],[3],[4],[14],[15] | $ 0 | [8],[9],[10],[13],[16] | |||||||||
Investment, interest rate | [8],[9],[11],[12],[13],[16] | 10.25% | 10.25% | 10.25% | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[14] | $ 2,353 | [8],[9],[10],[16],[20] | |||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8% | 8% | 8% | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[14] | $ 0 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 8% | 8% | 8% | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 5 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[14],[15] | $ 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[14],[15] | 0 | |||||||||||
Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 30,625 | [3],[4],[7] | $ 30,625 | [9],[10],[11] | |||||||||
Investment, interest rate | 12.43% | [3],[6],[7] | 12.43% | [3],[6],[7] | 12.43% | [3],[6],[7] | 9.50% | [9],[11],[12] | 9.50% | [9],[11],[12] | 9.50% | [9],[11],[12] | |
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,257 | [1],[3],[4] | $ 3,979 | [8],[9],[10] | |||||||||
Investment, interest rate | 9% | [1],[3],[6],[7] | 9% | [1],[3],[6],[7] | 9% | [1],[3],[6],[7] | 9% | [8],[9],[11],[12] | 9% | [8],[9],[11],[12] | 9% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | ||||||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 0 | ||||||||||||
Investment, Identifier [Axis]: CCO Holdings LLC, Cable & Satellite, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 2,097 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, Identifier [Axis]: CITGO Holding, Inc., Oil & Gas Refining & Marketing, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 7,857 | |||||||||||
Investment, interest rate | [9],[11],[12] | 9.25% | 9.25% | 9.25% | |||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., Oil & Gas Refining & Marketing, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 795 | |||||||||||
Investment, interest rate | [9],[11],[12] | 9.37% | 9.37% | 9.37% | |||||||||
Investment, Identifier [Axis]: CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[17] | $ 727 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 14,294 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.31% | 9.31% | 9.31% | |||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 37 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.07% | 12.07% | 12.07% | |||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 3,031 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.07% | 12.07% | 12.07% | |||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,557 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.07% | 12.07% | 12.07% | |||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,024 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.07% | 12.07% | 12.07% | |||||||||
Investment, Identifier [Axis]: Carvana Co., Automotive Retail, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 6,700 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 5.63% | 5.63% | 5.63% | |||||||||
Investment, Identifier [Axis]: CircusTrix Holdings, LLC, Leisure Facilities, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 10,692 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 8.62% | 8.62% | 8.62% | |||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,632 | [3],[4],[14] | $ 4,311 | [9],[10],[16] | |||||||||
Investment, interest rate | 7.50% | [3],[6],[7],[14] | 7.50% | [3],[6],[7],[14] | 7.50% | [3],[6],[7],[14] | 7.50% | [9],[11],[12],[16] | 7.50% | [9],[11],[12],[16] | 7.50% | [9],[11],[12],[16] | |
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 176 | [3],[4],[14] | $ 1,374 | [9],[10],[16] | |||||||||
Investment, interest rate | 7.75% | [3],[6],[7],[14] | 7.75% | [3],[6],[7],[14] | 7.75% | [3],[6],[7],[14] | 5.13% | [9],[11],[12],[16] | 5.13% | [9],[11],[12],[16] | 5.13% | [9],[11],[12],[16] | |
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 676 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 7.75% | 7.75% | 7.75% | |||||||||
Investment, Identifier [Axis]: Condor Merger Sub Inc., Systems Software, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,420 | [3],[4] | $ 8,420 | [9],[10] | |||||||||
Investment, interest rate | 7.38% | [3],[6],[7] | 7.38% | [3],[6],[7] | 7.38% | [3],[6],[7] | 7.38% | [9],[11],[12] | 7.38% | [9],[11],[12] | 7.38% | [9],[11],[12] | |
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 22,084 | [1],[3],[4],[7],[17] | $ 22,537 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.62% | 11.62% | 11.62% | |||||||||
Investment, Identifier [Axis]: Convergeone Holdings, Inc., IT Consulting & Other Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 11,913 | |||||||||||
Investment, interest rate | [9],[11],[12] | 8.12% | 8.12% | 8.12% | |||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 916 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 11% | 11% | 11% | |||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 13,712 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 8.88% | 8.88% | 8.88% | |||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | 0 | |||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 13,157 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.82% | 12.82% | 12.82% | |||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 14,750 | [3],[4],[7] | $ 10,336 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.39% | [3],[6],[7] | 10.39% | [3],[6],[7] | 10.39% | [3],[6],[7] | 7.65% | [9],[11],[12] | 7.65% | [9],[11],[12] | 7.65% | [9],[11],[12] | |
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 933 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [6],[7] | 11.47% | 11.47% | 11.47% | |||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 18,013 | [1],[3],[4],[7] | $ 18,200 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 11.52% | [1],[3],[6],[7] | 11.52% | [1],[3],[6],[7] | 11.52% | [1],[3],[6],[7] | 8.81% | [8],[9],[11],[12] | 8.81% | [8],[9],[11],[12] | 8.81% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,950 | [3],[4],[7] | $ 5,000 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.12% | [3],[6],[7] | 10.12% | [3],[6],[7] | 10.12% | [3],[6],[7] | 7.33% | [9],[11],[12] | 7.33% | [9],[11],[12] | 7.33% | [9],[11],[12] | |
Investment, Identifier [Axis]: Delivery Hero FinCo LLC, Internet & Direct Marketing Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11],[16] | $ 4,988 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 8.49% | 8.49% | 8.49% | |||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 17,465 | [1],[2],[3],[4],[14] | $ 4,183 | [8],[9],[10],[13],[16] | |||||||||
Investment, interest rate | 3% | [1],[2],[3],[6],[7],[14] | 3% | [1],[2],[3],[6],[7],[14] | 3% | [1],[2],[3],[6],[7],[14] | 10% | [8],[9],[11],[12],[13],[16] | 10% | [8],[9],[11],[12],[13],[16] | 10% | [8],[9],[11],[12],[13],[16] | |
Investment, Identifier [Axis]: Delta Topco, Inc., Systems Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 6,680 | |||||||||||
Investment, interest rate | [9],[11],[12] | 9.34% | 9.34% | 9.34% | |||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 20,757 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 14.54% | 14.54% | 14.54% | |||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 24,396 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 12.67% | 12.67% | 12.67% | |||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4] | $ 654 | |||||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 284 | [1],[2],[3],[4],[7] | $ 251 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 12.49% | [1],[2],[3],[6],[7] | 12.49% | [1],[2],[3],[6],[7] | 12.49% | [1],[2],[3],[6],[7] | 9.41% | [8],[9],[11],[12],[13] | 9.41% | [8],[9],[11],[12],[13] | 9.41% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 12,386 | [1],[3],[4],[7] | $ 9,902 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.49% | [1],[3],[6],[7] | 12.49% | [1],[3],[6],[7] | 12.49% | [1],[3],[6],[7] | 9.91% | [8],[9],[11],[12] | 9.91% | [8],[9],[11],[12] | 9.91% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,641 | [3],[4],[7] | $ 19,242 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.43% | [3],[6],[7] | 10.43% | [3],[6],[7] | 10.43% | [3],[6],[7] | 8.12% | [9],[11],[12] | 8.12% | [9],[11],[12] | 8.12% | [9],[11],[12] | |
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,574 | [1],[4],[7] | $ 0 | [8],[10],[11],[13],[21],[22] | |||||||||
Investment, interest rate | 10.54% | [1],[6],[7] | 10.54% | [1],[6],[7] | 10.54% | [1],[6],[7] | 5% | 5% | 5% | ||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[10],[11],[21],[22] | $ 14,333 | |||||||||||
Investment, interest rate | [8],[11],[12],[21],[22] | 8.68% | 8.68% | 8.68% | |||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[4],[7] | $ 14,068 | |||||||||||
Investment, interest rate | [1],[6],[7] | 10.54% | 10.54% | 10.54% | |||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[4],[7] | $ 2,090 | |||||||||||
Investment, interest rate | [1],[2],[6],[7] | 10.42% | 10.42% | 10.42% | |||||||||
Investment, Identifier [Axis]: Eagleview Technology Corporation, Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,974 | [1],[3],[4],[7] | $ 8,974 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 11.17% | [8],[9],[11],[12] | 11.17% | [8],[9],[11],[12] | 11.17% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,065 | [1],[3],[4],[14] | $ 10,418 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 3% | [1],[3],[6],[7],[14] | 3% | [1],[3],[6],[7],[14] | 3% | [1],[3],[6],[7],[14] | 3% | [8],[9],[11],[12],[16] | 3% | [8],[9],[11],[12],[16] | 3% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,772 | [1],[3],[4],[14] | $ 0 | [8],[9],[10],[13],[16] | |||||||||
Investment, interest rate | 3% | [1],[3],[6],[7],[14] | 3% | [1],[3],[6],[7],[14] | 3% | [1],[3],[6],[7],[14] | 3% | [8],[9],[11],[12],[13],[16] | 3% | [8],[9],[11],[12],[13],[16] | 3% | [8],[9],[11],[12],[13],[16] | |
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[14] | $ 0 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7],[14] | 3% | 3% | 3% | |||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[14] | $ 0 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7],[14] | 3% | 3% | 3% | |||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 14,736 | |||||||||||
Investment, interest rate | [1],[3],[7] | 11.32% | 11.32% | 11.32% | |||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software,First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 31,074 | [3],[4],[7] | $ 25,061 | [9],[10],[11] | |||||||||
Investment, interest rate | 12.18% | [3],[6],[7] | 12.18% | [3],[6],[7] | 12.18% | [3],[6],[7] | 9.87% | [9],[11],[12] | 9.87% | [9],[11],[12] | 9.87% | [9],[11],[12] | |
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 59,950 | [1],[2],[3],[4] | $ 27,850 | [8],[9],[10],[23] | |||||||||
Investment, interest rate | 9% | [1],[2],[3],[6],[7] | 9% | [1],[2],[3],[6],[7] | 9% | [1],[2],[3],[6],[7] | 9% | [8],[9],[11],[12],[23] | 9% | [8],[9],[11],[12],[23] | 9% | [8],[9],[11],[12],[23] | |
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[14] | $ 258 | |||||||||||
Investment, interest rate | [1],[2],[3],[7],[14] | 12.55% | 12.55% | 12.55% | |||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 11,742 | |||||||||||
Investment, interest rate | [1],[3],[7],[14] | 12.55% | 12.55% | 12.55% | |||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, interest rate | 9% | 9% | 9% | ||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,918 | [1],[3],[4],[14] | $ 9,466 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 11% | [1],[3],[6],[7],[14] | 11% | [1],[3],[6],[7],[14] | 11% | [1],[3],[6],[7],[14] | 11% | [8],[9],[11],[12],[16] | 11% | [8],[9],[11],[12],[16] | 11% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,881 | [3],[4],[14] | $ 4,881 | [9],[10],[16] | |||||||||
Investment, interest rate | 6% | [3],[6],[7],[14] | 6% | [3],[6],[7],[14] | 6% | [3],[6],[7],[14] | 6% | [9],[11],[12],[16] | 6% | [9],[11],[12],[16] | 6% | [9],[11],[12],[16] | |
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 1,280 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 10.60% | 10.60% | 10.60% | |||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 25,128 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.67% | 10.67% | 10.67% | |||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 1,638 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 12.64% | 12.64% | 12.64% | |||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 23,774 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.64% | 12.64% | 12.64% | |||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 2,456 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 10.57% | 10.57% | 10.57% | |||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 5,572 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.37% | 7.37% | 7.37% | |||||||||
Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | € | [3],[4],[7],[14] | € 1,000 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 6.56% | 6.56% | 6.56% | |||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 17,444 | [1],[3],[4],[7] | $ 14,311 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.42% | [1],[3],[6],[7] | 13.42% | [1],[3],[6],[7] | 13.42% | [1],[3],[6],[7] | 11.04% | [8],[9],[11],[12] | 11.04% | [8],[9],[11],[12] | 11.04% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., Education Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 14,347 | [3],[4],[7] | $ 9,392 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.67% | [3],[6],[7] | 10.67% | [3],[6],[7] | 10.67% | [3],[6],[7] | 8.38% | [9],[11],[12] | 8.38% | [9],[11],[12] | 8.38% | [9],[11],[12] | |
Investment, Identifier [Axis]: Harrow , Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 7,448 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 11.89% | 11.89% | 11.89% | |||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[14] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 1,432 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.04% | 12.04% | 12.04% | |||||||||
Investment, Identifier [Axis]: Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[14] | $ 6,808 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 4.46% | 4.46% | 4.46% | |||||||||
Investment, Identifier [Axis]: IAMGOLD Corporation, Gold, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 23,975 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 13.62% | 13.62% | 13.62% | |||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 44,550 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.40% | 11.40% | 11.40% | |||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Products, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 35,625 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.42% | 9.42% | 9.42% | |||||||||
Investment, Identifier [Axis]: IPC Corp., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 40,587 | [1],[3],[4],[7] | $ 34,357 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 11.92% | [1],[3],[6],[7] | 11.92% | [1],[3],[6],[7] | 11.92% | [1],[3],[6],[7] | 9.44% | [8],[9],[11],[12] | 9.44% | [8],[9],[11],[12] | 9.44% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 8,569 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.42% | 9.42% | 9.42% | |||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 22,619 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.67% | 11.67% | 11.67% | |||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[20] | $ 13,083 | |||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 12,161 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 12.45% | 12.45% | 12.45% | |||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 688 | |||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | 26,613 | |||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | 787 | |||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,179 | [1],[4],[7],[14] | $ 6,817 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 11.14% | [1],[6],[7],[14] | 11.14% | [1],[6],[7],[14] | 11.14% | [1],[6],[7],[14] | 11% | [8],[9],[11],[12],[16] | 11% | [8],[9],[11],[12],[16] | 11% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[13],[16] | $ 0 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13],[16] | 11% | 11% | 11% | |||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 33,414 | [1],[3],[4],[7] | $ 18,660 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.93% | [1],[3],[6],[7] | 12.93% | [1],[3],[6],[7] | 12.93% | [1],[3],[6],[7] | 8.55% | [8],[9],[11],[12] | 8.55% | [8],[9],[11],[12] | 8.55% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 13,674 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 12.17% | 12.17% | 12.17% | |||||||||
Investment, Identifier [Axis]: Ivanti Software, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 13,939 | [3],[4],[7] | $ 10,247 | [9],[10],[11] | |||||||||
Investment, interest rate | 12.78% | [3],[6],[7] | 12.78% | [3],[6],[7] | 12.78% | [3],[6],[7] | 10.33% | [9],[11],[12] | 10.33% | [9],[11],[12] | 10.33% | [9],[11],[12] | |
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 36,234 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.62% | 10.62% | 10.62% | |||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 528 | |||||||||||
Investment, interest rate | [9],[11],[12] | 11.12% | 11.12% | 11.12% | |||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 329 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 10.17% | 10.17% | 10.17% | |||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 272 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 11.84% | 11.84% | 11.84% | |||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 13,623 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.17% | 10.17% | 10.17% | |||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 16,752 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.84% | 11.84% | 11.84% | |||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 38,015 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.80% | 11.80% | 11.80% | |||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 1,710 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 9.12% | 9.12% | 9.12% | |||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 19,236 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.12% | 9.12% | 9.12% | |||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 2,736 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.42% | 11.42% | 11.42% | |||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 23,494 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.42% | 11.42% | 11.42% | |||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., Electronic Components, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 2,140 | |||||||||||
Investment, interest rate | [9],[11],[12] | 9.87% | 9.87% | 9.87% | |||||||||
Investment, Identifier [Axis]: LaserShip, Inc., Air Freight & Logistics, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 2,394 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.38% | 10.38% | 10.38% | |||||||||
Investment, Identifier [Axis]: Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[7],[14] | $ 26,422 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 14.95% | 14.95% | 14.95% | |||||||||
Investment, Identifier [Axis]: Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 45,243 | [1],[3],[4],[7] | $ 41,008 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 10.65% | [1],[3],[6],[7] | 10.65% | [1],[3],[6],[7] | 10.65% | [1],[3],[6],[7] | 8.67% | [8],[9],[11],[12] | 8.67% | [8],[9],[11],[12] | 8.67% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4] | ||||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,403 | [1],[3],[4],[7] | $ 4,357 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.99% | [1],[3],[6],[7] | 13.99% | [1],[3],[6],[7] | 13.99% | [1],[3],[6],[7] | 11.38% | [8],[9],[11],[12] | 11.38% | [8],[9],[11],[12] | 11.38% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,939 | [1],[2],[3],[4],[7] | $ 2,370 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 13.99% | [1],[2],[3],[6],[7] | 13.99% | [1],[2],[3],[6],[7] | 13.99% | [1],[2],[3],[6],[7] | 11.38% | [8],[9],[11],[12],[13] | 11.38% | [8],[9],[11],[12],[13] | 11.38% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 964 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 11.42% | 11.42% | 11.42% | |||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 18,390 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.50% | 9.50% | 9.50% | |||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 20,125 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.52% | 11.52% | 11.52% | |||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 2,631 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.52% | 11.52% | 11.52% | |||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 1,466 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 12.83% | 12.83% | 12.83% | |||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 40,538 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.89% | 12.89% | 12.89% | |||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 13,973 | [1],[3],[4],[7] | $ 29,565 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 10.99% | [1],[3],[6],[7] | 10.99% | [1],[3],[6],[7] | 10.99% | [1],[3],[6],[7] | 9.17% | [8],[9],[11],[12] | 9.17% | [8],[9],[11],[12] | 9.17% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 21,328 | [1],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [1],[3],[6],[7] | 10.99% | 10.99% | 10.99% | |||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,568 | [1],[3],[4],[14] | $ 17,203 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [8],[9],[11],[12],[16] | 11.50% | [8],[9],[11],[12],[16] | 11.50% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,284 | [1],[3],[4],[14] | $ 0 | [8],[9],[10],[13],[16] | |||||||||
Investment, interest rate | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [1],[3],[6],[7],[14] | 11.50% | [8],[9],[11],[12],[13],[16] | 11.50% | [8],[9],[11],[12],[13],[16] | 11.50% | [8],[9],[11],[12],[13],[16] | |
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 8,568 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 11.50% | 11.50% | 11.50% | |||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,106 | [1],[3],[4],[14] | $ 7,215 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 8% | [1],[3],[6],[7],[14] | 8% | [1],[3],[6],[7],[14] | 8% | [1],[3],[6],[7],[14] | 8% | [8],[9],[11],[12],[16] | 8% | [8],[9],[11],[12],[16] | 8% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[13],[16] | $ 0 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13],[16] | 8% | 8% | 8% | |||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 45,665 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.64% | 10.64% | 10.64% | |||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 5,248 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.52% | 12.52% | 12.52% | |||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 46,687 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.52% | 12.52% | 12.52% | |||||||||
Investment, Identifier [Axis]: Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 54,559 | [1],[3],[4],[7] | $ 46,499 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.51% | [1],[3],[6],[7] | 12.51% | [1],[3],[6],[7] | 12.51% | [1],[3],[6],[7] | 9.89% | [8],[9],[11],[12] | 9.89% | [8],[9],[11],[12] | 9.89% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: NFP Corp., Diversified Financial Services, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4] | $ 10,191 | |||||||||||
Investment, interest rate | [3],[6],[7] | 6.88% | 6.88% | 6.88% | |||||||||
Investment, Identifier [Axis]: NFP Corp., Other Diversified Financial Services, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 10,191 | |||||||||||
Investment, interest rate | [9],[11],[12] | 6.88% | 6.88% | 6.88% | |||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 73,362 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.29% | 12.29% | 12.29% | |||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[16] | $ 58,713 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 9.99% | 9.99% | 9.99% | |||||||||
Investment, Identifier [Axis]: Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 30,339 | [1],[3],[4],[7] | $ 22,560 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.99% | [1],[3],[6],[7] | 13.99% | [1],[3],[6],[7] | 13.99% | [1],[3],[6],[7] | 12.17% | [8],[9],[11],[12] | 12.17% | [8],[9],[11],[12] | 12.17% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 64,606 | [1],[3],[4],[7] | $ 50,459 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 14.89% | [1],[3],[6],[7] | 14.89% | [1],[3],[6],[7] | 14.89% | [1],[3],[6],[7] | 14.17% | [8],[9],[11],[12] | 14.17% | [8],[9],[11],[12] | 14.17% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 58,349 | [1],[2],[4],[7],[14],[24] | $ 59,662 | [8],[10],[11],[13],[16],[21],[22],[25] | |||||||||
Investment, interest rate | 9.76% | [1],[2],[6],[7],[14],[24] | 9.76% | [1],[2],[6],[7],[14],[24] | 9.76% | [1],[2],[6],[7],[14],[24] | 6.30% | [8],[11],[12],[13],[16],[21],[22],[25] | 6.30% | [8],[11],[12],[13],[16],[21],[22],[25] | 6.30% | [8],[11],[12],[13],[16],[21],[22],[25] | |
Investment, Identifier [Axis]: OEConnection LLC, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 3,323 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.12% | 7.12% | 7.12% | |||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,323 | [1],[3],[4],[7] | $ 7,519 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.49% | [1],[3],[6],[7] | 12.49% | [1],[3],[6],[7] | 12.49% | [1],[3],[6],[7] | 10.05% | [8],[9],[11],[12] | 10.05% | [8],[9],[11],[12] | 10.05% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 25,712 | [1],[3],[4],[7] | $ 21,557 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | [8],[9],[11],[12] | 5.08% | 5.08% | 5.08% | |||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | 1,210 | |||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | 0 | |||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 15,231 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 13.12% | 13.12% | 13.12% | |||||||||
Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,519 | [3],[4] | $ 7,776 | [9],[10] | |||||||||
Investment, interest rate | 7.75% | [3],[6],[7] | 7.75% | [3],[6],[7] | 7.75% | [3],[6],[7] | 7.75% | [9],[11],[12] | 7.75% | [9],[11],[12] | 7.75% | [9],[11],[12] | |
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 0 | |||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 26,154 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.28% | 9.28% | 9.28% | |||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11],[13] | $ 2,228 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[13] | 9.25% | 9.25% | 9.25% | |||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 10,895 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.32% | 12.32% | 12.32% | |||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 38,414 | [1],[3],[4],[7] | $ 33,775 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.01% | [1],[3],[6],[7] | 12.01% | [1],[3],[6],[7] | 12.01% | [1],[3],[6],[7] | 10.42% | [8],[9],[11],[12] | 10.42% | [8],[9],[11],[12] | 10.42% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,676 | [3],[4],[7] | $ 9,850 | [9],[10],[11] | |||||||||
Investment, interest rate | 10.42% | [3],[6],[7] | 10.42% | [3],[6],[7] | 10.42% | [3],[6],[7] | 8.13% | [9],[11],[12] | 8.13% | [9],[11],[12] | 8.13% | [9],[11],[12] | |
Investment, Identifier [Axis]: Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 22,375 | [1],[3],[4],[7] | $ 17,976 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 11.57% | [1],[3],[6],[7] | 11.57% | [1],[3],[6],[7] | 11.57% | [1],[3],[6],[7] | 8.88% | [8],[9],[11],[12] | 8.88% | [8],[9],[11],[12] | 8.88% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Planview Parent, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 36,499 | [1],[3],[4],[7] | $ 28,627 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.74% | [1],[3],[6],[7] | 12.74% | [1],[3],[6],[7] | 12.74% | [1],[3],[6],[7] | 10.92% | [8],[9],[11],[12] | 10.92% | [8],[9],[11],[12] | 10.92% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,003 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 13.45% | 13.45% | 13.45% | |||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 67,244 | [1],[3],[4],[7] | $ 48,689 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.45% | [1],[3],[6],[7] | 13.45% | [1],[3],[6],[7] | 13.45% | [1],[3],[6],[7] | 10.68% | [8],[9],[11],[12] | 10.68% | [8],[9],[11],[12] | 10.68% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 24,503 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.78% | 12.78% | 12.78% | |||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 2,819 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.78% | 12.78% | 12.78% | |||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 23,275 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.01% | 10.01% | 10.01% | |||||||||
Investment, Identifier [Axis]: Project Boost Purchaser, LLC, Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 5,250 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.12% | 11.12% | 11.12% | |||||||||
Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | £ 4,626 | [1],[3],[4],[7],[14] | £ 3,501 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 11.21% | [1],[3],[6],[7],[14] | 11.21% | [1],[3],[6],[7],[14] | 11.21% | [1],[3],[6],[7],[14] | 8.39% | [8],[9],[11],[12],[16] | 8.39% | [8],[9],[11],[12],[16] | 8.39% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: RP Escrow Issuer LLC, Health Care Distributors, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 1,325 | |||||||||||
Investment, interest rate | [9],[11],[12] | 5.25% | 5.25% | 5.25% | |||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 3,400 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.33% | 7.33% | 7.33% | |||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 4,755 | |||||||||||
Investment, interest rate | [9],[11],[12] | 9.25% | 9.25% | 9.25% | |||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 32,329 | [1],[3],[4],[7] | 24,692 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.92% | 11.92% | 11.92% | |||||||||
Investment, Identifier [Axis]: Renaissance Holding Corp., Diversified Banks, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 3,542 | |||||||||||
Investment, interest rate | [9],[11],[12] | 10.12% | 10.12% | 10.12% | |||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 36,707 | [1],[3],[4],[7],[14] | $ 37,656 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 13.90% | [1],[3],[6],[7],[14] | 13.90% | [1],[3],[6],[7],[14] | 13.90% | [1],[3],[6],[7],[14] | 11.92% | [8],[9],[11],[12],[16] | 11.92% | [8],[9],[11],[12],[16] | 11.92% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 13,504 | [1],[3],[4],[7],[14] | $ 11,393 | [8],[9],[10],[11],[13],[16] | |||||||||
Investment, interest rate | 13.90% | [1],[3],[6],[7],[14] | 13.90% | [1],[3],[6],[7],[14] | 13.90% | [1],[3],[6],[7],[14] | 11.92% | [8],[9],[11],[12],[13],[16] | 11.92% | [8],[9],[11],[12],[13],[16] | 11.92% | [8],[9],[11],[12],[13],[16] | |
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 8,010 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 14.18% | 14.18% | 14.18% | |||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc, Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 15,874 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[4] | 15,874 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[4] | 1,359 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 1,359 | ||||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 4,452 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 10.38% | 10.38% | 10.38% | |||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 12,034 | [1],[3],[4],[7] | $ 9,109 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.63% | [1],[3],[6],[7] | 13.63% | [1],[3],[6],[7] | 13.63% | [1],[3],[6],[7] | 10.74% | [8],[9],[11],[12] | 10.74% | [8],[9],[11],[12] | 10.74% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 1,500 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.63% | 7.63% | 7.63% | |||||||||
Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 25,527 | [1],[3],[4],[7] | $ 20,766 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.40% | [1],[3],[6],[7] | 12.40% | [1],[3],[6],[7] | 12.40% | [1],[3],[6],[7] | 10.42% | [8],[9],[11],[12] | 10.42% | [8],[9],[11],[12] | 10.42% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Sabert Corporation, Metal & Glass Containers, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 1,691 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.63% | 7.63% | 7.63% | |||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 25,558 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 15.24% | 15.24% | 15.24% | |||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 112,656 | [1],[2],[4],[7],[14],[24] | $ 96,250 | [8],[10],[11],[13],[16],[21],[22],[25] | |||||||||
Investment, interest rate | 12.26% | [1],[2],[6],[7],[14],[24] | 12.26% | [1],[2],[6],[7],[14],[24] | 12.26% | [1],[2],[6],[7],[14],[24] | 8.80% | [8],[11],[12],[13],[16],[21],[22],[25] | 8.80% | [8],[11],[12],[13],[16],[21],[22],[25] | 8.80% | [8],[11],[12],[13],[16],[21],[22],[25] | |
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 7,191 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.88% | 12.88% | 12.88% | |||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 2,697 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.88% | 12.88% | 12.88% | |||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[14] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[14] | 0 | |||||||||||
Investment, Identifier [Axis]: SiO2 Medical Products, Inc., Metal & Glass Containers, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10] | $ 46,121 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, Identifier [Axis]: SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 821 | [1],[3],[4],[7] | $ 3,195 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 13.04% | [1],[3],[6],[7] | 10.48% | [8],[9],[11],[12] | 10.48% | [8],[9],[11],[12] | 10.48% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 618 | [1],[2],[3],[4],[7] | $ 866 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 10.42% | [1],[2],[3],[6],[7] | 10.42% | [1],[2],[3],[6],[7] | 10.42% | [1],[2],[3],[6],[7] | 8.03% | [8],[9],[11],[12],[13] | 8.03% | [8],[9],[11],[12],[13] | 8.03% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,488 | [1],[3],[4],[7] | $ 4,534 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 10.67% | [1],[3],[6],[7] | 10.67% | [1],[3],[6],[7] | 10.67% | [1],[3],[6],[7] | 8.30% | [8],[9],[11],[12] | 8.30% | [8],[9],[11],[12] | 8.30% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | € | [1],[3],[4],[7],[14] | € 23,731 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.32% | 12.32% | 12.32% | |||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Other Diversified Financial Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | [8],[9],[10],[11],[16] | £ 16,911 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 10% | 10% | 10% | |||||||||
Investment, Identifier [Axis]: Sunland Asphalt & Construction, LLC, Construction & Engineering, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 42,618 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 8.88% | 8.88% | 8.88% | |||||||||
Investment, Identifier [Axis]: Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 49,520 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 13.32% | 13.32% | 13.32% | |||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 3,466 | |||||||||||
Investment, interest rate | [9],[11],[12] | 7.42% | 7.42% | 7.42% | |||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[26] | $ 1,552 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[26] | 12.44% | 12.44% | 12.44% | |||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[26] | $ 32,104 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[26] | 12.51% | 12.51% | 12.51% | |||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7],[26] | $ 2,749 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[26] | 12.51% | 12.51% | 12.51% | |||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7],[26] | $ 1,099 | |||||||||||
Investment, interest rate | [1],[2],[3],[6],[7],[26] | 12.51% | 12.51% | 12.51% | |||||||||
Investment, Identifier [Axis]: Swordfish Merger Sub LLC, Auto Parts & Equipment, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 12,500 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 9.81% | 9.81% | 9.81% | |||||||||
Investment, Identifier [Axis]: TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,984 | [3],[4],[5],[14] | $ 4,984 | [8],[9],[10],[16] | |||||||||
Investment, interest rate | 11.50% | [3],[5],[6],[7],[14] | 11.50% | [3],[5],[6],[7],[14] | 11.50% | [3],[5],[6],[7],[14] | 11.50% | [8],[9],[11],[12],[16] | 11.50% | [8],[9],[11],[12],[16] | 11.50% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[14] | $ 50,419 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 13% | 13% | 13% | |||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[11] | $ 12,032 | |||||||||||
Investment, interest rate | [9],[11],[12] | 8.15% | 8.15% | 8.15% | |||||||||
Investment, Identifier [Axis]: Tacala, LLC, Restaurants, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 12,843 | [3],[4],[7] | $ 9,448 | [9],[10],[11] | |||||||||
Investment, interest rate | 13.43% | [3],[6],[7] | 13.43% | [3],[6],[7] | 13.43% | [3],[6],[7] | 10.62% | [9],[11],[12] | 10.62% | [9],[11],[12] | 10.62% | [9],[11],[12] | |
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | [1],[2],[3],[4],[7],[14] | $ 0 | [8],[9],[10],[11],[13],[16] | |||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 28,826 | [1],[3],[4],[7],[14] | $ 23,215 | [8],[9],[10],[11],[16] | |||||||||
Investment, interest rate | 11.42% | [1],[3],[6],[7],[14] | 11.42% | [1],[3],[6],[7],[14] | 11.42% | [1],[3],[6],[7],[14] | 8.68% | [8],[9],[11],[12],[16] | 8.68% | [8],[9],[11],[12],[16] | 8.68% | [8],[9],[11],[12],[16] | |
Investment, Identifier [Axis]: Tecta America Corp., Construction & Engineering, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 5,203 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.62% | 11.62% | 11.62% | |||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,861 | [1],[2],[3],[4],[7] | $ 1,231 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | 15.17% | [1],[2],[3],[6],[7] | 15.17% | [1],[2],[3],[6],[7] | 15.17% | [1],[2],[3],[6],[7] | 12.20% | [8],[9],[11],[12],[13] | 12.20% | [8],[9],[11],[12],[13] | 12.20% | [8],[9],[11],[12],[13] | |
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 23,423 | [1],[3],[4],[7] | $ 18,323 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 15.26% | [1],[3],[6],[7] | 15.26% | [1],[3],[6],[7] | 15.26% | [1],[3],[6],[7] | 12.11% | [8],[9],[11],[12] | 12.11% | [8],[9],[11],[12] | 12.11% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Ten-X LLC, Interactive Media & Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 19,947 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.32% | 11.32% | 11.32% | |||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Common Stock | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10] | ||||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 29,663 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 13.17% | 13.17% | 13.17% | |||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 19,163 | [1],[3],[4],[7],[17] | $ 15,674 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.44% | 10.44% | 10.44% | |||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | 4,641 | [1],[3],[4],[7],[17] | $ 3,789 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | [8],[9],[11],[12] | 16.17% | 16.17% | 16.17% | |||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | 46,832 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 37,494 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.17% | 11.17% | 11.17% | |||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,671 | [1],[3],[4],[7] | $ 6,016 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 11.42% | [1],[3],[6],[7] | 11.42% | [1],[3],[6],[7] | 11.42% | [1],[3],[6],[7] | 9.12% | [8],[9],[11],[12] | 9.12% | [8],[9],[11],[12] | 9.12% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[7],[14] | $ 1,000 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 13.06% | 13.06% | 13.06% | |||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[14] | $ 4,500 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [3],[4],[14] | $ 300 | |||||||||||
Investment, interest rate | [3],[6],[7],[14] | 4.75% | 4.75% | 4.75% | |||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 4,500 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10],[16] | $ 300 | |||||||||||
Investment, interest rate | [9],[11],[12],[16] | 4.75% | 4.75% | 4.75% | |||||||||
Investment, Identifier [Axis]: Virgin Pulse, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,140 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.68% | 12.68% | 12.68% | |||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,792 | [3],[4],[7] | $ 7,564 | [9],[10],[11] | |||||||||
Investment, interest rate | 9.27% | [3],[6],[7] | 9.27% | [3],[6],[7] | 9.27% | [3],[6],[7] | 6.56% | [9],[11],[12] | 6.56% | [9],[11],[12] | 6.56% | [9],[11],[12] | |
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 6,000 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.56% | 10.56% | 10.56% | |||||||||
Investment, Identifier [Axis]: WPEngine, Inc., Application Software, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 40,536 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 10.19% | 10.19% | 10.19% | |||||||||
Investment, Identifier [Axis]: WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,000 | [1],[3],[4],[7] | $ 5,000 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.65% | [1],[3],[6],[7] | 12.65% | [1],[3],[6],[7] | 12.65% | [1],[3],[6],[7] | 10.67% | [8],[9],[11],[12] | 10.67% | [8],[9],[11],[12] | 10.67% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 2,316 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 19.64% | 19.64% | 19.64% | |||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,565 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 21.68% | 21.68% | 21.68% | |||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 1,323 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 21.68% | 21.68% | 21.68% | |||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,983 | [3],[4],[7] | $ 25,499 | [9],[10],[11] | |||||||||
Investment, interest rate | 11.67% | [3],[6],[7] | 11.67% | [3],[6],[7] | 11.67% | [3],[6],[7] | 9.37% | [9],[11],[12] | 9.37% | [9],[11],[12] | 9.37% | [9],[11],[12] | |
Investment, Identifier [Axis]: Zayo Group Holdings, Inc., Alternative Carriers, Fixed Rate Bond | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [9],[10] | $ 250 | |||||||||||
Investment, interest rate | [9],[11],[12] | 4% | 4% | 4% | |||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [8],[9],[10],[11] | $ 19,578 | |||||||||||
Investment, interest rate | [8],[9],[11],[12] | 11.92% | 11.92% | 11.92% | |||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals,First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 19,578 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 9.32% | 9.32% | 9.32% | |||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | [8],[9],[10],[11],[16] | £ 18,000 | |||||||||||
Investment, interest rate | [8],[9],[11],[12],[16] | 9.72% | 9.72% | 9.72% | |||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited,Specialized Finance, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | £ | [1],[3],[4],[7],[14] | £ 20,000 | |||||||||||
Investment, interest rate | [1],[3],[6],[7],[14] | 12.72% | 12.72% | 12.72% | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 377 | [1],[2],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [1],[2],[3],[6],[7] | 12.14% | 12.14% | 12.14% | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 24,427 | [1],[3],[4],[7] | $ 19,203 | [8],[9],[10],[11] | |||||||||
Investment, interest rate | 12.63% | [1],[3],[6],[7] | 12.63% | [1],[3],[6],[7] | 12.63% | [1],[3],[6],[7] | 9.49% | [8],[9],[11],[12] | 9.49% | [8],[9],[11],[12] | 9.49% | [8],[9],[11],[12] | |
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,636 | [1],[3],[4],[7] | $ 0 | [8],[9],[10],[11],[13] | |||||||||
Investment, interest rate | [1],[3],[6],[7] | 12.63% | 12.63% | 12.63% | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[3],[4],[7] | $ 5,212 | |||||||||||
Investment, interest rate | [1],[3],[6],[7] | 11.75% | 11.75% | 11.75% | |||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | [1],[2],[3],[4],[7] | 0 | |||||||||||
SLF JV I | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 332,637 | $ 383,194 | |||||||||||
Number of borrowers | borrower | 48 | 48 | 48 | 60 | 60 | 60 | |||||||
SLF JV I | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,518 | ||||||||||||
Investment, interest rate | 9.80% | 9.80% | 9.80% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,149 | ||||||||||||
Investment, interest rate | 11.90% | 11.90% | 11.90% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,771 | ||||||||||||
Investment, interest rate | 12.15% | 12.15% | 12.15% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | ||||||||||||
SLF JV I | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,134 | $ 4,176 | |||||||||||
Investment, interest rate | 11.63% | 11.63% | 11.63% | 9.67% | 9.67% | 9.67% | |||||||
SLF JV I | Investment, Identifier [Axis]: Access CIG, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,596 | $ 10,093 | |||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | 6.82% | 6.82% | 6.82% | |||||||
SLF JV I | Investment, Identifier [Axis]: Altice France S.A., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,969 | $ 3,000 | |||||||||||
Investment, interest rate | 9.63% | 9.63% | 9.63% | 6.91% | 6.91% | 6.91% | |||||||
SLF JV I | Investment, Identifier [Axis]: Alvogen Pharma US, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,798 | $ 9,267 | |||||||||||
Investment, interest rate | 13.04% | 13.04% | 13.04% | 11.20% | 11.20% | 11.20% | |||||||
SLF JV I | Investment, Identifier [Axis]: American Rock Salt Company LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,957 | ||||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: American Tire Distributors, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,824 | $ 4,873 | |||||||||||
Investment, interest rate | 11.81% | 11.81% | 11.81% | 9.03% | 9.03% | 9.03% | |||||||
SLF JV I | Investment, Identifier [Axis]: Amplify Finco Pty Ltd., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,720 | $ 7,800 | |||||||||||
Investment, interest rate | 9.54% | 9.54% | 9.54% | 7.92% | 7.92% | 7.92% | |||||||
SLF JV I | Investment, Identifier [Axis]: Anastasia Parent, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,523 | $ 1,539 | |||||||||||
Investment, interest rate | 9.40% | 9.40% | 9.40% | 7.42% | 7.42% | 7.42% | |||||||
SLF JV I | Investment, Identifier [Axis]: Apptio, Inc., First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 154 | ||||||||||||
Investment, interest rate | 8.46% | 8.46% | 8.46% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Apptio, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,615 | ||||||||||||
Investment, interest rate | 8.46% | 8.46% | 8.46% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,052 | $ 5,052 | |||||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.37% | 8.37% | 8.37% | |||||||
SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,000 | ||||||||||||
Investment, interest rate | 7.70% | 7.70% | 7.70% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,950 | ||||||||||||
Investment, interest rate | 9.42% | 9.42% | 9.42% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,990 | ||||||||||||
Investment, interest rate | 9.67% | 9.67% | 9.67% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,346 | $ 4,346 | |||||||||||
Investment, interest rate | 10.68% | 10.68% | 10.68% | 8.37% | 8.37% | 8.37% | |||||||
SLF JV I | Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,289 | $ 6,338 | |||||||||||
Investment, interest rate | 11.49% | 11.49% | 11.49% | 8.78% | 8.78% | 8.78% | |||||||
SLF JV I | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,753 | $ 6,371 | |||||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,306 | $ 1,771 | |||||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: BYJU's Alpha, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,444 | ||||||||||||
Investment, interest rate | 8.98% | 8.98% | 8.98% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,575 | ||||||||||||
Investment, interest rate | 6.03% | 6.03% | 6.03% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: CITGO Petroleum Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,038 | ||||||||||||
Investment, interest rate | 9.37% | 9.37% | 9.37% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 600 | $ 0 | |||||||||||
Investment, interest rate | 11.57% | 11.57% | 11.57% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,354 | $ 4,358 | |||||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | 9.12% | 9.12% | 9.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,983 | $ 449 | |||||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | 9.12% | 9.12% | 9.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 3 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,960 | ||||||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: City Football Group Limited, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,451 | ||||||||||||
Investment, interest rate | 6.48% | 6.48% | 6.48% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Convergeone Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,373 | ||||||||||||
Investment, interest rate | 8.12% | 8.12% | 8.12% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,343 | $ 5,375 | |||||||||||
Investment, interest rate | 10.39% | 10.39% | 10.39% | 7.65% | 7.65% | 7.65% | |||||||
SLF JV I | Investment, Identifier [Axis]: Curium Bidco S.à.r.l., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,730 | $ 5,820 | |||||||||||
Investment, interest rate | 9.89% | 9.89% | 9.89% | 7.67% | 7.67% | 7.67% | |||||||
SLF JV I | Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,920 | $ 8,000 | |||||||||||
Investment, interest rate | 10.12% | 10.12% | 10.12% | 7.33% | 7.33% | 7.33% | |||||||
SLF JV I | Investment, Identifier [Axis]: Dealer Tire, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,992 | ||||||||||||
Investment, interest rate | 7.37% | 7.37% | 7.37% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Delivery Hero FinCo LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,035 | ||||||||||||
Investment, interest rate | 8.49% | 8.49% | 8.49% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: DirecTV Financing, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,799 | $ 6,436 | |||||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.12% | 8.12% | 8.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: Domtar Corporation, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,100 | ||||||||||||
Investment, interest rate | 8.26% | 8.26% | 8.26% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Eagle Parent Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,478 | ||||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Five Largest Loan Exposures To Borrowers | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 54,051 | $ 48,139 | |||||||||||
SLF JV I | Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,369 | $ 7,444 | |||||||||||
Investment, interest rate | 10.57% | 10.57% | 10.57% | 7.94% | 7.94% | 7.94% | |||||||
SLF JV I | Investment, Identifier [Axis]: Global Medical Response, Inc., First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,979 | ||||||||||||
Investment, interest rate | 7.37% | 7.37% | 7.37% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Global Medical Response, Inc., First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,192 | ||||||||||||
Investment, interest rate | 6.81% | 6.81% | 6.81% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,920 | $ 8,000 | |||||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.38% | 8.38% | 8.38% | |||||||
SLF JV I | Investment, Identifier [Axis]: INW Manufacturing, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,000 | $ 9,500 | |||||||||||
Investment, interest rate | 11.40% | 11.40% | 11.40% | 9.42% | 9.42% | 9.42% | |||||||
SLF JV I | Investment, Identifier [Axis]: Indivior Finance S.À.R.L., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,331 | $ 7,406 | |||||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.80% | 8.80% | 8.80% | |||||||
SLF JV I | Investment, Identifier [Axis]: Iris Holding, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,000 | ||||||||||||
Investment, interest rate | 7.89% | 7.89% | 7.89% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: KDC/ONE Development Corp Inc, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 10,000 | ||||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: LABL, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,962 | ||||||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: LTI Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,366 | ||||||||||||
Investment, interest rate | 6.37% | 6.37% | 6.37% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Largest Exposure To A Single Borrower | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,286 | $ 10,093 | |||||||||||
SLF JV I | Investment, Identifier [Axis]: LaserAway Intermediate Holdings II, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,369 | $ 7,444 | |||||||||||
Investment, interest rate | 11.32% | 11.32% | 11.32% | 8.23% | 8.23% | 8.23% | |||||||
SLF JV I | Investment, Identifier [Axis]: Lightbox Intermediate, L.P., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 11,249 | $ 7,367 | |||||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.67% | 8.67% | 8.67% | |||||||
SLF JV I | Investment, Identifier [Axis]: LogMeIn, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,860 | ||||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: MRI Software LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | ||||||||||||
SLF JV I | Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,139 | ||||||||||||
Investment, interest rate | 9.17% | 9.17% | 9.17% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,319 | ||||||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,211 | ||||||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: McAfee Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,940 | ||||||||||||
Investment, interest rate | 9.18% | 9.18% | 9.18% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Mindbody, Inc., First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | $ 0 | |||||||||||
SLF JV I | Investment, Identifier [Axis]: Mindbody, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,669 | $ 4,687 | |||||||||||
Investment, interest rate | 12.52% | 12.52% | 12.52% | 10.64% | 10.64% | 10.64% | |||||||
SLF JV I | Investment, Identifier [Axis]: Mitchell International, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,985 | ||||||||||||
Investment, interest rate | 9.18% | 9.18% | 9.18% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Northern Star Industries Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,615 | $ 6,685 | |||||||||||
Investment, interest rate | 10.15% | 10.15% | 10.15% | 7.87% | 7.87% | 7.87% | |||||||
SLF JV I | Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 10,987 | $ 7,777 | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | 7.12% | 7.12% | 7.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: Park Place Technologies, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,825 | $ 4,925 | |||||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | 8.13% | 8.13% | 8.13% | |||||||
SLF JV I | Investment, Identifier [Axis]: Peloton Interactive, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,486 | ||||||||||||
Investment, interest rate | 8.35% | 8.35% | 8.35% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Planview Parent, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,416 | ||||||||||||
Investment, interest rate | 9.65% | 9.65% | 9.65% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Planview Parent, Inc., Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,503 | $ 4,503 | |||||||||||
Investment, interest rate | 12.74% | 12.74% | 12.74% | 10.92% | 10.92% | 10.92% | |||||||
SLF JV I | Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 318 | $ 0 | |||||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,116 | $ 6,796 | |||||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | 10.68% | 10.68% | 10.68% | |||||||
SLF JV I | Investment, Identifier [Axis]: Renaissance Holding Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,000 | ||||||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: RevSpring, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 9,625 | ||||||||||||
Investment, interest rate | 7.67% | 7.67% | 7.67% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 138 | $ 8,201 | |||||||||||
Investment, interest rate | 10.86% | 10.86% | 10.86% | 8.06% | 8.06% | 8.06% | |||||||
SLF JV I | Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,113 | $ 138 | |||||||||||
Investment, interest rate | 10.88% | 10.88% | 10.88% | 8.04% | 8.04% | 8.04% | |||||||
SLF JV I | Investment, Identifier [Axis]: SM Wellness Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,977 | ||||||||||||
Investment, interest rate | 10.38% | 10.38% | 10.38% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: SPX Flow, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,801 | $ 7,500 | |||||||||||
Investment, interest rate | 9.92% | 9.92% | 9.92% | 7.63% | 7.63% | 7.63% | |||||||
SLF JV I | Investment, Identifier [Axis]: Sabert Corporation, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,536 | ||||||||||||
Investment, interest rate | 7.63% | 7.63% | 7.63% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Sorenson Communications, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,553 | ||||||||||||
Investment, interest rate | 9.17% | 9.17% | 9.17% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Southern Veterinary Partners, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,680 | ||||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Spanx, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,843 | $ 8,933 | |||||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.30% | 8.30% | 8.30% | |||||||
SLF JV I | Investment, Identifier [Axis]: Star Parent, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,000 | ||||||||||||
Investment, interest rate | 9.33% | 9.33% | 9.33% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Supermoose Borrower, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,743 | ||||||||||||
Investment, interest rate | 7.42% | 7.42% | 7.42% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Surgery Center Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,377 | ||||||||||||
Investment, interest rate | 6.51% | 6.51% | 6.51% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: TIBCO Software Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 8,215 | $ 6,256 | |||||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | 8.15% | 8.15% | 8.15% | |||||||
SLF JV I | Investment, Identifier [Axis]: Touchstone Acquisition, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,212 | $ 7,285 | |||||||||||
Investment, interest rate | 11.42% | 11.42% | 11.42% | 9.12% | 9.12% | 9.12% | |||||||
SLF JV I | Investment, Identifier [Axis]: Veritas US Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,305 | $ 6,365 | |||||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.67% | 8.67% | 8.67% | |||||||
SLF JV I | Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,965 | $ 1,985 | |||||||||||
Investment, interest rate | 9.27% | 9.27% | 9.27% | 6.56% | 6.56% | 6.56% | |||||||
SLF JV I | Investment, Identifier [Axis]: WP CPP Holdings, LLC, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,000 | ||||||||||||
Investment, interest rate | 10.56% | 10.56% | 10.56% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: Windstream Services II, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,148 | $ 7,818 | |||||||||||
Investment, interest rate | 11.67% | 11.67% | 11.67% | 9.37% | 9.37% | 9.37% | |||||||
SLF JV I | Investment, Identifier [Axis]: Zayo Group Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,155 | ||||||||||||
Investment, interest rate | 6.12% | 6.12% | 6.12% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: athenahealth Group Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,320 | ||||||||||||
Investment, interest rate | 8.57% | 8.57% | 8.57% | ||||||||||
SLF JV I | Investment, Identifier [Axis]: eResearch Technology, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 7,331 | ||||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | ||||||||||
SLF JV I | Senior Secured Loans | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 332,637 | $ 383,194 | |||||||||||
SLF JV I | Weighted Average | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, interest rate | 10.62% | 10.62% | 10.62% | 8.33% | 8.33% | 8.33% | |||||||
Glick JV LLC | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 130,589 | $ 143,225 | |||||||||||
Number of borrowers | borrower | 38 | 38 | 38 | 43 | 43 | 43 | |||||||
Glick JV LLC | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,647 | ||||||||||||
Investment, interest rate | 9.80% | 9.80% | 9.80% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 574 | ||||||||||||
Investment, interest rate | 11.90% | 11.90% | 11.90% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,746 | ||||||||||||
Investment, interest rate | 12.15% | 12.15% | 12.15% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | $ 0 | |||||||||||
Glick JV LLC | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,716 | $ 1,734 | |||||||||||
Investment, interest rate | 11.63% | 11.63% | 11.63% | 9.67% | 9.67% | 9.67% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Access CIG, LLC | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,000 | ||||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Alvogen Pharma Inc, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,230 | $ 6,562 | |||||||||||
Investment, interest rate | 13.04% | 13.04% | 13.04% | 11.20% | 11.20% | 11.20% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: American Rock Salt Company LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,478 | ||||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: American Tire Distributors, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,860 | $ 2,889 | |||||||||||
Investment, interest rate | 11.81% | 11.81% | 11.81% | 9.03% | 9.03% | 9.03% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Amplify Finco Pty Ltd., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,895 | $ 2,925 | |||||||||||
Investment, interest rate | 9.54% | 9.54% | 9.54% | 7.92% | 7.92% | 7.92% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Amynta Agency Borrower Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,993 | ||||||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Anastasia Parent, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 907 | $ 917 | |||||||||||
Investment, interest rate | 9.40% | 9.40% | 9.40% | 7.42% | 7.42% | 7.42% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,078 | $ 2,078 | |||||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.37% | 8.37% | 8.37% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,000 | ||||||||||||
Investment, interest rate | 7.70% | 7.70% | 7.70% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,980 | ||||||||||||
Investment, interest rate | 9.42% | 9.42% | 9.42% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 995 | ||||||||||||
Investment, interest rate | 9.67% | 9.67% | 9.67% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,423 | ||||||||||||
Investment, interest rate | 10.68% | 10.68% | 10.68% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Asurion, LLC, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,423 | ||||||||||||
Investment, interest rate | 8.37% | 8.37% | 8.37% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,628 | ||||||||||||
Investment, interest rate | 11.49% | 11.49% | 11.49% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,656 | ||||||||||||
Investment, interest rate | 8.78% | 8.78% | 8.78% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,363 | $ 3,398 | |||||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 800 | $ 808 | |||||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: BYJU's Alpha, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,970 | ||||||||||||
Investment, interest rate | 8.98% | 8.98% | 8.98% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: CITGO Petroleum Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,519 | ||||||||||||
Investment, interest rate | 9.37% | 9.37% | 9.37% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: City Football Group Limited, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,481 | ||||||||||||
Investment, interest rate | 6.48% | 6.48% | 6.48% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,766 | $ 2,280 | |||||||||||
Investment, interest rate | 10.39% | 10.39% | 10.39% | 7.65% | 7.65% | 7.65% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Curium Bidco S.à.r.l., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,841 | $ 2,870 | |||||||||||
Investment, interest rate | 9.89% | 9.89% | 9.89% | 7.67% | 7.67% | 7.67% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: DTI Holdco, Inc First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,970 | ||||||||||||
Investment, interest rate | 10.12% | 10.12% | 10.12% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,000 | ||||||||||||
Investment, interest rate | 7.33% | 7.33% | 7.33% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: DirecTV Financing, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,460 | $ 2,730 | |||||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.12% | 8.12% | 8.12% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Domtar Corporation, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,503 | ||||||||||||
Investment, interest rate | 8.26% | 8.26% | 8.26% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Eagle Parent Corp., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,488 | ||||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Five Largest Loan Exposures To Borrowers | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 28,396 | $ 28,973 | |||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,930 | $ 3,970 | |||||||||||
Investment, interest rate | 10.57% | 10.57% | 10.57% | 7.94% | 7.94% | 7.94% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,960 | $ 4,000 | |||||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.38% | 8.38% | 8.38% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: INW Manufacturing, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,250 | $ 2,375 | |||||||||||
Investment, interest rate | 11.40% | 11.40% | 11.40% | 9.42% | 9.42% | 9.42% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Indivior Finance S.À.R.L., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,910 | $ 3,950 | |||||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.80% | 8.80% | 8.80% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Iris Holding, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,500 | $ 2,000 | |||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | 7.89% | 7.89% | 7.89% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: LTI Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,358 | ||||||||||||
Investment, interest rate | 6.37% | 6.37% | 6.37% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Largest Loan Exposure To A Single Borrower | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,230 | $ 6,562 | |||||||||||
Glick JV LLC | Investment, Identifier [Axis]: LaserAway Intermediate Holdings II, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,930 | $ 3,970 | |||||||||||
Investment, interest rate | 11.32% | 11.32% | 11.32% | 8.23% | 8.23% | 8.23% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: MRI Software LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 0 | $ 0 | |||||||||||
Glick JV LLC | Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,630 | $ 1,647 | |||||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | 9.17% | 9.17% | 9.17% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Northern Star Industries Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,198 | $ 5,252 | |||||||||||
Investment, interest rate | 10.15% | 10.15% | 10.15% | 7.87% | 7.87% | 7.87% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,849 | $ 3,888 | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | 7.12% | 7.12% | 7.12% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Planview Parent, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 683 | ||||||||||||
Investment, interest rate | 9.65% | 9.65% | 9.65% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Planview Parent, Inc., Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,842 | $ 2,842 | |||||||||||
Investment, interest rate | 12.74% | 12.74% | 12.74% | 10.92% | 10.92% | 10.92% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Revolver | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 226 | $ 0 | |||||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,182 | $ 4,465 | |||||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | 10.68% | 10.68% | 10.68% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 1 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 6,029 | $ 6,094 | |||||||||||
Investment, interest rate | 10.88% | 10.88% | 10.88% | 8.06% | 8.06% | 8.06% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 2 | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 103 | $ 102 | |||||||||||
Investment, interest rate | 10.86% | 10.86% | 10.86% | 8.04% | 8.04% | 8.04% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: SPX Flow, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 5,227 | $ 6,000 | |||||||||||
Investment, interest rate | 9.92% | 9.92% | 9.92% | 7.63% | 7.63% | 7.63% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Sabert Corporation, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,691 | ||||||||||||
Investment, interest rate | 7.63% | 7.63% | 7.63% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Southern Veterinary Partners, LLC | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,292 | ||||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Spanx, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,913 | $ 4,962 | |||||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.30% | 8.30% | 8.30% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Star Parent, Inc. | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 4,000 | ||||||||||||
Investment, interest rate | 9.33% | 9.33% | 9.33% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Supermoose Borrower, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,820 | ||||||||||||
Investment, interest rate | 7.42% | 7.42% | 7.42% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Surgery Center Holdings, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,377 | ||||||||||||
Investment, interest rate | 6.51% | 6.51% | 6.51% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: TIBCO Software Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,641 | $ 2,654 | |||||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | 8.15% | 8.15% | 8.15% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Touchstone Acquisition, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,993 | $ 3,024 | |||||||||||
Investment, interest rate | 11.42% | 11.42% | 11.42% | 9.12% | 9.12% | 9.12% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: Tribe Buyer LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,583 | ||||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 983 | $ 993 | |||||||||||
Investment, interest rate | 9.27% | 9.27% | 9.27% | 6.56% | 6.56% | 6.56% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: WP CPP Holdings, LLC, Second Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,000 | ||||||||||||
Investment, interest rate | 10.56% | 10.56% | 10.56% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: Windstream Services II, LLC, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 3,843 | $ 4,886 | |||||||||||
Investment, interest rate | 11.67% | 11.67% | 11.67% | 9.37% | 9.37% | 9.37% | |||||||
Glick JV LLC | Investment, Identifier [Axis]: athenahealth Group Inc., Health Care Technology, First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 1,772 | ||||||||||||
Investment, interest rate | 8.57% | 8.57% | 8.57% | ||||||||||
Glick JV LLC | Investment, Identifier [Axis]: eResearch Technology, Inc., First Lien Term Loan | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 2,444 | ||||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | ||||||||||
Glick JV LLC | Senior Secured Loans | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, principal | $ 130,589 | $ 143,225 | |||||||||||
Glick JV LLC | Weighted Average | |||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||||||||||||
Investment, interest rate | 10.77% | 10.77% | 10.77% | 8.52% | 8.52% | 8.52% | |||||||
[1] As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). |
Portfolio Investments - Portf_3
Portfolio Investments - Portfolio Listing (Details) € in Thousands, £ in Thousands, $ in Thousands | Sep. 30, 2023 USD ($) shares | Sep. 30, 2023 EUR (€) shares | Sep. 30, 2023 GBP (£) shares | Sep. 30, 2022 USD ($) shares | Sep. 30, 2022 EUR (€) shares | Sep. 30, 2022 GBP (£) shares | Sep. 30, 2021 USD ($) | |||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | $ 3,044,119 | $ 2,617,754 | ||||||||||||
Investments at fair value | 2,892,420 | 2,494,111 | ||||||||||||
SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 332,637 | 383,194 | ||||||||||||
Investment owned, at cost | 331,808 | 382,673 | ||||||||||||
Investments at fair value | 322,179 | 359,625 | ||||||||||||
OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 130,589 | 143,225 | ||||||||||||
Investment owned, at cost | 127,788 | 140,083 | ||||||||||||
Investments at fair value | $ 123,343 | $ 133,144 | ||||||||||||
Investment, Identifier [Axis]: 107 Fair Street LLC, Real Estate Development, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[3],[4],[5],[6] | 12.50% | 12.50% | 12.50% | ||||||||||
Investment, principal | [1],[3],[4],[6],[7] | $ 1,269 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[6] | 1,240 | ||||||||||||
Investments at fair value | [1],[3],[4],[6] | $ 1,214 | ||||||||||||
Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC, Real Estate Development, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 11% | 11% | 11% | ||||||||||
Investment, principal | [1],[3],[4],[7] | $ 18,869 | ||||||||||||
Investment owned, at cost | [1],[3],[4] | 18,687 | ||||||||||||
Investments at fair value | [1],[3],[4] | $ 18,443 | ||||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.80% | 9.80% | 9.80% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 389 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 387 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 727 | ||||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 7% | 7% | 7% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | (31) | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | 0 | ||||||||||||
Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[3],[4],[5],[6] | 12% | 12% | 12% | ||||||||||
Investment, principal | [1],[3],[4],[6],[7] | $ 4,070 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[6] | 4,038 | ||||||||||||
Investments at fair value | [1],[3],[4],[6] | $ 4,022 | ||||||||||||
Investment, Identifier [Axis]: A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14],[15] | 14.25% | 14.25% | 14.25% | ||||||||||
Investment, principal | [1],[4],[7],[14],[15] | $ 21,434 | ||||||||||||
Investment owned, at cost | [1],[4],[14],[15] | 21,612 | ||||||||||||
Investments at fair value | [1],[4],[14],[15] | 21,220 | ||||||||||||
Investment, Identifier [Axis]: A.T. Holdings II SÀRL, Biotechnology, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 6,021 | [1],[4],[7],[14] | 33,997 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 6,013 | [1],[4],[14] | 33,960 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 5,900 | [1],[4],[14] | $ 34,891 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6.25% | 6.25% | 6.25% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.80% | 9.80% | 9.80% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 14,685 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 14,217 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 14,431 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.90% | 11.90% | 11.90% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 3,446 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 3,411 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 3,383 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.15% | 12.15% | 12.15% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 17,901 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 17,743 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 17,575 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.13% | 12.13% | 12.13% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 963 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 948 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 945 | ||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | |||||||||||
Investment, interest rate | 9.80% | 9.80% | 9.80% | |||||||||||
Investment, principal | $ 8,518 | |||||||||||||
Investment owned, at cost | 8,389 | |||||||||||||
Investments at fair value | $ 8,371 | |||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | |||||||||||
Investment, interest rate | 9.80% | 9.80% | 9.80% | |||||||||||
Investment, principal | $ 4,647 | |||||||||||||
Investment owned, at cost | 4,579 | |||||||||||||
Investments at fair value | $ 4,567 | |||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | 6.50% | 6.50% | |||||||||||
Investment, interest rate | 11.90% | 11.90% | 11.90% | |||||||||||
Investment, principal | $ 1,149 | |||||||||||||
Investment owned, at cost | 1,135 | |||||||||||||
Investments at fair value | $ 1,128 | |||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 1 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | 6.50% | 6.50% | |||||||||||
Investment, interest rate | 11.90% | 11.90% | 11.90% | |||||||||||
Investment, principal | $ 574 | |||||||||||||
Investment owned, at cost | 568 | |||||||||||||
Investments at fair value | $ 564 | |||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | 6.50% | 6.50% | |||||||||||
Investment, interest rate | 12.15% | 12.15% | 12.15% | |||||||||||
Investment, principal | $ 6,771 | |||||||||||||
Investment owned, at cost | 6,701 | |||||||||||||
Investments at fair value | $ 6,648 | |||||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, First Lien Term Loan 2 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | 6.50% | 6.50% | |||||||||||
Investment, interest rate | 12.15% | 12.15% | 12.15% | |||||||||||
Investment, principal | $ 3,746 | |||||||||||||
Investment owned, at cost | 3,709 | |||||||||||||
Investments at fair value | $ 3,678 | |||||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[4],[5],[14] | 7.50% | [1],[4],[5],[14] | 7.50% | [1],[4],[5],[14] | 7.50% | [8],[9],[10],[16] | 7.50% | [8],[9],[10],[16] | 7.50% | [8],[9],[10],[16] | ||
Investment, interest rate | 13.04% | [1],[2],[4],[5],[14] | 13.04% | [1],[2],[4],[5],[14] | 13.04% | [1],[2],[4],[5],[14] | 11.20% | [8],[9],[10],[11],[16] | 11.20% | [8],[9],[10],[11],[16] | 11.20% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 6,589 | [1],[4],[5],[7],[14] | $ 6,589 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 6,305 | [1],[4],[5],[14] | 6,256 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 6,276 | [1],[4],[5],[14] | $ 6,262 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[3],[4],[14] | 7.50% | [1],[3],[4],[14] | 7.50% | [1],[3],[4],[14] | 7.50% | [8],[9],[10],[13],[16] | 7.50% | [8],[9],[10],[13],[16] | 7.50% | [8],[9],[10],[13],[16] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7],[14] | $ 0 | [8],[9],[10],[12],[13],[16] | ||||||||||
Investment owned, at cost | (38) | [1],[3],[4],[5],[14] | (38) | [8],[9],[10],[13],[16] | ||||||||||
Investments at fair value | $ (38) | [1],[3],[4],[5],[14] | $ (37) | [8],[9],[10],[13],[16] | ||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 28,948 | [1],[4],[14] | 28,948 | [1],[4],[14] | 28,948 | [1],[4],[14] | 28,948 | [8],[9],[16] | 28,948 | [8],[9],[16] | 28,948 | [8],[9],[16] | ||
Investment owned, at cost | $ 174 | [1],[4],[14] | $ 174 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 6 | [1],[4],[14] | $ 73 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [4],[5],[14] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [2],[4],[5],[14] | 8.86% | 8.86% | 8.86% | ||||||||||
Investment, principal | € | [4],[5],[7],[14] | € 5,500 | ||||||||||||
Investment owned, at cost | [4],[5],[14] | $ 6,024 | ||||||||||||
Investments at fair value | [4],[5],[14] | $ 5,825 | ||||||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[16] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 7.94% | 7.94% | 7.94% | ||||||||||
Investment, principal | € | [8],[9],[10],[12],[16] | € 24,838 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[16] | $ 27,752 | ||||||||||||
Investments at fair value | [8],[9],[10],[16] | $ 22,143 | ||||||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 17,870 | [1],[4] | 17,870 | [1],[4] | 17,870 | [1],[4] | 14,410 | [8],[9] | 14,410 | [8],[9] | 14,410 | [8],[9] | ||
Investment owned, at cost | $ 1,733 | [1],[4] | $ 1,352 | [8],[9] | ||||||||||
Investments at fair value | $ 2,826 | [1],[4] | $ 1,291 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.75% | [1],[4],[5] | 7.75% | [1],[4],[5] | 7.75% | [1],[4],[5] | 7.75% | [8],[9],[10] | 7.75% | [8],[9],[10] | 7.75% | [8],[9],[10] | ||
Investment, interest rate | 13.17% | [1],[2],[4],[5] | 13.17% | [1],[2],[4],[5] | 13.17% | [1],[2],[4],[5] | 10.88% | [8],[9],[10],[11] | 10.88% | [8],[9],[10],[11] | 10.88% | [8],[9],[10],[11] | ||
Investment, principal | $ 17,873 | [1],[4],[5],[7] | $ 14,414 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 17,655 | [1],[4],[5] | 14,154 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 17,687 | [1],[4],[5] | $ 13,910 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: APX Group Inc., Electrical Components & Equipment, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, principal | [9],[12],[16] | $ 2,075 | ||||||||||||
Investment owned, at cost | [9],[16] | 1,733 | ||||||||||||
Investments at fair value | [9],[16] | $ 1,645 | ||||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [9],[12] | $ 5,500 | ||||||||||||
Investment owned, at cost | [9] | 5,408 | ||||||||||||
Investments at fair value | [9] | $ 3,641 | ||||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, principal | [9],[12] | $ 2,500 | ||||||||||||
Investment owned, at cost | [9] | 2,220 | ||||||||||||
Investments at fair value | [9] | $ 1,926 | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, principal | $ 0 | |||||||||||||
Investment owned, at cost | (7) | $ (9) | ||||||||||||
Investments at fair value | $ (29) | $ (11) | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Revolver | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, principal | $ 0 | $ 0 | ||||||||||||
Investment owned, at cost | (3) | (4) | ||||||||||||
Investments at fair value | $ (12) | $ (5) | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, interest rate | 11.63% | 11.63% | 11.63% | 9.67% | 9.67% | 9.67% | ||||||||
Investment, principal | $ 4,134 | $ 4,176 | ||||||||||||
Investment owned, at cost | 4,076 | 4,103 | ||||||||||||
Investments at fair value | $ 3,892 | $ 4,080 | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, interest rate | 11.63% | 11.63% | 11.63% | 9.67% | 9.67% | 9.67% | ||||||||
Investment, principal | $ 1,716 | $ 1,734 | ||||||||||||
Investment owned, at cost | 1,692 | 1,704 | ||||||||||||
Investments at fair value | $ 1,616 | $ 1,694 | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[14] | 6% | 6% | 6% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[14] | (13) | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[14] | $ (23) | ||||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 11.63% | 11.63% | 11.63% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 3,276 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 3,267 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | 3,084 | ||||||||||||
Investment, Identifier [Axis]: ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[4],[7],[14],[15] | 12,222 | ||||||||||||
Investment owned, at cost | [1],[4],[14],[15] | 12,260 | ||||||||||||
Investments at fair value | [1],[4],[14],[15] | $ 11,795 | ||||||||||||
Investment, Identifier [Axis]: Access CIG, LLC | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | |||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | |||||||||||
Investment, principal | $ 2,000 | |||||||||||||
Investment owned, at cost | 1,960 | |||||||||||||
Investments at fair value | $ 1,978 | |||||||||||||
Investment, Identifier [Axis]: Access CIG, LLC, Diversified Support Services, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [9],[10],[11] | 10.82% | 10.82% | 10.82% | ||||||||||
Investment, principal | [9],[10],[12] | $ 20,000 | ||||||||||||
Investment owned, at cost | [9],[10] | 19,927 | ||||||||||||
Investments at fair value | [9],[10] | $ 19,075 | ||||||||||||
Investment, Identifier [Axis]: Access CIG, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 3.75% | 3.75% | 3.75% | ||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | 6.82% | 6.82% | 6.82% | ||||||||
Investment, principal | $ 8,596 | $ 10,093 | ||||||||||||
Investment owned, at cost | 8,503 | 10,028 | ||||||||||||
Investments at fair value | $ 8,499 | $ 9,692 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 11.55% | 11.55% | 11.55% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 2,033 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 2,013 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 2,027 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.55% | 11.55% | 11.55% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 20,234 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 20,150 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 20,194 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | |||||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (2) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (8) | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 9.14% | 9.14% | 9.14% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 500 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 462 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 495 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 15,976 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 15,686 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 15,944 | ||||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 0 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ (6) | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 7% | [8],[9],[10],[13] | 7% | [8],[9],[10],[13] | 7% | [8],[9],[10],[13] | ||
Investment, interest rate | 12.72% | [1],[2],[3],[4],[5] | 12.72% | [1],[2],[3],[4],[5] | 12.72% | [1],[2],[3],[4],[5] | 10.64% | [8],[9],[10],[11],[13] | 10.64% | [8],[9],[10],[11],[13] | 10.64% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 1,333 | [1],[3],[4],[5],[7] | $ 914 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 1,322 | [1],[3],[4],[5] | 890 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 1,324 | [1],[3],[4],[5] | $ 898 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.63% | 9.63% | 9.63% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 27,349 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 27,038 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 27,158 | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.34% | 12.34% | 12.34% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 6,400 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 6,335 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 6,380 | ||||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.34% | 12.34% | 12.34% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 25,332 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 25,288 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 25,253 | ||||||||||||
Investment, Identifier [Axis]: Aden & Anais Merger Sub, Inc., Apparel, Accessories & Luxury Goods, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 51,645 | 51,645 | 51,645 | ||||||||||
Investment owned, at cost | [8],[9] | $ 5,165 | ||||||||||||
Investments at fair value | [8],[9] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: AirStrip Technologies, Inc., Application Software, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 5,715 | [1],[4] | 5,715 | [1],[4] | 5,715 | [1],[4] | 5,715 | [8],[9] | 5,715 | [8],[9] | 5,715 | [8],[9] | ||
Investment owned, at cost | $ 90 | [1],[4] | $ 90 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 23,338 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 22,057 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 22,141 | ||||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[17] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [1],[4],[5],[7],[17] | $ 23,562 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[17] | 22,795 | ||||||||||||
Investments at fair value | [1],[4],[5],[17] | $ 9,797 | ||||||||||||
Investment, Identifier [Axis]: Altice France S.A., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | 4% | 4% | 4% | ||||||||
Investment, interest rate | 9.63% | 9.63% | 9.63% | 6.91% | 6.91% | 6.91% | ||||||||
Investment, principal | $ 2,969 | $ 3,000 | ||||||||||||
Investment owned, at cost | 2,853 | 2,841 | ||||||||||||
Investments at fair value | $ 2,810 | $ 2,730 | ||||||||||||
Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 5.50% | [2],[4],[5],[14] | 5.50% | [2],[4],[5],[14] | 5.50% | [2],[4],[5],[14] | 5.50% | [9],[10],[11],[16] | 5.50% | [9],[10],[11],[16] | 5.50% | [9],[10],[11],[16] | ||
Investment, principal | $ 4,050 | [4],[7],[14] | $ 4,050 | [9],[12],[16] | ||||||||||
Investment owned, at cost | 3,577 | [4],[14] | 3,518 | [9],[16] | ||||||||||
Investments at fair value | $ 2,918 | [4],[14] | $ 3,057 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 11.50% | 11.50% | 11.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 5% | 5% | 5% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 9,057 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 8,434 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 8,332 | ||||||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 598,283 | 598,283 | 598,283 | ||||||||||
Investment owned, at cost | [1],[4] | $ 642 | ||||||||||||
Investments at fair value | [1],[4] | $ 1,915 | ||||||||||||
Investment, Identifier [Axis]: Alvogen Pharma Inc, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | 7.50% | 7.50% | 7.50% | 7.50% | 7.50% | ||||||||
Investment, interest rate | 13.04% | 13.04% | 13.04% | 11.20% | 11.20% | 11.20% | ||||||||
Investment, principal | $ 6,230 | $ 6,562 | ||||||||||||
Investment owned, at cost | 6,185 | 6,489 | ||||||||||||
Investments at fair value | $ 5,819 | $ 6,529 | ||||||||||||
Investment, Identifier [Axis]: Alvogen Pharma US, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | 7.50% | 7.50% | 7.50% | 7.50% | 7.50% | ||||||||
Investment, interest rate | 13.04% | 13.04% | 13.04% | 11.20% | 11.20% | 11.20% | ||||||||
Investment, principal | $ 8,798 | $ 9,267 | ||||||||||||
Investment owned, at cost | 8,737 | 9,166 | ||||||||||||
Investments at fair value | $ 8,218 | $ 9,221 | ||||||||||||
Investment, Identifier [Axis]: Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | ||
Investment, interest rate | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 11.20% | [8],[9],[10],[11] | 11.20% | [8],[9],[10],[11] | 11.20% | [8],[9],[10],[11] | ||
Investment, principal | $ 17,053 | [1],[4],[5],[7] | $ 13,134 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 16,982 | [1],[4],[5] | 12,847 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 15,929 | [1],[4],[5] | $ 13,068 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 10% | 10% | 10% | ||||||||||
Investment, principal | [8],[9],[12],[16] | $ 24,043 | ||||||||||||
Investment owned, at cost | [8],[9],[16] | 23,747 | ||||||||||||
Investments at fair value | [8],[9],[16] | $ 23,923 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 471,253 | [4],[14] | 471,253 | [4],[14] | 471,253 | [4],[14] | 587,930 | [9],[16] | 587,930 | [9],[16] | 587,930 | [9],[16] | ||
Investment owned, at cost | $ 849 | [4],[14] | $ 5,308 | [9],[16] | ||||||||||
Investments at fair value | $ 4,298 | [4],[14] | $ 3,974 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 141,640 | [1],[4],[14],[18] | 141,640 | [1],[4],[14],[18] | 141,640 | [1],[4],[14],[18] | 124,780 | [8],[9],[16],[19] | 124,780 | [8],[9],[16],[19] | 124,780 | [8],[9],[16],[19] | ||
Investment owned, at cost | $ 566 | [1],[4],[14],[18] | $ 485 | [8],[9],[16],[19] | ||||||||||
Investments at fair value | $ 368 | [1],[4],[14],[18] | $ 212 | [8],[9],[16],[19] | ||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 28,464 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 28,329 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 27,687 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 2,121 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 1,945 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 2,063 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 27,692 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 27,582 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 26,936 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 2,064 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 1,891 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 2,007 | ||||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 10% | 10% | 10% | ||||||||||
Investment, principal | [8],[9],[12],[16] | $ 23,522 | ||||||||||||
Investment owned, at cost | [8],[9],[16] | 23,264 | ||||||||||||
Investments at fair value | [8],[9],[16] | $ 23,404 | ||||||||||||
Investment, Identifier [Axis]: American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.75% | [1],[4],[5] | 8.75% | [1],[4],[5] | 8.75% | [1],[4],[5] | 8.75% | [8],[9],[10] | 8.75% | [8],[9],[10] | 8.75% | [8],[9],[10] | ||
Investment, interest rate | 14.14% | [1],[2],[4],[5] | 14.14% | [1],[2],[4],[5] | 14.14% | [1],[2],[4],[5] | 12.30% | [8],[9],[10],[11] | 12.30% | [8],[9],[10],[11] | 12.30% | [8],[9],[10],[11] | ||
Investment, principal | $ 17,048 | [1],[4],[5],[7] | $ 14,760 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 16,440 | [1],[4],[5] | 14,492 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 15,087 | [1],[4],[5] | $ 13,284 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: American Rock Salt Company LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | |||||||||||
Investment, principal | $ 4,957 | |||||||||||||
Investment owned, at cost | 4,734 | |||||||||||||
Investments at fair value | $ 4,614 | |||||||||||||
Investment, Identifier [Axis]: American Rock Salt Company LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | |||||||||||
Investment, principal | $ 2,478 | |||||||||||||
Investment owned, at cost | 2,367 | |||||||||||||
Investments at fair value | $ 2,307 | |||||||||||||
Investment, Identifier [Axis]: American Tire Distributors, Inc., Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | [4],[5] | 6.25% | [4],[5] | 6.25% | [4],[5] | 6.25% | [9],[10] | 6.25% | [9],[10] | 6.25% | [9],[10] | ||
Investment, interest rate | 11.81% | [2],[4],[5] | 11.81% | [2],[4],[5] | 11.81% | [2],[4],[5] | 9.03% | [9],[10],[11] | 9.03% | [9],[10],[11] | 9.03% | [9],[10],[11] | ||
Investment, principal | $ 19,115 | [4],[5],[7] | $ 9,895 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 18,278 | [4],[5] | 9,772 | [9],[10] | ||||||||||
Investments at fair value | $ 16,798 | [4],[5] | $ 9,293 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: American Tire Distributors, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | ||||||||
Investment, interest rate | 11.81% | 11.81% | 11.81% | 9.03% | 9.03% | 9.03% | ||||||||
Investment, principal | $ 4,824 | $ 4,873 | ||||||||||||
Investment owned, at cost | 4,763 | 4,812 | ||||||||||||
Investments at fair value | $ 4,239 | $ 4,576 | ||||||||||||
Investment, Identifier [Axis]: American Tire Distributors, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | ||||||||
Investment, interest rate | 11.81% | 11.81% | 11.81% | 9.03% | 9.03% | 9.03% | ||||||||
Investment, principal | $ 2,860 | $ 2,889 | ||||||||||||
Investment owned, at cost | 2,825 | 2,853 | ||||||||||||
Investments at fair value | $ 2,514 | $ 2,714 | ||||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.15% | 4.15% | 4.15% | 4.25% | 4.25% | 4.25% | ||||||||
Investment, interest rate | 9.54% | 9.54% | 9.54% | 7.92% | 7.92% | 7.92% | ||||||||
Investment, principal | $ 7,720 | $ 7,800 | ||||||||||||
Investment owned, at cost | 7,643 | 7,722 | ||||||||||||
Investments at fair value | $ 7,720 | $ 7,527 | ||||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.15% | 4.15% | 4.15% | 4.25% | 4.25% | 4.25% | ||||||||
Investment, interest rate | 9.54% | 9.54% | 9.54% | 7.92% | 7.92% | 7.92% | ||||||||
Investment, principal | $ 2,895 | $ 2,925 | ||||||||||||
Investment owned, at cost | 2,866 | 2,896 | ||||||||||||
Investments at fair value | $ 2,895 | $ 2,823 | ||||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[16] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 7.92% | 7.92% | 7.92% | ||||||||||
Investment, principal | [8],[9],[10],[12],[16] | $ 15,220 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[16] | 13,973 | ||||||||||||
Investments at fair value | [8],[9],[10],[16] | $ 14,687 | ||||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[4],[5],[14] | 8% | [1],[4],[5],[14] | 8% | [1],[4],[5],[14] | 8% | [8],[9],[10],[16] | 8% | [8],[9],[10],[16] | 8% | [8],[9],[10],[16] | ||
Investment, interest rate | 13.54% | [1],[2],[4],[5],[14] | 13.54% | [1],[2],[4],[5],[14] | 13.54% | [1],[2],[4],[5],[14] | 11.67% | [8],[9],[10],[11],[16] | 11.67% | [8],[9],[10],[11],[16] | 11.67% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 12,500 | [1],[4],[5],[7],[14] | $ 12,500 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 12,188 | [1],[4],[5],[14] | 12,188 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 11,865 | [1],[4],[5],[14] | $ 11,958 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Amynta Agency Borrower Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | |||||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | |||||||||||
Investment, principal | $ 2,993 | |||||||||||||
Investment owned, at cost | 2,913 | |||||||||||||
Investments at fair value | $ 2,997 | |||||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | ||||||||
Investment, interest rate | 9.40% | 9.40% | 9.40% | 7.42% | 7.42% | 7.42% | ||||||||
Investment, principal | $ 1,523 | $ 1,539 | ||||||||||||
Investment owned, at cost | 1,191 | 1,203 | ||||||||||||
Investments at fair value | $ 1,099 | $ 1,232 | ||||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | ||||||||
Investment, interest rate | 9.40% | 9.40% | 9.40% | 7.42% | 7.42% | 7.42% | ||||||||
Investment, principal | $ 907 | $ 917 | ||||||||||||
Investment owned, at cost | 705 | 712 | ||||||||||||
Investments at fair value | $ 654 | $ 734 | ||||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [4],[5] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [2],[4],[5] | 9.40% | 9.40% | 9.40% | ||||||||||
Investment, principal | [4],[5],[7] | $ 3,700 | ||||||||||||
Investment owned, at cost | [4],[5] | 3,067 | ||||||||||||
Investments at fair value | [4],[5] | $ 2,669 | ||||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Products, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.42% | 7.42% | 7.42% | ||||||||||
Investment, principal | [9],[10],[12] | $ 2,736 | ||||||||||||
Investment owned, at cost | [9],[10] | 2,260 | ||||||||||||
Investments at fair value | [9],[10] | $ 2,189 | ||||||||||||
Investment, Identifier [Axis]: Ankura Consulting Group LLC, Research & Consulting Services, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.78% | 10.78% | 10.78% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 4,346 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 4,281 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 3,813 | ||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 8.46% | 8.46% | 8.46% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 892 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 863 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 846 | ||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 8.46% | 8.46% | 8.46% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 34,458 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 33,737 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 33,738 | ||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 8.46% | 8.46% | 8.46% | |||||||||||
Investment, principal | $ 154 | |||||||||||||
Investment owned, at cost | 151 | |||||||||||||
Investments at fair value | $ 146 | |||||||||||||
Investment, Identifier [Axis]: Apptio, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 8.46% | 8.46% | 8.46% | |||||||||||
Investment, principal | $ 4,615 | |||||||||||||
Investment owned, at cost | 4,580 | |||||||||||||
Investments at fair value | $ 4,519 | |||||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 7% | [8],[9],[10],[16] | 7% | [8],[9],[10],[16] | 7% | [8],[9],[10],[16] | ||
Investment, interest rate | 10.95% | [1],[2],[4],[5],[14] | 10.95% | [1],[2],[4],[5],[14] | 10.95% | [1],[2],[4],[5],[14] | 8% | [8],[9],[10],[11],[16] | 8% | [8],[9],[10],[11],[16] | 8% | [8],[9],[10],[11],[16] | ||
Investment, principal | € | € 3,017 | [1],[4],[5],[7],[14] | € 1,964 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | $ 3,331 | [1],[4],[5],[14] | $ 2,176 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 3,226 | [1],[4],[5],[14] | $ 1,927 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | [1],[4],[5],[14] | 5.75% | [1],[4],[5],[14] | 5.75% | [1],[4],[5],[14] | 7% | [8],[9],[10],[16] | 7% | [8],[9],[10],[16] | 7% | [8],[9],[10],[16] | ||
Investment, interest rate | 11.57% | [1],[2],[4],[5],[14] | 11.57% | [1],[2],[4],[5],[14] | 11.57% | [1],[2],[4],[5],[14] | 9.19% | [8],[9],[10],[11],[16] | 9.19% | [8],[9],[10],[11],[16] | 9.19% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 10,519 | [1],[4],[5],[7],[14] | £ 18,636 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 10,400 | [1],[4],[5],[14] | $ 23,139 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 10,624 | [1],[4],[5],[14] | $ 20,826 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 5.75% | [8],[9],[10],[16] | 5.75% | [8],[9],[10],[16] | 5.75% | [8],[9],[10],[16] | ||
Investment, interest rate | 12.46% | [1],[2],[4],[5],[14] | 12.46% | [1],[2],[4],[5],[14] | 12.46% | [1],[2],[4],[5],[14] | 8.81% | [8],[9],[10],[11],[16] | 8.81% | [8],[9],[10],[11],[16] | 8.81% | [8],[9],[10],[11],[16] | ||
Investment, principal | £ 4,949 | [1],[4],[5],[7],[14] | $ 10,519 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | $ 6,318 | [1],[4],[5],[14] | 10,357 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 6,101 | [1],[4],[5],[14] | $ 10,328 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 7% | [1],[4],[5],[14] | 5.75% | [8],[9],[10],[13],[16] | 5.75% | [8],[9],[10],[13],[16] | 5.75% | [8],[9],[10],[13],[16] | ||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.46% | 12.46% | 12.46% | ||||||||||
Investment, principal | £ | £ 23,675 | [1],[4],[5],[7],[14] | £ 0 | [8],[9],[10],[12],[13],[16] | ||||||||||
Investment owned, at cost | $ 28,713 | [1],[4],[5],[14] | $ (44) | [8],[9],[10],[13],[16] | ||||||||||
Investments at fair value | $ 29,185 | [1],[4],[5],[14] | 0 | [8],[9],[10],[13],[16] | ||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 9.70% | 9.70% | 9.70% | ||||||||||
Investment, principal | £ | [1],[4],[5],[7],[14] | £ 3,649 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | $ 4,094 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 3,914 | ||||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | 1,783,332 | 1,783,332 | |||||||||||
Investments at fair value | $ 89 | 370 | ||||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | 6.75% | 6.75% | |||||||||||
Investment, interest rate | 12.14% | 12.14% | 12.14% | |||||||||||
Investment, principal | $ 21,852 | |||||||||||||
Investments at fair value | $ 21,823 | 24,225 | ||||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | 1,129,453 | 1,129,453 | |||||||||||
Investments at fair value | $ 1,005 | $ 1,223 | ||||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | [1],[20] | 1,783,332 | [1],[20] | 1,783,332 | [1],[20] | 1,609,201 | [8],[21] | 1,609,201 | [8],[21] | 1,609,201 | [8],[21] | ||
Investment owned, at cost | $ 804 | [1],[20] | $ 764 | [8],[21] | ||||||||||
Investments at fair value | $ 89 | [1],[20] | $ 370 | [8],[21] | $ 587 | |||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [1],[3],[5],[20] | 6.75% | [1],[3],[5],[20] | 6.75% | [1],[3],[5],[20] | 6.75% | [8],[10],[13],[21] | 6.75% | [8],[10],[13],[21] | 6.75% | [8],[10],[13],[21] | ||
Investment, interest rate | 12.14% | [1],[2],[3],[5],[20] | 12.14% | [1],[2],[3],[5],[20] | 12.14% | [1],[2],[3],[5],[20] | 10.42% | [8],[10],[11],[13],[21] | 10.42% | [8],[10],[11],[13],[21] | 10.42% | [8],[10],[11],[13],[21] | ||
Investment, principal | $ 21,852 | [1],[3],[5],[7],[20] | $ 24,490 | [8],[10],[12],[13],[21] | ||||||||||
Investment owned, at cost | 21,855 | [1],[3],[5],[20] | 24,490 | [8],[10],[13],[21] | ||||||||||
Investments at fair value | $ 21,823 | [1],[3],[5],[20] | $ 24,225 | [8],[10],[13],[21] | 15,712 | |||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | [1],[20] | 1,129,453 | [1],[20] | 1,129,453 | [1],[20] | 1,019,169 | [8],[21] | 1,019,169 | [8],[21] | 1,019,169 | [8],[21] | ||
Investment owned, at cost | $ 1,159 | [1],[20] | $ 1,019 | [8],[21] | ||||||||||
Investments at fair value | $ 1,005 | [1],[20] | $ 1,223 | [8],[21] | 1,152 | |||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | [1],[20] | 78,045 | [1],[20] | 78,045 | [1],[20] | 70,425 | [8],[21] | 70,425 | [8],[21] | 70,425 | [8],[21] | ||
Investment owned, at cost | $ 0 | [1],[20] | $ 0 | [8],[21] | ||||||||||
Investments at fair value | $ 0 | [1],[20] | 0 | [8],[21] | 0 | |||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | 78,045 | 78,045 | |||||||||||
Investments at fair value | $ 0 | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Associated Asphalt Partners, LLC, Construction Materials, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, interest rate | [9],[10],[11] | 8.06% | 8.06% | 8.06% | ||||||||||
Investment, principal | [9],[10],[12] | $ 2,501 | ||||||||||||
Investment owned, at cost | [9],[10] | 2,331 | ||||||||||||
Investments at fair value | [9],[10] | $ 1,934 | ||||||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [4],[5] | 5.25% | [4],[5] | 5.25% | [4],[5] | 5.25% | [9],[10] | 5.25% | [9],[10] | 5.25% | [9],[10] | ||
Investment, interest rate | 10.90% | [2],[4],[5] | 10.90% | [2],[4],[5] | 10.90% | [2],[4],[5] | 8.37% | [9],[10],[11] | 8.37% | [9],[10],[11] | 8.37% | [9],[10],[11] | ||
Investment, principal | $ 8,490 | [4],[5],[7] | $ 5,640 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 8,168 | [4],[5] | 5,482 | [9],[10] | ||||||||||
Investments at fair value | $ 6,414 | [4],[5] | $ 4,822 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.37% | 8.37% | 8.37% | ||||||||
Investment, principal | $ 5,052 | $ 5,052 | ||||||||||||
Investment owned, at cost | 4,888 | 4,858 | ||||||||||||
Investments at fair value | $ 3,817 | $ 4,319 | ||||||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.37% | 8.37% | 8.37% | ||||||||
Investment, principal | $ 2,078 | $ 2,078 | ||||||||||||
Investment owned, at cost | 2,039 | 2,033 | ||||||||||||
Investments at fair value | $ 1,570 | $ 1,777 | ||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 7.70% | 7.70% | 7.70% | |||||||||||
Investment, principal | $ 5,000 | |||||||||||||
Investment owned, at cost | 4,753 | |||||||||||||
Investments at fair value | $ 4,276 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 7.70% | 7.70% | 7.70% | |||||||||||
Investment, principal | $ 2,000 | |||||||||||||
Investment owned, at cost | 1,901 | |||||||||||||
Investments at fair value | $ 1,711 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.42% | 9.42% | 9.42% | |||||||||||
Investment, principal | $ 4,950 | |||||||||||||
Investment owned, at cost | 4,747 | |||||||||||||
Investments at fair value | $ 4,809 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 9.67% | 9.67% | 9.67% | |||||||||||
Investment, principal | $ 1,990 | |||||||||||||
Investment owned, at cost | 1,884 | |||||||||||||
Investments at fair value | $ 1,937 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, First Lien Term Loan 1 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.42% | 9.42% | 9.42% | |||||||||||
Investment, principal | $ 1,980 | |||||||||||||
Investment owned, at cost | 1,899 | |||||||||||||
Investments at fair value | $ 1,924 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, First Lien Term Loan 2 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 9.67% | 9.67% | 9.67% | |||||||||||
Investment, principal | $ 995 | |||||||||||||
Investment owned, at cost | 942 | |||||||||||||
Investments at fair value | $ 968 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, Property & Casualty Insurance, Second Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | |||||||||||
Investment, interest rate | 10.68% | 10.68% | 10.68% | |||||||||||
Investment, principal | $ 2,423 | |||||||||||||
Investment owned, at cost | 2,244 | |||||||||||||
Investments at fair value | $ 2,158 | |||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, Second Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.68% | 10.68% | 10.68% | 8.37% | 8.37% | 8.37% | ||||||||
Investment, principal | $ 4,346 | $ 4,346 | ||||||||||||
Investment owned, at cost | 4,036 | 3,981 | ||||||||||||
Investments at fair value | $ 3,871 | $ 3,347 | ||||||||||||
Investment, Identifier [Axis]: Asurion, LLC, Second Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | |||||||||||
Investment, interest rate | 8.37% | 8.37% | 8.37% | |||||||||||
Investment, principal | $ 2,423 | |||||||||||||
Investment owned, at cost | 2,212 | |||||||||||||
Investments at fair value | $ 1,866 | |||||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 11% | 11% | 11% | ||||||||||
Investment, principal | [8],[9],[12],[16] | $ 13,346 | ||||||||||||
Investment owned, at cost | [8],[9],[16] | 12,929 | ||||||||||||
Investments at fair value | [8],[9],[16] | 12,812 | ||||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [8],[9],[12],[16],[22] | 8,309 | ||||||||||||
Investment owned, at cost | [8],[9],[16],[22] | 8,264 | ||||||||||||
Investments at fair value | [8],[9],[16],[22] | $ 8,309 | ||||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9],[16] | 328,149 | 328,149 | 328,149 | ||||||||||
Investment owned, at cost | [8],[9],[16] | $ 973 | ||||||||||||
Investments at fair value | [8],[9],[16] | $ 16 | ||||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[4],[5],[14] | 6% | [1],[4],[5],[14] | 6% | [1],[4],[5],[14] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | ||
Investment, interest rate | 11.49% | [1],[2],[4],[5],[14] | 11.49% | [1],[2],[4],[5],[14] | 11.49% | [1],[2],[4],[5],[14] | 8.78% | [8],[9],[10],[11],[16] | 8.78% | [8],[9],[10],[11],[16] | 8.78% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 29,509 | [1],[4],[5],[7],[14] | $ 22,425 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 29,164 | [1],[4],[5],[14] | 22,086 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 28,284 | [1],[4],[5],[14] | $ 21,326 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 11.49% | 11.49% | 11.49% | |||||||||||
Investment, principal | $ 3,628 | |||||||||||||
Investment owned, at cost | 3,586 | |||||||||||||
Investments at fair value | $ 3,478 | |||||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, interest rate | 11.49% | 11.49% | 11.49% | 8.78% | 8.78% | 8.78% | ||||||||
Investment, principal | $ 6,289 | $ 6,338 | ||||||||||||
Investment owned, at cost | 6,216 | 6,242 | ||||||||||||
Investments at fair value | $ 6,028 | $ 6,027 | ||||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 8.78% | 8.78% | 8.78% | |||||||||||
Investment, principal | $ 3,656 | |||||||||||||
Investment owned, at cost | 3,601 | |||||||||||||
Investments at fair value | $ 3,476 | |||||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (108) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (78) | ||||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 50,470 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 49,679 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 49,688 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 1,753 | $ 6,371 | ||||||||||||
Investment owned, at cost | 1,742 | 6,311 | ||||||||||||
Investments at fair value | $ 1,711 | $ 6,148 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 1 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 3,363 | $ 3,398 | ||||||||||||
Investment owned, at cost | 3,332 | 3,366 | ||||||||||||
Investments at fair value | $ 3,282 | $ 3,279 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 6,306 | $ 1,771 | ||||||||||||
Investment owned, at cost | 6,247 | 1,751 | ||||||||||||
Investments at fair value | $ 6,155 | $ 1,664 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 2 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 800 | $ 808 | ||||||||||||
Investment owned, at cost | 795 | 800 | ||||||||||||
Investments at fair value | $ 780 | $ 760 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 8.12% | 8.12% | 8.12% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 2,546 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 2,503 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 2,395 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 10.65% | 10.65% | 10.65% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 3,247 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 3,216 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 3,169 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 10.65% | 10.65% | 10.65% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,261 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 1,269 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,231 | ||||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | ||
Investment, interest rate | 14.15% | [1],[2],[4],[5] | 14.15% | [1],[2],[4],[5] | 14.15% | [1],[2],[4],[5] | 11.62% | [8],[9],[10],[11] | 11.62% | [8],[9],[10],[11] | 11.62% | [8],[9],[10],[11] | ||
Investment, principal | $ 8,920 | [1],[4],[5],[7] | $ 7,166 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 8,819 | [1],[4],[5] | 7,059 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 8,492 | [1],[4],[5] | $ 6,915 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [8],[9],[10],[13] | 8.50% | [8],[9],[10],[13] | 8.50% | [8],[9],[10],[13] | ||
Investment, interest rate | 14.15% | [1],[2],[4],[5] | 14.15% | [1],[2],[4],[5] | 14.15% | [1],[2],[4],[5] | 11.62% | [8],[9],[10],[11],[13] | 11.62% | [8],[9],[10],[11],[13] | 11.62% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 2,091 | [1],[4],[5],[7] | $ 4,227 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 2,068 | [1],[4],[5] | 4,070 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 1,991 | [1],[4],[5] | $ 3,839 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 14.15% | 14.15% | 14.15% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 4,361 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 4,297 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 4,152 | ||||||||||||
Investment, Identifier [Axis]: BYJU's Alpha, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 8.98% | 8.98% | 8.98% | |||||||||||
Investment, principal | $ 7,444 | |||||||||||||
Investment owned, at cost | 7,347 | |||||||||||||
Investments at fair value | $ 5,455 | |||||||||||||
Investment, Identifier [Axis]: BYJU's Alpha, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 8.98% | 8.98% | 8.98% | |||||||||||
Investment, principal | $ 3,970 | |||||||||||||
Investment owned, at cost | 3,919 | |||||||||||||
Investments at fair value | $ 2,909 | |||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 13% | 13% | 13% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 2,221 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 2,188 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 2,178 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.02% | 11.02% | 11.02% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 40,660 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 40,440 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 40,213 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 1,702 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 1,660 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 1,617 | ||||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 8.31% | 8.31% | 8.31% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 33,078 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 32,612 | ||||||||||||
Investments at fair value | [8],[9],[10] | 32,053 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [8],[9],[12],[13],[16],[22] | 0 | ||||||||||||
Investment owned, at cost | [8],[9],[13],[16],[22] | 0 | ||||||||||||
Investments at fair value | [8],[9],[13],[16],[22] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 8% | [1],[2],[4],[5],[14] | 8% | [1],[2],[4],[5],[14] | 8% | [1],[2],[4],[5],[14] | 10.25% | [8],[9],[10],[11],[16] | 10.25% | [8],[9],[10],[11],[16] | 10.25% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 6,757 | [1],[4],[7],[14] | $ 5,322 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 6,560 | [1],[4],[14] | 5,111 | [8],[9],[16] | ||||||||||
Investments at fair value | 6,225 | [1],[4],[14] | $ 5,114 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[13],[16] | 10.25% | 10.25% | 10.25% | ||||||||||
Investment, principal | 3,316 | [1],[4],[7],[14],[15] | $ 0 | [8],[9],[12],[13],[16] | ||||||||||
Investment owned, at cost | 3,335 | [1],[4],[14],[15] | 0 | [8],[9],[13],[16] | ||||||||||
Investments at fair value | $ 3,169 | [1],[4],[14],[15] | 0 | [8],[9],[13],[16] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8% | 8% | 8% | ||||||||||
Investment, principal | $ 0 | [1],[3],[4],[7],[14] | 2,353 | [8],[9],[12],[16],[22] | ||||||||||
Investment owned, at cost | 0 | [1],[3],[4],[14] | 2,353 | [8],[9],[16],[22] | ||||||||||
Investments at fair value | $ 0 | [1],[3],[4],[14] | $ 2,353 | [8],[9],[16],[22] | ||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 8% | 8% | 8% | ||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[14] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[14] | 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 5 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[3],[4],[7],[14],[15] | 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[14],[15] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[14],[15] | 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[3],[4],[7],[14],[15] | 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[14],[15] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[14],[15] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 26,131 | [1],[4],[14] | 26,131 | [1],[4],[14] | 26,131 | [1],[4],[14] | 21,177 | [8],[9],[16] | 21,177 | [8],[9],[16] | 21,177 | [8],[9],[16] | ||
Investment owned, at cost | $ 225 | [1],[4],[14] | $ 125 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 3 | [1],[4],[14] | $ 98 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [4],[5] | 7% | [4],[5] | 7% | [4],[5] | 7% | [9],[10] | 7% | [9],[10] | 7% | [9],[10] | ||
Investment, interest rate | 12.43% | [2],[4],[5] | 12.43% | [2],[4],[5] | 12.43% | [2],[4],[5] | 9.50% | [9],[10],[11] | 9.50% | [9],[10],[11] | 9.50% | [9],[10],[11] | ||
Investment, principal | $ 30,625 | [4],[5],[7] | $ 30,625 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 30,370 | [4],[5] | 30,276 | [9],[10] | ||||||||||
Investments at fair value | $ 29,989 | [4],[5] | $ 29,017 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3% | 3% | 3% | |||||||||||
Investment, interest rate | 6.03% | 6.03% | 6.03% | |||||||||||
Investment, principal | $ 9,575 | |||||||||||||
Investment owned, at cost | 9,566 | |||||||||||||
Investments at fair value | $ 8,977 | |||||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [1],[4] | 394,297 | [1],[4] | 394,297 | [1],[4] | 298,460 | [8],[9] | 298,460 | [8],[9] | 298,460 | [8],[9] | ||
Investment owned, at cost | $ 424 | [1],[4] | $ 298 | [8],[9] | ||||||||||
Investments at fair value | $ 158 | [1],[4] | $ 349 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 9% | [1],[2],[4],[5] | 9% | [1],[2],[4],[5] | 9% | [1],[2],[4],[5] | 9% | [8],[9],[10],[11] | 9% | [8],[9],[10],[11] | 9% | [8],[9],[10],[11] | ||
Investment, principal | $ 5,257 | [1],[4],[7] | $ 3,979 | [8],[9],[12] | ||||||||||
Investment owned, at cost | 5,258 | [1],[4] | 3,980 | [8],[9] | ||||||||||
Investments at fair value | $ 5,251 | [1],[4] | $ 3,960 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,708,618 | [1],[4] | 1,708,618 | [1],[4] | 1,708,618 | [1],[4] | 1,293,324 | [8],[9] | 1,293,324 | [8],[9] | 1,293,324 | [8],[9] | ||
Investment owned, at cost | $ 1,711 | [1],[4] | $ 1,293 | [8],[9] | ||||||||||
Investments at fair value | $ 1,999 | [1],[4] | $ 1,280 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [1],[4] | 394,297 | [1],[4] | 394,297 | [1],[4] | 298,460 | [8],[9] | 298,460 | [8],[9] | 298,460 | [8],[9] | ||
Investment owned, at cost | $ 395 | [1],[4] | $ 298 | [8],[9] | ||||||||||
Investments at fair value | $ 442 | [1],[4] | $ 295 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Common Stock | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 171,000 | 171,000 | 171,000 | 171,000 | 171,000 | 171,000 | ||||||||
Investment owned, at cost | $ 0 | $ 0 | ||||||||||||
Investments at fair value | $ 0 | $ 0 | ||||||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 829 | [1] | 829 | [1] | 829 | [1] | 829 | [8],[23],[24] | 829 | [8],[23],[24] | 829 | [8],[23],[24] | ||
Investment, principal | $ 0 | |||||||||||||
Investment owned, at cost | $ 0 | [1] | 0 | [8],[23],[24] | ||||||||||
Investments at fair value | $ 0 | [1] | $ 0 | [8],[23],[24] | 0 | |||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 34,984,460 | [1] | 34,984,460 | [1] | 34,984,460 | [1] | 34,984,460 | [8],[23],[24] | 34,984,460 | [8],[23],[24] | 34,984,460 | [8],[23],[24] | ||
Investment, principal | $ 0 | |||||||||||||
Investment owned, at cost | $ 34,984 | [1] | 34,984 | [8],[23],[24] | ||||||||||
Investments at fair value | $ 27,638 | [1] | $ 27,638 | [8],[23],[24] | 27,638 | |||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Preferred Equity | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 7,193,540,000 | 7,193,540,000 | 7,193,540,000 | 7,193,540 | 7,193,540 | 7,193,540 | ||||||||
Investment owned, at cost | $ 7,194 | $ 7,194 | ||||||||||||
Investments at fair value | $ 5,683 | $ 5,683 | ||||||||||||
Investment, Identifier [Axis]: CCO Holdings LLC, Cable & Satellite, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, principal | [9],[12],[16] | $ 2,097 | ||||||||||||
Investment owned, at cost | [9],[16] | 1,746 | ||||||||||||
Investments at fair value | [9],[16] | $ 1,603 | ||||||||||||
Investment, Identifier [Axis]: CITGO Holding, Inc., Oil & Gas Refining & Marketing, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [9],[12] | $ 7,857 | ||||||||||||
Investment owned, at cost | [9] | 7,857 | ||||||||||||
Investments at fair value | [9] | $ 7,807 | ||||||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | |||||||||||
Investment, interest rate | 9.37% | 9.37% | 9.37% | |||||||||||
Investment, principal | $ 7,038 | |||||||||||||
Investment owned, at cost | 6,967 | |||||||||||||
Investments at fair value | $ 7,057 | |||||||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | |||||||||||
Investment, interest rate | 9.37% | 9.37% | 9.37% | |||||||||||
Investment, principal | $ 3,519 | |||||||||||||
Investment owned, at cost | 3,484 | |||||||||||||
Investments at fair value | $ 3,529 | |||||||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., Oil & Gas Refining & Marketing, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 6.25% | 6.25% | 6.25% | ||||||||||
Investment, interest rate | [9],[10],[11] | 9.37% | 9.37% | 9.37% | ||||||||||
Investment, principal | [9],[10],[12] | $ 795 | ||||||||||||
Investment owned, at cost | [9],[10] | 770 | ||||||||||||
Investments at fair value | [9],[10] | $ 797 | ||||||||||||
Investment, Identifier [Axis]: CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[17] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [1],[4],[5],[7],[17] | $ 727 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[17] | 462 | ||||||||||||
Investments at fair value | [1],[4],[5],[17] | $ 396 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.31% | 9.31% | 9.31% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 14,294 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 13,471 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 13,143 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 37 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 37 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 37 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 3,031 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 2,899 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 3,031 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,557 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 1,489 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,557 | ||||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.07% | 12.07% | 12.07% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,024 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 994 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,024 | ||||||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Health Care Services, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | [1],[20] | 1,080,399 | [1],[20] | 1,080,399 | [1],[20] | 1,080,399 | [8],[21] | 1,080,399 | [8],[21] | 1,080,399 | [8],[21] | ||
Investment owned, at cost | $ 1,080 | [1],[20] | $ 1,080 | [8],[21] | ||||||||||
Investments at fair value | $ 432 | [1],[20] | 378 | [8],[21] | 838 | |||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | 1,080,399 | 1,080,399 | |||||||||||
Investments at fair value | $ 432 | $ 378 | ||||||||||||
Investment, Identifier [Axis]: Carvana Co., Automotive Retail, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 5.63% | 5.63% | 5.63% | ||||||||||
Investment, principal | [9],[12],[16] | $ 6,700 | ||||||||||||
Investment owned, at cost | [9],[16] | 5,825 | ||||||||||||
Investments at fair value | [9],[16] | $ 4,724 | ||||||||||||
Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, interest rate | 11.57% | 11.57% | 11.57% | |||||||||||
Investment, principal | $ 600 | $ 0 | ||||||||||||
Investment owned, at cost | 592 | (10) | ||||||||||||
Investments at fair value | $ 581 | $ (11) | ||||||||||||
Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | 9.12% | 9.12% | 9.12% | ||||||||
Investment, principal | $ 2,354 | $ 4,358 | ||||||||||||
Investment owned, at cost | 2,322 | 4,286 | ||||||||||||
Investments at fair value | $ 2,281 | $ 4,280 | ||||||||||||
Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | 9.12% | 9.12% | 9.12% | ||||||||
Investment, principal | $ 1,983 | $ 449 | ||||||||||||
Investment owned, at cost | 1,954 | 432 | ||||||||||||
Investments at fair value | $ 1,921 | $ 413 | ||||||||||||
Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 3 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | |||||||||||
Investment, interest rate | 11.55% | 11.55% | 11.55% | |||||||||||
Investment, principal | $ 1,960 | |||||||||||||
Investment owned, at cost | 1,935 | |||||||||||||
Investments at fair value | $ 1,899 | |||||||||||||
Investment, Identifier [Axis]: CircusTrix Holdings, LLC, Leisure Facilities, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 8.62% | 8.62% | 8.62% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 10,692 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 10,004 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 10,209 | ||||||||||||
Investment, Identifier [Axis]: City Football Group Limited, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.50% | 3.50% | 3.50% | |||||||||||
Investment, interest rate | 6.48% | 6.48% | 6.48% | |||||||||||
Investment, principal | $ 6,451 | |||||||||||||
Investment owned, at cost | 6,419 | |||||||||||||
Investments at fair value | $ 6,166 | |||||||||||||
Investment, Identifier [Axis]: City Football Group Limited, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.50% | 3.50% | 3.50% | |||||||||||
Investment, interest rate | 6.48% | 6.48% | 6.48% | |||||||||||
Investment, principal | $ 2,481 | |||||||||||||
Investment owned, at cost | 2,469 | |||||||||||||
Investments at fair value | $ 2,372 | |||||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 7.50% | [2],[4],[5],[14] | 7.50% | [2],[4],[5],[14] | 7.50% | [2],[4],[5],[14] | 7.50% | [9],[10],[11],[16] | 7.50% | [9],[10],[11],[16] | 7.50% | [9],[10],[11],[16] | ||
Investment, principal | $ 2,632 | [4],[7],[14] | $ 4,311 | [9],[12],[16] | ||||||||||
Investment owned, at cost | 2,632 | [4],[14] | 4,311 | [9],[16] | ||||||||||
Investments at fair value | $ 2,017 | [4],[14] | $ 3,132 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 7.75% | [2],[4],[5],[14] | 7.75% | [2],[4],[5],[14] | 7.75% | [2],[4],[5],[14] | 5.13% | [9],[10],[11],[16] | 5.13% | [9],[10],[11],[16] | 5.13% | [9],[10],[11],[16] | ||
Investment, principal | $ 176 | [4],[7],[14] | $ 1,374 | [9],[12],[16] | ||||||||||
Investment owned, at cost | 170 | [4],[14] | 1,229 | [9],[16] | ||||||||||
Investments at fair value | $ 141 | [4],[14] | $ 1,163 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [9],[12],[16] | $ 676 | ||||||||||||
Investment owned, at cost | [9],[16] | 648 | ||||||||||||
Investments at fair value | [9],[16] | $ 512 | ||||||||||||
Investment, Identifier [Axis]: Condor Merger Sub Inc., Systems Software, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 7.38% | [2],[4],[5] | 7.38% | [2],[4],[5] | 7.38% | [2],[4],[5] | 7.38% | [9],[10],[11] | 7.38% | [9],[10],[11] | 7.38% | [9],[10],[11] | ||
Investment, principal | $ 8,420 | [4],[7] | $ 8,420 | [9],[12] | ||||||||||
Investment owned, at cost | 8,261 | [4] | 8,243 | [9] | ||||||||||
Investments at fair value | $ 7,059 | [4] | $ 6,900 | [9] | ||||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[4],[5],[17] | 8.50% | [1],[4],[5],[17] | 8.50% | [1],[4],[5],[17] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | ||
Investment, interest rate | [8],[9],[10],[11] | 11.62% | 11.62% | 11.62% | ||||||||||
Investment, principal | $ 22,084 | [1],[4],[5],[7],[17] | $ 22,537 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 21,336 | [1],[4],[5],[17] | 21,642 | [8],[9],[10] | ||||||||||
Investments at fair value | 16,040 | [1],[4],[5],[17] | 20,396 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | 706 | [1],[4] | 648 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 457 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Convergeone Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | |||||||||||
Investment, interest rate | 8.12% | 8.12% | 8.12% | |||||||||||
Investment, principal | $ 7,373 | |||||||||||||
Investment owned, at cost | 7,206 | |||||||||||||
Investments at fair value | $ 5,320 | |||||||||||||
Investment, Identifier [Axis]: Convergeone Holdings, Inc., IT Consulting & Other Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [9],[10],[11] | 8.12% | 8.12% | 8.12% | ||||||||||
Investment, principal | [9],[10],[12] | $ 11,913 | ||||||||||||
Investment owned, at cost | [9],[10] | 11,697 | ||||||||||||
Investments at fair value | [9],[10] | $ 8,596 | ||||||||||||
Investment, Identifier [Axis]: Conviva Inc., Application Software, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 417,851 | [1],[4] | 417,851 | [1],[4] | 417,851 | [1],[4] | 417,851 | [8],[9] | 417,851 | [8],[9] | 417,851 | [8],[9] | ||
Investment owned, at cost | $ 605 | [1],[4] | $ 605 | [8],[9] | ||||||||||
Investments at fair value | $ 894 | [1],[4] | $ 894 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 1,099 | 1,099 | 1,099 | ||||||||||
Investment owned, at cost | [8],[9] | $ 690 | ||||||||||||
Investments at fair value | [8],[9] | $ 2,340 | ||||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 11% | 11% | 11% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 916 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 898 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 898 | ||||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 8.88% | 8.88% | 8.88% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 13,712 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 13,554 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 13,583 | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (20) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (20) | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.82% | 12.82% | 12.82% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 13,157 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 12,855 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 12,858 | ||||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (15) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (13) | ||||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.39% | 10.39% | 10.39% | 7.65% | 7.65% | 7.65% | ||||||||
Investment, principal | $ 6,343 | $ 5,375 | ||||||||||||
Investment owned, at cost | 5,983 | 5,053 | ||||||||||||
Investments at fair value | $ 6,285 | $ 5,035 | ||||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.39% | 10.39% | 10.39% | 7.65% | 7.65% | 7.65% | ||||||||
Investment, principal | $ 2,766 | $ 2,280 | ||||||||||||
Investment owned, at cost | 2,607 | 2,143 | ||||||||||||
Investments at fair value | $ 2,741 | $ 2,136 | ||||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [4],[5] | 5% | [4],[5] | 5% | [4],[5] | 5% | [9],[10] | 5% | [9],[10] | 5% | [9],[10] | ||
Investment, interest rate | 10.39% | [2],[4],[5] | 10.39% | [2],[4],[5] | 10.39% | [2],[4],[5] | 7.65% | [9],[10],[11] | 7.65% | [9],[10],[11] | 7.65% | [9],[10],[11] | ||
Investment, principal | $ 14,750 | [4],[5],[7] | $ 10,336 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 14,173 | [4],[5] | 9,716 | [9],[10] | ||||||||||
Investments at fair value | $ 14,616 | [4],[5] | $ 9,681 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | ||
Investment, interest rate | [2],[5] | 11.47% | 11.47% | 11.47% | ||||||||||
Investment, principal | $ 933 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 920 | [1],[3],[4],[5] | (13) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 918 | [1],[3],[4],[5] | $ (26) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | ||
Investment, interest rate | 11.52% | [1],[2],[4],[5] | 11.52% | [1],[2],[4],[5] | 11.52% | [1],[2],[4],[5] | 8.81% | [8],[9],[10],[11] | 8.81% | [8],[9],[10],[11] | 8.81% | [8],[9],[10],[11] | ||
Investment, principal | $ 18,013 | [1],[4],[5],[7] | $ 18,200 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 17,690 | [1],[4],[5] | 17,790 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 17,812 | [1],[4],[5] | $ 17,843 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Curium Bidco S.à.r.l., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4% | 4% | 4% | ||||||||
Investment, interest rate | 9.89% | 9.89% | 9.89% | 7.67% | 7.67% | 7.67% | ||||||||
Investment, principal | $ 8,730 | $ 5,820 | ||||||||||||
Investment owned, at cost | 8,642 | 5,776 | ||||||||||||
Investments at fair value | $ 8,730 | $ 5,587 | ||||||||||||
Investment, Identifier [Axis]: Curium Bidco S.à.r.l., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4% | 4% | 4% | ||||||||
Investment, interest rate | 9.89% | 9.89% | 9.89% | 7.67% | 7.67% | 7.67% | ||||||||
Investment, principal | $ 2,841 | $ 2,870 | ||||||||||||
Investment owned, at cost | 2,820 | 2,849 | ||||||||||||
Investments at fair value | $ 2,841 | $ 2,756 | ||||||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 10.12% | 10.12% | 10.12% | |||||||||||
Investment, principal | $ 2,970 | |||||||||||||
Investment owned, at cost | 2,922 | |||||||||||||
Investments at fair value | $ 2,899 | |||||||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | 4.75% | 4.75% | 4.75% | ||||||||
Investment, interest rate | 10.12% | 10.12% | 10.12% | 7.33% | 7.33% | 7.33% | ||||||||
Investment, principal | $ 7,920 | $ 8,000 | ||||||||||||
Investment owned, at cost | 7,792 | 7,849 | ||||||||||||
Investments at fair value | $ 7,729 | $ 7,616 | ||||||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 7.33% | 7.33% | 7.33% | |||||||||||
Investment, principal | $ 3,000 | |||||||||||||
Investment owned, at cost | 2,943 | |||||||||||||
Investments at fair value | $ 2,856 | |||||||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | [4],[5] | 4.75% | [4],[5] | 4.75% | [4],[5] | 4.75% | [9],[10] | 4.75% | [9],[10] | 4.75% | [9],[10] | ||
Investment, interest rate | 10.12% | [2],[4],[5] | 10.12% | [2],[4],[5] | 10.12% | [2],[4],[5] | 7.33% | [9],[10],[11] | 7.33% | [9],[10],[11] | 7.33% | [9],[10],[11] | ||
Investment, principal | $ 4,950 | [4],[5],[7] | $ 5,000 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 4,871 | [4],[5] | 4,906 | [9],[10] | ||||||||||
Investments at fair value | $ 4,831 | [4],[5] | $ 4,760 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Dealer Tire, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 7.37% | 7.37% | 7.37% | |||||||||||
Investment, principal | $ 2,992 | |||||||||||||
Investment owned, at cost | 2,935 | |||||||||||||
Investments at fair value | $ 2,924 | |||||||||||||
Investment, Identifier [Axis]: Delivery Hero FinCo LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | 5.75% | 5.75% | |||||||||||
Investment, interest rate | 8.49% | 8.49% | 8.49% | |||||||||||
Investment, principal | $ 6,035 | |||||||||||||
Investment owned, at cost | 5,876 | |||||||||||||
Investments at fair value | $ 5,756 | |||||||||||||
Investment, Identifier [Axis]: Delivery Hero FinCo LLC, Internet & Direct Marketing Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10],[16] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [9],[10],[11],[16] | 8.49% | 8.49% | 8.49% | ||||||||||
Investment, principal | [9],[10],[12],[16] | $ 4,988 | ||||||||||||
Investment owned, at cost | [9],[10],[16] | 4,882 | ||||||||||||
Investments at fair value | [9],[10],[16] | $ 4,757 | ||||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 2 | [1],[4],[14] | 2 | [1],[4],[14] | 2 | [1],[4],[14] | 2 | [8],[9],[16] | 2 | [8],[9],[16] | 2 | [8],[9],[16] | ||
Investment owned, at cost | $ 2 | [1],[4],[14] | $ 2 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 2 | [1],[4],[14] | $ 2 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 419 | [1],[4],[14] | 419 | [1],[4],[14] | 419 | [1],[4],[14] | 419 | [8],[9],[16] | 419 | [8],[9],[16] | 419 | [8],[9],[16] | ||
Investment owned, at cost | $ 419 | [1],[4],[14] | $ 419 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 419 | [1],[4],[14] | $ 419 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 3% | [1],[2],[3],[4],[5],[14] | 3% | [1],[2],[3],[4],[5],[14] | 3% | [1],[2],[3],[4],[5],[14] | 10% | [8],[9],[10],[11],[13],[16] | 10% | [8],[9],[10],[11],[13],[16] | 10% | [8],[9],[10],[11],[13],[16] | ||
Investment, principal | $ 17,465 | [1],[3],[4],[7],[14] | $ 4,183 | [8],[9],[12],[13],[16] | ||||||||||
Investment owned, at cost | 17,465 | [1],[3],[4],[14] | 4,183 | [8],[9],[13],[16] | ||||||||||
Investments at fair value | $ 17,465 | [1],[3],[4],[14] | $ 4,183 | [8],[9],[13],[16] | ||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 31 | [1],[4],[14] | 31 | [1],[4],[14] | 31 | [1],[4],[14] | 31 | [8],[9],[16] | 31 | [8],[9],[16] | 31 | [8],[9],[16] | ||
Investment owned, at cost | $ 0 | [1],[4],[14] | $ 0 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 0 | [1],[4],[14] | $ 0 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Delta Topco, Inc., Systems Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [9],[10],[11] | 9.34% | 9.34% | 9.34% | ||||||||||
Investment, principal | [9],[10],[12] | $ 6,680 | ||||||||||||
Investment owned, at cost | [9],[10] | 6,647 | ||||||||||||
Investments at fair value | [9],[10] | $ 5,934 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 9% | 9% | 9% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 14.54% | 14.54% | 14.54% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 20,757 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 20,146 | ||||||||||||
Investments at fair value | [1],[4],[5] | 20,653 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 9% | 9% | 9% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 12.67% | 12.67% | 12.67% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 24,396 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 23,083 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 22,993 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 9% | 9% | 9% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | (135) | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ (129) | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[4],[7] | 654 | ||||||||||||
Investment owned, at cost | [1],[4] | 653 | ||||||||||||
Investments at fair value | [1],[4] | $ 631 | ||||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 6,397,254 | [1],[4] | 6,397,254 | [1],[4] | 6,397,254 | [1],[4] | 5,403,823 | [8],[9] | 5,403,823 | [8],[9] | 5,403,823 | [8],[9] | ||
Investment owned, at cost | $ 1,642 | [1],[4] | $ 1,405 | [8],[9] | ||||||||||
Investments at fair value | $ 1,152 | [1],[4] | $ 1,297 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 6.50% | [8],[9],[10],[13] | 6.50% | [8],[9],[10],[13] | 6.50% | [8],[9],[10],[13] | ||
Investment, interest rate | 12.49% | [1],[2],[3],[4],[5] | 12.49% | [1],[2],[3],[4],[5] | 12.49% | [1],[2],[3],[4],[5] | 9.41% | [8],[9],[10],[11],[13] | 9.41% | [8],[9],[10],[11],[13] | 9.41% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 284 | [1],[3],[4],[5],[7] | $ 251 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 265 | [1],[3],[4],[5] | 228 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 252 | [1],[3],[4],[5] | $ 239 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | ||
Investment, interest rate | 12.49% | [1],[2],[4],[5] | 12.49% | [1],[2],[4],[5] | 12.49% | [1],[2],[4],[5] | 9.91% | [8],[9],[10],[11] | 9.91% | [8],[9],[10],[11] | 9.91% | [8],[9],[10],[11] | ||
Investment, principal | $ 12,386 | [1],[4],[5],[7] | $ 9,902 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 12,208 | [1],[4],[5] | 9,599 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 12,101 | [1],[4],[5] | $ 9,793 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [4],[5] | 5% | [4],[5] | 5% | [4],[5] | 5% | [9],[10] | 5% | [9],[10] | 5% | [9],[10] | ||
Investment, interest rate | 10.43% | [2],[4],[5] | 10.43% | [2],[4],[5] | 10.43% | [2],[4],[5] | 8.12% | [9],[10],[11] | 8.12% | [9],[10],[11] | 8.12% | [9],[10],[11] | ||
Investment, principal | $ 4,641 | [4],[5],[7] | $ 19,242 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 4,619 | [4],[5] | 18,970 | [9],[10] | ||||||||||
Investments at fair value | $ 4,546 | [4],[5] | $ 17,973 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: DirecTV Financing, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 5,799 | $ 6,436 | ||||||||||||
Investment owned, at cost | 5,715 | 6,332 | ||||||||||||
Investments at fair value | $ 5,681 | $ 6,012 | ||||||||||||
Investment, Identifier [Axis]: DirecTV Financing, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.12% | 8.12% | 8.12% | ||||||||
Investment, principal | $ 2,460 | $ 2,730 | ||||||||||||
Investment owned, at cost | 2,435 | 2,703 | ||||||||||||
Investments at fair value | $ 2,410 | $ 2,549 | ||||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 30,031 | [1] | 30,031 | [1] | 30,031 | [1] | 30,031 | [8],[23],[24] | 30,031 | [8],[23],[24] | 30,031 | [8],[23],[24] | ||
Investment owned, at cost | $ 15,222 | [1] | $ 15,222 | [8],[23],[24] | ||||||||||
Investments at fair value | $ 2,711 | [1] | $ 4,946 | [8],[23],[24] | 18,065 | |||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [1],[5] | 5% | [1],[5] | 5% | [1],[5] | 5% | [8],[10],[13],[23],[24] | 5% | [8],[10],[13],[23],[24] | 5% | [8],[10],[13],[23],[24] | ||
Investment, interest rate | 10.54% | [1],[2],[5] | 10.54% | [1],[2],[5] | 10.54% | [1],[2],[5] | 5% | 5% | 5% | |||||
Investment, principal | $ 5,574 | [1],[5],[7] | $ 0 | [8],[10],[12],[13],[23],[24] | ||||||||||
Investment owned, at cost | 5,574 | [1],[5] | 0 | [8],[10],[13],[23],[24] | ||||||||||
Investments at fair value | $ 5,574 | [1],[5] | $ 0 | [8],[10],[13],[23],[24] | 0 | |||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[10],[23],[24] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [8],[10],[11],[23],[24] | 8.68% | 8.68% | 8.68% | ||||||||||
Investment, principal | [8],[10],[12],[23],[24] | $ 14,333 | ||||||||||||
Investment owned, at cost | [8],[10],[23],[24] | 14,333 | ||||||||||||
Investments at fair value | 14,333 | [8],[10],[23],[24] | 27,381 | |||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[5] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [1],[2],[5] | 10.54% | 10.54% | 10.54% | ||||||||||
Investment, principal | [1],[5],[7] | $ 14,068 | ||||||||||||
Investment owned, at cost | [1],[5] | 14,068 | ||||||||||||
Investments at fair value | $ 14,068 | [1],[5] | 14,333 | |||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[5] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [1],[2],[3],[5] | 10.42% | 10.42% | 10.42% | ||||||||||
Investment, principal | [1],[3],[5],[7] | $ 2,090 | ||||||||||||
Investment owned, at cost | [1],[3],[5] | 2,090 | ||||||||||||
Investments at fair value | $ 2,090 | [1],[3],[5] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Domtar Corporation, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 8.26% | 8.26% | 8.26% | |||||||||||
Investment, principal | $ 4,100 | |||||||||||||
Investment owned, at cost | 4,065 | |||||||||||||
Investments at fair value | $ 3,921 | |||||||||||||
Investment, Identifier [Axis]: Domtar Corporation, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 8.26% | 8.26% | 8.26% | |||||||||||
Investment, principal | $ 2,503 | |||||||||||||
Investment owned, at cost | 2,478 | |||||||||||||
Investments at fair value | $ 2,394 | |||||||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 12,500 | [1],[4] | 12,500 | [1],[4] | 12,500 | [1],[4] | 12,500 | [8],[9] | 12,500 | [8],[9] | 12,500 | [8],[9] | ||
Investment owned, at cost | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 488 | [1],[4] | 488 | [1],[4] | 488 | [1],[4] | 488 | [8],[9] | 488 | [8],[9] | 488 | [8],[9] | ||
Investment owned, at cost | $ 488 | [1],[4] | $ 488 | [8],[9] | ||||||||||
Investments at fair value | $ 1,345 | [1],[4] | $ 966 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Eagle Parent Corp., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | |||||||||||
Investment, principal | $ 4,478 | |||||||||||||
Investment owned, at cost | 4,373 | |||||||||||||
Investments at fair value | $ 4,367 | |||||||||||||
Investment, Identifier [Axis]: Eagle Parent Corp., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | |||||||||||
Investment, principal | $ 2,488 | |||||||||||||
Investment owned, at cost | 2,429 | |||||||||||||
Investments at fair value | $ 2,426 | |||||||||||||
Investment, Identifier [Axis]: Eagleview Technology Corporation, Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | ||
Investment, interest rate | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 11.17% | [8],[9],[10],[11] | 11.17% | [8],[9],[10],[11] | 11.17% | [8],[9],[10],[11] | ||
Investment, principal | $ 8,974 | [1],[4],[5],[7] | $ 8,974 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 8,884 | [1],[4],[5] | 8,884 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 7,987 | [1],[4],[5] | $ 8,503 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 3% | [1],[2],[4],[5],[14] | 3% | [1],[2],[4],[5],[14] | 3% | [1],[2],[4],[5],[14] | 3% | [8],[9],[10],[11],[16] | 3% | [8],[9],[10],[11],[16] | 3% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 11,065 | [1],[4],[7],[14] | $ 10,418 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 10,953 | [1],[4],[14] | 10,275 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 10,677 | [1],[4],[14] | $ 10,231 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 3% | [1],[2],[4],[5],[14] | 3% | [1],[2],[4],[5],[14] | 3% | [1],[2],[4],[5],[14] | 3% | [8],[9],[10],[11],[13],[16] | 3% | [8],[9],[10],[11],[13],[16] | 3% | [8],[9],[10],[11],[13],[16] | ||
Investment, principal | $ 1,772 | [1],[4],[7],[14] | $ 0 | [8],[9],[12],[13],[16] | ||||||||||
Investment owned, at cost | 1,748 | [1],[4],[14] | 3 | [8],[9],[13],[16] | ||||||||||
Investments at fair value | $ 1,710 | [1],[4],[14] | $ 0 | [8],[9],[13],[16] | ||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[3],[4],[5],[14] | 3% | 3% | 3% | ||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[14] | 1 | ||||||||||||
Investments at fair value | [1],[3],[4],[14] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[3],[4],[5],[14] | 3% | 3% | 3% | ||||||||||
Investment, principal | [1],[3],[4],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[14] | 1 | ||||||||||||
Investments at fair value | [1],[3],[4],[14] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[4],[5] | 11.32% | 11.32% | 11.32% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 14,736 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 14,368 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 14,368 | ||||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software,First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (41) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (41) | ||||||||||||
Investment, Identifier [Axis]: FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [4],[5] | 6.75% | [4],[5] | 6.75% | [4],[5] | 6.75% | [9],[10] | 6.75% | [9],[10] | 6.75% | [9],[10] | ||
Investment, interest rate | 12.18% | [2],[4],[5] | 12.18% | [2],[4],[5] | 12.18% | [2],[4],[5] | 9.87% | [9],[10],[11] | 9.87% | [9],[10],[11] | 9.87% | [9],[10],[11] | ||
Investment, principal | $ 31,074 | [4],[5],[7] | $ 25,061 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 29,127 | [4],[5] | 24,685 | [9],[10] | ||||||||||
Investments at fair value | $ 19,917 | [4],[5] | $ 21,646 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 9% | [1],[2],[3],[4],[5] | 9% | [1],[2],[3],[4],[5] | 9% | [1],[2],[3],[4],[5] | 9% | [8],[9],[10],[11],[25] | 9% | [8],[9],[10],[11],[25] | 9% | [8],[9],[10],[11],[25] | ||
Investment, principal | $ 59,950 | [1],[3],[4],[7] | $ 27,850 | [8],[9],[12],[25] | ||||||||||
Investment owned, at cost | 59,950 | [1],[3],[4] | 27,850 | [8],[9],[25] | ||||||||||
Investments at fair value | $ 59,950 | [1],[3],[4] | $ 27,850 | [8],[9],[25] | ||||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 3,750 | [1],[4],[14] | 3,750 | [1],[4],[14] | 3,750 | [1],[4],[14] | 2,500 | [8],[9],[16],[25] | 2,500 | [8],[9],[16],[25] | 2,500 | [8],[9],[16],[25] | ||
Investment owned, at cost | $ 0 | [1],[4],[14] | $ 0 | [8],[9],[16],[25] | ||||||||||
Investments at fair value | $ 3 | [1],[4],[14] | $ 3 | [8],[9],[16],[25] | ||||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[14] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[3],[4],[5],[14] | 12.55% | 12.55% | 12.55% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[14] | $ 258 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[14] | 234 | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[14] | $ 234 | ||||||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[4],[5],[14] | 12.55% | 12.55% | 12.55% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 11,742 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 11,509 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | 11,511 | ||||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 9% | 9% | 9% | |||||||||||
Investments at fair value | $ 0 | 7,500 | ||||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, Membership Interest | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1 | 1 | 1 | |||||||||||
Investments at fair value | $ 0 | 698 | ||||||||||||
Investment, Identifier [Axis]: Five Largest Loan Exposures To Borrowers | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 54,051 | 48,139 | ||||||||||||
Investment, Identifier [Axis]: Five Largest Loan Exposures To Borrowers | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | $ 28,396 | $ 28,973 | ||||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 11% | [1],[2],[4],[5],[14] | 11% | [1],[2],[4],[5],[14] | 11% | [1],[2],[4],[5],[14] | 11% | [8],[9],[10],[11],[16] | 11% | [8],[9],[10],[11],[16] | 11% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 11,918 | [1],[4],[7],[14] | $ 9,466 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 11,612 | [1],[4],[14] | 9,071 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 11,144 | [1],[4],[14] | $ 9,008 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 417,011 | [1],[4],[14] | 417,011 | [1],[4],[14] | 417,011 | [1],[4],[14] | 331,200 | [8],[9],[16] | 331,200 | [8],[9],[16] | 331,200 | [8],[9],[16] | ||
Investment owned, at cost | $ 427 | [1],[4],[14] | $ 405 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 42 | [1],[4],[14] | $ 66 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 6% | [2],[4],[5],[14] | 6% | [2],[4],[5],[14] | 6% | [2],[4],[5],[14] | 6% | [9],[10],[11],[16] | 6% | [9],[10],[11],[16] | 6% | [9],[10],[11],[16] | ||
Investment, principal | $ 4,881 | [4],[7],[14] | $ 4,881 | [9],[12],[16] | ||||||||||
Investment owned, at cost | 4,469 | [4],[14] | 4,420 | [9],[16] | ||||||||||
Investments at fair value | $ 3,577 | [4],[14] | $ 3,845 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 10.60% | 10.60% | 10.60% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 1,280 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 1,268 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 1,262 | ||||||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.67% | 10.67% | 10.67% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 25,128 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 24,915 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 24,851 | ||||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 1,638 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 1,535 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 1,535 | ||||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.64% | 12.64% | 12.64% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 23,774 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 23,110 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 23,110 | ||||||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.57% | 10.57% | 10.57% | 7.94% | 7.94% | 7.94% | ||||||||
Investment, principal | $ 7,369 | $ 7,444 | ||||||||||||
Investment owned, at cost | 7,295 | 7,369 | ||||||||||||
Investments at fair value | $ 6,190 | $ 6,029 | ||||||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.57% | 10.57% | 10.57% | 7.94% | 7.94% | 7.94% | ||||||||
Investment, principal | $ 3,930 | $ 3,970 | ||||||||||||
Investment owned, at cost | 3,891 | 3,930 | ||||||||||||
Investments at fair value | $ 3,301 | $ 3,216 | ||||||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 5% | 5% | 5% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 10.57% | 10.57% | 10.57% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 2,456 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 2,055 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 2,063 | ||||||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 7.37% | 7.37% | 7.37% | |||||||||||
Investment, principal | $ 1,979 | |||||||||||||
Investment owned, at cost | 1,979 | |||||||||||||
Investments at fair value | $ 1,722 | |||||||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.25% | 4.25% | 4.25% | |||||||||||
Investment, interest rate | 6.81% | 6.81% | 6.81% | |||||||||||
Investment, principal | $ 2,192 | |||||||||||||
Investment owned, at cost | 2,165 | |||||||||||||
Investments at fair value | $ 1,912 | |||||||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.37% | 7.37% | 7.37% | ||||||||||
Investment, principal | [9],[10],[12] | $ 5,572 | ||||||||||||
Investment owned, at cost | [9],[10] | 5,435 | ||||||||||||
Investments at fair value | [9],[10] | $ 4,848 | ||||||||||||
Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [4],[5],[14] | 2.85% | 2.85% | 2.85% | ||||||||||
Investment, interest rate | [2],[4],[5],[14] | 6.56% | 6.56% | 6.56% | ||||||||||
Investment, principal | € | [4],[5],[7],[14] | € 1,000 | ||||||||||||
Investment owned, at cost | [4],[5],[14] | $ 876 | ||||||||||||
Investments at fair value | [4],[5],[14] | $ 963 | ||||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (27) | [1],[3],[4],[5] | (27) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (35) | [1],[3],[4],[5] | $ (25) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | ||
Investment, interest rate | 13.42% | [1],[2],[4],[5] | 13.42% | [1],[2],[4],[5] | 13.42% | [1],[2],[4],[5] | 11.04% | [8],[9],[10],[11] | 11.04% | [8],[9],[10],[11] | 11.04% | [8],[9],[10],[11] | ||
Investment, principal | $ 17,444 | [1],[4],[5],[7] | $ 14,311 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 17,276 | [1],[4],[5] | 14,041 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 17,096 | [1],[4],[5] | $ 14,060 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (54) | [1],[3],[4],[5] | (54) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (70) | [1],[3],[4],[5] | $ (50) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., Education Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [4],[5] | 5.25% | [4],[5] | 5.25% | [4],[5] | 5.25% | [9],[10] | 5.25% | [9],[10] | 5.25% | [9],[10] | ||
Investment, interest rate | 10.67% | [2],[4],[5] | 10.67% | [2],[4],[5] | 10.67% | [2],[4],[5] | 8.38% | [9],[10],[11] | 8.38% | [9],[10],[11] | 8.38% | [9],[10],[11] | ||
Investment, principal | $ 14,347 | [4],[5],[7] | $ 9,392 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 13,871 | [4],[5] | 9,080 | [9],[10] | ||||||||||
Investments at fair value | $ 13,618 | [4],[5] | $ 8,582 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.38% | 8.38% | 8.38% | ||||||||
Investment, principal | $ 7,920 | $ 8,000 | ||||||||||||
Investment owned, at cost | 7,731 | 7,774 | ||||||||||||
Investments at fair value | $ 7,517 | $ 7,310 | ||||||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.38% | 8.38% | 8.38% | ||||||||
Investment, principal | $ 3,960 | $ 4,000 | ||||||||||||
Investment owned, at cost | 3,865 | 3,887 | ||||||||||||
Investments at fair value | $ 3,759 | $ 3,655 | ||||||||||||
Investment, Identifier [Axis]: Harrow , Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 11.89% | 11.89% | 11.89% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 7,448 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 7,296 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 7,301 | ||||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[14] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[14] | (82) | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[14] | $ (79) | ||||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.04% | 12.04% | 12.04% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 1,432 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 1,399 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 1,404 | ||||||||||||
Investment, Identifier [Axis]: Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [2],[4],[5],[14] | 4.46% | 4.46% | 4.46% | ||||||||||
Investment, principal | [4],[7],[14] | $ 6,808 | ||||||||||||
Investment owned, at cost | [4],[14] | 5,490 | ||||||||||||
Investments at fair value | [4],[14] | $ 5,873 | ||||||||||||
Investment, Identifier [Axis]: IAMGOLD Corporation, Gold, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 8.25% | 8.25% | 8.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 13.62% | 13.62% | 13.62% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 23,975 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 23,310 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 23,328 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | ||||||||
Investment, interest rate | 11.40% | 11.40% | 11.40% | 9.42% | 9.42% | 9.42% | ||||||||
Investment, principal | $ 9,000 | $ 9,500 | ||||||||||||
Investment owned, at cost | 8,839 | 9,282 | ||||||||||||
Investments at fair value | $ 7,080 | $ 8,408 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | ||||||||
Investment, interest rate | 11.40% | 11.40% | 11.40% | 9.42% | 9.42% | 9.42% | ||||||||
Investment, principal | $ 2,250 | $ 2,375 | ||||||||||||
Investment owned, at cost | 2,210 | 2,320 | ||||||||||||
Investments at fair value | $ 1,770 | $ 2,102 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.40% | 11.40% | 11.40% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 44,550 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 42,918 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 35,046 | ||||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Products, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.42% | 9.42% | 9.42% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 35,625 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 34,806 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 31,528 | ||||||||||||
Investment, Identifier [Axis]: IPC Corp., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 6.50% | [8],[9],[10] | 6.50% | [8],[9],[10] | 6.50% | [8],[9],[10] | ||
Investment, interest rate | 11.92% | [1],[2],[4],[5] | 11.92% | [1],[2],[4],[5] | 11.92% | [1],[2],[4],[5] | 9.44% | [8],[9],[10],[11] | 9.44% | [8],[9],[10],[11] | 9.44% | [8],[9],[10],[11] | ||
Investment, principal | $ 40,587 | [1],[4],[5],[7] | $ 34,357 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 39,935 | [1],[4],[5] | 33,612 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 38,963 | [1],[4],[5] | $ 32,639 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.42% | 9.42% | 9.42% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 8,569 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 8,401 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 8,407 | ||||||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 11.67% | 11.67% | 11.67% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 22,619 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 22,162 | ||||||||||||
Investments at fair value | [8],[9],[10] | 22,275 | ||||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [8],[9],[12],[22] | 13,083 | ||||||||||||
Investment owned, at cost | [8],[9],[22] | 13,083 | ||||||||||||
Investments at fair value | [8],[9],[22] | $ 13,083 | ||||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 12.45% | 12.45% | 12.45% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 12,161 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 11,944 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 11,942 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 350,241 | 350,241 | 350,241 | |||||||||||
Investment owned, at cost | $ 0 | |||||||||||||
Investments at fair value | $ 147 | |||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 688 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 688 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 688 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 10.75% | 10.75% | 10.75% | |||||||||||
Investment, principal | [1],[4],[5],[7] | $ 26,613 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 26,492 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 24,484 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 787 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 771 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 787 | ||||||||||||
Investment, Identifier [Axis]: Indivior Finance S.À.R.L., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.80% | 8.80% | 8.80% | ||||||||
Investment, principal | $ 7,331 | $ 7,406 | ||||||||||||
Investment owned, at cost | 7,249 | 7,293 | ||||||||||||
Investments at fair value | $ 7,340 | $ 7,286 | ||||||||||||
Investment, Identifier [Axis]: Indivior Finance S.À.R.L., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.90% | 10.90% | 10.90% | 8.80% | 8.80% | 8.80% | ||||||||
Investment, principal | $ 3,910 | $ 3,950 | ||||||||||||
Investment owned, at cost | 3,866 | 3,890 | ||||||||||||
Investments at fair value | $ 3,915 | $ 3,886 | ||||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[5],[14] | 5.75% | 5.75% | 5.75% | ||||||||||
Investment, interest rate | 11.14% | [1],[2],[5],[14] | 11.14% | [1],[2],[5],[14] | 11.14% | [1],[2],[5],[14] | 11% | [8],[9],[10],[11],[16] | 11% | [8],[9],[10],[11],[16] | 11% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 7,179 | [1],[5],[7],[14] | $ 6,817 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 6,969 | [1],[5],[14] | 6,553 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 6,568 | [1],[5],[14] | $ 6,408 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[13],[16] | 11% | 11% | 11% | ||||||||||
Investment, principal | [8],[9],[12],[13],[16] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[13],[16] | 0 | ||||||||||||
Investments at fair value | [8],[9],[13],[16] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 112,990 | [1],[4],[14] | 112,990 | [1],[4],[14] | 112,990 | [1],[4],[14] | 56,999 | [8],[9],[16] | 56,999 | [8],[9],[16] | 56,999 | [8],[9],[16] | ||
Investment owned, at cost | $ 300 | [1],[4],[14] | $ 135 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 105 | [1],[4],[14] | $ 609 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Diversified Financial Services, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 1,078,284 | 1,078,284 | 1,078,284 | ||||||||||
Investment owned, at cost | [1],[4] | $ 113 | ||||||||||||
Investments at fair value | [1],[4] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Other Diversified Financial Services, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 1,078,284 | 1,078,284 | 1,078,284 | ||||||||||
Investment owned, at cost | [8],[9] | $ 113 | ||||||||||||
Investments at fair value | [8],[9] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (99) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (86) | ||||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 5% | [8],[9],[10] | 5% | [8],[9],[10] | 5% | [8],[9],[10] | ||
Investment, interest rate | 12.93% | [1],[2],[4],[5] | 12.93% | [1],[2],[4],[5] | 12.93% | [1],[2],[4],[5] | 8.55% | [8],[9],[10],[11] | 8.55% | [8],[9],[10],[11] | 8.55% | [8],[9],[10],[11] | ||
Investment, principal | $ 33,414 | [1],[4],[5],[7] | $ 18,660 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 32,539 | [1],[4],[5] | 18,567 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 32,659 | [1],[4],[5] | $ 18,134 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 12.17% | 12.17% | 12.17% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 13,674 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 13,514 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 13,154 | ||||||||||||
Investment, Identifier [Axis]: Iris Holding, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 7.89% | 7.89% | 7.89% | |||||||||||
Investment, principal | $ 5,000 | |||||||||||||
Investment owned, at cost | 4,624 | |||||||||||||
Investments at fair value | $ 4,610 | |||||||||||||
Investment, Identifier [Axis]: Iris Holding, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 4.75% | 4.75% | 4.75% | ||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | 7.89% | 7.89% | 7.89% | ||||||||
Investment, principal | $ 4,500 | $ 2,000 | ||||||||||||
Investment owned, at cost | 4,350 | 1,846 | ||||||||||||
Investments at fair value | $ 4,349 | $ 1,844 | ||||||||||||
Investment, Identifier [Axis]: Ivanti Software, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [4],[5] | 7.25% | [4],[5] | 7.25% | [4],[5] | 7.25% | [9],[10] | 7.25% | [9],[10] | 7.25% | [9],[10] | ||
Investment, interest rate | 12.78% | [2],[4],[5] | 12.78% | [2],[4],[5] | 12.78% | [2],[4],[5] | 10.33% | [9],[10],[11] | 10.33% | [9],[10],[11] | 10.33% | [9],[10],[11] | ||
Investment, principal | $ 13,939 | [4],[5],[7] | $ 10,247 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 12,661 | [4],[5] | 10,196 | [9],[10] | ||||||||||
Investments at fair value | 10,094 | [4],[5] | $ 7,702 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: JP Morgan Prime Money Market Fund, Institutional Shares | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | 83,262 | |||||||||||||
Investments at fair value | $ 83,262 | |||||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.62% | 10.62% | 10.62% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 36,234 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 35,170 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 36,392 | ||||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [9],[10],[11] | 11.12% | 11.12% | 11.12% | ||||||||||
Investment, principal | [9],[10],[12] | $ 528 | ||||||||||||
Investment owned, at cost | [9],[10] | 478 | ||||||||||||
Investments at fair value | [9],[10] | $ 481 | ||||||||||||
Investment, Identifier [Axis]: KDC/ONE Development Corp Inc, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | |||||||||||
Investment, interest rate | 10.32% | 10.32% | 10.32% | |||||||||||
Investment, principal | $ 10,000 | |||||||||||||
Investment owned, at cost | 9,666 | |||||||||||||
Investments at fair value | $ 9,665 | |||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 10.17% | 10.17% | 10.17% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 329 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 311 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 292 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 11.84% | 11.84% | 11.84% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 272 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 246 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 238 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (47) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (47) | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.17% | 10.17% | 10.17% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 13,623 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 13,487 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 13,351 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.84% | 11.84% | 11.84% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 16,752 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 16,623 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 16,500 | ||||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.80% | 11.80% | 11.80% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 38,015 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 37,447 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 37,445 | ||||||||||||
Investment, Identifier [Axis]: LABL, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | |||||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | |||||||||||
Investment, principal | $ 3,962 | |||||||||||||
Investment owned, at cost | 3,815 | |||||||||||||
Investments at fair value | $ 3,955 | |||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | ||
Investment, interest rate | [8],[9],[10],[11],[13] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 1,710 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (41) | [1],[3],[4],[5] | 1,672 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (172) | [1],[3],[4],[5] | $ 1,651 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.12% | 9.12% | 9.12% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 19,236 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 18,894 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 18,707 | ||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 2,736 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 2,595 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 2,558 | ||||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 23,494 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 23,128 | ||||||||||||
Investments at fair value | [1],[4],[5] | 21,967 | ||||||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., Electronic Components, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 6.75% | 6.75% | 6.75% | ||||||||||
Investment, interest rate | [9],[10],[11] | 9.87% | 9.87% | 9.87% | ||||||||||
Investment, principal | [9],[10],[12] | $ 2,140 | ||||||||||||
Investment owned, at cost | [9],[10] | 2,092 | ||||||||||||
Investments at fair value | [9],[10] | $ 1,890 | ||||||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.25% | 3.25% | 3.25% | |||||||||||
Investment, interest rate | 6.37% | 6.37% | 6.37% | |||||||||||
Investment, principal | $ 7,366 | |||||||||||||
Investment owned, at cost | 7,282 | |||||||||||||
Investments at fair value | $ 6,835 | |||||||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.25% | 3.25% | 3.25% | |||||||||||
Investment, interest rate | 6.37% | 6.37% | 6.37% | |||||||||||
Investment, principal | $ 1,358 | |||||||||||||
Investment owned, at cost | 1,192 | |||||||||||||
Investments at fair value | 1,260 | |||||||||||||
Investment, Identifier [Axis]: Largest Exposure To A Single Borrower | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 11,286 | 10,093 | ||||||||||||
Investment, Identifier [Axis]: Largest Loan Exposure To A Single Borrower | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | $ 6,230 | $ 6,562 | ||||||||||||
Investment, Identifier [Axis]: LaserAway Intermediate Holdings II, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | ||||||||
Investment, interest rate | 11.32% | 11.32% | 11.32% | 8.23% | 8.23% | 8.23% | ||||||||
Investment, principal | $ 7,369 | $ 7,444 | ||||||||||||
Investment owned, at cost | 7,269 | 7,318 | ||||||||||||
Investments at fair value | $ 7,267 | $ 7,323 | ||||||||||||
Investment, Identifier [Axis]: LaserAway Intermediate Holdings II, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | 5.75% | ||||||||
Investment, interest rate | 11.32% | 11.32% | 11.32% | 8.23% | 8.23% | 8.23% | ||||||||
Investment, principal | $ 3,930 | $ 3,970 | ||||||||||||
Investment owned, at cost | 3,877 | 3,903 | ||||||||||||
Investments at fair value | $ 3,876 | $ 3,905 | ||||||||||||
Investment, Identifier [Axis]: LaserShip, Inc., Air Freight & Logistics, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.38% | 10.38% | 10.38% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 2,394 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 2,370 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 1,867 | ||||||||||||
Investment, Identifier [Axis]: Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [4],[5],[14] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, interest rate | [2],[4],[5],[14] | 14.95% | 14.95% | 14.95% | ||||||||||
Investment, principal | [4],[5],[7],[14] | $ 26,422 | ||||||||||||
Investment owned, at cost | [4],[5],[14] | 24,920 | ||||||||||||
Investments at fair value | [4],[5],[14] | $ 27,512 | ||||||||||||
Investment, Identifier [Axis]: Lift Brands Holdings, Inc., Leisure Facilities, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 2,000,000 | [1],[4] | 2,000,000 | [1],[4] | 2,000,000 | [1],[4] | 2,000,000 | [8],[9] | 2,000,000 | [8],[9] | 2,000,000 | [8],[9] | ||
Investment owned, at cost | $ 1,399 | [1],[4] | $ 1,399 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Lightbox Intermediate, L.P., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.65% | 10.65% | 10.65% | 8.67% | 8.67% | 8.67% | ||||||||
Investment, principal | $ 11,249 | $ 7,367 | ||||||||||||
Investment owned, at cost | 11,106 | 7,315 | ||||||||||||
Investments at fair value | $ 10,912 | $ 7,109 | ||||||||||||
Investment, Identifier [Axis]: Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [1],[4],[5] | 5% | [1],[4],[5] | 5% | [1],[4],[5] | 5% | [8],[9],[10] | 5% | [8],[9],[10] | 5% | [8],[9],[10] | ||
Investment, interest rate | 10.65% | [1],[2],[4],[5] | 10.65% | [1],[2],[4],[5] | 10.65% | [1],[2],[4],[5] | 8.67% | [8],[9],[10],[11] | 8.67% | [8],[9],[10],[11] | 8.67% | [8],[9],[10],[11] | ||
Investment, principal | $ 45,243 | [1],[4],[5],[7] | $ 41,008 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 44,717 | [1],[4],[5] | 40,243 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 43,886 | [1],[4],[5] | $ 39,573 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 559 | [1],[4] | 559 | [1],[4] | 559 | [1],[4] | 451 | [8],[9] | 451 | [8],[9] | 451 | [8],[9] | ||
Investment, principal | [1],[4],[7] | |||||||||||||
Investment owned, at cost | 563 | [1],[4] | $ 451 | [8],[9] | ||||||||||
Investments at fair value | $ 372 | [1],[4] | $ 451 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | ||
Investment, interest rate | 13.99% | [1],[2],[4],[5] | 13.99% | [1],[2],[4],[5] | 13.99% | [1],[2],[4],[5] | 11.38% | [8],[9],[10],[11] | 11.38% | [8],[9],[10],[11] | 11.38% | [8],[9],[10],[11] | ||
Investment, principal | $ 5,403 | [1],[4],[5],[7] | $ 4,357 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 5,348 | [1],[4],[5] | 4,285 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 5,160 | [1],[4],[5] | $ 4,226 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[3],[4],[5] | 8.50% | [1],[3],[4],[5] | 8.50% | [1],[3],[4],[5] | 8.50% | [8],[9],[10],[13] | 8.50% | [8],[9],[10],[13] | 8.50% | [8],[9],[10],[13] | ||
Investment, interest rate | 13.99% | [1],[2],[3],[4],[5] | 13.99% | [1],[2],[3],[4],[5] | 13.99% | [1],[2],[3],[4],[5] | 11.38% | [8],[9],[10],[11],[13] | 11.38% | [8],[9],[10],[11],[13] | 11.38% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 2,939 | [1],[3],[4],[5],[7] | $ 2,370 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 2,884 | [1],[3],[4],[5] | 2,323 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 2,745 | [1],[3],[4],[5] | $ 2,265 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: LogMeIn, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 7.80% | 7.80% | 7.80% | |||||||||||
Investment, principal | $ 7,860 | |||||||||||||
Investment owned, at cost | 7,751 | |||||||||||||
Investments at fair value | $ 5,494 | |||||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [1],[3],[4],[5] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | 6% | [8],[9],[10],[13] | ||
Investment, interest rate | [1],[2],[3],[4],[5] | 11.42% | 11.42% | 11.42% | ||||||||||
Investment, principal | $ 964 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 936 | [1],[3],[4],[5] | (23) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 938 | [1],[3],[4],[5] | $ (54) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 18,390 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 18,088 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 17,691 | ||||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.52% | 11.52% | 11.52% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 20,125 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 19,912 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 19,823 | ||||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.52% | 11.52% | 11.52% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 2,631 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 2,587 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 2,591 | ||||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5] | 12.83% | 12.83% | 12.83% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 1,466 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 1,215 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 1,282 | ||||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.89% | 12.89% | 12.89% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 40,538 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 39,873 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 39,833 | ||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [1],[3],[4],[5] | 5.50% | [1],[3],[4],[5] | 5.50% | [1],[3],[4],[5] | 5.50% | [8],[9],[10],[13] | 5.50% | [8],[9],[10],[13] | 5.50% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (28) | [1],[3],[4],[5] | (13) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (47) | [1],[3],[4],[5] | $ (51) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [1],[4],[5] | 5.50% | [1],[4],[5] | 5.50% | [1],[4],[5] | 5.50% | [8],[9],[10] | 5.50% | [8],[9],[10] | 5.50% | [8],[9],[10] | ||
Investment, interest rate | 10.99% | [1],[2],[4],[5] | 10.99% | [1],[2],[4],[5] | 10.99% | [1],[2],[4],[5] | 9.17% | [8],[9],[10],[11] | 9.17% | [8],[9],[10],[11] | 9.17% | [8],[9],[10],[11] | ||
Investment, principal | $ 13,973 | [1],[4],[5],[7] | $ 29,565 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 13,936 | [1],[4],[5] | 29,128 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 13,685 | [1],[4],[5] | $ 28,734 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | [1],[4],[5] | 5.50% | [1],[4],[5] | 5.50% | [1],[4],[5] | 5.50% | [8],[9],[10],[13] | 5.50% | [8],[9],[10],[13] | 5.50% | [8],[9],[10],[13] | ||
Investment, interest rate | [1],[2],[4],[5] | 10.99% | 10.99% | 10.99% | ||||||||||
Investment, principal | $ 21,328 | [1],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 21,021 | [1],[4],[5] | (12) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 20,888 | [1],[4],[5] | $ (96) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, principal | $ 0 | |||||||||||||
Investment owned, at cost | (3) | (3) | ||||||||||||
Investments at fair value | $ (7) | $ (10) | ||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Revolver | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, principal | $ 0 | $ 0 | ||||||||||||
Investment owned, at cost | (1) | (1) | ||||||||||||
Investments at fair value | $ (3) | $ (4) | ||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 9.17% | 9.17% | 9.17% | |||||||||||
Investment, principal | $ 6,139 | |||||||||||||
Investment owned, at cost | 6,104 | |||||||||||||
Investments at fair value | $ 5,966 | |||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | 5.50% | ||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | 9.17% | 9.17% | 9.17% | ||||||||
Investment, principal | $ 1,630 | $ 1,647 | ||||||||||||
Investment owned, at cost | 1,616 | 1,632 | ||||||||||||
Investments at fair value | $ 1,596 | $ 1,600 | ||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | |||||||||||
Investment, principal | $ 8,319 | |||||||||||||
Investment owned, at cost | 8,164 | |||||||||||||
Investments at fair value | $ 8,147 | |||||||||||||
Investment, Identifier [Axis]: MRI Software LLC, First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 10.99% | 10.99% | 10.99% | |||||||||||
Investment, principal | $ 2,211 | |||||||||||||
Investment owned, at cost | 2,210 | |||||||||||||
Investments at fair value | $ 2,165 | |||||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [8],[9],[10],[11],[16] | 11.50% | [8],[9],[10],[11],[16] | 11.50% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 8,568 | [1],[4],[7],[14] | $ 17,203 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 8,495 | [1],[4],[14] | 16,954 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 8,132 | [1],[4],[14] | $ 16,644 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [1],[2],[4],[5],[14] | 11.50% | [8],[9],[10],[11],[13],[16] | 11.50% | [8],[9],[10],[11],[13],[16] | 11.50% | [8],[9],[10],[11],[13],[16] | ||
Investment, principal | $ 4,284 | [1],[4],[7],[14] | $ 0 | [8],[9],[12],[13],[16] | ||||||||||
Investment owned, at cost | 4,247 | [1],[4],[14] | 0 | [8],[9],[13],[16] | ||||||||||
Investments at fair value | $ 4,066 | [1],[4],[14] | $ 0 | [8],[9],[13],[16] | ||||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 11.50% | 11.50% | 11.50% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 8,568 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 8,495 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 8,132 | ||||||||||||
Investment, Identifier [Axis]: McAfee Corp., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 9.18% | 9.18% | 9.18% | |||||||||||
Investment, principal | $ 5,940 | |||||||||||||
Investment owned, at cost | 5,654 | |||||||||||||
Investments at fair value | $ 5,812 | |||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 8% | [1],[2],[4],[5],[14] | 8% | [1],[2],[4],[5],[14] | 8% | [1],[2],[4],[5],[14] | 8% | [8],[9],[10],[11],[16] | 8% | [8],[9],[10],[11],[16] | 8% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 9,106 | [1],[4],[7],[14] | $ 7,215 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 8,580 | [1],[4],[14] | 6,650 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 8,013 | [1],[4],[14] | $ 6,440 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11],[13],[16] | 8% | 8% | 8% | ||||||||||
Investment, principal | [8],[9],[12],[13],[16] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[13],[16] | 1 | ||||||||||||
Investments at fair value | [8],[9],[13],[16] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9],[16] | 209,588 | 209,588 | 209,588 | ||||||||||
Investment owned, at cost | [8],[9],[16] | $ 480 | ||||||||||||
Investments at fair value | [8],[9],[16] | $ 170 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4],[14] | 259,877 | 259,877 | 259,877 | ||||||||||
Investment, principal | [1],[4],[7],[14] | |||||||||||||
Investment owned, at cost | [1],[4],[14] | 545 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 78 | ||||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4],[14] | 66,817 | 66,817 | 66,817 | ||||||||||
Investment, principal | [1],[4],[7],[14] | |||||||||||||
Investment owned, at cost | [1],[4],[14] | 23 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 33 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | 7% | 7% | 8% | 8% | 8% | ||||||||
Investment, principal | $ 0 | $ 0 | ||||||||||||
Investment owned, at cost | (2) | (4) | ||||||||||||
Investments at fair value | $ (8) | $ (12) | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | 7% | 7% | 7% | 7% | 7% | ||||||||
Investment, interest rate | 12.52% | 12.52% | 12.52% | 10.64% | 10.64% | 10.64% | ||||||||
Investment, principal | $ 4,669 | $ 4,687 | ||||||||||||
Investment owned, at cost | 4,648 | 4,651 | ||||||||||||
Investments at fair value | $ 4,594 | $ 4,570 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 7% | [1],[3],[4],[5] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (43) | [1],[3],[4],[5] | (54) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (76) | [1],[3],[4],[5] | $ (100) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.64% | 10.64% | 10.64% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 45,665 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 44,689 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 44,523 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.52% | 12.52% | 12.52% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 5,248 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 5,220 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 5,164 | ||||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.52% | 12.52% | 12.52% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 46,687 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 46,239 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 45,940 | ||||||||||||
Investment, Identifier [Axis]: Mitchell International, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 9.18% | 9.18% | 9.18% | |||||||||||
Investment, principal | $ 2,985 | |||||||||||||
Investment owned, at cost | 2,845 | |||||||||||||
Investments at fair value | $ 2,941 | |||||||||||||
Investment, Identifier [Axis]: Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [1],[4],[5] | 6.75% | [1],[4],[5] | 6.75% | [1],[4],[5] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | ||
Investment, interest rate | 12.51% | [1],[2],[4],[5] | 12.51% | [1],[2],[4],[5] | 12.51% | [1],[2],[4],[5] | 9.89% | [8],[9],[10],[11] | 9.89% | [8],[9],[10],[11] | 9.89% | [8],[9],[10],[11] | ||
Investment, principal | $ 54,559 | [1],[4],[5],[7] | $ 46,499 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 54,236 | [1],[4],[5] | 45,802 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 53,168 | [1],[4],[5] | $ 45,421 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: NFP Corp., Diversified Financial Services, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [2],[4],[5] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, principal | [4],[7] | $ 10,191 | ||||||||||||
Investment owned, at cost | [4] | 9,831 | ||||||||||||
Investments at fair value | [4] | $ 8,743 | ||||||||||||
Investment, Identifier [Axis]: NFP Corp., Other Diversified Financial Services, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, principal | [9],[12] | $ 10,191 | ||||||||||||
Investment owned, at cost | [9] | 9,773 | ||||||||||||
Investments at fair value | [9] | $ 7,966 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.29% | 12.29% | 12.29% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 73,362 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 72,459 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 69,694 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | |||||||||||
Investment owned, at cost | [1],[4],[5],[14] | $ 0 | ||||||||||||
Investments at fair value | [4],[14] | $ 903 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | |||||||||||
Investment owned, at cost | [4],[5],[14] | $ 0 | ||||||||||||
Investments at fair value | [4],[14] | $ 903 | ||||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[16] | 6.88% | 6.88% | 6.88% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 9.99% | 9.99% | 9.99% | ||||||||||
Investment, principal | [8],[9],[10],[12],[16] | $ 58,713 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[16] | 57,655 | ||||||||||||
Investments at fair value | [8],[9],[10],[16] | $ 56,805 | ||||||||||||
Investment, Identifier [Axis]: Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [1],[4],[5] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | 8.50% | [8],[9],[10] | ||
Investment, interest rate | 13.99% | [1],[2],[4],[5] | 13.99% | [1],[2],[4],[5] | 13.99% | [1],[2],[4],[5] | 12.17% | [8],[9],[10],[11] | 12.17% | [8],[9],[10],[11] | 12.17% | [8],[9],[10],[11] | ||
Investment, principal | $ 30,339 | [1],[4],[5],[7] | $ 22,560 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 30,021 | [1],[4],[5] | 22,241 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 29,007 | [1],[4],[5] | $ 21,524 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 9.50% | [1],[4],[5] | 9.50% | [1],[4],[5] | 9.50% | [1],[4],[5] | 10.50% | [8],[9],[10] | 10.50% | [8],[9],[10] | 10.50% | [8],[9],[10] | ||
Investment, interest rate | 14.89% | [1],[2],[4],[5] | 14.89% | [1],[2],[4],[5] | 14.89% | [1],[2],[4],[5] | 14.17% | [8],[9],[10],[11] | 14.17% | [8],[9],[10],[11] | 14.17% | [8],[9],[10],[11] | ||
Investment, principal | $ 64,606 | [1],[4],[5],[7] | $ 50,459 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 64,720 | [1],[4],[5] | 49,301 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 63,185 | [1],[4],[5] | $ 51,972 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Northern Star Industries Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.76% | 4.76% | 4.76% | 4.75% | 4.75% | 4.75% | ||||||||
Investment, interest rate | 10.15% | 10.15% | 10.15% | 7.87% | 7.87% | 7.87% | ||||||||
Investment, principal | $ 6,615 | $ 6,685 | ||||||||||||
Investment owned, at cost | 6,608 | 6,673 | ||||||||||||
Investments at fair value | $ 6,565 | $ 6,484 | ||||||||||||
Investment, Identifier [Axis]: Northern Star Industries Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.76% | 4.76% | 4.76% | 4.75% | 4.75% | 4.75% | ||||||||
Investment, interest rate | 10.15% | 10.15% | 10.15% | 7.87% | 7.87% | 7.87% | ||||||||
Investment, principal | $ 5,198 | $ 5,252 | ||||||||||||
Investment owned, at cost | 5,192 | 5,243 | ||||||||||||
Investments at fair value | 5,159 | 5,095 | ||||||||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Membership Interest | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | 0 | [3],[14],[26],[27] | 0 | [13],[16],[23],[24],[28],[29] | ||||||||||
Investments at fair value | $ 0 | [3],[14],[26],[27] | $ 0 | [13],[16],[23],[24],[28],[29] | 0 | |||||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | [1],[3],[5],[14],[26] | 4.50% | [1],[3],[5],[14],[26] | 4.50% | [1],[3],[5],[14],[26] | 4.50% | [8],[10],[13],[16],[23],[24],[28] | 4.50% | [8],[10],[13],[16],[23],[24],[28] | 4.50% | [8],[10],[13],[16],[23],[24],[28] | ||
Investment, interest rate | 9.76% | [1],[2],[3],[5],[14],[26] | 9.76% | [1],[2],[3],[5],[14],[26] | 9.76% | [1],[2],[3],[5],[14],[26] | 6.30% | [8],[10],[11],[13],[16],[23],[24],[28] | 6.30% | [8],[10],[11],[13],[16],[23],[24],[28] | 6.30% | [8],[10],[11],[13],[16],[23],[24],[28] | ||
Investment, principal | $ 58,349 | [1],[3],[5],[7],[14],[26] | $ 59,662 | [8],[10],[12],[13],[16],[23],[24],[28] | ||||||||||
Investment owned, at cost | 50,330 | [1],[3],[5],[14],[26] | 50,194 | [8],[10],[13],[16],[23],[24],[28] | ||||||||||
Investments at fair value | $ 50,017 | [1],[3],[5],[14],[26] | $ 50,283 | [8],[10],[13],[16],[23],[24],[28] | 55,582 | |||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4% | 4% | 4% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.12% | 7.12% | 7.12% | ||||||||||
Investment, principal | [9],[10],[12] | $ 3,323 | ||||||||||||
Investment owned, at cost | [9],[10] | 3,162 | ||||||||||||
Investments at fair value | [9],[10] | $ 3,207 | ||||||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | ||
Investment, interest rate | 12.49% | [1],[2],[4],[5] | 12.49% | [1],[2],[4],[5] | 12.49% | [1],[2],[4],[5] | 10.05% | [8],[9],[10],[11] | 10.05% | [8],[9],[10],[11] | 10.05% | [8],[9],[10],[11] | ||
Investment, principal | $ 9,323 | [1],[4],[5],[7] | $ 7,519 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 9,210 | [1],[4],[5] | 7,389 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 9,183 | [1],[4],[5] | $ 7,237 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | 4% | 4% | 4% | ||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | 7.12% | 7.12% | 7.12% | ||||||||
Investment, principal | $ 10,987 | $ 7,777 | ||||||||||||
Investment owned, at cost | 10,827 | 7,741 | ||||||||||||
Investments at fair value | $ 10,971 | $ 7,505 | ||||||||||||
Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | 4% | 4% | 4% | ||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | 7.12% | 7.12% | 7.12% | ||||||||
Investment, principal | $ 3,849 | $ 3,888 | ||||||||||||
Investment owned, at cost | 3,830 | 3,871 | ||||||||||||
Investments at fair value | $ 3,843 | $ 3,752 | ||||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 10% | [1],[4],[5] | 10% | [1],[4],[5] | 10% | [1],[4],[5] | 2% | [8],[9],[10] | 2% | [8],[9],[10] | 2% | [8],[9],[10] | ||
Investment, interest rate | [8],[9],[10],[11] | 5.08% | 5.08% | 5.08% | ||||||||||
Investment, principal | $ 25,712 | [1],[4],[5],[7] | $ 21,557 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 25,615 | [1],[4],[5] | 21,267 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 25,069 | [1],[4],[5] | $ 21,557 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 10% | [1],[3],[4],[5] | 10% | [1],[3],[4],[5] | 10% | [1],[3],[4],[5] | 2% | [8],[9],[10],[13] | 2% | [8],[9],[10],[13] | 2% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (11) | [1],[3],[4],[5] | (31) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (69) | [1],[3],[4],[5] | $ 0 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 10% | 10% | 10% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 1,210 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 1,193 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 1,169 | ||||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (42) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (36) | ||||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 13.12% | 13.12% | 13.12% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 15,231 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 14,892 | ||||||||||||
Investments at fair value | [1],[4],[5] | 14,945 | ||||||||||||
Investment, Identifier [Axis]: Other cash accounts | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | 62,277 | |||||||||||||
Investments at fair value | $ 62,277 | |||||||||||||
Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 7.75% | [2],[4],[5] | 7.75% | [2],[4],[5] | 7.75% | [2],[4],[5] | 7.75% | [9],[10],[11] | 7.75% | [9],[10],[11] | 7.75% | [9],[10],[11] | ||
Investment, principal | $ 4,519 | [4],[7] | $ 7,776 | [9],[12] | ||||||||||
Investment owned, at cost | 4,550 | [4] | 7,820 | [9] | ||||||||||
Investments at fair value | $ 3,305 | [4] | $ 5,846 | [9] | ||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 7% | 7% | 7% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 0 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | (21) | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ (13) | ||||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.28% | 9.28% | 9.28% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 26,154 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 25,712 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 25,893 | ||||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[13] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[13] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [8],[9],[10],[12],[13] | $ 2,228 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[13] | 2,186 | ||||||||||||
Investments at fair value | [8],[9],[10],[13] | $ 2,203 | ||||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (53) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (54) | ||||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.32% | 12.32% | 12.32% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 10,895 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 10,505 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 10,495 | ||||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 100,000 | [1],[4] | 100,000 | [1],[4] | 100,000 | [1],[4] | 80,515 | [8],[9] | 80,515 | [8],[9] | 80,515 | [8],[9] | ||
Investment owned, at cost | $ 109 | [1],[4] | $ 79 | [8],[9] | ||||||||||
Investments at fair value | $ 248 | [1],[4] | $ 89 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [1],[3],[4],[5] | 6.50% | [1],[3],[4],[5] | 6.50% | [1],[3],[4],[5] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (34) | [1],[3],[4],[5] | (34) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (3) | [1],[3],[4],[5] | $ (49) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | ||
Investment, interest rate | 12.01% | [1],[2],[4],[5] | 12.01% | [1],[2],[4],[5] | 12.01% | [1],[2],[4],[5] | 10.42% | [8],[9],[10],[11] | 10.42% | [8],[9],[10],[11] | 10.42% | [8],[9],[10],[11] | ||
Investment, principal | $ 38,414 | [1],[4],[5],[7] | $ 33,775 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 37,960 | [1],[4],[5] | 32,931 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 38,380 | [1],[4],[5] | $ 33,116 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Park Place Technologies, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.42% | 10.42% | 10.42% | 8.13% | 8.13% | 8.13% | ||||||||
Investment, principal | $ 9,825 | $ 4,925 | ||||||||||||
Investment owned, at cost | 9,492 | 4,781 | ||||||||||||
Investments at fair value | $ 9,698 | $ 4,687 | ||||||||||||
Investment, Identifier [Axis]: Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [4],[5] | 5% | [4],[5] | 5% | [4],[5] | 5% | [9],[10] | 5% | [9],[10] | 5% | [9],[10] | ||
Investment, interest rate | 10.42% | [2],[4],[5] | 10.42% | [2],[4],[5] | 10.42% | [2],[4],[5] | 8.13% | [9],[10],[11] | 8.13% | [9],[10],[11] | 8.13% | [9],[10],[11] | ||
Investment, principal | $ 9,676 | [4],[5],[7] | $ 9,850 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 9,518 | [4],[5] | 9,460 | [9],[10] | ||||||||||
Investments at fair value | $ 9,551 | [4],[5] | $ 9,374 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Peloton Interactive, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | 6.50% | 6.50% | |||||||||||
Investment, interest rate | 8.35% | 8.35% | 8.35% | |||||||||||
Investment, principal | $ 5,486 | |||||||||||||
Investment owned, at cost | 5,251 | |||||||||||||
Investments at fair value | $ 5,371 | |||||||||||||
Investment, Identifier [Axis]: Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | ||
Investment, interest rate | 11.57% | [1],[2],[4],[5] | 11.57% | [1],[2],[4],[5] | 11.57% | [1],[2],[4],[5] | 8.88% | [8],[9],[10],[11] | 8.88% | [8],[9],[10],[11] | 8.88% | [8],[9],[10],[11] | ||
Investment, principal | $ 22,375 | [1],[4],[5],[7] | $ 17,976 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 22,189 | [1],[4],[5] | 17,690 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 21,896 | [1],[4],[5] | $ 17,537 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 7.25% | [8],[9],[10] | 7.25% | [8],[9],[10] | 7.25% | [8],[9],[10] | ||
Investment, interest rate | 12.74% | [1],[2],[4],[5] | 12.74% | [1],[2],[4],[5] | 12.74% | [1],[2],[4],[5] | 10.92% | [8],[9],[10],[11] | 10.92% | [8],[9],[10],[11] | 10.92% | [8],[9],[10],[11] | ||
Investment, principal | $ 36,499 | [1],[4],[5],[7] | $ 28,627 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 35,458 | [1],[4],[5] | 28,198 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 33,214 | [1],[4],[5] | $ 27,482 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.65% | 9.65% | 9.65% | |||||||||||
Investment, principal | $ 2,416 | |||||||||||||
Investment owned, at cost | 2,298 | |||||||||||||
Investments at fair value | $ 2,390 | |||||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.65% | 9.65% | 9.65% | |||||||||||
Investment, principal | $ 683 | |||||||||||||
Investment owned, at cost | 650 | |||||||||||||
Investments at fair value | $ 676 | |||||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., Second Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | 7.25% | 7.25% | 7.25% | 7.25% | 7.25% | ||||||||
Investment, interest rate | 12.74% | 12.74% | 12.74% | 10.92% | 10.92% | 10.92% | ||||||||
Investment, principal | $ 4,503 | $ 4,503 | ||||||||||||
Investment owned, at cost | 4,435 | 4,435 | ||||||||||||
Investments at fair value | $ 4,098 | $ 4,323 | ||||||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., Second Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | 7.25% | 7.25% | 7.25% | 7.25% | 7.25% | ||||||||
Investment, interest rate | 12.74% | 12.74% | 12.74% | 10.92% | 10.92% | 10.92% | ||||||||
Investment, principal | $ 2,842 | $ 2,842 | ||||||||||||
Investment owned, at cost | 2,799 | 2,799 | ||||||||||||
Investments at fair value | $ 2,586 | $ 2,728 | ||||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [1],[3],[4],[5] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | 8% | [8],[9],[10],[13] | ||
Investment, interest rate | [1],[2],[3],[4],[5] | 13.45% | 13.45% | 13.45% | ||||||||||
Investment, principal | $ 3,003 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 2,926 | [1],[3],[4],[5] | (53) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 2,801 | [1],[3],[4],[5] | $ (111) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | ||
Investment, interest rate | 13.45% | [1],[2],[4],[5] | 13.45% | [1],[2],[4],[5] | 13.45% | [1],[2],[4],[5] | 10.68% | [8],[9],[10],[11] | 10.68% | [8],[9],[10],[11] | 10.68% | [8],[9],[10],[11] | ||
Investment, principal | $ 67,244 | [1],[4],[5],[7] | $ 48,689 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 66,353 | [1],[4],[5] | 47,951 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 64,406 | [1],[4],[5] | $ 47,155 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Revolver | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | 8% | 8% | 8% | 8% | 8% | ||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | |||||||||||
Investment, principal | $ 318 | $ 0 | ||||||||||||
Investment owned, at cost | 301 | (6) | ||||||||||||
Investments at fair value | $ 297 | $ (13) | ||||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Revolver | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | 8% | 8% | 8% | 8% | 8% | ||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | |||||||||||
Investment, principal | $ 226 | $ 0 | ||||||||||||
Investment owned, at cost | 216 | (5) | ||||||||||||
Investments at fair value | $ 211 | $ (10) | ||||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | 8% | 8% | 8% | 8% | 8% | ||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | 10.68% | 10.68% | 10.68% | ||||||||
Investment, principal | $ 8,116 | $ 6,796 | ||||||||||||
Investment owned, at cost | 7,850 | 6,694 | ||||||||||||
Investments at fair value | $ 7,773 | $ 6,582 | ||||||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | 8% | 8% | 8% | 8% | 8% | ||||||||
Investment, interest rate | 13.45% | 13.45% | 13.45% | 10.68% | 10.68% | 10.68% | ||||||||
Investment, principal | $ 5,182 | $ 4,465 | ||||||||||||
Investment owned, at cost | 5,029 | 4,398 | ||||||||||||
Investments at fair value | $ 4,964 | $ 4,325 | ||||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.78% | 12.78% | 12.78% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 24,503 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 24,255 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 24,081 | ||||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.78% | 12.78% | 12.78% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 2,819 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 2,797 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 2,771 | ||||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.01% | 10.01% | 10.01% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 23,275 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 22,722 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 22,810 | ||||||||||||
Investment, Identifier [Axis]: Project Boost Purchaser, LLC, Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 11.12% | 11.12% | 11.12% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 5,250 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 5,168 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 5,047 | ||||||||||||
Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.75% | [1],[4],[5],[14] | 5.75% | [1],[4],[5],[14] | 5.75% | [1],[4],[5],[14] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | ||
Investment, interest rate | 11.21% | [1],[2],[4],[5],[14] | 11.21% | [1],[2],[4],[5],[14] | 11.21% | [1],[2],[4],[5],[14] | 8.39% | [8],[9],[10],[11],[16] | 8.39% | [8],[9],[10],[11],[16] | 8.39% | [8],[9],[10],[11],[16] | ||
Investment, principal | £ | £ 4,626 | [1],[4],[5],[7],[14] | £ 3,501 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | $ 5,897 | [1],[4],[5],[14] | $ 4,646 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 5,166 | [1],[4],[5],[14] | $ 3,367 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: QuorumLabs, Inc., Application Software, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 64,887,669 | [1],[4] | 64,887,669 | [1],[4] | 64,887,669 | [1],[4] | 64,887,669 | [8],[9] | 64,887,669 | [8],[9] | 64,887,669 | [8],[9] | ||
Investment owned, at cost | $ 375 | [1],[4] | $ 375 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: RP Escrow Issuer LLC, Health Care Distributors, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 5.25% | 5.25% | 5.25% | ||||||||||
Investment, principal | [9],[12] | $ 1,325 | ||||||||||||
Investment owned, at cost | [9] | 1,218 | ||||||||||||
Investments at fair value | [9] | $ 1,097 | ||||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4.25% | 4.25% | 4.25% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.33% | 7.33% | 7.33% | ||||||||||
Investment, principal | [9],[10],[12] | $ 3,400 | ||||||||||||
Investment owned, at cost | [9],[10] | 3,202 | ||||||||||||
Investments at fair value | [9],[10] | $ 2,880 | ||||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 9.25% | 9.25% | 9.25% | ||||||||||
Investment, principal | [9],[12] | $ 4,755 | ||||||||||||
Investment owned, at cost | [9] | 4,720 | ||||||||||||
Investments at fair value | [9] | $ 3,109 | ||||||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [1],[3],[4],[5] | 6.50% | [1],[3],[4],[5] | 6.50% | [1],[3],[4],[5] | 6.50% | [8],[9],[10],[13] | 6.50% | [8],[9],[10],[13] | 6.50% | [8],[9],[10],[13] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | (43) | [1],[3],[4],[5] | (43) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ (47) | [1],[3],[4],[5] | $ (64) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 6.50% | [1],[4],[5] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | ||
Investment, interest rate | [1],[2],[4],[5] | 11.92% | 11.92% | 11.92% | ||||||||||
Investment, principal | $ 32,329 | [1],[4],[5],[7] | $ 24,692 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 32,070 | [1],[4],[5] | 24,265 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 31,779 | [1],[4],[5] | $ 24,101 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Renaissance Holding Corp., Diversified Banks, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [9],[10],[11] | 10.12% | 10.12% | 10.12% | ||||||||||
Investment, principal | [9],[10],[12] | $ 3,542 | ||||||||||||
Investment owned, at cost | [9],[10] | 3,515 | ||||||||||||
Investments at fair value | [9],[10] | $ 3,402 | ||||||||||||
Investment, Identifier [Axis]: Renaissance Holding Corp., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | |||||||||||
Investment, principal | $ 5,000 | |||||||||||||
Investment owned, at cost | 4,860 | |||||||||||||
Investments at fair value | $ 4,969 | |||||||||||||
Investment, Identifier [Axis]: RevSpring, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 7.67% | 7.67% | 7.67% | |||||||||||
Investment, principal | $ 9,625 | |||||||||||||
Investment owned, at cost | 9,607 | |||||||||||||
Investments at fair value | $ 9,304 | |||||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.25% | [1],[4],[5],[14] | 8.25% | [1],[4],[5],[14] | 8.25% | [1],[4],[5],[14] | 8.25% | [8],[9],[10],[16] | 8.25% | [8],[9],[10],[16] | 8.25% | [8],[9],[10],[16] | ||
Investment, interest rate | 13.90% | [1],[2],[4],[5],[14] | 13.90% | [1],[2],[4],[5],[14] | 13.90% | [1],[2],[4],[5],[14] | 11.92% | [8],[9],[10],[11],[16] | 11.92% | [8],[9],[10],[11],[16] | 11.92% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 36,707 | [1],[4],[5],[7],[14] | $ 37,656 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 35,548 | [1],[4],[5],[14] | 35,775 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 34,505 | [1],[4],[5],[14] | $ 36,187 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8.25% | [1],[4],[5],[14] | 8.25% | [1],[4],[5],[14] | 8.25% | [1],[4],[5],[14] | 8.25% | [8],[9],[10],[13],[16] | 8.25% | [8],[9],[10],[13],[16] | 8.25% | [8],[9],[10],[13],[16] | ||
Investment, interest rate | 13.90% | [1],[2],[4],[5],[14] | 13.90% | [1],[2],[4],[5],[14] | 13.90% | [1],[2],[4],[5],[14] | 11.92% | [8],[9],[10],[11],[13],[16] | 11.92% | [8],[9],[10],[11],[13],[16] | 11.92% | [8],[9],[10],[11],[13],[16] | ||
Investment, principal | $ 13,504 | [1],[4],[5],[7],[14] | $ 11,393 | [8],[9],[10],[12],[13],[16] | ||||||||||
Investment owned, at cost | 13,058 | [1],[4],[5],[14] | 10,583 | [8],[9],[10],[13],[16] | ||||||||||
Investments at fair value | $ 12,694 | [1],[4],[5],[14] | $ 10,760 | [8],[9],[10],[13],[16] | ||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 204,454 | [1],[4],[14] | 204,454 | [1],[4],[14] | 204,454 | [1],[4],[14] | 164,660 | [8],[9],[16] | 164,660 | [8],[9],[16] | 164,660 | [8],[9],[16] | ||
Investment owned, at cost | $ 1,202 | [1],[4],[14] | $ 1,202 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 756 | [1],[4],[14] | $ 74 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 1,037 | 1,037 | 1,037 | ||||||||||
Investment owned, at cost | [1],[4] | $ 1,037 | ||||||||||||
Investments at fair value | [1],[4] | $ 951 | ||||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 14.18% | 14.18% | 14.18% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 8,010 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 7,799 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 7,778 | ||||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (35) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (68) | ||||||||||||
Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 1 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.23% | 5.23% | 5.23% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.86% | 10.86% | 10.86% | 8.06% | 8.06% | 8.06% | ||||||||
Investment, principal | $ 138 | $ 8,201 | ||||||||||||
Investment owned, at cost | 138 | 8,194 | ||||||||||||
Investments at fair value | $ 94 | $ 7,176 | ||||||||||||
Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 1 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.88% | 10.88% | 10.88% | 8.06% | 8.06% | 8.06% | ||||||||
Investment, principal | $ 6,029 | $ 6,094 | ||||||||||||
Investment owned, at cost | 6,025 | 6,082 | ||||||||||||
Investments at fair value | $ 4,110 | $ 5,332 | ||||||||||||
Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 2 | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.23% | 5.23% | 5.23% | ||||||||
Investment, interest rate | 10.88% | 10.88% | 10.88% | 8.04% | 8.04% | 8.04% | ||||||||
Investment, principal | $ 8,113 | $ 138 | ||||||||||||
Investment owned, at cost | 8,111 | 138 | ||||||||||||
Investments at fair value | $ 5,531 | $ 121 | ||||||||||||
Investment, Identifier [Axis]: SHO Holding I Corporation, First Lien Term Loan 2 | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.23% | 5.23% | 5.23% | 5.23% | 5.23% | 5.23% | ||||||||
Investment, interest rate | 10.86% | 10.86% | 10.86% | 8.04% | 8.04% | 8.04% | ||||||||
Investment, principal | $ 103 | $ 102 | ||||||||||||
Investment owned, at cost | 102 | 102 | ||||||||||||
Investments at fair value | 70 | 90 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc, Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 15,874 | |||||||||||||
Investments at fair value | $ 15,874 | $ 0 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1] | 1,184,630 | 1,184,630 | 1,184,630 | ||||||||||
Investment owned, at cost | [1] | $ 40,093 | ||||||||||||
Investments at fair value | [1] | $ 36,226 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1] | 66,686 | 66,686 | 66,686 | ||||||||||
Investment owned, at cost | [1] | $ 0 | ||||||||||||
Investments at fair value | [1] | 0 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[7] | 15,874 | ||||||||||||
Investment owned, at cost | [1] | 14,100 | ||||||||||||
Investments at fair value | [1] | 15,874 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | [1],[3],[7] | 1,359 | ||||||||||||
Investment owned, at cost | [1],[3] | 1,337 | ||||||||||||
Investments at fair value | [1],[3] | $ 1,359 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal & Glass Containers, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 415 | 415 | 415 | ||||||||||
Investment owned, at cost | [8],[9] | $ 681 | ||||||||||||
Investments at fair value | [8],[9] | 681 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 1,184,630 | 1,184,630 | 1,184,630 | |||||||||||
Investments at fair value | $ 36,226 | 0 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, principal | 1,359 | |||||||||||||
Investments at fair value | $ 1,359 | 0 | ||||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 66,686 | 66,686 | 66,686 | |||||||||||
Investments at fair value | $ 0 | $ 0 | ||||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.75% | 4.75% | 4.75% | |||||||||||
Investment, interest rate | 10.38% | 10.38% | 10.38% | |||||||||||
Investment, principal | $ 2,977 | |||||||||||||
Investment owned, at cost | 2,580 | |||||||||||||
Investments at fair value | $ 2,799 | |||||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 10.38% | 10.38% | 10.38% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 4,452 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 3,806 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 4,184 | ||||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [1],[4],[5] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | 8% | [8],[9],[10] | ||
Investment, interest rate | 13.63% | [1],[2],[4],[5] | 13.63% | [1],[2],[4],[5] | 13.63% | [1],[2],[4],[5] | 10.74% | [8],[9],[10],[11] | 10.74% | [8],[9],[10],[11] | 10.74% | [8],[9],[10],[11] | ||
Investment, principal | $ 12,034 | [1],[4],[5],[7] | $ 9,109 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 11,250 | [1],[4],[5] | 8,972 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 9,928 | [1],[4],[5] | $ 8,289 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: SPX Flow, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | ||||||||
Investment, interest rate | 9.92% | 9.92% | 9.92% | 7.63% | 7.63% | 7.63% | ||||||||
Investment, principal | $ 8,801 | $ 7,500 | ||||||||||||
Investment owned, at cost | 8,442 | 7,184 | ||||||||||||
Investments at fair value | $ 8,794 | $ 6,966 | ||||||||||||
Investment, Identifier [Axis]: SPX Flow, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | ||||||||
Investment, interest rate | 9.92% | 9.92% | 9.92% | 7.63% | 7.63% | 7.63% | ||||||||
Investment, principal | $ 5,227 | $ 6,000 | ||||||||||||
Investment owned, at cost | 5,032 | 5,734 | ||||||||||||
Investments at fair value | $ 5,224 | $ 5,572 | ||||||||||||
Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.63% | 7.63% | 7.63% | ||||||||||
Investment, principal | [9],[10],[12] | $ 1,500 | ||||||||||||
Investment owned, at cost | [9],[10] | 1,410 | ||||||||||||
Investments at fair value | [9],[10] | $ 1,393 | ||||||||||||
Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [1],[4],[5] | 6.75% | [1],[4],[5] | 6.75% | [1],[4],[5] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | ||
Investment, interest rate | 12.40% | [1],[2],[4],[5] | 12.40% | [1],[2],[4],[5] | 12.40% | [1],[2],[4],[5] | 10.42% | [8],[9],[10],[11] | 10.42% | [8],[9],[10],[11] | 10.42% | [8],[9],[10],[11] | ||
Investment, principal | $ 25,527 | [1],[4],[5],[7] | $ 20,766 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 23,859 | [1],[4],[5] | 19,550 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 19,954 | [1],[4],[5] | $ 18,188 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Sabert Corporation, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | |||||||||||
Investment, interest rate | 7.63% | 7.63% | 7.63% | |||||||||||
Investment, principal | $ 2,536 | |||||||||||||
Investment owned, at cost | 2,511 | |||||||||||||
Investments at fair value | $ 2,435 | |||||||||||||
Investment, Identifier [Axis]: Sabert Corporation, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | |||||||||||
Investment, interest rate | 7.63% | 7.63% | 7.63% | |||||||||||
Investment, principal | $ 1,691 | |||||||||||||
Investment owned, at cost | 1,674 | |||||||||||||
Investments at fair value | $ 1,623 | |||||||||||||
Investment, Identifier [Axis]: Sabert Corporation, Metal & Glass Containers, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.63% | 7.63% | 7.63% | ||||||||||
Investment, principal | [9],[10],[12] | $ 1,691 | ||||||||||||
Investment owned, at cost | [9],[10] | 1,610 | ||||||||||||
Investments at fair value | [9],[10] | 1,623 | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 10% | 10% | 10% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | (95) | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ (93) | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 10% | 10% | 10% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 15.24% | 15.24% | 15.24% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 25,558 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 24,777 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 24,791 | ||||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 991,019 | 991,019 | 991,019 | ||||||||||
Investment owned, at cost | [1],[4] | $ 327 | ||||||||||||
Investments at fair value | [1],[4] | $ 1,625 | ||||||||||||
Investment, Identifier [Axis]: Scilex Holding Co, Biotechnology, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [4],[14] | 9,307 | 9,307 | 9,307 | ||||||||||
Investment owned, at cost | [4],[14] | $ 78 | ||||||||||||
Investments at fair value | [4],[14] | 13 | ||||||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, at cost | 54,791 | [3],[14],[26],[27],[30] | 49,322 | [13],[16],[23],[24],[28],[29],[31] | ||||||||||
Investments at fair value | $ 28,878 | [3],[14],[26],[27],[30] | $ 20,715 | [13],[16],[23],[24],[28],[29],[31] | 37,651 | |||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[3],[5],[14],[26] | 7% | [1],[3],[5],[14],[26] | 7% | [1],[3],[5],[14],[26] | 7% | [8],[10],[13],[16],[23],[24],[28] | 7% | [8],[10],[13],[16],[23],[24],[28] | 7% | [8],[10],[13],[16],[23],[24],[28] | ||
Investment, interest rate | 12.26% | [1],[2],[3],[5],[14],[26] | 12.26% | [1],[2],[3],[5],[14],[26] | 12.26% | [1],[2],[3],[5],[14],[26] | 8.80% | [8],[10],[11],[13],[16],[23],[24],[28] | 8.80% | [8],[10],[11],[13],[16],[23],[24],[28] | 8.80% | [8],[10],[11],[13],[16],[23],[24],[28] | ||
Investment, principal | $ 112,656 | [1],[3],[5],[7],[14],[26] | $ 96,250 | [8],[10],[12],[13],[16],[23],[24],[28] | ||||||||||
Investment owned, at cost | 112,656 | [1],[3],[5],[14],[26] | 96,250 | [8],[10],[13],[16],[23],[24],[28] | ||||||||||
Investments at fair value | $ 112,656 | [1],[3],[5],[14],[26] | $ 96,250 | [8],[10],[13],[16],[23],[24],[28] | $ 96,250 | |||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.88% | 12.88% | 12.88% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 7,191 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 6,934 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 6,937 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.88% | 12.88% | 12.88% | ||||||||||
Investment, principal | [1],[4],[5],[7],[14] | $ 2,697 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | 2,601 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 2,602 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[14] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[14] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[14] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[14] | 7.88% | 7.88% | 7.88% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[14] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[14] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[14] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4],[14] | 58,210 | 58,210 | 58,210 | ||||||||||
Investment owned, at cost | [1],[4],[14] | $ 182 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 87 | ||||||||||||
Investment, Identifier [Axis]: ShareThis, Inc., Application Software, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 345,452 | [1],[4] | 345,452 | [1],[4] | 345,452 | [1],[4] | 345,452 | [8],[9] | 345,452 | [8],[9] | 345,452 | [8],[9] | ||
Investment owned, at cost | $ 367 | [1],[4] | $ 367 | [8],[9] | ||||||||||
Investments at fair value | $ 0 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: SiO2 Medical Products, Inc., Metal & Glass Containers, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [8],[9],[10],[11] | 5.50% | 5.50% | 5.50% | ||||||||||
Investment, principal | [8],[9],[12] | $ 46,121 | ||||||||||||
Investment owned, at cost | [8],[9] | 45,413 | ||||||||||||
Investments at fair value | [8],[9] | $ 45,295 | ||||||||||||
Investment, Identifier [Axis]: SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [1],[4],[5] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | 7.50% | [8],[9],[10] | ||
Investment, interest rate | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 13.04% | [1],[2],[4],[5] | 10.48% | [8],[9],[10],[11] | 10.48% | [8],[9],[10],[11] | 10.48% | [8],[9],[10],[11] | ||
Investment, principal | $ 821 | [1],[4],[5],[7] | $ 3,195 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 813 | [1],[4],[5] | 3,163 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 776 | [1],[4],[5] | $ 2,997 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Sorenson Communications, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.50% | 5.50% | 5.50% | |||||||||||
Investment, interest rate | 9.17% | 9.17% | 9.17% | |||||||||||
Investment, principal | $ 2,553 | |||||||||||||
Investment owned, at cost | 2,528 | |||||||||||||
Investments at fair value | $ 2,454 | |||||||||||||
Investment, Identifier [Axis]: Sorrento Therapeutics, Inc., Biotechnology, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 66,000 | [4],[14] | 66,000 | [4],[14] | 66,000 | [4],[14] | 50,000 | [9],[16] | 50,000 | [9],[16] | 50,000 | [9],[16] | ||
Investment owned, at cost | $ 139 | [4],[14] | $ 197 | [9],[16] | ||||||||||
Investments at fair value | $ 6 | [4],[14] | $ 79 | [9],[16] | ||||||||||
Investment, Identifier [Axis]: Southern Veterinary Partners, LLC | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | |||||||||||
Investment, principal | $ 3,292 | |||||||||||||
Investment owned, at cost | 3,275 | |||||||||||||
Investments at fair value | $ 3,276 | |||||||||||||
Investment, Identifier [Axis]: Southern Veterinary Partners, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.43% | 9.43% | 9.43% | |||||||||||
Investment, principal | $ 7,680 | |||||||||||||
Investment owned, at cost | 7,642 | |||||||||||||
Investments at fair value | $ 7,643 | |||||||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | [1],[3],[4],[5] | 5% | [1],[3],[4],[5] | 5% | [1],[3],[4],[5] | 5.25% | [8],[9],[10],[13] | 5.25% | [8],[9],[10],[13] | 5.25% | [8],[9],[10],[13] | ||
Investment, interest rate | 10.42% | [1],[2],[3],[4],[5] | 10.42% | [1],[2],[3],[4],[5] | 10.42% | [1],[2],[3],[4],[5] | 8.03% | [8],[9],[10],[11],[13] | 8.03% | [8],[9],[10],[11],[13] | 8.03% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 618 | [1],[3],[4],[5],[7] | $ 866 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 576 | [1],[3],[4],[5] | 813 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 577 | [1],[3],[4],[5] | $ 796 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | [1],[4],[5] | 5.25% | [1],[4],[5] | 5.25% | [1],[4],[5] | 5.25% | [8],[9],[10] | 5.25% | [8],[9],[10] | 5.25% | [8],[9],[10] | ||
Investment, interest rate | 10.67% | [1],[2],[4],[5] | 10.67% | [1],[2],[4],[5] | 10.67% | [1],[2],[4],[5] | 8.30% | [8],[9],[10],[11] | 8.30% | [8],[9],[10],[11] | 8.30% | [8],[9],[10],[11] | ||
Investment, principal | $ 4,488 | [1],[4],[5],[7] | $ 4,534 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 4,423 | [1],[4],[5] | 4,455 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 4,425 | [1],[4],[5] | $ 4,427 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Spanx, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.30% | 8.30% | 8.30% | ||||||||
Investment, principal | $ 8,843 | $ 8,933 | ||||||||||||
Investment owned, at cost | 8,713 | 8,776 | ||||||||||||
Investments at fair value | $ 8,717 | $ 8,721 | ||||||||||||
Investment, Identifier [Axis]: Spanx, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | 5.25% | ||||||||
Investment, interest rate | 10.67% | 10.67% | 10.67% | 8.30% | 8.30% | 8.30% | ||||||||
Investment, principal | $ 4,913 | $ 4,962 | ||||||||||||
Investment owned, at cost | 4,840 | 4,876 | ||||||||||||
Investments at fair value | $ 4,843 | $ 4,845 | ||||||||||||
Investment, Identifier [Axis]: Star Parent, Inc. | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.33% | 9.33% | 9.33% | |||||||||||
Investment, principal | $ 4,000 | |||||||||||||
Investment owned, at cost | 3,939 | |||||||||||||
Investments at fair value | $ 3,916 | |||||||||||||
Investment, Identifier [Axis]: Star Parent, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4% | 4% | 4% | |||||||||||
Investment, interest rate | 9.33% | 9.33% | 9.33% | |||||||||||
Investment, principal | $ 8,000 | |||||||||||||
Investment owned, at cost | 7,880 | |||||||||||||
Investments at fair value | $ 7,834 | |||||||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.32% | 12.32% | 12.32% | ||||||||||
Investment, principal | € | [1],[4],[5],[7],[14] | € 23,731 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | $ 26,772 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 24,937 | ||||||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Other Diversified Financial Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[16] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 10% | 10% | 10% | ||||||||||
Investment, principal | £ | [8],[9],[10],[12],[16] | £ 16,911 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[16] | $ 19,414 | ||||||||||||
Investments at fair value | [8],[9],[10],[16] | $ 16,360 | ||||||||||||
Investment, Identifier [Axis]: Sunland Asphalt & Construction, LLC, Construction & Engineering, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 8.88% | 8.88% | 8.88% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 42,618 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 41,654 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 41,723 | ||||||||||||
Investment, Identifier [Axis]: Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 8% | 8% | 8% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 13.32% | 13.32% | 13.32% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 49,520 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 48,536 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 49,148 | ||||||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 3.75% | 3.75% | 3.75% | ||||||||||
Investment, interest rate | [9],[10],[11] | 7.42% | 7.42% | 7.42% | ||||||||||
Investment, principal | [9],[10],[12] | $ 3,466 | ||||||||||||
Investment owned, at cost | [9],[10] | 3,141 | ||||||||||||
Investments at fair value | [9],[10] | $ 3,056 | ||||||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 7.42% | 7.42% | 7.42% | |||||||||||
Investment, principal | $ 7,743 | |||||||||||||
Investment owned, at cost | 7,479 | |||||||||||||
Investments at fair value | $ 6,827 | |||||||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 7.42% | 7.42% | 7.42% | |||||||||||
Investment, principal | $ 2,820 | |||||||||||||
Investment owned, at cost | 2,712 | |||||||||||||
Investments at fair value | $ 2,487 | |||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[32] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[32] | 12.44% | 12.44% | 12.44% | ||||||||||
Investment, principal | [1],[4],[5],[7],[32] | $ 1,552 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[32] | 1,540 | ||||||||||||
Investments at fair value | [1],[4],[5],[32] | $ 1,478 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[32] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[32] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [1],[4],[5],[7],[32] | $ 32,104 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[32] | 31,861 | ||||||||||||
Investments at fair value | [1],[4],[5],[32] | $ 30,579 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[32] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[32] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [1],[4],[5],[7],[32] | $ 2,749 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[32] | 2,726 | ||||||||||||
Investments at fair value | [1],[4],[5],[32] | $ 2,618 | ||||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5],[32] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [1],[2],[3],[4],[5],[32] | 12.51% | 12.51% | 12.51% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7],[32] | $ 1,099 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5],[32] | 1,062 | ||||||||||||
Investments at fair value | [1],[3],[4],[5],[32] | $ 943 | ||||||||||||
Investment, Identifier [Axis]: Surgery Center Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 6.51% | 6.51% | 6.51% | |||||||||||
Investment, principal | $ 3,377 | |||||||||||||
Investment owned, at cost | 3,365 | |||||||||||||
Investments at fair value | $ 3,213 | |||||||||||||
Investment, Identifier [Axis]: Surgery Center Holdings, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | |||||||||||
Investment, interest rate | 6.51% | 6.51% | 6.51% | |||||||||||
Investment, principal | $ 3,377 | |||||||||||||
Investment owned, at cost | 3,365 | |||||||||||||
Investments at fair value | $ 3,213 | |||||||||||||
Investment, Identifier [Axis]: Swordfish Merger Sub LLC, Auto Parts & Equipment, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6.75% | 6.75% | 6.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 9.81% | 9.81% | 9.81% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 12,500 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 12,474 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 11,469 | ||||||||||||
Investment, Identifier [Axis]: TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | 11.50% | [2],[4],[5],[6],[14] | 11.50% | [2],[4],[5],[6],[14] | 11.50% | [2],[4],[5],[6],[14] | 11.50% | [8],[9],[10],[11],[16] | 11.50% | [8],[9],[10],[11],[16] | 11.50% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 4,984 | [4],[6],[7],[14] | $ 4,984 | [8],[9],[12],[16] | ||||||||||
Investment owned, at cost | 4,894 | [4],[6],[14] | 4,866 | [8],[9],[16] | ||||||||||
Investments at fair value | $ 4,785 | [4],[6],[14] | $ 4,872 | [8],[9],[16] | ||||||||||
Investment, Identifier [Axis]: THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 13% | 13% | 13% | ||||||||||
Investment, principal | [1],[4],[7],[14] | $ 50,419 | ||||||||||||
Investment owned, at cost | [1],[4],[14] | 49,842 | ||||||||||||
Investments at fair value | [1],[4],[14] | $ 49,869 | ||||||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [9],[10] | 4.50% | 4.50% | 4.50% | ||||||||||
Investment, interest rate | [9],[10],[11] | 8.15% | 8.15% | 8.15% | ||||||||||
Investment, principal | [9],[10],[12] | $ 12,032 | ||||||||||||
Investment owned, at cost | [9],[10] | 10,949 | ||||||||||||
Investments at fair value | [9],[10] | $ 10,827 | ||||||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | ||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | 8.15% | 8.15% | 8.15% | ||||||||
Investment, principal | $ 8,215 | $ 6,256 | ||||||||||||
Investment owned, at cost | 7,559 | 5,693 | ||||||||||||
Investments at fair value | $ 7,913 | $ 5,629 | ||||||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | 4.50% | ||||||||
Investment, interest rate | 9.99% | 9.99% | 9.99% | 8.15% | 8.15% | 8.15% | ||||||||
Investment, principal | $ 2,641 | $ 2,654 | ||||||||||||
Investment owned, at cost | 2,439 | 2,415 | ||||||||||||
Investments at fair value | $ 2,544 | $ 2,388 | ||||||||||||
Investment, Identifier [Axis]: Tacala, LLC, Restaurants, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 8% | [4],[5] | 8% | [4],[5] | 8% | [4],[5] | 7.50% | [9],[10] | 7.50% | [9],[10] | 7.50% | [9],[10] | ||
Investment, interest rate | 13.43% | [2],[4],[5] | 13.43% | [2],[4],[5] | 13.43% | [2],[4],[5] | 10.62% | [9],[10],[11] | 10.62% | [9],[10],[11] | 10.62% | [9],[10],[11] | ||
Investment, principal | $ 12,843 | [4],[5],[7] | $ 9,448 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 12,603 | [4],[5] | 9,338 | [9],[10] | ||||||||||
Investments at fair value | $ 12,464 | [4],[5] | $ 8,692 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[3],[4],[5],[14] | 6% | [1],[3],[4],[5],[14] | 6% | [1],[3],[4],[5],[14] | 6% | [8],[9],[10],[13],[16] | 6% | [8],[9],[10],[13],[16] | 6% | [8],[9],[10],[13],[16] | ||
Investment, principal | $ 0 | [1],[3],[4],[5],[7],[14] | $ 0 | [8],[9],[10],[12],[13],[16] | ||||||||||
Investment owned, at cost | (29) | [1],[3],[4],[5],[14] | (29) | [8],[9],[10],[13],[16] | ||||||||||
Investments at fair value | $ (22) | [1],[3],[4],[5],[14] | $ (28) | [8],[9],[10],[13],[16] | ||||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[4],[5],[14] | 6% | [1],[4],[5],[14] | 6% | [1],[4],[5],[14] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | 6% | [8],[9],[10],[16] | ||
Investment, interest rate | 11.42% | [1],[2],[4],[5],[14] | 11.42% | [1],[2],[4],[5],[14] | 11.42% | [1],[2],[4],[5],[14] | 8.68% | [8],[9],[10],[11],[16] | 8.68% | [8],[9],[10],[11],[16] | 8.68% | [8],[9],[10],[11],[16] | ||
Investment, principal | $ 28,826 | [1],[4],[5],[7],[14] | $ 23,215 | [8],[9],[10],[12],[16] | ||||||||||
Investment owned, at cost | 28,595 | [1],[4],[5],[14] | 22,815 | [8],[9],[10],[16] | ||||||||||
Investments at fair value | $ 28,537 | [1],[4],[5],[14] | $ 22,843 | [8],[9],[10],[16] | ||||||||||
Investment, Identifier [Axis]: Tecta America Corp., Construction & Engineering, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.50% | 8.50% | 8.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 11.62% | 11.62% | 11.62% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 5,203 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 5,125 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 5,034 | ||||||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 9.75% | [1],[3],[4],[5] | 9.75% | [1],[3],[4],[5] | 9.75% | [1],[3],[4],[5] | 9.25% | [8],[9],[10],[13] | 9.25% | [8],[9],[10],[13] | 9.25% | [8],[9],[10],[13] | ||
Investment, interest rate | 15.17% | [1],[2],[3],[4],[5] | 15.17% | [1],[2],[3],[4],[5] | 15.17% | [1],[2],[3],[4],[5] | 12.20% | [8],[9],[10],[11],[13] | 12.20% | [8],[9],[10],[11],[13] | 12.20% | [8],[9],[10],[11],[13] | ||
Investment, principal | $ 1,861 | [1],[3],[4],[5],[7] | $ 1,231 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 1,845 | [1],[3],[4],[5] | 1,210 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 1,802 | [1],[3],[4],[5] | $ 1,187 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 9.75% | [1],[4],[5] | 9.75% | [1],[4],[5] | 9.75% | [1],[4],[5] | 9.25% | [8],[9],[10] | 9.25% | [8],[9],[10] | 9.25% | [8],[9],[10] | ||
Investment, interest rate | 15.26% | [1],[2],[4],[5] | 15.26% | [1],[2],[4],[5] | 15.26% | [1],[2],[4],[5] | 12.11% | [8],[9],[10],[11] | 12.11% | [8],[9],[10],[11] | 12.11% | [8],[9],[10],[11] | ||
Investment, principal | $ 23,423 | [1],[4],[5],[7] | $ 18,323 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 23,207 | [1],[4],[5] | 17,956 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 22,814 | [1],[4],[5] | $ 17,865 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Ten-X LLC, Interactive Media & Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.32% | 11.32% | 11.32% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 19,947 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 19,013 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 19,199 | ||||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 668,879 | 668,879 | 668,879 | ||||||||||
Investment, principal | [8],[9],[12] | |||||||||||||
Investment owned, at cost | [8],[9] | 2,028 | ||||||||||||
Investments at fair value | [8],[9] | $ 4,077 | ||||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 9.50% | 9.50% | 9.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 13.17% | 13.17% | 13.17% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 29,663 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 29,352 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 29,031 | ||||||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.30% | [1],[4],[5],[17] | 7.30% | [1],[4],[5],[17] | 7.30% | [1],[4],[5],[17] | 7.30% | [8],[9],[10] | 7.30% | [8],[9],[10] | 7.30% | [8],[9],[10] | ||
Investment, interest rate | [8],[9],[10],[11] | 10.44% | 10.44% | 10.44% | ||||||||||
Investment, principal | $ 19,163 | [1],[4],[5],[7],[17] | $ 15,674 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 19,163 | [1],[4],[5],[17] | 15,605 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 18,340 | [1],[4],[5],[17] | $ 15,682 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 12.50% | [1],[4],[5],[17] | 12.50% | [1],[4],[5],[17] | 12.50% | [1],[4],[5],[17] | 12.50% | [8],[9],[10] | 12.50% | [8],[9],[10] | 12.50% | [8],[9],[10] | ||
Investment, interest rate | [8],[9],[10],[11] | 16.17% | 16.17% | 16.17% | ||||||||||
Investment, principal | $ 4,641 | [1],[4],[5],[7],[17] | $ 3,789 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 4,641 | [1],[4],[5],[17] | 3,774 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 4,170 | [1],[4],[5],[17] | $ 3,800 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7% | 7% | 7% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 46,832 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 45,698 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 37,231 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 10,616 | 10,616 | 10,616 | ||||||||||
Investment owned, at cost | [1],[4] | $ 120 | ||||||||||||
Investments at fair value | [1],[4] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 358,299 | 358,299 | 358,299 | ||||||||||
Investment owned, at cost | [1],[4] | $ 2,912 | ||||||||||||
Investments at fair value | [1],[4] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 60,862 | 60,862 | 60,862 | ||||||||||
Investment owned, at cost | [1],[4] | $ 1,207 | ||||||||||||
Investments at fair value | [1],[4] | $ 108 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 32,447 | 32,447 | 32,447 | ||||||||||
Investment owned, at cost | [1],[4] | $ 33,353 | ||||||||||||
Investments at fair value | [1],[4] | $ 31,701 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7% | 7% | 7% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 11.17% | 11.17% | 11.17% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 37,494 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 36,569 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 35,807 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 8,434 | 8,434 | 8,434 | ||||||||||
Investment owned, at cost | [8],[9] | $ 101 | ||||||||||||
Investments at fair value | [8],[9] | $ 69 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 284,650 | 284,650 | 284,650 | ||||||||||
Investment owned, at cost | [8],[9] | $ 2,409 | ||||||||||||
Investments at fair value | [8],[9] | $ 2,320 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 48,352 | 48,352 | 48,352 | ||||||||||
Investment owned, at cost | [8],[9] | $ 979 | ||||||||||||
Investments at fair value | [8],[9] | $ 979 | ||||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 4 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9],[13] | 23,201 | 23,201 | 23,201 | ||||||||||
Investment owned, at cost | [8],[9],[13] | $ 22,986 | ||||||||||||
Investments at fair value | [8],[9],[13] | $ 26,487 | ||||||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, interest rate | 11.42% | 11.42% | 11.42% | 9.12% | 9.12% | 9.12% | ||||||||
Investment, principal | $ 7,212 | $ 7,285 | ||||||||||||
Investment owned, at cost | 7,103 | 7,155 | ||||||||||||
Investments at fair value | $ 7,022 | $ 7,140 | ||||||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | 6% | 6% | 6% | 6% | 6% | ||||||||
Investment, interest rate | 11.42% | 11.42% | 11.42% | 9.12% | 9.12% | 9.12% | ||||||||
Investment, principal | $ 2,993 | $ 3,024 | ||||||||||||
Investment owned, at cost | 2,948 | 2,970 | ||||||||||||
Investments at fair value | $ 2,914 | $ 2,963 | ||||||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [1],[4],[5] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | 6% | [8],[9],[10] | ||
Investment, interest rate | 11.42% | [1],[2],[4],[5] | 11.42% | [1],[2],[4],[5] | 11.42% | [1],[2],[4],[5] | 9.12% | [8],[9],[10],[11] | 9.12% | [8],[9],[10],[11] | 9.12% | [8],[9],[10],[11] | ||
Investment, principal | $ 11,671 | [1],[4],[5],[7] | $ 6,016 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 11,646 | [1],[4],[5] | 5,908 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 11,363 | [1],[4],[5] | $ 5,895 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Tribe Buyer LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | |||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | |||||||||||
Investment, principal | $ 1,583 | |||||||||||||
Investment owned, at cost | 1,582 | |||||||||||||
Investments at fair value | $ 1,266 | |||||||||||||
Investment, Identifier [Axis]: Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [4],[5],[14] | 7.71% | 7.71% | 7.71% | ||||||||||
Investment, interest rate | [2],[4],[5],[14] | 13.06% | 13.06% | 13.06% | ||||||||||
Investment, principal | [4],[5],[7],[14] | $ 1,000 | ||||||||||||
Investment owned, at cost | [4],[5],[14] | 816 | ||||||||||||
Investments at fair value | [4],[5],[14] | $ 917 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [2],[4],[5],[14] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [4],[7],[14] | $ 4,500 | ||||||||||||
Investment owned, at cost | [4],[14] | 4,115 | ||||||||||||
Investments at fair value | [4],[14] | $ 2,953 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [2],[4],[5],[14] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, principal | [4],[7],[14] | $ 300 | ||||||||||||
Investment owned, at cost | [4],[14] | 264 | ||||||||||||
Investments at fair value | [4],[14] | $ 245 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 6.50% | 6.50% | 6.50% | ||||||||||
Investment, principal | [9],[12],[16] | $ 4,500 | ||||||||||||
Investment owned, at cost | [9],[16] | 4,060 | ||||||||||||
Investments at fair value | [9],[16] | $ 3,026 | ||||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11],[16] | 4.75% | 4.75% | 4.75% | ||||||||||
Investment, principal | [9],[12],[16] | $ 300 | ||||||||||||
Investment owned, at cost | [9],[16] | 258 | ||||||||||||
Investments at fair value | [9],[16] | $ 238 | ||||||||||||
Investment, Identifier [Axis]: Veritas US Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 5% | 5% | 5% | 5% | 5% | 5% | ||||||||
Investment, interest rate | 10.43% | 10.43% | 10.43% | 8.67% | 8.67% | 8.67% | ||||||||
Investment, principal | $ 6,305 | $ 6,365 | ||||||||||||
Investment owned, at cost | 6,257 | 6,290 | ||||||||||||
Investments at fair value | $ 5,500 | $ 5,087 | ||||||||||||
Investment, Identifier [Axis]: Virgin Pulse, Inc., Application Software, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 12.68% | 12.68% | 12.68% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,140 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 927 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,139 | ||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | [4],[5] | 3.75% | [4],[5] | 3.75% | [4],[5] | 3.75% | [9],[10] | 3.75% | [9],[10] | 3.75% | [9],[10] | ||
Investment, interest rate | 9.27% | [2],[4],[5] | 9.27% | [2],[4],[5] | 9.27% | [2],[4],[5] | 6.56% | [9],[10],[11] | 6.56% | [9],[10],[11] | 6.56% | [9],[10],[11] | ||
Investment, principal | $ 11,792 | [4],[5],[7] | $ 7,564 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 11,281 | [4],[5] | 6,989 | [9],[10] | ||||||||||
Investments at fair value | $ 11,127 | [4],[5] | $ 6,795 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 7.75% | 7.75% | 7.75% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.56% | 10.56% | 10.56% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 6,000 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 5,855 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 5,070 | ||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | ||||||||
Investment, interest rate | 9.27% | 9.27% | 9.27% | 6.56% | 6.56% | 6.56% | ||||||||
Investment, principal | $ 1,965 | $ 1,985 | ||||||||||||
Investment owned, at cost | 1,920 | 1,910 | ||||||||||||
Investments at fair value | $ 1,855 | $ 1,783 | ||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | 3.75% | ||||||||
Investment, interest rate | 9.27% | 9.27% | 9.27% | 6.56% | 6.56% | 6.56% | ||||||||
Investment, principal | $ 983 | $ 993 | ||||||||||||
Investment owned, at cost | 960 | 955 | ||||||||||||
Investments at fair value | $ 927 | $ 892 | ||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Second Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.75% | 7.75% | 7.75% | |||||||||||
Investment, interest rate | 10.56% | 10.56% | 10.56% | |||||||||||
Investment, principal | $ 6,000 | |||||||||||||
Investment owned, at cost | 5,972 | |||||||||||||
Investments at fair value | $ 5,070 | |||||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Second Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.75% | 7.75% | 7.75% | |||||||||||
Investment, interest rate | 10.56% | 10.56% | 10.56% | |||||||||||
Investment, principal | $ 3,000 | |||||||||||||
Investment owned, at cost | 2,986 | |||||||||||||
Investments at fair value | $ 2,534 | |||||||||||||
Investment, Identifier [Axis]: WPEngine, Inc., Application Software, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 6% | 6% | 6% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 10.19% | 10.19% | 10.19% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 40,536 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 39,947 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 40,131 | ||||||||||||
Investment, Identifier [Axis]: WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [1],[4],[5] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | 7% | [8],[9],[10] | ||
Investment, interest rate | 12.65% | [1],[2],[4],[5] | 12.65% | [1],[2],[4],[5] | 12.65% | [1],[2],[4],[5] | 10.67% | [8],[9],[10],[11] | 10.67% | [8],[9],[10],[11] | 10.67% | [8],[9],[10],[11] | ||
Investment, principal | $ 5,000 | [1],[4],[5],[7] | $ 5,000 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 4,925 | [1],[4],[5] | 4,925 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 4,263 | [1],[4],[5] | $ 4,538 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 19.64% | 19.64% | 19.64% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 2,316 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 2,293 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 2,264 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 21.68% | 21.68% | 21.68% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,565 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 1,551 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,464 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 15% | 15% | 15% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 21.68% | 21.68% | 21.68% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 1,323 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 1,311 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 1,237 | ||||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 4,871 | [1],[4] | 4,871 | [1],[4] | 4,871 | [1],[4] | 3,621 | [8],[9] | 3,621 | [8],[9] | 3,621 | [8],[9] | ||
Investment owned, at cost | $ 46 | [1],[4] | $ 0 | [8],[9] | ||||||||||
Investments at fair value | $ 107 | [1],[4] | $ 192 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | ||||||||
Investment, interest rate | 11.67% | 11.67% | 11.67% | 9.37% | 9.37% | 9.37% | ||||||||
Investment, principal | $ 6,148 | $ 7,818 | ||||||||||||
Investment owned, at cost | 6,008 | 7,596 | ||||||||||||
Investments at fair value | $ 5,939 | $ 7,115 | ||||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | 6.25% | ||||||||
Investment, interest rate | 11.67% | 11.67% | 11.67% | 9.37% | 9.37% | 9.37% | ||||||||
Investment, principal | $ 3,843 | $ 4,886 | ||||||||||||
Investment owned, at cost | 3,756 | 4,747 | ||||||||||||
Investments at fair value | $ 3,712 | $ 4,447 | ||||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 127,452 | [1],[4] | 127,452 | [1],[4] | 127,452 | [1],[4] | 18,032 | [8],[9] | 18,032 | [8],[9] | 18,032 | [8],[9] | ||
Investment owned, at cost | $ 2,057 | [1],[4] | $ 216 | [8],[9] | ||||||||||
Investments at fair value | $ 1,319 | [1],[4] | $ 296 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.25% | [4],[5] | 6.25% | [4],[5] | 6.25% | [4],[5] | 6.25% | [9],[10] | 6.25% | [9],[10] | 6.25% | [9],[10] | ||
Investment, interest rate | 11.67% | [2],[4],[5] | 11.67% | [2],[4],[5] | 11.67% | [2],[4],[5] | 9.37% | [9],[10],[11] | 9.37% | [9],[10],[11] | 9.37% | [9],[10],[11] | ||
Investment, principal | $ 8,983 | [4],[5],[7] | $ 25,499 | [9],[10],[12] | ||||||||||
Investment owned, at cost | 8,698 | [4],[5] | 24,632 | [9],[10] | ||||||||||
Investments at fair value | $ 8,678 | [4],[5] | $ 23,204 | [9],[10] | ||||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [8],[9] | 109,420 | 109,420 | 109,420 | ||||||||||
Investment owned, at cost | [8],[9] | $ 1,842 | ||||||||||||
Investments at fair value | [8],[9] | $ 1,799 | ||||||||||||
Investment, Identifier [Axis]: Zayo Group Holdings, Inc., Alternative Carriers, Fixed Rate Bond | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, interest rate | [9],[10],[11] | 4% | 4% | 4% | ||||||||||
Investment, principal | [9],[12] | $ 250 | ||||||||||||
Investment owned, at cost | [9] | 212 | ||||||||||||
Investments at fair value | [9] | $ 201 | ||||||||||||
Investment, Identifier [Axis]: Zayo Group Holdings, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3% | 3% | 3% | |||||||||||
Investment, interest rate | 6.12% | 6.12% | 6.12% | |||||||||||
Investment, principal | $ 2,155 | |||||||||||||
Investment owned, at cost | 2,000 | |||||||||||||
Investments at fair value | $ 1,812 | |||||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10] | 8.25% | 8.25% | 8.25% | ||||||||||
Investment, interest rate | [8],[9],[10],[11] | 11.92% | 11.92% | 11.92% | ||||||||||
Investment, principal | [8],[9],[10],[12] | $ 19,578 | ||||||||||||
Investment owned, at cost | [8],[9],[10] | 19,542 | ||||||||||||
Investments at fair value | [8],[9],[10] | $ 16,152 | ||||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals,First Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 4% | 4% | 4% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 9.32% | 9.32% | 9.32% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 19,578 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 19,568 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 19,489 | ||||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [8],[9],[10],[16] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [8],[9],[10],[11],[16] | 9.72% | 9.72% | 9.72% | ||||||||||
Investment, principal | £ | [8],[9],[10],[12],[16] | £ 18,000 | ||||||||||||
Investment owned, at cost | [8],[9],[10],[16] | $ 23,804 | ||||||||||||
Investments at fair value | [8],[9],[10],[16] | $ 16,552 | ||||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited,Specialized Finance, Second Lien Term Loan | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5],[14] | 7.50% | 7.50% | 7.50% | ||||||||||
Investment, interest rate | [1],[2],[4],[5],[14] | 12.72% | 12.72% | 12.72% | ||||||||||
Investment, principal | £ | [1],[4],[5],[7],[14] | £ 20,000 | ||||||||||||
Investment owned, at cost | [1],[4],[5],[14] | $ 25,841 | ||||||||||||
Investments at fair value | [1],[4],[5],[14] | $ 22,914 | ||||||||||||
Investment, Identifier [Axis]: athenahealth Group Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.25% | 3.25% | 3.25% | |||||||||||
Investment, interest rate | 8.57% | 8.57% | 8.57% | |||||||||||
Investment, principal | $ 4,320 | |||||||||||||
Investment owned, at cost | 4,080 | |||||||||||||
Investments at fair value | $ 4,251 | |||||||||||||
Investment, Identifier [Axis]: athenahealth Group Inc., Health Care Technology, First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 3.25% | 3.25% | 3.25% | |||||||||||
Investment, interest rate | 8.57% | 8.57% | 8.57% | |||||||||||
Investment, principal | $ 1,772 | |||||||||||||
Investment owned, at cost | 1,674 | |||||||||||||
Investments at fair value | $ 1,744 | |||||||||||||
Investment, Identifier [Axis]: athenahealth Group Inc., Health Care Technology, Preferred Equity | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | 21,523 | [1],[4] | 21,523 | [1],[4] | 21,523 | [1],[4] | 18,635 | [8],[9] | 18,635 | [8],[9] | 18,635 | [8],[9] | ||
Investment owned, at cost | $ 20,789 | [1],[4] | $ 18,264 | [8],[9] | ||||||||||
Investments at fair value | $ 20,074 | [1],[4] | $ 16,575 | [8],[9] | ||||||||||
Investment, Identifier [Axis]: eResearch Technology, Inc., First Lien Term Loan | SLF JV I | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | |||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | |||||||||||
Investment, principal | $ 7,331 | |||||||||||||
Investment owned, at cost | 7,258 | |||||||||||||
Investments at fair value | $ 6,859 | |||||||||||||
Investment, Identifier [Axis]: eResearch Technology, Inc., First Lien Term Loan | OCSI Glick JV LLC | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 4.50% | 4.50% | 4.50% | |||||||||||
Investment, interest rate | 7.62% | 7.62% | 7.62% | |||||||||||
Investment, principal | $ 2,444 | |||||||||||||
Investment owned, at cost | 2,419 | |||||||||||||
Investments at fair value | $ 2,286 | |||||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Revolver | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 6.75% | [1],[3],[4],[5] | 6.75% | [1],[3],[4],[5] | 6.75% | [1],[3],[4],[5] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | ||
Investment, interest rate | [1],[2],[3],[4],[5] | 12.14% | 12.14% | 12.14% | ||||||||||
Investment, principal | $ 377 | [1],[3],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 334 | [1],[3],[4],[5] | (31) | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 296 | [1],[3],[4],[5] | $ (32) | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | 6.75% | [8],[9],[10] | ||
Investment, interest rate | 12.63% | [1],[2],[4],[5] | 12.63% | [1],[2],[4],[5] | 12.63% | [1],[2],[4],[5] | 9.49% | [8],[9],[10],[11] | 9.49% | [8],[9],[10],[11] | 9.49% | [8],[9],[10],[11] | ||
Investment, principal | $ 24,427 | [1],[4],[5],[7] | $ 19,203 | [8],[9],[10],[12] | ||||||||||
Investment owned, at cost | 24,135 | [1],[4],[5] | 18,874 | [8],[9],[10] | ||||||||||
Investments at fair value | $ 23,548 | [1],[4],[5] | $ 18,867 | [8],[9],[10] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 7.25% | [1],[4],[5] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | 6.75% | [8],[9],[10],[13] | ||
Investment, interest rate | [1],[2],[4],[5] | 12.63% | 12.63% | 12.63% | ||||||||||
Investment, principal | $ 3,636 | [1],[4],[5],[7] | $ 0 | [8],[9],[10],[12],[13] | ||||||||||
Investment owned, at cost | 3,602 | [1],[4],[5] | 0 | [8],[9],[10],[13] | ||||||||||
Investments at fair value | $ 3,574 | [1],[4],[5] | $ 0 | [8],[9],[10],[13] | ||||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 7.25% | 7.25% | 7.25% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[4],[5] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, interest rate | [1],[2],[4],[5] | 11.75% | 11.75% | 11.75% | ||||||||||
Investment, principal | [1],[4],[5],[7] | $ 5,212 | ||||||||||||
Investment owned, at cost | [1],[4],[5] | 4,987 | ||||||||||||
Investments at fair value | [1],[4],[5] | $ 4,990 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment, basis spread, variable rate | [1],[3],[4],[5] | 8.75% | 8.75% | 8.75% | ||||||||||
Investment, principal | [1],[3],[4],[5],[7] | $ 0 | ||||||||||||
Investment owned, at cost | [1],[3],[4],[5] | 0 | ||||||||||||
Investments at fair value | [1],[3],[4],[5] | $ 0 | ||||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, Warrants | ||||||||||||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||||||||||||
Investment owned, balance (in shares) | shares | [1],[4] | 53,700 | 53,700 | 53,700 | ||||||||||
Investment owned, at cost | [1],[4] | $ 175 | ||||||||||||
Investments at fair value | [1],[4] | $ 258 | ||||||||||||
[1] As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). ten twenty ten twenty ten twenty ten twenty |
Portfolio Investments - Summari
Portfolio Investments - Summarized Balance Sheet Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||
Investments at fair value | $ 2,892,420 | $ 2,494,111 | |
Cash and cash equivalents | 136,450 | 23,528 | $ 29,334 |
Restricted cash | 9,089 | 2,836 | $ 2,301 |
Other assets | 1,681 | 1,665 | |
Total assets | 3,217,839 | 2,646,313 | |
Credit facilities payable | 710,000 | 700,000 | |
Secured borrowings | 18,106 | 0 | |
Due to affiliate | 4,310 | 3,180 | |
Total liabilities | 1,702,075 | 1,400,750 | |
Total liabilities and net assets | 3,217,839 | 2,646,313 | |
Investment owned, at cost | 3,044,119 | 2,617,754 | |
SLF JV I | |||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||
Investments at fair value | 322,179 | 359,625 | |
Cash and cash equivalents | 31,950 | 14,274 | |
Restricted cash | 2,987 | 5,642 | |
Other assets | 18,988 | 5,686 | |
Total assets | 376,104 | 385,227 | |
Credit facilities payable | 149,000 | 230,000 | |
Secured borrowings | 38,845 | 0 | |
Notes payable at fair value | 128,750 | 110,000 | |
Due to affiliate | 26,630 | 21,539 | |
Total liabilities | 343,225 | 361,539 | |
Members' equity | 32,879 | 23,688 | |
Total liabilities and net assets | 376,104 | 385,227 | |
Investment owned, at cost | 331,808 | 382,673 | |
Net proceeds | 128,750 | 110,000 | |
OCSI Glick JV LLC | |||
Investment Company, Nonconsolidated Subsidiary [Line Items] | |||
Investments at fair value | 123,343 | 133,144 | |
Cash and cash equivalents | 12,119 | 7,021 | |
Restricted cash | 184 | 1,788 | |
Other assets | 5,521 | 4,855 | |
Total assets | 141,167 | 146,808 | |
Credit facilities payable | 53,000 | 82,082 | |
Notes payable at fair value | 57,201 | 57,463 | |
Due to affiliate | 12,860 | 7,263 | |
Total liabilities | 141,167 | 146,808 | |
Members' equity | 0 | 0 | |
Total liabilities and net assets | 141,167 | 146,808 | |
Investment owned, at cost | 127,788 | 140,083 | |
Net proceeds | $ 66,685 | $ 68,185 |
Portfolio Investments - Summa_2
Portfolio Investments - Summarized Statement of Operations Information (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Total investment income | $ 379,286 | $ 262,520 | $ 209,385 | |
Interest expense | 111,642 | 46,929 | 30,518 | |
Total expenses | 204,036 | 113,591 | 111,092 | |
Net investment income before taxes | 180,775 | 151,929 | 99,901 | |
Net increase (decrease) in net assets resulting from operations | 117,331 | 29,223 | 237,260 | |
SLF JV I | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest income | 38,984 | 24,014 | 20,018 | |
Fee income | 290 | 198 | 565 | |
Total investment income | 39,274 | 24,212 | 20,583 | |
Other expenses | 442 | 253 | 260 | |
Total expenses | 33,988 | 17,112 | 14,410 | |
Net investment income before taxes | 5,286 | 7,100 | 6,173 | |
Net unrealized appreciation (depreciation) | 13,416 | (23,661) | 13,270 | |
Realized gain (loss) | (10,962) | 534 | 399 | |
Net increase (decrease) in net assets resulting from operations | 7,740 | (16,027) | 19,842 | |
SLF JV I | Senior Credit Facility | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest expense | 19,002 | 7,713 | 5,706 | |
SLF JV I | SLF JV I Notes | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest expense | 14,544 | 9,146 | $ 8,444 | |
OCSI Glick JV LLC | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest income | $ 4,643 | 14,043 | 9,703 | |
Fee income | 67 | 63 | 149 | |
Total investment income | 4,710 | 14,106 | 9,852 | |
Other expenses | 95 | 182 | 168 | |
Total expenses | 3,032 | 12,798 | 6,491 | |
Net investment income before taxes | 1,678 | 1,308 | 3,361 | |
Net unrealized appreciation (depreciation) | (1,710) | 1,254 | (3,216) | |
Realized gain (loss) | 32 | (2,562) | (145) | |
Net increase (decrease) in net assets resulting from operations | 0 | 0 | 0 | |
OCSI Glick JV LLC | Senior Credit Facility | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest expense | 1,157 | 6,560 | 2,747 | |
OCSI Glick JV LLC | Glick JV Notes | ||||
Investment Company, Nonconsolidated Subsidiary [Line Items] | ||||
Interest expense | $ 1,780 | $ 6,056 | $ 3,576 |
Fee Income (Details)
Fee Income (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue from Contract with Customer [Abstract] | |||
Fee income | $ 6,546 | $ 6,631 | $ 14,098 |
Recurring fee income | $ 900 | $ 900 | $ 600 |
Share Data and Net Assets - Sch
Share Data and Net Assets - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | ||
Earnings (loss) per common share — basic and diluted: | ||||
Net increase (decrease) in net assets resulting from operations | $ 117,331 | $ 29,223 | $ 237,260 | |
Weighted average common shares outstanding - basic (shares) | [1] | 72,119 | 60,727 | 54,039 |
Weighted average common shares outstanding - diluted (shares) | [1] | 72,119 | 60,727 | 54,039 |
Earnings (loss) per common share - basic (dollars per share) | [1] | $ 1.63 | $ 0.48 | $ 4.39 |
Earnings (loss) per common share - diluted (dollars per share) | [1] | $ 1.63 | $ 0.48 | $ 4.39 |
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis. |
Share Data and Net Assets - S_2
Share Data and Net Assets - Schedule of Changes in Net Assets (Details) - USD ($) $ in Thousands | 12 Months Ended | ||||||
Jan. 23, 2023 | Mar. 19, 2021 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |||
Investment Company, Net Assets [Roll Forward] | |||||||
Beginning of period (shares) | 61,125,000 | ||||||
Net assets at beginning of period | $ 1,245,563 | [1] | $ 1,312,823 | $ 914,879 | |||
Net investment income | 180,697 | 148,621 | 97,106 | ||||
Net unrealized appreciation (depreciation) | (28,555) | (136,248) | 114,519 | ||||
Net realized gains (losses) | (33,155) | 17,179 | 26,420 | ||||
(Provision) benefit for taxes on realized and unrealized gains (losses) | (1,656) | (329) | (785) | ||||
Net increase (decrease) in net assets from stockholder transactions | (185,900) | (118,657) | (82,020) | ||||
Reclassification of additional paid-in capital | 0 | ||||||
Issuance of common stock in connection with the OSI2 Merger (shares) | 15,860,200 | 13,133,337 | |||||
Issuance of common stock in connection with mergers | 334,034 | 0 | 242,704 | ||||
Issuance of common stock in connection with the "at the market" offering | $ 1,300 | $ 20,622 | $ 0 | ||||
Issuance of common stock under dividend reinvestment plan (shares) | 297,336 | 165,651 | 112,573 | ||||
Issuance of common stock under dividend reinvestment plan | $ 5,854 | $ 3,409 | $ 2,170 | ||||
Repurchase of common stock under dividend reinvestment plan | $ (2,418) | $ (1,857) | (2,170) | ||||
End of period (shares) | 77,225,000 | 61,125,000 | |||||
Net assets at end of period | $ 1,515,764 | [1] | $ 1,245,563 | [1] | $ 1,312,823 | ||
Common Stock | |||||||
Investment Company, Net Assets [Roll Forward] | |||||||
Beginning of period (shares) | 61,125,000 | 60,120,000 | 46,987,000 | ||||
Net assets at beginning of period | $ 611 | $ 601 | $ 470 | ||||
Issuance of common stock in connection with the OSI2 Merger (shares) | 15,860,000 | 13,133,000 | |||||
Issuance of common stock in connection with mergers | $ 159 | $ 131 | |||||
Issuance of common stock in connection with the "at the market" offering (shares) | 69,000 | 934,000 | |||||
Issuance of common stock in connection with the "at the market" offering | $ 1 | $ 9 | |||||
Issuance of common stock under dividend reinvestment plan (shares) | 297,000 | 166,000 | 113,000 | ||||
Issuance of common stock under dividend reinvestment plan | $ 3 | $ 2 | $ 1 | ||||
Repurchase of common stock under dividend reinvestment plan (shares) | (126,000) | (95,000) | (113,000) | ||||
Repurchase of common stock under dividend reinvestment plan | $ (2) | $ (1) | $ (1) | ||||
End of period (shares) | 77,225,000 | 61,125,000 | 60,120,000 | ||||
Net assets at end of period | $ 772 | $ 611 | $ 601 | ||||
Additional paid-in-capital | |||||||
Investment Company, Net Assets [Roll Forward] | |||||||
Net assets at beginning of period | 1,827,721 | 1,805,557 | 1,488,713 | ||||
Reclassification of additional paid-in capital | 74,271 | ||||||
Issuance of common stock in connection with mergers | 333,875 | 242,573 | |||||
Issuance of common stock in connection with the "at the market" offering | 1,299 | 20,613 | |||||
Issuance of common stock under dividend reinvestment plan | 5,851 | 3,407 | 2,169 | ||||
Repurchase of common stock under dividend reinvestment plan | (2,416) | (1,856) | (2,169) | ||||
Net assets at end of period | 2,166,330 | 1,827,721 | 1,805,557 | ||||
Accumulated Overdistributed Earnings | |||||||
Investment Company, Net Assets [Roll Forward] | |||||||
Net assets at beginning of period | (582,769) | (493,335) | (574,304) | ||||
Net investment income | 180,697 | 148,621 | 97,106 | ||||
Net unrealized appreciation (depreciation) | (28,555) | (136,248) | 114,519 | ||||
Net realized gains (losses) | (33,155) | 17,179 | 26,420 | ||||
(Provision) benefit for taxes on realized and unrealized gains (losses) | (1,656) | (329) | (785) | ||||
Net increase (decrease) in net assets from stockholder transactions | (185,900) | (118,657) | (82,020) | ||||
Reclassification of additional paid-in capital | (74,271) | ||||||
Net assets at end of period | $ (651,338) | $ (582,769) | $ (493,335) | ||||
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The issued and outstanding shares and net asset value per share reflect the reverse stock split on a retroactive basis. |
Share Data and Net Assets - S_3
Share Data and Net Assets - Schedule of Distributions (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||||||||||||||||
Sep. 29, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 30, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2019 | |
Investment Company, Changes in Net Assets [Line Items] | |||||||||||||||||
Amount per share (in dollars per share) | $ 2.61 | $ 1.95 | $ 1.515 | $ 1.17 | $ 1.14 | ||||||||||||
Distributions to stockholders | $ 180,000 | $ 115,300 | $ 79,800 | ||||||||||||||
Issuance of common stock under dividend reinvestment plan (shares) | 297,336 | 165,651 | 112,573 | ||||||||||||||
Issuance of common stock under dividend reinvestment plan | $ 5,854 | $ 3,409 | $ 2,170 | ||||||||||||||
Quarterly | |||||||||||||||||
Investment Company, Changes in Net Assets [Line Items] | |||||||||||||||||
Amount per share (in dollars per share) | $ 0.55 | $ 0.55 | $ 0.55 | $ 0.54 | $ 0.51 | $ 0.495 | $ 0.48 | $ 0.465 | $ 0.435 | $ 0.39 | $ 0.36 | $ 0.33 | |||||
Distributions to stockholders | $ 40,900 | $ 41,300 | $ 41,100 | $ 32,000 | $ 30,200 | $ 29,400 | $ 28,500 | $ 27,200 | $ 25,500 | $ 22,900 | $ 16,400 | $ 15,000 | |||||
Issuance of common stock under dividend reinvestment plan (shares) | 76,766 | 57,279 | 68,412 | 53,369 | 51,181 | 43,676 | 34,804 | 35,990 | 28,358 | 25,660 | 27,234 | 31,321 | |||||
Issuance of common stock under dividend reinvestment plan | $ 1,500 | $ 1,100 | $ 1,300 | $ 1,100 | $ 1,000 | $ 900 | $ 800 | $ 800 | $ 600 | $ 500 | $ 500 | $ 500 | |||||
Special | |||||||||||||||||
Investment Company, Changes in Net Assets [Line Items] | |||||||||||||||||
Amount per share (in dollars per share) | $ 0.42 | ||||||||||||||||
Distributions to stockholders | $ 24,800 | ||||||||||||||||
Issuance of common stock under dividend reinvestment plan (shares) | 41,510 | ||||||||||||||||
Issuance of common stock under dividend reinvestment plan | $ 800 |
Share Data and Net Assets - Nar
Share Data and Net Assets - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||||||
Feb. 08, 2023 | Jan. 23, 2023 | Feb. 07, 2022 | Mar. 19, 2021 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investment Company, Changes in Net Assets [Line Items] | |||||||
Issuance of common stock in connection with the OSI2 Merger (shares) | 15,860,200 | 13,133,337 | |||||
Issuance of common stock under dividend reinvestment plan (shares) | 297,336 | 165,651 | 112,573 | ||||
Aggregate offering price | $ 125 | $ 125 | |||||
At the Market | |||||||
Investment Company, Changes in Net Assets [Line Items] | |||||||
Number of shares issued (in shares) | 68,752 | 933,733 | |||||
Net proceeds | $ 1.3 | $ 20.6 | |||||
Common Stock | |||||||
Investment Company, Changes in Net Assets [Line Items] | |||||||
Issuance of common stock under dividend reinvestment plan (shares) | 171,645 | 70,794 |
Share Data and Net Assets - S_4
Share Data and Net Assets - Schedule of Common Stock Issued and Sold (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investment Company, Changes in Net Assets [Line Items] | |||
Gross Proceeds | $ 1,370 | $ 20,839 | $ 0 |
Placement Agent Fees | $ 235 | $ 215 | $ 0 |
At the Market | |||
Investment Company, Changes in Net Assets [Line Items] | |||
Number of Shares Issued (in shares) | 68,752 | 933,733 | |
Gross Proceeds | $ 1,384 | $ 21,049 | |
Placement Agent Fees | 14 | 210 | |
Net Proceeds | $ 1,370 | $ 20,839 | |
Average Sales Price per Share (in dollars per share) | $ 20.13 | $ 22.54 | |
Net proceeds excluding offering costs | $ 100 | $ 200 |
Borrowings - Narrative (Details
Borrowings - Narrative (Details) - USD ($) | 8 Months Ended | 12 Months Ended | |||||
Aug. 15, 2023 | May 18, 2021 | Feb. 25, 2020 | Sep. 30, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Line of Credit Facility [Line Items] | |||||||
Borrowings outstanding | $ 710,000,000 | $ 710,000,000 | $ 700,000,000 | ||||
Interest expense | 111,642,000 | 46,929,000 | $ 30,518,000 | ||||
Fair Value | 1,588,201,000 | $ 1,588,201,000 | $ 1,277,105,000 | ||||
Interest rate swap | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest rate | 2.70% | ||||||
Floating interest rate | 1.658% | ||||||
Notional amount | $ 350,000,000 | ||||||
Interest rate swap | Designated as Hedging Instrument | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest rate | 2.70% | ||||||
Notional amount | $ 350,000,000 | ||||||
Secured Overnight Financing Rate | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest rate | 2% | ||||||
Secured Overnight Financing Rate | Minimum | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 0.11448% | ||||||
Secured Overnight Financing Rate | Maximum | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 0.26161% | ||||||
London Interbank Offered Rate (LIBOR) | Interest rate swap | Designated as Hedging Instrument | |||||||
Line of Credit Facility [Line Items] | |||||||
Floating interest rate | 1.658% | ||||||
Base Rate | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest rate | 1% | ||||||
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest rate swap | Designated as Hedging Instrument | |||||||
Line of Credit Facility [Line Items] | |||||||
Floating interest rate | 0.26161% | ||||||
Citibank Facility | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest expense | $ 600,000 | ||||||
2025 Notes | |||||||
Line of Credit Facility [Line Items] | |||||||
Principal amount | $ 300,000,000 | 300,000,000 | 300,000,000 | 300,000,000 | |||
Net proceeds | 293,800,000 | ||||||
Unaccreted discount | 2,500,000 | $ 700,000 | $ 700,000 | 1,200,000 | |||
Underwriting commissions | 3,000,000 | ||||||
Offering costs | $ 700,000 | ||||||
Interest rate, percentage | 3.50% | 3.50% | 3.50% | ||||
Redemption price | 100% | ||||||
2027 Notes | |||||||
Line of Credit Facility [Line Items] | |||||||
Principal amount | $ 350,000,000 | $ 350,000,000 | $ 350,000,000 | 350,000,000 | |||
Net proceeds | 344,800,000 | ||||||
Unaccreted discount | 1,000,000 | $ 600,000 | $ 600,000 | 700,000 | |||
Underwriting commissions | 3,500,000 | ||||||
Offering costs | $ 700,000 | ||||||
Interest rate, percentage | 2.70% | 2.70% | 2.70% | ||||
Redemption price | 100% | ||||||
2029 Notes | |||||||
Line of Credit Facility [Line Items] | |||||||
Principal amount | $ 300,000,000 | $ 300,000,000 | $ 300,000,000 | ||||
Net proceeds | 292,900,000 | ||||||
Unaccreted discount | 3,500,000 | $ 3,400,000 | $ 3,400,000 | ||||
Underwriting commissions | 3,000,000 | ||||||
Offering costs | $ 600,000 | ||||||
Interest rate, percentage | 7.10% | 7.10% | 7.10% | ||||
Redemption price | 100% | ||||||
2029 Notes | Interest rate swap | Designated as Hedging Instrument | |||||||
Line of Credit Facility [Line Items] | |||||||
Interest rate | 7.10% | ||||||
Notional amount | $ 300,000,000 | ||||||
2029 Notes | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest rate swap | Designated as Hedging Instrument | |||||||
Line of Credit Facility [Line Items] | |||||||
Floating interest rate | 3.1255% | ||||||
Line of Credit | Revolving Credit Facility | Syndicated Facility | |||||||
Line of Credit Facility [Line Items] | |||||||
Borrowing capacity | $ 1,218,000,000 | $ 1,218,000,000 | |||||
Accordion feature, increase limit | 1,250,000,000 | 1,250,000,000 | |||||
Borrowing capacity subject to expiration | $ 1,035,000,000 | $ 1,035,000,000 | |||||
Debt instrument, covenant, total assets to total indebtedness, ratio, minimum threshold | 1.50 | 1.50 | |||||
Debt instrument, covenant, consolidated EBITDA to consolidated interest expense, ratio, minimum threshold | 2.25 | 2.25 | |||||
Borrowings outstanding | $ 430,000,000 | $ 430,000,000 | 540,000,000 | ||||
Fair value | $ 430,000,000 | $ 430,000,000 | $ 540,000,000 | ||||
Weighted average interest rate | 6.792% | 6.792% | 2.876% | 2.197% | |||
Interest expense inclusive of fees | $ 50,000,000 | $ 19,500,000 | $ 13,800,000 | ||||
Line of Credit | Revolving Credit Facility | Citibank Facility | |||||||
Line of Credit Facility [Line Items] | |||||||
Borrowings outstanding | 160,000,000 | ||||||
Fair value | $ 160,000,000 | ||||||
Weighted average interest rate | 6.781% | 6.781% | 3.179% | 2.086% | |||
Interest expense inclusive of fees | $ 8,000,000 | $ 5,800,000 | $ 1,900,000 | ||||
Line of Credit | Revolving Credit Facility | OSI2 Citibank Facility | |||||||
Line of Credit Facility [Line Items] | |||||||
Borrowing capacity | $ 400,000,000 | 400,000,000 | |||||
Borrowings outstanding | $ 280,000,000 | $ 280,000,000 | |||||
Weighted average interest rate | 7.666% | 7.666% | |||||
Interest expense inclusive of fees | $ 14,600,000 | ||||||
Unused capacity, commitment fee | 0.50% | ||||||
Commitment fee, unused capacity threshold percentage | 30% | 30% | |||||
Fair Value | $ 280,000,000 | $ 280,000,000 | |||||
Line of Credit | Revolving Credit Facility | OSI2 Citibank Facility | Secured Overnight Financing Rate | After Reinvestment Period | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 4% | ||||||
Line of Credit | Revolving Credit Facility | OSI2 Citibank Facility | Secured Overnight Financing Rate | Minimum | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 2.50% | ||||||
Line of Credit | Revolving Credit Facility | OSI2 Citibank Facility, Syndicated Loans | Secured Overnight Financing Rate | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 2% | ||||||
Line of Credit | Revolving Credit Facility | OSI2 Citibank Facility, All Other Loans | Secured Overnight Financing Rate | |||||||
Line of Credit Facility [Line Items] | |||||||
Debt instrument, basis spread, variable rate | 2.75% |
Borrowings - Components of the
Borrowings - Components of the Carrying Value of Notes (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Aug. 15, 2023 | Sep. 30, 2022 | May 18, 2021 | Feb. 25, 2020 |
Debt Instrument [Line Items] | |||||
Unamortized financing costs | $ (7,076) | $ (5,020) | |||
Net carrying value | 1,600,731 | 1,301,043 | |||
2025 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | 300,000 | 300,000 | $ 300,000 | ||
Unamortized financing costs | (1,100) | (1,800) | |||
Unaccreted discount | (700) | (1,200) | $ (2,500) | ||
Interest rate swap fair value adjustment | 0 | 0 | |||
Net carrying value | 298,200 | 297,000 | |||
Fair Value | 286,400 | 283,100 | |||
2027 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | 350,000 | 350,000 | $ 350,000 | ||
Unamortized financing costs | (2,500) | (3,200) | |||
Unaccreted discount | (600) | (700) | $ (1,000) | ||
Interest rate swap fair value adjustment | (40,500) | (42,000) | |||
Net carrying value | 306,400 | 304,100 | |||
Fair Value | 301,800 | $ 294,000 | |||
2029 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | 300,000 | $ 300,000 | |||
Unamortized financing costs | (3,500) | ||||
Unaccreted discount | (3,400) | $ (3,500) | |||
Interest rate swap fair value adjustment | (7,000) | ||||
Net carrying value | 286,100 | ||||
Fair Value | $ 290,000 |
Borrowings - Components of Inte
Borrowings - Components of Interest and Other Debt Expenses (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
2025 Notes | |||
Debt Instrument [Line Items] | |||
Coupon interest | $ 10.5 | $ 10.5 | $ 10.5 |
Amortization of financing costs and discount | 1.3 | 1.3 | 1.3 |
Effect of interest rate swap | 0 | 0 | 0 |
Total interest expense | $ 11.8 | $ 11.8 | $ 11.8 |
Coupon interest rate | 3.50% | 3.50% | 3.50% |
2027 Notes | |||
Debt Instrument [Line Items] | |||
Coupon interest | $ 9.5 | $ 9.5 | $ 3.5 |
Amortization of financing costs and discount | 0.9 | 0.9 | 0.3 |
Effect of interest rate swap | 13.4 | (0.4) | (1.1) |
Total interest expense | $ 23.8 | $ 10 | $ 2.7 |
Coupon interest rate | 6.539% | 2.585% | 1.813% |
2029 Notes | |||
Debt Instrument [Line Items] | |||
Coupon interest | $ 2.7 | ||
Amortization of financing costs and discount | 0.2 | ||
Effect of interest rate swap | 0.6 | ||
Total interest expense | $ 3.5 | ||
Coupon interest rate | 8.49% |
Taxable_Distributable Income _3
Taxable/Distributable Income and Dividend Distributions - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Investments, Owned, Federal Income Tax Note [Line Items] | |||
Undistributed ordinary income, net | $ 558,300 | ||
Valuation allowance | 8,100 | ||
Deferred tax assets | 8,100 | ||
(Provision) benefit for taxes on realized and unrealized gains (losses) | 1,656 | $ 329 | $ 785 |
Income tax expense (benefit) | 1,300 | 700 | |
Deferred taxes | 1,670 | (973) | 133 |
(Provision) benefit for taxes on net investment income | 0 | $ 3,308 | $ 2,795 |
Cost of investments | 3,070,000 | ||
Unrealized appreciation | 529,500 | ||
Unrealized depreciation | 704,500 | ||
Unrealized appreciation (depreciation) | 175,000 | ||
Short-Term Capital Loss Carryforward | |||
Investments, Owned, Federal Income Tax Note [Line Items] | |||
Undistributed ordinary income, net | 70,300 | ||
Long-Term Capital Loss Carryforward | |||
Investments, Owned, Federal Income Tax Note [Line Items] | |||
Undistributed ordinary income, net | $ 488,000 |
Taxable_Distributable Income _4
Taxable/Distributable Income and Dividend Distributions - Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | |||
Net increase (decrease) in net assets resulting from operations | $ 117,331 | $ 29,223 | $ 237,260 |
Net unrealized (appreciation) depreciation | 28,555 | 136,248 | (114,519) |
Book/tax difference due to organizational costs | 0 | (87) | (87) |
Book/tax difference due to capital losses suspended (utilized) | 34,607 | (16,490) | (41,625) |
Other book/tax differences | (14,691) | (6,506) | 11,863 |
Taxable/Distributable Income | $ 165,802 | $ 142,388 | $ 92,892 |
Taxable_Distributable Income _5
Taxable/Distributable Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Income Tax Disclosure [Abstract] | ||
Undistributed ordinary income, net | $ 33,525 | |
Net realized capital losses | (509,832) | |
Unrealized losses, net | (175,031) | |
Accumulated overdistributed earnings | $ (651,338) | $ (582,769) |
Realized Gains or Losses and _3
Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | $ (33,155) | $ 17,179 | $ 26,420 |
Net unrealized appreciation (depreciation) | (28,555) | (136,248) | 114,519 |
OSI2 Merger | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | (20,700) | ||
OCSI Merger | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | 34,100 | ||
Investments in debt securities | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | (49,100) | (94,100) | 70,000 |
Investments in equity securities | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | (4,900) | (35,400) | 36,300 |
Exited Investments | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | 25,400 | (11,700) | 6,600 |
Foreign currency forward contract | |||
Schedule of Investments [Line Items] | |||
Net unrealized appreciation (depreciation) | $ 100 | $ 4,900 | $ 1,700 |
Realized Gains or Losses and _4
Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | $ (33,155) | $ 17,179 | $ 26,420 |
SIO2 Medical Products Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (13,900) | ||
Convergeone Holdings Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (6,000) | ||
Foreign currency forward contracts | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (5,800) | 13,700 | |
Aden & Anais Merger Sub Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (5,200) | ||
Radiology Partners Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (4,200) | ||
Carvana Co. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (2,800) | ||
Impel Neuropharma Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (2,300) | ||
ASP Unifrax Holdings Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (2,100) | ||
WP CPP Holdings LLC | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (1,300) | (1,700) | |
Global Medical Response Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (1,000) | ||
Athenex Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 6,500 | ||
Tersera Therapeutics LLC | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 5,200 | ||
CorEvitas Group Holdings LP | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 4,000 | ||
OmniSYS Acquisition Corporation | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 2,200 | ||
First Star Speir Aviation Limited | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 1,900 | ||
TigerConnect Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 1,800 | ||
PLATO Learning Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 7,800 | ||
Keypath Education Holdings, LLC | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 6,800 | ||
L Squared Capital Partners LLC | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 3,400 | ||
LTI Holdings, Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 2,600 | ||
BX Commercial Mortgage Trust 2020-VIVA | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | 2,600 | ||
California Pizza Kitchen Inc. | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (1,800) | ||
Refac Optical Group | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | (1,300) | ||
Other, net | |||
Schedule of Investments [Line Items] | |||
Net realized gains (losses) | $ (4,300) | $ (700) | $ 6,300 |
Related Party Transactions (Det
Related Party Transactions (Details) | 12 Months Ended | ||||
May 03, 2019 | May 02, 2019 | Sep. 30, 2023 USD ($) component | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | |
Related Party Transaction [Line Items] | |||||
Base management fee and incentive fee payable | $ 19,547,000 | $ 15,940,000 | |||
Base management fee rate (as a percent) | 1% | 1.50% | |||
Base management fee, threshold (as a percent) | 200% | ||||
Base management fee | 44,899,000 | 39,556,000 | $ 32,288,000 | ||
Part I incentive fee | 35,831,000 | 26,644,000 | 21,598,000 | ||
Due to affiliate | $ 4,310,000 | 3,180,000 | |||
Affiliated Entity | |||||
Related Party Transaction [Line Items] | |||||
Related party transaction, termination, notice period | 60 days | ||||
Administrator expense | $ 1,500,000 | 1,500,000 | 1,700,000 | ||
General and administrative expenses | 300,000 | 300,000 | 200,000 | ||
Due to affiliate | 4,300,000 | 3,200,000 | |||
Oaktree Strategic Income Corporation Merger | |||||
Related Party Transaction [Line Items] | |||||
Investment company, contractual fee waived | $ 6,000,000 | ||||
Contractual fee waived, period otherwise receivable (in years) | 2 years | ||||
Contractual fee waived, per quarter | $ 750,000 | ||||
Oaktree Strategic Income II, Inc. Merger | |||||
Related Party Transaction [Line Items] | |||||
Investment company, contractual fee waived | 9,000,000 | ||||
Oaktree Strategic Income II, Inc Merger, Year One | |||||
Related Party Transaction [Line Items] | |||||
Investment company, contractual fee waived | 6,000,000 | ||||
Contractual fee waived, per quarter | 1,500,000 | ||||
Oaktree Strategic Income II, Inc Merger, Year Two | |||||
Related Party Transaction [Line Items] | |||||
Investment company, contractual fee waived | 3,000,000 | ||||
Contractual fee waived, per quarter | $ 750,000 | ||||
Investment Advisory Agreement | |||||
Related Party Transaction [Line Items] | |||||
Number of components | component | 2 | ||||
Related party transaction, termination, notice period | 60 days | ||||
Base management fee | $ 39,400,000 | 36,600,000 | 30,700,000 | ||
Management incentive rate | 1.50% | ||||
Investment Advisory Agreement | Affiliated Entity | |||||
Related Party Transaction [Line Items] | |||||
Part I incentive fee | $ 35,800,000 | 26,600,000 | 21,600,000 | ||
Incentive fee expense | 9,600,000 | 0 | 8,800,000 | ||
Accrued capital gains incentive fees expensed (reversed) | $ 0 | $ (8,800,000) | $ 17,600,000 | ||
Investment Advisory Agreement Incentive Rate Pre Incentive Fee Net Investment Income Below Catch Up | |||||
Related Party Transaction [Line Items] | |||||
Management incentive rate | 100% | ||||
Investment Advisory Agreement Incentive Rate Quarterly Catch Up Threshold | |||||
Related Party Transaction [Line Items] | |||||
Management incentive rate | 1.8182% | ||||
Investment Advisory Agreement Cumulative Pre Incentive Fee Net Investment Income | |||||
Related Party Transaction [Line Items] | |||||
Management incentive rate | 17.50% | ||||
Investment Advisory Agreement - Incentive Rate, Realized Capital Gains | Affiliated Entity | |||||
Related Party Transaction [Line Items] | |||||
Management incentive rate | 17.50% |
Financial Highlights - Portfoli
Financial Highlights - Portfolio Composition (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | |||||||||||||
Jun. 30, 2023 $ / shares | Mar. 31, 2023 $ / shares | Jan. 20, 2023 | Jun. 30, 2022 $ / shares | Mar. 31, 2022 $ / shares | Dec. 31, 2021 $ / shares | Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) $ / shares shares | Sep. 30, 2020 USD ($) $ / shares shares | Sep. 30, 2019 USD ($) $ / shares shares | ||||
Investment Company, Financial Highlights [Roll Forward] | ||||||||||||||
Net asset value per share at beginning of period (in dollars per share) | $ 20.38 | [1] | $ 21.84 | [1] | $ 19.47 | $ 19.81 | $ 18.26 | |||||||
Net investment income (in dollars per share) | 2.51 | [2] | 2.45 | [2] | 1.80 | [2] | 1.53 | 1.45 | ||||||
Net unrealized appreciation (depreciation) (in dollars per share) | (0.17) | (2.23) | 2.19 | (0.44) | 0.82 | |||||||||
Net realized gains (losses) (in dollars per share) | (0.46) | 0.28 | 0.49 | (0.30) | 0.44 | |||||||||
(Provision) benefit for taxes on realized and unrealized gains (losses) (in dollars per share) | (0.02) | (0.01) | (0.02) | 0.04 | (0.02) | |||||||||
Distributions of net investment income to stockholders (dollars per share) | (2.61) | (1.95) | (1.515) | (1.17) | (1.14) | |||||||||
Issuance of common stock (in dollars per share) | 0 | 0 | (0.57) | 0 | 0 | |||||||||
Net asset value per share at end of period (in dollars per share) | $ 19.58 | $ 19.66 | $ 20.67 | $ 21.79 | $ 22.03 | 19.63 | [1] | 20.38 | [1] | 21.84 | [1] | 19.47 | 19.81 | |
Per share market value at beginning of period (in dollars per share) | 18 | 21.18 | 14.52 | 15.54 | 14.88 | |||||||||
Per share market value at end of period (in dollars per share) | $ 20.12 | $ 18 | $ 21.18 | $ 14.52 | $ 15.54 | |||||||||
Total return | 27.30% | (6.71%) | 57.61% | 2.10% | 12.56% | |||||||||
Common shares outstanding at beginning of period (in shares) | shares | 61,125 | [1] | 60,120 | [1] | 46,987 | 46,987 | 46,987 | |||||||
Common shares outstanding at end of period (in shares) | shares | 77,225 | [1] | 61,125 | [1] | 60,120 | [1] | 46,987 | 46,987 | ||||||
Net assets at beginning of period | $ | $ 1,245,563 | $ 1,312,823 | $ 914,879 | $ 930,630 | $ 858,035 | |||||||||
Net assets at end of period | $ | 1,515,764 | 1,245,563 | 1,312,823 | 914,879 | 930,630 | |||||||||
Average net assets | $ | $ 1,437,728 | $ 1,308,518 | $ 1,150,662 | $ 871,305 | $ 909,264 | |||||||||
Ratio of net investment income to average net assets | 12.57% | 11.36% | 8.44% | 8.26% | 7.47% | |||||||||
Ratio of total expenses to average net assets | 14.19% | 8.68% | 9.65% | 7.57% | 9.65% | |||||||||
Ratio of net expenses to average net assets | 13.81% | 8.45% | 9.51% | 8.16% | 8.78% | |||||||||
Ratio of portfolio turnover to average investments at fair value | 26.12% | 26.99% | 39.66% | 38.99% | 32.50% | |||||||||
Weighted average outstanding debt | $ | $ 1,659,701 | $ 1,361,151 | $ 964,390 | $ 647,080 | $ 573,891 | |||||||||
Average debt per share (dollars per share) | $ 23.01 | $ 22.41 | $ 17.85 | $ 13.77 | $ 12.21 | |||||||||
Asset coverage ratio | 187.74% | 188.64% | 201.68% | 227.22% | 294.91% | |||||||||
Stock split, conversion ratio | 0.0033 | 0.3333 | ||||||||||||
[1]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis.[2]As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis. |
Derivative Instruments - Narrat
Derivative Instruments - Narrative (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
Due from broker | $ 54,260 | $ 45,530 |
Derivative Instruments - Schedu
Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap (Details) € in Thousands, £ in Thousands, $ in Thousands | Sep. 30, 2023 USD ($) | Sep. 30, 2023 EUR (€) | Sep. 30, 2023 GBP (£) | Sep. 30, 2022 USD ($) | Sep. 30, 2022 EUR (€) | Sep. 30, 2022 GBP (£) |
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Derivative assets at fair value | $ 4,910 | $ 6,789 | ||||
Derivative liability at fair value | 47,519 | 41,969 | ||||
Foreign currency forward contract | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Derivative assets at fair value | 4,910 | 6,789 | ||||
Derivative liability at fair value | 0 | 0 | ||||
Interest rate swap | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional amount | 350,000 | |||||
Derivative assets at fair value | 0 | |||||
Derivative liability at fair value | 47,519 | 41,969 | ||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 10, 2022, 1 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 43,179 | |||||
Notional Amount to be Sold | € | € 41,444 | |||||
Derivative assets at fair value | 2,466 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 10, 2022 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 43,179 | |||||
Notional Amount to be Sold | € | € 41,444 | |||||
Derivative assets at fair value | 2,466 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: EUR Foreign Currency Forward Contract, Maturing November 9, 2023 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 42,182 | |||||
Notional Amount to be Sold | € | € 38,026 | |||||
Derivative assets at fair value | 1,857 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 10, 2022 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 45,692 | |||||
Notional Amount to be Sold | £ | £ 37,033 | |||||
Derivative assets at fair value | 4,323 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 19, 2022, 2 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 45,692 | |||||
Notional Amount to be Sold | £ | £ 37,033 | |||||
Derivative assets at fair value | 4,323 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: GBP Foreign Currency Forward Contract, Maturing November 9, 2023 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional Amount to be Purchased | 72,098 | |||||
Notional Amount to be Sold | £ | £ 56,556 | |||||
Derivative assets at fair value | 3,053 | |||||
Derivative liability at fair value | 0 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing February 15, 2029 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional amount | 300,000 | |||||
Derivative assets at fair value | 0 | |||||
Derivative liability at fair value | 7,000 | |||||
Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing January 15, 2027 | ||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||||||
Notional amount | 350,000 | 350,000 | ||||
Derivative assets at fair value | 0 | |||||
Derivative liability at fair value | $ 40,519 | $ 41,969 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | $ 232,740 | $ 224,239 |
Debt and Equity Financing | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 205,600 | 175,200 |
Drawn amount | 154,200 | |
JV Financing | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | $ 27,100 | $ 49,000 |
Commitments and Contingencies_2
Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | $ 232,740 | $ 224,239 |
Investment, Identifier [Axis]: 107 Fair Street LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 4,227 | 0 |
Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 26,969 | 0 |
Investment, Identifier [Axis]: 109 Montgomery Owner LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 477 |
Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,343 | 0 |
Investment, Identifier [Axis]: ADC Therapeutics SA | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,020 | 3,020 |
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 396 | 0 |
Investment, Identifier [Axis]: Accupac, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 4,500 | 4,605 |
Investment, Identifier [Axis]: Acquia Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,376 | 1,326 |
Investment, Identifier [Axis]: Apptio, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 1,338 |
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 4,372 |
Investment, Identifier [Axis]: Assembled Brands Capital LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 7,514 | 2,008 |
Investment, Identifier [Axis]: Avalara, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 5,047 | 0 |
Investment, Identifier [Axis]: BAART Programs, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 8,645 |
Investment, Identifier [Axis]: Berner Food & Beverage, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,622 | 1,392 |
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 14,547 | 11,785 |
Investment, Identifier [Axis]: CorEvitas, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 915 |
Investment, Identifier [Axis]: Coupa Holdings, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,075 | 0 |
Investment, Identifier [Axis]: Coyote Buyer, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 400 | 1,333 |
Investment, Identifier [Axis]: Delta Leasing SPV II LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 14,639 | 27,187 |
Investment, Identifier [Axis]: Dialyze Holdings, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 3,431 |
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,078 | 826 |
Investment, Identifier [Axis]: Dominion Diagnostics, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,484 | 11,148 |
Investment, Identifier [Axis]: Establishment Labs Holdings Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,384 | 5,075 |
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,626 | 0 |
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 13,090 | 22,150 |
Investment, Identifier [Axis]: Finastra USA, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 960 | 0 |
Investment, Identifier [Axis]: GKD Index Partners, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 320 |
Investment, Identifier [Axis]: Galileo Parent, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,061 | 0 |
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 5,286 | 4,293 |
Investment, Identifier [Axis]: Harrow, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 4,011 | 0 |
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,458 | 0 |
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 4,195 |
Investment, Identifier [Axis]: Inventus Power, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,792 | 0 |
Investment, Identifier [Axis]: Kings Buyer, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 5,189 | 1,537 |
Investment, Identifier [Axis]: LSL Holdco, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,650 | 427 |
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,383 | 1,115 |
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 821 | 1,429 |
Investment, Identifier [Axis]: MND Holdings III Corp | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 9,122 | 0 |
Investment, Identifier [Axis]: MRI Software LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,261 | 5,196 |
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 5,734 |
Investment, Identifier [Axis]: Mesoblast, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 3,553 |
Investment, Identifier [Axis]: Mindbody, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 4,762 | 4,000 |
Investment, Identifier [Axis]: OCSI Glick JV LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 13,998 | 13,998 |
Investment, Identifier [Axis]: OTG Management, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,190 | 3,789 |
Investment, Identifier [Axis]: Oranje Holdco, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,904 | 0 |
Investment, Identifier [Axis]: PPW Aero Buyer, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,466 | 0 |
Investment, Identifier [Axis]: PRGX Global, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,127 | 2,518 |
Investment, Identifier [Axis]: Pluralsight, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,787 | 3,532 |
Investment, Identifier [Axis]: Relativity ODA LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,762 | 2,218 |
Investment, Identifier [Axis]: RumbleOn, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 4,822 |
Investment, Identifier [Axis]: SCP Eye Care Services, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,356 | 0 |
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 1,821 | 0 |
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 3,102 | 0 |
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 13,125 | 35,000 |
Investment, Identifier [Axis]: Seres Therapeutics, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 8,090 | 0 |
Investment, Identifier [Axis]: Spanx, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,473 | 2,226 |
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,199 | 1,527 |
Investment, Identifier [Axis]: Tahoe Bidco B.V. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 2,162 | 1,741 |
Investment, Identifier [Axis]: Telestream Holdings Corporation | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 407 | 528 |
Investment, Identifier [Axis]: Thrasio, LLC | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 0 | 2,578 |
Investment, Identifier [Axis]: iCIMs, Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | 7,466 | 6,930 |
Investment, Identifier [Axis]: scPharmaceuticals Inc. | ||
Financial Support for Nonconsolidated Legal Entity [Line Items] | ||
Unfunded commitments | $ 5,212 | $ 0 |
Merger with OSI2 (Details)
Merger with OSI2 (Details) $ in Thousands | Jan. 23, 2023 USD ($) shares | Sep. 30, 2023 USD ($) |
Business Acquisition [Line Items] | ||
Unrealized appreciation (depreciation) | $ 175,000 | |
Cash paid in lieu of issuing fractional shares | $ 19 | |
OSI2 Merger | ||
Business Acquisition [Line Items] | ||
Conversion ratio (in shares) | 0.9115 | |
Number of shares issued (in shares) | shares | 15,860,200 | |
Unrealized appreciation (depreciation) | $ (20,700) | |
Common stock issued by the Company | 334,034 | |
Transaction costs | 1,932 | |
Consideration paid | 335,966 | |
Investments | 592,809 | |
Cash and cash equivalents | 22,317 | |
Other assets | 6,679 | |
Total assets acquired | 621,805 | |
Debt | 225,000 | |
Other liabilities | 60,839 | |
Total liabilities acquired | 285,839 | |
Total net assets acquired | $ 335,966 |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent Event | Nov. 08, 2023 $ / shares |
Quarterly | |
Subsequent Event [Line Items] | |
Common stock, dividends, per share, declared (in dollars per share) | $ 0.55 |
Special | |
Subsequent Event [Line Items] | |
Common stock, dividends, per share, declared (in dollars per share) | $ 0.07 |
Schedule_12-14 - Schedule of In
Schedule 12-14 - Schedule of Investments in and Advances to Affiliates (Details) € in Thousands, £ in Thousands, $ in Thousands | 12 Months Ended | ||||||||||||
Sep. 30, 2023 USD ($) shares | Sep. 30, 2022 USD ($) shares | Sep. 30, 2023 EUR (€) shares | Sep. 30, 2023 GBP (£) shares | Sep. 30, 2022 EUR (€) shares | Sep. 30, 2022 GBP (£) shares | ||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 2,494,111 | ||||||||||||
Fair Value, Ending Balance | $ 2,892,420 | $ 2,494,111 | |||||||||||
Investment owned, percent of net assets | 190.82% | 200.24% | 190.82% | 190.82% | 200.24% | 200.24% | |||||||
Affiliate investments | |||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 26,196 | ||||||||||||
Fair Value, Ending Balance | 23,349 | $ 26,196 | |||||||||||
Control investments | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, ownership percentage | [1],[2] | 17.20% | 17.20% | 17.20% | |||||||||
Investment owned, balance, principal amount | 209,970 | $ 170,245 | |||||||||||
Net Realized Gain (Loss) | 0 | 1,868 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 25,763 | 20,459 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 214,165 | [1],[2] | 270,765 | ||||||||||
Gross Additions | 91,786 | 1,538 | |||||||||||
Gross Reductions | (8,860) | (58,138) | |||||||||||
Fair Value, Ending Balance | $ 297,091 | [3],[4] | $ 214,165 | [1],[2] | |||||||||
Investment owned, percent of net assets | 19.60% | [3],[4] | 17.20% | 19.60% | [3],[4] | 19.60% | [3],[4] | 17.20% | 17.20% | ||||
Affiliate Investments | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [5] | 2.10% | 2.10% | 2.10% | |||||||||
Investment owned, balance, principal amount | $ 21,852 | $ 24,490 | |||||||||||
Net Realized Gain (Loss) | 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 2,640 | 1,764 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 26,196 | [5] | 18,289 | ||||||||||
Gross Additions | 2,700 | 15,067 | |||||||||||
Gross Reductions | (5,547) | (7,160) | |||||||||||
Fair Value, Ending Balance | $ 23,349 | [6] | $ 26,196 | [5] | |||||||||
Investment owned, percent of net assets | 1.50% | [6] | 2.10% | 1.50% | [6] | 1.50% | [6] | 2.10% | 2.10% | ||||
Investment, Affiliated Issuer, Control and Affiliate | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | $ 231,822 | $ 194,735 | |||||||||||
Net Realized Gain (Loss) | 0 | 1,868 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 28,403 | 22,223 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 240,361 | 289,054 | |||||||||||
Gross Additions | 94,486 | 16,605 | |||||||||||
Gross Reductions | (14,407) | (65,298) | |||||||||||
Fair Value, Ending Balance | $ 320,440 | $ 240,361 | |||||||||||
Investment owned, percent of net assets | 21.10% | 19.30% | 21.10% | 21.10% | 19.30% | 19.30% | |||||||
Investment, Identifier [Axis]: 107 Fair Street LLC, Real Estate Development, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[9],[10],[11],[12] | 12.50% | 12.50% | 12.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[12],[13] | $ 1,269 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[12] | $ 1,214 | |||||||||||
Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC, Real Estate Development, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 11% | 11% | 11% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13] | $ 18,869 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10] | 18,443 | |||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.80% | 9.80% | 9.80% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 389 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 727 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 727 | |||||||||||
Investment, Identifier [Axis]: 109 Montgomery Owner LLC, Real Estate Operating Companies, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 7% | 7% | 7% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ 0 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 0 | |||||||||||
Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[9],[10],[11],[12] | 12% | 12% | 12% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[12],[13] | $ 4,070 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[12] | $ 4,022 | |||||||||||
Investment, Identifier [Axis]: A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20],[21] | 14.25% | 14.25% | 14.25% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20],[21] | $ 21,434 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20],[21] | $ 21,220 | |||||||||||
Investment, Identifier [Axis]: A.T. Holdings II SÀRL, Biotechnology, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | 20% | [7],[10],[20] | 10.50% | [14],[15],[22] | 20% | [7],[10],[20] | 20% | [7],[10],[20] | 10.50% | [14],[15],[22] | 10.50% | [14],[15],[22] | |
Investment owned, balance, principal amount | $ 6,021 | [7],[10],[13],[20] | $ 33,997 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 34,891 | |||||||||||
Fair Value, Ending Balance | 5,900 | [7],[10],[20] | $ 34,891 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6.25% | 6.25% | 6.25% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.80% | 9.80% | 9.80% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 14,685 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 14,431 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 14,431 | |||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.90% | 11.90% | 11.90% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 3,446 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 3,383 | |||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.15% | 12.15% | 12.15% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 17,901 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 17,575 | |||||||||||
Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.13% | 12.13% | 12.13% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 963 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 945 | |||||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[10],[11],[20] | 7.50% | [14],[15],[16],[22] | 7.50% | [7],[10],[11],[20] | 7.50% | [7],[10],[11],[20] | 7.50% | [14],[15],[16],[22] | 7.50% | [14],[15],[16],[22] | |
Investment, interest rate | 13.04% | [7],[8],[10],[11],[20] | 11.20% | [14],[15],[16],[17],[22] | 13.04% | [7],[8],[10],[11],[20] | 13.04% | [7],[8],[10],[11],[20] | 11.20% | [14],[15],[16],[17],[22] | 11.20% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 6,589 | [7],[10],[11],[13],[20] | $ 6,589 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 6,262 | |||||||||||
Fair Value, Ending Balance | $ 6,276 | [7],[10],[11],[20] | $ 6,262 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[9],[10],[20] | 7.50% | [14],[15],[16],[19],[22] | 7.50% | [7],[9],[10],[20] | 7.50% | [7],[9],[10],[20] | 7.50% | [14],[15],[16],[19],[22] | 7.50% | [14],[15],[16],[19],[22] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13],[20] | $ 0 | [14],[15],[16],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19],[22] | (37) | |||||||||||
Fair Value, Ending Balance | $ (38) | [7],[9],[10],[11],[20] | $ (37) | [14],[15],[16],[19],[22] | |||||||||
Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 28,948 | [7],[10],[20] | 28,948 | [14],[15],[22] | 28,948 | [7],[10],[20] | 28,948 | [7],[10],[20] | 28,948 | [14],[15],[22] | 28,948 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 73 | |||||||||||
Fair Value, Ending Balance | $ 6 | [7],[10],[20] | $ 73 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [10],[11],[20] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [8],[10],[11],[20] | 8.86% | 8.86% | 8.86% | |||||||||
Investment owned, balance, principal amount | € | [10],[11],[13],[20] | € 5,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[11],[20] | $ 5,825 | |||||||||||
Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[22] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 7.94% | 7.94% | 7.94% | |||||||||
Investment owned, balance, principal amount | € | [14],[15],[16],[18],[22] | € 24,838 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 22,143 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[22] | $ 22,143 | |||||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 17,870 | [7],[10] | 14,410 | [14],[15] | 17,870 | [7],[10] | 17,870 | [7],[10] | 14,410 | [14],[15] | 14,410 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 1,291 | |||||||||||
Fair Value, Ending Balance | $ 2,826 | [7],[10] | $ 1,291 | [14],[15] | |||||||||
Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.75% | [7],[10],[11] | 7.75% | [14],[15],[16] | 7.75% | [7],[10],[11] | 7.75% | [7],[10],[11] | 7.75% | [14],[15],[16] | 7.75% | [14],[15],[16] | |
Investment, interest rate | 13.17% | [7],[8],[10],[11] | 10.88% | [14],[15],[16],[17] | 13.17% | [7],[8],[10],[11] | 13.17% | [7],[8],[10],[11] | 10.88% | [14],[15],[16],[17] | 10.88% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 17,873 | [7],[10],[11],[13] | $ 14,414 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 13,910 | |||||||||||
Fair Value, Ending Balance | 17,687 | [7],[10],[11] | $ 13,910 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: APX Group Inc., Electrical Components & Equipment, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 5.75% | 5.75% | 5.75% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 2,075 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 1,645 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 1,645 | |||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 7.50% | 7.50% | 7.50% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 5,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 3,641 | |||||||||||
Fair Value, Ending Balance | [15] | $ 3,641 | |||||||||||
Investment, Identifier [Axis]: ASP Unifrax Holdings, Inc., Trading Companies & Distributors, Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 5.25% | 5.25% | 5.25% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 2,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | $ 1,926 | |||||||||||
Fair Value, Ending Balance | [15] | $ 1,926 | |||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[20] | 6% | 6% | 6% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[20] | $ (23) | |||||||||||
Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 11.63% | 11.63% | 11.63% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 3,276 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | 3,084 | |||||||||||
Investment, Identifier [Axis]: ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20],[21] | 12,222 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20],[21] | 11,795 | |||||||||||
Investment, Identifier [Axis]: Access CIG, LLC, Diversified Support Services, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 7.75% | 7.75% | 7.75% | |||||||||
Investment, interest rate | [15],[16],[17] | 10.82% | 10.82% | 10.82% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 20,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 19,075 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 19,075 | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 11.55% | 11.55% | 11.55% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 2,033 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 2,027 | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.55% | 11.55% | 11.55% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 20,234 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 20,194 | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | ||||||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | (8) | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 9.14% | 9.14% | 9.14% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 495 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 495 | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.12% | 9.12% | 9.12% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 15,976 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 15,944 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 15,944 | |||||||||||
Investment, Identifier [Axis]: Accupac, Inc., Personal Products, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 5.50% | 5.50% | 5.50% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ (6) | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ (6) | |||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[9],[10],[11] | 7% | [14],[15],[16],[19] | 7% | [7],[9],[10],[11] | 7% | [7],[9],[10],[11] | 7% | [14],[15],[16],[19] | 7% | [14],[15],[16],[19] | |
Investment, interest rate | 12.72% | [7],[8],[9],[10],[11] | 10.64% | [14],[15],[16],[17],[19] | 12.72% | [7],[8],[9],[10],[11] | 12.72% | [7],[8],[9],[10],[11] | 10.64% | [14],[15],[16],[17],[19] | 10.64% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 1,333 | [7],[9],[10],[11],[13] | $ 914 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 898 | |||||||||||
Fair Value, Ending Balance | 1,324 | [7],[9],[10],[11] | $ 898 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.63% | 9.63% | 9.63% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 27,349 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 27,158 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 27,158 | |||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.34% | 12.34% | 12.34% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 6,400 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 6,380 | |||||||||||
Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.34% | 12.34% | 12.34% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 25,332 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 25,253 | |||||||||||
Investment, Identifier [Axis]: Aden & Anais Merger Sub, Inc., Apparel, Accessories & Luxury Goods, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 51,645 | 51,645 | 51,645 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 0 | |||||||||||
Investment, Identifier [Axis]: AirStrip Technologies, Inc., Application Software, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 5,715 | [7],[10] | 5,715 | [14],[15] | 5,715 | [7],[10] | 5,715 | [7],[10] | 5,715 | [14],[15] | 5,715 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | 0 | [7],[10] | $ 0 | [14],[15] | |||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 11.64% | 11.64% | 11.64% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 23,338 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 22,141 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 22,141 | |||||||||||
Investment, Identifier [Axis]: All Web Leads, Inc., First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[23] | 8.50% | 8.50% | 8.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[23] | $ 23,562 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[23] | $ 9,797 | |||||||||||
Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 5.50% | [8],[10],[11],[20] | 5.50% | [15],[16],[17],[22] | 5.50% | [8],[10],[11],[20] | 5.50% | [8],[10],[11],[20] | 5.50% | [15],[16],[17],[22] | 5.50% | [15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 4,050 | [10],[13],[20] | $ 4,050 | [15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 3,057 | |||||||||||
Fair Value, Ending Balance | $ 2,918 | [10],[20] | $ 3,057 | [15],[22] | |||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 11.50% | 11.50% | 11.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[11] | 11.99% | 11.99% | 11.99% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 9,057 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 8,332 | |||||||||||
Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 598,283 | 598,283 | 598,283 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 1,915 | |||||||||||
Investment, Identifier [Axis]: Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [7],[10],[11] | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [14],[15],[16] | |
Investment, interest rate | 13.04% | [7],[8],[10],[11] | 11.20% | [14],[15],[16],[17] | 13.04% | [7],[8],[10],[11] | 13.04% | [7],[8],[10],[11] | 11.20% | [14],[15],[16],[17] | 11.20% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 17,053 | [7],[10],[11],[13] | $ 13,134 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 13,068 | |||||||||||
Fair Value, Ending Balance | 15,929 | [7],[10],[11] | $ 13,068 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 10% | 10% | 10% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18],[22] | $ 24,043 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 23,923 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22] | $ 23,923 | |||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 471,253 | [10],[20] | 587,930 | [15],[22] | 471,253 | [10],[20] | 471,253 | [10],[20] | 587,930 | [15],[22] | 587,930 | [15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 3,974 | |||||||||||
Fair Value, Ending Balance | $ 4,298 | [10],[20] | $ 3,974 | [15],[22] | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 141,640 | [7],[10],[20],[24] | 124,780 | [14],[15],[22],[25] | 141,640 | [7],[10],[20],[24] | 141,640 | [7],[10],[20],[24] | 124,780 | [14],[15],[22],[25] | 124,780 | [14],[15],[22],[25] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22],[25] | $ 212 | |||||||||||
Fair Value, Ending Balance | $ 368 | [7],[10],[20],[24] | $ 212 | [14],[15],[22],[25] | |||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 3.50% | 3.50% | 3.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 28,464 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 27,687 | |||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 3.50% | 3.50% | 3.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 2,121 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 2,063 | |||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 3.50% | 3.50% | 3.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 27,692 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 26,936 | |||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, First Lien Fixed Rate Bond 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 3.50% | 3.50% | 3.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 2,064 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | 2,007 | |||||||||||
Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 10% | 10% | 10% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18],[22] | $ 23,522 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 23,404 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22] | $ 23,404 | |||||||||||
Investment, Identifier [Axis]: American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.75% | [7],[10],[11] | 8.75% | [14],[15],[16] | 8.75% | [7],[10],[11] | 8.75% | [7],[10],[11] | 8.75% | [14],[15],[16] | 8.75% | [14],[15],[16] | |
Investment, interest rate | 14.14% | [7],[8],[10],[11] | 12.30% | [14],[15],[16],[17] | 14.14% | [7],[8],[10],[11] | 14.14% | [7],[8],[10],[11] | 12.30% | [14],[15],[16],[17] | 12.30% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 17,048 | [7],[10],[11],[13] | $ 14,760 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 13,284 | |||||||||||
Fair Value, Ending Balance | $ 15,087 | [7],[10],[11] | $ 13,284 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: American Tire Distributors, Inc., Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.25% | [10],[11] | 6.25% | [15],[16] | 6.25% | [10],[11] | 6.25% | [10],[11] | 6.25% | [15],[16] | 6.25% | [15],[16] | |
Investment, interest rate | 11.81% | [8],[10],[11] | 9.03% | [15],[16],[17] | 11.81% | [8],[10],[11] | 11.81% | [8],[10],[11] | 9.03% | [15],[16],[17] | 9.03% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 19,115 | [10],[11],[13] | $ 9,895 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 9,293 | |||||||||||
Fair Value, Ending Balance | 16,798 | [10],[11] | $ 9,293 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[22] | 4.25% | 4.25% | 4.25% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 7.92% | 7.92% | 7.92% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[22] | $ 15,220 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 14,687 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[22] | $ 14,687 | |||||||||||
Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[10],[11],[20] | 8% | [14],[15],[16],[22] | 8% | [7],[10],[11],[20] | 8% | [7],[10],[11],[20] | 8% | [14],[15],[16],[22] | 8% | [14],[15],[16],[22] | |
Investment, interest rate | 13.54% | [7],[8],[10],[11],[20] | 11.67% | [14],[15],[16],[17],[22] | 13.54% | [7],[8],[10],[11],[20] | 13.54% | [7],[8],[10],[11],[20] | 11.67% | [14],[15],[16],[17],[22] | 11.67% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 12,500 | [7],[10],[11],[13],[20] | $ 12,500 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 11,958 | |||||||||||
Fair Value, Ending Balance | $ 11,865 | [7],[10],[11],[20] | $ 11,958 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [10],[11] | 3.75% | 3.75% | 3.75% | |||||||||
Investment, interest rate | [8],[10],[11] | 9.40% | 9.40% | 9.40% | |||||||||
Investment owned, balance, principal amount | [10],[11],[13] | $ 3,700 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[11] | 2,669 | |||||||||||
Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Products, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 3.75% | 3.75% | 3.75% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.42% | 7.42% | 7.42% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 2,736 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 2,189 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 2,189 | |||||||||||
Investment, Identifier [Axis]: Ankura Consulting Group LLC, Research & Consulting Services, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8% | 8% | 8% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.78% | 10.78% | 10.78% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 4,346 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 3,813 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 3,813 | |||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 8.46% | 8.46% | 8.46% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 892 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 846 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 846 | |||||||||||
Investment, Identifier [Axis]: Apptio, Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 8.46% | 8.46% | 8.46% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 34,458 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 33,738 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 33,738 | |||||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11],[20] | 7% | [14],[15],[16],[22] | 7% | [7],[10],[11],[20] | 7% | [7],[10],[11],[20] | 7% | [14],[15],[16],[22] | 7% | [14],[15],[16],[22] | |
Investment, interest rate | 10.95% | [7],[8],[10],[11],[20] | 8% | [14],[15],[16],[17],[22] | 10.95% | [7],[8],[10],[11],[20] | 10.95% | [7],[8],[10],[11],[20] | 8% | [14],[15],[16],[17],[22] | 8% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | € | € 3,017 | [7],[10],[11],[13],[20] | € 1,964 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 1,927 | |||||||||||
Fair Value, Ending Balance | $ 3,226 | [7],[10],[11],[20] | $ 1,927 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.75% | [7],[10],[11],[20] | 7% | [14],[15],[16],[22] | 5.75% | [7],[10],[11],[20] | 5.75% | [7],[10],[11],[20] | 7% | [14],[15],[16],[22] | 7% | [14],[15],[16],[22] | |
Investment, interest rate | 11.57% | [7],[8],[10],[11],[20] | 9.19% | [14],[15],[16],[17],[22] | 11.57% | [7],[8],[10],[11],[20] | 11.57% | [7],[8],[10],[11],[20] | 9.19% | [14],[15],[16],[17],[22] | 9.19% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 10,519 | [7],[10],[11],[13],[20] | £ 18,636 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 20,826 | |||||||||||
Fair Value, Ending Balance | $ 10,624 | [7],[10],[11],[20] | $ 20,826 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11],[20] | 5.75% | [14],[15],[16],[22] | 7% | [7],[10],[11],[20] | 7% | [7],[10],[11],[20] | 5.75% | [14],[15],[16],[22] | 5.75% | [14],[15],[16],[22] | |
Investment, interest rate | 12.46% | [7],[8],[10],[11],[20] | 8.81% | [14],[15],[16],[17],[22] | 12.46% | [7],[8],[10],[11],[20] | 12.46% | [7],[8],[10],[11],[20] | 8.81% | [14],[15],[16],[17],[22] | 8.81% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 10,519 | [14],[15],[16],[18],[22] | £ 4,949 | [7],[10],[11],[13],[20] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 10,328 | |||||||||||
Fair Value, Ending Balance | $ 6,101 | [7],[10],[11],[20] | $ 10,328 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11],[20] | 5.75% | [14],[15],[16],[19],[22] | 7% | [7],[10],[11],[20] | 7% | [7],[10],[11],[20] | 5.75% | [14],[15],[16],[19],[22] | 5.75% | [14],[15],[16],[19],[22] | |
Investment, interest rate | [7],[8],[10],[11],[20] | 12.46% | 12.46% | 12.46% | |||||||||
Investment owned, balance, principal amount | £ | £ 23,675 | [7],[10],[11],[13],[20] | £ 0 | [14],[15],[16],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19],[22] | $ 0 | |||||||||||
Fair Value, Ending Balance | $ 29,185 | [7],[10],[11],[20] | $ 0 | [14],[15],[16],[19],[22] | |||||||||
Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 9.70% | 9.70% | 9.70% | |||||||||
Investment owned, balance, principal amount | £ | [7],[10],[11],[13],[20] | £ 3,649 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 3,914 | |||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | 1,783,332 | 1,783,332 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 370 | ||||||||||||
Gross Additions | 40 | ||||||||||||
Gross Reductions | (321) | ||||||||||||
Fair Value, Ending Balance | $ 89 | 370 | |||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | 6.75% | 6.75% | ||||||||||
Investment, interest rate | 12.14% | 12.14% | 12.14% | ||||||||||
Investment owned, balance, principal amount | $ 21,852 | ||||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 2,640 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 24,225 | ||||||||||||
Gross Additions | 2,467 | ||||||||||||
Gross Reductions | (4,869) | ||||||||||||
Fair Value, Ending Balance | $ 21,823 | 24,225 | |||||||||||
Investment owned, percent of net assets | 1.40% | 1.40% | 1.40% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | 1,129,453 | 1,129,453 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 1,223 | ||||||||||||
Gross Additions | 139 | ||||||||||||
Gross Reductions | (357) | ||||||||||||
Fair Value, Ending Balance | $ 1,005 | $ 1,223 | |||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,783,332 | [6],[7] | 1,609,201 | [5],[14] | 1,783,332 | [6],[7] | 1,783,332 | [6],[7] | 1,609,201 | [5],[14] | 1,609,201 | [5],[14] | |
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 370 | [5],[14] | 587 | ||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (217) | ||||||||||||
Fair Value, Ending Balance | $ 89 | [6],[7] | $ 370 | [5],[14] | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | [6],[7],[9],[11] | 6.75% | [5],[14],[16],[19] | 6.75% | [6],[7],[9],[11] | 6.75% | [6],[7],[9],[11] | 6.75% | [5],[14],[16],[19] | 6.75% | [5],[14],[16],[19] | |
Investment, interest rate | 12.14% | [6],[7],[8],[9],[11] | 10.42% | [5],[14],[16],[17],[19] | 12.14% | [6],[7],[8],[9],[11] | 12.14% | [6],[7],[8],[9],[11] | 10.42% | [5],[14],[16],[17],[19] | 10.42% | [5],[14],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 21,852 | [6],[7],[9],[11],[13] | $ 24,490 | [5],[14],[16],[18],[19] | |||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 1,764 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 24,225 | [5],[14],[16],[19] | 15,712 | ||||||||||
Gross Additions | 14,996 | ||||||||||||
Gross Reductions | (6,483) | ||||||||||||
Fair Value, Ending Balance | $ 21,823 | [6],[7],[9],[11] | $ 24,225 | [5],[14],[16],[19] | |||||||||
Investment owned, percent of net assets | 1.90% | 1.90% | 1.90% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,129,453 | [6],[7] | 1,019,169 | [5],[14] | 1,129,453 | [6],[7] | 1,129,453 | [6],[7] | 1,019,169 | [5],[14] | 1,019,169 | [5],[14] | |
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 1,223 | [5],[14] | 1,152 | ||||||||||
Gross Additions | 71 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 1,005 | [6],[7] | $ 1,223 | [5],[14] | |||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | [6],[7] | 70,425 | [5],[14] | 78,045 | [6],[7] | 78,045 | [6],[7] | 70,425 | [5],[14] | 70,425 | [5],[14] | |
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 0 | [5],[14] | 0 | ||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 0 | [6],[7] | $ 0 | [5],[14] | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Assembled Brands Capital LLC, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 78,045 | 78,045 | 78,045 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 0 | $ 0 | |||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Associated Asphalt Partners, LLC, Construction Materials, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 5.25% | 5.25% | 5.25% | |||||||||
Investment, interest rate | [15],[16],[17] | 8.06% | 8.06% | 8.06% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 2,501 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 1,934 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 1,934 | |||||||||||
Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.25% | [10],[11] | 5.25% | [15],[16] | 5.25% | [10],[11] | 5.25% | [10],[11] | 5.25% | [15],[16] | 5.25% | [15],[16] | |
Investment, interest rate | 10.90% | [8],[10],[11] | 8.37% | [15],[16],[17] | 10.90% | [8],[10],[11] | 10.90% | [8],[10],[11] | 8.37% | [15],[16],[17] | 8.37% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 8,490 | [10],[11],[13] | $ 5,640 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 4,822 | |||||||||||
Fair Value, Ending Balance | 6,414 | [10],[11] | $ 4,822 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 11% | 11% | 11% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18],[22] | $ 13,346 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 12,812 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22] | 12,812 | |||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [14],[15],[18],[22],[26] | 8,309 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22],[26] | 8,309 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22],[26] | $ 8,309 | |||||||||||
Investment, Identifier [Axis]: Athenex, Inc., Pharmaceuticals, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15],[22] | 328,149 | 328,149 | 328,149 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 16 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22] | $ 16 | |||||||||||
Investment, Identifier [Axis]: Aurora Lux Finco S.À.R.L., Airport Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 6% | [7],[10],[11],[20] | 6% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 6% | [14],[15],[16],[22] | |
Investment, interest rate | 11.49% | [7],[8],[10],[11],[20] | 8.78% | [14],[15],[16],[17],[22] | 11.49% | [7],[8],[10],[11],[20] | 11.49% | [7],[8],[10],[11],[20] | 8.78% | [14],[15],[16],[17],[22] | 8.78% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 29,509 | [7],[10],[11],[13],[20] | $ 22,425 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 21,326 | |||||||||||
Fair Value, Ending Balance | $ 28,284 | [7],[10],[11],[20] | $ 21,326 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (78) | |||||||||||
Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.64% | 12.64% | 12.64% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 50,470 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 49,688 | |||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 8.12% | 8.12% | 8.12% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 2,546 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ 2,395 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 2,395 | |||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 10.65% | 10.65% | 10.65% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 3,247 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 3,169 | |||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 10.65% | 10.65% | 10.65% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,261 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,231 | |||||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [7],[10],[11] | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [14],[15],[16] | |
Investment, interest rate | 14.15% | [7],[8],[10],[11] | 11.62% | [14],[15],[16],[17] | 14.15% | [7],[8],[10],[11] | 14.15% | [7],[8],[10],[11] | 11.62% | [14],[15],[16],[17] | 11.62% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 8,920 | [7],[10],[11],[13] | $ 7,166 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 6,915 | |||||||||||
Fair Value, Ending Balance | $ 8,492 | [7],[10],[11] | $ 6,915 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16],[19] | 8.50% | [7],[10],[11] | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16],[19] | 8.50% | [14],[15],[16],[19] | |
Investment, interest rate | 14.15% | [7],[8],[10],[11] | 11.62% | [14],[15],[16],[17],[19] | 14.15% | [7],[8],[10],[11] | 14.15% | [7],[8],[10],[11] | 11.62% | [14],[15],[16],[17],[19] | 11.62% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 2,091 | [7],[10],[11],[13] | $ 4,227 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 3,839 | |||||||||||
Fair Value, Ending Balance | $ 1,991 | [7],[10],[11] | $ 3,839 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 14.15% | 14.15% | 14.15% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 4,361 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 4,152 | |||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 13% | 13% | 13% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 2,221 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 2,178 | |||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.02% | 11.02% | 11.02% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 40,660 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 40,213 | |||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 10.75% | 10.75% | 10.75% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 1,702 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 1,617 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 1,617 | |||||||||||
Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 8.31% | 8.31% | 8.31% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 33,078 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 32,053 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | 32,053 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [14],[15],[18],[19],[22],[26] | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22],[26] | $ 0 | |||||||||||
Fair Value, Ending Balance | [14],[15],[19],[22],[26] | $ 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 8% | [7],[8],[10],[11],[20] | 10.25% | [14],[15],[16],[17],[22] | 8% | [7],[8],[10],[11],[20] | 8% | [7],[8],[10],[11],[20] | 10.25% | [14],[15],[16],[17],[22] | 10.25% | [14],[15],[16],[17],[22] | |
Investment, interest rate, paid in kind | [7],[10],[20] | 2.25% | 2.25% | 2.25% | |||||||||
Investment owned, balance, principal amount | $ 6,757 | [7],[10],[13],[20] | $ 5,322 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 5,114 | |||||||||||
Fair Value, Ending Balance | 6,225 | [7],[10],[20] | $ 5,114 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[19],[22] | 10.25% | 10.25% | 10.25% | |||||||||
Investment owned, balance, principal amount | 3,316 | [7],[10],[13],[20],[21] | $ 0 | [14],[15],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | 0 | |||||||||||
Fair Value, Ending Balance | $ 3,169 | [7],[10],[20],[21] | 0 | [14],[15],[19],[22] | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8% | 8% | 8% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 2.25% | 2.25% | 2.25% | |||||||||
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[13],[20] | 2,353 | [14],[15],[18],[22],[26] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22],[26] | 2,353 | |||||||||||
Fair Value, Ending Balance | $ 0 | [7],[9],[10],[20] | $ 2,353 | [14],[15],[22],[26] | |||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 8% | 8% | 8% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[20] | 2.25% | 2.25% | 2.25% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[20] | 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 5 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13],[20],[21] | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[20],[21] | 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13],[20],[21] | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[20],[21] | $ 0 | |||||||||||
Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 26,131 | [7],[10],[20] | 21,177 | [14],[15],[22] | 26,131 | [7],[10],[20] | 26,131 | [7],[10],[20] | 21,177 | [14],[15],[22] | 21,177 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 98 | |||||||||||
Fair Value, Ending Balance | $ 3 | [7],[10],[20] | $ 98 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [10],[11] | 7% | [15],[16] | 7% | [10],[11] | 7% | [10],[11] | 7% | [15],[16] | 7% | [15],[16] | |
Investment, interest rate | 12.43% | [8],[10],[11] | 9.50% | [15],[16],[17] | 12.43% | [8],[10],[11] | 12.43% | [8],[10],[11] | 9.50% | [15],[16],[17] | 9.50% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 30,625 | [10],[11],[13] | $ 30,625 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 29,017 | |||||||||||
Fair Value, Ending Balance | $ 29,989 | [10],[11] | $ 29,017 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [7],[10] | 298,460 | [14],[15] | 394,297 | [7],[10] | 394,297 | [7],[10] | 298,460 | [14],[15] | 298,460 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 349 | |||||||||||
Fair Value, Ending Balance | $ 158 | [7],[10] | $ 349 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 9% | [7],[8],[10],[11] | 9% | [14],[15],[16],[17] | 9% | [7],[8],[10],[11] | 9% | [7],[8],[10],[11] | 9% | [14],[15],[16],[17] | 9% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 5,257 | [7],[10],[13] | $ 3,979 | [14],[15],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 3,960 | |||||||||||
Fair Value, Ending Balance | $ 5,251 | [7],[10] | $ 3,960 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,708,618 | [7],[10] | 1,293,324 | [14],[15] | 1,708,618 | [7],[10] | 1,708,618 | [7],[10] | 1,293,324 | [14],[15] | 1,293,324 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 1,280 | |||||||||||
Fair Value, Ending Balance | $ 1,999 | [7],[10] | $ 1,280 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 394,297 | [7],[10] | 298,460 | [14],[15] | 394,297 | [7],[10] | 394,297 | [7],[10] | 298,460 | [14],[15] | 298,460 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 295 | |||||||||||
Fair Value, Ending Balance | $ 442 | [7],[10] | $ 295 | [14],[15] | |||||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 829 | [7] | 829 | [1],[2],[14] | 829 | [7] | 829 | [7] | 829 | [1],[2],[14] | 829 | [1],[2],[14] | |
Investment owned, balance, principal amount | $ 0 | ||||||||||||
Net Realized Gain (Loss) | $ 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | [1],[2],[14] | 0 | ||||||||||
Gross Additions | 0 | 0 | |||||||||||
Gross Reductions | 0 | 0 | |||||||||||
Fair Value, Ending Balance | $ 0 | [7] | $ 0 | [1],[2],[14] | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | 0% | 0% | 0% | |||||||
Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 34,984,460 | [7] | 34,984,460 | [1],[2],[14] | 34,984,460 | [7] | 34,984,460 | [7] | 34,984,460 | [1],[2],[14] | 34,984,460 | [1],[2],[14] | |
Investment owned, balance, principal amount | $ 0 | ||||||||||||
Net Realized Gain (Loss) | $ 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 27,638 | [1],[2],[14] | 27,638 | ||||||||||
Gross Additions | 0 | 0 | |||||||||||
Gross Reductions | 0 | 0 | |||||||||||
Fair Value, Ending Balance | $ 27,638 | [7] | $ 27,638 | [1],[2],[14] | |||||||||
Investment owned, percent of net assets | 1.80% | 2.20% | 1.80% | 1.80% | 2.20% | 2.20% | |||||||
Investment, Identifier [Axis]: CCO Holdings LLC, Cable & Satellite, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 4.50% | 4.50% | 4.50% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 2,097 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 1,603 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 1,603 | |||||||||||
Investment, Identifier [Axis]: CITGO Holding, Inc., Oil & Gas Refining & Marketing, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 9.25% | 9.25% | 9.25% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 7,857 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 7,807 | |||||||||||
Fair Value, Ending Balance | [15] | $ 7,807 | |||||||||||
Investment, Identifier [Axis]: CITGO Petroleum Corp., Oil & Gas Refining & Marketing, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 6.25% | 6.25% | 6.25% | |||||||||
Investment, interest rate | [15],[16],[17] | 9.37% | 9.37% | 9.37% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 795 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 797 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 797 | |||||||||||
Investment, Identifier [Axis]: CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[23] | 7.75% | 7.75% | 7.75% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[23] | $ 727 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[23] | 396 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.31% | 9.31% | 9.31% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 2% | 2% | 2% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 14,294 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 13,143 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 13,143 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.07% | 12.07% | 12.07% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 37 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 37 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.07% | 12.07% | 12.07% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 3,031 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 3,031 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.07% | 12.07% | 12.07% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,557 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,557 | |||||||||||
Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.07% | 12.07% | 12.07% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,024 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,024 | |||||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Health Care Services, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | [6],[7] | 1,080,399 | [5],[14] | 1,080,399 | [6],[7] | 1,080,399 | [6],[7] | 1,080,399 | [5],[14] | 1,080,399 | [5],[14] | |
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 378 | [5],[14] | 838 | ||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (460) | ||||||||||||
Fair Value, Ending Balance | $ 432 | [6],[7] | $ 378 | [5],[14] | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Caregiver Services, Inc., Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,080,399 | 1,080,399 | 1,080,399 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 378 | ||||||||||||
Gross Additions | 54 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 432 | $ 378 | |||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Carvana Co., Automotive Retail, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 5.63% | 5.63% | 5.63% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 6,700 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 4,724 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 4,724 | |||||||||||
Investment, Identifier [Axis]: CircusTrix Holdings, LLC, Leisure Facilities, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 8.62% | 8.62% | 8.62% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 10,692 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 10,209 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 10,209 | |||||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 7.50% | [8],[10],[11],[20] | 7.50% | [15],[16],[17],[22] | 7.50% | [8],[10],[11],[20] | 7.50% | [8],[10],[11],[20] | 7.50% | [15],[16],[17],[22] | 7.50% | [15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 2,632 | [10],[13],[20] | $ 4,311 | [15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 3,132 | |||||||||||
Fair Value, Ending Balance | $ 2,017 | [10],[20] | $ 3,132 | [15],[22] | |||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 7.75% | [8],[10],[11],[20] | 5.13% | [15],[16],[17],[22] | 7.75% | [8],[10],[11],[20] | 7.75% | [8],[10],[11],[20] | 5.13% | [15],[16],[17],[22] | 5.13% | [15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 176 | [10],[13],[20] | $ 1,374 | [15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 1,163 | |||||||||||
Fair Value, Ending Balance | 141 | [10],[20] | $ 1,163 | [15],[22] | |||||||||
Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 7.75% | 7.75% | 7.75% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 676 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 512 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 512 | |||||||||||
Investment, Identifier [Axis]: Condor Merger Sub Inc., Systems Software, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 7.38% | [8],[10],[11] | 7.38% | [15],[16],[17] | 7.38% | [8],[10],[11] | 7.38% | [8],[10],[11] | 7.38% | [15],[16],[17] | 7.38% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 8,420 | [10],[13] | $ 8,420 | [15],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 6,900 | |||||||||||
Fair Value, Ending Balance | $ 7,059 | [10] | $ 6,900 | [15] | |||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[10],[11],[23] | 8.50% | [14],[15],[16] | 8.50% | [7],[10],[11],[23] | 8.50% | [7],[10],[11],[23] | 8.50% | [14],[15],[16] | 8.50% | [14],[15],[16] | |
Investment, interest rate | [14],[15],[16],[17] | 11.62% | 11.62% | 11.62% | |||||||||
Investment owned, balance, principal amount | $ 22,084 | [7],[10],[11],[13],[23] | $ 22,537 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 20,396 | |||||||||||
Fair Value, Ending Balance | 16,040 | [7],[10],[11],[23] | 20,396 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Warrants | |||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 457 | |||||||||||
Fair Value, Ending Balance | 0 | [7],[10] | $ 457 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Convergeone Holdings, Inc., IT Consulting & Other Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [15],[16],[17] | 8.12% | 8.12% | 8.12% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 11,913 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 8,596 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 8,596 | |||||||||||
Investment, Identifier [Axis]: Conviva Inc., Application Software, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 417,851 | [7],[10] | 417,851 | [14],[15] | 417,851 | [7],[10] | 417,851 | [7],[10] | 417,851 | [14],[15] | 417,851 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 894 | |||||||||||
Fair Value, Ending Balance | 894 | [7],[10] | $ 894 | [14],[15] | |||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 1,099 | 1,099 | 1,099 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 2,340 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 2,340 | |||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 4.75% | 4.75% | 4.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 11% | 11% | 11% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 916 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 898 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 898 | |||||||||||
Investment, Identifier [Axis]: CorEvitas, LLC, Health Care Technology, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 8.88% | 8.88% | 8.88% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 13,712 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 13,583 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 13,583 | |||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (20) | |||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.82% | 12.82% | 12.82% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 13,157 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 12,858 | |||||||||||
Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (13) | |||||||||||
Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [10],[11] | 5% | [15],[16] | 5% | [10],[11] | 5% | [10],[11] | 5% | [15],[16] | 5% | [15],[16] | |
Investment, interest rate | 10.39% | [8],[10],[11] | 7.65% | [15],[16],[17] | 10.39% | [8],[10],[11] | 10.39% | [8],[10],[11] | 7.65% | [15],[16],[17] | 7.65% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 14,750 | [10],[11],[13] | $ 10,336 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 9,681 | |||||||||||
Fair Value, Ending Balance | $ 14,616 | [10],[11] | $ 9,681 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [7],[9],[10],[11] | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [14],[15],[16],[19] | |
Investment, interest rate | [8],[11] | 11.47% | 11.47% | 11.47% | |||||||||
Investment owned, balance, principal amount | $ 933 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (26) | |||||||||||
Fair Value, Ending Balance | $ 918 | [7],[9],[10],[11] | $ (26) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [7],[10],[11] | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [14],[15],[16] | |
Investment, interest rate | 11.52% | [7],[8],[10],[11] | 8.81% | [14],[15],[16],[17] | 11.52% | [7],[8],[10],[11] | 11.52% | [7],[8],[10],[11] | 8.81% | [14],[15],[16],[17] | 8.81% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 18,013 | [7],[10],[11],[13] | $ 18,200 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 17,843 | |||||||||||
Fair Value, Ending Balance | $ 17,812 | [7],[10],[11] | $ 17,843 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 4.75% | [10],[11] | 4.75% | [15],[16] | 4.75% | [10],[11] | 4.75% | [10],[11] | 4.75% | [15],[16] | 4.75% | [15],[16] | |
Investment, interest rate | 10.12% | [8],[10],[11] | 7.33% | [15],[16],[17] | 10.12% | [8],[10],[11] | 10.12% | [8],[10],[11] | 7.33% | [15],[16],[17] | 7.33% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 4,950 | [10],[11],[13] | $ 5,000 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 4,760 | |||||||||||
Fair Value, Ending Balance | 4,831 | [10],[11] | $ 4,760 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Delivery Hero FinCo LLC, Internet & Direct Marketing Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16],[22] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [15],[16],[17],[22] | 8.49% | 8.49% | 8.49% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18],[22] | $ 4,988 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16],[22] | $ 4,757 | |||||||||||
Fair Value, Ending Balance | [15],[16],[22] | $ 4,757 | |||||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 2 | [7],[10],[20] | 2 | [14],[15],[22] | 2 | [7],[10],[20] | 2 | [7],[10],[20] | 2 | [14],[15],[22] | 2 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 2 | |||||||||||
Fair Value, Ending Balance | $ 2 | [7],[10],[20] | $ 2 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 419 | [7],[10],[20] | 419 | [14],[15],[22] | 419 | [7],[10],[20] | 419 | [7],[10],[20] | 419 | [14],[15],[22] | 419 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 419 | |||||||||||
Fair Value, Ending Balance | $ 419 | [7],[10],[20] | $ 419 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 3% | [7],[8],[9],[10],[11],[20] | 10% | [14],[15],[16],[17],[19],[22] | 3% | [7],[8],[9],[10],[11],[20] | 3% | [7],[8],[9],[10],[11],[20] | 10% | [14],[15],[16],[17],[19],[22] | 10% | [14],[15],[16],[17],[19],[22] | |
Investment, interest rate, paid in kind | [7],[9],[10],[20] | 7% | 7% | 7% | |||||||||
Investment owned, balance, principal amount | $ 17,465 | [7],[9],[10],[13],[20] | $ 4,183 | [14],[15],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | 4,183 | |||||||||||
Fair Value, Ending Balance | $ 17,465 | [7],[9],[10],[20] | $ 4,183 | [14],[15],[19],[22] | |||||||||
Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 31 | [7],[10],[20] | 31 | [14],[15],[22] | 31 | [7],[10],[20] | 31 | [7],[10],[20] | 31 | [14],[15],[22] | 31 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 0 | |||||||||||
Fair Value, Ending Balance | 0 | [7],[10],[20] | $ 0 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Delta Topco, Inc., Systems Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [15],[16],[17] | 9.34% | 9.34% | 9.34% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 6,680 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 5,934 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 5,934 | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 9% | 9% | 9% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 14.54% | 14.54% | 14.54% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 20,757 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 20,653 | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 9% | 9% | 9% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 12.67% | 12.67% | 12.67% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 2% | 2% | 2% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 24,396 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 22,993 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 22,993 | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 9% | 9% | 9% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ (129) | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ (129) | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | [7],[10] | 8% | 8% | 8% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13] | $ 654 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 631 | |||||||||||
Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 6,397,254 | [7],[10] | 5,403,823 | [14],[15] | 6,397,254 | [7],[10] | 6,397,254 | [7],[10] | 5,403,823 | [14],[15] | 5,403,823 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 1,297 | |||||||||||
Fair Value, Ending Balance | $ 1,152 | [7],[10] | $ 1,297 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[9],[10],[11] | 6.50% | [14],[15],[16],[19] | 7% | [7],[9],[10],[11] | 7% | [7],[9],[10],[11] | 6.50% | [14],[15],[16],[19] | 6.50% | [14],[15],[16],[19] | |
Investment, interest rate | 12.49% | [7],[8],[9],[10],[11] | 9.41% | [14],[15],[16],[17],[19] | 12.49% | [7],[8],[9],[10],[11] | 12.49% | [7],[8],[9],[10],[11] | 9.41% | [14],[15],[16],[17],[19] | 9.41% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 284 | [7],[9],[10],[11],[13] | $ 251 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 239 | |||||||||||
Fair Value, Ending Balance | $ 252 | [7],[9],[10],[11] | $ 239 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [7],[10],[11] | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [14],[15],[16] | |
Investment, interest rate | 12.49% | [7],[8],[10],[11] | 9.91% | [14],[15],[16],[17] | 12.49% | [7],[8],[10],[11] | 12.49% | [7],[8],[10],[11] | 9.91% | [14],[15],[16],[17] | 9.91% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 12,386 | [7],[10],[11],[13] | $ 9,902 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 9,793 | |||||||||||
Fair Value, Ending Balance | $ 12,101 | [7],[10],[11] | $ 9,793 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [10],[11] | 5% | [15],[16] | 5% | [10],[11] | 5% | [10],[11] | 5% | [15],[16] | 5% | [15],[16] | |
Investment, interest rate | 10.43% | [8],[10],[11] | 8.12% | [15],[16],[17] | 10.43% | [8],[10],[11] | 10.43% | [8],[10],[11] | 8.12% | [15],[16],[17] | 8.12% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 4,641 | [10],[11],[13] | $ 19,242 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 17,973 | |||||||||||
Fair Value, Ending Balance | $ 4,546 | [10],[11] | $ 17,973 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 30,031 | [7] | 30,031 | [1],[2],[14] | 30,031 | [7] | 30,031 | [7] | 30,031 | [1],[2],[14] | 30,031 | [1],[2],[14] | |
Net Realized Gain (Loss) | $ 0 | $ 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | 3,308 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 4,946 | [1],[2],[14] | 18,065 | ||||||||||
Gross Additions | 0 | 0 | |||||||||||
Gross Reductions | (2,235) | (13,119) | |||||||||||
Fair Value, Ending Balance | $ 2,711 | [7] | $ 4,946 | [1],[2],[14] | |||||||||
Investment owned, percent of net assets | 0.20% | 0.40% | 0.20% | 0.20% | 0.40% | 0.40% | |||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [7],[11] | 5% | [1],[2],[14],[16],[19] | 5% | [7],[11] | 5% | [7],[11] | 5% | [1],[2],[14],[16],[19] | 5% | [1],[2],[14],[16],[19] | |
Investment, interest rate | 10.54% | [7],[8],[11] | 5% | 10.54% | [7],[8],[11] | 10.54% | [7],[8],[11] | 5% | 5% | ||||
Investment owned, balance, principal amount | $ 5,574 | [7],[11],[13] | $ 0 | [1],[2],[14],[16],[18],[19] | |||||||||
Net Realized Gain (Loss) | 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 266 | 57 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | [1],[2],[14],[16],[19] | 0 | ||||||||||
Gross Additions | 5,574 | 0 | |||||||||||
Gross Reductions | 0 | 0 | |||||||||||
Fair Value, Ending Balance | $ 5,574 | [7],[11] | $ 0 | [1],[2],[14],[16],[19] | |||||||||
Investment owned, percent of net assets | 0.40% | 0% | 0.40% | 0.40% | 0% | 0% | |||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [1],[2],[14],[16] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [1],[2],[14],[16],[17] | 8.68% | 8.68% | 8.68% | |||||||||
Investment owned, balance, principal amount | [1],[2],[14],[16],[18] | $ 14,333 | |||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 1,367 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 14,333 | [1],[2],[14],[16] | 27,381 | ||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (13,048) | ||||||||||||
Fair Value, Ending Balance | [1],[2],[14],[16] | $ 14,333 | |||||||||||
Investment owned, percent of net assets | 1.20% | 1.20% | 1.20% | ||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [7],[8],[11] | 10.54% | 10.54% | 10.54% | |||||||||
Investment owned, balance, principal amount | [7],[11],[13] | $ 14,068 | |||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 1,459 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 14,333 | ||||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (265) | ||||||||||||
Fair Value, Ending Balance | $ 14,068 | [7],[11] | $ 14,333 | ||||||||||
Investment owned, percent of net assets | 0.90% | 0.90% | 0.90% | ||||||||||
Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [7],[8],[9],[11] | 10.42% | 10.42% | 10.42% | |||||||||
Investment owned, balance, principal amount | [7],[9],[11],[13] | $ 2,090 | |||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 10 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 2,090 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 2,090 | [7],[9],[11] | $ 0 | ||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | ||||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 12,500 | [7],[10] | 12,500 | [14],[15] | 12,500 | [7],[10] | 12,500 | [7],[10] | 12,500 | [14],[15] | 12,500 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | $ 0 | [7],[10] | $ 0 | [14],[15] | |||||||||
Investment, Identifier [Axis]: EOS Fitness Opco Holdings, LLC, Leisure Facilities, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 488 | [7],[10] | 488 | [14],[15] | 488 | [7],[10] | 488 | [7],[10] | 488 | [14],[15] | 488 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 966 | |||||||||||
Fair Value, Ending Balance | $ 1,345 | [7],[10] | $ 966 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Eagleview Technology Corporation, Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [7],[10],[11] | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [14],[15],[16] | |
Investment, interest rate | 13.04% | [7],[8],[10],[11] | 11.17% | [14],[15],[16],[17] | 13.04% | [7],[8],[10],[11] | 13.04% | [7],[8],[10],[11] | 11.17% | [14],[15],[16],[17] | 11.17% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 8,974 | [7],[10],[11],[13] | $ 8,974 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 8,503 | |||||||||||
Fair Value, Ending Balance | $ 7,987 | [7],[10],[11] | $ 8,503 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 3% | [7],[8],[10],[11],[20] | 3% | [14],[15],[16],[17],[22] | 3% | [7],[8],[10],[11],[20] | 3% | [7],[8],[10],[11],[20] | 3% | [14],[15],[16],[17],[22] | 3% | [14],[15],[16],[17],[22] | |
Investment, interest rate, paid in kind | 6% | [7],[10],[20] | 6% | [14],[15],[22] | 6% | [7],[10],[20] | 6% | [7],[10],[20] | 6% | [14],[15],[22] | 6% | [14],[15],[22] | |
Investment owned, balance, principal amount | $ 11,065 | [7],[10],[13],[20] | $ 10,418 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 10,231 | |||||||||||
Fair Value, Ending Balance | $ 10,677 | [7],[10],[20] | $ 10,231 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 3% | [7],[8],[10],[11],[20] | 3% | [14],[15],[16],[17],[19],[22] | 3% | [7],[8],[10],[11],[20] | 3% | [7],[8],[10],[11],[20] | 3% | [14],[15],[16],[17],[19],[22] | 3% | [14],[15],[16],[17],[19],[22] | |
Investment, interest rate, paid in kind | [7],[10],[20] | 6% | 6% | 6% | |||||||||
Investment owned, balance, principal amount | $ 1,772 | [7],[10],[13],[20] | $ 0 | [14],[15],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | 0 | |||||||||||
Fair Value, Ending Balance | $ 1,710 | [7],[10],[20] | $ 0 | [14],[15],[19],[22] | |||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[9],[10],[11],[20] | 3% | 3% | 3% | |||||||||
Investment, interest rate, paid in kind | [7],[9],[10],[20] | 6% | 6% | 6% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[20] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[9],[10],[11],[20] | 3% | 3% | 3% | |||||||||
Investment, interest rate, paid in kind | [7],[9],[10],[20] | 6% | 6% | 6% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[20] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[10],[11] | 11.32% | 11.32% | 11.32% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 14,736 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 14,368 | |||||||||||
Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software,First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 6% | 6% | 6% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (41) | |||||||||||
Investment, Identifier [Axis]: FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | [10],[11] | 6.75% | [15],[16] | 6.75% | [10],[11] | 6.75% | [10],[11] | 6.75% | [15],[16] | 6.75% | [15],[16] | |
Investment, interest rate | 12.18% | [8],[10],[11] | 9.87% | [15],[16],[17] | 12.18% | [8],[10],[11] | 12.18% | [8],[10],[11] | 9.87% | [15],[16],[17] | 9.87% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 31,074 | [10],[11],[13] | $ 25,061 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 21,646 | |||||||||||
Fair Value, Ending Balance | $ 19,917 | [10],[11] | $ 21,646 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 9% | [7],[8],[9],[10],[11] | 9% | [14],[15],[16],[17],[27] | 9% | [7],[8],[9],[10],[11] | 9% | [7],[8],[9],[10],[11] | 9% | [14],[15],[16],[17],[27] | 9% | [14],[15],[16],[17],[27] | |
Investment owned, balance, principal amount | $ 59,950 | [7],[9],[10],[13] | $ 27,850 | [14],[15],[18],[27] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[27] | 27,850 | |||||||||||
Fair Value, Ending Balance | $ 59,950 | [7],[9],[10] | $ 27,850 | [14],[15],[27] | |||||||||
Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 3,750 | [7],[10],[20] | 2,500 | [14],[15],[22],[27] | 3,750 | [7],[10],[20] | 3,750 | [7],[10],[20] | 2,500 | [14],[15],[22],[27] | 2,500 | [14],[15],[22],[27] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22],[27] | $ 3 | |||||||||||
Fair Value, Ending Balance | $ 3 | [7],[10],[20] | $ 3 | [14],[15],[22],[27] | |||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[20] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[9],[10],[11],[20] | 12.55% | 12.55% | 12.55% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[20] | $ 258 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[20] | $ 234 | |||||||||||
Investment, Identifier [Axis]: Finastra USA, Inc.Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[10],[11],[20] | 12.55% | 12.55% | 12.55% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 11,742 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | 11,511 | |||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 9% | 9% | 9% | ||||||||||
Net Realized Gain (Loss) | $ 7,500 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | 7,500 | |||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (7,500) | ||||||||||||
Fair Value, Ending Balance | $ 0 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: First Star Speir Aviation Limited, Airlines, Membership Interest | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1 | 1 | 1 | ||||||||||
Net Realized Gain (Loss) | $ (5,632) | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 158 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | $ 0 | 698 | |||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | (698) | ||||||||||||
Fair Value, Ending Balance | $ 0 | ||||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 11% | [7],[8],[10],[11],[20] | 11% | [14],[15],[16],[17],[22] | 11% | [7],[8],[10],[11],[20] | 11% | [7],[8],[10],[11],[20] | 11% | [14],[15],[16],[17],[22] | 11% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 11,918 | [7],[10],[13],[20] | $ 9,466 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 9,008 | |||||||||||
Fair Value, Ending Balance | $ 11,144 | [7],[10],[20] | $ 9,008 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 417,011 | [7],[10],[20] | 331,200 | [14],[15],[22] | 417,011 | [7],[10],[20] | 417,011 | [7],[10],[20] | 331,200 | [14],[15],[22] | 331,200 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 66 | |||||||||||
Fair Value, Ending Balance | $ 42 | [7],[10],[20] | $ 66 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 6% | [8],[10],[11],[20] | 6% | [15],[16],[17],[22] | 6% | [8],[10],[11],[20] | 6% | [8],[10],[11],[20] | 6% | [15],[16],[17],[22] | 6% | [15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 4,881 | [10],[13],[20] | $ 4,881 | [15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 3,845 | |||||||||||
Fair Value, Ending Balance | 3,577 | [10],[20] | $ 3,845 | [15],[22] | |||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 10.60% | 10.60% | 10.60% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 1,280 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 1,262 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 1,262 | |||||||||||
Investment, Identifier [Axis]: GKD Index Partners, LLC, Specialized Finance, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.67% | 10.67% | 10.67% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 25,128 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 24,851 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 24,851 | |||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 12.64% | 12.64% | 12.64% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 1,638 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 1,535 | |||||||||||
Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.64% | 12.64% | 12.64% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 23,774 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 23,110 | |||||||||||
Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 5% | 5% | 5% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 10.57% | 10.57% | 10.57% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 2,456 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 2,063 | |||||||||||
Investment, Identifier [Axis]: Global Medical Response, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4.25% | 4.25% | 4.25% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.37% | 7.37% | 7.37% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 5,572 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 4,848 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 4,848 | |||||||||||
Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [10],[11],[20] | 2.85% | 2.85% | 2.85% | |||||||||
Investment, interest rate | [8],[10],[11],[20] | 6.56% | 6.56% | 6.56% | |||||||||
Investment owned, balance, principal amount | € | [10],[11],[13],[20] | € 1,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[11],[20] | $ 963 | |||||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [7],[9],[10],[11] | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (25) | |||||||||||
Fair Value, Ending Balance | $ (35) | [7],[9],[10],[11] | $ (25) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [7],[10],[11] | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [14],[15],[16] | |
Investment, interest rate | 13.42% | [7],[8],[10],[11] | 11.04% | [14],[15],[16],[17] | 13.42% | [7],[8],[10],[11] | 13.42% | [7],[8],[10],[11] | 11.04% | [14],[15],[16],[17] | 11.04% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 17,444 | [7],[10],[11],[13] | $ 14,311 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 14,060 | |||||||||||
Fair Value, Ending Balance | $ 17,096 | [7],[10],[11] | $ 14,060 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [7],[9],[10],[11] | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (50) | |||||||||||
Fair Value, Ending Balance | $ (70) | [7],[9],[10],[11] | $ (50) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Harbor Purchaser Inc., Education Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.25% | [10],[11] | 5.25% | [15],[16] | 5.25% | [10],[11] | 5.25% | [10],[11] | 5.25% | [15],[16] | 5.25% | [15],[16] | |
Investment, interest rate | 10.67% | [8],[10],[11] | 8.38% | [15],[16],[17] | 10.67% | [8],[10],[11] | 10.67% | [8],[10],[11] | 8.38% | [15],[16],[17] | 8.38% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 14,347 | [10],[11],[13] | $ 9,392 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 8,582 | |||||||||||
Fair Value, Ending Balance | $ 13,618 | [10],[11] | $ 8,582 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Harrow , Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 11.89% | 11.89% | 11.89% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 7,448 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 7,301 | |||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[20] | 6.50% | 6.50% | 6.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[20] | $ (79) | |||||||||||
Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.04% | 12.04% | 12.04% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 1,432 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 1,404 | |||||||||||
Investment, Identifier [Axis]: Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [8],[10],[11],[20] | 4.46% | 4.46% | 4.46% | |||||||||
Investment owned, balance, principal amount | [10],[13],[20] | $ 6,808 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | $ 5,873 | |||||||||||
Investment, Identifier [Axis]: IAMGOLD Corporation, Gold, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 8.25% | 8.25% | 8.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 13.62% | 13.62% | 13.62% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 23,975 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 23,328 | |||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.40% | 11.40% | 11.40% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 44,550 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 35,046 | |||||||||||
Investment, Identifier [Axis]: INW Manufacturing, LLC, Personal Products, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.42% | 9.42% | 9.42% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 35,625 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 31,528 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 31,528 | |||||||||||
Investment, Identifier [Axis]: IPC Corp., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.50% | [7],[10],[11] | 6.50% | [14],[15],[16] | 6.50% | [7],[10],[11] | 6.50% | [7],[10],[11] | 6.50% | [14],[15],[16] | 6.50% | [14],[15],[16] | |
Investment, interest rate | 11.92% | [7],[8],[10],[11] | 9.44% | [14],[15],[16],[17] | 11.92% | [7],[8],[10],[11] | 11.92% | [7],[8],[10],[11] | 9.44% | [14],[15],[16],[17] | 9.44% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 40,587 | [7],[10],[11],[13] | $ 34,357 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 32,639 | |||||||||||
Fair Value, Ending Balance | 38,963 | [7],[10],[11] | $ 32,639 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.42% | 9.42% | 9.42% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 8,569 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 8,407 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 8,407 | |||||||||||
Investment, Identifier [Axis]: Immucor, Inc., Health Care Supplies, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8% | 8% | 8% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 11.67% | 11.67% | 11.67% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 3.50% | 3.50% | 3.50% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 22,619 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 22,275 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | 22,275 | |||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance, principal amount | [14],[15],[18],[26] | 13,083 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[26] | 13,083 | |||||||||||
Fair Value, Ending Balance | [14],[15],[26] | $ 13,083 | |||||||||||
Investment, Identifier [Axis]: Impel Neuropharma, Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.75% | 8.75% | 8.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 12.45% | 12.45% | 12.45% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 12,161 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 11,942 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 11,942 | |||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 350,241 | 350,241 | 350,241 | ||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | $ 147 | ||||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 10.75% | 10.75% | 10.75% | |||||||||
Investment, interest rate, paid in kind | [7],[9],[10],[11] | 16.06% | 16.06% | 16.06% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 688 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 688 | |||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 10.75% | 10.75% | 10.75% | ||||||||||
Investment, interest rate, paid in kind | [7],[10],[11] | 16.06% | 16.06% | 16.06% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 26,613 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 24,484 | |||||||||||
Investment, Identifier [Axis]: Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 10.75% | 10.75% | 10.75% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[11] | 16.05% | 16.05% | 16.05% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 787 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 787 | |||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[11],[20] | 5.75% | 5.75% | 5.75% | |||||||||
Investment, interest rate | 11.14% | [7],[8],[11],[20] | 11% | [14],[15],[16],[17],[22] | 11.14% | [7],[8],[11],[20] | 11.14% | [7],[8],[11],[20] | 11% | [14],[15],[16],[17],[22] | 11% | [14],[15],[16],[17],[22] | |
Investment, interest rate, paid in kind | [7],[11],[20] | 2.75% | 2.75% | 2.75% | |||||||||
Investment owned, balance, principal amount | $ 7,179 | [7],[11],[13],[20] | $ 6,817 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 6,408 | |||||||||||
Fair Value, Ending Balance | 6,568 | [7],[11],[20] | $ 6,408 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[19],[22] | 11% | 11% | 11% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18],[19],[22] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | $ 0 | |||||||||||
Fair Value, Ending Balance | [14],[15],[19],[22] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Innocoll Pharmaceuticals Limited, Health Care Technology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 112,990 | [7],[10],[20] | 56,999 | [14],[15],[22] | 112,990 | [7],[10],[20] | 112,990 | [7],[10],[20] | 56,999 | [14],[15],[22] | 56,999 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 609 | |||||||||||
Fair Value, Ending Balance | $ 105 | [7],[10],[20] | $ 609 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Diversified Financial Services, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 1,078,284 | 1,078,284 | 1,078,284 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Integral Development Corporation, Other Diversified Financial Services, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 1,078,284 | 1,078,284 | 1,078,284 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (86) | |||||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[10],[11] | 5% | [14],[15],[16] | 7.50% | [7],[10],[11] | 7.50% | [7],[10],[11] | 5% | [14],[15],[16] | 5% | [14],[15],[16] | |
Investment, interest rate | 12.93% | [7],[8],[10],[11] | 8.55% | [14],[15],[16],[17] | 12.93% | [7],[8],[10],[11] | 12.93% | [7],[8],[10],[11] | 8.55% | [14],[15],[16],[17] | 8.55% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 33,414 | [7],[10],[11],[13] | $ 18,660 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 18,134 | |||||||||||
Fair Value, Ending Balance | 32,659 | [7],[10],[11] | $ 18,134 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Inventus Power, Inc., Electrical Components & Equipment, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 12.17% | 12.17% | 12.17% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 13,674 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 13,154 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 13,154 | |||||||||||
Investment, Identifier [Axis]: Ivanti Software, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.25% | [10],[11] | 7.25% | [15],[16] | 7.25% | [10],[11] | 7.25% | [10],[11] | 7.25% | [15],[16] | 7.25% | [15],[16] | |
Investment, interest rate | 12.78% | [8],[10],[11] | 10.33% | [15],[16],[17] | 12.78% | [8],[10],[11] | 12.78% | [8],[10],[11] | 10.33% | [15],[16],[17] | 10.33% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 13,939 | [10],[11],[13] | $ 10,247 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 7,702 | |||||||||||
Fair Value, Ending Balance | 10,094 | [10],[11] | $ 7,702 | [15],[16] | |||||||||
Investment, Identifier [Axis]: JP Morgan Prime Money Market Fund, Institutional Shares | |||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | 83,262 | ||||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.62% | 10.62% | 10.62% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 36,234 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 36,392 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 36,392 | |||||||||||
Investment, Identifier [Axis]: Jazz Acquisition, Inc., Aerospace & Defense, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 8% | 8% | 8% | |||||||||
Investment, interest rate | [15],[16],[17] | 11.12% | 11.12% | 11.12% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 528 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 481 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 481 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 10.17% | 10.17% | 10.17% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 329 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ 292 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 292 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 11.84% | 11.84% | 11.84% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 272 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 238 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | (47) | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.17% | 10.17% | 10.17% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 13,623 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 13,351 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 13,351 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.84% | 11.84% | 11.84% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 16,752 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 16,500 | |||||||||||
Investment, Identifier [Axis]: Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6.50% | 6.50% | 6.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.80% | 11.80% | 11.80% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 38,015 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 37,445 | |||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [7],[9],[10],[11] | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [14],[15],[16],[19] | |
Investment, interest rate | [14],[15],[16],[17],[19] | 9.12% | 9.12% | 9.12% | |||||||||
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 1,710 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 1,651 | |||||||||||
Fair Value, Ending Balance | (172) | [7],[9],[10],[11] | $ 1,651 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.12% | 9.12% | 9.12% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 19,236 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 18,707 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 18,707 | |||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.42% | 11.42% | 11.42% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 2,736 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 2,558 | |||||||||||
Investment, Identifier [Axis]: LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.42% | 11.42% | 11.42% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 23,494 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 21,967 | |||||||||||
Investment, Identifier [Axis]: LTI Holdings, Inc., Electronic Components, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 6.75% | 6.75% | 6.75% | |||||||||
Investment, interest rate | [15],[16],[17] | 9.87% | 9.87% | 9.87% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 2,140 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 1,890 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 1,890 | |||||||||||
Investment, Identifier [Axis]: LaserShip, Inc., Air Freight & Logistics, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.38% | 10.38% | 10.38% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 2,394 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 1,867 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 1,867 | |||||||||||
Investment, Identifier [Axis]: Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [10],[11],[20] | 9.50% | 9.50% | 9.50% | |||||||||
Investment, interest rate | [8],[10],[11],[20] | 14.95% | 14.95% | 14.95% | |||||||||
Investment owned, balance, principal amount | [10],[11],[13],[20] | $ 26,422 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[11],[20] | $ 27,512 | |||||||||||
Investment, Identifier [Axis]: Lift Brands Holdings, Inc., Leisure Facilities, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 2,000,000 | [7],[10] | 2,000,000 | [14],[15] | 2,000,000 | [7],[10] | 2,000,000 | [7],[10] | 2,000,000 | [14],[15] | 2,000,000 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | $ 0 | [7],[10] | $ 0 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [7],[10],[11] | 5% | [14],[15],[16] | 5% | [7],[10],[11] | 5% | [7],[10],[11] | 5% | [14],[15],[16] | 5% | [14],[15],[16] | |
Investment, interest rate | 10.65% | [7],[8],[10],[11] | 8.67% | [14],[15],[16],[17] | 10.65% | [7],[8],[10],[11] | 10.65% | [7],[8],[10],[11] | 8.67% | [14],[15],[16],[17] | 8.67% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 45,243 | [7],[10],[11],[13] | $ 41,008 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 39,573 | |||||||||||
Fair Value, Ending Balance | $ 43,886 | [7],[10],[11] | $ 39,573 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 559 | [7],[10] | 451 | [14],[15] | 559 | [7],[10] | 559 | [7],[10] | 451 | [14],[15] | 451 | [14],[15] | |
Investment owned, balance, principal amount | [7],[10],[13] | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 451 | |||||||||||
Fair Value, Ending Balance | $ 372 | [7],[10] | $ 451 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [7],[10],[11] | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [14],[15],[16] | |
Investment, interest rate | 13.99% | [7],[8],[10],[11] | 11.38% | [14],[15],[16],[17] | 13.99% | [7],[8],[10],[11] | 13.99% | [7],[8],[10],[11] | 11.38% | [14],[15],[16],[17] | 11.38% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 5,403 | [7],[10],[11],[13] | $ 4,357 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 4,226 | |||||||||||
Fair Value, Ending Balance | $ 5,160 | [7],[10],[11] | $ 4,226 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[9],[10],[11] | 8.50% | [14],[15],[16],[19] | 8.50% | [7],[9],[10],[11] | 8.50% | [7],[9],[10],[11] | 8.50% | [14],[15],[16],[19] | 8.50% | [14],[15],[16],[19] | |
Investment, interest rate | 13.99% | [7],[8],[9],[10],[11] | 11.38% | [14],[15],[16],[17],[19] | 13.99% | [7],[8],[9],[10],[11] | 13.99% | [7],[8],[9],[10],[11] | 11.38% | [14],[15],[16],[17],[19] | 11.38% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 2,939 | [7],[9],[10],[11],[13] | $ 2,370 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 2,265 | |||||||||||
Fair Value, Ending Balance | $ 2,745 | [7],[9],[10],[11] | $ 2,265 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [7],[9],[10],[11] | 6% | [7],[9],[10],[11] | 6% | [14],[15],[16],[19] | 6% | [14],[15],[16],[19] | |
Investment, interest rate | [7],[8],[9],[10],[11] | 11.42% | 11.42% | 11.42% | |||||||||
Investment owned, balance, principal amount | $ 964 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (54) | |||||||||||
Fair Value, Ending Balance | 938 | [7],[9],[10],[11] | $ (54) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.50% | 9.50% | 9.50% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 18,390 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 17,691 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 17,691 | |||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.52% | 11.52% | 11.52% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 20,125 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 19,823 | |||||||||||
Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.52% | 11.52% | 11.52% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 2,631 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 2,591 | |||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11] | 12.83% | 12.83% | 12.83% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 1,466 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 1,282 | |||||||||||
Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.89% | 12.89% | 12.89% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 40,538 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 39,833 | |||||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.50% | [7],[9],[10],[11] | 5.50% | [14],[15],[16],[19] | 5.50% | [7],[9],[10],[11] | 5.50% | [7],[9],[10],[11] | 5.50% | [14],[15],[16],[19] | 5.50% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (51) | |||||||||||
Fair Value, Ending Balance | $ (47) | [7],[9],[10],[11] | $ (51) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.50% | [7],[10],[11] | 5.50% | [14],[15],[16] | 5.50% | [7],[10],[11] | 5.50% | [7],[10],[11] | 5.50% | [14],[15],[16] | 5.50% | [14],[15],[16] | |
Investment, interest rate | 10.99% | [7],[8],[10],[11] | 9.17% | [14],[15],[16],[17] | 10.99% | [7],[8],[10],[11] | 10.99% | [7],[8],[10],[11] | 9.17% | [14],[15],[16],[17] | 9.17% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 13,973 | [7],[10],[11],[13] | $ 29,565 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 28,734 | |||||||||||
Fair Value, Ending Balance | $ 13,685 | [7],[10],[11] | $ 28,734 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.50% | [7],[10],[11] | 5.50% | [14],[15],[16],[19] | 5.50% | [7],[10],[11] | 5.50% | [7],[10],[11] | 5.50% | [14],[15],[16],[19] | 5.50% | [14],[15],[16],[19] | |
Investment, interest rate | [7],[8],[10],[11] | 10.99% | 10.99% | 10.99% | |||||||||
Investment owned, balance, principal amount | $ 21,328 | [7],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (96) | |||||||||||
Fair Value, Ending Balance | $ 20,888 | [7],[10],[11] | $ (96) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [14],[15],[16],[17],[22] | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [14],[15],[16],[17],[22] | 11.50% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 8,568 | [7],[10],[13],[20] | $ 17,203 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 16,644 | |||||||||||
Fair Value, Ending Balance | $ 8,132 | [7],[10],[20] | $ 16,644 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [14],[15],[16],[17],[19],[22] | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [7],[8],[10],[11],[20] | 11.50% | [14],[15],[16],[17],[19],[22] | 11.50% | [14],[15],[16],[17],[19],[22] | |
Investment owned, balance, principal amount | $ 4,284 | [7],[10],[13],[20] | $ 0 | [14],[15],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | 0 | |||||||||||
Fair Value, Ending Balance | $ 4,066 | [7],[10],[20] | $ 0 | [14],[15],[19],[22] | |||||||||
Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 11.50% | 11.50% | 11.50% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 8,568 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 8,132 | |||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 8% | [7],[8],[10],[11],[20] | 8% | [14],[15],[16],[17],[22] | 8% | [7],[8],[10],[11],[20] | 8% | [7],[8],[10],[11],[20] | 8% | [14],[15],[16],[17],[22] | 8% | [14],[15],[16],[17],[22] | |
Investment, interest rate, paid in kind | 1.75% | [7],[10],[20] | 1.75% | [14],[15],[22] | 1.75% | [7],[10],[20] | 1.75% | [7],[10],[20] | 1.75% | [14],[15],[22] | 1.75% | [14],[15],[22] | |
Investment owned, balance, principal amount | $ 9,106 | [7],[10],[13],[20] | $ 7,215 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 6,440 | |||||||||||
Fair Value, Ending Balance | 8,013 | [7],[10],[20] | $ 6,440 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17],[19],[22] | 8% | 8% | 8% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[19],[22] | 1.75% | 1.75% | 1.75% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18],[19],[22] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19],[22] | 0 | |||||||||||
Fair Value, Ending Balance | [14],[15],[19],[22] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15],[22] | 209,588 | 209,588 | 209,588 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 170 | |||||||||||
Fair Value, Ending Balance | [14],[15],[22] | $ 170 | |||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10],[20] | 259,877 | 259,877 | 259,877 | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 78 | |||||||||||
Investment, Identifier [Axis]: Mesoblast, Inc., Biotechnology, Warrants 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10],[20] | 66,817 | 66,817 | 66,817 | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 33 | |||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 7% | [7],[9],[10],[11] | 7% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (100) | |||||||||||
Fair Value, Ending Balance | (76) | [7],[9],[10],[11] | $ (100) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.64% | 10.64% | 10.64% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 1.50% | 1.50% | 1.50% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 45,665 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 44,523 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 44,523 | |||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.52% | 12.52% | 12.52% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 5,248 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 5,164 | |||||||||||
Investment, Identifier [Axis]: Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.52% | 12.52% | 12.52% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 46,687 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 45,940 | |||||||||||
Investment, Identifier [Axis]: Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [7],[10],[11] | 6.75% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [14],[15],[16] | |
Investment, interest rate | 12.51% | [7],[8],[10],[11] | 9.89% | [14],[15],[16],[17] | 12.51% | [7],[8],[10],[11] | 12.51% | [7],[8],[10],[11] | 9.89% | [14],[15],[16],[17] | 9.89% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 54,559 | [7],[10],[11],[13] | $ 46,499 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 45,421 | |||||||||||
Fair Value, Ending Balance | $ 53,168 | [7],[10],[11] | $ 45,421 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: NFP Corp., Diversified Financial Services, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [8],[10],[11] | 6.88% | 6.88% | 6.88% | |||||||||
Investment owned, balance, principal amount | [10],[13] | $ 10,191 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10] | 8,743 | |||||||||||
Investment, Identifier [Axis]: NFP Corp., Other Diversified Financial Services, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 6.88% | 6.88% | 6.88% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 10,191 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | $ 7,966 | |||||||||||
Fair Value, Ending Balance | [15] | $ 7,966 | |||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 6.88% | 6.88% | 6.88% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.29% | 12.29% | 12.29% | |||||||||
Investment, interest rate, paid in kind | [7],[10],[11],[20] | 2% | 2% | 2% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 73,362 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 69,694 | |||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | ||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | $ 903 | |||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery & Supplies & Components, Warrants 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 487,870 | 487,870 | 487,870 | ||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | $ 903 | |||||||||||
Investment, Identifier [Axis]: NN, Inc., Industrial Machinery, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[22] | 6.88% | 6.88% | 6.88% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 9.99% | 9.99% | 9.99% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[22] | $ 58,713 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 56,805 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[22] | $ 56,805 | |||||||||||
Investment, Identifier [Axis]: Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [7],[10],[11] | 8.50% | [7],[10],[11] | 8.50% | [14],[15],[16] | 8.50% | [14],[15],[16] | |
Investment, interest rate | 13.99% | [7],[8],[10],[11] | 12.17% | [14],[15],[16],[17] | 13.99% | [7],[8],[10],[11] | 13.99% | [7],[8],[10],[11] | 12.17% | [14],[15],[16],[17] | 12.17% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 30,339 | [7],[10],[11],[13] | $ 22,560 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 21,524 | |||||||||||
Fair Value, Ending Balance | $ 29,007 | [7],[10],[11] | $ 21,524 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 9.50% | [7],[10],[11] | 10.50% | [14],[15],[16] | 9.50% | [7],[10],[11] | 9.50% | [7],[10],[11] | 10.50% | [14],[15],[16] | 10.50% | [14],[15],[16] | |
Investment, interest rate | 14.89% | [7],[8],[10],[11] | 14.17% | [14],[15],[16],[17] | 14.89% | [7],[8],[10],[11] | 14.89% | [7],[8],[10],[11] | 14.17% | [14],[15],[16],[17] | 14.17% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 64,606 | [7],[10],[11],[13] | $ 50,459 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 51,972 | |||||||||||
Fair Value, Ending Balance | $ 63,185 | [7],[10],[11] | $ 51,972 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Membership Interest | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, ownership percentage | 87.50% | [9],[20],[28],[29] | 87.50% | [1],[2],[19],[22],[30],[31] | 87.50% | [9],[20],[28],[29] | 87.50% | [9],[20],[28],[29] | 87.50% | [1],[2],[19],[22],[30],[31] | 87.50% | [1],[2],[19],[22],[30],[31] | |
Net Realized Gain (Loss) | $ 0 | $ 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | [1],[2],[19],[22],[30],[31] | 0 | ||||||||||
Gross Additions | 0 | 0 | |||||||||||
Gross Reductions | 0 | 0 | |||||||||||
Fair Value, Ending Balance | $ 0 | [9],[20],[28],[29] | $ 0 | [1],[2],[19],[22],[30],[31] | |||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | 0% | 0% | 0% | |||||||
Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 4.50% | [7],[9],[11],[20],[28] | 4.50% | [1],[2],[14],[16],[19],[22],[30] | 4.50% | [7],[9],[11],[20],[28] | 4.50% | [7],[9],[11],[20],[28] | 4.50% | [1],[2],[14],[16],[19],[22],[30] | 4.50% | [1],[2],[14],[16],[19],[22],[30] | |
Investment, interest rate | 9.76% | [7],[8],[9],[11],[20],[28] | 6.30% | [1],[2],[14],[16],[17],[19],[22],[30] | 9.76% | [7],[8],[9],[11],[20],[28] | 9.76% | [7],[8],[9],[11],[20],[28] | 6.30% | [1],[2],[14],[16],[17],[19],[22],[30] | 6.30% | [1],[2],[14],[16],[17],[19],[22],[30] | |
Investment owned, balance, principal amount | $ 58,349 | [7],[9],[11],[13],[20],[28] | $ 59,662 | [1],[2],[14],[16],[18],[19],[22],[30] | |||||||||
Net Realized Gain (Loss) | 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 6,748 | 4,667 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 50,283 | [1],[2],[14],[16],[19],[22],[30] | 55,582 | ||||||||||
Gross Additions | 1,448 | 1,538 | |||||||||||
Gross Reductions | (1,714) | (6,837) | |||||||||||
Fair Value, Ending Balance | $ 50,017 | [7],[9],[11],[20],[28] | $ 50,283 | [1],[2],[14],[16],[19],[22],[30] | |||||||||
Investment owned, percent of net assets | 3.30% | 4% | 3.30% | 3.30% | 4% | 4% | |||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4% | 4% | 4% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.12% | 7.12% | 7.12% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 3,323 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 3,207 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 3,207 | |||||||||||
Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [7],[10],[11] | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [14],[15],[16] | |
Investment, interest rate | 12.49% | [7],[8],[10],[11] | 10.05% | [14],[15],[16],[17] | 12.49% | [7],[8],[10],[11] | 12.49% | [7],[8],[10],[11] | 10.05% | [14],[15],[16],[17] | 10.05% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 9,323 | [7],[10],[11],[13] | $ 7,519 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 7,237 | |||||||||||
Fair Value, Ending Balance | $ 9,183 | [7],[10],[11] | $ 7,237 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 10% | [7],[10],[11] | 2% | [14],[15],[16] | 10% | [7],[10],[11] | 10% | [7],[10],[11] | 2% | [14],[15],[16] | 2% | [14],[15],[16] | |
Investment, interest rate | [14],[15],[16],[17] | 5.08% | 5.08% | 5.08% | |||||||||
Investment, interest rate, paid in kind | 15.67% | [7],[10],[11] | 8% | [14],[15],[16] | 15.67% | [7],[10],[11] | 15.67% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [14],[15],[16] | |
Investment owned, balance, principal amount | $ 25,712 | [7],[10],[11],[13] | $ 21,557 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 21,557 | |||||||||||
Fair Value, Ending Balance | $ 25,069 | [7],[10],[11] | $ 21,557 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 10% | [7],[9],[10],[11] | 2% | [14],[15],[16],[19] | 10% | [7],[9],[10],[11] | 10% | [7],[9],[10],[11] | 2% | [14],[15],[16],[19] | 2% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 0 | |||||||||||
Fair Value, Ending Balance | $ (69) | [7],[9],[10],[11] | $ 0 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 10% | 10% | 10% | |||||||||
Investment, interest rate, paid in kind | [7],[9],[10],[11] | 15.64% | 15.64% | 15.64% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 1,210 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 1,169 | |||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.75% | 7.75% | 7.75% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (36) | |||||||||||
Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.75% | 7.75% | 7.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 13.12% | 13.12% | 13.12% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 15,231 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 14,945 | |||||||||||
Investment, Identifier [Axis]: Other cash accounts | |||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | $ 62,277 | ||||||||||||
Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 7.75% | [8],[10],[11] | 7.75% | [15],[16],[17] | 7.75% | [8],[10],[11] | 7.75% | [8],[10],[11] | 7.75% | [15],[16],[17] | 7.75% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 4,519 | [10],[13] | $ 7,776 | [15],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 5,846 | |||||||||||
Fair Value, Ending Balance | 3,305 | [10] | $ 5,846 | [15] | |||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 7% | 7% | 7% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (13) | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ (13) | |||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.28% | 9.28% | 9.28% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 26,154 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 25,893 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 25,893 | |||||||||||
Investment, Identifier [Axis]: PFNY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[19] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[19] | 9.25% | 9.25% | 9.25% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18],[19] | $ 2,228 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | $ 2,203 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[19] | $ 2,203 | |||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7% | 7% | 7% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (54) | |||||||||||
Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.32% | 12.32% | 12.32% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 10,895 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 10,495 | |||||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 100,000 | [7],[10] | 80,515 | [14],[15] | 100,000 | [7],[10] | 100,000 | [7],[10] | 80,515 | [14],[15] | 80,515 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 89 | |||||||||||
Fair Value, Ending Balance | $ 248 | [7],[10] | $ 89 | [14],[15] | |||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.50% | [7],[9],[10],[11] | 6.75% | [14],[15],[16],[19] | 6.50% | [7],[9],[10],[11] | 6.50% | [7],[9],[10],[11] | 6.75% | [14],[15],[16],[19] | 6.75% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (49) | |||||||||||
Fair Value, Ending Balance | $ (3) | [7],[9],[10],[11] | $ (49) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.50% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.50% | [7],[10],[11] | 6.50% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [14],[15],[16] | |
Investment, interest rate | 12.01% | [7],[8],[10],[11] | 10.42% | [14],[15],[16],[17] | 12.01% | [7],[8],[10],[11] | 12.01% | [7],[8],[10],[11] | 10.42% | [14],[15],[16],[17] | 10.42% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 38,414 | [7],[10],[11],[13] | $ 33,775 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 33,116 | |||||||||||
Fair Value, Ending Balance | $ 38,380 | [7],[10],[11] | $ 33,116 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [10],[11] | 5% | [15],[16] | 5% | [10],[11] | 5% | [10],[11] | 5% | [15],[16] | 5% | [15],[16] | |
Investment, interest rate | 10.42% | [8],[10],[11] | 8.13% | [15],[16],[17] | 10.42% | [8],[10],[11] | 10.42% | [8],[10],[11] | 8.13% | [15],[16],[17] | 8.13% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 9,676 | [10],[11],[13] | $ 9,850 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 9,374 | |||||||||||
Fair Value, Ending Balance | $ 9,551 | [10],[11] | $ 9,374 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [7],[10],[11] | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [14],[15],[16] | |
Investment, interest rate | 11.57% | [7],[8],[10],[11] | 8.88% | [14],[15],[16],[17] | 11.57% | [7],[8],[10],[11] | 11.57% | [7],[8],[10],[11] | 8.88% | [14],[15],[16],[17] | 8.88% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 22,375 | [7],[10],[11],[13] | $ 17,976 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 17,537 | |||||||||||
Fair Value, Ending Balance | $ 21,896 | [7],[10],[11] | $ 17,537 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Planview Parent, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.25% | [7],[10],[11] | 7.25% | [14],[15],[16] | 7.25% | [7],[10],[11] | 7.25% | [7],[10],[11] | 7.25% | [14],[15],[16] | 7.25% | [14],[15],[16] | |
Investment, interest rate | 12.74% | [7],[8],[10],[11] | 10.92% | [14],[15],[16],[17] | 12.74% | [7],[8],[10],[11] | 12.74% | [7],[8],[10],[11] | 10.92% | [14],[15],[16],[17] | 10.92% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 36,499 | [7],[10],[11],[13] | $ 28,627 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 27,482 | |||||||||||
Fair Value, Ending Balance | $ 33,214 | [7],[10],[11] | $ 27,482 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [7],[9],[10],[11] | 8% | [7],[9],[10],[11] | 8% | [14],[15],[16],[19] | 8% | [14],[15],[16],[19] | |
Investment, interest rate | [7],[8],[9],[10],[11] | 13.45% | 13.45% | 13.45% | |||||||||
Investment owned, balance, principal amount | $ 3,003 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (111) | |||||||||||
Fair Value, Ending Balance | $ 2,801 | [7],[9],[10],[11] | $ (111) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [7],[10],[11] | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [14],[15],[16] | |
Investment, interest rate | 13.45% | [7],[8],[10],[11] | 10.68% | [14],[15],[16],[17] | 13.45% | [7],[8],[10],[11] | 13.45% | [7],[8],[10],[11] | 10.68% | [14],[15],[16],[17] | 10.68% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 67,244 | [7],[10],[11],[13] | $ 48,689 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 47,155 | |||||||||||
Fair Value, Ending Balance | $ 64,406 | [7],[10],[11] | $ 47,155 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.78% | 12.78% | 12.78% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 24,503 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 24,081 | |||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.78% | 12.78% | 12.78% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 2,819 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 2,771 | |||||||||||
Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.01% | 10.01% | 10.01% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 23,275 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 22,810 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 22,810 | |||||||||||
Investment, Identifier [Axis]: Project Boost Purchaser, LLC, Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8% | 8% | 8% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 11.12% | 11.12% | 11.12% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 5,250 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 5,047 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 5,047 | |||||||||||
Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.75% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 5.75% | [7],[10],[11],[20] | 5.75% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 6% | [14],[15],[16],[22] | |
Investment, interest rate | 11.21% | [7],[8],[10],[11],[20] | 8.39% | [14],[15],[16],[17],[22] | 11.21% | [7],[8],[10],[11],[20] | 11.21% | [7],[8],[10],[11],[20] | 8.39% | [14],[15],[16],[17],[22] | 8.39% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | £ | £ 4,626 | [7],[10],[11],[13],[20] | £ 3,501 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 3,367 | |||||||||||
Fair Value, Ending Balance | $ 5,166 | [7],[10],[11],[20] | $ 3,367 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: QuorumLabs, Inc., Application Software, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 64,887,669 | [7],[10] | 64,887,669 | [14],[15] | 64,887,669 | [7],[10] | 64,887,669 | [7],[10] | 64,887,669 | [14],[15] | 64,887,669 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | 0 | [7],[10] | $ 0 | [14],[15] | |||||||||
Investment, Identifier [Axis]: RP Escrow Issuer LLC, Health Care Distributors, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 5.25% | 5.25% | 5.25% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 1,325 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 1,097 | |||||||||||
Fair Value, Ending Balance | [15] | $ 1,097 | |||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4.25% | 4.25% | 4.25% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.33% | 7.33% | 7.33% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 3,400 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 2,880 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 2,880 | |||||||||||
Investment, Identifier [Axis]: Radiology Partners, Inc., Health Care Distributors, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 9.25% | 9.25% | 9.25% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 4,755 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | $ 3,109 | |||||||||||
Fair Value, Ending Balance | [15] | $ 3,109 | |||||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.50% | [7],[9],[10],[11] | 6.50% | [14],[15],[16],[19] | 6.50% | [7],[9],[10],[11] | 6.50% | [7],[9],[10],[11] | 6.50% | [14],[15],[16],[19] | 6.50% | [14],[15],[16],[19] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (64) | |||||||||||
Fair Value, Ending Balance | $ (47) | [7],[9],[10],[11] | $ (64) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 6.50% | [7],[10],[11] | 6.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [14],[15],[16] | |
Investment, interest rate | [7],[8],[10],[11] | 11.92% | 11.92% | 11.92% | |||||||||
Investment, interest rate, paid in kind | [14],[15],[16] | 10.59% | 10.59% | 10.59% | |||||||||
Investment owned, balance, principal amount | $ 32,329 | [7],[10],[11],[13] | $ 24,692 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 24,101 | |||||||||||
Fair Value, Ending Balance | 31,779 | [7],[10],[11] | $ 24,101 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Renaissance Holding Corp., Diversified Banks, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [15],[16],[17] | 10.12% | 10.12% | 10.12% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 3,542 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 3,402 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 3,402 | |||||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.25% | [7],[10],[11],[20] | 8.25% | [14],[15],[16],[22] | 8.25% | [7],[10],[11],[20] | 8.25% | [7],[10],[11],[20] | 8.25% | [14],[15],[16],[22] | 8.25% | [14],[15],[16],[22] | |
Investment, interest rate | 13.90% | [7],[8],[10],[11],[20] | 11.92% | [14],[15],[16],[17],[22] | 13.90% | [7],[8],[10],[11],[20] | 13.90% | [7],[8],[10],[11],[20] | 11.92% | [14],[15],[16],[17],[22] | 11.92% | [14],[15],[16],[17],[22] | |
Investment, interest rate, paid in kind | [7],[10],[11],[20] | 0.50% | 0.50% | 0.50% | |||||||||
Investment owned, balance, principal amount | $ 36,707 | [7],[10],[11],[13],[20] | $ 37,656 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 36,187 | |||||||||||
Fair Value, Ending Balance | $ 34,505 | [7],[10],[11],[20] | $ 36,187 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8.25% | [7],[10],[11],[20] | 8.25% | [14],[15],[16],[19],[22] | 8.25% | [7],[10],[11],[20] | 8.25% | [7],[10],[11],[20] | 8.25% | [14],[15],[16],[19],[22] | 8.25% | [14],[15],[16],[19],[22] | |
Investment, interest rate | 13.90% | [7],[8],[10],[11],[20] | 11.92% | [14],[15],[16],[17],[19],[22] | 13.90% | [7],[8],[10],[11],[20] | 13.90% | [7],[8],[10],[11],[20] | 11.92% | [14],[15],[16],[17],[19],[22] | 11.92% | [14],[15],[16],[17],[19],[22] | |
Investment, interest rate, paid in kind | [7],[10],[11],[20] | 0.50% | 0.50% | 0.50% | |||||||||
Investment owned, balance, principal amount | $ 13,504 | [7],[10],[11],[13],[20] | $ 11,393 | [14],[15],[16],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19],[22] | 10,760 | |||||||||||
Fair Value, Ending Balance | $ 12,694 | [7],[10],[11],[20] | $ 10,760 | [14],[15],[16],[19],[22] | |||||||||
Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 204,454 | [7],[10],[20] | 164,660 | [14],[15],[22] | 204,454 | [7],[10],[20] | 204,454 | [7],[10],[20] | 164,660 | [14],[15],[22] | 164,660 | [14],[15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | $ 74 | |||||||||||
Fair Value, Ending Balance | $ 756 | [7],[10],[20] | $ 74 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 1,037 | 1,037 | 1,037 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 951 | |||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 8.75% | 8.75% | 8.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 14.18% | 14.18% | 14.18% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 8,010 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 7,778 | |||||||||||
Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 8.75% | 8.75% | 8.75% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (68) | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc, Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | 12% | 12% | 12% | ||||||||||
Investment owned, balance, principal amount | $ 15,874 | ||||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 340 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 16,653 | ||||||||||||
Gross Reductions | (779) | ||||||||||||
Fair Value, Ending Balance | $ 15,874 | $ 0 | |||||||||||
Investment owned, percent of net assets | 1% | 1% | 1% | ||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7] | 1,184,630 | 1,184,630 | 1,184,630 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7] | $ 36,226 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7] | 66,686 | 66,686 | 66,686 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7] | $ 0 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | [7] | 12% | 12% | 12% | |||||||||
Investment owned, balance, principal amount | [7],[13] | $ 15,874 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7] | $ 15,874 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | [7],[9] | 12% | 12% | 12% | |||||||||
Investment owned, balance, principal amount | [7],[9],[13] | $ 1,359 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9] | 1,359 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal & Glass Containers, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 415 | 415 | 415 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 681 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 681 | |||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 1,184,630 | 1,184,630 | 1,184,630 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 40,093 | ||||||||||||
Gross Reductions | (3,867) | ||||||||||||
Fair Value, Ending Balance | $ 36,226 | 0 | |||||||||||
Investment owned, percent of net assets | 2.40% | 2.40% | 2.40% | ||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Delayed Draw Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate, paid in kind | 12% | 12% | 12% | ||||||||||
Investment owned, balance, principal amount | $ 1,359 | ||||||||||||
Net Realized Gain (Loss) | 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 14 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 1,359 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 1,359 | 0 | |||||||||||
Investment owned, percent of net assets | 0.10% | 0.10% | 0.10% | ||||||||||
Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 66,686 | 66,686 | 66,686 | ||||||||||
Net Realized Gain (Loss) | $ 0 | ||||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 0 | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 0 | ||||||||||||
Gross Additions | 0 | ||||||||||||
Gross Reductions | 0 | ||||||||||||
Fair Value, Ending Balance | $ 0 | $ 0 | |||||||||||
Investment owned, percent of net assets | 0% | 0% | 0% | ||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 4.75% | 4.75% | 4.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 10.38% | 10.38% | 10.38% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 4,452 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 4,184 | |||||||||||
Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [7],[10],[11] | 8% | [7],[10],[11] | 8% | [14],[15],[16] | 8% | [14],[15],[16] | |
Investment, interest rate | 13.63% | [7],[8],[10],[11] | 10.74% | [14],[15],[16],[17] | 13.63% | [7],[8],[10],[11] | 13.63% | [7],[8],[10],[11] | 10.74% | [14],[15],[16],[17] | 10.74% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 12,034 | [7],[10],[11],[13] | $ 9,109 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 8,289 | |||||||||||
Fair Value, Ending Balance | 9,928 | [7],[10],[11] | $ 8,289 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.63% | 7.63% | 7.63% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 1,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 1,393 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 1,393 | |||||||||||
Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [7],[10],[11] | 6.75% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [14],[15],[16] | |
Investment, interest rate | 12.40% | [7],[8],[10],[11] | 10.42% | [14],[15],[16],[17] | 12.40% | [7],[8],[10],[11] | 12.40% | [7],[8],[10],[11] | 10.42% | [14],[15],[16],[17] | 10.42% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 25,527 | [7],[10],[11],[13] | $ 20,766 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 18,188 | |||||||||||
Fair Value, Ending Balance | 19,954 | [7],[10],[11] | $ 18,188 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Sabert Corporation, Metal & Glass Containers, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.63% | 7.63% | 7.63% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 1,691 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 1,623 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 1,623 | |||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 10% | 10% | 10% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ (93) | |||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 10% | 10% | 10% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 15.24% | 15.24% | 15.24% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 25,558 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 24,791 | |||||||||||
Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 991,019 | 991,019 | 991,019 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 1,625 | |||||||||||
Investment, Identifier [Axis]: Scilex Holding Co, Biotechnology, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [10],[20] | 9,307 | 9,307 | 9,307 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | $ 13 | |||||||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, ownership percentage | 87.50% | [9],[20],[28],[29],[32] | 87.50% | [1],[2],[19],[22],[30],[31],[33] | 87.50% | [9],[20],[28],[29],[32] | 87.50% | [9],[20],[28],[29],[32] | 87.50% | [1],[2],[19],[22],[30],[31],[33] | 87.50% | [1],[2],[19],[22],[30],[31],[33] | |
Net Realized Gain (Loss) | $ 0 | $ 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 4,200 | 2,901 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 20,715 | [1],[2],[19],[22],[30],[31],[33] | 37,651 | ||||||||||
Gross Additions | 8,163 | 0 | |||||||||||
Gross Reductions | 0 | (16,936) | |||||||||||
Fair Value, Ending Balance | $ 28,878 | [9],[20],[28],[29],[32] | $ 20,715 | [1],[2],[19],[22],[30],[31],[33] | |||||||||
Investment owned, percent of net assets | 1.90% | 1.70% | 1.90% | 1.90% | 1.70% | 1.70% | |||||||
Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[9],[11],[20],[28] | 7% | [1],[2],[14],[16],[19],[22],[30] | 7% | [7],[9],[11],[20],[28] | 7% | [7],[9],[11],[20],[28] | 7% | [1],[2],[14],[16],[19],[22],[30] | 7% | [1],[2],[14],[16],[19],[22],[30] | |
Investment, interest rate | 12.26% | [7],[8],[9],[11],[20],[28] | 8.80% | [1],[2],[14],[16],[17],[19],[22],[30] | 12.26% | [7],[8],[9],[11],[20],[28] | 12.26% | [7],[8],[9],[11],[20],[28] | 8.80% | [1],[2],[14],[16],[17],[19],[22],[30] | 8.80% | [1],[2],[14],[16],[17],[19],[22],[30] | |
Investment owned, balance, principal amount | $ 112,656 | [7],[9],[11],[13],[20],[28] | $ 96,250 | [1],[2],[14],[16],[18],[19],[22],[30] | |||||||||
Net Realized Gain (Loss) | 0 | 0 | |||||||||||
Amount of Interest, Fees or Dividends Credited in Income | 12,726 | 8,001 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | 96,250 | [1],[2],[14],[16],[19],[22],[30] | 96,250 | ||||||||||
Gross Additions | 16,406 | 0 | |||||||||||
Gross Reductions | 0 | 0 | |||||||||||
Fair Value, Ending Balance | $ 112,656 | [7],[9],[11],[20],[28] | $ 96,250 | [1],[2],[14],[16],[19],[22],[30] | |||||||||
Investment owned, percent of net assets | 7.40% | 7.70% | 7.40% | 7.40% | 7.70% | 7.70% | |||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 7.88% | 7.88% | 7.88% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.88% | 12.88% | 12.88% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 7,191 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 6,937 | |||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 7.88% | 7.88% | 7.88% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.88% | 12.88% | 12.88% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[20] | $ 2,697 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 2,602 | |||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[20] | 7.88% | 7.88% | 7.88% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[20] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[20] | 7.88% | 7.88% | 7.88% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[20] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[20] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10],[20] | 58,210 | 58,210 | 58,210 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | $ 87 | |||||||||||
Investment, Identifier [Axis]: ShareThis, Inc., Application Software, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 345,452 | [7],[10] | 345,452 | [14],[15] | 345,452 | [7],[10] | 345,452 | [7],[10] | 345,452 | [14],[15] | 345,452 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 0 | |||||||||||
Fair Value, Ending Balance | 0 | [7],[10] | $ 0 | [14],[15] | |||||||||
Investment, Identifier [Axis]: SiO2 Medical Products, Inc., Metal & Glass Containers, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [14],[15],[16],[17] | 5.50% | 5.50% | 5.50% | |||||||||
Investment, interest rate, paid in kind | [14],[15] | 8.50% | 8.50% | 8.50% | |||||||||
Investment owned, balance, principal amount | [14],[15],[18] | $ 46,121 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 45,295 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 45,295 | |||||||||||
Investment, Identifier [Axis]: SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [7],[10],[11] | 7.50% | [7],[10],[11] | 7.50% | [14],[15],[16] | 7.50% | [14],[15],[16] | |
Investment, interest rate | 13.04% | [7],[8],[10],[11] | 10.48% | [14],[15],[16],[17] | 13.04% | [7],[8],[10],[11] | 13.04% | [7],[8],[10],[11] | 10.48% | [14],[15],[16],[17] | 10.48% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 821 | [7],[10],[11],[13] | $ 3,195 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 2,997 | |||||||||||
Fair Value, Ending Balance | $ 776 | [7],[10],[11] | $ 2,997 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Sorrento Therapeutics, Inc., Biotechnology, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 66,000 | [10],[20] | 50,000 | [15],[22] | 66,000 | [10],[20] | 66,000 | [10],[20] | 50,000 | [15],[22] | 50,000 | [15],[22] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 79 | |||||||||||
Fair Value, Ending Balance | $ 6 | [10],[20] | $ 79 | [15],[22] | |||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5% | [7],[9],[10],[11] | 5.25% | [14],[15],[16],[19] | 5% | [7],[9],[10],[11] | 5% | [7],[9],[10],[11] | 5.25% | [14],[15],[16],[19] | 5.25% | [14],[15],[16],[19] | |
Investment, interest rate | 10.42% | [7],[8],[9],[10],[11] | 8.03% | [14],[15],[16],[17],[19] | 10.42% | [7],[8],[9],[10],[11] | 10.42% | [7],[8],[9],[10],[11] | 8.03% | [14],[15],[16],[17],[19] | 8.03% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 618 | [7],[9],[10],[11],[13] | $ 866 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 796 | |||||||||||
Fair Value, Ending Balance | $ 577 | [7],[9],[10],[11] | $ 796 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 5.25% | [7],[10],[11] | 5.25% | [14],[15],[16] | 5.25% | [7],[10],[11] | 5.25% | [7],[10],[11] | 5.25% | [14],[15],[16] | 5.25% | [14],[15],[16] | |
Investment, interest rate | 10.67% | [7],[8],[10],[11] | 8.30% | [14],[15],[16],[17] | 10.67% | [7],[8],[10],[11] | 10.67% | [7],[8],[10],[11] | 8.30% | [14],[15],[16],[17] | 8.30% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 4,488 | [7],[10],[11],[13] | $ 4,534 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 4,427 | |||||||||||
Fair Value, Ending Balance | $ 4,425 | [7],[10],[11] | $ 4,427 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.32% | 12.32% | 12.32% | |||||||||
Investment owned, balance, principal amount | € | [7],[10],[11],[13],[20] | € 23,731 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 24,937 | |||||||||||
Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.À.R.L., Other Diversified Financial Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[22] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 10% | 10% | 10% | |||||||||
Investment owned, balance, principal amount | £ | [14],[15],[16],[18],[22] | £ 16,911 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 16,360 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[22] | $ 16,360 | |||||||||||
Investment, Identifier [Axis]: Sunland Asphalt & Construction, LLC, Construction & Engineering, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 8.88% | 8.88% | 8.88% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 42,618 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 41,723 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 41,723 | |||||||||||
Investment, Identifier [Axis]: Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 8% | 8% | 8% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 13.32% | 13.32% | 13.32% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 49,520 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 49,148 | |||||||||||
Investment, Identifier [Axis]: Supermoose Borrower, LLC, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 3.75% | 3.75% | 3.75% | |||||||||
Investment, interest rate | [15],[16],[17] | 7.42% | 7.42% | 7.42% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 3,466 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 3,056 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 3,056 | |||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[34] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[34] | 12.44% | 12.44% | 12.44% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[34] | $ 1,552 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[34] | $ 1,478 | |||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[34] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[34] | 12.51% | 12.51% | 12.51% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[34] | $ 32,104 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[34] | $ 30,579 | |||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[34] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[34] | 12.51% | 12.51% | 12.51% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13],[34] | $ 2,749 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[34] | $ 2,618 | |||||||||||
Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11],[34] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [7],[8],[9],[10],[11],[34] | 12.51% | 12.51% | 12.51% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13],[34] | $ 1,099 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11],[34] | 943 | |||||||||||
Investment, Identifier [Axis]: Swordfish Merger Sub LLC, Auto Parts & Equipment, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6.75% | 6.75% | 6.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 9.81% | 9.81% | 9.81% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 12,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 11,469 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 11,469 | |||||||||||
Investment, Identifier [Axis]: TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | 11.50% | [8],[10],[11],[12],[20] | 11.50% | [14],[15],[16],[17],[22] | 11.50% | [8],[10],[11],[12],[20] | 11.50% | [8],[10],[11],[12],[20] | 11.50% | [14],[15],[16],[17],[22] | 11.50% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 4,984 | [10],[12],[13],[20] | $ 4,984 | [14],[15],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[22] | 4,872 | |||||||||||
Fair Value, Ending Balance | $ 4,785 | [10],[12],[20] | $ 4,872 | [14],[15],[22] | |||||||||
Investment, Identifier [Axis]: THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 13% | 13% | 13% | |||||||||
Investment owned, balance, principal amount | [7],[10],[13],[20] | $ 50,419 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[20] | 49,869 | |||||||||||
Investment, Identifier [Axis]: TIBCO Software Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [15],[16] | 4.50% | 4.50% | 4.50% | |||||||||
Investment, interest rate | [15],[16],[17] | 8.15% | 8.15% | 8.15% | |||||||||
Investment owned, balance, principal amount | [15],[16],[18] | $ 12,032 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | $ 10,827 | |||||||||||
Fair Value, Ending Balance | [15],[16] | $ 10,827 | |||||||||||
Investment, Identifier [Axis]: Tacala, LLC, Restaurants, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 8% | [10],[11] | 7.50% | [15],[16] | 8% | [10],[11] | 8% | [10],[11] | 7.50% | [15],[16] | 7.50% | [15],[16] | |
Investment, interest rate | 13.43% | [8],[10],[11] | 10.62% | [15],[16],[17] | 13.43% | [8],[10],[11] | 13.43% | [8],[10],[11] | 10.62% | [15],[16],[17] | 10.62% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 12,843 | [10],[11],[13] | $ 9,448 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 8,692 | |||||||||||
Fair Value, Ending Balance | $ 12,464 | [10],[11] | $ 8,692 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[9],[10],[11],[20] | 6% | [14],[15],[16],[19],[22] | 6% | [7],[9],[10],[11],[20] | 6% | [7],[9],[10],[11],[20] | 6% | [14],[15],[16],[19],[22] | 6% | [14],[15],[16],[19],[22] | |
Investment owned, balance, principal amount | $ 0 | [7],[9],[10],[11],[13],[20] | $ 0 | [14],[15],[16],[18],[19],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19],[22] | (28) | |||||||||||
Fair Value, Ending Balance | $ (22) | [7],[9],[10],[11],[20] | $ (28) | [14],[15],[16],[19],[22] | |||||||||
Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 6% | [7],[10],[11],[20] | 6% | [7],[10],[11],[20] | 6% | [14],[15],[16],[22] | 6% | [14],[15],[16],[22] | |
Investment, interest rate | 11.42% | [7],[8],[10],[11],[20] | 8.68% | [14],[15],[16],[17],[22] | 11.42% | [7],[8],[10],[11],[20] | 11.42% | [7],[8],[10],[11],[20] | 8.68% | [14],[15],[16],[17],[22] | 8.68% | [14],[15],[16],[17],[22] | |
Investment owned, balance, principal amount | $ 28,826 | [7],[10],[11],[13],[20] | $ 23,215 | [14],[15],[16],[18],[22] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | 22,843 | |||||||||||
Fair Value, Ending Balance | 28,537 | [7],[10],[11],[20] | $ 22,843 | [14],[15],[16],[22] | |||||||||
Investment, Identifier [Axis]: Tecta America Corp., Construction & Engineering, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.50% | 8.50% | 8.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 11.62% | 11.62% | 11.62% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 5,203 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 5,034 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 5,034 | |||||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 9.75% | [7],[9],[10],[11] | 9.25% | [14],[15],[16],[19] | 9.75% | [7],[9],[10],[11] | 9.75% | [7],[9],[10],[11] | 9.25% | [14],[15],[16],[19] | 9.25% | [14],[15],[16],[19] | |
Investment, interest rate | 15.17% | [7],[8],[9],[10],[11] | 12.20% | [14],[15],[16],[17],[19] | 15.17% | [7],[8],[9],[10],[11] | 15.17% | [7],[8],[9],[10],[11] | 12.20% | [14],[15],[16],[17],[19] | 12.20% | [14],[15],[16],[17],[19] | |
Investment owned, balance, principal amount | $ 1,861 | [7],[9],[10],[11],[13] | $ 1,231 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 1,187 | |||||||||||
Fair Value, Ending Balance | $ 1,802 | [7],[9],[10],[11] | $ 1,187 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 9.75% | [7],[10],[11] | 9.25% | [14],[15],[16] | 9.75% | [7],[10],[11] | 9.75% | [7],[10],[11] | 9.25% | [14],[15],[16] | 9.25% | [14],[15],[16] | |
Investment, interest rate | 15.26% | [7],[8],[10],[11] | 12.11% | [14],[15],[16],[17] | 15.26% | [7],[8],[10],[11] | 15.26% | [7],[8],[10],[11] | 12.11% | [14],[15],[16],[17] | 12.11% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 23,423 | [7],[10],[11],[13] | $ 18,323 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 17,865 | |||||||||||
Fair Value, Ending Balance | $ 22,814 | [7],[10],[11] | $ 17,865 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Ten-X LLC, Interactive Media & Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.32% | 11.32% | 11.32% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 19,947 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 19,199 | |||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 668,879 | 668,879 | 668,879 | |||||||||
Investment owned, balance, principal amount | [14],[15],[18] | ||||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 4,077 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 4,077 | |||||||||||
Investment, Identifier [Axis]: TerSera Therapeutics LLC, Pharmaceuticals, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 9.50% | 9.50% | 9.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 13.17% | 13.17% | 13.17% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 29,663 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 29,031 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 29,031 | |||||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.30% | [7],[10],[11],[23] | 7.30% | [14],[15],[16] | 7.30% | [7],[10],[11],[23] | 7.30% | [7],[10],[11],[23] | 7.30% | [14],[15],[16] | 7.30% | [14],[15],[16] | |
Investment, interest rate | [14],[15],[16],[17] | 10.44% | 10.44% | 10.44% | |||||||||
Investment owned, balance, principal amount | $ 19,163 | [7],[10],[11],[13],[23] | $ 15,674 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 15,682 | |||||||||||
Fair Value, Ending Balance | $ 18,340 | [7],[10],[11],[23] | $ 15,682 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 12.50% | [7],[10],[11],[23] | 12.50% | [14],[15],[16] | 12.50% | [7],[10],[11],[23] | 12.50% | [7],[10],[11],[23] | 12.50% | [14],[15],[16] | 12.50% | [14],[15],[16] | |
Investment, interest rate | [14],[15],[16],[17] | 16.17% | 16.17% | 16.17% | |||||||||
Investment owned, balance, principal amount | $ 4,641 | [7],[10],[11],[13],[23] | $ 3,789 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 3,800 | |||||||||||
Fair Value, Ending Balance | $ 4,170 | [7],[10],[11],[23] | $ 3,800 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7% | 7% | 7% | |||||||||
Investment, interest rate, paid in kind | 12.65% | 12.65% | 12.65% | ||||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 46,832 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 37,231 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 10,616 | 10,616 | 10,616 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 358,299 | 358,299 | 358,299 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 0 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 60,862 | 60,862 | 60,862 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 108 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, Preferred Equity 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 32,447 | 32,447 | 32,447 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 31,701 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7% | 7% | 7% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 11.17% | 11.17% | 11.17% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 37,494 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 35,807 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 35,807 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 8,434 | 8,434 | 8,434 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 69 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 69 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 284,650 | 284,650 | 284,650 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 2,320 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 2,320 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 48,352 | 48,352 | 48,352 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 979 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 979 | |||||||||||
Investment, Identifier [Axis]: Thrasio, LLC, Internet & Direct Marketing Retail, Preferred Equity 4 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15],[19] | 23,201 | 23,201 | 23,201 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[19] | $ 26,487 | |||||||||||
Fair Value, Ending Balance | [14],[15],[19] | $ 26,487 | |||||||||||
Investment, Identifier [Axis]: Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [7],[10],[11] | 6% | [7],[10],[11] | 6% | [14],[15],[16] | 6% | [14],[15],[16] | |
Investment, interest rate | 11.42% | [7],[8],[10],[11] | 9.12% | [14],[15],[16],[17] | 11.42% | [7],[8],[10],[11] | 11.42% | [7],[8],[10],[11] | 9.12% | [14],[15],[16],[17] | 9.12% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 11,671 | [7],[10],[11],[13] | $ 6,016 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 5,895 | |||||||||||
Fair Value, Ending Balance | $ 11,363 | [7],[10],[11] | $ 5,895 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [10],[11],[20] | 7.71% | 7.71% | 7.71% | |||||||||
Investment, interest rate | [8],[10],[11],[20] | 13.06% | 13.06% | 13.06% | |||||||||
Investment owned, balance, principal amount | [10],[11],[13],[20] | $ 1,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[11],[20] | $ 917 | |||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [8],[10],[11],[20] | 6.50% | 6.50% | 6.50% | |||||||||
Investment owned, balance, principal amount | [10],[13],[20] | $ 4,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | $ 2,953 | |||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [8],[10],[11],[20] | 4.75% | 4.75% | 4.75% | |||||||||
Investment owned, balance, principal amount | [10],[13],[20] | $ 300 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [10],[20] | 245 | |||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 6.50% | 6.50% | 6.50% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 4,500 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | 3,026 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 3,026 | |||||||||||
Investment, Identifier [Axis]: Uniti Group LP, Specialized REITs, Fixed Rate Bond 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17],[22] | 4.75% | 4.75% | 4.75% | |||||||||
Investment owned, balance, principal amount | [15],[18],[22] | $ 300 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[22] | $ 238 | |||||||||||
Fair Value, Ending Balance | [15],[22] | $ 238 | |||||||||||
Investment, Identifier [Axis]: Virgin Pulse, Inc., Application Software, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 12.68% | 12.68% | 12.68% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,140 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,139 | |||||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 3.75% | [10],[11] | 3.75% | [15],[16] | 3.75% | [10],[11] | 3.75% | [10],[11] | 3.75% | [15],[16] | 3.75% | [15],[16] | |
Investment, interest rate | 9.27% | [8],[10],[11] | 6.56% | [15],[16],[17] | 9.27% | [8],[10],[11] | 9.27% | [8],[10],[11] | 6.56% | [15],[16],[17] | 6.56% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 11,792 | [10],[11],[13] | $ 7,564 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 6,795 | |||||||||||
Fair Value, Ending Balance | 11,127 | [10],[11] | $ 6,795 | [15],[16] | |||||||||
Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 7.75% | 7.75% | 7.75% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.56% | 10.56% | 10.56% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 6,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 5,070 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 5,070 | |||||||||||
Investment, Identifier [Axis]: WPEngine, Inc., Application Software, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 6% | 6% | 6% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 10.19% | 10.19% | 10.19% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 40,536 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 40,131 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 40,131 | |||||||||||
Investment, Identifier [Axis]: WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [7],[10],[11] | 7% | [7],[10],[11] | 7% | [14],[15],[16] | 7% | [14],[15],[16] | |
Investment, interest rate | 12.65% | [7],[8],[10],[11] | 10.67% | [14],[15],[16],[17] | 12.65% | [7],[8],[10],[11] | 12.65% | [7],[8],[10],[11] | 10.67% | [14],[15],[16],[17] | 10.67% | [14],[15],[16],[17] | |
Investment owned, balance, principal amount | $ 5,000 | [7],[10],[11],[13] | $ 5,000 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 4,538 | |||||||||||
Fair Value, Ending Balance | 4,263 | [7],[10],[11] | $ 4,538 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 15% | 15% | 15% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 19.64% | 19.64% | 19.64% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 2,316 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 2,264 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 2,264 | |||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 15% | 15% | 15% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 21.68% | 21.68% | 21.68% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,565 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,464 | |||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 15% | 15% | 15% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 21.68% | 21.68% | 21.68% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 1,323 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 1,237 | |||||||||||
Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 4,871 | [7],[10] | 3,621 | [14],[15] | 4,871 | [7],[10] | 4,871 | [7],[10] | 3,621 | [14],[15] | 3,621 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 192 | |||||||||||
Fair Value, Ending Balance | $ 107 | [7],[10] | $ 192 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 127,452 | [7],[10] | 18,032 | [14],[15] | 127,452 | [7],[10] | 127,452 | [7],[10] | 18,032 | [14],[15] | 18,032 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 296 | |||||||||||
Fair Value, Ending Balance | $ 1,319 | [7],[10] | $ 296 | [14],[15] | |||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.25% | [10],[11] | 6.25% | [15],[16] | 6.25% | [10],[11] | 6.25% | [10],[11] | 6.25% | [15],[16] | 6.25% | [15],[16] | |
Investment, interest rate | 11.67% | [8],[10],[11] | 9.37% | [15],[16],[17] | 11.67% | [8],[10],[11] | 11.67% | [8],[10],[11] | 9.37% | [15],[16],[17] | 9.37% | [15],[16],[17] | |
Investment owned, balance, principal amount | $ 8,983 | [10],[11],[13] | $ 25,499 | [15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15],[16] | 23,204 | |||||||||||
Fair Value, Ending Balance | 8,678 | [10],[11] | $ 23,204 | [15],[16] | |||||||||
Investment, Identifier [Axis]: Windstream Services II, LLC, Integrated Telecommunication Services, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [14],[15] | 109,420 | 109,420 | 109,420 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | 1,799 | |||||||||||
Fair Value, Ending Balance | [14],[15] | $ 1,799 | |||||||||||
Investment, Identifier [Axis]: Zayo Group Holdings, Inc., Alternative Carriers, Fixed Rate Bond | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, interest rate | [15],[16],[17] | 4% | 4% | 4% | |||||||||
Investment owned, balance, principal amount | [15],[18] | $ 250 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [15] | 201 | |||||||||||
Fair Value, Ending Balance | [15] | $ 201 | |||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16] | 8.25% | 8.25% | 8.25% | |||||||||
Investment, interest rate | [14],[15],[16],[17] | 11.92% | 11.92% | 11.92% | |||||||||
Investment owned, balance, principal amount | [14],[15],[16],[18] | $ 19,578 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | $ 16,152 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16] | $ 16,152 | |||||||||||
Investment, Identifier [Axis]: Zep Inc., Specialty Chemicals,First Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 4% | 4% | 4% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 9.32% | 9.32% | 9.32% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 19,578 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | 19,489 | |||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [14],[15],[16],[22] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [14],[15],[16],[17],[22] | 9.72% | 9.72% | 9.72% | |||||||||
Investment owned, balance, principal amount | £ | [14],[15],[16],[18],[22] | £ 18,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[22] | $ 16,552 | |||||||||||
Fair Value, Ending Balance | [14],[15],[16],[22] | $ 16,552 | |||||||||||
Investment, Identifier [Axis]: Zephyr Bidco Limited,Specialized Finance, Second Lien Term Loan | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11],[20] | 7.50% | 7.50% | 7.50% | |||||||||
Investment, interest rate | [7],[8],[10],[11],[20] | 12.72% | 12.72% | 12.72% | |||||||||
Investment owned, balance, principal amount | £ | [7],[10],[11],[13],[20] | £ 20,000 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11],[20] | $ 22,914 | |||||||||||
Investment, Identifier [Axis]: athenahealth Group Inc., Health Care Technology, Preferred Equity | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | 21,523 | [7],[10] | 18,635 | [14],[15] | 21,523 | [7],[10] | 21,523 | [7],[10] | 18,635 | [14],[15] | 18,635 | [14],[15] | |
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15] | $ 16,575 | |||||||||||
Fair Value, Ending Balance | $ 20,074 | [7],[10] | $ 16,575 | [14],[15] | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Revolver | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 6.75% | [7],[9],[10],[11] | 6.75% | [14],[15],[16],[19] | 6.75% | [7],[9],[10],[11] | 6.75% | [7],[9],[10],[11] | 6.75% | [14],[15],[16],[19] | 6.75% | [14],[15],[16],[19] | |
Investment, interest rate | [7],[8],[9],[10],[11] | 12.14% | 12.14% | 12.14% | |||||||||
Investment owned, balance, principal amount | $ 377 | [7],[9],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | (32) | |||||||||||
Fair Value, Ending Balance | $ 296 | [7],[9],[10],[11] | $ (32) | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.25% | [7],[10],[11] | 6.75% | [14],[15],[16] | 7.25% | [7],[10],[11] | 7.25% | [7],[10],[11] | 6.75% | [14],[15],[16] | 6.75% | [14],[15],[16] | |
Investment, interest rate | 12.63% | [7],[8],[10],[11] | 9.49% | [14],[15],[16],[17] | 12.63% | [7],[8],[10],[11] | 12.63% | [7],[8],[10],[11] | 9.49% | [14],[15],[16],[17] | 9.49% | [14],[15],[16],[17] | |
Investment, interest rate, paid in kind | [7],[10] | ||||||||||||
Investment owned, balance, principal amount | $ 24,427 | [7],[10],[11],[13] | $ 19,203 | [14],[15],[16],[18] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16] | 18,867 | |||||||||||
Fair Value, Ending Balance | $ 23,548 | [7],[10],[11] | $ 18,867 | [14],[15],[16] | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | 7.25% | [7],[10],[11] | 6.75% | [14],[15],[16],[19] | 7.25% | [7],[10],[11] | 7.25% | [7],[10],[11] | 6.75% | [14],[15],[16],[19] | 6.75% | [14],[15],[16],[19] | |
Investment, interest rate | [7],[8],[10],[11] | 12.63% | 12.63% | 12.63% | |||||||||
Investment owned, balance, principal amount | $ 3,636 | [7],[10],[11],[13] | $ 0 | [14],[15],[16],[18],[19] | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Beginning Balance | [14],[15],[16],[19] | 0 | |||||||||||
Fair Value, Ending Balance | $ 3,574 | [7],[10],[11] | $ 0 | [14],[15],[16],[19] | |||||||||
Investment, Identifier [Axis]: iCIMs, Inc., Application Software, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 7.25% | 7.25% | 7.25% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 0 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[10],[11] | 8.75% | 8.75% | 8.75% | |||||||||
Investment, interest rate | [7],[8],[10],[11] | 11.75% | 11.75% | 11.75% | |||||||||
Investment owned, balance, principal amount | [7],[10],[11],[13] | $ 5,212 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10],[11] | $ 4,990 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 8.75% | 8.75% | 8.75% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 0 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment, basis spread, variable rate | [7],[9],[10],[11] | 8.75% | 8.75% | 8.75% | |||||||||
Investment owned, balance, principal amount | [7],[9],[10],[11],[13] | $ 0 | |||||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[9],[10],[11] | $ 0 | |||||||||||
Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, Warrants | |||||||||||||
Schedule of Investments [Line Items] | |||||||||||||
Investment owned, balance (in shares) | shares | [7],[10] | 53,700 | 53,700 | 53,700 | |||||||||
Investments in and Advances to Affiliates, at Fair Value [Roll Forward] | |||||||||||||
Fair Value, Ending Balance | [7],[10] | $ 258 | |||||||||||
[1]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[2]Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[3]As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.[4]Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.[5]Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.[6]Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.[7] As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). ten twenty ten twenty ten twenty ten twenty |